<SEC-DOCUMENT>0001628280-23-015212.txt : 20230503
<SEC-HEADER>0001628280-23-015212.hdr.sgml : 20230503
<ACCEPTANCE-DATETIME>20230503160702
ACCESSION NUMBER:		0001628280-23-015212
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230503
DATE AS OF CHANGE:		20230503

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARDELYX, INC.
		CENTRAL INDEX KEY:			0001437402
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36485
		FILM NUMBER:		23883711

	BUSINESS ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555
		BUSINESS PHONE:		510-745-7047

	MAIL ADDRESS:	
		STREET 1:		34175 ARDENWOOD BLVD.
		CITY:			FREMONT
		STATE:			CA
		ZIP:			94555

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NTERYX INC
		DATE OF NAME CHANGE:	20080611
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ardx-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:5e53bfed-5618-4e24-885d-bb49c3b2394c,g:e63de3a8-8715-46e5-89c4-d16db17c8afb,d:ea6a0b1ea655406093eb9e951c03313e--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ardx="http://www.ardelyx.com/20230331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ardx-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8wLTEtMS0xLTU4MDc3_5ee2ac52-e7e2-45c9-842f-fadb601a9be6">0001437402</ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8xLTEtMS0xLTU4MDc3_c02e61e6-2bac-4d3b-abad-0cac6d6a5ac1">12-31</ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8yLTEtMS0xLTU4MDc3_73444ad5-05bf-4ceb-85ca-57e2494c1d74">2023</ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8zLTEtMS0xLTU4MDc3_84dd57bc-49e7-436e-b569-3f9f58691885">Q1</ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF80LTEtMS0xLTU4MDc3_41fa3fe9-42b1-4811-a4aa-3cea4ce2efe0">false</ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV84Mi9mcmFnOjRhYTNjNDk3ZTE3MzQyYmNiOTY3YzRhYWVkYTZhMTY4L3RleHRyZWdpb246NGFhM2M0OTdlMTczNDJiY2I5NjdjNGFhZWRhNmExNjhfNTMx_b57924bc-f07d-458c-91ac-ab563c636991" escape="true">SUBSEQUENT EVENTS[</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ardx-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i932880f720fe40d8811f3a60e39b01d9_I20230428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6fb93e39ef444d8695c887cc09b73b80_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2066d1e80c264bcd99c9924963c7c7a2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3856b2b0524045fc9db6e2c44a8cf2c2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad51cff0cb0e45ad810a4a4575f2c6c1_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea4a8d7b8d644fb08f9938d356a671ec_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a79ad494fe042bdbf346769d0ee7b48_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5bfad961f86457581b6f4e9d7d22270_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fc5e3d4b4f406d86613fc88394fa6d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db9eb9e722e416eb7e2bf74dcb73ce3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2a18458262545e9818256bcffdfdbe9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65db80588fcc4d449903945de63379d9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2922df2535ca423a89973f8f65fca675_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95d3925bde5c401ca56d5a208ae6d39b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b66658c70174c7b964c4278cadb803b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b50ab59575f44aab60c0aaa8d0ca9f7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96ca73985d3c4d82b3a1980bbe2e8e76_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52f0e7c126f849cc86ce9adbfbd89603_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4732bae904484aa5a7c90237b85d7ac9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4bd3bd1b1284974bcdb1a2b8b9df930_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic18098bd479c463a8c870397cfa95c5e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4809599b3f643b0b0ebea13fe0a5062_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f50508ad334e6eb7ed23017eb62096_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if280f015aeed4a60931d60002bd4d221_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57175b056d77462ea9709d3fefc23984_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61e2e4a4f64d40aab8d29960cdd46227_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id804dfa2f8bf4491961e64ab1900b30b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a28be02017a44cf8e2c9f9690207ec4_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c831a5fa23047d39e1d3768ebd72dfa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5547c702f0548338c9eda648f780448_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702563bc994044d4830a60b075943f6b_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ardx:segment</xbrli:measure></xbrli:unit><xbrli:context id="ia0d688e400e645008fb72d473b88ac99_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic936e46468054162a36dcf4e97de128d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie12a2be0e30248e18c0e219442faa6a9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie631368284b2408aad835684afa02e95_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0524220fccc7435abcb990a758edda9f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id884382c6adf4ee689a124f5a304b668_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0d87663204949f4982bae6de6a652c0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52a556a61d24bc0b97c984c978c2ced_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc0743eef5b24b739e5fe93758972073_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i702ac6a7149a4273b8841d440aaca4c1_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>ardx:investment</xbrli:measure></xbrli:unit><xbrli:context id="if787129ae8904e9fa759cc369c4db88f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iadea2dc595e045b693f4c3806a5d3b16_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3daca4f51d947b5945b812330581364_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85a8b0761bd5415db96033f744c6140a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c74497a62594f85876db914b650f7c4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i588c4fa500554006860c6007e40ee0a5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ad9611ed2ff4e919a234ed94bba8aed_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i883fa34c97c54813bb2d78e911d603f8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide24937bdbc64ce28cc5e6cbfbd5e742_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifaf58162db324fe59ce07df2c57faf57_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8afaa29db094d8f940e22612a879ea8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib68a978d30bb4163a635630e070edcb7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dda51aa0a8049d1968ca0f7b120ceef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89592ca2da2742faaa3ad4dd4f55e876_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9ba30f7b5548f8acfc7d00df9d940a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dece602bb7b484e80d6317ab479a4e9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab7f44ca18fe47858c896bf995bca00b_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766e68b72c6f4313991c6e312bae923e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ad81d2394b2450fba8397056389cb20_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i803ae491ae4247699729cd6edb089399_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19b484f382e14cee9bae114778c4b2ee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e493e744f814e32a4f525d3b099f39a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199726c1e7c64eed97aea0f720596607_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45e32429d8b040ce8d79b9dde9e922f7_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecb4976c60f342fa953b24367cd3820e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669a009daaeb4d2db79701235b95e376_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39295831f6047c59873ab434e7a7cf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede9e2d88ec041849965bcef8bfb9c17_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57102aa94d874a13b6507d22ca28cdc0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dd2aff3e0974780a6b2aa931ebb28f9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae1010cf9f614aa9b7166c1b910413d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic892b663020e42b1bd246832a5009260_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2db82a67dfd141e8a7a89f9559c2902d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fb1446d2f5f4438a3d7554393bc9a1f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i242fd96eb50447d3991a0de8c6a76b37_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44fae79f843e424798285c554872b550_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63206a33055f4c71bee2ac6cc2b4f155_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8517689b41a2471a8481ff5ea1df4049_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9711e441836a4f0d870c15d342503a53_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87660283b17b44d686672983be8c5c21_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69de1d9e70cd4b0088ef12543981f292_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i440c55b90eec415db702e87c2679f87b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0576a7417fb0498fb1ea19dcab1a3146_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5d8d964b58e482b9ff481926c12e415_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if376b021c40b4857af8ed796b6f678c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebfb6b4b245549c1925014c3d197a60d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4861c96b38f245e58dee1fb635b16e2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i644fdcb9f2ec487eb5257a431392d340_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if10e10eb21804ecea009554e9a64bbfe_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9daeb86042c74be28a77bbfb542222af_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077fb918ffd34a16a2ba56d845e7c0eb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i45042f4036a348d9ac0c4307237e2fe3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35fb475dbd8e4857a5165d3acdca2256_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d628cc8068943659267d334778f7341_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff654685dbff4d14b4f04d9a1f3d82ad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2484e9556a94cb28d490b54b7654b83_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d95d2f372e4305b5ab02ab183e81cc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6abe21dd0e894e529281c08515f218a9_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70fd6a1343d4c07ab6c0418986dd561_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d909b1486e465d9d1e0fae1f8ce528_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94828b9e8bfc49a9821ddf83aaed8bd3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4d507187469461589702c69e8af394f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i083920320a754056a514534f83b44efb_D20171101-20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bd3e10bb611407aa9b181ac0b231f2b_I20171130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife5f1ab287944b9d9bde070bbcbc67e0_D20171101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i288cfb8144d94e34b13ad2293ba44e8a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="jpy"><xbrli:measure>iso4217:JPY</xbrli:measure></xbrli:unit><xbrli:context id="i39875fb6603e44a9a08e3395ebc9b749_I20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="payment_tranche"><xbrli:measure>ardx:payment_tranche</xbrli:measure></xbrli:unit><xbrli:context id="ie00d1c1778d04b16b85402b79f1486b1_I20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2907f661c6604d53a0fd946c446d11e8_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib45bb64e3dd84ca6aef388e7e5e6f6e7_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8a535f9627a421383052d6cea68607f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863345a922844c66bd8d54af304f6cdf_D20180301-20180331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-01</xbrli:startDate><xbrli:endDate>2018-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63261ab5ac574aa09e991359cd4c71ad_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i3052a28a1e664c948b14b97c701206d4_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e4c9709e43489db08f10738e1a7672_D20150601-20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-06-01</xbrli:startDate><xbrli:endDate>2015-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b884d0ed6cd421f8a251db830a1fdce_I20150630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57d1ca4ad84940028b209e173e66500a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i731cea5b5a1d4df7b9a2e29a37cd3494_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86a688e614d249fb9330ee9f05c52190_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659312f8037b43898d098e16388710fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace679a5607d492699456f44241140e4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f7c183ef764b48ab94110300434074_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia95bc99b5de94628b6f1a6c5d5185452_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e9a3bf71e144239ab9f7e4ab68a77fb_D20220601-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6b3392a8c3747ae86ad7d9a483555ca_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieebd3c9bdbf5498bb3059d158b5c146a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d8e929085924d668d54e66064fca686_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id26a7d8749644b05b1f668cab705f3da_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65852187d2a644d0b3d856dac714bdd5_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bde4623e9a04dc39eee1626eaee265d_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94ae49ee7695430e996b24c23504b630_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i638a555d6cc245828c93ab8f2f4152fd_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermBLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f29b0505e0a4f2687c88c38e53ea1dc_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b5ab525e6ab435aaf3c6a02a1de068a_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c94dd239cb747d4badb5a4357da4ad9_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia083898fba8644ae8992ef5a76d16d15_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3eef16572d6e4271b1f76a0150bcab0d_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f1ad1d3f45248538bc7fb75b496d6b7_I20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c8ecd2354241aaae56ac9dd1838668_I20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i144ee9ba68854c9cb614235c5e0c2141_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i409069f3154040ff8c6970a5bfafb1ee_D20220223-20220223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-23</xbrli:startDate><xbrli:endDate>2022-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33de1b72f71545d986edc3214d5d9beb_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb8182a2d794133b5db7776b72a7c32_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id77334cdee644ae3adb652a17ffda146_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb1c667d3f6845b9821defdd369f3334_D20220201-20220228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad99515dc2cb43bbac4c617f035dbea6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic39c3311ee344cb6bd0f358d159ff052_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie825c96e303040cbac67e9975c1d3916_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i378e186ad3f24c9db722bd214a0cd23c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70a72bd3fdec4799bf7cbc921bbe7771_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9097418276724d54ae8d794f40b08e52_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76f025b503164e55a2c09bb438e74e2c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i417a6c105f4849fc8598601744a8fe4a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3182ceda3b1f402a8c202c06dedcee6f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1c3cd44c6894dfbaeaedc130ea028db_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc6e80a67a6b4e47b639149a2c278dfd_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3794a3d76c384e9fa5e39ef7474a6713_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a1c090223594681b449fb7259dff90c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40d30043fca4421a8cdd707a81f722ba_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ia852c2d1c80946b885ed9b389837f281_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90fedc697a1647b9a3c9a1fdd6f348f5_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38ec05cddf3c49969f8932f33a355bdd_I20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08f1310f62044e3a8e64483b5dd18dda_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i847e1d01ce2b4b5196fbe950423d7527_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i210c86e09a944a939b0007a9a24d4ece_I20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71e4928ba21947689d3e92f7f3fc1047_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1377563bc1bf4114b883c22f97c51e4a_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id437a6bae6684761a2b82865b44768bb_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72321f082eb4141ae92b05ddd125028_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdbd17f499a48b8a163d1b51e42ad39_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97aaff4ee70847809b2728fcf21c8527_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0beb2c643043e5ac96aa6e57782a75_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i569028c12e1a4c889833813e64570cc9_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc784fcdb3041df855d022e9e60e484_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38458ac6496e4b97bcf456606e115021_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab6e5d2a709c4d4a89b9436290d7efe6_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3414587956434b98b32c8ddc23e1990e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee67a217ee640f3ae98f97ef8b95003_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b51b129be104da4b12d3221e1e2ce43_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1cf5f5ae42646abb1e513d35f625822_D20210730-20210812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-08-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>ardx:claim</xbrli:measure></xbrli:unit><xbrli:unit id="defendant"><xbrli:measure>ardx:defendant</xbrli:measure></xbrli:unit><xbrli:context id="i85da43d6cf444786a450dbf73698f7f9_D20220719-20220719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-19</xbrli:startDate><xbrli:endDate>2022-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfbdf47e462e49459e70036c484a3c1f_D20211207-20220329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001437402</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:GoVersusRaabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-07</xbrli:startDate><xbrli:endDate>2022-03-29</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iea6a0b1ea655406093eb9e951c03313e_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">WASHINGTON, DC 20549</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTIw_ab70b336-9cd2-450e-95da-6f702803689c">10-Q</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6M2Y2YjdhODM3YWMyNDU3YWJkNTBhYjc2ODQzOTgyYzgvdGFibGVyYW5nZTozZjZiN2E4MzdhYzI0NTdhYmQ1MGFiNzY4NDM5ODJjOF8wLTAtMS0xLTU4MDc3_89823e31-acf5-4956-9915-7dc1229a5c8e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8xMzg_0383135b-e634-40f5-a585-76efe0aad028">March&#160;31, 2023</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:3.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.062%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6NGNkMTBhYjdjMGQwNGJhMDgwODNjMDQzNjVkMzNmMDIvdGFibGVyYW5nZTo0Y2QxMGFiN2MwZDA0YmEwODA4M2MwNDM2NWQzM2YwMl8wLTAtMS0xLTU4MDc3_11e697c5-f2f9-41eb-a3be-936ea9bda28b">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI2_c5fe2caf-4315-47f3-b141-7583d6817b36">001-36485</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><img src="ardx-20230331_g1.jpg" alt="Ardelyx-Logomark-RGB.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:60px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI3_37382cc1-417c-496b-a369-f680b718c791">ARDELYX,&#160;INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6ZDQ4ZGY4ZmRmNWFlNGI2OWE0ZGMwOThmOTFlYjZmNjUvdGFibGVyYW5nZTpkNDhkZjhmZGY1YWU0YjY5YTRkYzA5OGY5MWViNmY2NV8wLTAtMS0xLTU4MDc3_a1f166f8-6629-4a08-80ad-28ed27551b61">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6ZDQ4ZGY4ZmRmNWFlNGI2OWE0ZGMwOThmOTFlYjZmNjUvdGFibGVyYW5nZTpkNDhkZjhmZGY1YWU0YjY5YTRkYzA5OGY5MWViNmY2NV8wLTEtMS0xLTU4MDc3_001206af-a21f-4b4f-9aab-5150f82579b9">26-1303944</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI4_498146a6-7bf1-4002-9c2a-fe01817913a9">400 Fifth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE0_273cafd0-95d7-464a-ac77-af576ae17e08">Suite 210</ix:nonNumeric>, <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE2_8b65c84e-8cbd-4933-98b5-ffa60eb0df78">Waltham</ix:nonNumeric>, <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE3_970ae751-05ba-4f43-ba1e-c49cdb01d802">Massachusetts</ix:nonNumeric> <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTA3_48e7b4d6-6a7b-46a9-a348-08630159154e">02451</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices) (Zip Code)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTIz_0a8f7a39-382c-4117-8e39-e7e7487b9a3f">510</ix:nonNumeric>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTEw_9be98edb-37bf-4484-bcfd-4ccd56af0911">745-1700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:23.391%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.245%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MWVhOWRiMmJmZDIxNGNhNzhjNmRjY2M1MzU1YjAzMzMvdGFibGVyYW5nZToxZWE5ZGIyYmZkMjE0Y2E3OGM2ZGNjYzUzNTViMDMzM18xLTAtMS0xLTU4MDc3_58a20bbd-5e58-44d1-a607-8699ef2cec5a">Common Stock, par value $0.0001</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MWVhOWRiMmJmZDIxNGNhNzhjNmRjY2M1MzU1YjAzMzMvdGFibGVyYW5nZToxZWE5ZGIyYmZkMjE0Y2E3OGM2ZGNjYzUzNTViMDMzM18xLTItMS0xLTU4MDc3_36bb7ecd-7529-4460-9a6a-e98eb3173074">ARDX</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MWVhOWRiMmJmZDIxNGNhNzhjNmRjY2M1MzU1YjAzMzMvdGFibGVyYW5nZToxZWE5ZGIyYmZkMjE0Y2E3OGM2ZGNjYzUzNTViMDMzM18xLTQtMS0xLTU4MDc3_878c893c-66a3-4a10-b422-20797491e6b7">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE4_d7e41cce-8fe9-453b-9c41-50d371e21946">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTA5_a58076f3-8f5d-43d4-a282-68aee53ca1db">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span><span style="font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:120%"></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MjAxZTdhNzhhNzBmNDQzMDk0NThkZjNmNGJiNzEwNmEvdGFibGVyYW5nZToyMDFlN2E3OGE3MGY0NDMwOTQ1OGRmM2Y0YmI3MTA2YV8yLTEtMS0xLTU4OTUx_e56e64fe-286b-4138-bf27-f8443ad7f01a">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MjAxZTdhNzhhNzBmNDQzMDk0NThkZjNmNGJiNzEwNmEvdGFibGVyYW5nZToyMDFlN2E3OGE3MGY0NDMwOTQ1OGRmM2Y0YmI3MTA2YV8yLTUtMS0xLTU4MDc3_b798df14-f8b3-40f0-8b75-7b73c58e7349">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MjAxZTdhNzhhNzBmNDQzMDk0NThkZjNmNGJiNzEwNmEvdGFibGVyYW5nZToyMDFlN2E3OGE3MGY0NDMwOTQ1OGRmM2Y0YmI3MTA2YV80LTUtMS0xLTU4MDc3_b1d6fa47-8794-46d8-aba2-67adb0e14e0e">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:4pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI1_8f3a54ac-9c97-43db-a434-69818844ad3b">&#9746;</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of issued and outstanding shares of the registrant&#8217;s Common Stock, $0.0001 par value per share, as of April&#160;28, 2023, was <ix:nonFraction unitRef="shares" contextRef="i932880f720fe40d8811f3a60e39b01d9_I20230428" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTAx_68c76548-9ebb-46ec-8d92-9f1fede44818">214,462,429</ix:nonFraction>.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context requires otherwise, in this Quarterly Report on Form 10-Q the terms &#8220;Ardelyx&#8221;, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and &#8220;the Company&#8221; refer to Ardelyx, Inc.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing of receipt from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) of an Acknowledgement of Receipt letter for our new drug application (&#8220;NDA&#8221;) for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease patients (&#8220;CKD&#8221;) on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy, and our current expectation that such letter will include the classification of the resubmission and the goal review date for our NDA; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the development of a label for the commercialization of XPHOZAH and our belief regarding what indication may be included in such a label;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the potential for FDA approval for the NDA for XPHOZAH;  </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the timing of the FDA&#8217;s review of the NDA for XPHOZAH and, if approved, our current expectations regarding our timing to launch XPHOZAH; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to address our operating cash flow requirements with our current cash, cash equivalents and short-term investments, cash generated from the sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and if approved, sales of XPHOZAH, the potential receipt of anticipated milestone payments from our collaboration partners, the potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending;</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to RDX013 and RDX020; </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to obtain additional capital; and </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other risks and uncertainties, including those under the caption &#8220;Risk Factors.&#8221;</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have based these forward-looking statements largely on management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and management&#8217;s beliefs and assumptions, and these forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Factors that could cause actual results or conditions to differ from those anticipated by these and other forward-looking statements include those more fully described in the &#8220;ITEM 1A. RISK FACTORS&#8221; section and elsewhere in this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update any forward-looking statement publicly, or to revise any forward-looking statement to reflect events or developments occurring after the date of this Quarterly Report on Form 10-Q, even if new information becomes available in the future. Thus, you should not assume that our silence over time means that actual events are bearing out as expressed or implied in any such forward-looking statement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF PRINCIPAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal risks and uncertainties affecting our business include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require additional financing for the foreseeable future as we invest in the commercialization of IBSRELA in the U.S., and prepare for and commercialize XPHOZAH in the U.S., if approved. The inability to access necessary capital </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">when needed on acceptable terms, or at all, could force us to reduce our efforts to commercialize IBSRELA or, delay or limit the commercialization of XPHOZAH, if approved.</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have generated limited revenue from product sales and may never be profitable. </span></div><div><span><br/></span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA; secure adequate coverage and reimbursement for IBSRELA; or generate sufficient revenue from product sales of IBSRELA.</span></div><div><span><br/></span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are pursuing regulatory approval for XPHOZAH. There can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are successful in obtaining regulatory approval for XPHOZAH, there is no guarantee that we will achieve sufficient market acceptance for XPHOZAH; secure adequate coverage and reimbursement for XPHOZAH; or generate sufficient revenue from product sales of XPHOZAH. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IBSRELA and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product.</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party payor coverage and reimbursement status of newly-commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, for XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA and, if approved and commercialized, of XPHOZAH, and our future development efforts for tenapanor may be materially harmed. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The summary risk factors described above should be read together with the text of the full risk factors below in the section entitled &#8220;Risk Factors&#8221; and the other information set forth in this Quarterly Report on Form 10-Q, including our consolidated financial statements and the related notes, as well as in other documents that we file with the U.S. Securities and Exchange Commission. The risks summarized above or described in full below are not the only risks that we face. Additional risks and uncertainties not precisely known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, results of operations, and future growth prospects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARDELYX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are trademarks of Ardelyx. All other trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.685%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PAGE</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_13">PART I. FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_16">Item 1. Financial Statements:</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_19">Condensed Balance Sheets (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_22">Condensed Statements of Operations and Comprehensive Loss (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_25">Condensed Statements of Changes in Stockholders' Equity (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_28">Condensed Statements of Cash Flows (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_31">Notes to Condensed Financial Statements (unaudited)</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_85">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iea6a0b1ea655406093eb9e951c03313e_121">Item 3. Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iea6a0b1ea655406093eb9e951c03313e_124">Item 4. Controls and Procedures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_127">PART II. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_130">Item 1. Legal Proceedings</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_133">Item 1A. Risk Factors</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_136">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_139">Item 3. Defaults Upon Senior Securities</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_142">Item 4. Mine Safety Disclosures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_145">Item 5. Other Information</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_148">Item 6. Exhibits</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_151">Signatures</a></span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS</span></div><div><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNC0xLTEtMS01ODA3Nw_8555c5a2-4714-44b4-94d4-32b7dc82b616">92,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNC0zLTEtMS01ODA3Nw_889ef05c-1c43-48ff-9c77-9a7c0264e8bb">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNS0xLTEtMS01ODA3Nw_73f166ba-4661-4b79-a2d8-568127fccf48">37,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNS0zLTEtMS01ODA3Nw_4c0ea3b7-c7d1-40e1-bbce-a00be26900a3">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNi0xLTEtMS01ODA3Nw_194acb50-1071-4c9d-b0c9-643fa24be268">12,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNi0zLTEtMS01ODA3Nw_58c84d7c-186e-4c61-a7e9-76983163a31b">7,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNy0xLTEtMS01ODA3Nw_f4ca1e12-1209-40b9-8e8a-89776f652783">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNy0zLTEtMS01ODA3Nw_b6b26f84-1690-499d-a35f-83d34f2678c2">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOC0xLTEtMS01ODA3Nw_38c597d9-5fac-4c64-a2ec-4671c495e0e6">13,835</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOC0zLTEtMS01ODA3Nw_201e62d5-1622-45a8-a194-9c0dec951520">13,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOS0xLTEtMS01ODA3Nw_54e73a2a-f774-4954-ac63-b9d713d08bad">5,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOS0zLTEtMS01ODA3Nw_cc865f42-31d4-4bb7-8d1e-de05d0f96133">5,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTAtMS0xLTEtNTgwNzc_0b3997d3-1fb1-4a3b-9d01-b847d9d4a54e">167,047</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTAtMy0xLTEtNTgwNzc_00a4a617-8071-46e8-be44-30f190c8532a">153,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMS0xLTEtNTgzOTE_abe71248-4550-4d85-8e23-2e7324234739">40,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMy0xLTEtNTgzOTE_733cc68d-7bc9-4f35-8045-a87a159b7fcf">25,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMS0xLTEtNTgwNzc_c71c5fb8-6ed7-4bb4-9b3a-21bb79b1ba23">7,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMy0xLTEtNTgwNzc_b8c32a53-7d49-4c16-8b12-7623686f4049">9,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTItMS0xLTEtNTgwNzc_84f50b65-1aaa-4970-8335-a7f3024f53fe">1,102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTItMy0xLTEtNTgwNzc_13eed775-9977-415f-821e-fa7d11a02822">1,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTQtMS0xLTEtNTgwNzc_79cb9aa0-5b67-402c-89ac-8a1965fd2547">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTQtMy0xLTEtNTgwNzc_62c98c83-b548-493c-815a-2fbef82d5186">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTUtMS0xLTEtNTgwNzc_ca0def20-53bd-4bd3-b1f3-0bdabaf93993">217,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTUtMy0xLTEtNTgwNzc_9b89f8a1-7329-49fa-ad20-585e80d5a843">190,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTgtMS0xLTEtNTgwNzc_31a13f1c-7056-481a-af4a-fe63873bcb1c">10,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTgtMy0xLTEtNTgwNzc_435dffc6-8377-4064-a9cc-381108a676a8">10,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTktMS0xLTEtNTgwNzc_8661ae48-b153-40a7-aff1-d6b6ea1139ef">5,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTktMy0xLTEtNTgwNzc_b984b407-dc68-4293-b26f-d8b3ff8c65f1">7,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjAtMS0xLTEtNTgwNzc_8f86646f-cbb0-48a1-88aa-f48b2d3ff30b">26,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjAtMy0xLTEtNTgwNzc_944f32e6-24ab-4118-afc8-9e6ff2d7f1ca">26,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjEtMS0xLTEtNTgwNzc_65f4e5e0-f308-4152-b093-3c3a2f3dce9d">3,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjEtMy0xLTEtNTgwNzc_e2191630-5005-4636-b01d-f9d917992a1f">3,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjItMS0xLTEtNTgwNzc_39f601b6-6833-4735-9690-db29618ce322">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjItMy0xLTEtNTgwNzc_b4b24c00-a1e7-4a88-b1ba-1d822f28cdcd">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjMtMS0xLTEtNTgwNzc_0ffbaff3-5e70-4594-922c-ea14d12c7df2">11,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjMtMy0xLTEtNTgwNzc_c98520ff-7fdb-4f89-92fd-24668bb7effd">12,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjQtMS0xLTEtNTgwNzc_cc53fbca-01e1-4c10-8193-6697415e8002">63,063</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjQtMy0xLTEtNTgwNzc_54ca7a0c-2393-490b-afac-946f8645fdb6">65,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjUtMS0xLTEtNTgwNzc_40155aa3-aa66-4fd3-a37d-84e8603fea1e">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjUtMy0xLTEtNTgwNzc_d821884d-520a-4132-a414-490900ed314a">5,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjctMS0xLTEtNTgwNzc_e13288b2-3cf6-40e9-9645-8aa084cb0a68">11,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjctMy0xLTEtNTgwNzc_7b6d3f8c-4fed-422c-ae9f-d930f5897c26">9,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred royalty obligation related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:DeferredRoyaltyObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjgtMS0xLTEtNTgwNzc_7da3ddbc-fffe-4211-88b8-ee36ba0321d8">12,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="ardx:DeferredRoyaltyObligationNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjgtMy0xLTEtNTgwNzc_8eb5979d-0c77-45eb-8f2a-935dc59336f9">11,254</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjktMS0xLTEtNTgwNzc_a7604d67-7e88-4584-9b31-4a8680753027">91,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjktMy0xLTEtNTgwNzc_472764ac-6b28-4114-84e2-981d671cfa40">91,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 14)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzAtMS0xLTEtNTgwNzc_063e9f61-1376-4b1c-8bf0-0c26acb1c9de"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzAtMy0xLTEtNTgwNzc_e63264d9-71fa-478a-962a-66e3190f08cf"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8yMQ_b47a075e-6f92-475a-b045-53f6d9a9e113"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8yMQ_dcc0866f-bf97-49d7-9172-7a3141f00633">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8zNQ_42663b23-4ae4-4da0-8b5c-a9e0e9765a64"><ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8zNQ_5f57dc06-fdd8-437c-8324-63b548b44ce4">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_0a4e1da7-a045-413f-859e-151f5c575888"><ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_5565429f-169d-48a5-9d42-6901dc2ad5a4"><ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_82e719a2-e5fc-4946-a871-559e5ae2083d"><ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_8e53936d-6336-447b-9e08-a2feb455e9d6">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMS0xLTEtNTgwNzc_2c34cee4-611d-4e1f-926a-47b46a8f3cbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMy0xLTEtNTgwNzc_8f43e5a9-42a3-47c7-8c32-d957463fdd20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8xOA_015b392e-7742-4c68-8e19-7cc945a0b02b"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8xOA_7e6415b5-d0cf-4c56-b2ec-841f181f8fa6">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8zMg_42a21d41-9850-41a8-be1f-40b51bfc6a59"><ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8zMg_d49902d9-4af8-4695-9948-8be2c0a8d442">300,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF81NA_7dfd8ab6-b576-4b85-865f-35d9614f7197"><ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF81NA_94443183-748f-4409-96ba-a047d5d1d07f">214,462,050</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF82MQ_0239454d-86a7-4463-adbb-41ce4173945f"><ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF82MQ_fac2b182-b031-428e-829d-38dc1f6903b9">198,575,016</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMS0xLTEtNTgwNzc_512111dd-4ae9-411c-a941-57e68f1e4714">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMy0xLTEtNTgwNzc_7282df36-407b-4f2c-90d7-fc83ec6995cc">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzQtMS0xLTEtNTgwNzc_f1e119c5-99e9-4e91-af1e-81d9e4f1d520">932,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzQtMy0xLTEtNTgwNzc_daddcbce-2f7d-4f8a-89dd-e21fc9964c51">878,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzUtMS0xLTEtNTgwNzc_e24863ca-f9db-48c6-856e-34214cf29d0f">806,910</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzUtMy0xLTEtNTgwNzc_9afdec92-2693-446c-a605-cec6c8034388">780,137</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzYtMS0xLTEtNTgwNzc_7a650600-1665-441c-8a5e-d51499a561ad">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzYtMy0xLTEtNTgwNzc_ccdcd9c2-33fb-4733-9a09-9bfe20bcbbb1">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzctMS0xLTEtNTgwNzc_235dbf6c-245f-496d-928a-2ac23132dc45">125,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzctMy0xLTEtNTgwNzc_79e2115a-b6e0-49c4-b411-67a91660e2ee">98,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzgtMS0xLTEtNTgwNzc_d8277279-7095-4657-93f3-df10d237a364">217,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzgtMy0xLTEtNTgwNzc_fc09f755-46a5-4727-8d16-80cc97ed6c2e">190,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.789%"><tr><td style="width:1.0%"></td><td style="width:70.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.909%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.911%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fb93e39ef444d8695c887cc09b73b80_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMy0xLTEtMS01ODA3Nw_728dab60-d64c-4326-ace6-51eae7fd246b">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2066d1e80c264bcd99c9924963c7c7a2_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMy0zLTEtMS01ODA3Nw_8b42a534-f6e1-47c9-b4b3-dc036630f0f9">450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3856b2b0524045fc9db6e2c44a8cf2c2_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNC0xLTEtMS01ODA3Nw_94e07c5a-904e-406d-82d3-e6bf17dedf06">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad51cff0cb0e45ad810a4a4575f2c6c1_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNC0zLTEtMS01ODA3Nw_a3295653-f419-4b48-94a6-0d49028cb89d">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea4a8d7b8d644fb08f9938d356a671ec_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNS0xLTEtMS01ODA3Nw_264a3e9c-15c2-405b-9548-c2076f6c73ac">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a79ad494fe042bdbf346769d0ee7b48_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNS0zLTEtMS01ODA3Nw_59f407be-a4a3-4e0a-a492-46c5e9f18f9f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNy0xLTEtMS01ODA3Nw_7295421c-1870-4678-af2b-e4e1be03e938">11,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNy0zLTEtMS01ODA3Nw_344fa0e6-8662-4b22-8ad9-9381597a83ee">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfOS0xLTEtMS01ODA3Nw_ed655b57-57b9-4b86-a770-320a1cae9350">1,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfOS0zLTEtMS01ODA3Nw_c7e38098-5d63-44b6-b5df-82982dd44fc7">85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTAtMS0xLTEtNTgwNzc_d0b4414d-4320-4f12-8486-484d9dd81874">9,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTAtMy0xLTEtNTgwNzc_60b7d2b2-1ddb-492c-af80-d355fe660d80">8,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTEtMS0xLTEtNTgwNzc_eb59048e-07b7-4916-a646-778b77223d4c">26,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTEtMy0xLTEtNTgwNzc_4d183b41-e560-4714-aecc-b71968ece81e">19,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTItMS0xLTEtNTgwNzc_e19a9c05-cbcc-4ee8-800b-381df76fe988">37,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTItMy0xLTEtNTgwNzc_1bbc15af-5e50-4cc8-82b9-7b22beb28495">28,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTMtMS0xLTEtNTgwNzc_b8fe71c0-1f73-4c2e-bd30-3d771303c3e0">26,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTMtMy0xLTEtNTgwNzc_6bc80542-9ad9-4136-9611-d98709c9543b">27,807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTQtMS0xLTEtNTgwNzc_5ce7b6ed-8f13-44d9-b752-75a8773ea534">1,028</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTQtMy0xLTEtNTgwNzc_1d584563-aa9b-4485-abe6-93835f4c1683">746</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfAdvanceRoyalty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTUtMS0xLTEtNTgwNzc_b340ae10-b2f7-463b-84b4-b785e221a3d4">969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfAdvanceRoyalty" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTUtMy0xLTEtNTgwNzc_956750e7-67c7-4e61-ab98-6dc7b6fd3e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTYtMS0xLTEtNTgwNzc_f8b8e482-e7cc-4e36-8d78-0277b01765ba">1,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTYtMy0xLTEtNTgwNzc_5dab9210-ea2c-42cd-bd10-76f7fcf1ba3e">484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTctMS0xLTEtNTgwNzc_ded7d8e5-1887-46f7-9c61-b163497b4392">26,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTctMy0xLTEtNTgwNzc_65131862-785a-4017-a981-4fc1027293bb">28,069</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTgtMS0xLTEtNTgwNzc_1bd99c3a-2c12-41e6-88d8-6e2bdd97f123">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTgtMy0xLTEtNTgwNzc_c291eb8d-544e-420d-91f6-85d2fd3724ae">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTktMS0xLTEtNTgwNzc_e4d5b482-947f-4e05-a6dc-9769a1fd3ccf">26,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTktMy0xLTEtNTgwNzc_26fc15c3-c0d1-4c82-b442-9cf0dbb30cfa">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of  common stock - basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMS0xLTEtNTgwNzc_575bbec2-5877-4464-bd98-8f8a146a7c70"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMS0xLTEtNTgwNzc_bdc2aa34-2b87-4883-aff9-4d4797747afd">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMy0xLTEtNTgwNzc_8d255744-bcfa-454f-8b32-4796fbf6236b"><ix:nonFraction unitRef="usdPerShare" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMy0xLTEtNTgwNzc_9a4941f5-c124-496c-a43d-c85cb01cc45e">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per share - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMS0xLTEtNTgwNzc_5fe20d64-f214-4bc5-82aa-d1a0eb5ae0e2"><ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMS0xLTEtNTgwNzc_6a733c5a-b97e-441c-9141-7b355dd86683">207,023,127</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMy0xLTEtNTgwNzc_567004c8-8db7-47fd-8168-584c90d1e984"><ix:nonFraction unitRef="shares" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMy0xLTEtNTgwNzc_94bc9076-4bc7-46cd-8f98-228558b0c9cb">130,934,795</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjMtMS0xLTEtNTgwNzc_4e43641e-eb26-433c-8932-da1540d68b77">26,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjMtMy0xLTEtNTgwNzc_5e935bf5-3fc9-45d7-b1d2-98e7d59f6875">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjQtMS0xLTEtNTgwNzc_684a1ae7-016c-458c-8c99-b1552198dc6b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjQtMy0xLTEtNTgwNzc_491cf5d6-febf-4b56-bf41-a4be9d188b54">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjUtMS0xLTEtNTgwNzc_ea075c9b-fbc8-4e23-b635-562d67ac9bf7">26,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjUtMy0xLTEtNTgwNzc_ae6a399a-ba27-4554-a21a-3c79137d421c">28,153</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Three Months ended March&#160;31, 2023 and 2022</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except shares)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5bfad961f86457581b6f4e9d7d22270_I20221231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy0xLTEtMS01ODA3Nw_084513f0-1dab-4695-8cce-fa841264d14f">198,575,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5bfad961f86457581b6f4e9d7d22270_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy0zLTEtMS01ODA3Nw_8a5273b6-6c32-47e4-a587-4cb22609f9a1">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49fc5e3d4b4f406d86613fc88394fa6d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy01LTEtMS01ODA3Nw_df7a9715-7f4e-456e-8613-73909d521e66">878,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5db9eb9e722e416eb7e2bf74dcb73ce3_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy03LTEtMS01ODA3Nw_e0ca0ab7-26ba-4195-8b18-7ae94d8edcfd">780,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2a18458262545e9818256bcffdfdbe9_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy05LTEtMS01ODA3Nw_b88dd74a-445a-4208-a7fb-e6a6e7af166a">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy0xMS0xLTEtNTgwNzc_7130bb3b-325d-4b30-bb77-32e13dd50dd0">98,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNC0xLTEtMS01ODA3Nw_1f366df6-40fa-4fcd-8425-c3bab352efe1">165,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNC01LTEtMS01ODA3Nw_3a520d09-3740-4a12-90f3-e7509423f374">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNC0xMS0xLTEtNTgwNzc_5d5f4784-b04a-4f00-b67b-dcc2aa0792e9">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNi0xLTEtMS01ODA3Nw_cafad80e-5c91-4119-b7ed-53d87a2e7191">36,001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNi01LTEtMS01ODA3Nw_e02d6b6b-b8d9-4d3d-9941-7440230ae5a1">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNi0xMS0xLTEtNTgwNzc_71aecd0c-8a7d-4fef-9b00-e8ae31324548">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNy0xLTEtMS01ODA3Nw_35e8fc16-2afc-4a25-9122-93d2615157f2">207,773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS0xLTEtMS01ODA3Nw_2c453ec8-d548-4c01-a8f6-2d1d609bdbad">15,477,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS0zLTEtMS01ODA3Nw_dd9e4236-9f1f-4b44-9a68-c6fbcc67ae06">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS01LTEtMS01ODA3Nw_cfae60fd-55b3-4a5d-a093-dec24628da0d">50,718</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS0xMS0xLTEtNTgwNzc_76c5d9a0-709a-4f1a-b195-c131354451a7">50,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTAtNS0xLTEtNTgwNzc_1fa03708-ff50-4364-bece-ab30aa48ef8a">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTAtMTEtMS0xLTU4MDc3_ff5b0558-4c20-47fe-b3b4-2e14a8f6a531">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2922df2535ca423a89973f8f65fca675_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTEtOS0xLTEtNTgwNzc_9f54ecfb-e405-48f0-be8e-541cb84f702d">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTEtMTEtMS0xLTU4MDc3_64d57c57-0ee5-4839-a7f3-412f091539be">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95d3925bde5c401ca56d5a208ae6d39b_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTItNy0xLTEtNTgwNzc_c5ef3707-2938-4c2d-8dec-5e388543d5ad">26,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTItMTEtMS0xLTU4MDc3_fd7c5f82-67c5-4925-8877-f96fecc0744d">26,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3b66658c70174c7b964c4278cadb803b_I20230331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtMS0xLTEtNTgwNzc_71e71d62-b7d3-4bbb-a04c-9c4e575c00fe">214,462,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b66658c70174c7b964c4278cadb803b_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtMy0xLTEtNTgwNzc_ba44b822-68b6-46d9-af6c-274f1c5a017f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b50ab59575f44aab60c0aaa8d0ca9f7_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtNS0xLTEtNTgwNzc_e30465ea-d89d-4af9-860f-760b76a6d855">932,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i96ca73985d3c4d82b3a1980bbe2e8e76_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtNy0xLTEtNTgwNzc_c82b57bd-ede3-420b-9086-6c0172af8c30">806,910</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52f0e7c126f849cc86ce9adbfbd89603_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtOS0xLTEtNTgwNzc_b623f48d-bb00-4e9b-9f2f-e926a9178151">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtMTEtMS0xLTU4MDc3_68b3c191-0b11-43c4-b5d5-0d55c3e7b046">125,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"></span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:27.913%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.651%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.654%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4732bae904484aa5a7c90237b85d7ac9_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy0xLTEtMS01ODA3Nw_f2e6a3d0-0df7-4649-820e-103aab5701de">130,182,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4732bae904484aa5a7c90237b85d7ac9_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy0zLTEtMS01ODA3Nw_9c6b48d5-e58a-469a-8bbc-e854c2cd0223">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4bd3bd1b1284974bcdb1a2b8b9df930_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy01LTEtMS01ODA3Nw_65e58832-7819-4c29-aaee-1c237f6111ab">795,540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic18098bd479c463a8c870397cfa95c5e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy03LTEtMS01ODA3Nw_560892e5-78e7-432c-a819-ec3b3ad85752">712,930</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4809599b3f643b0b0ebea13fe0a5062_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy05LTEtMS01ODA3Nw_9f9c3664-d928-421f-9303-09fe72113a6b">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f50508ad334e6eb7ed23017eb62096_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy0xMS0xLTEtNTgwNzc_3a5ef842-ce87-4e17-8558-d1ac79dc7a0c">82,617</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNC0xLTEtMS01ODA3Nw_cd759762-124b-459a-aab3-a97bf7ac35e5">127,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if280f015aeed4a60931d60002bd4d221_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNC01LTEtMS01ODA3Nw_4b7b39d3-3339-43bb-b102-30046170ee62">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNC0xMS0xLTEtNTgwNzc_92edd8d1-ad03-4961-b41a-89369493ac21">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon vesting of restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNy0xLTEtMS01ODA3Nw_2f9b58e7-4da9-48f9-b744-f2331203612e">113,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock in at the market offering</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS0xLTEtMS01ODA3Nw_cfdc3dca-5f07-4119-b3c4-90bb7569ece1">5,907,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS0zLTEtMS01ODA3Nw_06d4d601-2b33-42a5-ae51-389c875c45b3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if280f015aeed4a60931d60002bd4d221_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS01LTEtMS01ODA3Nw_c6c7b271-bd21-495f-99ad-acafa97e5163">5,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS0xMS0xLTEtNTgwNzc_a9abde45-efc4-4a9c-aa3c-49acd32edc23">5,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if280f015aeed4a60931d60002bd4d221_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTAtNS0xLTEtNTgwNzc_74eb2242-684e-4522-aa59-928d138db604">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTAtMTEtMS0xLTU4MDc3_a9aa88c4-17c6-4e11-9ced-e4e88f47345e">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57175b056d77462ea9709d3fefc23984_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTEtOS0xLTEtNTgwNzc_1c151cfe-0b5f-4f2f-a04f-314dfa58da2d">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTEtMTEtMS0xLTU4MDc3_9480c1a1-2f03-48b5-ab2e-80fe7094afa3">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i61e2e4a4f64d40aab8d29960cdd46227_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTItNy0xLTEtNTgwNzc_aa657dca-fef2-40f1-ab2a-b4b5b4af4905">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTItMTEtMS0xLTU4MDc3_a53ef67b-4110-40d3-9fe6-c241023007a7">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance as of March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id804dfa2f8bf4491961e64ab1900b30b_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtMS0xLTEtNTgwNzc_af0c79f5-f1a3-45a3-904e-e87c54bbb923">136,330,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id804dfa2f8bf4491961e64ab1900b30b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtMy0xLTEtNTgwNzc_c602d32b-72b2-45b7-9a27-a3e91ed9d14e">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a28be02017a44cf8e2c9f9690207ec4_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtNS0xLTEtNTgwNzc_6e77b08d-dbb4-49b3-b7f6-74715bbfe545">805,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c831a5fa23047d39e1d3768ebd72dfa_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtNy0xLTEtNTgwNzc_ad9af0a7-4185-4cad-bcab-cf587cf4e692">741,001</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie5547c702f0548338c9eda648f780448_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtOS0xLTEtNTgwNzc_1971bb7d-e9a5-4498-92ef-2ec814af4f3c">88</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702563bc994044d4830a60b075943f6b_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtMTEtMS0xLTU4MDc3_505d691a-4303-4be6-88d9-1e0acf472af6">64,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMy0xLTEtMS01ODA3Nw_2f46fb96-0926-4f0a-8633-983dfdb6bff6">26,773</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMy0zLTEtMS01ODA3Nw_3d9637cf-a049-4365-897d-f78013ffa928">28,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNS0xLTEtMS01ODc5Nw_a2dd6376-6407-49c2-99f0-581ceec21dbf">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNS0zLTEtMS01ODc5Nw_c33a795e-8a78-4284-bf4d-8722ba909bdf">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNi0xLTEtMS01ODA3Nw_c5ffb626-6456-4622-b1be-e4135636491c">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNi0zLTEtMS01ODA3Nw_0bb06b2a-b262-4f23-87fd-7f07f6cf870e">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNy0xLTEtMS01ODA3Nw_06c54d1f-970c-488e-94c1-15d8b37fa656">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNy0zLTEtMS01ODA3Nw_4c7ffc98-7255-4964-a486-5f5f7415f3fc">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in derivative liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOC0xLTEtMS01ODA3Nw_176c197e-63bc-4492-973e-52089fb3a642">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOC0zLTEtMS01ODA3Nw_9f04b969-511d-42fd-966e-b7ba7f8e59a2">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt refinancing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:GainsLossesOnRestructuringOfDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOS0xLTEtMS01ODA3Nw_ffb63b63-d8a6-4586-8189-91267c633622">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainsLossesOnRestructuringOfDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOS0zLTEtMS01ODA3Nw_c42fa6ab-4ded-4243-85ef-4976259a6e9a">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTAtMS0xLTEtNTgwNzc_71981d99-0fda-4b70-9c76-ae771dac50ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTAtMy0xLTEtNTgwNzc_8f4ddb3e-f8fb-4972-a1ec-b75d0493f55a">710</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of long-lived assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMS0xLTEtNjAyODI_76440837-1e43-4162-9bd3-7c237569b62c">429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMy0xLTEtNjAyODI_c57dd955-3a7c-4aa8-87e0-4eaea9eb8c5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMS0xLTEtNTgwNzc_71b9605b-bb78-4d85-a3e6-df417844c3b8">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMy0xLTEtNTgwNzc_8129db3d-1f64-43a2-b020-33c8a321da82">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTQtMS0xLTEtNTgwNzc_148adc5b-da25-4c14-b820-30dd98ba9631">4,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTQtMy0xLTEtNTgwNzc_5ac856d8-dcaf-4af8-a4f0-b6ad10a8cb59">3,892</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTUtMS0xLTEtNTgwNzc_332547b1-056e-40b4-ba99-9b71a6729225">16,601</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTUtMy0xLTEtNTgwNzc_9a284503-f428-4f01-be3f-ced541999a6a">3,487</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid commercial manufacturing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTYtMS0xLTEtNTgwNzc_7e702fc1-1611-4640-849a-b81ffe6e85a2">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTYtMy0xLTEtNTgwNzc_0bb351aa-fdb9-4b4e-8276-d76c4401a643">9,393</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTctMS0xLTEtNTgwNzc_859467db-5956-4371-b9ec-c033f1ef298b">774</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTctMy0xLTEtNTgwNzc_21f0147b-3dab-4dff-ba51-a9cf006b40e1">9,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTgtMS0xLTEtNTgwNzc_d9af6da4-7a8b-4677-8f5b-cd4515cbcef1">346</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTgtMy0xLTEtNTgwNzc_c2e47f68-3bc6-4f60-8be3-fa7f3de7e14b">753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTktMS0xLTEtNTgwNzc_07b799df-ef93-43a3-b9f4-aec3a4cc7057">2,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTktMy0xLTEtNTgwNzc_5ab20f63-21a4-4d96-a49e-95356c49662c">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjAtMS0xLTEtNTgwNzc_f407a33e-3a61-482c-ba4e-a2e805f2cbcb">937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjAtMy0xLTEtNTgwNzc_659798cd-adc0-47aa-a5be-1e972115579b">836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjEtMS0xLTEtNTgwNzc_25423668-3f7f-449f-bfe7-369adb889bf2">1,396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjEtMy0xLTEtNTgwNzc_2f31dbd0-7f32-4a00-ac4a-e3a054750c63">1,041</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjItMS0xLTEtNTgwNzc_b73ae2ea-5ce5-49fb-b60b-32d4d6989bcd">3,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjItMy0xLTEtNTgwNzc_e01d9550-a950-40b1-91a5-705cde0b5e44">3,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjMtMS0xLTEtNTgwNzc_30cc39f4-b2b4-4658-9e42-69a2faeae3ef">44,795</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjMtMy0xLTEtNTgwNzc_d4210a47-42e0-41f9-95f7-c72e26c7f4d8">27,620</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and redemptions of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjUtMS0xLTEtNTgwNzc_e38803b7-ac80-4563-a0f6-08eb835bfe1b">11,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjUtMy0xLTEtNTgwNzc_9d86404b-8a96-4a9c-a761-5e0a2a4ffe7a">27,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjYtMS0xLTEtNTgwNzc_2016697c-95ee-4391-9eda-fa4477f744f9">20,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjYtMy0xLTEtNTgwNzc_b3a98e6e-bfe6-4cd4-b271-553a97fb1bb8">25,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjctMS0xLTEtNTgwNzc_cbfd944f-5ad3-40e0-a0d4-366384c329a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjctMy0xLTEtNTgwNzc_cc8821e3-8f32-41db-b3fb-a3a6d5b3349d">795</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjgtMS0xLTEtNTgwNzc_c1453d7a-832f-491a-9434-4ee59c8f8f25">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjgtMy0xLTEtNTgwNzc_f4d3752e-ae40-453f-bee4-b0ad11d241d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjktMS0xLTEtNTgwNzc_fbbdf827-9de6-4f27-a557-f02e6d369222">9,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjktMy0xLTEtNTgwNzc_f9cbf7d7-56c5-4aca-9304-a32beff30cc3">2,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from 2022 Loan, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzEtMS0xLTEtNTgwNzc_d6a65a97-c45a-4d55-96f5-90ccead7624b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzEtMy0xLTEtNTgwNzc_0cc472c6-8d94-46f0-b741-81b7376c57b2">26,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for 2018 Loan, net of costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzItMS0xLTEtNTgwNzc_04d3e45f-4336-46ed-8479-dc7d3d63ed3c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:RepaymentsOfSecuredDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzItMy0xLTEtNTgwNzc_65d719a3-3731-43be-a45b-c36d942c9c4f">33,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in at the market offering, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzctMS0xLTEtNTgwNzc_4b4eeee2-e4cb-46d4-b7a8-e893c47fc4d6">50,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzctMy0xLTEtNTgwNzc_35f8bfe9-14c2-41ad-bbfa-a46b38d92aac">5,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzgtMS0xLTEtNTgwNzc_7f8ed64b-1047-4b94-9a17-a0ffc281d3c9">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzgtMy0xLTEtNTgwNzc_cc33b33e-9fe6-4322-9e6e-72a87b5a8876">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDEtMS0xLTEtNTgwNzc_1c0986dd-758c-46d8-ba9d-7dc6c176d7ec">50,919</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDEtMy0xLTEtNTgwNzc_27de5b3c-19a1-4da9-a27e-13bc8e137bac">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDItMS0xLTEtNTgwNzc_b7860fd8-1a1b-4c76-8618-a7679ba7dbb5">3,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDItMy0xLTEtNTgwNzc_545bd496-e25f-43ac-abfc-a8e40c42812c">25,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDMtMS0xLTEtNTgwNzc_526a6dde-077a-4b12-aa7c-c739abe9e125">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87f50508ad334e6eb7ed23017eb62096_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDMtMy0xLTEtNTgwNzc_1959cc41-1a9e-4dc1-aa2e-6ea7d94d70fb">72,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDQtMS0xLTEtNTgwNzc_187a050c-7def-4dd5-9e15-c292e62d2b9a">92,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i702563bc994044d4830a60b075943f6b_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDQtMy0xLTEtNTgwNzc_daa91035-ac84-45d1-bcdb-1c27a5275f5b">47,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDYtMS0xLTEtNTgwNzc_cd6435d6-e048-43cc-aa83-d969c7fa83d3">860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDYtMy0xLTEtNTgwNzc_6531fc4b-7dd2-46d1-ba2f-bf6baae20b6e">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDctMS0xLTEtNTgwNzc_8cfe2e8f-190c-4c52-b8d7-c191ee829c77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDctMy0xLTEtNTgwNzc_c96dd1a5-3819-4b4b-8b1e-cada3708da0b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Supplementary disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of derivative in connection with issuance of loan payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="ardx:DerivativeIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNTEtMS0xLTEtNTgwNzc_0ed73fc5-6c3c-4113-963f-3276d7de290c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="ardx:DerivativeIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNTEtMy0xLTEtNTgwNzc_27252d43-ecd5-41b6-bf59-4af444aea910">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARDELYX,&#160;INC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(amounts in thousands, except per share amounts and where otherwise noted)</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_34"></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTc_f10db0d7-8e1f-4dcd-959d-a643dd9a4378" continuedAt="i9009ea7244df439abca437ebb24583f2" escape="true">ORGANIZATION AND BASIS OF PRESENTATION</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><ix:continuation id="i9009ea7244df439abca437ebb24583f2" continuedAt="i7611a3c9260643adbece89f299d1a1aa"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (&#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). In April 2023, we resubmitted a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the approval of XPHOZAH (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy, under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery phase asset, RDX020 for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMjg5_372dbe63-ae23-47bc-a40b-52efaec57140">one</ix:nonFraction> business segment, which is the development and commercialization of biopharmaceutical products.</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTg_f56ea377-31e7-45c5-a5a5-b655199b8d96" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2022. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2023, or for any other interim period or future year.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTI_88b8127e-9b5d-4f55-94ed-9b45fcf5f554" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of approximately $<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-5" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMjQ0OA_f0485ceb-8e9f-499f-ad78-5100c448dafd">130.4</ix:nonFraction>&#160;million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of March&#160;31, 2023 is $<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMjU0Mg_8bc1570c-5cf9-476a-a847-acac008f4871">806.9</ix:nonFraction>&#160;million. Our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these condensed financial statements on May&#160;3, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these condensed financial statements. We plan to address our operating cash flow requirements with our current cash, cash equivalents and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, our potential receipt of anticipated milestones payments from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i7611a3c9260643adbece89f299d1a1aa"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash, cash equivalents and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 2 to our audited financial statements for the fiscal year ended December&#160;31, 2022, included in our Annual Report on Form 10-K. There have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTU_cc44aff9-1486-45dc-9202-b66f4a4f59f5" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements subsequent to filing our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="iea6a0b1ea655406093eb9e951c03313e_37"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfMjMxMg_ef014fbb-f129-4a12-ab14-a6a1becccedd" continuedAt="idd461e2b73de4eb6b2c27747ac40df52" escape="true">CASH, CASH EQUIVALENTS AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="idd461e2b73de4eb6b2c27747ac40df52" continuedAt="i7f800fdc64634c83a35ea0c9a5f27cda"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfMjMxMw_3ce4c2f1-37f8-4065-b9b2-5e7668181d95" continuedAt="i2ba80432592a4cb6a5a20d42ea41a9ee" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and short-term investments as of March&#160;31, 2023 and December&#160;31, 2022 are summarized below (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.914%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.416%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d688e400e645008fb72d473b88ac99_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNC0xLTEtMS01ODA3Nw_3755db2f-9ff3-438a-b7d9-94326e7226cd">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0d688e400e645008fb72d473b88ac99_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNC03LTEtMS01ODA3Nw_09f1bac5-8777-47b3-a0f1-9a73ab621d30">7,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic936e46468054162a36dcf4e97de128d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNS0xLTEtMS01ODA3Nw_3492fe7f-847d-44b0-81a6-8a804f6c8ea4">84,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic936e46468054162a36dcf4e97de128d_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNS03LTEtMS01ODA3Nw_70d1b3e6-063e-4d71-b18e-4d750b845ec7">84,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfOC0xLTEtMS01ODA3Nw_630c3578-afdb-4045-8b70-a25bd9da745d">92,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfOC03LTEtMS01ODA3Nw_6c799c0f-cc04-48fd-a24a-5320f3fc6478">92,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtMS0xLTEtNTgwNzc_f8c558b1-8c7f-460b-ba07-0653de14e3af">23,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtMy0xLTEtNTgwNzc_4639b065-fd3f-4f35-afc3-b9633d40b2f1">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtNS0xLTEtNTgwNzc_e434b322-a2bd-4e0e-8e88-fac8515d854e">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtNy0xLTEtNTgwNzc_36becf21-8640-4956-b499-2f95b243b18e">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie631368284b2408aad835684afa02e95_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtMS0xLTEtNTgwNzc_42af485b-8e00-473e-8474-8dd4e980a3c9">12,618</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie631368284b2408aad835684afa02e95_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtMy0xLTEtNTgwNzc_ce9fa4c2-5091-44eb-9908-ef92a7911035">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie631368284b2408aad835684afa02e95_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtNS0xLTEtNTgwNzc_bf19b186-f02f-46b6-8d7a-341eafa78206">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie631368284b2408aad835684afa02e95_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtNy0xLTEtNTgwNzc_799f3515-3394-46e6-9ca9-acb27183fdf3">12,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0524220fccc7435abcb990a758edda9f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtMS0xLTEtNTgwNzc_a87462ab-208a-493a-a576-748cb1929811">1,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0524220fccc7435abcb990a758edda9f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtMy0xLTEtNTgwNzc_ced05eb3-208d-4747-b75d-ca72bea117c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0524220fccc7435abcb990a758edda9f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtNS0xLTEtNTgwNzc_1107a2b7-6cb2-439a-bf62-f84f29d3b0ae">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0524220fccc7435abcb990a758edda9f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtNy0xLTEtNTgwNzc_2f0c0556-58c7-4fcf-adec-0851ef80a016">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtMS0xLTEtNTgwNzc_c7a3cd85-ef4a-44a1-9e0e-4df9deb7cb1d">37,906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtMy0xLTEtNTgwNzc_5d45bd7f-7c08-4668-bef6-6c75dc10b14d">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtNS0xLTEtNTgwNzc_f1526a52-d0bf-480f-bffc-4bcbebade49a">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtNy0xLTEtNTgwNzc_51f25b37-516e-4b88-8acc-5b20329eeee3">37,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtMS0xLTEtNTgwNzc_594a98e6-3f4c-4bb4-8129-1be505bdcc04">130,393</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtMy0xLTEtNTgwNzc_adff7718-2865-4943-8aef-5d9301a06898">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtNS0xLTEtNTgwNzc_5ceda6d2-e77a-4ffc-a824-3e4dfbee7d50">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtNy0xLTEtNTgwNzc_43115a44-b8d3-4d2c-9828-777112fd71b4">130,373</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i7f800fdc64634c83a35ea0c9a5f27cda"><div style="text-align:justify"><ix:continuation id="i2ba80432592a4cb6a5a20d42ea41a9ee"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.075%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id884382c6adf4ee689a124f5a304b668_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNC0xLTEtMS01ODA3Nw_da30f8a7-6461-4903-87c0-9a5766184ae8">11,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id884382c6adf4ee689a124f5a304b668_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNC03LTEtMS01ODA3Nw_60de364b-503d-40a5-96e8-b13b4a47fd03">11,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d87663204949f4982bae6de6a652c0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNS0xLTEtMS01ODA3Nw_f1e417c7-c2b4-4056-9890-daf3446206c4">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0d87663204949f4982bae6de6a652c0_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNS03LTEtMS01ODA3Nw_e6149b42-ab1c-4105-a0b5-b1d9bfe86251">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfOC0xLTEtMS01ODA3Nw_902eb8fb-93aa-4651-9bc0-5540f9720e43">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfOC03LTEtMS01ODA3Nw_5017b2dd-285c-4594-9a10-ee2a568e84ef">96,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtMS0xLTEtNTgwNzc_63bd9c3b-aa46-4210-bc4f-53bc49834e0d">25,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtMy0xLTEtNTgwNzc_61cfea11-c751-4fc0-a9c7-1f1415815ca9">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtNS0xLTEtNTgwNzc_565c5768-46c2-4d48-bf0e-54ec089a81e3">51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtNy0xLTEtNTgwNzc_b48a53c6-b50e-4eff-a2df-255d20c3e80d">25,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtMS0xLTEtNTgwNzc_a4cdb1bd-d710-4717-94e6-6ec3db6dc70d">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtMy0xLTEtNTgwNzc_e1b4b639-7e0f-485d-b5b7-e1f92f35dda2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtNS0xLTEtNTgwNzc_c43560d3-5e41-4669-8744-94ab16de4824">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtNy0xLTEtNTgwNzc_520497f3-9d65-4f41-9148-096beda42be7">999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItMS0xLTEtNTgwNzc_588af114-6d8c-4652-b6c4-98aef41e4237">1,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItMy0xLTEtNTgwNzc_943264b7-c78a-4faf-96d3-fe9800d62091">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItNS0xLTEtNTgwNzc_54e1ec8f-b02c-4325-b3aa-3811d060d41a">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItNy0xLTEtNTgwNzc_375fd65b-4d11-4c76-83f3-df27de3e5c5a">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtMS0xLTEtNTgwNzc_1d0b3e37-1f80-44d5-8414-0a551716f03f">27,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtMy0xLTEtNTgwNzc_84dece6b-258b-4035-b0bd-b8fc6e0a7d22">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtNS0xLTEtNTgwNzc_6d54c3dd-d821-4665-915e-98ba1a6e040d">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtNy0xLTEtNTgwNzc_ae15b541-d1a0-419b-ab72-8caacf7a28ac">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="ardx:InvestmentsAndCashAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctMS0xLTEtNTgwNzc_6ffbbbb7-cf96-429d-98d6-ec001c3d3890">123,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctMy0xLTEtNTgwNzc_1313d5cd-f6e1-4089-bbd9-963f18b43f10">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctNS0xLTEtNTgwNzc_2b7ef108-826e-4a23-bb09-98c8b74b521d">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctNy0xLTEtNTgwNzc_b122c032-8923-4a24-840b-f4a2692022e0">123,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive loss within stockholders&#8217; equity on our condensed balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income, net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the short-term available-for sale securities held as of March&#160;31, 2023 and December&#160;31, 2022 had contractual maturities of less than <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODE5MjU0_67959fd0-591b-456f-904d-cb82e4dbe212"><ix:nonNumeric contextRef="i702ac6a7149a4273b8841d440aaca4c1_D20220101-20221231" name="ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODE5MjU0_d170a811-9e0c-4903-b033-dec257e5aeb7">one year</ix:nonNumeric></ix:nonNumeric>. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired or subject to credit losses, we write it down through the statement of operations and comprehensive loss to its fair value and establish that value as a new cost basis for the investment. Our unrealized losses as of March&#160;31, 2023 and December&#160;31, 2022 were not material. We determined that none of our available-for-sale securities were other-than-temporarily impaired as of March&#160;31, 2023 and December&#160;31, 2022, and <ix:nonFraction unitRef="investment" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODIwMzM2_0d4d035f-a3f7-48fd-9d01-a4d45bf89e72"><ix:nonFraction unitRef="investment" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODIwMzM2_f2fc5fae-fdc8-429f-b629-0e5b8b3e003b">no</ix:nonFraction></ix:nonFraction> investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_40"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfMjU5MQ_f2f68bc4-841d-4ac8-8278-f409db34b82e" continuedAt="i77f050ba3b2f4ae7850ff7248c4d8404" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="i77f050ba3b2f4ae7850ff7248c4d8404" continuedAt="i1188d2c6c7d0426a890bcafd0a6caef2"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfMjU4OA_250fbc5f-dbe7-47f0-8ef9-40ccba390246" continuedAt="if1edd09fb26a40c39b14bfe8a4c36984" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i1188d2c6c7d0426a890bcafd0a6caef2" continuedAt="i82d98738bfff497c9661fb6eec8d56ed"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfMjU4OQ_741897bb-5c66-47bd-a884-748acb65ddf5" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if787129ae8904e9fa759cc369c4db88f_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy0xLTEtMS01ODA3Nw_f2d49633-6880-48f7-9c4b-98de16ff2b11">84,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iadea2dc595e045b693f4c3806a5d3b16_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy0zLTEtMS01ODA3Nw_24ad43bc-e02a-4d64-bfd6-15088079f538">84,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3daca4f51d947b5945b812330581364_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy01LTEtMS01ODA3Nw_07cbb4ef-355b-4026-9ba0-e893e3f4e361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a8b0761bd5415db96033f744c6140a_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy03LTEtMS01ODA3Nw_58949255-4346-4e59-9470-2ca4525da89b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c74497a62594f85876db914b650f7c4_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC0xLTEtMS01ODA3Nw_a7cbd015-ee33-4add-8ab0-0c8edbb606bf">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i588c4fa500554006860c6007e40ee0a5_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC0zLTEtMS01ODA3Nw_86d71c86-8ebe-488f-afc7-dee979eb57e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ad9611ed2ff4e919a234ed94bba8aed_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC01LTEtMS01ODA3Nw_9d2f51db-62f2-4c1d-a564-afc33a6df21b">23,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i883fa34c97c54813bb2d78e911d603f8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC03LTEtMS01ODA3Nw_bb8a18ef-a5d7-42ed-ad26-36f4979936b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide24937bdbc64ce28cc5e6cbfbd5e742_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS0xLTEtMS01ODA3Nw_bade551e-6393-4d8a-be4a-7e9556ce3087">12,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifaf58162db324fe59ce07df2c57faf57_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS0zLTEtMS01ODA3Nw_8b350d8c-43f4-4c20-934a-f67c865c07c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8afaa29db094d8f940e22612a879ea8_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS01LTEtMS01ODA3Nw_427b0020-846e-4583-b4dd-2c99533efa0e">12,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib68a978d30bb4163a635630e070edcb7_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS03LTEtMS01ODA3Nw_67ca3d4d-4f53-48b9-9a45-80739dd39b98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dda51aa0a8049d1968ca0f7b120ceef_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy0xLTEtMS01ODA3Nw_a8449a5f-95a4-4e8c-a43f-b2dcb4f699d1">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89592ca2da2742faaa3ad4dd4f55e876_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy0zLTEtMS01ODA3Nw_ecf35676-ec16-4f4e-a91b-caa6473f568b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9ba30f7b5548f8acfc7d00df9d940a_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy01LTEtMS01ODA3Nw_60d59a40-6e7c-4f15-930e-90909173419b">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4dece602bb7b484e80d6317ab479a4e9_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy03LTEtMS01ODA3Nw_f86bc9cf-0f7f-4db6-be60-45bb157db404">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7f44ca18fe47858c896bf995bca00b_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS0xLTEtMS01ODA3Nw_7408b24c-9aa7-4571-814d-3d2aec8e3c62">122,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766e68b72c6f4313991c6e312bae923e_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS0zLTEtMS01ODA3Nw_29b6d2d2-cf7e-4e55-b8bb-a68502244d38">84,501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad81d2394b2450fba8397056389cb20_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS01LTEtMS01ODA3Nw_a1b7c324-da13-4ef2-b247-1c15356ad98d">37,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803ae491ae4247699729cd6edb089399_I20230331" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS03LTEtMS01ODA3Nw_077a231e-c641-4c46-b8c2-072e43c96659">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19b484f382e14cee9bae114778c4b2ee_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItMS0xLTEtNTgwNzc_f4a31e52-cb90-4f49-b072-38c5212292bb">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e493e744f814e32a4f525d3b099f39a_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItMy0xLTEtNTgwNzc_729b1001-5367-4290-aadd-a5519161c49a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199726c1e7c64eed97aea0f720596607_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItNS0xLTEtNTgwNzc_dd28da0d-6bf6-4d3a-bee6-b27b0457b33f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45e32429d8b040ce8d79b9dde9e922f7_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItNy0xLTEtNTgwNzc_f2b9805c-d414-45f6-9c5c-bee68a8434fe">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab7f44ca18fe47858c896bf995bca00b_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtMS0xLTEtNTgwNzc_7df5211e-a80d-4bf3-9ec6-26d6ffb8545a">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766e68b72c6f4313991c6e312bae923e_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtMy0xLTEtNTgwNzc_00cb6429-d141-4f00-98b2-b5564d8067c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ad81d2394b2450fba8397056389cb20_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtNS0xLTEtNTgwNzc_de2bcc62-6e4b-4694-9d17-6884128b7478">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i803ae491ae4247699729cd6edb089399_I20230331" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtNy0xLTEtNTgwNzc_4b1a757a-9784-48e7-be16-f0b2550dd487">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecb4976c60f342fa953b24367cd3820e_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy0xLTEtMS01ODA3Nw_4c093ae0-5017-4409-a79d-3dc0905aef11">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i669a009daaeb4d2db79701235b95e376_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy0zLTEtMS01ODA3Nw_9873eddc-8849-4bb0-9103-e2d2b08596d4">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic39295831f6047c59873ab434e7a7cf7_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy01LTEtMS01ODA3Nw_6477d5d7-cef7-4aa4-9ad1-48435e407db9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede9e2d88ec041849965bcef8bfb9c17_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy03LTEtMS01ODA3Nw_1e879518-f9c3-4255-b105-3681008bd46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57102aa94d874a13b6507d22ca28cdc0_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC0xLTEtMS01ODA3Nw_bb22f6f5-747e-48ec-ad41-e3f8aa71ed90">25,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8dd2aff3e0974780a6b2aa931ebb28f9_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC0zLTEtMS01ODA3Nw_a9ef636f-cec1-465b-bf8f-23bd87b7934e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1010cf9f614aa9b7166c1b910413d5_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC01LTEtMS01ODA3Nw_fd3db347-2773-45d9-ae31-0e2657f4a946">25,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic892b663020e42b1bd246832a5009260_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC03LTEtMS01ODA3Nw_76b9f927-f519-42d6-8023-5996e207d969">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db82a67dfd141e8a7a89f9559c2902d_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS0xLTEtMS01ODA3Nw_97a3675f-491a-46c6-8efd-cd8970dd217e">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb1446d2f5f4438a3d7554393bc9a1f_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS0zLTEtMS01ODA3Nw_f4a21fdd-f8e6-4bcb-b0c3-d42486dccd6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i242fd96eb50447d3991a0de8c6a76b37_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS01LTEtMS01ODA3Nw_c92c1777-7420-4201-af6f-c6cb0477c595">999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44fae79f843e424798285c554872b550_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS03LTEtMS01ODA3Nw_bbec08d9-3ffb-4ad8-a55f-b211b3fded52">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63206a33055f4c71bee2ac6cc2b4f155_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi0xLTEtMS01ODA3Nw_c5f547c3-e5a9-4013-a44a-30750d9f3be0">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8517689b41a2471a8481ff5ea1df4049_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi0zLTEtMS01ODA3Nw_ec9860f2-2e78-4551-8ab5-3c87c87163fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9711e441836a4f0d870c15d342503a53_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi01LTEtMS01ODA3Nw_116cacda-8f5f-4fc0-b5e8-ee3df6c65ebf">1,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87660283b17b44d686672983be8c5c21_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi03LTEtMS01ODA3Nw_ee37994b-d7c6-4052-b49c-1f88816b1511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69de1d9e70cd4b0088ef12543981f292_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS0xLTEtMS01ODA3Nw_d0a90809-f4d9-4e5d-93fe-1826a258f9ce">112,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440c55b90eec415db702e87c2679f87b_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS0zLTEtMS01ODA3Nw_16e7a96d-0915-482c-8edb-d4d0dff12337">84,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0576a7417fb0498fb1ea19dcab1a3146_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS01LTEtMS01ODA3Nw_985c024e-9c14-47bd-9ca7-17466993b78e">27,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d8d964b58e482b9ff481926c12e415_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS03LTEtMS01ODA3Nw_12c299b9-1699-40aa-96d4-8746f3f854e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if376b021c40b4857af8ed796b6f678c4_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItMS0xLTEtNTgwNzc_7c1dc8e2-6c83-4a3c-a79d-fb853632a4c6">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebfb6b4b245549c1925014c3d197a60d_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItMy0xLTEtNTgwNzc_f668dd90-4f3d-4c32-ae12-f636b96968f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4861c96b38f245e58dee1fb635b16e2b_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItNS0xLTEtNTgwNzc_49ef4e27-ad27-4f7c-9e32-a85cc3be8531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i644fdcb9f2ec487eb5257a431392d340_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItNy0xLTEtNTgwNzc_47905b47-d7f4-47b6-92be-4f07943ffad6">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69de1d9e70cd4b0088ef12543981f292_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtMS0xLTEtNTgwNzc_5ea25859-905c-429a-8a31-173d10fe6043">1,656</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i440c55b90eec415db702e87c2679f87b_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtMy0xLTEtNTgwNzc_4917eda7-fdac-4495-84e8-eccd88b8f43d">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0576a7417fb0498fb1ea19dcab1a3146_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtNS0xLTEtNTgwNzc_69fbb1c1-af8b-43d9-ab67-71635a1a0ef9">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5d8d964b58e482b9ff481926c12e415_I20221231" decimals="-3" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtNy0xLTEtNTgwNzc_211de9fd-f6f1-4a58-aed5-c367627a7879">1,656</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and the 2022 Exit Fee, as defined and discussed in </span><ix:continuation id="if1edd09fb26a40c39b14bfe8a4c36984" continuedAt="i52d5205cb4604749af04144f348ea245"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span></ix:continuation></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="i52d5205cb4604749af04144f348ea245" continuedAt="i7201be4c8453425ab36ec3fdff5efd0d"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2023 and December&#160;31, 2022, due to their short-term nature. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have <ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfNTQ5NzU1ODE4OTE1_9153827a-44f4-42d7-aefe-e987ab7ccde7"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfNTQ5NzU1ODE4OTE1_d7172663-a9ec-4568-aa67-9355aff48fc5">no</ix:nonFraction></ix:nonFraction>t recorded an allowance for credit losses for these securities as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of March&#160;31, 2023 and December&#160;31, 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 2 inputs used to estimate the fair value of the liability.</span></div></ix:continuation></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><ix:continuation id="i82d98738bfff497c9661fb6eec8d56ed"><ix:continuation id="i7201be4c8453425ab36ec3fdff5efd0d"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of March&#160;31, 2023 and December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be paid to us by Kyowa Kirin Co., Ltd. ("Kyowa Kirin") over the life of the agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of the liability.</span></ix:continuation></ix:continuation></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNzI1_8c8e6e11-df48-47fc-ad4e-fa6722ba5f15" continuedAt="ia4213df03e8b4bd1ad3e93fb97aff911" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="ia4213df03e8b4bd1ad3e93fb97aff911" continuedAt="iddb7e0bef7db436a97dbaafa069926cf"><div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNzI2_5db9b7a0-ca69-4850-84dc-9c9f0e129da8" continuedAt="i2a99c57d9eb14336809f3a675bdc24e9" escape="true"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNzI2_d9f26f40-8d15-410b-8d2f-41cde20694ac" continuedAt="i91de0df484554e3b85b0e782f51417df" escape="true">Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><ix:continuation id="i2a99c57d9eb14336809f3a675bdc24e9"><ix:continuation id="i91de0df484554e3b85b0e782f51417df"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"></td><td style="width:64.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.546%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMS0yLTEtMS01OTcyNQ_79f3c415-f732-4306-9624-7775c6cd254d">21,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryRawMaterials" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMS0yLTEtMS01ODA3Nw_123656cb-c626-46d7-a59a-c400cc5ca3a1">22,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMi0yLTEtMS01OTcyNQ_f1b4120d-1e95-4b4d-b99c-7854b345aaae">22,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryWorkInProcess" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMi0yLTEtMS01ODA3Nw_2a82a730-2445-4eda-b7bc-6e562292403c">5,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMy0yLTEtMS01OTcyNQ_89068557-e082-4b2b-88c1-42f9b617a67d">679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMy0yLTEtMS01ODA3Nw_cbc49ad4-ddc0-4a32-9337-e80358f82c7b">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNC0yLTEtMS01OTcyNQ_dcc3f97e-6e1b-4c6a-99c6-704eb4da46c9">44,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNC0yLTEtMS01ODA3Nw_5245b5ee-92fb-47de-9fb3-914bc4d0ade6">28,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNi0yLTEtMS01OTczNQ_63f77af8-7067-4260-8792-e91f9bfdd0f0">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNi0yLTEtMS01ODA3Nw_44f243b0-efaf-4bd9-8753-f24ba10f193a">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNy0yLTEtMS01OTczNQ_5bbda677-5f5c-4bfe-9556-8197ccaf21e1">40,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNy0yLTEtMS01ODA3Nw_eacaa38d-1db5-4077-96b9-fd69c17619dc">25,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfOC0yLTEtMS01OTczNQ_11c5b431-4d85-45bf-b50e-b7a978cc9eef">44,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfOC0yLTEtMS01ODA3Nw_8a5cde44-5661-433c-b949-76df537b5834">28,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iddb7e0bef7db436a97dbaafa069926cf">Prepaid commercial manufacturing of $<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-5" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNTQ5NzU1ODE1MTkx_8ed05eb5-a0ab-42b2-84ac-83b3b3e41907">13.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-5" name="ardx:PrepaidCommercialManufacturingCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNTQ5NzU1ODE1MTk5_c7fc6b84-f9f0-4123-8231-ae9f1382cb2e">13.6</ix:nonFraction>&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, consisted of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months.</ix:continuation> </span></div><div><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNzUz_6e4790b2-8eaa-406e-9ae5-9d8b9a6edd37" continuedAt="ic2fd1667991246688d11ad9bfeb3b1fd" escape="true">PRODUCT REVENUE, NET</ix:nonNumeric></span></div><div style="text-indent:18pt"><span><br/></span></div><ix:continuation id="ic2fd1667991246688d11ad9bfeb3b1fd"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $<ix:nonFraction unitRef="usd" contextRef="if10e10eb21804ecea009554e9a64bbfe_D20230101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfMjgw_beca11ee-63fd-4182-bfa6-bbc35bf91c11">11.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9daeb86042c74be28a77bbfb542222af_D20220101-20220331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfMTY0OTI2NzQ0NjI5MA_031d1316-111d-434a-aff2-72582d046b51">0.5</ix:nonFraction> million during the three months ended March&#160;31, 2023 and 2022, respectively. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up <ix:nonFraction unitRef="number" contextRef="i077fb918ffd34a16a2ba56d845e7c0eb_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNTQ5NzU1ODE0OTcx_d7016b3f-c3a2-4144-954a-fa43ed28aa76">22.2</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i45042f4036a348d9ac0c4307237e2fe3_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNDQ4_9baf88e9-41bb-4a03-b4f0-0b8ce62652cf">21.6</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i35fb475dbd8e4857a5165d3acdca2256_D20220101-20220331" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNDYw_75ff93be-b8f3-4c58-a4d3-7ed201df77a7">20.8</ix:nonFraction>%, respectively, of our product sales, net during the three months ended March&#160;31, 2023.</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNzU0_14a56f5c-4d07-426e-b03f-c4d2f17ff9a7" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Wholesaler and GPO Fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d628cc8068943659267d334778f7341_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS0xLTEtMS01ODA3Nw_f0283c62-29a4-4451-bd6c-4a1025d21beb">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff654685dbff4d14b4f04d9a1f3d82ad_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS0zLTEtMS01ODA3Nw_01db96b1-f6db-4e5b-8825-189a412aafaf">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2484e9556a94cb28d490b54b7654b83_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS01LTEtMS01ODA3Nw_855dd474-2bdd-4024-9982-e97771e93279">1,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS03LTEtMS01ODA3Nw_2b0e0a18-d499-4f82-8279-d5aa41d87b5e">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d95d2f372e4305b5ab02ab183e81cc_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesProvisions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi0xLTEtMS01ODA3Nw_cc2e73d9-3872-423f-bc2b-692c4990a1b9">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abe21dd0e894e529281c08515f218a9_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi0zLTEtMS01ODA3Nw_a23439a1-3bda-4be7-b6ce-c62f6e9452ef">2,361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70fd6a1343d4c07ab6c0418986dd561_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi01LTEtMS01ODA3Nw_bec9ba34-94a5-4ed8-8617-7daa4b324f06">2,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesProvisions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi03LTEtMS01ODA3Nw_bbb6c416-444c-4c7c-96bc-2608325c9fbe">5,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26d95d2f372e4305b5ab02ab183e81cc_D20230101-20230331" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0xLTEtMS01OTc2Nw_c998f3ab-d2b8-427f-9313-fb4edc41c5cc">726</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6abe21dd0e894e529281c08515f218a9_D20230101-20230331" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0zLTEtMS01OTc2Nw_e82c317a-7638-4217-9349-30c55f7f3ac3">1,685</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie70fd6a1343d4c07ab6c0418986dd561_D20230101-20230331" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy01LTEtMS01OTc2Nw_4db8ba2a-a588-43e7-b7c2-5b37ec9812ce">1,909</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy03LTEtMS01OTc2Nw_93dfb9b6-1eb4-46d1-88d4-a5af932544d4">4,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d909b1486e465d9d1e0fae1f8ce528_I20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0xLTEtMS01ODA3Nw_af5b04c9-be3f-4755-bbb9-a58959c8755f">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94828b9e8bfc49a9821ddf83aaed8bd3_I20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0zLTEtMS01ODA3Nw_62edba38-6659-41e6-84c9-71cff9359f07">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4d507187469461589702c69e8af394f_I20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy01LTEtMS01ODA3Nw_2d6a164c-25af-4820-880a-a38587ff18de">1,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:ContractWithCustomerGrossToNetSalesAccruals" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy03LTEtMS01ODA3Nw_8f286c2e-9d6a-4628-a4ff-b043ebecb3df">4,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMTAzOTk_97f97662-134c-48f6-8a91-3a80f1830fe8" continuedAt="i2d34e75584d647b087335e028311edd4" escape="true">COLLABORATION AND LICENSING AGREEMENTS </ix:nonNumeric></span></div><ix:continuation id="i2d34e75584d647b087335e028311edd4" continuedAt="ib4d706f16c554b3694fc1fe92c8e83d3"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;Kyowa Kirin&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with Kyowa Kirin (&#8220;2017 Kyowa Kirin Agreement&#8221;), under which we granted Kyowa Kirin an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 Kyowa Kirin Agreement, Kyowa Kirin is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for Kyowa Kirin&#8217;s use in development and commercialization throughout the term of the 2017 Kyowa Kirin Agreement, provided that Kyowa Kirin may exercise an option to manufacture the tenapanor drug substance under certain conditions. In October 2022, we entered into a Commercial Supply Agreement with Kyowa Kirin to further define the obligations of the parties with respect to the commercial supply of tenapanor drug substance (&#8220;2022 Kyowa Kirin Supply Agreement&#8221;). As detailed below under the heading &#8220;Deferred revenue&#8217; we have received advanced payments from Kyowa Kirin for the manufacturing of tenapanor drug substance that will be used to satisfy Kyowa Kirin needs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, Kyowa Kirin, is a customer. Under the terms of the 2017 Kyowa Kirin Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i083920320a754056a514534f83b44efb_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzIxMA_dd4c8e7f-f1cc-43e2-8eff-ff35331981b4">30.0</ix:nonFraction>&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 Kyowa Kirin Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2017 Kyowa Kirin Agreement, Kyowa Kirin paid us an up-front license fee of $<ix:nonFraction unitRef="usd" contextRef="i083920320a754056a514534f83b44efb_D20171101-20171130" decimals="-5" name="ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzYzNg_dd4c8e7f-f1cc-43e2-8eff-ff35331981b4">30.0</ix:nonFraction>&#160;million. We may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i1bd3e10bb611407aa9b181ac0b231f2b_I20171130" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzY3Ng_9e3abeb1-9d50-4e8b-990e-96cd30f6a3c5">55.0</ix:nonFraction>&#160;million in total development and regulatory milestones, of which $<ix:nonFraction unitRef="usd" contextRef="ife5f1ab287944b9d9bde070bbcbc67e0_D20171101-20230331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzczNg_f921ac16-bd43-401f-871c-4a7b8847632d">20.0</ix:nonFraction>&#160;million has been received and recognized as revenue as of March&#160;31, 2023. We may also be eligible to receive approximately &#165;<ix:nonFraction unitRef="jpy" contextRef="i288cfb8144d94e34b13ad2293ba44e8a_I20230331" decimals="-8" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzg0Mg_99ae6fdd-5064-43f3-9acd-8d4e6f67b856">8.5</ix:nonFraction>&#160;billion for commercialization milestones, or approximately $<ix:nonFraction unitRef="usd" contextRef="i288cfb8144d94e34b13ad2293ba44e8a_I20230331" decimals="-5" name="ardx:CollaborativeArrangementPotentialCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzg5Ng_cf3e3579-9eeb-4e70-a55c-2e78322928ba">64.1</ix:nonFraction>&#160;million at the currency exchange rate on March&#160;31, 2023, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments was fully constrained at March&#160;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a second amendment to the 2017 Kyowa Kirin Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and Kyowa Kirin have agreed to a reduction in the royalty rate payable to us by Kyowa Kirin upon net sales of tenapanor for hyperphosphatemia in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future commercial milestones and royalties we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, Kyowa Kirin agreed to pay us up to an additional $<ix:nonFraction unitRef="usd" contextRef="i39875fb6603e44a9a08e3395ebc9b749_I20220430" decimals="-5" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTYxMw_2c92ca97-9173-4f26-a2ac-e9137db8513b">40.0</ix:nonFraction>&#160;million payable in <ix:nonFraction unitRef="payment_tranche" contextRef="i39875fb6603e44a9a08e3395ebc9b749_I20220430" decimals="INF" name="ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTYyNw_fc6d4197-54e2-4394-a14f-6cb3cf02a75d">two</ix:nonFraction> tranches, with the first payment due following Kyowa Kirin's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following Kyowa Kirin&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that Kyowa Kirin submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from Kyowa Kirin for an aggregate of $<ix:nonFraction unitRef="usd" contextRef="ie00d1c1778d04b16b85402b79f1486b1_I20221031" decimals="-5" name="ardx:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTQ5NzU1ODMwNjg2_796af493-6cef-4eb5-ab92-f798a2538364">35.0</ix:nonFraction> million for milestone payments and payments under the 2022 Amendment. We received these payments during the fourth quarter of 2022 and recorded them as licensing revenue on our statement of operations and comprehensive loss. The remaining variable consideration related to the reduction in the royalty rate was fully constrained at March&#160;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the 2017 Kyowa Kirin Agreement. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="ib4d706f16c554b3694fc1fe92c8e83d3" continuedAt="i8502dadf3c04426cafac357089c0a0d1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun Pharma ("Fosun Agreement") for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2907f661c6604d53a0fd946c446d11e8_D20171201-20171231" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzI4Mw_bb40d7b6-3979-4a8a-a959-639b6a6ac459">12.0</ix:nonFraction> million in up-front license fees which was recognized as revenue when the agreement was executed. Based on our assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ib45bb64e3dd84ca6aef388e7e5e6f6e7_D20230101-20230331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzM5MQ_6e01ac71-4818-4664-a2b3-7fff62ecf022">110.0</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="if8a535f9627a421383052d6cea68607f_I20230331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzQwNA_e278728d-6e32-40c6-87d8-d0559b89194c">3.0</ix:nonFraction> million has been received and recognized as revenue as of March&#160;31, 2023, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ib45bb64e3dd84ca6aef388e7e5e6f6e7_D20230101-20230331" decimals="INF" name="ardx:ThresholdPercentageOfSalesForTieredRoyalties" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzYxMQ_49bbd0a2-6e2a-4833-a999-9c557bd97190">20</ix:nonFraction>%. The variable consideration related to the remaining development milestone payments was fully constrained at March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the Fosun Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight Therapeutics, Inc., ("Knight Agreement") for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on our assessment, we determined that the license and the manufacturing supply services were the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Knight Agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i863345a922844c66bd8d54af304f6cdf_D20180301-20180331" decimals="-5" name="us-gaap:ProceedsFromLicenseFeesReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODI5Nw_56f944c1-92a5-407a-81c0-495f6748da0f">2.3</ix:nonFraction> million non-refundable, one-time upfront payment in March 2018 and may be eligible to receive additional development and commercialization milestone payments worth up to CAD <ix:nonFraction unitRef="cad" contextRef="i63261ab5ac574aa09e991359cd4c71ad_D20230101-20230331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODM2Ng_49adcb18-efb5-4728-aa56-e6e456b652f4">22.2</ix:nonFraction>&#160;million, or approximately $<ix:nonFraction unitRef="usd" contextRef="i63261ab5ac574aa09e991359cd4c71ad_D20230101-20230331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODQzNg_16b2d071-31f2-41ed-881b-8e369caaf9b0">16.3</ix:nonFraction> million at the currency exchange rate on March&#160;31, 2023, of which $<ix:nonFraction unitRef="usd" contextRef="i3052a28a1e664c948b14b97c701206d4_I20230331" decimals="-5" name="ardx:CollaborativeArrangementPotentialDevelopmentMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODQ4NQ_cf02ebf4-20b6-4a99-9b3f-cce30d35760a">0.7</ix:nonFraction> million has been received and recognized as revenue as of March&#160;31, 2023. We are also eligible to receive royalties ranging from the mid-single digits to the low twenties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments was fully constrained at March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the Knight Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of <ix:nonFraction unitRef="number" contextRef="i54e4c9709e43489db08f10738e1a7672_D20150601-20150630" decimals="INF" name="ardx:PercentageOfRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTMxOQ_fd99eeaf-2ff7-44c4-a105-1dc2aa79bc53">10</ix:nonFraction>% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) <ix:nonFraction unitRef="number" contextRef="i54e4c9709e43489db08f10738e1a7672_D20150601-20150630" decimals="INF" name="ardx:PercentageOfNonRoyaltyRevenue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTQwNA_260f1769-41c9-487d-b236-00352b36fdaa">20</ix:nonFraction>% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or other NHE3 products, up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="i3b884d0ed6cd421f8a251db830a1fdce_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTUxNA_8e72f77e-a7f7-4839-9303-f4b20ac35864">75.0</ix:nonFraction> million in aggregate for (i) and (ii). As of March&#160;31, 2023, to date in aggregate, we have recognized $<ix:nonFraction unitRef="usd" contextRef="i57d1ca4ad84940028b209e173e66500a_I20230331" decimals="-5" name="ardx:CostOfRevenueAggregateAmountRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTU5OQ_0643ffa8-ccd1-4e6b-be65-d93a1fc0dda0">16.4</ix:nonFraction> million of the $<ix:nonFraction unitRef="usd" contextRef="i3b884d0ed6cd421f8a251db830a1fdce_I20150630" decimals="-5" name="ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTYwOQ_8e72f77e-a7f7-4839-9303-f4b20ac35864">75.0</ix:nonFraction> million, which has been recorded as cost of revenue, and have paid AstraZeneca $<ix:nonFraction unitRef="usd" contextRef="i57d1ca4ad84940028b209e173e66500a_I20230331" decimals="-5" name="ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTY4Mw_7e30eeb9-52b6-44e5-a87e-ac5f7516d6d3">11.9</ix:nonFraction> million. During the three months ended March&#160;31, 2023, we recognized and recorded $<ix:nonFraction unitRef="usd" contextRef="i731cea5b5a1d4df7b9a2e29a37cd3494_D20230101-20230331" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTQ5NzU1ODQ4MTE1_a2868808-558b-4ed6-bcb3-03d45bfbcbf1">1.2</ix:nonFraction> million as cost of revenue related to the AstraZeneca Termination Agreement. During the three months ended March&#160;31, 2022 we recognized $<ix:nonFraction unitRef="usd" contextRef="i86a688e614d249fb9330ee9f05c52190_D20220101-20220331" decimals="-5" name="us-gaap:CostOfRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTg4Mg_a311d98d-c242-4db1-9e90-5c0f5f8d4e2a">0.1</ix:nonFraction> million as cost of revenue related to the AstraZeneca Termination Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i8502dadf3c04426cafac357089c0a0d1"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMTA0MDA_a72bb004-0b62-4660-ae5c-6ffbf62e31af" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period, which are all attributable to the 2017 Kyowa Kirin Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659312f8037b43898d098e16388710fb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMS0xLTEtMS01ODA3Nw_f1381207-1a13-4045-b5ba-9a7805c1e5eb">4,211</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace679a5607d492699456f44241140e4_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMS0zLTEtMS01ODA3Nw_327ecfa2-329a-489c-90cc-8086226428e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMy0xLTEtMS01ODA3Nw_a5a8fef2-0bbc-41d8-a110-89afea563331">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331" xsi:nil="true" name="ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMy0zLTEtMS01ODA3Nw_cc818316-26bf-4607-b237-5350be3fd276"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfNC0xLTEtMS01ODA3Nw_74f3ed3a-dbce-42eb-bfaf-2b91d9978cc5">525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfNC0zLTEtMS01ODA3Nw_1a764730-afef-4579-8b19-ef949bc4fad4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f7c183ef764b48ab94110300434074_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfOC0xLTEtMS01ODA3Nw_decf79ba-bd4a-43a5-814f-c9f2b7427294">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95bc99b5de94628b6f1a6c5d5185452_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfOC0zLTEtMS01ODA3Nw_1782337c-f61c-4291-803c-e3ca0e7c08e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.030%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659312f8037b43898d098e16388710fb_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMS0xLTEtMS01ODA3Nw_8b526927-0341-4146-8b04-bb30a4a59a81">9,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace679a5607d492699456f44241140e4_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMS0zLTEtMS01ODA3Nw_38bfffe5-1309-4490-8b06-88fe42e94144">4,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMy0xLTEtMS01ODA3Nw_ddc24af6-1325-413b-a697-533f0e927605">3,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMy0zLTEtMS01ODA3Nw_c663133d-7f8e-45d9-a039-9c05367d7102">3,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNC0xLTEtMS01ODA3Nw_6d7d7ab6-1943-4a99-b651-a07b40c0e198">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNC0zLTEtMS01ODA3Nw_e2caf3d5-c8a2-4a57-81c3-f8aefa26d613">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331" decimals="-3" name="ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNS0xLTEtMS01ODA3Nw_954d918c-0717-49f2-a73a-2da1668a7059">809</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331" decimals="-3" name="ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNS0zLTEtMS01ODA3Nw_3777427d-495e-4ba8-a182-446df4534084">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52f7c183ef764b48ab94110300434074_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNy0xLTEtMS01ODA3Nw_23431cde-8fbf-41b4-9fe6-2adb94dfd5c6">11,498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia95bc99b5de94628b6f1a6c5d5185452_I20220331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNy0zLTEtMS01ODA3Nw_4e54914f-1ceb-45ee-af04-8e6f09fd7657">8,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;text-align:justify"><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:AssetRetirementObligationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNDU4MQ_b50d91f0-8066-4165-9cfe-fc155efc60a9" continuedAt="i6e8bfd9a63044d03979465f5fce1ee12" escape="true">DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i6e8bfd9a63044d03979465f5fce1ee12" continuedAt="i718a58f43dd5482b8fbc99ac6fa7edc4"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $<ix:nonFraction unitRef="usd" contextRef="i7e9a3bf71e144239ab9f7e4ab68a77fb_D20220601-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInRoyaltiesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODIzOTkz_26a832a1-ae74-4e63-bca6-035458f905ce">20.0</ix:nonFraction> million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with Kyowa Kirin based upon Kyowa Kirin's net sales of tenapanor in Japan for hyperphosphatemia. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $<ix:nonFraction unitRef="usd" contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI0MzMw_43ebacc9-64dc-4c34-b92e-325ecc81f2a0">10.0</ix:nonFraction> million upfront payment, and we are eligible to receive a $<ix:nonFraction unitRef="usd" contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI0Mzg0_1c779472-9a23-4f59-ae5f-49bd8a09905e">5.0</ix:nonFraction> million payment following Kyowa Kirin's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $<ix:nonFraction unitRef="usd" contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI0NTA3_4515864c-534c-484a-b9a0-7edbc3cebb78">5.0</ix:nonFraction> million payment in the event net sales by Kyowa Kirin in Japan exceed a certain annual target level by the end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 Kyowa Kirin Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 Kyowa Kirin Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 Kyowa Kirin Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 Kyowa Kirin Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 Kyowa Kirin Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i718a58f43dd5482b8fbc99ac6fa7edc4"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received the $<ix:nonFraction unitRef="usd" contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI2MzU5_43ebacc9-64dc-4c34-b92e-325ecc81f2a0">10.0</ix:nonFraction> million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation related to the sale of future royalties ("deferred royalty obligation") on our balance sheet. Due to our ongoing manufacturing obligations under the 2017 Kyowa Kirin Agreement, we account for the proceeds as imputed debt and therefore will recognize royalties received under the arrangement as non-cash royalty revenue. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from Kyowa Kirin. As part of the sale, we incurred approximately $<ix:nonFraction unitRef="usd" contextRef="ieebd3c9bdbf5498bb3059d158b5c146a_I20230331" decimals="-5" name="ardx:ContractWithCustomerLiabilityTransactionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI3MDU4_01c56bf6-a175-4755-9916-9df65e07dde2">0.4</ix:nonFraction> million in transaction costs, which, along with the deferred royalty obligation, are being amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by Kyowa Kirin, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be received from Kyowa Kirin under the 2017 Kyowa Kirin agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to HCR are made in U.S. dollars while the underlying sales of the products by Kyowa Kirin are made in Japanese yen, and other events or circumstances that could result in reduced royalty payments from Kyowa Kirin, which are not within our control, and all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the deferred royalty obligation. We periodically assess the estimated royalty payments from Kyowa Kirin and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation. As of March&#160;31, 2023, our effective interest rate used to amortize the liability is <ix:nonFraction unitRef="number" contextRef="i3d8e929085924d668d54e66064fca686_D20230101-20230331" decimals="3" name="ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI4Nzk3_4e2b144b-66bf-449f-9737-22e1cf34a075">34.4</ix:nonFraction>%. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-5" name="us-gaap:AmortizationOfAdvanceRoyalty" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNDM2MA_79561f72-75c6-4d09-af75-bd727f3ad91e">1.0</ix:nonFraction> million of non-cash interest expense for the amortization of the deferred royalty obligation. As of March&#160;31, 2023, we have received <ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromRoyaltiesReceived" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNDQ3Ng_c61ba55f-ac90-46c4-b994-e8396db57cd1">no</ix:nonFraction> royalty payments from Kyowa Kirin and, therefore, the deferred royalty obligation has not begun to be reduced.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div id="iea6a0b1ea655406093eb9e951c03313e_55"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNzU0Nw_a87f06d1-e8b2-40a0-9853-7ea9865b00fb" continuedAt="if8cbf79e3cd14ac6be1cf95a7f9cfc65" escape="true">BORROWING </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="if8cbf79e3cd14ac6be1cf95a7f9cfc65" continuedAt="i5fd7b0bbca7b4144afb1f0c3dc6b3a8e"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;2018 Lenders&#8221;). The 2018 Loan Agreement provided for a loan facility for up to $<ix:nonFraction unitRef="usd" contextRef="id26a7d8749644b05b1f668cab705f3da_I20180531" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNDAx_e1571a37-6cbf-439f-8976-1be311042174">50.0</ix:nonFraction> million with a maturity date of November&#160;1, 2022 (the &#8220;2018 Loan&#8221;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $<ix:nonFraction unitRef="usd" contextRef="id26a7d8749644b05b1f668cab705f3da_I20180531" decimals="-5" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTM1_21e4c608-31ae-46bd-8188-b06a342a3cdb">25.0</ix:nonFraction>&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNzg3_03750d93-1b45-4021-aebf-70835b059489">1.5</ix:nonFraction> million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investment Corp. Loan Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (&#8220;Closing Date&#8221;), we entered into a loan and security agreement (&#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (&#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement was subsequently amended on August 1, 2022 and February 9, 2023. We concluded that the Loan amendments were modifications to the 2022 Loan Agreement and are accounted for accordingly. The 2022 Loan Agreement as amended provides for a senior secured loan facility, with $<ix:nonFraction unitRef="usd" contextRef="i65852187d2a644d0b3d856dac714bdd5_D20220223-20220223" decimals="-5" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODI4Mjgz_58e9e7d9-4b81-40e2-8171-97cebc987acc">27.5</ix:nonFraction> million (&#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $<ix:nonFraction unitRef="usd" contextRef="i1bde4623e9a04dc39eee1626eaee265d_I20220223" decimals="-5" name="ardx:RemainingFundingBasedOnConditionalMilestoneAchievement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODI4MzQ4_90dba6c7-5547-4831-93d8-10d2be449508">22.5</ix:nonFraction> million which we may borrow on or prior to December 20, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by November 30, 2023, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (&#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027. </span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i5fd7b0bbca7b4144afb1f0c3dc6b3a8e" continuedAt="i68a0370d662c4ff5a34524abd046cdbd"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan as amended bear interest at a floating per annum interest rate with <ix:nonFraction unitRef="number" contextRef="i94ae49ee7695430e996b24c23504b630_D20220223-20220223" decimals="4" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM3MTQ0_685f5bfe-a3d5-4dfd-8555-71489f5ebb3f">7.95</ix:nonFraction>% plus the greater of (a) one percent (<ix:nonFraction unitRef="number" contextRef="i638a555d6cc245828c93ab8f2f4152fd_D20220223-20220223" decimals="INF" name="ardx:DebtInstrumentVariableRateBaseOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM3MTg1_8eb4484f-9b4e-42f8-8bc6-56ea86c84521">1.00</ix:nonFraction>%) per annum and (b)(i) <ix:nonFraction unitRef="number" contextRef="i638a555d6cc245828c93ab8f2f4152fd_D20220223-20220223" decimals="5" name="ardx:DebtInstrumentVariableRatePlusOption" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM3MjEx_4cebded1-e320-48c3-bca0-99c9e32df451">0.022</ix:nonFraction>% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024, which date will be extended to March 31, 2025 if we receive approval by the FDA for our NDA for XPHOZAH on or prior to November 30, 2023 or achieve a defined net product revenue threshold for 2023. Accordingly, beginning on April 1, 2024 or April 1, 2025, we will be required to make monthly payments of interest plus repayment of the 2022 Loan in consecutive equal monthly installments of principal over <ix:nonNumeric contextRef="i65852187d2a644d0b3d856dac714bdd5_D20220223-20220223" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMDQ5_1caac3e1-2a28-4834-81ca-1f0fe62db2ae">36</ix:nonNumeric> months or <ix:nonNumeric contextRef="i3f29b0505e0a4f2687c88c38e53ea1dc_D20220223-20220223" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMDU2_4029fc5f-5fe5-4ce8-bb06-708f988845fc">24</ix:nonNumeric> months, respectively. We were obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i0b5ab525e6ab435aaf3c6a02a1de068a_I20220223" decimals="-5" name="ardx:DebtInstrumentClosingFeeAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMTAw_98182d9f-5115-4a83-bd19-740670c4586c">0.2</ix:nonFraction> million, upon the closing of the Term A Loan, and we are obligated to pay $<ix:nonFraction unitRef="usd" contextRef="i1bde4623e9a04dc39eee1626eaee265d_I20220223" decimals="-5" name="ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMTcw_dd56165e-b40e-494a-bb17-495743334dcc">0.1</ix:nonFraction> million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to <ix:nonFraction unitRef="number" contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223" decimals="INF" name="ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwNDE2_24d9854a-b169-4da9-8c3d-20695ce58e72">4.95</ix:nonFraction>% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) <ix:nonFraction unitRef="number" contextRef="ia083898fba8644ae8992ef5a76d16d15_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwNzUx_7e788547-fe81-4ce5-bfd3-d6d5c7164ce2">3</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) <ix:nonFraction unitRef="number" contextRef="i3eef16572d6e4271b1f76a0150bcab0d_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwODgy_6a69b9f7-5623-43e3-aa07-f3e19d389783">2</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) <ix:nonFraction unitRef="number" contextRef="i0f1ad1d3f45248538bc7fb75b496d6b7_I20220223" decimals="INF" name="ardx:DebtInstrumentPrepaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMxMDcz_25670614-5187-4b9c-a7c0-c512a7b30ad5">1</ix:nonFraction>% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of <ix:nonFraction unitRef="number" contextRef="i33c8ecd2354241aaae56ac9dd1838668_I20220228" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMxNDky_98097814-baad-43f1-93c6-e628bd00ffe7">2</ix:nonFraction>% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="i144ee9ba68854c9cb614235c5e0c2141_D20220223-20220223" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMxNjc1_7ff5ec04-b4ae-4c1e-a04e-ece3f4ffc848">100.0</ix:nonFraction> million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire <ix:nonNumeric contextRef="i144ee9ba68854c9cb614235c5e0c2141_D20220223-20220223" name="ardx:LoanAgreementExitFeeTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfMjc0ODc3OTA5MTc4NQ_65e024bf-13b2-444b-9fb2-5081d30b3baa">10</ix:nonNumeric> years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (<ix:nonFraction unitRef="number" contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMyNzA0_b5e211a4-44e9-404e-b681-821f7c2b9c72">80</ix:nonFraction>%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (<ix:nonNumeric contextRef="i409069f3154040ff8c6970a5bfafb1ee_D20220223-20220223" name="ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMyODUy_f37ac6fe-2484-433a-992b-e9b84b7677d0">6</ix:nonNumeric>) month basis and tested monthly, is less than sixty percent (<ix:nonFraction unitRef="number" contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223" decimals="INF" name="ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMyOTE3_e174ac34-0d1c-4781-a75e-8cbc53441c03">60</ix:nonFraction>%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to <ix:nonFraction unitRef="number" contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223" decimals="INF" name="ardx:DebtInstrumentInterestRateOnDefaultPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM0MDQ2_cc9de9d2-de7b-42ca-ba77-90e153b8b1c9">4</ix:nonFraction>% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of March&#160;31, 2023 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization and Basis of Presentation: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these condensed financial statements.</span></div></ix:continuation><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i68a0370d662c4ff5a34524abd046cdbd"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNzU0OQ_7ff92822-afe6-4b30-9b7b-0cf291582541" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMC0xLTEtMS01ODA3Nw_777d84aa-4410-49e1-8662-104483b21138">28,861</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMS0xLTEtMS01ODA3Nw_7c012467-3387-4be9-9994-ec13a9a94135">1,282</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:DebtInstrumentFeeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMi0xLTEtMS01ODA3Nw_185df367-c65c-4708-aacf-31606885e42a">699</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMy0xLTEtMS01ODA3Nw_c5d2ccf1-2f1b-4e72-8f6e-373414ddecfe">26,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LoansPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfNC0xLTEtMS01ODA3Nw_d4d71771-5042-4abb-b27d-ddcba4e8fca4">26,880</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LongTermLoansPayable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfNS0xLTEtMS01ODA3Nw_fd56942e-6963-4d18-a6c7-95b5deeaedde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iea6a0b1ea655406093eb9e951c03313e_58"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. &#160;<ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNDUxNQ_6ffc4aad-c0c5-4580-8c9a-18c632afc628" continuedAt="i6713b133a871403caf8930a169553b8c" escape="true">DERIVATIVE LIABILITIES</ix:nonNumeric></span></div><ix:continuation id="i6713b133a871403caf8930a169553b8c" continuedAt="ide765c52d8484c7986e55c4e5622dae0"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $<ix:nonFraction unitRef="usd" contextRef="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIwNjky_03750d93-1b45-4021-aebf-70835b059489">1.5</ix:nonFraction> million in cash ("2018 Exit Fee") upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of XPHOZAH and (ii) FDA approval of IBSRELA, which was obtained on September 12, 2019 (&#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expense and other current liabilities on the accompanying condensed balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the estimated fair value of the 2018 Exit Fee was $<ix:nonFraction unitRef="usd" contextRef="i33de1b72f71545d986edc3214d5d9beb_I20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIxNDU0_f3f46261-4382-42c3-9e22-cb355de554bd">1.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idfb8182a2d794133b5db7776b72a7c32_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIxNDYy_21625c6c-6eea-4899-bb51-2e7c5f6e1eaa">1.2</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: (i) our estimates of both the probability and timing of a potential $<ix:nonFraction unitRef="usd" contextRef="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531" decimals="-5" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIxOTEw_03750d93-1b45-4021-aebf-70835b059489">1.5</ix:nonFraction> million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals, and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative instrument and it is estimated that a <ix:nonFraction unitRef="number" contextRef="id77334cdee644ae3adb652a17ffda146_I20230331" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIyMzA5_647d5f95-d2ce-40b6-82b6-99ce451792d0">10</ix:nonFraction>% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $<ix:nonFraction unitRef="usd" contextRef="id77334cdee644ae3adb652a17ffda146_I20230331" decimals="-5" name="ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIyNDQ0_fe7645e4-4459-40cb-afd3-5f75207b222f">0.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of <ix:nonFraction unitRef="number" contextRef="i33c8ecd2354241aaae56ac9dd1838668_I20220228" decimals="INF" name="ardx:ExitFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI0NjIx_98097814-baad-43f1-93c6-e628bd00ffe7">2</ix:nonFraction>% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $<ix:nonFraction unitRef="usd" contextRef="ibb1c667d3f6845b9821defdd369f3334_D20220201-20220228" decimals="-5" name="ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI0ODA0_f34b6bdb-3a92-4dc5-b694-db2420a9f6a6">100.0</ix:nonFraction> million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the estimated fair value of the 2022 Exit Fee was $<ix:nonFraction unitRef="usd" contextRef="iad99515dc2cb43bbac4c617f035dbea6_I20230331" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI1NDAw_a8f40429-7c40-458a-a637-266a45ac237f">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ic39c3311ee344cb6bd0f358d159ff052_I20221231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI2ODQz_4df79c98-bde8-4df6-8b15-7ac105c3d1ca">0.4</ix:nonFraction> million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis by November 30, 2023, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a <ix:nonFraction unitRef="number" contextRef="ie825c96e303040cbac67e9975c1d3916_I20220331" decimals="2" name="ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI2MzQ0_5ed17218-d80a-4880-b6fd-5c9f5611a8cb">10</ix:nonFraction>% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="ide765c52d8484c7986e55c4e5622dae0"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNDUxNg_ede32e6b-ca39-4dac-8e25-3772f296793c" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our condensed statements of operations and comprehensive loss and were as follows for the three months ended March&#160;31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:63.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.325%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i378e186ad3f24c9db722bd214a0cd23c_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMS0xLTEtMS01ODA3Nw_be2fdbff-0dd0-4e57-9d27-4aec1856e2ca">1,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70a72bd3fdec4799bf7cbc921bbe7771_I20211231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMS0zLTEtMS01ODA3Nw_f72d8c45-e12e-4325-863c-5a341542a910">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9097418276724d54ae8d794f40b08e52_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMi0xLTEtMS01ODA3Nw_03933c8b-f1a1-4899-902e-8a387f1cea0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76f025b503164e55a2c09bb438e74e2c_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMi0zLTEtMS01ODA3Nw_1744adf2-0e91-4789-8056-36ced858d61c">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i417a6c105f4849fc8598601744a8fe4a_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNC0xLTEtMS01ODA3Nw_79313a5a-0c15-4d34-93a9-5a311b61bf00">48</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3182ceda3b1f402a8c202c06dedcee6f_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNC0zLTEtMS01ODA3Nw_d70d2027-1fb4-4730-b323-c27e540d120a">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c3cd44c6894dfbaeaedc130ea028db_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNS0xLTEtMS01ODA3Nw_4189678c-7a2a-4f59-adde-b29d555e8cd3">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc6e80a67a6b4e47b639149a2c278dfd_D20220101-20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNS0zLTEtMS01ODA3Nw_5f617b7d-205d-4b67-9e3c-9e0e6510318f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3794a3d76c384e9fa5e39ef7474a6713_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNi0xLTEtMS01ODA3Nw_2868bfc2-7c3c-42a0-8c82-dcb5badbca70">1,726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a1c090223594681b449fb7259dff90c_I20220331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNi0zLTEtMS01ODA3Nw_89c5d1b9-2091-4b5c-9ec5-8a094464e776">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="iea6a0b1ea655406093eb9e951c03313e_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY2_3670b816-544c-45de-ba6c-1c176ff15912" continuedAt="i2f65d8da63a842cca158a8762192678c" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i2f65d8da63a842cca158a8762192678c" continuedAt="i852b8abd373340108081eb9e8c5d76ad"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. </span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY3_2fa79b5c-bce8-4296-9170-c12c7f1a307a" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.174%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.177%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMS0xLTEtMS01ODA3Nw_7cf7ebe8-3ff0-4f96-93e2-72bfbcf0f786">7,972</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMS0zLTEtMS01ODA3Nw_bb9990b3-48d1-41e1-adb9-efd00e42c903">9,295</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMy0xLTEtMS01ODA3Nw_b010bae3-4dc4-4b1a-836b-28518d958528">3,998</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMy0zLTEtMS01ODA3Nw_9f39dfae-8247-43fc-bf5d-f67fb165b205">3,894</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNC0xLTEtMS01ODA3Nw_8f4af06d-12ab-4d2a-a031-42aadd5f541f">4,814</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNC0zLTEtMS01ODA3Nw_c1897ff4-f0f0-449c-a69f-f8a0a219f58f">5,855</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNS0xLTEtMS01ODA3Nw_e9484d45-d306-453e-856e-4acf6e133cd1">8,812</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNS0zLTEtMS01ODA3Nw_0ea70d7e-80fd-4d6d-b905-321f88cca015">9,749</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNy0xLTEtMS01ODA3Nw_c6843cc3-844e-4ae3-97d5-5f6f63adb998">2.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNy0zLTEtMS01ODA3Nw_9e0eaa33-910e-4673-9368-5ff25d708fb0">2.4</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfOC0xLTEtMS01ODA3Nw_87572797-ba20-46d1-bc31-8d215dc440ae">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfOC0zLTEtMS01ODA3Nw_f0d3ef0a-f910-4468-9ba9-ac6681c0dee0">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY4_21ede784-fcda-49a6-8ebb-eb876640bf6d" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease costs, which are included in operating expenses in our condensed statements of operations and comprehensive loss, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMi0xLTEtMS01ODA3Nw_f7a8753e-8f34-4aa4-b011-ba07e56b7cf4">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMi0zLTEtMS01ODA3Nw_91ccc65b-1364-4c0e-bc2e-01ea7d482663">1,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMy0xLTEtMS01ODA3Nw_40746798-02d0-4de3-9721-5e2b41181dd1">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMy0zLTEtMS01ODA3Nw_d35435f7-6550-4e14-a584-cd18dcabade8">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i852b8abd373340108081eb9e8c5d76ad"><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY5_f7706a1d-0214-413f-b52f-ed5da5af8e07" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMC0xLTEtMS01ODA3Nw_d3cc60dc-cb5b-4dd8-b167-5a10ff570767">3,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMS0xLTEtMS01ODA3Nw_a9103b09-b9ca-44f7-8f7b-6480feb22b28">4,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMi0xLTEtMS01ODA3Nw_bf2aa311-2f67-4678-846e-7851a5f39a04">1,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMy0xLTEtMS01ODA3Nw_7108122d-f194-4d2e-84c1-c6c355671820">252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="ardx:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfNS0xLTEtMS01ODA3Nw_4ccf3f0b-1f9c-42bc-adbf-cecf334c823f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfNi0xLTEtMS01ODA3Nw_febc9b2d-43c8-4250-ace4-677d5eaad993">9,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfNy0xLTEtMS01ODA3Nw_61f06b34-b686-47a7-9b52-2f1da11ad10d">693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfOC0xLTEtMS01ODA3Nw_e36c4fac-e289-4ee0-9543-e55c14d6c4ca">8,812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfOS0xLTEtMS01ODA3Nw_24d8ef6e-85c3-46f3-97b1-543a563d83fa">3,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMTAtMS0xLTEtNTgwNzc_41c9cfe6-7080-43b3-ba68-ac59f72b1bc8">4,814</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a sub-lease Agreement (the &#8220;Sub-lease&#8221;) with Chronus Health, Inc. ("Chronus). The Sub-lease permits use by Chronus of a portion of the space in our facility in Fremont, California. We lease the facility from a different counterparty under a separate head lease that commenced in September 2008 and has been amended multiple times to add space and to extend the lease term through March 2025. We have sub-leased to Chronus approximately <ix:nonFraction unitRef="sqft" contextRef="i40d30043fca4421a8cdd707a81f722ba_I20230331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNjA0NzMxMzk1NzEwMg_84dad655-500e-4268-820a-8580c1559879">21,644</ix:nonFraction> square feet of the <ix:nonFraction unitRef="sqft" contextRef="ia852c2d1c80946b885ed9b389837f281_I20230331" decimals="0" name="us-gaap:AreaOfRealEstateProperty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNjA0NzMxMzk1NzExMA_ec9b0119-5644-4e6c-85b3-e130b185bbac">72,500</ix:nonFraction> square foot building's interior space, plus corresponding exterior support space and parking. The term of the Sub-lease shall expire on February 1, 2025. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Sub-lease we recognized an impairment of long-lived assets totaling $<ix:nonFraction unitRef="usd" contextRef="i90fedc697a1647b9a3c9a1fdd6f348f5_D20230101-20230331" decimals="-5" name="us-gaap:OperatingLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNTQ5NzU1ODE4MDk5_4b5b2fd0-4420-4b3f-a500-5c0b422489ef">0.4</ix:nonFraction> million during the three months ended March&#160;31, 2023, which consisted primarily of impairment to the Fremont facility right-of-use asset. The Sub-lease commenced in April 2023 and we have recognized no income from the sub-lease as of March&#160;31, 2023.</span></div></ix:continuation><div id="iea6a0b1ea655406093eb9e951c03313e_64"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMjE5NA_ad50e710-a4d4-47fa-898c-06f4ab1a982e" continuedAt="ieced8088424c4cc693cd35804ab618e5" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="ieced8088424c4cc693cd35804ab618e5"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offerings Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under a Registration Statement which was filed in July 2020 for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i38ec05cddf3c49969f8932f33a355bdd_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTA5OA_694295ed-b6e4-4dc1-abcf-9f91d0578492">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="i38ec05cddf3c49969f8932f33a355bdd_I20210831" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTMzNA_694295ed-b6e4-4dc1-abcf-9f91d0578492">150.0</ix:nonFraction> million in shares of our common stock through Jefferies. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, received a commission of up to <ix:nonFraction unitRef="number" contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTU3Nw_599dbc31-2978-4a0c-b7ab-549b6bb08562">3</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2023 we sold <ix:nonFraction unitRef="shares" contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTcyMg_6fbd54aa-702b-49ea-afe9-54061d67374f">15.5</ix:nonFraction> million shares and received gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTc2Mw_c1e85444-4cc1-484f-98d1-9c39025ca23f">51.9</ix:nonFraction> million at a weighted average sales price of approximately $<ix:nonFraction unitRef="usdPerShare" contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331" decimals="2" name="ardx:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTgxNw_e88659ac-457a-44d6-ada3-7a0af1c6905b">3.35</ix:nonFraction> per share under the 2021 Open Market Sales Agreement. As of March&#160;31, 2023, we have sold a total of <ix:nonFraction unitRef="shares" contextRef="i08f1310f62044e3a8e64483b5dd18dda_I20230331" decimals="-5" name="ardx:EquitySalesAgreementSharesIssuedSinceInception" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMjA5OA_3cd96b4e-00a2-496d-97a2-6f08cfd6444b">95.2</ix:nonFraction> million shares and received the maximum gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i08f1310f62044e3a8e64483b5dd18dda_I20230331" decimals="-5" name="ardx:EquitySalesAgreementProceedsFromSharesIssuedSinceInception" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMjE0OQ_e8970505-21a9-41b0-be9d-4ac1774cfa03">150.0</ix:nonFraction> million under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i847e1d01ce2b4b5196fbe950423d7527_I20230131" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfNTQ5NzU1ODE3MTg0_d14ef385-e063-4c49-8ee2-eb218b148fb8">250.0</ix:nonFraction> million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $<ix:nonFraction unitRef="usd" contextRef="i210c86e09a944a939b0007a9a24d4ece_I20230131" decimals="INF" name="ardx:MaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfNTQ5NzU1ODE3NDMy_f84bd699-bbf5-42de-b9b4-454eecbd648a">150.0</ix:nonFraction> million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to <ix:nonFraction unitRef="number" contextRef="i71e4928ba21947689d3e92f7f3fc1047_D20230101-20230131" decimals="INF" name="ardx:StockIssuanceCostCommissionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfNTQ5NzU1ODE3NzUw_b85e8a4f-90f1-4402-b847-1613cb43b930">3.0</ix:nonFraction>% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. As of March&#160;31, 2023, there have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2NA_d4b64791-a38a-4b44-922e-868f905987dc" continuedAt="i98827e21294244348add061f442065bd" escape="true">EQUITY INCENTIVE PLANS</ix:nonNumeric></span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><ix:continuation id="i98827e21294244348add061f442065bd" continuedAt="i2f852c133bd84fe09f8d64d61ab754e8"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2NQ_45ba54fb-7a03-4664-9f15-4b1b71f8dd81" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:70.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.759%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.761%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1377563bc1bf4114b883c22f97c51e4a_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMi0xLTEtMS01ODA3Nw_04eaaa44-a978-42a0-be68-c71ffe173f87">2,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id437a6bae6684761a2b82865b44768bb_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMi0zLTEtMS01ODA3Nw_6a0bafd8-727e-41de-aa19-29c9c5bf786e">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia72321f082eb4141ae92b05ddd125028_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMy0xLTEtMS01ODA3Nw_3d7ff2d9-101d-4598-b9b2-6ba462dae4fe">824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cdbd17f499a48b8a163d1b51e42ad39_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMy0zLTEtMS01ODA3Nw_6311ad1a-3736-4c43-b16f-810290f6f210">1,214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfNS0xLTEtMS01ODA3Nw_e8f2fd6a-2e37-4a66-a4bd-1ddbc2091217">2,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfNS0zLTEtMS01ODA3Nw_d587269d-c5b2-412c-bacf-3f80ec14dfd5">3,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2Ng_5a1244c4-eb5c-45cf-8ec9-f1dc7eb24bd3" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.323%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97aaff4ee70847809b2728fcf21c8527_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMS0xLTEtMS01ODA3Nw_380f1f06-1159-4e37-b5e9-319fe2bf11cf">21,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e0beb2c643043e5ac96aa6e57782a75_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMS0zLTEtMS01ODA3Nw_de545355-0c66-4fe3-8fef-0395deaafcb0">3.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMi0xLTEtMS01ODA3Nw_178589d0-c51e-49ce-9a7b-62aaf55176d2">7,309</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMi0zLTEtMS01ODA3Nw_eb99b23d-7a02-4689-9d37-cd20d36ad3f9">3.3</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i569028c12e1a4c889833813e64570cc9_I20230331" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMy0xLTEtMS01ODA3Nw_b3aabedb-1aa9-4ad9-b8dc-b66b2a64e647">292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMy0zLTEtMS01ODA3Nw_314d3429-2f36-4685-9ab8-3f1926465314">0.3</ix:nonNumeric></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2Nw_4907251a-d6cb-4df9-b944-9886dffe0bc5" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:59.354%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMS0xLTEtMS01ODA3Nw_49c88788-04ca-45f5-bc7b-42a73c0ee733">13,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMS0zLTEtMS01ODA3Nw_d19c3ecd-7756-41b9-a11b-eff6400053b6">4.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMi0xLTEtMS01ODA3Nw_adb4ed13-3af9-4ccb-a3f1-886fe0bea6a4">6,472</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMi0zLTEtMS01ODA3Nw_88bf651d-2463-43b0-ab3a-98928a40e951">2.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMy0xLTEtMS01ODA3Nw_fa45d1bd-8c9b-45b2-946d-d7fca3418a1e">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMy0zLTEtMS01ODA3Nw_143cfa17-2cae-425b-a48b-3b37a08111ec">1.65</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNC0xLTEtMS01ODA3Nw_e0bdc9bb-aa2c-4748-8c3f-9a7f6186924c">56</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNC0zLTEtMS01ODA3Nw_67be8eba-bf7d-40e4-be10-1aad6fbab827">5.84</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNS0xLTEtMS01ODA3Nw_257f8bcd-30c1-4c88-b0a4-facb48a8ed74">20,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNS0zLTEtMS01ODA3Nw_00daba24-dc6e-4ad6-b43e-6baa3463f8ac">4.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNi0xLTEtMS01ODA3Nw_cdaff733-1cd5-45fb-9642-76bce9f04d1a">9,185</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNi0zLTEtMS01ODA3Nw_431e36b5-0629-40ba-83db-31e19a945dd1">5.97</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><ix:continuation id="i2f852c133bd84fe09f8d64d61ab754e8" continuedAt="ied650a0a222d41dbb568b6171871aaa6"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2OA_a81df142-86b8-49ae-8850-550bbf8d0bc2" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iffc784fcdb3041df855d022e9e60e484_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMS0xLTEtMS01ODA3Nw_d3f4b0f9-1087-4149-b7c2-5a79a1e3ce0b">1,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iffc784fcdb3041df855d022e9e60e484_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMS0zLTEtMS01ODA3Nw_7583ee25-ba59-4b8c-9c18-931bda7cf146">2.17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMi0xLTEtMS01ODA3Nw_752fd6c0-b714-450f-b128-e95c741bd9e9">1,784</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMi0zLTEtMS01ODA3Nw_a709b5d2-387a-402c-84c5-b58040c81f53">2.78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMy0xLTEtMS01ODA3Nw_5f385c16-8ffe-4d6d-8b42-6d0270770761">208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMy0zLTEtMS01ODA3Nw_bc491041-a52d-418e-a83c-36177dba075e">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNC0xLTEtMS01ODA3Nw_8542f338-5867-40b1-b88b-2b5eaff1427b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNC0zLTEtMS01ODA3Nw_71920061-89bf-4f9b-8c52-581de82869e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNS0xLTEtMS01ODA3Nw_a3555aeb-2f5d-41aa-a276-168962422b81">2,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNS0zLTEtMS01ODA3Nw_633be465-7840-42af-92dc-425265483884">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we sold approximately <ix:nonFraction unitRef="shares" contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTIzMA_414e06e1-05a2-4529-9e85-13e9e5716cd3">0.2</ix:nonFraction> million shares of our common stock under the ESPP. The shares were purchased by employees at an average purchase price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331" decimals="2" name="ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTM0Nw_93f8d916-5325-4d8f-8edb-428622e24f09">0.83</ix:nonFraction> per share resulting in proceeds to us of approximately $<ix:nonFraction unitRef="usd" contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331" decimals="-5" name="us-gaap:ProceedsFromStockPlans" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTQwNQ_b894a51e-067d-420a-afce-0c77c06a418d">0.1</ix:nonFraction> million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div></ix:continuation><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied650a0a222d41dbb568b6171871aaa6">Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the three months ended March&#160;31, 2023, we issued <ix:nonFraction unitRef="shares" contextRef="i38458ac6496e4b97bcf456606e115021_D20230101-20230331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTY2Ng_aecab418-6964-4f2d-9f28-a211de6a1059">no</ix:nonFraction> shares of our common stock to members of the board of directors in accordance with the program.</ix:continuation> </span></div><div id="iea6a0b1ea655406093eb9e951c03313e_73"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RleHRyZWdpb246NjUzNmU1Y2JiOTgwNDgyMmIxYWMwMzNkMDg3MjgwNWVfOTQw_a628d829-ca60-4f15-818c-4a6666d27401" continuedAt="i728d623f923c48928b60b65c75be85b6" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:continuation id="i728d623f923c48928b60b65c75be85b6"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three months ended March&#160;31, 2023 and 2022, all potential common shares were determined to be anti-dilutive. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RleHRyZWdpb246NjUzNmU1Y2JiOTgwNDgyMmIxYWMwMzNkMDg3MjgwNWVfOTQx_fe4af8bd-b806-4791-969f-175824cf4c5a" escape="true"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfMi0xLTEtMS01ODA3Nw_797a9159-cf6e-4521-8501-0f23a366fed5">26,773</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfMi0zLTEtMS01ODA3Nw_e3f39439-a797-474b-bd99-2539a2fbba49">28,071</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0xLTEtMS01ODA3Nw_1ad1197c-662f-4b11-8e73-9c8e357186af"><ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0xLTEtMS01ODA3Nw_4a62271b-e979-4a80-b6a6-0f047b8b6500">207,023</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0zLTEtMS01ODA3Nw_6be147f6-0b7b-4c4c-aac6-9c7c74ff3bb2"><ix:nonFraction unitRef="shares" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0zLTEtMS01ODA3Nw_ea82c96f-963d-4205-b796-3b502843c81b">130,935</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0xLTEtMS01ODA3Nw_6d33f965-059d-44df-be1a-8b2854173443"><ix:nonFraction unitRef="usdPerShare" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0xLTEtMS01ODA3Nw_c0c8c457-ba99-481c-b6fc-db5ea3523b89">0.13</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0zLTEtMS01ODA3Nw_c589ed2b-4fa4-4069-942f-13059322e8e5"><ix:nonFraction unitRef="usdPerShare" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0zLTEtMS01ODA3Nw_c77a3f8a-e073-4cda-b9c0-4852c1855820">0.21</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div></ix:nonNumeric><ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RleHRyZWdpb246NjUzNmU1Y2JiOTgwNDgyMmIxYWMwMzNkMDg3MjgwNWVfOTQy_d65e5dbd-38cf-4f55-8834-2c9241d7897f" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:69.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e0beb2c643043e5ac96aa6e57782a75_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfMi0xLTEtMS01ODA3Nw_7437164d-2ad2-4396-b215-2e0eb07bacb2">19,855</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab6e5d2a709c4d4a89b9436290d7efe6_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfMi0zLTEtMS01ODA3Nw_f1c4d620-e98b-4f00-b67b-977f97f58217">13,266</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNC0xLTEtMS01ODA3Nw_570add34-8cee-41ec-8ccc-31cd9e9140e1">2,931</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3414587956434b98b32c8ddc23e1990e_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNC0zLTEtMS01ODA3Nw_fb51c3a9-b3c8-4bf9-8c2a-8d83d4b2fea6">4,412</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idee67a217ee640f3ae98f97ef8b95003_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNi0xLTEtMS01ODA3Nw_e3b9e762-7426-4f2c-89ba-99a853fd943d">205</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9b51b129be104da4b12d3221e1e2ce43_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNi0zLTEtMS01ODA3Nw_1213074a-bb5a-4ebc-83d5-644d10a59223">154</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNy0xLTEtMS01ODA3Nw_efba8f49-26ec-4241-ad89-1b51f38a46b3">22,991</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNy0zLTEtMS01ODA3Nw_af49ad7b-e4c6-4a93-ba00-51c147be66ef">17,832</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14. <ix:nonNumeric contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfMjg2MQ_4d2b0714-5389-43df-a5e7-b913e45c37b5" continuedAt="i17c00d38e78a4904b8a9346757094a55" escape="true">CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i17c00d38e78a4904b8a9346757094a55"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, <ix:nonFraction unitRef="claim" contextRef="ib1cf5f5ae42646abb1e513d35f625822_D20210730-20210812" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODE5MzE5_bf43f123-a543-469d-b840-21ac52ea4601">two</ix:nonFraction> putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and <ix:nonFraction unitRef="defendant" contextRef="ib1cf5f5ae42646abb1e513d35f625822_D20210730-20210812" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODE5NDgw_045852fb-fc43-44c3-a0e3-e645935ff83a">two</ix:nonFraction> current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and Siegel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On July 19, 2022, the court consolidated the <ix:nonFraction unitRef="claim" contextRef="i85da43d6cf444786a450dbf73698f7f9_D20220719-20220719" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODIwMjEy_fa70f8d1-4bf7-45f5-8b65-7014e5816ed0">two</ix:nonFraction> putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#8217;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their complaint and defendants filed an opposition to the motion for leave to further amend the complaint. On April 6, 2023, the court granted plaintiff&#8217;s motion for leave to further amend the complaint. With the second amended complaint, the plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between March 6, 2020 and July 19, 2021.  The parties have stipulated to a schedule for the filing of Defendants second motion to dismiss on June 2, 2023, and a hearing on the motion to dismiss to held on September 14, 2023. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, <ix:nonFraction unitRef="claim" contextRef="icfbdf47e462e49459e70036c484a3c1f_D20211207-20220329" decimals="INF" name="us-gaap:LossContingencyNewClaimsFiledNumber" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODIwOTg4_f104ad26-bcbc-4033-b572-1086b2e895fa">two</ix:nonFraction> verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets, for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#8217;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from <ix:nonFraction unitRef="defendant" contextRef="icfbdf47e462e49459e70036c484a3c1f_D20211207-20220329" decimals="INF" name="us-gaap:LossContingencyNumberOfDefendants" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODIxODQ5_a148b08f-63a5-462a-9a58-af4b6aeb1a87">two</ix:nonFraction> executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of March&#160;31, 2023, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and <ix:nonFraction unitRef="usd" contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfMjgxNA_8e3cdf79-78e3-423c-a9b3-fdc003dc610f">no</ix:nonFraction> contingent liabilities were accrued as of March&#160;31, 2023.</span></div></ix:continuation><div id="iea6a0b1ea655406093eb9e951c03313e_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the condensed financial statements and notes thereto included elsewhere in this report and with the audited financial statements and related notes thereto included as part of our Annual Report on Form&#160;10-K for the&#160;year ended December&#160;31, 2022. This discussion and analysis and other parts of this report contain forward-looking statements that involve risk and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the section of this report entitled &#8220;Risk Factors.&#8221; These forward-looking statements speak only as of the date hereof. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason. Unless the context requires otherwise, the terms &#8220;Ardelyx&#8221;, &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221;, and &#8220;our&#8221; refer to Ardelyx,&#160;Inc.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_88"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent, and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). In April 2023, we resubmitted a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the approval of XPHOZAH (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy, under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery stage asset, RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since commencing operations in October 2007, substantially all our efforts have been dedicated to our research and development (&#8220;R&amp;D&#8221;) activities, including developing tenapanor and developing our proprietary drug discovery and design platform. We realized our first product sales of IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) in March 2022. As of March&#160;31, 2023, we had an accumulated deficit of $806.9 million.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we invest in the commercialization of IBSRELA, seek to gain approval in the U.S. for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor); prepare for and commercialize XPHOZAH in the U.S., if approved; and incur manufacturing and development cost for tenapanor. To date, we have funded our operations from the sale and issuance of common stock and convertible preferred stock, funds from our collaboration partnerships, which includes license fees, milestones and product supply revenue, funds from our loan agreements with our lenders, as well as from sales of IBSRELA.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commercial Product</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA for IBS-C</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our unique discovery platform and deep understanding of the primary mechanism of sodium transport in the intestine resulted in our discovery and development of IBSRELA, a first-in-class, FDA approved, sodium hydrogen exchange 3 ("NHE3") inhibitor for the treatment of IBS-C in adults. IBSRELA acts locally in the gut and is minimally absorbed. IBS-C is a gastrointestinal ("GI") disorder characterized by both abdominal pain and altered bowel movements, and is estimated to affect 12 million people in the U.S. IBS-C is associated with significantly impaired quality of life, reduced productivity, and substantial economic burden. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We recognized our first sales of IBSRELA in the U.S. in March 2022. For our commercial launch of IBSRELA, we designed a market-responsive commercial strategy and built a commercial organization highly experienced in launching novel therapies into specialty areas. The dynamics of the IBS-C market reflect an established patient base, limited number of competitors all confined to a single mechanism of action, concentrated number of prescribers, and recognized unmet need. In addition, market research indicated a favorable response to the IBSRELA product profile as a novel mechanism therapy. These dynamics enabled a targeted promotional focus on patients currently being managed for IBS-C by the approximately 9,000 high-writing healthcare providers that account for 50% of IBS-C prescriptions. Central to our go to market strategy for IBSRELA has been our highly experienced specialty sales force, many with existing relationships across their GI target base, full company engagement, and innovative peer-to-peer and digital initiatives. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect competition for IBSRELA will come largely from the three prescription products indicated for IBS-C: Linzess (linaclotide), Amitiza (lubiprostone) and Trulance (plecanatide). Generic lubiprostone is also available in the U.S. Additionally, over-the-counter products, not indicated for IBS-C are commonly used to treat the constipation component of IBS-C, alone and in combination with the IBS-C-indicated prescription therapies.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma") in China and Knight Therapeutics, Inc. ("Knight") in Canada for IBSRELA for IBS-C. Knight is currently marketing IBSRELA in Canada.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Pipeline</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Development Candidate XPHOZAH: A Potential New Approach for the Control of Serum Phosphorus in Adult Patients with CKD on Dialysis Who Have Had an Inadequate Response or Intolerance to a Phosphate Binder Therapy</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH (tenapanor) is a first-in-class medicine being developed for the control of serum phosphorus, or hyperphosphatemia, in adult patients with CKD on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy. XPHOZAH has a unique mechanism of action and acts locally in the gut to inhibit NHE3. This results in the tightening of the epithelial cell junctions, thereby significantly reducing paracellular uptake of phosphate, the primary pathway of phosphate absorption. It is estimated that there are more than 550,000 adult patients with CKD on dialysis in the U.S. and approximately 80% of those patients are being treated with phosphate lowering therapies. Seventy-seven percent of patients treated with phosphate binders to treat hyperphosphatemia were unable to consistently maintain phosphorous levels &lt;=5.5 mg/dL over a six-month period. If approved, XPHOZAH would be the first therapy for phosphate management that blocks phosphate absorption at the primary site of uptake. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, we submitted a NDA to the FDA for XPHOZAH. The NDA was supported by three Phase 3 trials involving more than 1,200 adult patients that evaluated the use of tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis, with two trials evaluating tenapanor as monotherapy and one trial evaluating tenapanor as part of a dual mechanism approach with phosphate binders. All three Phase 3 trials met their primary and key secondary endpoints.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2021, we received a Complete Response Letter ("CRL") from the FDA&#8217;s Division of Cardiology and Nephrology ("the Division") regarding our NDA for XPHOZAH. In December 2021 we submitted a Formal Dispute Resolution Request ("FDRR") to the Office of Cardiology, Hematology, Endocrinology and Nephrology ("OCHEN"). At the request of the FDA&#8217;s Office of New Drugs ("OND"), as part of our second level of appeal of the CRL, a Cardiovascular and Renal Drug Advisory Committee meeting on was held on November 16, 2022 with the committee voting that the benefits of XPHOZAH outweigh its risks nine to four as a monotherapy and ten to two, with one abstention, in combination with phosphate binder therapy. In December 2022, the OND granted our appeal to the CRL for the NDA for XPHOZAH and directed the Division to work with us to develop an appropriate label for the commercialization of XPHOZAH. We believe that a label could reflect an indication for patients whose hyperphosphatemia is insufficiently managed on binder therapy. On February 13, 2023, we participated in a Type A meeting with the Division where we discussed the resubmission of the NDA, and the information to be contained in the resubmitted NDA. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2023, we resubmitted a NDA to the FDA for the approval of XPHOZAH for the control of serum phosphate in adult patients with CKD on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy. An Acknowledgement of Receipt letter from the FDA, confirming the resubmission is complete, is expected in mid-May. We expect that the letter will include the classification of the resubmission and the review goal date. We currently expect that the FDA will act upon the XPHOZAH NDA in the second half of 2023, and that, if approved, we will launch XPHOZAH in the second half of 2023.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established commercial agreements with Kyowa Kirin, Co. Ltd. ("Kyowa Kirin") in Japan, Fosun Pharma in China and Knight in Canada for tenapanor for hyperphosphatemia. In October 2022, Kyowa Kirin submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Discovery and Developmental Assets</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a small molecule potassium secretagogue program, RDX013, for the potential treatment of hyperkalemia, or elevated serum potassium. Hyperkalemia is a common problem in patients with heart and kidney disease, particularly in patients taking customary blood pressure medications known as renin-angiotensin-aldosterone system ("RAAS") inhibitors. RDX013 is a novel mechanism agent designed to target the underlying biological mechanisms of potassium secretion to lower elevated potassium. We have completed a Phase 2 dose ranging clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia in CKD patients who are not on dialysis. While the results of the study demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a discovery program targeting the inhibition of the chloride bicarbonate exchanger for the treatment of metabolic acidosis, a highly prevalent comorbidity in CKD patients that is strongly correlated with disease progression and adverse outcomes. We have identified lead compounds that are potent, selective and proprietary inhibitors of bicarbonate secretion. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently expect to meaningfully advance either of these two assets until such time as we have determined our available resources can support additional activities after prioritization of the commercialization of IBSRELA and, if approved, XPHOZAH.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Partners</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusive rights to tenapanor in the U.S. and we have established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight in Canada for the development and commercialization of tenapanor for certain indications in their respective territories. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight (&#8220;Knight Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. In March 2021, Knight announced the commercial availability of IBSRELA in Canada, following its approval by Health Canada in April 2020. Under the terms of the Knight Agreement, Knight paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3&#160;million non-refundable, one-time payment in March 2018. We may also be eligible to receive approximately CAD 22.2&#160;million for development and commercialization milestones, or approximately $16.3&#160;million at the currency exchange rate on March&#160;31, 2023, of which $0.7&#160;million has been received and recognized as revenue as of March&#160;31, 2023. We are also eligible to receive royalties throughout the term of the agreement, and a transfer price for manufacturing services. The variable consideration related to the remaining development milestone payments has not been included in the transaction price as they were fully constrained at March&#160;31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with Kyowa Kirin (&#8220;2017 Kyowa Kirin Agreement&#8221;) for the development, commercialization and distribution of tenapanor in Japan for cardiorenal indications. Under the terms of the 2017 Kyowa Kirin Agreement, we received a $30.0&#160;million upfront payment from Kyowa Kirin, and we may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0&#160;million in total development and regulatory milestones, of which $20.0&#160;million has been received and recognized as revenue as of March&#160;31, 2023. We may also be eligible to receive approximately &#165;8.5 billion for commercialization milestones, or approximately $64.1&#160;million at the currency exchange rate on March&#160;31, 2023, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 11, 2022, we entered into a second amendment to the 2017 Kyowa Kirin Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and Kyowa Kirin agreed to a reduction in the royalty rate payable to us by Kyowa Kirin upon net sales of tenapanor in Japan. The royalty rate was reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, Kyowa Kirin agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment received in the fourth quarter of 2022 following Kyowa Kirin&#8217;s October 2022 filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following Kyowa Kirin&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that Kyowa Kirin submitted a NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from Kyowa Kirin for an aggregate of $35.0 million for milestone payments and payments under the 2022 Amendment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun Pharma (&#8220;Fosun Agreement&#8221;) for the development and commercialization of tenapanor in China for both hyperphosphatemia and IBS-C. Under the terms of the Fosun Agreement, Fosun paid us a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0&#160;million upfront</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">license fee. We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0&#160;million, of which $3.0&#160;million has been received and recognized as revenue as of March&#160;31, 2023, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to 20%.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impact of COVID-19</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global COVID-19 pandemic has impacted the operational decisions of companies worldwide. We have undertaken measures to protect our employees, partners, collaborators, and vendors, some of which impact our operations. To date, we have been able to continue our operations with our workforce, most of whom have the ability to work in company-provided offices or remotely, and our pre-existing infrastructure that supports secure access to our internal systems. For a discussion of risks of COVID-19 relating to our business, see &#8220;Part II: Other Information-Item 1A.- Risk Factors- Risks Related to Our Business-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221; As of the date of issuance of this financial report, we are not aware of any specific event or circumstance that would require updates to our estimates and judgments or revisions to the carrying value of our assets or liabilities. These estimates may change as new events occur and additional information is obtained.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_94"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of financial condition and results of operations is based on our condensed financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Critical accounting policies are those that require significant judgment and/or estimates by management at the time that financial statements are prepared such that materially different results might have been reported if other assumptions had been made. These estimates form the basis for making judgments about the carrying values of assets and liabilities. We base our estimates and judgments on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ materially from these estimates.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical accounting policies that we believe impact significant judgments and estimates used in the preparation of our condensed financial statements presented in this report are described in Part II, Item 7, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our Annual Report on Form 10-K filed with the SEC on March 2, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the&#160;three months ended March&#160;31, 2023, we did not adopt any new critical accounting policies and significant judgements and estimates. </span></div><div id="iea6a0b1ea655406093eb9e951c03313e_97"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of recent accounting pronouncements that we have adopted or may expect to adopt is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1 &#8211; Organization and Basis of Presentation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed financial statements (see Part I, Item 1 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Condensed Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, of this Quarterly Report on Form 10-Q).</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_100"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue to date has been generated primarily through license, research and development collaborative agreements with various collaboration partners. We realized our first commercial product sales of IBSRELA beginning in March 2022. In the future, we may generate revenue from a combination of our own product sales and payments in connection with our current or future collaborative partnerships, including license fees, other upfront payments, milestone payments, royalties and payments for drug product and/or drug substance. We expect that any revenue we generate will fluctuate in future periods as a result of, among other factors: the extent to which we are successful in our commercialization of IBSRELA; whether we are able to gain approval from the FDA for our NDA for XPHOZAH; our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors; whether and the extent to which we are successful in our commercialization of XPHOZAH, if approved; whether or when XPHOZAH, if approved, along with other oral ESRD-related drugs without an injectable or intravenous equivalent, are bundled into the end stage renal disease (&#8220;ESRD&#8221;) prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur; the timing and progress of goods and services provided pursuant to our current or future collaborative partnerships; our or our collaborators&#8217; achievement of clinical, regulatory or commercialization milestones, to the extent achieved; the timing and amount of any payments to us relating to the aforementioned milestones; addressing any competing technological and market developments; maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; attracting, hiring, and retaining qualified personnel; and the extent to which tenapanor or other licensed products are approved and successfully commercialized by a collaboration partner. If our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current collaboration partners or any future collaboration partners fail to obtain regulatory approval for tenapanor or other licensed products, our ability to generate future revenue from our collaborative arrangements, and our results of operations and financial position, would be materially and adversely affected. Our past revenue performance is not necessarily indicative of results to be expected in future periods.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue consists of the cost of commercial goods sold to our Customers and international partners under product supply agreements, as well as royalty expense based on sales of tenapanor. We capitalize inventory costs associated with the production of our products after regulatory approval or when, based on management&#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized. Otherwise, such costs are expensed as research and development. A portion of the costs of IBSRELA units recognized as revenue during the three months ended March&#160;31, 2023 were expensed prior to the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. We believe our cost of revenue for the three months ended March&#160;31, 2023 would have been $0.4 million higher if we had not previously expensed certain material and production costs with respect to the units sold. The increase in cost of revenue as of March 31, 2022 would have been immaterial. As of March&#160;31, 2023 and December&#160;31, 2022, we had approximately $26.9&#160;million and $28.0&#160;million, respectively, of inventory on hand that was previously expensed as research and development expense and will not be reported as cost of revenue sold in future periods when sales of IBSRELA are recognized as revenue.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of revenue includes payments due to AstraZeneca AB (&#8220;AstraZeneca&#8221;), which under the terms of a termination agreement entered into in 2015 (&#8220;AZ Termination Agreement&#8221;) is entitled to (i) future royalties at a rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from our collaboration partners in connection with the development and commercialization of tenapanor or other NHE3 products.&#160;We have agreed to pay&#160;AstraZeneca up to a maximum of $75.0 million in the aggregate for (i) and (ii). We recognize these expenses as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to AstraZeneca. To date, we have recognized an aggregate of $16.4 million as cost of revenue under the AZ Termination Agreement. See details in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Collaboration and Licensing Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, under AstraZeneca, in the notes to our financial statement of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the October 2021 restructuring plan, we eliminated our internal research organization and we do not currently expect to meaningfully advance our discovery efforts with respect to our discovery and developmental assets until such time as we have determined our available resources can support additional activities after prioritization of the commercialization of IBSRELA and, if approved, XPHOZAH. We recognize all research and development expenses as they are incurred to support the discovery, research, development and manufacturing of our product candidates. Research and development expenses include, but are not limited to, the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external research and development expenses incurred under agreements with consultants, third-party contract research organizations (&#8220;CROs&#8221;) and investigative sites where a substantial portion of our clinical studies are conducted, and with contract manufacturing organizations where our clinical supplies are produced;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with supplies and materials consumed in connection with our research operations;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with producing XPHOZAH prior to FDA approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with producing discovery and developmental assets prior to FDA approval;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other costs associated with research, clinical development and regulatory activities;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, which include salaries, bonuses, benefits, travel and stock-based compensation; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation and amortization expense, information technology expense and other supplies.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses relate to sales and marketing, finance, human resources, legal and other administrative activities, including information technology investments. Selling, general and administrative expenses consist primarily of personnel costs, outside professional services, marketing, advertising and legal expenses, facilities costs not otherwise allocated to research and development and other general and administrative costs.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense represents the interest paid on our loan payable.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-cash interest expense related to the sale of future royalties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense related to the sale of future royalties represents the imputed interest expense on our deferred royalty obligation related to the sale of future royalties using the effective interest method. As further described in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in June 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with Kyowa Kirin based upon Kyowa Kirin's net sales of tenapanor in Japan for hyperphosphatemia. As part of the HCR Agreement, we received a $10.0 million upfront payment from HCR in June 2022 and recorded it as a deferred royalty obligation on our balance sheet. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from Kyowa Kirin.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists of interest income earned on our cash and cash equivalents and available-for-sale investments, the periodic revaluation of the exit fee related to our loan, gains on sales of property and equipment, and currency exchange gains and losses. </span></div><div id="iea6a0b1ea655406093eb9e951c03313e_103"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations as of March&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2023, for any other interim period, or for any other future year.</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">three months ended March&#160;31, 2023 and 2022</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our total revenue (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.138%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product supply revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,369&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,901&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total revenues during the three months ended March&#160;31, 2023 is primarily attributable to $11.4&#160;million of net product sales for IBSRELA to our customers subsequent to the commercial launch of IBSRELA in March 2022. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our operating expenses (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:58.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.497%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.912%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,537&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,803&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,464&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,433&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase to cost of revenue for the three months ended March&#160;31, 2023 is primarily attributable to payments due to AstraZeneca under the AZ Termination Agreement for IBSRELA net product sales during the three months ended March&#160;31, 2023. In addition, during the three months ended March&#160;31, 2023, we incurred $0.4 million cost of goods sold for net product sales of IBSRELA.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our research and development expenses (dollars in thousands):</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:64.033%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.247%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.541%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.208%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.393%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.767%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External R&amp;D expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,095&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities, equipment and depreciation expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(484)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,093&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,851&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in our external R&amp;D expenses for the three months ended March&#160;31, 2023 was not material and was primarily the result of external regulatory consulting for tenapanor.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in selling, general and administrative expenses for the three months ended March&#160;31, 2023 was primarily due  to increased costs associated with the commercial launch of IBSRELA. The increases consisted of headcount and related personnel costs and external spending for disease awareness initiatives, commercial infrastructure and strategy. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our interest expense (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:61.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,028)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(746)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(282)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in interest expense for the three months ended March&#160;31, 2023 was due to a higher variable interest rate applied to our loan balance primarily resulting from market fluctuations.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Cash Interest Expense Related to the Sale of Future Royalties</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our interest expense (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:61.178%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.811%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.743%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash interest expense related to the sale of future royalties</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(969)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="24" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a) There was no non-cash interest expense related to the sales of future royalties during the prior year period.</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-cash interest expense related to the sales of future royalties for the three months ended March&#160;31, 2023 was due to the recognized amortization of the deferred royalty obligation that we recorded following the receipt of the $10.0&#160;million upfront payment from HCR during June 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Income, net</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our other income, net (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:61.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.717%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.719%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change <br/>2023 vs. 2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,302&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">818&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in other income, net for the three months ended March&#160;31, 2023 is primarily due to increased income on our investments resulting from higher returns on larger investment balances throughout the period.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_106"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of our cash, cash equivalents and investments (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.426%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change $</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,487&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liquid funds</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,373&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,909&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,464&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of approximately $130.4&#160;million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of March&#160;31, 2023 is $806.9&#160;million. Our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our plans for the next twelve months following the filing of these condensed financial statements on May&#160;3, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these condensed financial statements. We plan to address our operating cash flow requirements with our current cash, cash equivalents and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, the potential receipt of anticipated milestone payments from our collaboration partners, the potential receipt of anticipated payments from Kyowa Kirin under the 2022 Amendment, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash, cash equivalents and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these condensed financial statements, our liquidity, financial condition and business prospects will be materially affected. These condensed financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under a Registration Statement which was filed in July 2020 for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, received a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2023 we sold 15.5 million shares and received gross proceeds of $51.9 million at a weighted average sales price of approximately $3.35 per share under the 2021 Open Market Sales Agreement. As of March&#160;31, 2023, we have sold a total of 95.2 million shares and received the maximum gross proceeds of $150.0 million under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. As of March&#160;31, 2023, there have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into a loan and security agreement (&#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp ("SLR"). The 2022 Loan Agreement was subsequently amended on August 1, 2022 and February 9, 2023.  The 2022 Loan Agreement as amended provides for a senior secured term loan facility, with $27.5 million funded at closing and an additional $22.5 million that we may borrow on or prior to December 20, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by November 30, 2023 and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial funding of $27.5 million was used to repay the 2018 Loan and is funding our ongoing operations. We had $25.0 million principal from the 2018 Loan outstanding as of the closing date, as well as the 2018 Exit Fee in the amount of $1.5 million. Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. In connection with entering into the 2022 Loan Agreement, we entered into the 2022 Exit Fee agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded if certain conditions are met.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that our collaboration partner, Kyowa Kirin, submitted a New Drug Application to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis. In accordance with the terms of the 2022 Amendment, Kyowa Kirin paid an aggregate of $35.0 million to us in milestone payments and payments associated with the 2022 Amendment during the quarter ended December 31, 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of cash have been from the sale and issuance of common stock (in both public offerings and private placements), private placements of convertible preferred stock, funds from our collaboration partnerships, funds from our 2018 Loan Agreement and 2022 Loan Agreement, as well as from sales of IBSRELA. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary uses of cash have been to fund operating expenses, primarily research and development expenditures, as well as pre-commercial and commercial expenses. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in securing approval for our NDA for XPHOZAH, and the time and cost associated with securing such approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing, selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH; </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral ESRD-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur; </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of revenue, if any, that may be received by Kyowa Kirin in connection with the 2022 Kyowa Kirin Amendment;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of royalties we may receive as a result of sales of tenapanor by our collaboration partners in China and Canada, if any;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements for the discovery and/or development of other potential product candidates, including RDX013 and RDX020;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please see the risk factors set forth in Part II, Item 1A, Risk Factors, in this Quarterly Report on Form 10-Q for additional risks associated with our capital requirements.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CASH FLOW ACTIVITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows (dollars in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.128%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change 2022 vs. 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(44,795)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,175)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,777)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(519)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,924)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,653)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,351)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div id="iea6a0b1ea655406093eb9e951c03313e_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Operating Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities during the three months ended March&#160;31, 2023 increased by $17.2 million primarily as a result of changes to our operating assets and liabilities related to expenditures for commercial manufacturing and inventory for the production of IBSRELA.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_112"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Investing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by investing activities decreased by $12.1 million due to the timing of our investment maturities and purchases.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows from Financing Activities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) financing activities increased by $51.0 million primarily due to net proceeds from issuance of our common stock pursuant to the at the market offerings of $50.7 million during the three months ended March&#160;31, 2023 compared to $5.9 million during the three months ended March&#160;31, 2022. In addition, during the three months ended March&#160;31, 2022 we expended net $6.1 million in conjunction with entering into the 2022 Loan and repaying the principal outstanding under the 2018 Loan.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_121"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are subject to market risks, including interest rate fluctuation exposure through our investments, in the ordinary course of our business. However, the goals of our investment policy are the preservation of capital, fulfillment of liquidity needs and fiduciary control of cash. To achieve our goal of maximizing income without assuming significant market risk, we maintain our excess cash and cash equivalents in money market funds and short-term debt securities. Because of the short-term maturities of our cash equivalents, we do not believe that a decrease in interest rates would have any material negative impact on the fair value of our cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of $130.4&#160;million, which consist of bank deposits and money market funds, as well as high quality fixed income instruments including commercial paper and asset backed securities. The credit rating of our short-term investments must be rated A-1/P-1, or better by Standard and Poor&#8217;s and Moody&#8217;s Investors Service. Asset-backed securities must be rated AAA/Aaa. Money Market funds must be rated AAA/Aaa. Such interest-earning instruments carry a degree of interest rate risk. However, because our investments are high quality and short-term in duration, we believe that our exposure to interest rate risk is not significant and that a 10% movement in market interest rates would not have a significant impact on the total value of our portfolio, as noted above. We do not enter into investments for trading or speculative purposes.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate fluctuation exposure through our borrowings under the Loan Agreement and our investment in money market accounts which bear a variable interest rate. Borrowings under the 2022 Loan as amended bear interest at a floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website. A hypothetical increase in one-month CME Term SOFR of 100 basis points above the current one-month CME Term SOFR rate would have increased our interest expense by approximately $0.1&#160;million for the three months ended March&#160;31, 2023. As of March&#160;31, 2023, we had an aggregate principal amount of $27.5&#160;million outstanding pursuant to our 2022 Loan Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The majority of our transactions are denominated in U.S. dollars. However, we do have certain transactions that are denominated in currencies other than the U.S. dollar, primarily Swiss francs and the euro, and we therefore are subject to foreign exchange risk. The fluctuation in the value of the U.S. dollar against other currencies affects the reported amounts of expenses, assets and liabilities associated with a limited number of manufacturing activities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not use derivative financial instruments for speculative trading purposes, nor do we hedge foreign currency exchange rate exposure in a manner that entirely offsets the earnings effects of changes in foreign currency exchange rates. The counterparties to our forward foreign currency exchange contracts are creditworthy commercial banks, which minimizes the risk of counterparty nonperformance.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had no open forward foreign currency exchange contracts.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_124"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule&#160;13a-15(b)&#160;under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), our management, under the supervision and with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act) as of March&#160;31, 2023. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objective and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation, our principal executive officer and principal financial officer have concluded that, as of March&#160;31, 2023, our disclosure controls and procedures were effective at a reasonable assurance level.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 there were no changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inherent Limitations on Effectiveness of Controls</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting has inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper management override. Because of such limitations, there is a risk that material misstatements will not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_127"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II.&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_130"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and Siegel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On July 19, 2022, the court consolidated the two putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#8217;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their complaint and defendants filed an opposition to the motion for leave to further amend the complaint. On April 6, 2023, the court granted plaintiff&#8217;s motion for leave to further amend the complaint. With the second amended complaint, the plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between March 6, 2020 and July 19, 2021.  The parties have stipulated to a schedule for the filing of Defendants second motion to dismiss on June 2, 2023, and a hearing on the motion to dismiss to be held on September 14, 2023. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#8217;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of March&#160;31, 2023, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of March&#160;31, 2023.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;&#160;RISK FACTORS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. You should carefully consider these risks, as well as other information in this Quarterly Report on Form 10-Q, including our financial statements and the notes thereto and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations, cash flows, the trading price of our common stock and our growth prospects. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Financial Condition and Capital Requirements</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception and will incur losses in the future, which makes it difficult for us to assess our future viability; although our financial statements have been prepared on a going concern basis, our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our operating plans for the next twelve months, raising substantial doubt regarding our ability to continue as a going concern. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022, we commenced the commercialization of our first product, IBSRELA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tenapanor) for the treatment of irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;) in adult patients and have generated limited revenue from product sales to date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not profitable and have incurred losses in each year since our inception in October 2007, and we do not know whether or when we will become profitable. We continue to incur significant commercialization, development and other expenses related to our ongoing operations. As of March&#160;31, 2023, we had an accumulated deficit of $806.9&#160;million. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur substantial operating losses for the foreseeable future as we commercialize IBSRELA, seek to gain approval for XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tenapanor) for the control of serum phosphorus in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy; prepare for, and commercialize XPHOZAH, if approved; and incur manufacturing and development costs for tenapanor. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young LLP, our independent registered public accounting firm, included an explanatory paragraph in their opinion that accompanied our audited financial statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed on March 2, 2023, indicating our current liquidity position raises substantial doubt about our ability to continue as a going concern. We plan to address our operating cash flow requirements with our current cash, cash equivalents and short-term investments, cash generated from the sales of IBSRELA, and if approved, cash generated from the sales of XPHOZAH, our potential receipt of anticipated milestone payments from our collaboration partners, our potential receipt of anticipated payments from our collaboration partner, Kyowa Kirin, Co., Ltd. (&#8220;Kyowa Kirin&#8221;) in connection with the transaction entered into with Kyowa Kirin in April 2022 (&#8220;2022 Kyowa Kirin Amendment&#8221;) which amended our License Agreement entered into with Kyowa Kirin in 2017; with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash, cash equivalents and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months, our liquidity, financial condition and business prospects will be materially affected. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our prior losses, combined with expected future losses, have had and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. Further, the net losses we incur may fluctuate significantly from quarter-to-quarter and year-to-year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have substantial net operating loss and tax credit carryforwards for Federal and California income tax purposes. Such net operating losses and tax credits carryforwards may be reduced as a result of certain intercompany restructuring transactions. In addition, the future utilization of such net operating loss and tax credit carryforwards and credits will be subject to limitations, pursuant to Sections 382 and 383 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;).  In general, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a cumulative change of more than 50 percentage points (by value) in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss (&#8220;NOL&#8221;) carryforwards and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may be limited. We have experienced ownership changes in the past and may experience additional ownership changes in the future, as a result of subsequent changes in our stock ownership, some of which are outside our control. Accordingly, we may not be able to utilize a material portion of our NOL carryforwards, even if we achieve profitability.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require additional financing for the foreseeable future as we invest in the commercialization of IBSRELA in the U.S, and prepare for and commercialize XPHOZAH in the U.S., if approved. The inability to access necessary capital when needed on acceptable terms, or at all, could force us to reduce our efforts to commercialize IBSRELA or delay or limit the commercialization of XPHOZAH, if approved. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, most of our resources have been dedicated to our research and development activities, including developing tenapanor. We believe that we will continue to expend substantial resources for the foreseeable future, including, costs associated with our efforts to commercialize IBSRELA, which we began selling in the U.S. in March 2022; costs associated with our efforts to pursue approval for our NDA for XPHOZAH; conducting pediatric clinical trials for IBSRELA and XPHOZAH, if approved; and manufacturing for IBSRELA and, if approved XPHOZAH. Our future funding requirements will depend on many factors, including, but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we are able to generate product revenue from sales of IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in securing approval for our NDA for XPHOZAH, and the time and cost associated with securing such approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party reimbursement for IBSRELA and, if approved, the sales price and the availability of adequate third-party reimbursement for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the manufacturing, selling and marketing costs associated with IBSRELA and, if approved, XPHOZAH; </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral ESRD-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur; </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to maintain our existing collaboration partnerships and to establish additional collaboration partnerships, in-license/out-license, joint ventures or other similar arrangements and the financial terms of such agreements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt and amount of any milestones that may be received from our collaboration partners in connection with tenapanor, if any</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of revenue, if any, that may be received from Kyowa Kirin in connection with the 2022 Kyowa Kirin Amendment;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing, receipt, and amount of royalties we may receive as a result of sales of tenapanor by our collaboration partners in China and Canada, if any;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cash requirements for the discovery and/or development of other potential product candidates, including RDX013 and RDX020;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the time and cost necessary to respond to technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">brought by others in connection with the development, manufacture or commercialization of tenapanor or any of our product candidates; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the payment of interest and principal related to our loan and security agreement entered into with SLR Investment Corp. in February 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional funds may not be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to limit or reduce our commercialization of IBSRELA, or delay or limit the commercialization of XPHOZAH, if approved, or delay or limit additional clinical trials for tenapanor. Additionally, our inability to access capital on a timely basis and on terms that are acceptable to us may force us to restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA or XPHOZAH, if approved, through the use of alternative structures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have generated limited revenue from product sales and may never be profitable. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling IBSRELA in the U.S. in March 2022, and have generated limited revenue from product sales to date. We have no other products approved for sale. On April 17, 2023, we resubmitted our NDA for XPHOZAH following the U.S. Food and Drug Administration&#8217;s (&#8220;FDA&#8221;) Center for Drug Evaluation and Research, Office of New Drugs (&#8220;OND&#8221;) decision to grant our appeal of the Complete Response Letter (&#8220;CRL&#8221;) for the NDA for XPHOZAH. We expect to receive an Acknowledgement of Receipt letter from the FDA in mid-May, and that such letter will include the classification of the resubmission and the goal review date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurances that our NDA for XPHOZAH will be approved by the FDA. There can be no assurances that we will be successful in increasing the amount of product revenue from sales of IBSRELA. There can be no assurances that we will generate sufficient product revenue from sales of IBSRELA and, if approved, XPHOZAH, to cover our expenses. Our ability to generate product revenue from sales or pursuant to milestone or royalty payments depends heavily on many factors, including but not limited to:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to successfully commercialize IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining market acceptance of IBSRELA as a viable treatment option for IBS-C;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we are successful in our efforts to secure approval for our NDA for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral ESRD-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide an adequate (in amount and quality) supply of product to support the market demand for IBSRELA and, if approved, XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">addressing any competing technological and market developments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets, and know-how, and our ability to develop, manufacture and commercialize our product candidates and products without infringing intellectual property rights of others; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attracting, hiring, and retaining qualified personnel.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our commercialization of IBSRELA, and if we are successful in obtaining regulatory approval to market XPHOZAH, our revenue will be dependent, in part, upon the size of the markets in the U.S. and the label for which approval is granted, accepted price for the product, and the ability to get reimbursement at any price. While there is significant uncertainty related to the insurance coverage and reimbursement of newly approved products in general in the U.S., there is additional uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH, which, if approved, will be marketed for the control of serum phosphorus in adult patients with CKD on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy or for another other related indication. If we are successful in obtaining regulatory approval to market XPHOZAH for such indication, our ability to generate and sustain future revenues from sales of XPHOZAH, may be dependent upon whether and when XPHOZAH, along with other oral end stage renal disease (&#8220;ESRD&#8221;)-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur. See &#8220;Third-party payor coverage and reimbursement status of newly approved products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue&#8221; below. Additionally, if the number of adult patients for IBSRELA or, if approved XPHOZAH, is not as significant as we estimate, the indication approved by regulatory authorities for XPHOZAH is narrower than we expect, coverage and reimbursement for either IBSRELA or XPHOZAH, if approved, are not available in the manner and to the extent we expect, or the reasonably accepted population for treatment is narrowed by competition, physician choice or treatment guidelines, we may not generate significant revenue from the sale of IBSRELA or XPHOZAH, if approved. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to generate adequate revenue from product sales would likely depress our market value and could impair our ability to raise capital, expand our business, discover or develop other product candidates or continue our operations. A decline in the value of our common stock could cause our stockholders to lose all or part of their investment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Risks Related to Our Business</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on the successful commercialization of IBSRELA, and there is no guarantee that we will achieve sufficient market acceptance for IBSRELA, secure adequate coverage and reimbursement for IBSRELA, or generate sufficient revenue from product sales of IBSRELA. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began selling IBSRELA in the U.S. in March 2022. The overall commercial success of IBSRELA will depend on a number of factors, including the following:</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for IBSRELA;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and sustain an adequate level of coverage and reimbursement for IBSRELA by third-party payors;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of IBSRELA as a treatment for adult patients with IBS-C;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the size of the treatable patient population; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales, market access and marketing efforts; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether physicians view IBSRELA as a safe and effective treatment for adult patients with IBS-C, which will impact the adoption of IBSRELA by physicians for the treatment of IBS-C;</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of IBSRELA compared to alternative and competing treatments; </span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of IBSRELA;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to IBSRELA;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights directed to IBSRELA, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of IBSRELA following approval.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of potential revenue we may achieve from the commercialization of IBSRELA is subject to these and other factors, and may be unpredictable from quarter-to-quarter. If the number of patients in the market for IBSRELA or the price that the market can bear is not as significant as we estimate, or if we are not able to secure adequate physician and patient acceptance of IBSRELA or adequate coverage and reimbursement for IBSRELA, we may not generate sufficient revenue from sales of IBSRELA. Any failure of IBSRELA to achieve market acceptance, sufficient third-party coverage or reimbursement, or commercial success would adversely affect our results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are pursuing regulatory approval for XPHOZAH. There can be no assurances that we will be successful in obtaining such regulatory approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pursuing regulatory approval for XPHOZAH. To date, we have invested a significant amount of our efforts and financial resources in the research and development of XPHOZAH. On July 28, 2021, we received a CRL from the FDA&#8217;s Division of Cardiology and Nephrology (&#8220;Division&#8221;) regarding our NDA for XPHOZAH. According to the CRL, the Division determined that the magnitude of the treatment effect observed in our Phase 3 clinical trials was small and of unclear clinical significance. Following an End-of-Review Type A meeting (&#8220;End of Review Meeting&#8221;) in October 2021, with the Division, we submitted a Formal Dispute Resolution Request (&#8220;FDRR&#8221;) in December 2021. The FDRR was focused on demonstrating that the data submitted in the NDA supported the clinical significance of the treatment effect of tenapanor in the control of serum phosphorus in adult patients with CKD on dialysis. On February 4, 2022, we received an Appeal Denied Letter ("ADL") from the Office of Cardiology, Hematology, Endocrinology and Nephrology (&#8220;OCHEN&#8221;). On February 18, 2022, we submitted an appeal of the ADL to the OND. In April 2022, we received an interim response from the OND requesting additional input from the Cardiovascular and Renal Drug Advisory Committee (&#8220;CRDAC&#8221;). A CRDAC meeting was held in November 2022 with the Committee voting that the benefits of XPHOZAH outweigh its risks nine to four as a monotherapy and ten to two, with one abstention, in combination with phosphate binder therapy. In December 2022, the OND granted our appeal of the CRL for the NDA for XPHOZAH and directed the Division to work with us to develop an appropriate label for the commercialization of XPHOZAH. We believe that a label could reflect an indication for the control of serum phosphorus in adult patients with CKD on dialysis who have an inadequate response or intolerance to a phosphate binder therapy. On February 13, 2023, we participated in a Type A meeting with the Division where we discussed the resubmission of the NDA, and the information to be contained in the resubmitted NDA. We resubmitted the NDA for XPHOZAH on April 17, 2023. In mid-May, we expect to receive notification from the Division acknowledging receipt of the NDA and including the classification of the resubmission (Class 1 or Class 2) and the review goal date. We currently expect that the FDA will act upon the XPHOZAH NDA in the second half of 2023, and that, if approved, we will launch XPHOZAH in the second half of 2023. There can be no assurances that the granting of our appeal to the CRL and resubmission of our NDA will result in approval of our NDA for XPHOZAH. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval may result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are successful in obtaining regulatory approval for XPHOZAH, there is no guarantee that we will achieve sufficient market acceptance for XPHOZAH, secure adequate coverage and reimbursement for XPHOZAH or generate sufficient revenue from product sales of XPHOZAH. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be successful in obtaining FDA approval for XPHOZAH, and if we are able to obtain approval, there is no guarantee that we will achieve sufficient market acceptance for XPHOZAH, secure adequate coverage and reimbursement for XPHOZAH or generate sufficient revenue from product sales of XPHOZAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are successful in obtaining approval for XPHOZAH, the commercial success of XPHOZAH will depend on a number of factors, including the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or when XPHOZAH, along with other oral ESRD-related drugs without an injectable or intravenous equivalent, are bundled into the ESRD prospective payment system, and the manner in which such introduction into the ESRD prospective payment system may occur;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of the third-party manufacturers we contract with to provide an adequate (in amount and quality) supply of product to support the market demand for both IBSRELA and XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether or not the content and breadth of the label approved by the FDA for XPHOZAH may materially and adversely impact our ability to commercialize the product for the approved indication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of adverse side effects of XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of XPHOZAH as safe, effective and well-tolerated by patients and the medical community, and, the extent to which the issuance of a CRL by the FDA has impacted the potential acceptance of XPHOZAH as safe, effective and well-tolerated;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the commercialization of IBSRELA and XPHOZAH and the complex pricing and reimbursement negotiations that may arise with marketing products containing the same active ingredient at different doses for separate indications;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability, perceived advantages, relative cost, relative safety and relative efficacy of XPHOZAH compared to alternative and competing treatments;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and sustaining an adequate level of coverage and reimbursement for XPHOZAH by third-party payors;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in lawsuits in connection with enforcing intellectual property rights in and to XPHOZAH;</span></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our potential involvement in third-party interference, opposition, derivation or similar proceedings with respect to our patent rights, and avoiding other challenges to our patent rights and patent infringement claims; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety and tolerability profile of XPHOZAH following approval. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA and/or, if approved and commercialized, XPHOZAH, may cause undesirable side effects or have other properties that could limit the commercial success of the product. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by IBSRELA and/or, if approved, XPHOZAH could cause us or regulatory authorities to interrupt, delay or halt the commercialization of the product. Despite our receipt of marketing approval for IBSRELA and the completion of our Phase 3 clinical program for XPHOZAH, the prevalence and/or severity of side effects caused by IBSRELA and/or, if approved and commercialized, XPHOZAH could result in a number of potentially significant negative consequences could occur, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be required to recall the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof, including the imposition of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) which could require creation of a Medication Guide or patient package insert outlining the risks of such side effects for distribution to patients, a communication plan to educate healthcare providers of the drugs&#8217; risks, as well as other elements to assure safe use of the product, such as a patient registry and training and certification of prescribers;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or a collaboration partner may be subject to fines, injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities may require the addition of new labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product may become less competitive; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our reputation may suffer. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing events could prevent us, or a collaboration partner, from achieving or maintaining market acceptance of IBSRELA and/or, if approved, XPHOZAH, and could result in the loss of significant revenue to us, which would materially and adversely affect our results of operations and business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third-party payor coverage and reimbursement status of newly commercialized products are uncertain. Failure to obtain or maintain adequate coverage and reimbursement for IBSRELA and, if approved, XPHOZAH could limit our ability to market those products and decrease our ability to generate revenue.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pricing, coverage and reimbursement of IBSRELA and XPHOZAH, if approved, must be adequate to support a commercial infrastructure. The availability and adequacy of coverage and reimbursement by governmental and private payors are essential for most patients to be able to afford treatments. Sales of IBSRELA and, if approved and commercialized, XPHOZAH, will depend substantially, both domestically and abroad, on the extent to which the costs of the product will be paid for by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or reimbursed by government authorities, private health insurers, and other third-party payors. If coverage and reimbursement are not available, or are available only to limited levels, we, or our collaboration partners, may not be able to successfully commercialize IBSRELA, or XPHOZAH, if approved. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize a return on our investment.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the U.S., the principal decisions about coverage and reimbursement for new drugs are typically made by the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the United States Department of Health and Human Services responsible for administering the Medicare program, as CMS decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for products such as ours.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increased uncertainty related to insurance coverage and reimbursement for drugs, like XPHOZAH, which, if approved, may be marketed for the control of serum phosphorus in adult patients with CKD on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy or for another other related indication. In January 2011, CMS implemented a new prospective payment system for dialysis treatment. Under the ESRD prospective payment system, CMS generally makes a single bundled payment to the dialysis facility for each dialysis treatment that covers all items and services routinely required for dialysis treatments furnished to Medicare beneficiaries in Medicare-certified ESRD facilities or at their home, including the cost of certain routine drugs. The inclusion of oral medications without injectable or intravenous equivalents in the bundled payment was initially delayed until January 1, 2014, and through several subsequent legislative actions was delayed until January 1, 2025. As a result, absent further legislation or regulation on this matter, beginning in 2025, oral ESRD-related drugs without injectable or intravenous equivalents will be included in the ESRD bundle and separate Medicare payment for these drugs will no longer be available, as is the case today under Medicare Part D. While it is too early to project the full impact that bundling may have on sales of XPHOZAH, if approved and commercialized, and on our business should XPHOZAH be brought into the bundle in 2025, or at any time, we may be unable to sell XPHOZAH, if approved, to dialysis providers on a profitable basis.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., international operations are generally subject to extensive governmental price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, Japan, China and other countries has and will continue to put pressure on the pricing and usage of IBSRELA and XPHOZAH, even if regulatory approval is received in such countries. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medicinal products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the U.S., the reimbursement for our products may be reduced compared with the U.S. and may be insufficient to generate commercially reasonable revenue and profits. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, these caps may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of IBSRELA, and if approved and commercialized, XPHOZAH, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely completely on third parties to manufacture IBSRELA and XPHOZAH. If they are unable to comply with applicable regulatory requirements, unable to source sufficient raw materials, experience manufacturing or distribution difficulties or are otherwise unable to manufacture sufficient quantities to meet demand, our commercialization of IBSRELA and, if approved and commercialized, XPHOZAH and our development efforts for tenapanor may be materially harmed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have, nor do we plan to acquire, the infrastructure or capability internally to manufacture IBSRELA or XPHOZAH on a commercial scale, or to manufacture our drug supplies for use in the conduct of our nonclinical and clinical studies. The facilities used by our contract manufacturing organizations (&#8220;CMOs&#8221;) to manufacture our drug supply are subject to inspection by the FDA. Our ability to control the manufacturing process of our product candidates is limited to the contractual requirements and obligations we impose on our CMOs. Although they are contractually required to do so, we are completely dependent on our CMOs for compliance with the regulatory requirements, known as current Good Manufacturing Practice requirements (&#8220;cGMPs&#8221;), for manufacture of both active drug substances and finished drug products.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment. Manufacturers of pharmaceutical products often encounter difficulties in commercial production. These problems may include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, and shortages of qualified personnel, as well as compliance with federal, state and foreign regulations and the challenges associated with complex supply chain management. Even if our CMOs do not experience problems and commercial manufacturing is achieved, their maximum or available manufacturing capacities may be insufficient to meet commercial demand. Finding alternative manufacturers or adding additional manufacturers requires a significant amount of time and involves significant expense. New manufacturers would need to develop and implement the necessary production techniques and processes, which along with their facilities, would need to be inspected and approved by the regulatory authorities in each applicable territory. In addition, the raw materials necessary to make API for our products are acquired from a limited number of sources. Any delay or disruption in the availability of these raw materials could result in production disruptions, delays or higher costs with consequent adverse effects on us.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our CMOs fail to adhere to applicable GMP or other regulatory requirements, experience delays or disruptions in the availability of raw materials or experience manufacturing or distribution problems, we may suffer significant consequences, including the inability to meet our product requirements for our clinical development programs, and if tenapanor is commercialized for any indication, such events could result in product seizures or recalls, loss of product approval, fines and sanctions, reputational damage, shipment delays, inventory shortages, inventory write-offs and other product-related charges and increased manufacturing costs. As a result, or if maximum or available manufacturing capacities are insufficient to meet demand, our development or our commercialization efforts for IBSRELA and/or, if approved, XPHOZAH may be materially harmed.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating activities may be restricted as a result of covenants related to the indebtedness under our loan and security agreement and we may be required to repay the outstanding indebtedness in an event of default, which could have a materially adverse effect on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022, we entered into a loan and security agreement with SLR Investment Corp. (&#8220;Lender&#8221;) pursuant to which the Lender agreed to provide us with a loan facility for up to $50.0 million with a maturity date of March 1, 2027, and on August 1, 2022 and February 9, 2023, we entered into amendments to the loan and security agreement (collectively, the &#8220;2022 Loan Agreement.&#8221;). The loan was funded in the amount of $27.5 million on February 23, 2022 and the remaining $22.5 million may be funded by December 20, 2023 upon the satisfaction of both (i) receipt from the FDA of approval of the NDA for XPHOZAH on or prior to November 30, 2023 and (ii) our achievement of certain product revenue milestone targets described in the 2022 Loan Agreement. Until we have repaid all funded indebtedness, the loan and security agreement subjects us to various customary covenants, including requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock, to redeem capital stock, to enter into licensing agreements, to engage in transactions with affiliates, and to encumber our intellectual property. Our business may be adversely affected by these restrictions on our ability to operate our business. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are permitted to make interest only payments on the loan facility through March 2024, with principal repayments commencing on April 1, 2024, however, this interest only period will be extended to March 2025 with principal repayments delayed to April 1, 2025 if (i) we secure approval from the FDA for our NDA for XPHOZAH by November 30, 2023 or (ii) we achieve certain product revenue targets described in the 2022 Loan Agreement for the year ended December 31, 2023. In addition, we may be required to repay the outstanding indebtedness under the loan facility if an event of default occurs under the loan and security agreement. An event of default will occur if, among other things, we fail to make payments under the loan and security agreement; we breach any of our covenants under the loan and security agreement, subject to specified cure periods with respect to certain breaches; the Lender determines that a material adverse change has occurred; we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings; we are unable to pay our debts as they become due; or we default on contracts with third parties which would permit the Lender to accelerate the maturity of such indebtedness or that could have a material adverse change on us. We may not have enough available cash or be able to raise additional funds through equity or debt financings to repay such indebtedness at the time any such event of default occurs. In this case, we may be required to limit or reduce our activities necessary to commercialize IBSRELA and/or, if approved, XPHOZAH, or delay or limit clinical trials for tenapanor or other product candidates. The Lender could also exercise its rights as collateral agent to take possession of and to dispose of the collateral securing the term loans, which collateral includes substantially all of our property (excluding intellectual property, which is subject to a negative pledge). Our business, financial condition and results of operations could be materially adversely affected as a result of any of these events.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Additional Risks Related to Our Business and Industry</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical studies to demonstrate the safety and efficacy of the product candidates in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. For example, while the results of our Phase 2 clinical trial evaluating RDX013 for the treatment of hyperkalemia demonstrated an acceptable safety and tolerability profile for RDX013 and supported proof of concept in its ability to lower serum potassium levels, with statistically significant reductions compared to placebo after eight days of treatment, the study did not meet its primary endpoint of significantly reducing serum potassium levels compared to placebo after four weeks of treatment. We currently expect that the next step for the program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study at such time as we have determined that our available resources support conducting such an additional clinical study. There can be no assurances that any additional clinical study that we determine to conduct with RDX013 will be successful.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if we conduct additional clinical trials with RDX013 or any other product candidates, we could encounter delays in our future development if any clinical trials are suspended or terminated by us, by the IRBs of the institutions in which the trial is being conducted, or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, identifying and qualifying patients to participate in any clinical trials is critical to the success of the clinical trials. The timing of any future clinical trials, including any additional RDX013 clinical trial that we may determine to conduct, will depend, in part, on the speed at which we can recruit patients to participate in testing our product candidates. Patients may be unwilling to participate in our clinical studies because of concerns about adverse events observed with the current standard of care, competitor products and/or other investigational agents, in each case for the same indications and/or similar patient populations. In addition, patients currently receiving treatment with the current standard of care or a competitor product may be reluctant to participate in a clinical trial with an investigational drug, or our inclusion and exclusion criteria for our clinical trials may present challenges in identifying acceptable patients. As a result, the timeline for recruiting patients and conducting clinical trials may be delayed. These delays could result in increased costs, delays in advancing our development of the program, or termination of the clinical studies altogether. Any of these occurrences may significantly harm our business, financial condition and prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will rely on third parties to conduct all of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for additional products or commercialize our product candidates. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to independently conduct nonclinical studies or clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as Contract Research Organizations (&#8220;CROs&#8217;), to conduct clinical trials on our product candidates. The third parties with whom we contract for execution of the clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not our employees, and except for contractual duties and obligations, we control only certain aspects of their activities and have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely, and will continue to rely, on these third parties to conduct our nonclinical studies and our clinical trials, we remain responsible for ensuring that each of our studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on third parties does not relieve us of our regulatory responsibilities. We, and these third parties are required to comply with current GLPs for nonclinical studies, and good clinical practices (&#8220;GCPs&#8221;) for clinical studies. GLPs and GCPs are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area (&#8220;EEA&#8221;) and comparable foreign regulatory authorities for all of our products in nonclinical and clinical development, respectively. Regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our third-party contractors fail to comply with applicable regulatory requirements, including GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, the European Medicines Agency (&#8220;EMA&#8221;), or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which could add additional costs and could delay the regulatory approval process. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, and our competitors may discover, develop or commercialize products faster or more successfully than us.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are highly competitive, and we face significant competition from companies in the biotechnology, pharmaceutical and other related markets that are researching and marketing products designed to address diseases that we are currently developing products to treat. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for IBSRELA largely comes from three prescription products marketed for certain patients with IBS-C that we are aware of, including Linzess (linaclotide), Amitiza (lubiprostone) and Trulance (plecanatide). Generic lubiprostone is also available in the U.S. Additionally, over-the-counter products not indicated for IBS-C are commonly used to treat the constipation component of IBS-C, alone and in combination with the IBS-C-indicated prescription therapies.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XPHOZAH, if approved will compete with phosphate binders. The various types of phosphate binders commercialized in the U.S. include the following: Calcium acetate (several prescription brands including PhosLo and Phoslyra); Lanthanum carbonate (Fosrenol); Sevelamer hydrochloride (Renagel); Sevelamer carbonate (Renvela); Sucroferric oxyhydroxide (Velphoro); and Ferric citrate (Auryxia). All of the listed phosphate binders are available as generics in the U.S., with the exception of Velphoro and Auryxia. Additionally, over-the-counter calcium carbonate, such as Tums and Caltrate, is also used to bind phosphorus.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the currently available phosphate binders, we are aware of at least four other binders in development, including fermagate (Alpharen), an iron-based binder in Phase 3 being developed by Opko Health, Inc., PT20, an iron-based binder in Phase 3 being developed by Shield Therapeutics, AP-301 in Phase 2 being developed by Alebund Pharmaceutical (Hong Kong) Limited, and lanthanum dioxycarbonate (Renazorb), which has demonstrated pharmacodynamic bioequivalence to Fosrenol. Renazorb is being developed by Unicycive Therapeutics, which has announced its plans to file an NDA via the 505(b)(2) pathway in mid-2023. Additionally, Chugai and Alebund are developing EOS789, an inhibitor of phosphate transporters NaPi-2b, PiT-1, and PiT-2, thus far studied in a phase 1 clinical trial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that our competitors' drugs may be less expensive and more effective than our product candidates, or may render our product candidates obsolete. It is also possible that our competitors will commercialize competing drugs or treatments before we or our collaboration partners can launch any products developed from our product candidates. We also may face increased competition in the future as new companies enter into our target markets. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaboration partnerships or licensing relationships with our competitors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may experience difficulties in managing our current activities and growth given our level of managerial, operational, financial and other resources. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have continued to work to optimize our management composition, personnel and systems to support our current activities for future growth, these resources may not be adequate for this purpose. Our need to effectively execute our business strategy requires that we:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage any commercialization activities in which we may engage effectively;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our clinical trials effectively;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our internal development efforts effectively while carrying out our contractual obligations to licensors, contractors, collaborators, government agencies and other third parties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to improve our operational, financial and management controls, reporting systems and procedures; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">retain and motivate our remaining employees and potentially identify, recruit, and integrate additional employees. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to maintain or expand our managerial, operational, financial and other resources to the extent required to manage our development and commercialization activities, our business will be materially adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of IBSRELA and/or, if approved, XPHOZAH. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the clinical testing of our product candidates and our commercial launch of IBSRELA and will face further risk following the commercial launch of XPHOZAH in the second half of 2023, if approved. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for the product;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory investigations, product recalls or withdrawals, or labeling, marketing or promotional restrictions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize or co-promote IBSRELA and/or, if approved, XPHOZAH. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of any products we develop. Although we maintain product liability insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to attract, retain and motivate our executives, senior management and key personnel, our business will suffer. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, medical, manufacturing, and sales and marketing personnel is critical to our success. We are highly dependent on our executives, senior management and certain other key employees. The loss of the services of our executives, senior management or other key employees could impede the achievement of our development and commercial objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executives, senior management and other key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. We may be unable to hire, train or motivate these key personnel on acceptable terms given the intense competition among numerous biopharmaceutical companies for similar personnel, particularly in our geographic regions. If we are unable to continue to attract and retain high quality personnel, our ability to grow and pursue our business strategy will be limited. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or perceived failures to comply with applicable data protection, privacy and security laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The global data protection landscape is rapidly evolving, and we are or may become subject to numerous state, federal and foreign laws, requirements and regulations governing the collection, use, disclosure, retention, and security of personal data, such as information that we may collect in connection with clinical trials in the U.S. and abroad. Implementation standards and enforcement practices are likely to remain uncertain for the foreseeable future, and we cannot yet determine the impact future laws, regulations, standards, or perception of their requirements may have on our business. This evolution may create uncertainty in our business; affect our ability to operate in certain jurisdictions, or to collect, store, transfer use and share personal information; necessitate the acceptance of more onerous obligations in our contracts; result in liability; or impose additional costs on us. The cost of compliance with these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing our processing of personal information could result in negative publicity, government investigations and enforcement actions, claims by third parties and damage to our reputation, any of which could have a material adverse effect on our operations, financial performance and business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our operations and business grow, we may become subject to or affected by new or additional data protection laws and regulations and face increased scrutiny or attention from regulatory authorities. In the U.S., the Health Insurance Portability and Accountability Act of 1996, as amended, and regulations promulgated thereunder (collectively &#8220;HIPAA&#8221;) imposes, among other things, certain standards relating to the privacy, security, transmission, and breach reporting of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Depending on the facts and circumstances, we could be subject to significant penalties if we violate HIPAA.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have also adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. Such laws and regulations will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us and our future customers and strategic partners. For example, the California Consumer Privacy Act ("CCPA") went into effect on January 1, 2020. The CCPA creates individual privacy rights for California consumers and increases the privacy and security obligations of entities handling certain personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood of, and risk associated with data breach litigation. Further, the California Privacy Rights Act ("CPRA") generally went into effect on January 1, 2023 and significantly amends the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may also be required. Similar laws have passed in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Virginia, Connecticut, Utah and Colorado, and have been proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the U.S. The enactment of such laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the Federal Trade Commission (&#8220;FTC&#8221;) and many state Attorneys General continue to enforce federal and state consumer protection laws against companies for online collection, use, dissemination and security practices that appear to be unfair or deceptive. For example, according to the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure can constitute unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also or may become subject to rapidly evolving data protection laws, rules and regulations in foreign jurisdictions. For example, in Europe, the European Union General Data Protection Regulation (&#8220;GDPR&#8221;) went into effect in May 2018 and imposes strict requirements for processing the personal data of individuals within the European Economic Area (&#8220;EEA&#8221;). Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Among other requirements, the GDPR regulates transfers of personal data subject to the GDPR to third countries that have not been found to provide adequate protection to such personal data, including the U.S.; in July 2020, the Court of Justice of the EU (&#8220;CJEU&#8221;) limited how organizations could lawfully transfer personal data from the EU/EEA to the U.S. by invalidating the Privacy Shield for purposes of international transfers and imposing further restrictions on the use of standard contractual clauses. In March 2022, the U.S. and EU announced a new regulatory regime intended to replace the invalidated regulations; however, this new EU-U.S. Data Privacy Framework has not been implemented beyond an executive order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and regulatory decisions subsequent to the CJEU decision of July 2020 have taken a restrictive approach to international data transfers. Relatedly, following the United Kingdom&#8217;s withdrawal from the EEA and the European Union, and the expiry of the transition period, companies have had to comply with both the GDPR and the GDPR as incorporated into United Kingdom national law, the latter regime having the ability to separately fine up to the greater of &#163;17.5 million or 4% of global turnover. As we continue to expand into other foreign countries and jurisdictions, we may be subject to additional laws and regulations that may affect how we conduct business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we work to comply with applicable laws, regulations and standards, our contractual obligations and other legal obligations, these requirements are evolving and may be modified, interpreted and applied in an inconsistent manner from one jurisdiction to another, and may conflict with one another or other legal obligations with which we must comply. Any failure or perceived failure by us or our employees, representatives, contractors, consultants, CROs, collaborators, or other third parties to comply with such requirements or adequately address privacy and security concerns, even if unfounded, could result in additional cost and liability to us, damage our reputation, and adversely affect our business and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaborators, CROs and other contractors and consultants depend on information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators, CROs, and other contractors and consultants collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information technology systems and infrastructure to operate our business. In the ordinary course of our business, we and our collaborators, CROs and other contractors and consultants collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we and our collaborators, CROs and other contractors and consultants do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures designed to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information technology systems and infrastructure, and those of our current and any future collaborators, CROs, contractors and consultants and other third parties on which we rely, are vulnerable to attack, damage and interruption from computer viruses, malware (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ransomware), natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, phishing attacks and other social engineering schemes, attachments to emails, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a security breach or disruption or data loss, particularly through cyberattacks or cyber intrusion, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. We may also face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate forensic evidence. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain of our service providers are from time to time subject to cyberattacks and security incidents. We do not believe that we have experienced any significant system failure, accident or security breach to date, but if such an event were to occur and cause interruptions in our operations, it could result in a material disruption to our business. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable. Moreover, if a computer security breach affects our systems or those of our collaborators, CROs or other contractors, or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors&#8217; views of us and could have a material adverse effect on the price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to implement and maintain effective internal controls over financial reporting could result in errors in our financial statements that could result in a restatement of our financial statements and cause us to fail to meet our reporting obligations. If we cannot in the future favorably assess the effectiveness of our internal controls over financial reporting, investor confidence in the reliability of our financial reports may be adversely affected, which could have a material adverse effect on the trading price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have formed in the past, and may form in the future, collaboration partnerships, joint ventures and/or licensing arrangements, and we may not realize the benefits of such collaborations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have current collaboration partnerships for the commercialization of tenapanor in certain foreign countries, and we may form additional collaboration partnerships, create joint ventures or enter into additional licensing arrangements with third parties in the U.S. and abroad that we believe will complement or augment our existing business. In particular, we have formed collaboration partnerships with Kyowa Kirin for commercialization of tenapanor for hyperphosphatemia in Japan; with Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. ("Fosun Pharma") for commercialization of tenapanor for hyperphosphatemia and IBS-C in China and related territories; in Canada with Knight Therapeutics, Inc. ("Knight") for commercialization of tenapanor for IBS-C and hyperphosphatemia; and with METiS Therapeutics, Inc. (&#8220;METiS&#8221;) for the development and commercialization of a portfolio of TGR5 agonist compounds for all therapeutic areas. We face significant competition in seeking appropriate collaboration partners, and the process to identify an appropriate partner and negotiate appropriate terms is time-consuming and complex. Any delays in identifying suitable additional collaboration partners and entering into agreements to develop our product candidates could also delay the commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. There is no guarantee that our current collaboration partnerships or any such arrangements we enter into in the future will be successful, or that any collaboration partner will </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commit sufficient resources to the development, regulatory approval, and commercialization effort for such products, or that such alliances will result in us achieving revenues that justify such transactions. We received a CRL from the FDA regarding our NDA for XPHOZAH. Following the OND&#8217;s decision to grant our appeal of the CRL, we resubmitted our NDA for XPHOZAH in mid-April 2023. There can be no assurances that the granting of our appeal of the CRL and resubmission of our NDA will result in approval of our NDA for XPHOZAH. Even if we are successful in obtaining approval for the NDA, the delay in obtaining such approval may result in delay in the regulatory process for our partners, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing effects of the COVID-19 pandemic, or any other outbreak of epidemic diseases, or the perception of their effects, could have a material adverse effect on our business, financial condition, results of operations or cash flows. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outbreaks of epidemic, pandemic, or contagious diseases, such as the current novel coronavirus (&#8220;COVID-19&#8221;) pandemic or, historically, the Ebola virus, Middle East Respiratory Syndrome, Severe Acute Respiratory Syndrome or the H1N1 virus, could disrupt our business. Economic and health conditions related to the COVID-19 pandemic in the U.S. and across most of the globe remain uncertain and continue to evolve. The continuing effects of the coronavirus pandemic may result in delays in the manufacture of tenapanor, or in the delivery of key intermediates or raw materials required to manufacture tenapanor or delays in clinical development activities by us, or our collaboration partners. Such effects could also materially and negatively impact our ability to successfully commercialize IBSRELA and/or, if approved, XPHOZAH, or the ability of our collaboration partners to successfully commercialize such products, if approved for marketing and sale by the foreign regulatory authorities, including our ability, and that of our collaboration partners to educate physicians and patients about the benefits, administration and use of the product. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Although we have reopened our offices and invited our personnel to return to the office, we continue to permit our personnel to work remotely, which could negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber-security risk, create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees, manufacturing sites, research or clinical trial sites and important agencies and contractors. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The FDA and comparable foreign regulatory agencies may continue to experience operational interruptions or delays, which may impact timelines for regulatory submission, trial initiation and regulatory approval. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The full effects of the COVID-19 remain unknown. The extent to which the outbreak may continue to impact our business, including, our commercialization and manufacturing will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as access to physician offices for our commercial and medical teams, business closures or supply chain or business disruptions. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may consider strategic transactions, such as acquisitions of companies, asset purchases, and/or in-licensing of products, product candidates or technologies. In addition, if we are unable to access capital on a timely basis and on terms that are acceptable to us, we may be forced to further restructure certain aspects of our business or identify and complete one or more strategic collaborations or other transactions in order to fund the commercialization of IBSRELA, and if approved, XPHOZAH, and/or the development of discovery and developmental assets through the use of alternative structures. Additional potential transactions that we may consider include a variety of different business arrangements, including spin-offs, spin outs, collaboration partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Any such transaction may require us to incur non-recurring or other charges, may increase our near- and long-term expenditures and may pose significant integration challenges or disrupt our management or business, which could adversely affect our operations and financial results. For example, these transactions may entail numerous operational and financial risks, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">up-front, milestone and royalty payments, equity investments and financial support of new research and development candidates including increase of personnel, all of which may be substantial;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exposure to unknown liabilities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">disruption of our business and diversion of our management&#8217;s time and attention in order to develop acquired products, product candidates or technologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incurrence of substantial debt or dilutive issuances of equity securities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">higher-than-expected acquisition and integration costs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">write-downs of assets or goodwill or impairment charges;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased amortization expenses;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty and cost in combining the operations and personnel of any acquired businesses with our operations and personnel;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of relationships with key suppliers or customers of any acquired businesses due to changes in management and ownership; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to retain key employees of any acquired businesses. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and could have a material adverse effect on our business, results of operations, financial condition and prospects. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our CMOs manufacture tenapanor API outside of the U.S., and we may seek and obtain approval to commercialize IBSRELA and XPHOZAH outside of the U.S., and as a result a variety of risks associated with international operations could materially adversely affect our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our collaboration partners may decide to seek marketing approval for IBSRELA or XPHOZAH outside the U.S. Additionally, we have contractual agreements with CMOs involving the manufacture of tenapanor API outside of the U.S., and may otherwise engage in business outside of the U.S., including entering into additional contractual agreements with third parties. We are subject to additional risks related to entering these international business markets and relationships, including:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different regulatory requirements for drug approvals in foreign countries;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing U.S. and foreign drug import and export rules;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced protection for intellectual property rights in foreign countries;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected changes in tariffs, trade barriers and regulatory requirements;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">different reimbursement systems, and different competitive drugs;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign taxes, including withholding of payroll taxes;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in another country;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the U.S.;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential liability resulting from development work conducted by these distributors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves the use of hazardous materials and we and third-parties with whom we contract must comply with environmental laws and regulations, which can be expensive and restrict how we do business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and manufacturers and suppliers with whom we may contract are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of hazardous materials, including the components of our tenapanor and our product candidates. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, and business operations, and could result in environmental damage requiring costly clean-up and resulting in liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. We cannot guarantee that the safety procedures utilized by third-party manufacturers and suppliers with whom we may contract will comply with the standards prescribed by laws and regulations or will eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by earthquakes or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently occupy a leased facility located in the San Francisco Bay Area, which in the past has experienced severe earthquakes. We do not carry earthquake insurance. Earthquakes or other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our leased facilities, including our California facility, that damaged critical infrastructure supporting access to systems such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted operations, it may be difficult or time consuming to restore some business of our business functions.  The disaster recovery and business continuity plans we have in place currently are not wholistic in coverage and may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Government Regulation</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Despite having received regulatory approval for IBSRELA, and even if we receive regulatory approval for XPHOZAH, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, IBSRELA and, if approved, XPHOZAH could be subject to other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a drug is approved by the FDA or foreign regulatory authorities, the manufacturing processes, labeling, packaging, distribution, pharmacovigilance, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP regulations for any clinical trials that we conduct post-approval. As such, we and our third-party CMOs will be subject to continual review and periodic inspections to assess compliance with regulatory requirements. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, and quality control. Regulatory authorities may also impose significant restrictions on a product&#8217;s indicated uses or marketing or impose ongoing requirements for potentially costly post-marketing studies. Furthermore, any new legislation addressing drug safety issues could result in delays or increased costs to assure compliance. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be required to report certain adverse reactions and production problems, if any, to the FDA, and to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we may not promote our products for indications or uses for which they do not have FDA approval. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning or untitled letters or fines;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension or revocation of existing regulatory approvals;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of any of our ongoing clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications submitted by us;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on our or our CMOs&#8217; operations; or</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize IBSRELA and, if approved, XPHOZAH. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the FDA&#8217;s policies may change, and additional government regulations may be enacted. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the U.S. or abroad. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise review and process regulatory submissions in a timely manner, which could negatively impact our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and process regulatory submissions can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown occurs, or if global health concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our CMOs are subject to significant regulation with respect to manufacturing IBSRELA and XPHOZAH. The manufacturing facilities on which we rely may not continue to meet regulatory requirements or may not be able to meet supply demands. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All entities involved in the preparation of product for commercial sale, or product candidates for clinical trials, including our existing CMOs are subject to extensive regulation. Components of a finished therapeutic product approved for commercial sale or used in late-stage clinical studies must be manufactured in accordance with cGMP regulations. These regulations govern manufacturing processes and procedures (including record keeping) and the implementation and operation of quality systems to control and assure the quality of investigational products and products approved for sale. Poor control of production processes can lead to the introduction of contaminants or to inadvertent changes in the properties or stability of our products or product candidates that may not be detectable in final product testing. We or our CMOs must supply all necessary documentation in support of an NDA or comparable regulatory filing on a timely basis and must adhere to cGMP regulations enforced by the FDA and other regulatory agencies through their facilities inspection programs. The facilities and quality systems of some or all of our CMOs must pass a pre-approval inspection for compliance with the applicable regulations as a condition of regulatory approval of our product candidates. In addition, the regulatory authorities may, at any time, audit or inspect a manufacturing facility involved with the manufacture of our product or the associated quality systems for compliance with the regulations applicable to the activities being conducted. Although we oversee the CMOs, we cannot control the manufacturing process of, and are completely dependent on, our CMOs for compliance with the regulatory requirements. If these facilities do not pass a pre-approval plant inspection, regulatory approval of the products may not be granted or may be substantially delayed until any violations are corrected to the satisfaction of the regulatory authority, if ever. In addition, we have no control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory authorities also may, at any time following approval of a product for sale, audit the manufacturing facilities of our CMOs. If any such inspection or audit identifies a failure to comply with applicable regulations or if a violation of our product specifications or applicable regulations occurs independent of such an inspection or audit, we or the relevant regulatory authority may require remedial measures that may be costly and/or time consuming for us or a third party to implement, and that may include the temporary or permanent suspension of a clinical study or commercial sales or the temporary or permanent suspension of production or closure of a facility. Any such remedial measures imposed upon us or third parties with whom we contract could materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of our third-party manufacturers fail to maintain regulatory compliance, the FDA or other applicable regulatory authority can impose regulatory sanctions including, among other things, refusal to approve a pending application for a new drug product, withdrawal of an approval, or suspension of production. As a result, our business, financial condition, and results of operations may be materially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if supply from one approved manufacturer is interrupted, an alternative manufacturer would need to be qualified through an NDA, a supplemental NDA or equivalent foreign regulatory filing, which could result in further delay. The regulatory agencies may also require additional studies if a new manufacturer is relied upon for commercial production. Switching manufacturers may involve substantial costs and is likely to result in a delay in our desired clinical and commercial timelines. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These factors could cause us to incur higher costs and could cause the delay or termination of clinical studies, regulatory submissions, required approvals, or commercialization of our product candidates. Furthermore, if our suppliers fail to meet contractual requirements and we are unable to secure one or more replacement suppliers capable of production at a substantially equivalent cost, our clinical studies may be delayed, or we could lose potential revenue. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply or are found to have failed to comply with FDA and other regulations related to the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations relating to the promotion of products for unapproved uses are complex and subject to substantial interpretation by the FDA and other government agencies. With respect to the commercialization of IBSRELA and/or, if approved, XPHOZAH we will be restricted from marketing the product outside of its approved labeling, also referred to as off-label promotion. However, physicians may nevertheless prescribe an approved product to their patients in a manner that is inconsistent with the approved label, which is an off-label use. We have implemented compliance and training programs designed to ensure that our sales and marketing practices comply with applicable regulations regarding off-label promotion. Notwithstanding these programs, the FDA or other government agencies may allege or find that our practices constitute prohibited promotion of our product candidates for unapproved uses. We also cannot be sure that our employees will comply with company policies and applicable regulations regarding the promotion of products for unapproved uses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years, a significant number of pharmaceutical and biotechnology companies have been the target of inquiries and investigations by various federal and state regulatory, investigative, prosecutorial and administrative entities in connection with the promotion of products for unapproved uses and other sales practices, including the Department of Justice and various U.S. Attorneys&#8217; Offices, the Office of Inspector General of the Department of Health and Human Services, the FDA, the FTC and various state Attorneys General offices. These investigations have alleged violations of various federal and state laws and regulations, including claims asserting antitrust violations, violations of the Federal Food, Drug, and Cosmetic Act, the False Claims Act, the Prescription Drug Marketing Act, anti-kickback laws, and other alleged violations in connection with the promotion of products for unapproved uses, pricing and Medicare and/or Medicaid reimbursement. Many of these investigations originate as &#8220;qui tam&#8221; actions under the False Claims Act. Under the False Claims Act, any individual can bring a claim on behalf of the government alleging that a person or entity has presented a false claim, or caused a false claim to be submitted, to the government for payment. The person bringing a qui tam suit is entitled to a share of any recovery or settlement. Qui tam suits, also commonly referred to as &#8220;whistleblower suits,&#8221; are often brought by current or former employees. In a qui tam suit, the government must decide whether to intervene and prosecute the case. If it declines, the individual may pursue the case alone. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA or any other governmental agency initiates an enforcement action against us or if we are the subject of a qui tam suit and it is determined that we violated prohibitions relating to the promotion of products for unapproved uses, we could be subject to substantial civil or criminal fines or damage awards and other sanctions such as consent decrees and corporate integrity agreements pursuant to which our activities would be subject to ongoing scrutiny and monitoring to ensure compliance with applicable laws and regulations. Any such fines, awards or other sanctions would have an adverse effect on our revenue, business, financial prospects and reputation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IBSRELA and/or, if approved, XPHOZAH may cause or contribute to adverse medical events that we are required to report to regulatory agencies and if we fail to do so we could be subject to sanctions that would materially harm our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action, including criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants, CMOs and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, principal investigators, CROs, collaboration partners, consultants, CMOs and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or unauthorized activities that violate any of the following: FDA regulations, including those laws that require the reporting of true, complete and accurate financial and other information to the FDA; manufacturing standards; or federal and state healthcare fraud and abuse laws and regulations. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. These activities also include the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain regulatory approvals in foreign jurisdictions would prevent us from marketing our products internationally. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product in the EEA (which is composed of the 27 Member States of the European Union plus Norway, Iceland and Liechtenstein), and many other foreign jurisdictions, separate regulatory approvals are required. In the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (&#8220;MA&#8221;). Before the MA is granted, the EMA or the competent authorities of the Member States of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The approval procedures vary among countries and can involve additional clinical testing, and the time required to obtain approval may differ from that required to obtain FDA approval. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Approval by the FDA does not ensure approval by regulatory authorities in other countries, and approval by one or more foreign regulatory authorities does not ensure approval by regulatory authorities in other foreign countries or by the FDA. However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process in others. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We may not be able to file for regulatory approvals or to do so on a timely basis, and even if we do file, we may not receive necessary approvals to commercialize our products in any market. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our collaboration partners are subject to healthcare laws, regulation and enforcement; our failure or the failure of any such collaboration partners to comply with these laws could have a material adverse effect on our results of operations and financial conditions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaboration partners are subject to additional healthcare statutory and regulatory requirements and enforcement by the federal government and the states and foreign governments in which we conduct our business. The laws that may affect our ability to operate as a commercial organization include:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Civil Monetary Penalties law, which prohibits, among other things, offering or transferring remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#8217;s decision to order or receive items or services reimbursable by the government from a particular provider or supplier;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act requirements under the Affordable Care Act (&#8220;ACA&#8221;), which requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to CMS information related to payments and other transfers of value to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain non-physician practitioners (physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiologist assistants and certified nurse midwives), and teaching hospitals, and ownership and investment interests held by physicians (as defined by the statute) and their immediate family members;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the applicable compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or pricing information and marketing expenditures; and </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">European and other foreign law equivalents of each of the laws, including reporting requirements detailing interactions with and payments to healthcare providers. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The risk of our being found in violation of these laws is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are open to a variety of interpretations. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#8217;s attention from the operation of our business. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, the exclusion from participation in federal and state healthcare programs and imprisonment, any of which could adversely affect our ability to market our products and adversely impact our financial results. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory healthcare reforms in the U.S. may make it more difficult and costly for us to obtain regulatory clearance or approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional clinical trials to be conducted prior to obtaining approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes to manufacturing methods;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, replacement, or discontinuance of one or more of our products; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional record keeping. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition and results of operations. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the full impact of recent healthcare reform and other changes in the healthcare industry and in healthcare spending is currently unknown, and may adversely affect our business model. In the U.S., the ACA was enacted in 2010 with a goal of reducing the cost of healthcare and substantially changing the way healthcare is financed by both government and private insurers. Since its enactment, there have been judicial, executive and Congressional challenges to certain aspects of the ACA. The ACA, among other things, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations, established annual fees and taxes on manufacturers of certain branded prescription drugs, and created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the U.S. since the ACA was enacted. These new laws, among other things, included aggregate reductions of Medicare payments to providers that will remain in effect through 2032, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022, unless additional action is taken by Congress, additional specific reductions in Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and an increase in the statute of limitations period for the government to recover overpayments to providers from three to five years. More recently, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#8217;s average manufacturer price, beginning January 1, 2024. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, there has also been heightened governmental scrutiny over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. On August 16, 2022, the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;) was signed into law. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023), and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of the Department of Health and Human Services to implement many of these provisions through guidance, as opposed to regulation, for the initial years. For that and other reasons, it is currently unclear how the IRA will be effectuated. Additionally, individual states have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and to encourage importation from other countries and bulk purchasing. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict the reform initiatives that may be adopted in the future or whether initiatives that have been adopted will be repealed or modified. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate Program or other governmental pricing programs in the U.S., we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, results of operations and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the commercial launch of IBSRELA, we participate in the Medicaid Drug Rebate Program (&#8220;MDRP&#8221;) and other federal and state government pricing programs in the U.S., and we may participate in additional government pricing programs in the future. These programs generally require manufacturers to pay rebates or otherwise provide discounts to government payors in connection with drugs that are dispensed to beneficiaries of these programs. Medicaid drug rebates are based on pricing data that we will be obligated to report on a monthly and quarterly basis to CMS, the federal agency that administers the MDRP and Medicare programs. For the MDRP, these data include the average manufacturer price (&#8220;AMP&#8221;) and the best price (&#8220;BP&#8221;) for each drug. If we become aware that our MDRP price reporting submission for a prior period was incorrect or has changed as a result of recalculation of the pricing data, we must resubmit the corrected data for up to three years after those data originally were due. In addition, there is increased focus by the Office of Inspector General within the U.S. Department of Health and Human Services on the methodologies used by manufacturers to calculate AMP, and BP, to assess manufacturer compliance with MDRP reporting requirements. If we fail to provide information timely or are found to have knowingly submitted false information to the government, we may be subject to civil monetary penalties and other sanctions, including termination from the MDRP, which would result in payment not being available for our covered drugs under Medicaid. Failure to make necessary disclosures and/or to identify overpayments could result in allegations against us under the Federal False Claims Act and other laws and regulations. </span></div><div style="text-align:justify;text-indent:28pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law requires that a manufacturer that participates in the MDRP also participate in the Public Health Service&#8217;s 340B drug pricing program (&#8220;340B program&#8221;) in order for federal funds to be available for the manufacturer&#8217;s drugs under Medicaid. We participate in the 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), and requires us to charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for our covered drugs. These 340B covered entities include a variety of community health clinics and other entities that receive health services grants from the Public Health Service, as well as hospitals that serve a disproportionate share of low-income patients. The 340B ceiling price is calculated using a statutory formula, which is based on the AMP and rebate amount for the covered drug as calculated under the MDRP. In general, products subject to Medicaid price reporting and rebate liability are also subject to the 340B ceiling price calculation and discount requirement. We are obligated to report 340B ceiling prices to HRSA on a quarterly basis, and HRSA publishes them to 340B covered entities. HRSA has finalized regulations regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities for 340B-eligible drugs. HRSA has also finalized an administrative dispute resolution process through which 340B covered entities may pursue claims against participating manufacturers for overcharges, and through which manufacturers may pursue claims against 340B covered entities for engaging in unlawful diversion or duplicate discounting of 340B drugs.</span></div><div style="text-align:justify;text-indent:28pt"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to be eligible to have drug products paid for with federal funds under Medicaid and purchased by certain federal agencies and grantees, we also participate in the U.S. Department of Veterans Affairs (&#8220;VA&#8221;) Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Under the VA/FSS program, we are obligated to report the Non-Federal Average Manufacturer Price (&#8220;Non-FAMP&#8221;) for our covered drugs to the VA and charge certain federal agencies no more than the Federal Ceiling Price, which is calculated based on Non-FAMP using a statutory formula. These four agencies are the VA, the U.S. Department of Defense, the U.S. Coast Guard, and the U.S. Public Health Service (including the Indian Health Service). We are also required to pay rebates on products purchased by military personnel and dependents through the TRICARE retail pharmacy program. If we fail to provide timely information or are found to have knowingly submitted false information, we may be subject to civil monetary penalties. </span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states continue to consider and have enacted legislation to limit the growth of healthcare costs, including the cost of prescription drugs and combination products. A number of states have either implemented or are considering implementation of drug price transparency legislation that may prevent or limit our ability to take price increases at certain rates or frequencies. Requirements under such laws include advance notice of planned price increases, reporting price increase amounts and factors considered in taking such increases, wholesale acquisition cost information disclosure to prescribers, purchasers, and state agencies, and new product notice and reporting. Such legislation could limit the price or payment for IBSRELA and, if approved and launched, XPHOZAH, and a number of states are authorized to impose civil monetary penalties or pursue other enforcement mechanisms against manufacturers who fail to comply with drug price transparency requirements, including the untimely, inaccurate, or incomplete reporting of drug pricing information. If we are found to have violated state law requirements, we may become subject to penalties or other enforcement mechanisms, which could have a material adverse effect on our business. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:28pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations are complex, vary among products and programs, and are often subject to interpretation by us, governmental or regulatory agencies, and the courts. The terms, scope and complexity of these government pricing programs change frequently, as do interpretations of applicable requirements for pricing and rebate calculations. Responding to current and future changes may increase our costs and the complexity of compliance will be time consuming. Any required refunds to the U.S. government or responding to a government investigation or enforcement action would be expensive and time consuming and could have a material adverse effect on our business, results of operations and financial condition. Price recalculations under the MDRP also may affect the ceiling price at which we are required to offer products under the 340B program. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we fail to submit the required price data on a timely basis, or if we are found to have charged 340B covered entities more than the statutorily mandated ceiling price. In the event that CMS were to terminate our Medicaid rebate agreement, no federal payments would be available under Medicaid or Medicare for IBSRELA or, if approved and launched, XPHOZAH. We cannot offer any assurances that our submissions will not be found to be incomplete or incorrect.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Intellectual Property</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success will depend on our ability to obtain, maintain and protect our intellectual property rights </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success and ability to compete depend in part on our ability to obtain, maintain and enforce issued patents, trademarks and other intellectual property rights and proprietary technology in the U.S. and elsewhere. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality procedures and patent, trademark, copyright, trade secret and other intellectual property laws to protect the proprietary aspects of our products, product candidates, brands, technologies, trade secrets, know-how and data. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property rights and proprietary information. Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the U.S. and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation, or misappropriation of our patents, trademarks, data, technology, and other intellectual property rights and products by others; and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated, or otherwise violated by others.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely in part on our portfolio of issued and pending patent applications in the U.S. and other countries to protect our intellectual property and competitive position. However, it is also possible that we may fail to identify patentable aspects of inventions made in the course of our development, manufacture and commercialization activities before it is too late to obtain patent protection on them. If we fail to timely file for patent protection in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors, and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best interests of our business. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or technologies in a non-infringing manner that would be competitive with one or more of our products or technologies, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the U.S., the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Though an issued patent is presumed valid and enforceable, its issuance is not conclusive as to its validity or its enforceability and it may not provide us with adequate proprietary protection or competitive advantages against competitors with similar products or services. Patents, if issued, may be challenged, deemed unenforceable, invalidated, narrowed or circumvented. Proceedings challenging our patents or patent applications could result in either loss of the patent, or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Any successful challenge to our patents and patent applications could deprive us of exclusive rights necessary for our commercial success. In addition, defending such challenges in such proceedings may be costly. Thus, any patents that we may own may not provide the anticipated level of, or any, protection against competitors. Furthermore, an adverse decision may result in a third party receiving a patent right sought by us, which in turn could affect our ability to develop, manufacture or commercialize our products or technologies. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our patents, or any of our pending patent applications, if issued, will include claims having a scope sufficient to protect our products or product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our pending patent applications will issue as patents;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We were the first to make the inventions covered by each of our patents and pending patent applications;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We were the first to file patent applications for these inventions;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Others will not develop, manufacture and/or commercialize similar or alternative products or technologies that do not infringe our patents;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any of our challenged patents will be found to ultimately be valid and enforceable;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any patents issued to us will provide a basis for an exclusive market for our commercially viable products or technologies will provide us with any competitive advantages or will not be challenged by third parties;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will develop additional proprietary technologies or products that are separately patentable; or</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our commercial activities or products will not infringe upon the patents of others.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become subject to third-party claims alleging infringement, misappropriation or violation of such third parties&#8217; patents or other intellectual property rights and/or third-party claims seeking to invalidate our patents, which would be costly, time consuming and, if successfully asserted against us, delay or prevent the development, manufacture or commercialization of our products or product candidates. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture or commercialize our products and product candidates without infringing, misappropriating or otherwise violating the intellectual property rights of third parties. There have been many lawsuits and other proceedings asserting infringement or misappropriation of patents and other intellectual property rights in the pharmaceutical and biotechnology industries, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we take steps to ensure that we do not infringe upon, misappropriate or otherwise violate the intellectual property rights of others, there can be no assurances that we will not be subject to claims alleging that the manufacture, use or sale of IBSRELA or XPHOZAH or of any other product candidates infringes existing or future third-party patents, or that such claims, if any, will not be successful. Because patent applications can take many years to issue and may be confidential for 18 months or more after filing, and because pending patent claims can be revised before issuance, there may be applications now pending which may later result in issued patents that may be infringed by the manufacture, use or sale of IBSRELA or XPHOZAH or other product candidates. Moreover, we may face patent infringement claims from non-practicing entities that have no relevant product revenue and against whom our own patent portfolio may thus have no deterrent effect. We may be unaware of one or more issued patents that would be infringed by the manufacture, sale or use of IBSRELA or XPHOZAH or our other product candidates. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights. These proceedings could cause us to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents. We may be required to indemnify future collaboration partners against such claims. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If a patent infringement suit were brought against us, we could be forced to stop or delay development, manufacturing or sales of the product or product candidate that is the subject of the suit. As a result of patent infringement claims, or in order to avoid potential claims, we may choose to seek, or be required to seek, a license from the third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, we may be unable to maintain such licenses and the rights may be nonexclusive, which would give our competitors access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or forced to redesign it if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms, or unable to maintain such licenses when granted. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also could be ordered to pay substantial damages, including treble damages and attorney&#8217;s fees if we are found to be willfully infringing a third party&#8217;s patents or other intellectual property right. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or technologies, which could have a negative impact on the commercial success of our current and any future products or technologies. If we were to challenge the validity of any such third party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third party claim of patent infringement. Even if we are successful in defending against such claims, such litigation can be expensive and time consuming to litigate and would divert management&#8217;s attention from our core business. Any of these events could harm our business significantly. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to infringement claims against us, third parties may also raise similar claims before administrative bodies in the U.S. or abroad. Such mechanisms include reexamination, post grant review, inter parties review, derivation or opposition proceedings before the United States Patent and Trademark Office (&#8220;USPTO&#8221;) or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. If third parties prepare and file patent applications in the U.S. that also claim technology similar or identical to ours, we may have to participate in interference or derivation proceedings in the USPTO to determine which party is entitled to a patent on the disputed invention. We may also become involved in similar opposition proceedings in the European Patent Office or similar offices in other jurisdictions regarding our intellectual property rights with respect to our products and technology. Since patent applications are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Such administrative proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or product candidates. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or technologies. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our intellectual property related to IBSRELA, XPHOZAH, RDX013 or any future product candidates is not adequate or if we are not able to successfully enforce our intellectual property rights, the commercial value of IBSRELA, if approved, XPHOZAH, or other product candidates may be adversely affected and we may not be able to compete effectively in our market.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or license may fail to result in issued patents in the U.S. or in foreign countries. Additionally, our research and development efforts may result in product candidates for which patent protection is limited or not available. Even if patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. For example, U.S. patents can be challenged by any person before the new USPTO Patent Trial and Appeals Board at any time before one year after that person is served an infringement complaint based on the patents. Patents granted by the European Patent Office may be similarly opposed by any person within nine months from the publication of the grant. Similar proceedings are available in other jurisdictions, and in the U.S., Europe and other jurisdictions third parties can raise questions of validity with a patent office even before a patent has granted. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. For example, a third party may develop a competitive product that provides therapeutic benefits similar to one or more of our product candidates but has a sufficiently different composition to fall outside the scope of our patent protection. If the breadth or strength of protection provided by the patents and patent applications we hold or pursue with respect to IBSRELA, XPHOZAH, RDX013 or any future product candidates is successfully challenged, then our ability to commercialize such product could be negatively affected, and we may face unexpected competition that could have a material adverse impact on our business. Further, we have reported that we have completed the data analysis from our Phase 2 clinical trial evaluating the safety and efficacy of RDX013 for the treatment of hyperkalemia, and that we currently expect that the next steps for the RDX013 program will be to evaluate a new formulation that potentially enhances subject compliance and the efficacy of RDX013 in an additional Phase 2 clinical study. We currently expect to delay further development of RDX013 until such time as we have determined that our available resources support conducting such additional formulation work and an additional clinical study. As a result of this delay in our development program for RDX013, the period of time during which we or our collaboration partners could market RDX013 under patent protection would be reduced.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even where laws provide protection, costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. If we or one of our collaboration partners were to initiate legal proceedings against a third party to enforce a patent covering a product or product candidate, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to validity, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability against our intellectual property related to a product or a product candidate, we would lose at least part, and perhaps all, of the patent protection on such product or product candidate. Such a loss of patent protection would have a material adverse impact on our business. Moreover, our competitors could counterclaim that we infringe their intellectual property, and some of our competitors have substantially greater intellectual property portfolios than we do. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the composition and use of IBSRELA are currently claimed by four (4) issued patents that are listed in the FDA&#8217;s Orange Book, we cannot assure that we will be successful in defending against third parties asserting that any of our patents are invalid or otherwise unenforceable or not infringed by the third parties&#8217; products, or in competing against third parties seeking to introduce generic equivalents of IBSRELA or any of our future products. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the Hatch-Waxman Act provides non-patent regulatory exclusivity for five years from the date of the first FDA approval of a new chemical entity (&#8220;NCE&#8221;) in a NDA. The FDA is prohibited during those five years from approving an Abbreviated New Drug Application (&#8220;ANDA&#8221;) that references the NDA that has been granted NCE exclusivity. However, if a patent is included in the FDA Orange Book, a generic manufacturer may file an ANDA that references a NDA product with granted NCE exclusivity after four years from the NDA approval date accompanied by a Paragraph IV certification asserting that the Orange Book patents are invalid or unenforceable, or that the generic product does not infringe the Orange Book patents. The Hatch-Waxman Act does not prevent the filing or approval of another full NDA where the NDA applicant has conducted its own pre-clinical and adequate and well-controlled clinical trials to independently demonstrate safety and effectiveness. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where NCE exclusivity has been granted for an NDA, as in the case of IBSRELA, if an ANDA sponsor has provided a Paragraph IV certification to the FDA when filing an ANDA, the ANDA sponsor must also send a notice to the NCE NDA owner. The NCE NDA owner may then initiate a patent infringement lawsuit in response to the Paragraph IV certification. The filing of patent infringement lawsuit within 45 days after the NCE NDA owner&#8217;s receipt of a notice of the Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the NCE NDA owner&#8217;s receipt of the Paragraph IV certification notice or a final decision in the infringement case in favor of the ANDA sponsor. There can be no assurances that an ANDA that references our IBSRELA NDA and includes a Paragraph IV certification will not be filed when permitted, or that we will be successful in enforcing our Orange Book listed patents against such ANDA sponsor. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secret protection and confidentiality agreements to protect proprietary know-how that may not be patentable, processes for which patents may be difficult to obtain and/or enforce and any other elements of our drug discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Although we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology, to assign their inventions to us, and endeavor to execute confidentiality agreements with all such parties, we cannot be certain that we have executed such agreements with all parties who may have helped to develop our intellectual property or who had access to our proprietary information, nor can we be certain that our agreements will not be breached by such consultants, advisors or third parties, or by our former employees. The breach of such agreements by individuals or entities who were actively involved in the discovery and design of our products or potential drug candidates, or in the development of our discovery and design platform could require us to pursue legal action to protect our trade secrets and confidential information, which would be expensive, and the outcome of which would be unpredictable. If we are not successful in prohibiting the continued breach of such agreements, our business could be negatively impacted. We cannot guarantee that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the U.S. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the U.S. and abroad. If we are unable to prevent material disclosure of the intellectual property related to our technologies to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Although we have obtained patent term extension in the U.S. under the Hatch-Waxman Act, extending the term of marketing exclusivity for tenapanor, if we do not obtain patent term extension in foreign countries under similar legislation, our business may be materially harmed. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the approval by the FDA for our NDA to market tenapanor for IBS-C, we obtained patent term restoration under the Hatch-Waxman Act until August 1, 2033 for U.S. patent no. 8,541,448 covering our approved product or the use thereof. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA approved product. Patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Despite seeking patent term extension for tenapanor, we may not be granted patent term extension in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration in any particular foreign country, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product in such foreign country will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USPTO and various foreign patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions to maintain patent applications and issued patents. Noncompliance with these requirements can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to enforce our intellectual property rights throughout the world. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Europe&#8217;s planned Unified Patent Court may, in particular, present uncertainties for our ability to protect and enforce our patent rights against competitors in Europe. In 2012, the European Patent Package (&#8220;EU Patent Package&#8221;) regulations were passed with the goal of providing a single pan-European Unitary Patent and a new European Unified Patent Court (&#8220;UPC&#8221;), for litigation involving European patents. Implementation of the EU Patent Package will likely occur in the first half of 2023. Under the UPC, all European patents, including those issued prior to ratification of the European Patent Package, will by default automatically fall under the jurisdiction of the UPC. The UPC will provide our competitors with a new forum to centrally revoke our European patents, and allow for the possibility of a competitor to obtain pan-European injunctions. It will be several years before we will understand the scope of patent rights that will be recognized and the strength of patent remedies that will be provided by the UPC. Under the EU Patent Package as currently proposed, we will have the right to opt our patents out of the UPC over the first seven years of the court&#8217;s existence, but doing so may preclude us from realizing the benefits of the new unified court.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our products. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. In addition, changes in the law and legal decisions by courts in the U.S. and foreign countries may affect our ability to obtain and enforce adequate intellectual property protection for our technology. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property, including know-how or trade secrets, of a third party, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees, consultants and contractors were previously employed at or engaged by other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees, consultants and contractors do not use the intellectual property and other proprietary information or know-how or trade secrets of others in their work for us, and do not perform work for us that is in conflict with their obligations to another employer or any other entity, we may be subject to claims that we or these employees, consultants and contractors have used or disclosed such intellectual property, including know-how, trade secrets or other proprietary information. In addition, an employee, advisor or consultant who performs work for us may have obligations to a third party that are in conflict with their obligations to us, and as a result such third party may claim an ownership interest in the intellectual property arising out of work performed for us. We are not aware of any threatened or pending claims related to these matters, but in the future litigation may be necessary to defend against such claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, or access to consultants and contractors. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while we typically require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own, which may result in claims by or against us related to the ownership of such intellectual property. If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and scientific personnel. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price may be volatile and our stockholders may not be able to resell shares of our common stock at or above the price they paid. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock is highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include those discussed in this &#8220;Risk Factors&#8221; section and others such as:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or lack of success with regards to our commercialization of IBSRELA;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of regulatory decisions regarding our NDA seeking marketing approval for XPHOZAH;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success or lack of success with regards to our commercial launch of XPHOZAH, if approved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of regulatory inspections of our facilities or those of our CMOs, or specific label restrictions or patient populations for XPHOZAH&#8217;s use, if approved, or changes or delays in the regulatory review process;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements regarding whether XPHOZAH, if approved, alone or with other oral only medications, will be included in the ESRD prospective payment system, and the time and manner in which such transition is achieved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements relating to our current or future collaboration partnerships;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of therapeutic innovations or new products by us or our competitors;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse actions taken by regulatory agencies with respect to our product label, our clinical trials, manufacturing supply chain or sales and marketing activities;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes or developments in laws or regulations applicable to our approved products or our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our testing and clinical trials;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to meet any of our projected timelines or goals with regard to the commercialization of IBSRELA, the commercial launch of XPHOZAH, if approved, or the clinical development and commercialization of any of our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to acquire or license or discover additional product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any intellectual property infringement actions in which we may become involved;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to obtain adequate intellectual property protection for our product candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements concerning our competitors or the pharmaceutical industry in general;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achievement of expected product sales and profitability;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacture, supply or distribution shortages;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated fluctuations in our operating results;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA or other U.S. or foreign regulatory actions affecting us or our industry or other healthcare reform measures in the U.S.;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in financial estimates or recommendations by securities analysts;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trading volume of our common stock;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock by us, our executive officers and directors or our stockholders in the future;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of debt securities and sales or licensing of assets;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic and market conditions and overall fluctuations in the U.S. equity markets; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the loss of any of our key scientific or management personnel. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility that may have been unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the attention of our management would be diverted from the operation of our business, which could seriously harm our financial position. Any adverse determination in litigation could also subject us to significant liabilities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may decline. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. If we issue common stock or securities convertible into common stock, our common stockholders would experience additional dilution and, as a result, our stock price may decline. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company, and our management will devote substantial time to new compliance initiatives. We may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in sanctions or other penalties that would harm our business. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incur significant legal, accounting and other expenses as a public company, including costs resulting from public company reporting obligations under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;) and regulations regarding corporate governance practices. The listing requirements of The Nasdaq Global Market require that we satisfy certain corporate governance requirements relating to director independence, distributing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and a code of conduct. Our management and other personnel will need to devote a substantial amount of time to ensure that we comply with all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make some activities more time consuming and costly. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 404 of The Sarbanes-Oxley Act of 2002 (&#8220;Section 404&#8221;) and the related rules of the Securities and Exchange Commission (&#8220;SEC&#8221;) which generally require, among other things, our management to report on the effectiveness of our internal control over financial reporting, subject to certain exceptions applicable to non-accelerated filers. Our compliance with Section 404 requires that we incur substantial expense and expend significant management efforts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of our review and testing of our internal controls, we may identify deficiencies and be unable to remediate them before we must provide the required reports. Furthermore, if we have a material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information and cause the trading price of our stock to fall. In addition, as a public company we are required to file accurate and timely quarterly and annual reports with the SEC under the Exchange Act. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from The Nasdaq Global Market or other adverse consequences that would materially harm our business. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be adversely affected by the global economic environment. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to attract and retain collaboration partners or customers, invest in and grow our business and meet our financial obligations depends on our operating and financial performance, which, in turn, is subject to numerous factors, including the prevailing economic conditions and financial, business and other factors beyond our control, such as the rate of unemployment, the number of uninsured persons in the U.S., presidential elections, other political influences and inflationary pressures. Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets, including the current inflationary environment and rising interest rates. Adverse developments that affect financial institutions, transactional counterparties, or other third parties, or concerns or rumors about these events, have in the past and may in the future lead to market-wide liquidity problems. For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation, which appointed the U.S. Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver. Similarly, other institutions have been and may continue to be swept into receivership. We currently have no borrowing or deposit exposure to directly impacted institutions and have not experienced an adverse impact to our liquidity or to our business operations, financial condition, or results of operations as a result of these recent events. However, uncertainty may remain over liquidity concerns in the broader financial services industry, and there may be unpredictable impacts to our business and our industry. We cannot anticipate all the ways in which the global economic climate and global financial market conditions could adversely impact our business in the future.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with reduced profitability and the potential financial instability of our collaboration partners or customers, many of which may be adversely affected by volatile conditions in the financial markets. For example, unemployment and underemployment, and the resultant loss of insurance, may decrease the demand for healthcare services and pharmaceuticals. If fewer patients are seeking medical care because they do not have insurance coverage, our collaboration partners or customers may experience reductions in revenues, profitability and/or cash flow that could lead them to reduce their support of our programs or financing activities. If collaboration partners or customers are not successful in generating sufficient revenue or are precluded from securing financing, they may not be able to pay, or may delay payment of, accounts receivable that are owed to us. In addition, volatility in the financial markets could cause significant fluctuations in the interest rate and currency markets. We currently do not hedge for these risks. The foregoing events, in turn, could adversely affect our financial condition and liquidity. In addition, if economic challenges in the U.S. result in widespread and prolonged unemployment, either regionally or on a national basis, or if certain provisions of the Patient Protection and ACA, as amended by the Health Care and Education Reconciliation Act, collectively known as the ACA, are repealed, a substantial number of people may become uninsured or underinsured. To the extent economic challenges result in fewer individuals pursuing or being able to afford our product candidates once commercialized, our business, results of operations, financial condition and cash flows could be adversely affected. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment of management. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could significantly reduce the value of our shares to a potential acquirer or delay or prevent changes in control or changes in our management without the consent of our board of directors. The provisions in our charter documents include the following:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote to remove a director for cause, and the prohibition on removal of directors without cause;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of our board of directors to alter our bylaws without obtaining stockholder approval;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required approval of at least two-thirds of the shares entitled to vote at an election of directors to adopt, amend or repeal our bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirement that a special meeting of stockholders may be called only by the chairman of the board of directors, the chief executive officer, the president or the board of directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of directors; and</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders&#8217; meeting, which may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to obtain control of us. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, these provisions would apply even if we were to receive an offer that some stockholders may consider beneficial. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of directors has approved the transaction. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements that we have entered into with our directors and officers provide that:</span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such a person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnities, except with respect to proceedings authorized by our board of directors or brought to enforce a right to indemnification. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. </span></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, employees and agents. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently intend to pay dividends on our common stock, and, consequently, our stockholders&#8217; ability to achieve a return on their investment will depend on appreciation in the price of our common stock. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if any, to fund our growth. Additionally, the terms of our loan and security agreements could restrict our ability to pay dividends. Therefore, our stockholders are not likely to receive any dividends on our common stock for the foreseeable future. Since we do not intend to pay dividends, our stockholders&#8217; ability to receive a return on their investment will depend on any future appreciation in the market value of our common stock. There is no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continuing impact of &#8220;Brexit&#8221; may have a negative effect on our business.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a national referendum and subsequent legislation the United Kingdom formally withdrew from the European Union, commonly referred to as &#8220;Brexit&#8221; and ratified a trade and cooperation agreement governing its future relationship with the European Union. Among other things, the agreement became effective in 2021, addresses trade, economic arrangements, law enforcement, judicial cooperation and governance. Because the agreement merely sets forth a framework that in many respects requires complex additional bilateral negotiations between the United Kingdom and the European Union significant uncertainty remains about how the precise terms of the relationship between the parties will differ from the terms before withdrawal. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot yet predict the full implications of Brexit, including whether it will increase our operational costs or otherwise have a negative effect on our business, financial condition or results of operations, which could reduce the price of our common stock.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_136"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unregistered Sales of Equity Securities</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Proceeds</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="iea6a0b1ea655406093eb9e951c03313e_139"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="iea6a0b1ea655406093eb9e951c03313e_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trading Plans</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the period from February 27, 2023, to March 31, 2023, our Section 16 officers and directors adopted or terminated contracts, instructions or written plans for the purchase or sale of our securities as noted below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.637%"><tr><td style="width:1.0%"></td><td style="width:19.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.818%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.474%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.847%"></td><td style="width:0.1%"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Action</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date</span></td><td colspan="6" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Arrangement</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Shares to be Sold</span></td><td colspan="3" rowspan="2" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration Date</span></td></tr><tr style="height:23pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rule 10b5-1*</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Rule 10b5-1**</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert Blanks, Chief Regulatory and Quality Assurance Officer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,748&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2023</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Grammer, Esq. Chief Legal and Administrative Officer</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2023</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laura Williams, M.D., M.P.H., Chief Medical Officer</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adoption</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 24, 2023</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,876&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 15, 2023</span></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*Intended to satisfy the affirmative defense of Rule 10b5-1(c)</span></div></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">** Not intended to satisfy the affirmative defense of Rule 10b5-1(c)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;Exhibits </span></div><div style="margin-top:17pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Filed<br/>Herewith</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312523010411/d429337dex12.htm">Open Market Sale Agreement</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312523010411/d429337dex12.htm">S</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;text-decoration:underline;top:-3.5pt;vertical-align:baseline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312523010411/d429337dex12.htm">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000119312523010411/d429337dex12.htm">, dated January 18, 2023, by and between Ardelyx, Inc. and Jefferies LLC.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/19/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828023006041/slr-ardelyxxsecondamendmen.htm">Second Amendment to Loan and Security Agreement dated February 9, 2023, by and between Ardelyx, Inc. and SLR Investment Corp.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1437402/000162828023006041/ardelyx_psgxmsaamendment1.htm">First Amendment to the Manufacturing Services Agreement dated February 27, 2023, between Ardelyx, Inc. and Patheon Pharmaceuticals Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.27(b)&#8224;&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20230331xex311.htm">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20230331xex312.htm">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ardx-20230331xex321.htm">Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following financial statements, formatted in Inline Extensible Business Reporting Language (XBRL): (i) Condensed Balance Sheets as of March&#160;31, 2023 and December&#160;31, 2022, (ii) Condensed Statements of Operations and Comprehensive Loss for the three months ended March&#160;31, 2023 and 2022, (iii) Condensed Statements of Cash Flows for the three months ended March&#160;31, 2023 and 2022, and (iv) Notes to Unaudited Condensed Financial Statements.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in Inline XBRL and contained in Exhibit 101.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;&#160;&#160;&#160;&#160;Certain portions of this exhibit have been redacted pursuant to Item 601(b)(10) of Regulation S-K. A copy of the omitted portions will be furnished supplementally to the Securities and Exchange Commission upon request.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="iea6a0b1ea655406093eb9e951c03313e_151"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:12pt;text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iea6a0b1ea655406093eb9e951c03313e_10">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:47.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ardelyx, Inc.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: May 3, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Robert Felsch</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Vice President and Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Principal Accounting Officer)</span></td></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ardx-20230331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id8daf69ddeb94516a5011c7c86ffcf7b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael Raab, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 3, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ardx-20230331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i0075e42737f4401aaf7d41a34319882c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Justin Renz, certify that&#58;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Ardelyx, Inc.&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:10pt;padding-left:54pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 3, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial &#38; Operations Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ardx-20230331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i66c9ce90affe45eebe0027c9919147b4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:10pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Ardelyx, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ending March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Michael Raab, President and Chief Executive Officer of the Company, and Justin Renz, Chief Financial &#38; Operations Officer of the Company, respectively, do each hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 3, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Michael Raab</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Michael Raab<br>President, Chief Executive Officer and Director<br>(Principal Executive Officer)</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.939%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May 3, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Justin Renz</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Justin Renz<br>Chief Financial &#38; Operations Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>ardx-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5e53bfed-5618-4e24-885d-bb49c3b2394c,g:e63de3a8-8715-46e5-89c4-d16db17c8afb-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ardx="http://www.ardelyx.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ardelyx.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ardx-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ardelyx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETS" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS">
        <link:definition>0000002 - Statement - CONDENSED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDBALANCESHEETSParenthetical" roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical">
        <link:definition>0000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
        <link:definition>0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000007 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestments" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments">
        <link:definition>0000008 - Disclosure - Cash, Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.ardelyx.com/role/FairValueMeasurements">
        <link:definition>0000009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.ardelyx.com/role/Inventory">
        <link:definition>0000010 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNet" roleURI="http://www.ardelyx.com/role/ProductRevenueNet">
        <link:definition>0000011 - Disclosure - Product Revenue, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreements" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements">
        <link:definition>0000012 - Disclosure - Collaboration and Licensing Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties">
        <link:definition>0000013 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowing" roleURI="http://www.ardelyx.com/role/Borrowing">
        <link:definition>0000014 - Disclosure - Borrowing</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilities" roleURI="http://www.ardelyx.com/role/DerivativeLiabilities">
        <link:definition>0000015 - Disclosure - Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.ardelyx.com/role/Leases">
        <link:definition>0000016 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.ardelyx.com/role/StockholdersEquity">
        <link:definition>0000017 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlans" roleURI="http://www.ardelyx.com/role/EquityIncentivePlans">
        <link:definition>0000018 - Disclosure - Equity Incentive Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.ardelyx.com/role/NetLossPerShare">
        <link:definition>0000019 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Contingencies" roleURI="http://www.ardelyx.com/role/Contingencies">
        <link:definition>0000020 - Disclosure - Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.ardelyx.com/role/SubsequentEvents">
        <link:definition>0000021 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationPolicies" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies">
        <link:definition>0000022 - Disclosure - Organization and Basis of Presentation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsTables" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables">
        <link:definition>0000023 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables">
        <link:definition>0000024 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.ardelyx.com/role/InventoryTables">
        <link:definition>0000025 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetTables" roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables">
        <link:definition>0000026 - Disclosure - Product Revenue, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsTables" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables">
        <link:definition>0000027 - Disclosure - Collaboration and Licensing Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingTables" roleURI="http://www.ardelyx.com/role/BorrowingTables">
        <link:definition>0000028 - Disclosure - Borrowing (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilitiesTables" roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesTables">
        <link:definition>0000029 - Disclosure - Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.ardelyx.com/role/LeasesTables">
        <link:definition>0000030 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansTables" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables">
        <link:definition>0000031 - Disclosure - Equity Incentive Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.ardelyx.com/role/NetLossPerShareTables">
        <link:definition>0000032 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>0000033 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
        <link:definition>0000034 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1">
        <link:definition>0000034 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandInvestmentsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails">
        <link:definition>0000035 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
        <link:definition>0000036 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000037 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleDetails" roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails">
        <link:definition>0000038 - Disclosure - Inventory - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryScheduleDetails_1" roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails_1">
        <link:definition>0000038 - Disclosure - Inventory - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.ardelyx.com/role/InventoryNarrativeDetails">
        <link:definition>0000039 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetNarrativeDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails">
        <link:definition>0000040 - Disclosure - Product Revenue, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProductRevenueNetGrosstoNetSalesAccrualsDetails" roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails">
        <link:definition>0000041 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsNarrativeDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails">
        <link:definition>0000042 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicensingAgreementsDeferredRevenueDetails" roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails">
        <link:definition>0000043 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails">
        <link:definition>0000044 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingNarrativeDetails" roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails">
        <link:definition>0000045 - Disclosure - Borrowing - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails">
        <link:definition>0000046 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingFuturePaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1">
        <link:definition>0000046 - Disclosure - Borrowing - Future Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilitiesNarrativeDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails">
        <link:definition>0000047 - Disclosure - Derivative Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeLiabilitiesChangesinFairValueDetails" roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails">
        <link:definition>0000048 - Disclosure - Derivative Liabilities - Changes in Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalDetailsofLeasesDetails" roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails">
        <link:definition>0000049 - Disclosure - Leases - Additional Details of Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseCostsDetails" roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails">
        <link:definition>0000050 - Disclosure - Leases - Lease Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails">
        <link:definition>0000051 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesUndiscountedCashPaymentObligationsDetails_1" roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1">
        <link:definition>0000051 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails">
        <link:definition>0000052 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails">
        <link:definition>0000053 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails">
        <link:definition>0000054 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
        <link:definition>0000055 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansStockOptionsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails">
        <link:definition>0000056 - Disclosure - Equity Incentive Plans - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansRestrictedStockUnitsDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails">
        <link:definition>0000057 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityIncentivePlansNarrativeDetails" roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails">
        <link:definition>0000058 - Disclosure - Equity Incentive Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareComputationofNetLossPerCommonShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails">
        <link:definition>0000059 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" roleURI="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails">
        <link:definition>0000060 - Disclosure - Net Loss Per Share - Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesDetails" roleURI="http://www.ardelyx.com/role/ContingenciesDetails">
        <link:definition>0000061 - Disclosure - Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" abstract="false" name="ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ExitFeePercentage" abstract="false" name="ExitFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_AmerisourceBergenDrugCorporationMember" abstract="true" name="AmerisourceBergenDrugCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentVariableRatePlusOption" abstract="false" name="DebtInstrumentVariableRatePlusOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" abstract="false" name="CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccruals" abstract="false" name="ContractWithCustomerGrossToNetSalesAccruals" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ExitFee2022Member" abstract="true" name="ExitFee2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" abstract="false" name="CollaborationAndLicensingAgreementsUpfrontLicenseFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FacilityFremontCaliforniaMember" abstract="true" name="FacilityFremontCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ExitFee2018Member" abstract="true" name="ExitFee2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesProvisions" abstract="false" name="ContractWithCustomerGrossToNetSalesProvisions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LeaseArrangementsAxis" abstract="true" name="LeaseArrangementsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityTransactionCosts" abstract="false" name="ContractWithCustomerLiabilityTransactionCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ardx_CollaborationAndLicensingAgreementsAbstract" abstract="true" name="CollaborationAndLicensingAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_TermLoan2022AMember" abstract="true" name="TermLoan2022AMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" abstract="false" name="ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KnightTherapeuticsIncMember" abstract="true" name="KnightTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerRebatesMember" abstract="true" name="ContractWithCustomerRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" abstract="false" name="ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialDevelopmentMilestones" abstract="false" name="CollaborativeArrangementPotentialDevelopmentMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" abstract="false" name="AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" abstract="false" name="DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" abstract="false" name="LoanAgreementFutureObligationUponFundingOrOtherEvents" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" abstract="false" name="FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2021AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CollaborativeArrangementPotentialCommercializationMilestones" abstract="false" name="CollaborativeArrangementPotentialCommercializationMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentPrepaymentFeePercentage" abstract="false" name="DebtInstrumentPrepaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_StrezsakVersusArdelyxIncMember" abstract="true" name="StrezsakVersusArdelyxIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_HealthCareRoyaltyPartnersIVLPMember" abstract="true" name="HealthCareRoyaltyPartnersIVLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" abstract="false" name="ContractWithCustomerGrossToCreditsOrDeductionsIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" abstract="true" name="ContractWithCustomerOtherFeesCopayAndReturnsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" abstract="true" name="GrossToNetSalesAccrualAndReserveClassificationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" abstract="true" name="LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_MaximumAggregateOfferingPrice" abstract="false" name="MaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerDiscountsAndChargebacksMember" abstract="true" name="ContractWithCustomerDiscountsAndChargebacksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_AstrazenecaMember" abstract="true" name="AstrazenecaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_CardinalHealthMember" abstract="true" name="CardinalHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_PrepaidCommercialManufacturingCurrent" abstract="false" name="PrepaidCommercialManufacturingCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_TermLoan2022Member" abstract="true" name="TermLoan2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ThresholdPercentageOfSalesForTieredRoyalties" abstract="false" name="ThresholdPercentageOfSalesForTieredRoyalties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LeaseArrangementsDomain" abstract="true" name="LeaseArrangementsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" abstract="false" name="PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" abstract="false" name="ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" abstract="false" name="IncreaseDecreaseInPrepaidCommercialManufacturingExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" abstract="false" name="ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" abstract="false" name="LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" abstract="false" name="LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" abstract="false" name="CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" abstract="false" name="CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_DebtInstrumentInterestRateOnDefaultPercentage" abstract="false" name="DebtInstrumentInterestRateOnDefaultPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_TermLoan2018Member" abstract="true" name="TermLoan2018Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ProductSupplyRevenueMember" abstract="true" name="ProductSupplyRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_CostOfRevenueAggregateAmountRecognized" abstract="false" name="CostOfRevenueAggregateAmountRecognized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ProductIBSRELAMember" abstract="true" name="ProductIBSRELAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentVariableRateBaseOption" abstract="false" name="DebtInstrumentVariableRateBaseOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_AstraZenecaTerminationAgreementMember" abstract="true" name="AstraZenecaTerminationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DerivativeIssued" abstract="false" name="DerivativeIssued" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ardx_StockIssuanceCostCommissionPercent" abstract="false" name="StockIssuanceCostCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_LoanAgreementExitFeeTerm" abstract="false" name="LoanAgreementExitFeeTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ardx_DeferredRoyaltyObligationNoncurrent" abstract="false" name="DeferredRoyaltyObligationNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_KyowaKirinCo.LtdMember" abstract="true" name="KyowaKirinCo.LtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" abstract="false" name="ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" abstract="false" name="ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" abstract="false" name="FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PercentageOfRoyaltyRevenue" abstract="false" name="PercentageOfRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" abstract="false" name="EquitySalesAgreementProceedsFromSharesIssuedSinceInception" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_EquitySalesAgreementSharesIssuedSinceInception" abstract="false" name="EquitySalesAgreementSharesIssuedSinceInception" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ardx_TermLoan2022BMember" abstract="true" name="TermLoan2022BMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" abstract="false" name="ScheduleOfGrossToNetSalesAccrualsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" abstract="false" name="RemainingFundingBasedOnConditionalMilestoneAchievement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_PercentageOfNonRoyaltyRevenue" abstract="false" name="PercentageOfNonRoyaltyRevenue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_TermBLoanMember" abstract="true" name="TermBLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" abstract="false" name="LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" abstract="true" name="OpenMarketSalesAgreement2023AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_GoVersusRaabMember" abstract="true" name="GoVersusRaabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_McKessonCorporationMember" abstract="true" name="McKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_DebtInstrumentClosingFeeAmount" abstract="false" name="DebtInstrumentClosingFeeAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" abstract="true" name="ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ardx_InvestmentsAndCashAmortizedCost" abstract="false" name="InvestmentsAndCashAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" abstract="true" name="ContractWithCustomerGrossToNetSalesAccrualRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>ardx-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5e53bfed-5618-4e24-885d-bb49c3b2394c,g:e63de3a8-8715-46e5-89c4-d16db17c8afb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_7546fcff-5fea-4114-994b-5da9adcbd916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:to="loc_us-gaap_InventoryGross_7546fcff-5fea-4114-994b-5da9adcbd916" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_27e67aeb-1f2e-480f-b6d4-da56654848cb" xlink:href="ardx-20230331.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_27e67aeb-1f2e-480f-b6d4-da56654848cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_09700d93-0587-4d9c-9e77-3d4b4de3e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_09700d93-0587-4d9c-9e77-3d4b4de3e03e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_148c4d17-8247-4cfd-980b-36d346a76df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_148c4d17-8247-4cfd-980b-36d346a76df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f9b8c1a2-9bc2-4e15-b3f1-079042a22aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_f9b8c1a2-9bc2-4e15-b3f1-079042a22aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cf31d18-0a93-4664-b0af-08c1baed8502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_18a8322d-c9a7-47b0-833d-2cc23fbbced9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5cf31d18-0a93-4664-b0af-08c1baed8502" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e4bd278b-a8c8-4d51-a218-5380c6b5cfd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e4bd278b-a8c8-4d51-a218-5380c6b5cfd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f7623e95-f0e5-4049-a159-d1edbec47473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:to="loc_us-gaap_AccountsPayableCurrent_f7623e95-f0e5-4049-a159-d1edbec47473" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5d80853a-ae7e-4850-b96b-1826b459be7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5d80853a-ae7e-4850-b96b-1826b459be7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_cb93e8b4-f079-4894-b32a-dd2c51525e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:to="loc_us-gaap_LoansPayableCurrent_cb93e8b4-f079-4894-b32a-dd2c51525e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_6919137d-d69b-4aac-bb86-d21f4b10514c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_6919137d-d69b-4aac-bb86-d21f4b10514c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1a7954f0-a167-47e2-9ceb-fac13d08416b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_42d7a2e1-bf4a-4ce2-87dc-7058dd2a6fdd" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_1a7954f0-a167-47e2-9ceb-fac13d08416b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d2511264-dab5-4eff-a69a-20d0d2b4064e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_fc1a5df3-61d5-4f59-85cc-f49b85e6b9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d2511264-dab5-4eff-a69a-20d0d2b4064e" xlink:to="loc_us-gaap_PreferredStockValue_fc1a5df3-61d5-4f59-85cc-f49b85e6b9bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_07324b2f-04e4-4541-8d59-2d6fc4f7f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d2511264-dab5-4eff-a69a-20d0d2b4064e" xlink:to="loc_us-gaap_CommonStockValue_07324b2f-04e4-4541-8d59-2d6fc4f7f72f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8bded6a9-1956-4b3d-92c3-2c53b411ede7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d2511264-dab5-4eff-a69a-20d0d2b4064e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8bded6a9-1956-4b3d-92c3-2c53b411ede7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_220b82f8-cc2d-4926-aaff-a9f8d518ce42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d2511264-dab5-4eff-a69a-20d0d2b4064e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_220b82f8-cc2d-4926-aaff-a9f8d518ce42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb993ddb-7952-428d-b4e4-2a5c249584aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_d2511264-dab5-4eff-a69a-20d0d2b4064e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_eb993ddb-7952-428d-b4e4-2a5c249584aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d3f6f0da-41c2-4ff9-b3fb-44c74dd2fa50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c93b6cfc-9adc-4775-8d6e-b7d8213c91a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d3f6f0da-41c2-4ff9-b3fb-44c74dd2fa50" xlink:to="loc_us-gaap_AssetsCurrent_c93b6cfc-9adc-4775-8d6e-b7d8213c91a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_96b390b3-6dd2-4c0b-9c2f-dfeeb32565a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d3f6f0da-41c2-4ff9-b3fb-44c74dd2fa50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_96b390b3-6dd2-4c0b-9c2f-dfeeb32565a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_12b6f896-fbba-498e-a2fe-facfda689b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d3f6f0da-41c2-4ff9-b3fb-44c74dd2fa50" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_12b6f896-fbba-498e-a2fe-facfda689b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c6ee38a8-41c5-4dc1-bcb2-0c251d16b0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d3f6f0da-41c2-4ff9-b3fb-44c74dd2fa50" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c6ee38a8-41c5-4dc1-bcb2-0c251d16b0cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_3dd6e748-0794-424a-b385-0e6d69156e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_d3f6f0da-41c2-4ff9-b3fb-44c74dd2fa50" xlink:to="loc_us-gaap_InventoryNoncurrent_3dd6e748-0794-424a-b385-0e6d69156e5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cb1ee1f4-97e1-4bff-a4cb-ce6f336913eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fe8b7ef7-92de-4775-b312-6af6d8be8a61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cb1ee1f4-97e1-4bff-a4cb-ce6f336913eb" xlink:to="loc_us-gaap_Liabilities_fe8b7ef7-92de-4775-b312-6af6d8be8a61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_6506d690-4bca-46d2-a298-d5242418f807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cb1ee1f4-97e1-4bff-a4cb-ce6f336913eb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_6506d690-4bca-46d2-a298-d5242418f807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_16d96740-b45e-4bfa-b620-32e703e35a55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cb1ee1f4-97e1-4bff-a4cb-ce6f336913eb" xlink:to="loc_us-gaap_StockholdersEquity_16d96740-b45e-4bfa-b620-32e703e35a55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7657efea-7de5-443f-aa41-4ee4f0699f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e3689898-2417-4b1f-9f7d-715c747bdea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7657efea-7de5-443f-aa41-4ee4f0699f2e" xlink:to="loc_us-gaap_LiabilitiesCurrent_e3689898-2417-4b1f-9f7d-715c747bdea5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3bde78e2-b4d0-4e50-9052-eed653084378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7657efea-7de5-443f-aa41-4ee4f0699f2e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_3bde78e2-b4d0-4e50-9052-eed653084378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_50392fe9-1f68-4110-bf39-854c6fec79c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7657efea-7de5-443f-aa41-4ee4f0699f2e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_50392fe9-1f68-4110-bf39-854c6fec79c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent_c4f777fb-8465-446d-9256-2b64716ac809" xlink:href="ardx-20230331.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7657efea-7de5-443f-aa41-4ee4f0699f2e" xlink:to="loc_ardx_DeferredRoyaltyObligationNoncurrent_c4f777fb-8465-446d-9256-2b64716ac809" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe04fc63-087c-4ee9-aee5-8e37a499cc98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_1a87a9ee-f7e0-4cb5-87b0-1d023f7c348b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe04fc63-087c-4ee9-aee5-8e37a499cc98" xlink:to="loc_us-gaap_InterestExpense_1a87a9ee-f7e0-4cb5-87b0-1d023f7c348b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_df01d6d3-985d-4001-8ac0-94e67e12655b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe04fc63-087c-4ee9-aee5-8e37a499cc98" xlink:to="loc_us-gaap_OperatingIncomeLoss_df01d6d3-985d-4001-8ac0-94e67e12655b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_8bb2fb67-318f-437e-9c5a-f206f4c098f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe04fc63-087c-4ee9-aee5-8e37a499cc98" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_8bb2fb67-318f-437e-9c5a-f206f4c098f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_aa9a75a8-1e8a-4ab0-b98f-6f441a7dc630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fe04fc63-087c-4ee9-aee5-8e37a499cc98" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_aa9a75a8-1e8a-4ab0-b98f-6f441a7dc630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9ee6a3fe-8f6f-47e2-be39-3c76236d8890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c31aba9-429a-4193-9ae8-4bddbe91f0dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9ee6a3fe-8f6f-47e2-be39-3c76236d8890" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2c31aba9-429a-4193-9ae8-4bddbe91f0dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8ec9ca80-f717-4d35-abff-feb05044713b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9ee6a3fe-8f6f-47e2-be39-3c76236d8890" xlink:to="loc_us-gaap_CostsAndExpenses_8ec9ca80-f717-4d35-abff-feb05044713b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5891d6e-5e14-4ec2-88c2-d6e99c7de00b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d79e3ffb-a15f-42c3-9fdf-1b6fedf4040f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5891d6e-5e14-4ec2-88c2-d6e99c7de00b" xlink:to="loc_us-gaap_NetIncomeLoss_d79e3ffb-a15f-42c3-9fdf-1b6fedf4040f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bec4a69a-27c9-4f67-9a4e-0b778325e79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_d5891d6e-5e14-4ec2-88c2-d6e99c7de00b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_bec4a69a-27c9-4f67-9a4e-0b778325e79f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0aeae43d-3522-44e0-990b-605dcca0136a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d32dd7df-5bd4-4671-a3e5-f715c5656297" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0aeae43d-3522-44e0-990b-605dcca0136a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_d32dd7df-5bd4-4671-a3e5-f715c5656297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_61f8e0ac-e2ea-48e8-85f6-c020c04b5fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0aeae43d-3522-44e0-990b-605dcca0136a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_61f8e0ac-e2ea-48e8-85f6-c020c04b5fd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_46de74c5-a21c-418e-9d16-ba0f587b5e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_ca0fb9fb-9890-4484-9a14-627b080f5fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_46de74c5-a21c-418e-9d16-ba0f587b5e43" xlink:to="loc_us-gaap_CostOfRevenue_ca0fb9fb-9890-4484-9a14-627b080f5fe2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a460fecd-b192-40e0-881d-41a068e39161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_46de74c5-a21c-418e-9d16-ba0f587b5e43" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a460fecd-b192-40e0-881d-41a068e39161" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f35496a-d361-4dc0-8587-514d0da3dfe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_46de74c5-a21c-418e-9d16-ba0f587b5e43" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9f35496a-d361-4dc0-8587-514d0da3dfe4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_501840f2-be8f-4ec6-a9f7-da4e3808dd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5a431976-a0b0-436a-9fc9-16096d31fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_501840f2-be8f-4ec6-a9f7-da4e3808dd74" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5a431976-a0b0-436a-9fc9-16096d31fc27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_31e93974-2a8e-45bb-84c4-8e2a64dc9259" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_501840f2-be8f-4ec6-a9f7-da4e3808dd74" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_31e93974-2a8e-45bb-84c4-8e2a64dc9259" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_180222ca-af1d-4f76-8cca-a881c0086844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_501840f2-be8f-4ec6-a9f7-da4e3808dd74" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_180222ca-af1d-4f76-8cca-a881c0086844" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f347dad7-271e-434e-8a02-87c4949ba4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_501840f2-be8f-4ec6-a9f7-da4e3808dd74" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_f347dad7-271e-434e-8a02-87c4949ba4fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_602d7bd0-c0c4-4b49-a859-73ed403e32e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_602d7bd0-c0c4-4b49-a859-73ed403e32e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0050b5a4-5656-4a91-94af-4f1bff250711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0050b5a4-5656-4a91-94af-4f1bff250711" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_71523424-20d5-49fa-a61f-003abfceadab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_71523424-20d5-49fa-a61f-003abfceadab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2db0868d-0180-4093-a41d-e3a684e706d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_ShareBasedCompensation_2db0868d-0180-4093-a41d-e3a684e706d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_548916c6-e9ac-416d-a6b2-65f7ae9b19e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_NetIncomeLoss_548916c6-e9ac-416d-a6b2-65f7ae9b19e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_79a3f751-9d67-4069-be45-132bf2bd2083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_79a3f751-9d67-4069-be45-132bf2bd2083" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7bbfab23-159d-4df9-8bf6-fd103b47760a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7bbfab23-159d-4df9-8bf6-fd103b47760a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_8bcb32d9-931a-4c7d-85bd-529b3a066e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_8bcb32d9-931a-4c7d-85bd-529b3a066e7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_e63a8056-a055-4bbf-94d7-e2faef9a0b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_e63a8056-a055-4bbf-94d7-e2faef9a0b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7a036187-c20f-414b-b9f3-cf6914d09ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_7a036187-c20f-414b-b9f3-cf6914d09ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_76f7ef11-ddde-45b5-a123-5a54b838da56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_76f7ef11-ddde-45b5-a123-5a54b838da56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_4b404572-b570-41fd-a34d-2372b3a56666" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_4b404572-b570-41fd-a34d-2372b3a56666" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_c3d15517-4e96-4be4-9fff-1277c78569fd" xlink:href="ardx-20230331.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_c3d15517-4e96-4be4-9fff-1277c78569fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_9bd16cf6-6e1c-473a-997f-7425f162d42b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_9bd16cf6-6e1c-473a-997f-7425f162d42b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c390e7c4-0288-4c6e-add9-c1b6953c7569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c390e7c4-0288-4c6e-add9-c1b6953c7569" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f38f8e49-7933-4299-8625-be2d5eacb97a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f38f8e49-7933-4299-8625-be2d5eacb97a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_609d2993-1ec7-4576-b315-716973c4b8ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_609d2993-1ec7-4576-b315-716973c4b8ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_3de9488f-0596-4447-929a-3748bdb46c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4beac262-5a94-450e-a89e-acf29bf64509" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_3de9488f-0596-4447-929a-3748bdb46c9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1777c64-b37a-448e-b8df-7e1625c27ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_832d4164-a878-4c8d-93db-ebb458dea3c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1777c64-b37a-448e-b8df-7e1625c27ebc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_832d4164-a878-4c8d-93db-ebb458dea3c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ad9c192a-3d3c-4b3b-ac64-250e46cebedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1777c64-b37a-448e-b8df-7e1625c27ebc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ad9c192a-3d3c-4b3b-ac64-250e46cebedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_c508c5be-0802-4659-9a51-8a65b437ce36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1777c64-b37a-448e-b8df-7e1625c27ebc" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_c508c5be-0802-4659-9a51-8a65b437ce36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ae78be0c-f3f8-472d-97af-ee69ae7c3414" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1777c64-b37a-448e-b8df-7e1625c27ebc" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_ae78be0c-f3f8-472d-97af-ee69ae7c3414" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a36a2cf-166b-4ad3-bb3a-6c43863414fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e2b418ea-e418-48e0-abf3-22717a8e5b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a36a2cf-166b-4ad3-bb3a-6c43863414fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e2b418ea-e418-48e0-abf3-22717a8e5b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec0b0e57-5ca2-4f3d-8334-22dd1930dbaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a36a2cf-166b-4ad3-bb3a-6c43863414fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec0b0e57-5ca2-4f3d-8334-22dd1930dbaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8017aae-4758-47b2-96b7-ae7b38bd0ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7a36a2cf-166b-4ad3-bb3a-6c43863414fb" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f8017aae-4758-47b2-96b7-ae7b38bd0ec1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_19cb47b3-fdf6-4805-9046-3544936d6405" xlink:href="ardx-20230331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_ef93eb22-a4ed-4c1e-bd11-ef08eb6bc452" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_19cb47b3-fdf6-4805-9046-3544936d6405" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_ef93eb22-a4ed-4c1e-bd11-ef08eb6bc452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_4962c3ab-5955-4ad1-85e2-e805c46764e9" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_19cb47b3-fdf6-4805-9046-3544936d6405" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_4962c3ab-5955-4ad1-85e2-e805c46764e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_aa08844d-7261-45b6-9b92-2402732b204c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_19cb47b3-fdf6-4805-9046-3544936d6405" xlink:to="loc_us-gaap_InvestmentsAndCash_aa08844d-7261-45b6-9b92-2402732b204c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf3e61b6-49e2-4acd-a1df-0f889e13f1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30dc8837-ae20-4235-b748-b537fb7863c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf3e61b6-49e2-4acd-a1df-0f889e13f1fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_30dc8837-ae20-4235-b748-b537fb7863c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6dec540f-b8fd-470f-a056-68906e527e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf3e61b6-49e2-4acd-a1df-0f889e13f1fd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_6dec540f-b8fd-470f-a056-68906e527e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_713c064f-39fa-426a-b1f9-a4e51d6ed83d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf3e61b6-49e2-4acd-a1df-0f889e13f1fd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_713c064f-39fa-426a-b1f9-a4e51d6ed83d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_bbfd8fdd-bca7-42d0-91ba-222e87b4caef" xlink:href="ardx-20230331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47ab0962-4773-46dc-8fc4-f507155c2a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_bbfd8fdd-bca7-42d0-91ba-222e87b4caef" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_47ab0962-4773-46dc-8fc4-f507155c2a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5f56a72e-176b-4d31-860c-8c29ba2968ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost_bbfd8fdd-bca7-42d0-91ba-222e87b4caef" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5f56a72e-176b-4d31-860c-8c29ba2968ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#InventoryScheduleDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f91138c8-341f-48d0-a8f7-6dc1a465f361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_b6576651-be6f-4c98-bcc7-3f26bbdaeb89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f91138c8-341f-48d0-a8f7-6dc1a465f361" xlink:to="loc_us-gaap_InventoryFinishedGoods_b6576651-be6f-4c98-bcc7-3f26bbdaeb89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_70211c71-15f1-4611-8326-b2b16ff73299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f91138c8-341f-48d0-a8f7-6dc1a465f361" xlink:to="loc_us-gaap_InventoryRawMaterials_70211c71-15f1-4611-8326-b2b16ff73299" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0a7164f3-6d2f-4d4a-8768-7afd7c5b51cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f91138c8-341f-48d0-a8f7-6dc1a465f361" xlink:to="loc_us-gaap_InventoryWorkInProcess_0a7164f3-6d2f-4d4a-8768-7afd7c5b51cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#InventoryScheduleDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f5dca029-2452-455d-a097-172bad235ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_073ab84d-d815-4147-9adf-a038650634dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5dca029-2452-455d-a097-172bad235ef4" xlink:to="loc_us-gaap_InventoryGross_073ab84d-d815-4147-9adf-a038650634dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_36da28e1-4c69-41f0-8495-6e62bcec5347" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5dca029-2452-455d-a097-172bad235ef4" xlink:to="loc_us-gaap_InventoryNoncurrent_36da28e1-4c69-41f0-8495-6e62bcec5347" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_6f97299c-7e7d-4816-b904-d7141e3efcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_3ee947a1-afa7-4a29-a211-f08c23ef37f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6f97299c-7e7d-4816-b904-d7141e3efcfd" xlink:to="loc_us-gaap_LoansPayableCurrent_3ee947a1-afa7-4a29-a211-f08c23ef37f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_f1d5f85d-f105-4103-847d-eeacf5f5c04d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_6f97299c-7e7d-4816-b904-d7141e3efcfd" xlink:to="loc_us-gaap_LongTermLoansPayable_f1d5f85d-f105-4103-847d-eeacf5f5c04d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_300f2e7c-44a6-46ad-80be-c8416ccb196e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_e3c0dd7a-36af-4104-bf4d-56d62f610d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_300f2e7c-44a6-46ad-80be-c8416ccb196e" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_e3c0dd7a-36af-4104-bf4d-56d62f610d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3216f48-b95d-45a2-b92a-1f035dd224d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_300f2e7c-44a6-46ad-80be-c8416ccb196e" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_d3216f48-b95d-45a2-b92a-1f035dd224d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_be5a74b2-f95d-48d7-a4e6-a26443f77c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_300f2e7c-44a6-46ad-80be-c8416ccb196e" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_be5a74b2-f95d-48d7-a4e6-a26443f77c7b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesAdditionalDetailsofLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3dabcae0-a67d-4df4-a300-709ce53dd682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3228dbab-a072-4d67-804c-eb912179eebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3dabcae0-a67d-4df4-a300-709ce53dd682" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3228dbab-a072-4d67-804c-eb912179eebf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_224b7428-1e3e-4aa9-ad7f-f03d451606e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3dabcae0-a67d-4df4-a300-709ce53dd682" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_224b7428-1e3e-4aa9-ad7f-f03d451606e2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9641d004-c4b6-4a8a-99c3-1eb409c42d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6177cbd5-a43e-4890-862c-4f66667c3d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9641d004-c4b6-4a8a-99c3-1eb409c42d0b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6177cbd5-a43e-4890-862c-4f66667c3d02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_4d48609d-0a49-4969-aa44-370007599820" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9641d004-c4b6-4a8a-99c3-1eb409c42d0b" xlink:to="loc_us-gaap_OperatingLeaseLiability_4d48609d-0a49-4969-aa44-370007599820" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89a6cf42-87e0-4939-bf46-8a24c1048db2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e96b683a-ee57-4d72-a01f-744260a50ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89a6cf42-87e0-4939-bf46-8a24c1048db2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e96b683a-ee57-4d72-a01f-744260a50ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_35609a24-1d78-4b57-b15e-83984eb4b0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89a6cf42-87e0-4939-bf46-8a24c1048db2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_35609a24-1d78-4b57-b15e-83984eb4b0a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cfe15d51-c1c3-4624-9c56-533bd3a5d94e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89a6cf42-87e0-4939-bf46-8a24c1048db2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_cfe15d51-c1c3-4624-9c56-533bd3a5d94e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7a19a355-2d11-42bf-88d1-05a73fc6ec3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89a6cf42-87e0-4939-bf46-8a24c1048db2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_7a19a355-2d11-42bf-88d1-05a73fc6ec3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_2d22f72d-1edf-426f-9018-8842c63fb886" xlink:href="ardx-20230331.xsd#ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89a6cf42-87e0-4939-bf46-8a24c1048db2" xlink:to="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_2d22f72d-1edf-426f-9018-8842c63fb886" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>ardx-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5e53bfed-5618-4e24-885d-bb49c3b2394c,g:e63de3a8-8715-46e5-89c4-d16db17c8afb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended" id="if1d70b06766349b9940f2b460ed55e7b_CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_22d771b3-674f-483a-b6a7-2c4524af26aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_RevenuesAbstract_22d771b3-674f-483a-b6a7-2c4524af26aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae440eb5-69df-47f6-aad3-963661a85167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_22d771b3-674f-483a-b6a7-2c4524af26aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae440eb5-69df-47f6-aad3-963661a85167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_cdce5318-5185-4c84-8e58-75cc88abec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_CostOfRevenue_cdce5318-5185-4c84-8e58-75cc88abec4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_59a079ca-5823-457b-b534-94a31ebedd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_59a079ca-5823-457b-b534-94a31ebedd5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4395700-030b-4579-baf0-5bbeb81efcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4395700-030b-4579-baf0-5bbeb81efcec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4db068bf-4690-49dd-8cdf-ace00bbbd473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_CostsAndExpenses_4db068bf-4690-49dd-8cdf-ace00bbbd473" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b80f73f6-08ec-450c-9767-037e536404db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_OperatingIncomeLoss_b80f73f6-08ec-450c-9767-037e536404db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4a2d9697-66e5-4745-9350-c38f4e5daad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_InterestExpense_4a2d9697-66e5-4745-9350-c38f4e5daad2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_447ff905-90f2-41a4-8b5c-d39e2c4ccf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_447ff905-90f2-41a4-8b5c-d39e2c4ccf0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fdcc04ec-5cb9-4a6c-8416-b672a3ebb760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fdcc04ec-5cb9-4a6c-8416-b672a3ebb760" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40d5d6ea-9ba3-4188-b067-33d2e1ca5563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40d5d6ea-9ba3-4188-b067-33d2e1ca5563" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d4e6a21c-360e-486f-8b51-23a308b7a926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d4e6a21c-360e-486f-8b51-23a308b7a926" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a842e7f8-4cc0-448c-aad9-a94237d27b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_NetIncomeLoss_a842e7f8-4cc0-448c-aad9-a94237d27b34" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_907bb19b-389c-4881-bc1c-75cdc2e13c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_EarningsPerShareBasic_907bb19b-389c-4881-bc1c-75cdc2e13c4c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_88c407a9-2e20-473d-8df7-af27a95d41c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_88c407a9-2e20-473d-8df7-af27a95d41c4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d27aa54-2340-49d5-b274-361bb8f5b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d27aa54-2340-49d5-b274-361bb8f5b6fc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3b31164-b1c6-40bb-90f3-515bd38157f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3b31164-b1c6-40bb-90f3-515bd38157f6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87cc00a2-705d-4885-88dd-75203ff5ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fb2c045a-4dec-409b-aa71-e8a7bb9995cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fb2c045a-4dec-409b-aa71-e8a7bb9995cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_50a1cacd-e3d7-4216-9241-91957b9ae83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_50a1cacd-e3d7-4216-9241-91957b9ae83c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:to="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_550f5e76-2acc-4a35-ba0d-074d904882a2_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:to="loc_srt_ProductsAndServicesDomain_550f5e76-2acc-4a35-ba0d-074d904882a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:to="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_52842966-675d-4733-975c-87357918d0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:to="loc_us-gaap_ProductMember_52842966-675d-4733-975c-87357918d0ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_18132404-982c-4a7c-955d-f69b7b917555" xlink:href="ardx-20230331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:to="loc_ardx_ProductSupplyRevenueMember_18132404-982c-4a7c-955d-f69b7b917555" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_9fda976a-6435-40c6-930f-ff287b783141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:to="loc_us-gaap_LicenseMember_9fda976a-6435-40c6-930f-ff287b783141" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="i266ed104fb0844398d3dbd7915120b9a_CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7f277b9b-33d7-4eec-a7e1-77e99053da4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7f277b9b-33d7-4eec-a7e1-77e99053da4e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1277eb97-db98-47c2-9a38-f50f57c5e67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_SharesOutstanding_1277eb97-db98-47c2-9a38-f50f57c5e67f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e4b502e-e40a-491c-a4e0-f56c59f7940e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockholdersEquity_2e4b502e-e40a-491c-a4e0-f56c59f7940e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1da0cd3c-d5f8-4bfb-be25-96f3a1a808b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1da0cd3c-d5f8-4bfb-be25-96f3a1a808b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c458ceff-0cb3-43f1-b998-123fcd816ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c458ceff-0cb3-43f1-b998-123fcd816ae6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42a4143c-fa75-40b8-bae8-19fd6e807a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42a4143c-fa75-40b8-bae8-19fd6e807a30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0b9853c7-e217-43ee-ba67-506768c467f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0b9853c7-e217-43ee-ba67-506768c467f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e0248f2f-460b-42b2-b9df-7361f28a088b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e0248f2f-460b-42b2-b9df-7361f28a088b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_accc102e-ca87-44ac-b885-4626e020b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_accc102e-ca87-44ac-b885-4626e020b34c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd19ac05-468f-4a15-b91a-a4bd7ee3a295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd19ac05-468f-4a15-b91a-a4bd7ee3a295" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71ce7e78-2d1c-4b39-aaa9-3dfc820d3e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71ce7e78-2d1c-4b39-aaa9-3dfc820d3e3c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_46e2baaa-ee96-495c-917e-106d60d01c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_46e2baaa-ee96-495c-917e-106d60d01c4b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_226c61a0-d85d-48d0-b0f9-01081d845f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_NetIncomeLoss_226c61a0-d85d-48d0-b0f9-01081d845f80" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_383b4e06-6828-4fc4-b81e-280c2ae94023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9baa3d6e-b6b5-46f6-b6fa-2be3e58a05c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7f277b9b-33d7-4eec-a7e1-77e99053da4e" xlink:to="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1043937f-24a6-4bfe-b36f-ba5b5a37352e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:to="loc_us-gaap_EquityComponentDomain_1043937f-24a6-4bfe-b36f-ba5b5a37352e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:to="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2b20f745-ffe7-4191-a6b2-b5b107533ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_CommonStockMember_2b20f745-ffe7-4191-a6b2-b5b107533ca3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c5ea629a-a18e-4cf6-a10d-9618ce7c30ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c5ea629a-a18e-4cf6-a10d-9618ce7c30ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_737deab7-6094-49c8-a193-7bc90bcf3894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_RetainedEarningsMember_737deab7-6094-49c8-a193-7bc90bcf3894" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8be567d-c267-4ced-9c3a-5a33b9920dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8be567d-c267-4ced-9c3a-5a33b9920dd9" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended" id="ic50e9c22c6b74aa8a25e68ae405e6e88_CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_4cdd3de4-f5ef-4f53-af8a-db2a49301f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_4cdd3de4-f5ef-4f53-af8a-db2a49301f68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e8624b4-20ef-4b01-94fc-84c703653aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_4cdd3de4-f5ef-4f53-af8a-db2a49301f68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e8624b4-20ef-4b01-94fc-84c703653aff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab9249f9-1323-4b35-9d7d-7d8ebf8fd3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab9249f9-1323-4b35-9d7d-7d8ebf8fd3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_413291ec-f9db-4a67-b913-83eedfb882a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_413291ec-f9db-4a67-b913-83eedfb882a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37768e2c-da11-4fb0-8d5c-476997354329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37768e2c-da11-4fb0-8d5c-476997354329" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8e3b23b-24cc-4b42-b830-630eb570b52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8e3b23b-24cc-4b42-b830-630eb570b52f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_ab59df09-e5e0-4aa9-ba84-7f4836cec1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_ab59df09-e5e0-4aa9-ba84-7f4836cec1bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_fc2cd4cb-7e49-44a5-82c8-5b635b85a0c2" xlink:href="ardx-20230331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_fc2cd4cb-7e49-44a5-82c8-5b635b85a0c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_644ca3d5-7047-426d-8048-eebe28c5c4f1" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_644ca3d5-7047-426d-8048-eebe28c5c4f1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_ad9abd73-c280-4001-a59f-1bf9d21dd463" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_ad9abd73-c280-4001-a59f-1bf9d21dd463" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_549b75f0-55fc-45fd-9c25-dd813c779974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_InvestmentsAndCash_549b75f0-55fc-45fd-9c25-dd813c779974" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ec6aa231-d869-49de-9ec3-5fd2f384d959_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_ec6aa231-d869-49de-9ec3-5fd2f384d959_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_110f2d29-ac3e-4ec6-9fad-c7b369d76ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:to="loc_us-gaap_CashMember_110f2d29-ac3e-4ec6-9fad-c7b369d76ed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5f1059f3-ce15-4be8-98a9-4d5c79d88681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5f1059f3-ce15-4be8-98a9-4d5c79d88681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d29f1c60-06c0-45c0-b0cc-6943a6ede254_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d29f1c60-06c0-45c0-b0cc-6943a6ede254_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5a674a40-8bac-4864-bc2e-5134a1375ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5a674a40-8bac-4864-bc2e-5134a1375ab3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_cdbe9486-1362-4665-8c3b-9620df71dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_cdbe9486-1362-4665-8c3b-9620df71dc76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_15d9c399-1645-47ed-8e19-ed92ccdd3d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_15d9c399-1645-47ed-8e19-ed92ccdd3d3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ad580ad4-b86e-4581-916e-419a5a2d6c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ad580ad4-b86e-4581-916e-419a5a2d6c4e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended" id="i04d10e06f172445abf91d27e989095c2_FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_344d8be3-9f11-4ea1-bd2f-7821a0f7da1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_344d8be3-9f11-4ea1-bd2f-7821a0f7da1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c87d6067-d1e5-49c4-afa5-ccb16186a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_344d8be3-9f11-4ea1-bd2f-7821a0f7da1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c87d6067-d1e5-49c4-afa5-ccb16186a6ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6a1d57f-2053-42db-8d06-442e84d56279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6a1d57f-2053-42db-8d06-442e84d56279" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_964aa137-753e-495d-aa45-46c49351986f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6a1d57f-2053-42db-8d06-442e84d56279" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_964aa137-753e-495d-aa45-46c49351986f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5aa645a-3a22-4cb0-8ec0-46b5b59676b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5aa645a-3a22-4cb0-8ec0-46b5b59676b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c6f3c92c-4094-4e14-95e1-35938e871f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5aa645a-3a22-4cb0-8ec0-46b5b59676b6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c6f3c92c-4094-4e14-95e1-35938e871f2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d7006bc-0a6f-4a41-9795-4d5988ebd145_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0d7006bc-0a6f-4a41-9795-4d5988ebd145_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e68cb5bd-2199-4e53-aa04-d77f2cac26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e68cb5bd-2199-4e53-aa04-d77f2cac26bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_64f09076-8c1c-4081-868e-6110fbb3d8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_64f09076-8c1c-4081-868e-6110fbb3d8f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8587612d-953b-428d-921c-4720076257c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8587612d-953b-428d-921c-4720076257c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_641cb082-e630-4687-8cdd-47be560ad5a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_641cb082-e630-4687-8cdd-47be560ad5a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cdfa4553-2d85-4c43-a6f1-e63b403a1603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cdfa4553-2d85-4c43-a6f1-e63b403a1603" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b09f1de6-3df9-4e42-bd13-1541c1327ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_CommercialPaperMember_b09f1de6-3df9-4e42-bd13-1541c1327ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_caed91f1-82e4-48e2-be16-ed19a719425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_caed91f1-82e4-48e2-be16-ed19a719425a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a7ad9ff1-7bc7-44dc-8d96-480f7fa7ab70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a7ad9ff1-7bc7-44dc-8d96-480f7fa7ab70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e7817229-7dc1-404b-9ea1-6dc8dbb8c140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e7817229-7dc1-404b-9ea1-6dc8dbb8c140" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e917eb1c-5b34-42a1-86be-08a7d50f2e38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_e917eb1c-5b34-42a1-86be-08a7d50f2e38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b714b9c5-4e70-407d-8295-f94cf89fbd46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b714b9c5-4e70-407d-8295-f94cf89fbd46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_a2493809-adec-4c4b-8b4b-02e76da36b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b714b9c5-4e70-407d-8295-f94cf89fbd46" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_a2493809-adec-4c4b-8b4b-02e76da36b83" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended" id="ied5cf6686f6a4176b761490a68f28215_ProductRevenueNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32fb1da4-efed-4149-be7d-21f14cebb321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32fb1da4-efed-4149-be7d-21f14cebb321" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_727b9cb4-821f-4730-98bb-c9c24e870c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_727b9cb4-821f-4730-98bb-c9c24e870c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_07056edd-b87c-43c1-b3cc-9d622c55e840_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:to="loc_srt_ProductsAndServicesDomain_07056edd-b87c-43c1-b3cc-9d622c55e840_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9780fd6-f2c1-492f-9e6d-106638d449a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:to="loc_srt_ProductsAndServicesDomain_e9780fd6-f2c1-492f-9e6d-106638d449a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_dba4cde0-c05f-4c6d-9745-2acb4b91418b" xlink:href="ardx-20230331.xsd#ardx_ProductIBSRELAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_e9780fd6-f2c1-492f-9e6d-106638d449a0" xlink:to="loc_ardx_ProductIBSRELAMember_dba4cde0-c05f-4c6d-9745-2acb4b91418b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1867dcb9-2ec3-49e7-83d6-169a259c2b3f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1867dcb9-2ec3-49e7-83d6-169a259c2b3f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de80b258-20c7-4fba-8294-3bcef86df977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de80b258-20c7-4fba-8294-3bcef86df977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_261ead89-c4be-4b99-b20e-b24e0801657d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de80b258-20c7-4fba-8294-3bcef86df977" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_261ead89-c4be-4b99-b20e-b24e0801657d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_16514527-aaf7-4371-917f-ccea3cb3308c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_16514527-aaf7-4371-917f-ccea3cb3308c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_21f84c7c-ba64-488c-b799-dc085b7d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_21f84c7c-ba64-488c-b799-dc085b7d9f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_50a360bd-fb24-46c6-80c0-981bb54ae79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_21f84c7c-ba64-488c-b799-dc085b7d9f8f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_50a360bd-fb24-46c6-80c0-981bb54ae79e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4a1c585e-3994-4b35-80fa-85fc54a4a1b6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_4a1c585e-3994-4b35-80fa-85fc54a4a1b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_ac76d34f-14ff-45c8-9951-6cc97c012c3e" xlink:href="ardx-20230331.xsd#ardx_CardinalHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:to="loc_ardx_CardinalHealthMember_ac76d34f-14ff-45c8-9951-6cc97c012c3e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_5cacac72-1c30-48b1-b98d-177e9ce5c210" xlink:href="ardx-20230331.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_5cacac72-1c30-48b1-b98d-177e9ce5c210" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_ffebb7b3-48a7-49e1-a49a-4810ca631611" xlink:href="ardx-20230331.xsd#ardx_McKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:to="loc_ardx_McKessonCorporationMember_ffebb7b3-48a7-49e1-a49a-4810ca631611" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended" id="i57c0b792162449959b7c61ba0fa92b48_ProductRevenueNetGrosstoNetSalesAccrualsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0d0c6d7e-7b16-462d-a3e6-482ebabd9de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d0c6d7e-7b16-462d-a3e6-482ebabd9de9" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_70c79fb7-d9ab-4f17-aaa5-bc0614b5ff59" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_70c79fb7-d9ab-4f17-aaa5-bc0614b5ff59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesProvisions_defef042-e326-4657-98ac-ecd9663d1c84" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesProvisions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesProvisions_defef042-e326-4657-98ac-ecd9663d1c84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_43688a3e-eb80-477b-9c34-cb74b6d6246d" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_43688a3e-eb80-477b-9c34-cb74b6d6246d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_37936293-a730-4396-824f-35258682c222" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d0c6d7e-7b16-462d-a3e6-482ebabd9de9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345_default" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_2f1940d4-1207-4852-869b-cc41e4b0d56a" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_2f1940d4-1207-4852-869b-cc41e4b0d56a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember_46b6d152-90a3-41af-9549-0fe7fd81e824" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:to="loc_ardx_ContractWithCustomerRebatesMember_46b6d152-90a3-41af-9549-0fe7fd81e824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5667d8d1-dc26-498d-84a1-96ea33c8e3f5" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:to="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5667d8d1-dc26-498d-84a1-96ea33c8e3f5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended" id="i0f340ab1d60c4307a37d74b3d76f220b_CollaborationandLicensingAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_76f5d15d-237f-456c-87b7-34d32a0e9975" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_76f5d15d-237f-456c-87b7-34d32a0e9975" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_6f61d53d-0e4c-4a74-976b-23e317db0d20" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_6f61d53d-0e4c-4a74-976b-23e317db0d20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0ceaa95c-0e15-4b77-ac13-ce9963e3799e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0ceaa95c-0e15-4b77-ac13-ce9963e3799e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_bd18d27e-9945-4578-a215-af7921c556b7" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_bd18d27e-9945-4578-a215-af7921c556b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_d06f5681-4172-4dfd-95a7-15038531241b" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_d06f5681-4172-4dfd-95a7-15038531241b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_6b12508b-cbb5-459c-ae17-81bece90854d" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_6b12508b-cbb5-459c-ae17-81bece90854d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f01171cf-30a9-4e22-940c-d462e35a42cc" xlink:href="ardx-20230331.xsd#ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f01171cf-30a9-4e22-940c-d462e35a42cc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_6c59feb7-282c-4c95-9fe8-a5096e35780c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_6c59feb7-282c-4c95-9fe8-a5096e35780c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_361dc440-62dd-44f7-ae81-701514d5e441" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_361dc440-62dd-44f7-ae81-701514d5e441" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_564e75cb-dac6-477e-ba23-180d61c1c202" xlink:href="ardx-20230331.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_564e75cb-dac6-477e-ba23-180d61c1c202" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_f79c3f15-b382-4a5c-9548-010113b84ac8" xlink:href="ardx-20230331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_f79c3f15-b382-4a5c-9548-010113b84ac8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_4b99dc9a-6a87-4669-9c3a-65cf6baecc5b" xlink:href="ardx-20230331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_4b99dc9a-6a87-4669-9c3a-65cf6baecc5b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_dd5454dd-6888-49a9-8a1b-65cf5010aa38" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_dd5454dd-6888-49a9-8a1b-65cf5010aa38" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_ed1cf561-e3e9-4bd4-8bac-6e79178a142f" xlink:href="ardx-20230331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_ed1cf561-e3e9-4bd4-8bac-6e79178a142f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_b9bce2ba-9f0b-46f9-ae8c-4dde6e60580d" xlink:href="ardx-20230331.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_b9bce2ba-9f0b-46f9-ae8c-4dde6e60580d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_9988f04b-775c-4ddd-87e0-4d8f3a8ce81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_CostOfRevenue_9988f04b-775c-4ddd-87e0-4d8f3a8ce81a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_783be50f-b796-4d06-9747-92a90df420ef_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_783be50f-b796-4d06-9747-92a90df420ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_a5705410-cf58-4c08-86ce-7b8e6d70048b" xlink:href="ardx-20230331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_a5705410-cf58-4c08-86ce-7b8e6d70048b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_4b90534f-b511-489a-9ab6-e5b0ea7e9a66" xlink:href="ardx-20230331.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_4b90534f-b511-489a-9ab6-e5b0ea7e9a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_8af87b5e-8223-445b-8dd5-e398cbcf5e01" xlink:href="ardx-20230331.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_KnightTherapeuticsIncMember_8af87b5e-8223-445b-8dd5-e398cbcf5e01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_14ec9a69-5c9f-4ff8-ad3d-748c4e96ca30" xlink:href="ardx-20230331.xsd#ardx_AstrazenecaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_AstrazenecaMember_14ec9a69-5c9f-4ff8-ad3d-748c4e96ca30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c04c68db-2a59-4eec-a95f-f5fc99efaf5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c04c68db-2a59-4eec-a95f-f5fc99efaf5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_f175fd1d-56b5-4685-a699-67679079810e" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_f175fd1d-56b5-4685-a699-67679079810e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_2cabef5e-9e43-4d41-b964-105f38824250" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_2cabef5e-9e43-4d41-b964-105f38824250" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_0ece98e1-4274-4456-b9d5-4a43ff29652b" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_0ece98e1-4274-4456-b9d5-4a43ff29652b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_f3d3c235-c84d-47ee-8065-5775e3d2f11c" xlink:href="ardx-20230331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_f3d3c235-c84d-47ee-8065-5775e3d2f11c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:to="loc_srt_ProductsAndServicesDomain_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ece178e5-0f6a-4ec1-8a1f-e548d10e2df3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:to="loc_srt_ProductsAndServicesDomain_ece178e5-0f6a-4ec1-8a1f-e548d10e2df3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_33076a8e-ce4f-4020-a3d0-6f49b56d51b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ece178e5-0f6a-4ec1-8a1f-e548d10e2df3" xlink:to="loc_us-gaap_LicenseMember_33076a8e-ce4f-4020-a3d0-6f49b56d51b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended" id="i46640e98e5304dd59e877bef736237bd_CollaborationandLicensingAgreementsDeferredRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:href="ardx-20230331.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a402bb1-fa18-4136-b6fa-4cc46def9aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a402bb1-fa18-4136-b6fa-4cc46def9aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_4bf607d6-3ab0-4afd-9087-7f2436ec604b" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_4bf607d6-3ab0-4afd-9087-7f2436ec604b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_04cc5d1d-bea5-41a3-8d16-5b69606e44c6" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_04cc5d1d-bea5-41a3-8d16-5b69606e44c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ffbfc69-2ebe-46b3-89ba-412ad3224cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:href="ardx-20230331.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2105ea5f-7e72-493e-a29f-6a3f085131d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2105ea5f-7e72-493e-a29f-6a3f085131d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f64a2467-d48b-4038-b446-afd212933595" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f64a2467-d48b-4038-b446-afd212933595" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_6aba0b94-fe53-4ed0-8418-3f343b7a2122" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_6aba0b94-fe53-4ed0-8418-3f343b7a2122" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_5cc1d6a4-9cca-417e-81ce-b75cd8e45f7f" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_5cc1d6a4-9cca-417e-81ce-b75cd8e45f7f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_59924923-7c67-4a2e-965f-78d70a5131ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68bd013c-d648-498a-8ed9-e86ee468d508_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_68bd013c-d648-498a-8ed9-e86ee468d508_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dbcec75-1dde-4135-9aa7-5bf1c0da07cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dbcec75-1dde-4135-9aa7-5bf1c0da07cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_de41f128-cb03-462f-80f4-71780e9b4a73" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dbcec75-1dde-4135-9aa7-5bf1c0da07cd" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_de41f128-cb03-462f-80f4-71780e9b4a73" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="extended" id="if0c2e5af802c4e0bb5ab0af867f0bbcc_DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_500a4226-62cf-404c-99ae-b2a77898b2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_500a4226-62cf-404c-99ae-b2a77898b2d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_21147312-4efb-41ab-91b8-28a7cb7d51d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_ContractWithCustomerLiability_21147312-4efb-41ab-91b8-28a7cb7d51d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_80436242-867a-4909-9028-c05bbf161eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_80436242-867a-4909-9028-c05bbf161eab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_9c05956b-8083-47fc-bbf8-864407622345" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_9c05956b-8083-47fc-bbf8-864407622345" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_e8509085-0138-49e8-b884-0aa33bc32a38" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_e8509085-0138-49e8-b884-0aa33bc32a38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_18c9870f-4a1e-44f5-9ea1-f1ccd200c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_18c9870f-4a1e-44f5-9ea1-f1ccd200c8c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_8a323fb1-2c5b-46f1-84ba-a7fc74452ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_8a323fb1-2c5b-46f1-84ba-a7fc74452ce0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:to="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4663e1a-66a7-45e5-96b2-e86c4322ad8c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d4663e1a-66a7-45e5-96b2-e86c4322ad8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f82b3ff-585f-4c2a-8aa1-2f2ae70d87eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f82b3ff-585f-4c2a-8aa1-2f2ae70d87eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_527e6531-96cd-40ef-82d9-7b2f16e94b67" xlink:href="ardx-20230331.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f82b3ff-585f-4c2a-8aa1-2f2ae70d87eb" xlink:to="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_527e6531-96cd-40ef-82d9-7b2f16e94b67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:to="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4419ff8b-7f3d-407f-96fe-8c584d616427_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:to="loc_srt_ProductsAndServicesDomain_4419ff8b-7f3d-407f-96fe-8c584d616427_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dcd836d8-6cd0-4e89-9574-f20909dde167" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:to="loc_srt_ProductsAndServicesDomain_dcd836d8-6cd0-4e89-9574-f20909dde167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_54272bc2-620f-40a6-9fa5-d75d18f3aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dcd836d8-6cd0-4e89-9574-f20909dde167" xlink:to="loc_us-gaap_LicenseMember_54272bc2-620f-40a6-9fa5-d75d18f3aa3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended" id="i5984d1e494bc4c7dae2f0b4d13241307_BorrowingNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bb70ece8-789e-4750-97f2-5d7c8a333b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bb70ece8-789e-4750-97f2-5d7c8a333b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_decd61cd-b826-43a9-8340-7fc8c50426c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_decd61cd-b826-43a9-8340-7fc8c50426c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_da5876b8-2490-4600-b912-7d379769a9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_da5876b8-2490-4600-b912-7d379769a9c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c5f12842-7fde-4927-928d-ed4537b52d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c5f12842-7fde-4927-928d-ed4537b52d3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_34716a57-a669-478b-b348-c34f20028fe1" xlink:href="ardx-20230331.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_34716a57-a669-478b-b348-c34f20028fe1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0794629a-89fe-48f1-b5a9-d4f7cac154b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0794629a-89fe-48f1-b5a9-d4f7cac154b7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_e5f1081b-64b3-4662-8ae2-e46e4314c882" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_e5f1081b-64b3-4662-8ae2-e46e4314c882" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption_eb1271d9-b77b-4e25-8ebe-98b7606e8879" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentVariableRatePlusOption_eb1271d9-b77b-4e25-8ebe-98b7606e8879" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c7523fef-db17-42d6-8294-f66ffdacda6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentTerm_c7523fef-db17-42d6-8294-f66ffdacda6a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_882257c9-a100-4dd8-8847-176bd86e971a" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_882257c9-a100-4dd8-8847-176bd86e971a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d14c7dfb-8f78-42aa-8ec4-fa250fb10add" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d14c7dfb-8f78-42aa-8ec4-fa250fb10add" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_964f2246-fdb3-46bb-b62e-26b148795715" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_964f2246-fdb3-46bb-b62e-26b148795715" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ffdf560b-2833-48b6-87c2-d449abf35ee7" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ffdf560b-2833-48b6-87c2-d449abf35ee7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_c2fb05f8-f7db-4ed4-a887-56df18d8c9a1" xlink:href="ardx-20230331.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_ExitFeePercentage_c2fb05f8-f7db-4ed4-a887-56df18d8c9a1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1d58bbd3-7cfc-404d-b019-56b1f39757bd" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1d58bbd3-7cfc-404d-b019-56b1f39757bd" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_d12e1551-80fc-4212-a193-ba32a2b6c92d" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_d12e1551-80fc-4212-a193-ba32a2b6c92d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_e2b878c2-6b27-44f5-bbd1-af32baa4d00c" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_e2b878c2-6b27-44f5-bbd1-af32baa4d00c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_0624ede8-beb2-4757-8046-534da48060d3" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_0624ede8-beb2-4757-8046-534da48060d3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_ee88ddee-17c9-4a50-a97f-e1f8fa3d33c4" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_ee88ddee-17c9-4a50-a97f-e1f8fa3d33c4" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_7f1fde0d-04a1-4986-8067-8e1b585b9714" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_7f1fde0d-04a1-4986-8067-8e1b585b9714" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_55e91019-409a-4c95-bc99-8f1236d550c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_55e91019-409a-4c95-bc99-8f1236d550c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_0d1632e5-1aaa-481c-be06-afe28e2ed335" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:to="loc_ardx_ExitFee2018Member_0d1632e5-1aaa-481c-be06-afe28e2ed335" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_781441e1-4509-4f00-a941-6a30633ce391" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:to="loc_ardx_ExitFee2022Member_781441e1-4509-4f00-a941-6a30633ce391" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_992ea41b-b13c-4917-9e9f-bbc1e6b13876_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_992ea41b-b13c-4917-9e9f-bbc1e6b13876_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_bb08d54f-c6d9-42d8-8eca-ad92255ed8b9" xlink:href="ardx-20230331.xsd#ardx_TermLoan2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:to="loc_ardx_TermLoan2018Member_bb08d54f-c6d9-42d8-8eca-ad92255ed8b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:to="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_377abeb0-5ebf-4a44-9770-eb3c30439b02" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022AMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:to="loc_ardx_TermLoan2022AMember_377abeb0-5ebf-4a44-9770-eb3c30439b02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_04b728c5-a58b-4011-be36-0d6e67fa565c" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022BMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:to="loc_ardx_TermLoan2022BMember_04b728c5-a58b-4011-be36-0d6e67fa565c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermBLoanMember_c6dff7e8-b2d9-49f8-99b3-c55a7e6b3d64" xlink:href="ardx-20230331.xsd#ardx_TermBLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:to="loc_ardx_TermBLoanMember_c6dff7e8-b2d9-49f8-99b3-c55a7e6b3d64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d05efc7c-a414-4eb7-a94a-73c397c3818a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d05efc7c-a414-4eb7-a94a-73c397c3818a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_97a2be19-f082-4dc6-8b60-f3767c36f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d05efc7c-a414-4eb7-a94a-73c397c3818a" xlink:to="loc_us-gaap_LoansPayableMember_97a2be19-f082-4dc6-8b60-f3767c36f5e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_842bd989-22eb-44af-9422-ba3c98508004_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_842bd989-22eb-44af-9422-ba3c98508004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_195eee11-4463-471d-b105-09beb0d72ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_195eee11-4463-471d-b105-09beb0d72ad4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7be7a398-f361-45c8-97a0-4b4a398397fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7be7a398-f361-45c8-97a0-4b4a398397fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_37941d46-b26d-4cf3-b786-e95ca74d2294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_37941d46-b26d-4cf3-b786-e95ca74d2294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_29fff8b3-6922-42fb-bc02-a7e6aea7e877_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:to="loc_us-gaap_VariableRateDomain_29fff8b3-6922-42fb-bc02-a7e6aea7e877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_997bc564-e206-4e36-87f1-53932029bfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:to="loc_us-gaap_VariableRateDomain_997bc564-e206-4e36-87f1-53932029bfbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e79621f5-8d6c-427f-ad3d-5486be8f46e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_997bc564-e206-4e36-87f1-53932029bfbf" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e79621f5-8d6c-427f-ad3d-5486be8f46e4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#DerivativeLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="extended" id="ide5dc755ab774f85978a1a9f6e0597b8_DerivativeLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_eb21cda2-a800-47ce-8658-6f5ba12396ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_eb21cda2-a800-47ce-8658-6f5ba12396ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c6f2d73b-8d89-4871-b3eb-bab0d48df79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c6f2d73b-8d89-4871-b3eb-bab0d48df79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_da4f83e1-6c7b-45a3-937d-e776f6d2a79d" xlink:href="ardx-20230331.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_da4f83e1-6c7b-45a3-937d-e776f6d2a79d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_e82c31f4-22ac-4e2a-b8c8-3a21a1af1431" xlink:href="ardx-20230331.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_e82c31f4-22ac-4e2a-b8c8-3a21a1af1431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_80b4c519-f288-4317-9117-ccc17989c316" xlink:href="ardx-20230331.xsd#ardx_ExitFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_ExitFeePercentage_80b4c519-f288-4317-9117-ccc17989c316" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7068559a-71f1-4b9e-8536-34418841b451" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7068559a-71f1-4b9e-8536-34418841b451" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_259e488c-3bfc-4f7a-bca9-2e96627900e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_259e488c-3bfc-4f7a-bca9-2e96627900e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_c2e8f115-6162-4ca0-85b5-aa785fa57b23" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:to="loc_ardx_ExitFee2018Member_c2e8f115-6162-4ca0-85b5-aa785fa57b23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_de5774e1-e794-413b-b32d-8c3e9b327048" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:to="loc_ardx_ExitFee2022Member_de5774e1-e794-413b-b32d-8c3e9b327048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5eb31b13-0584-4b1d-a71f-eca36a94297f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5eb31b13-0584-4b1d-a71f-eca36a94297f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc85dfe5-44bb-4c62-b9da-4ce884a3fd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc85dfe5-44bb-4c62-b9da-4ce884a3fd40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c35523ae-5d76-435f-8c52-5562cef45839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc85dfe5-44bb-4c62-b9da-4ce884a3fd40" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c35523ae-5d76-435f-8c52-5562cef45839" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#DerivativeLiabilitiesChangesinFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="extended" id="i9cd1eaf1c1964d33bed059e17c9941ab_DerivativeLiabilitiesChangesinFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f5e9a876-4baa-4a44-9836-b605c8656dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f5e9a876-4baa-4a44-9836-b605c8656dc3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1c294d57-bc72-4382-b511-81e079e416d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1c294d57-bc72-4382-b511-81e079e416d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f83c3d87-28d0-4831-abf8-63384f35ad48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f83c3d87-28d0-4831-abf8-63384f35ad48" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd2fcc3-10bf-4297-94f6-d5a4d31e8ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd2fcc3-10bf-4297-94f6-d5a4d31e8ac4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b8e663fb-63d2-48ea-a5a9-c8106379266b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f5e9a876-4baa-4a44-9836-b605c8656dc3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_347ac0d4-b322-4337-857d-dc21fda7aa09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_347ac0d4-b322-4337-857d-dc21fda7aa09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_87c2c8d6-a33d-40be-8a1c-073b6fa7294f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_87c2c8d6-a33d-40be-8a1c-073b6fa7294f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_20e80a9f-62a1-4bbf-a8db-ac19a67b5e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_87c2c8d6-a33d-40be-8a1c-073b6fa7294f" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_20e80a9f-62a1-4bbf-a8db-ac19a67b5e9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9c8d5690-1171-4b45-a1b4-ae2d659110ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9c8d5690-1171-4b45-a1b4-ae2d659110ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_fefc27d9-956f-4d36-bffa-dd4c79f0fcaa" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:to="loc_ardx_ExitFee2018Member_fefc27d9-956f-4d36-bffa-dd4c79f0fcaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_fd89034e-cbbc-4aa6-917d-b3825f231334" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:to="loc_ardx_ExitFee2022Member_fd89034e-cbbc-4aa6-917d-b3825f231334" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="extended" id="ie367d3b40f324c24bffd7ca97388af11_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_337b3544-2622-4275-a22f-22c1d05df43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_337b3544-2622-4275-a22f-22c1d05df43d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_0fb58e0d-7df4-439d-b492-13e6f7b16c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_0fb58e0d-7df4-439d-b492-13e6f7b16c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:to="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_fa61465c-70e3-4696-b28b-a42f2417bd7d_default" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:to="loc_ardx_LeaseArrangementsDomain_fa61465c-70e3-4696-b28b-a42f2417bd7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_9230a57d-6958-4a86-9b28-4df08218766b" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:to="loc_ardx_LeaseArrangementsDomain_9230a57d-6958-4a86-9b28-4df08218766b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember_cf087199-4c74-4056-86a9-b14ce9c991a3" xlink:href="ardx-20230331.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ardx_LeaseArrangementsDomain_9230a57d-6958-4a86-9b28-4df08218766b" xlink:to="loc_ardx_FacilityFremontCaliforniaMember_cf087199-4c74-4056-86a9-b14ce9c991a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:to="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_761cce50-3a28-4c11-890e-90d5545f00c6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:to="loc_srt_RangeMember_761cce50-3a28-4c11-890e-90d5545f00c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:to="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0209e336-825a-4b48-960d-a976e68fc84b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:to="loc_srt_MinimumMember_0209e336-825a-4b48-960d-a976e68fc84b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af27d656-361e-46ae-be88-74b897636693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:to="loc_srt_MaximumMember_af27d656-361e-46ae-be88-74b897636693" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended" id="ifa0ea2a37006485eaa920f667db3c303_StockholdersEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_86b19ee1-4c1d-40e1-aeb8-296a956d05b3" xlink:href="ardx-20230331.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_86b19ee1-4c1d-40e1-aeb8-296a956d05b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_7e785735-2a81-4686-b136-f1cae2bed0a3" xlink:href="ardx-20230331.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_7e785735-2a81-4686-b136-f1cae2bed0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7a300b0a-9cc1-4a11-8eaf-64ba862bae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7a300b0a-9cc1-4a11-8eaf-64ba862bae0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3ba7013f-5058-4550-85e4-af22db23a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3ba7013f-5058-4550-85e4-af22db23a5ed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_f55e8cd6-4532-43e7-974f-3f774ef30ba0" xlink:href="ardx-20230331.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_f55e8cd6-4532-43e7-974f-3f774ef30ba0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_4bb5e107-9b65-4bb7-96c8-4b2fdc6a6be5" xlink:href="ardx-20230331.xsd#ardx_EquitySalesAgreementSharesIssuedSinceInception"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_4bb5e107-9b65-4bb7-96c8-4b2fdc6a6be5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_de5b5584-c2fb-4cb0-bc3a-ac2dcd3d764b" xlink:href="ardx-20230331.xsd#ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_de5b5584-c2fb-4cb0-bc3a-ac2dcd3d764b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_571405c0-b002-4d56-ab01-e3df5bb68188_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_571405c0-b002-4d56-ab01-e3df5bb68188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_d8cd6c62-9f63-469e-a767-cc743d390767" xlink:href="ardx-20230331.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_d8cd6c62-9f63-469e-a767-cc743d390767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_f4ef2018-e6a7-4230-9e1e-952575e3f590" xlink:href="ardx-20230331.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:to="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_f4ef2018-e6a7-4230-9e1e-952575e3f590" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e67a38e7-f87f-4931-96e9-58a831ebb6b9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:to="loc_us-gaap_ClassOfStockDomain_e67a38e7-f87f-4931-96e9-58a831ebb6b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_75578fc2-5ade-4ae9-9a0d-eecec55e2758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:to="loc_us-gaap_ClassOfStockDomain_75578fc2-5ade-4ae9-9a0d-eecec55e2758" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6b53bd84-5aec-4710-9106-4778ee01eb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_75578fc2-5ade-4ae9-9a0d-eecec55e2758" xlink:to="loc_us-gaap_CommonClassAMember_6b53bd84-5aec-4710-9106-4778ee01eb85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended" id="i54704a28e34f4ac4985d2f3458441f17_EquityIncentivePlansStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6a444e93-f6f5-40aa-901a-8c2c03b75958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fb6268f0-7705-4c53-8b55-1fe5640b8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6a444e93-f6f5-40aa-901a-8c2c03b75958" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fb6268f0-7705-4c53-8b55-1fe5640b8dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6a444e93-f6f5-40aa-901a-8c2c03b75958" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9de18ed4-e49d-4f97-b988-d981ae3aa2bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9de18ed4-e49d-4f97-b988-d981ae3aa2bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1af785bc-09ad-465c-9f18-74cecdae7f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1af785bc-09ad-465c-9f18-74cecdae7f16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78d1b967-057a-436e-8d60-a662a475fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78d1b967-057a-436e-8d60-a662a475fb52" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended" id="i146e109cc7694996bc2512902b190a73_EquityIncentivePlansUnrecognizedStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8165534-9005-4e80-8b1c-1be492f51d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8165534-9005-4e80-8b1c-1be492f51d62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3d733f0-f99e-4e52-a603-f518ec6377bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3d733f0-f99e-4e52-a603-f518ec6377bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:to="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_110b96a3-da56-4984-9e52-6ba10e23d4f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:to="loc_us-gaap_PlanNameDomain_110b96a3-da56-4984-9e52-6ba10e23d4f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_821de445-2a43-4f5d-a9c0-003d704c5bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:to="loc_us-gaap_PlanNameDomain_821de445-2a43-4f5d-a9c0-003d704c5bc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_6be4b3bd-fa01-41bc-8462-1688ecc1f232" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_821de445-2a43-4f5d-a9c0-003d704c5bc8" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_6be4b3bd-fa01-41bc-8462-1688ecc1f232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:to="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8edba548-61fa-4e55-ab28-df874e7c335e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8edba548-61fa-4e55-ab28-df874e7c335e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94f8ac31-9832-4b82-96f5-e1f13bb83ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94f8ac31-9832-4b82-96f5-e1f13bb83ed6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cd864cf4-5bd1-40a0-a454-9282c37cb2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cd864cf4-5bd1-40a0-a454-9282c37cb2b7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended" id="ic369401b2922465590d4095cab6fdb9b_EquityIncentivePlansRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b1e5c5a-32dd-42f4-b2be-45334c852e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b1e5c5a-32dd-42f4-b2be-45334c852e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2840bd73-2a0c-4dce-a2c3-2ffb8929d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2840bd73-2a0c-4dce-a2c3-2ffb8929d67e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3d67592-adc1-4c74-810c-6bf53fce45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3d67592-adc1-4c74-810c-6bf53fce45ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0a6fc258-91a6-48cd-a3c1-20c71732c029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0a6fc258-91a6-48cd-a3c1-20c71732c029" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15d8d868-0e20-4e23-afbb-a869dd0cb684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7ab49693-b5c1-4f5a-b868-9eaba17e1266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7ab49693-b5c1-4f5a-b868-9eaba17e1266" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f254a66d-732d-49f3-8cb2-c7dbfb28b813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f254a66d-732d-49f3-8cb2-c7dbfb28b813" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_da3ea7a1-0922-4e46-aac4-9e96161f8221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_da3ea7a1-0922-4e46-aac4-9e96161f8221" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_209e58c2-574a-4f1f-80b5-edcc1653a02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_209e58c2-574a-4f1f-80b5-edcc1653a02d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_add9d55a-92bf-4d52-bf72-d45f0c5a451b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:to="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15406126-bde8-4384-bee7-dd0405051c89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_15406126-bde8-4384-bee7-dd0405051c89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c8216e-dbf1-4e55-8918-840d6b2f2e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c8216e-dbf1-4e55-8918-840d6b2f2e8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e91ada-92e6-43fd-8d13-a6e73a3ab627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c8216e-dbf1-4e55-8918-840d6b2f2e8b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e91ada-92e6-43fd-8d13-a6e73a3ab627" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended" id="id0a868bb081f44c2a953e36e5dac9316_EquityIncentivePlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c8842b2e-b54a-4755-a0c8-adfab08d149b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c8842b2e-b54a-4755-a0c8-adfab08d149b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_12b0dec8-ca86-4aa9-8b05-926b5e448872" xlink:href="ardx-20230331.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_12b0dec8-ca86-4aa9-8b05-926b5e448872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_1c1fe809-055c-41e0-ba8b-4b03c435e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_ProceedsFromStockPlans_1c1fe809-055c-41e0-ba8b-4b03c435e9e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d4c41afd-b578-4312-98da-1af877162593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d4c41afd-b578-4312-98da-1af877162593" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:to="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6fdf40d7-4e6a-4559-99c4-9c089e4ce271_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:to="loc_us-gaap_PlanNameDomain_6fdf40d7-4e6a-4559-99c4-9c089e4ce271_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb7cda5a-7a94-4617-be0b-4ce995492625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:to="loc_us-gaap_PlanNameDomain_fb7cda5a-7a94-4617-be0b-4ce995492625" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_bee5f826-87bb-42b2-bec8-7935511031e2" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb7cda5a-7a94-4617-be0b-4ce995492625" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_bee5f826-87bb-42b2-bec8-7935511031e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:to="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cdde637f-a65f-4203-bea5-99153ac19339_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_cdde637f-a65f-4203-bea5-99153ac19339_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51244fbe-afa7-473e-b37e-c786cf846cf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51244fbe-afa7-473e-b37e-c786cf846cf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_e4e7767a-c965-4c5e-87f0-2a1eb6f054e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51244fbe-afa7-473e-b37e-c786cf846cf3" xlink:to="loc_srt_DirectorMember_e4e7767a-c965-4c5e-87f0-2a1eb6f054e0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="extended" id="if7914d32144d4cb7a9d45e3e8046660d_NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32f92e27-de1a-4d76-9268-f3e18d51eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84b4532c-0dad-4f47-a3eb-90fb4f2c9ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32f92e27-de1a-4d76-9268-f3e18d51eaae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84b4532c-0dad-4f47-a3eb-90fb4f2c9ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32f92e27-de1a-4d76-9268-f3e18d51eaae" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:to="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd7af919-7f87-4074-9504-02f7fb51bff1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd7af919-7f87-4074-9504-02f7fb51bff1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0985dc5d-2b85-4b49-8a88-72cfc22c07d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0985dc5d-2b85-4b49-8a88-72cfc22c07d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2b53e8b4-b475-4911-8758-1a5218730803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2b53e8b4-b475-4911-8758-1a5218730803" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_8c661c54-a1b9-4ac3-b050-464ba40acf9f" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_8c661c54-a1b9-4ac3-b050-464ba40acf9f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#ContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="extended" id="iaa4dc3ada7a245ee924fd46e770aa6f7_ContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_25ffcd3f-4259-4e28-be9c-0933dec079eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_25ffcd3f-4259-4e28-be9c-0933dec079eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_edcaae1b-40a6-4e03-8b09-607f200ebb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_edcaae1b-40a6-4e03-8b09-607f200ebb81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f83654a8-766d-4d6b-8151-a2ce323f1bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f83654a8-766d-4d6b-8151-a2ce323f1bbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:to="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_6e693654-353c-4bfc-be86-2d9dac4a1ed3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:to="loc_srt_LitigationCaseTypeDomain_6e693654-353c-4bfc-be86-2d9dac4a1ed3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:to="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StrezsakVersusArdelyxIncMember_59be7131-94eb-4fbe-9b6a-767560129240" xlink:href="ardx-20230331.xsd#ardx_StrezsakVersusArdelyxIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:to="loc_ardx_StrezsakVersusArdelyxIncMember_59be7131-94eb-4fbe-9b6a-767560129240" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GoVersusRaabMember_d38c9d3b-e8dc-4980-9807-172de037a06a" xlink:href="ardx-20230331.xsd#ardx_GoVersusRaabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:to="loc_ardx_GoVersusRaabMember_d38c9d3b-e8dc-4980-9807-172de037a06a" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>ardx-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5e53bfed-5618-4e24-885d-bb49c3b2394c,g:e63de3a8-8715-46e5-89c4-d16db17c8afb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_aa0e09b1-b887-4637-91d3-77583c94160b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cdb1a97f-0b3b-4ce0-95bd-5e8aefd95ba5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted operating lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_82a1d73a-2a0b-413b-8635-11200216187f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f0bb947a-2346-486c-9427-fc6271a84f70_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total repayment obligations</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_01f1d059-06e8-414a-908c-45e673bde1cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_b0d24aa0-f4c3-4181-8fc8-7e8a711beedc_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional default interest rate</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate On Default, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional default interest rate on the event of default.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:to="lab_ardx_DebtInstrumentInterestRateOnDefaultPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_2246d830-fa75-4d38-a30d-872b5b1a9181_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space area (sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_cdd47f1d-aeb4-43a4-9622-86e74a3f69ec_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_32750f56-ae62-4ce4-a259-6f3e1bbefee9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f83dd51a-0e16-4799-b278-03fb76b87a99_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_047b94e4-7e04-4f76-9bd0-9608ae145d9b_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Additional Details of Leases</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Additional Details Of Leases [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The tabular disclosure of additional details of the leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:href="ardx-20230331.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:to="lab_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b0ba3d14-2a45-4718-b263-4ed9356d9112_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_945874f5-d30b-4012-a16d-0bef00b9a0d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_a8dea82d-e67b-461b-96c2-d2685b9b2a98_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_us-gaap_LossContingencyNumberOfDefendants_label_en-US" xlink:label="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNumberOfDefendants" xlink:to="lab_us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8367dfbc-82c3-4295-ba4b-3291bc3045a1_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0359c1d1-ac1f-4b18-94a6-6a8f0b9fdee6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating per annum rate (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_105a21c0-096b-4a47-8115-50ae8995814d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1c05bcf7-e6af-46f7-84d4-3900e716109e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b9c4e246-41b9-420f-8871-4c97f28cb6fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_3e2fbd8a-0491-4b5f-b681-54f25659d4b8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon vesting of restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_7503dd69-0f52-4f83-8099-b8203bdb17e4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_78ce2c45-4c3e-4ef4-8a66-7a371caa40df_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_a9d6dfc0-b6e8-4927-9fea-cdb3722f01e6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_f727cff1-0b8a-48a5-9d50-6ea201f1e57c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After second anniversary to maturity date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_18237d92-6de9-4b4e-8e41-08b2971d46f0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_5f596d9c-26f6-4c31-8d2a-30aca94cbc65_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_9f04c3f6-694e-42f3-b824-f48dd6208652_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1bb276be-3975-471c-b361-110e21ec9c43_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5cbe5172-6b28-442c-ba2c-242e1a90b2ea_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_7e625c54-d54c-4ea1-b24e-755867b5d281_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Debt Payment Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_12c144d2-de80-4614-aebb-c0467ddd74bc_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undiscounted cash payment obligations</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_fc4485ff-36e0-45a3-9dc1-20dc3669584d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_6f09460f-0bab-4fda-a06e-c1ff217c3ccb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_45d159c8-92eb-4260-a69d-7e3fe336ae08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_aae3e275-0d8c-4c68-80d1-fe9ca88fabf4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_8072d387-7c00-4ffd-8ada-30ed75a5c216_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_1b754769-0298-4235-9b90-727f405ac12d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_1e71b23b-053d-4d3a-9330-a7fa89815c6f_periodStartLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_3891dd14-5f6b-4f62-9fd8-60a104b37593_periodEndLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_5b95be92-d784-422b-ba82-bebdba1f7404_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3c2be77c-f421-4353-946f-23728db498bc_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_1ba10a04-ef5a-4dd7-a4e4-34c4f3cbb705_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Copay and Returns</link:label>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Other Fees, Copay And Returns [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Other Fees, Copay And Returns</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:to="lab_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_2ba50a57-1c8c-47b9-8e59-1b19185607bd_terseLabel_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KKC</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_label_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kyowa Kirin Co. Ltd [Member]</link:label>
    <link:label id="lab_ardx_KyowaKirinCo.LtdMember_documentation_en-US" xlink:label="lab_ardx_KyowaKirinCo.LtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the information pertaining to Kyowa Kirin Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember" xlink:href="ardx-20230331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KyowaKirinCo.LtdMember" xlink:to="lab_ardx_KyowaKirinCo.LtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_74685beb-b21a-478e-9e19-54ab1ee07c37_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_290692ff-bc57-47e4-9285-4ffe3e2a87da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_4e444f8a-67c2-497a-b1b8-94f01b9252e4_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_17d262a3-e572-4855-847d-efcda769396a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_471d5630-ae98-44a2-b0b7-a72953381f51_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f7b84279-bb47-40e2-9604-3b7a94373006_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfAdvanceRoyalty_c5dfd510-bd4c-4d8e-a114-de8de606776e_negatedLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense related to the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_AmortizationOfAdvanceRoyalty_cf6b622e-9819-4eab-9ea5-f757aeb06647_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of the deferred royalty obligation</link:label>
    <link:label id="lab_us-gaap_AmortizationOfAdvanceRoyalty_label_en-US" xlink:label="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Advance Royalty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfAdvanceRoyalty" xlink:to="lab_us-gaap_AmortizationOfAdvanceRoyalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2c2a904d-adce-4da5-9180-450d1ecdfaff_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remainder of 2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_82b16b0a-b09c-40cc-87b4-849b379e5c52_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_f9e93c89-2497-4cba-af48-a8a5c0612c66_terseLabel_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining funding based on milestone achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_label_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:label id="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_documentation_en-US" xlink:label="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Funding Based On Conditional Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:href="ardx-20230331.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:to="lab_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2d734a09-cafe-44d8-b7ad-9e69592fce8d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_9b47b84b-7788-4776-a961-99fd36a2c498_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_32c87792-397c-40eb-a53e-6c70c61bb528_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5be74c74-d04b-45b6-88f0-e4ae103cece2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_33d1b7e5-0fe7-4e2a-8c5e-e9c8e2908e26_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6da915a4-31c1-4258-bc81-5915627b6672_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_4e844517-7395-4be1-8370-de23f9358e81_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9f6c9049-262a-454c-b527-f08def99943b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_83e11a50-c180-4ce0-b4ae-49a17647989a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_167c17d0-7fc2-4267-ab6b-36adcead4c39_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_d93749bf-b1fb-42fa-b42a-fe660a6aa516_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_6c7da32a-57e7-41ce-b2df-17ff980f005a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_41691f04-115c-4223-b24d-9546a3cff8a2_terseLabel_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_label_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Three</link:label>
    <link:label id="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_documentation_en-US" xlink:label="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:href="ardx-20230331.xsd#ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:to="lab_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_5ee919f8-dd2c-48b4-a29c-4ebedd8eeca7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited or canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_6e38520c-9364-4b46-86a1-105e30d328fc_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing fee</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_label_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:label id="lab_ardx_DebtInstrumentClosingFeeAmount_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Closing Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentClosingFeeAmount" xlink:to="lab_ardx_DebtInstrumentClosingFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_2964dd1e-d5ff-4627-867f-0a375fddec37_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_a505c38d-5aa4-4fff-a28b-89c42ffb8139_negatedTerseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Losses</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized losses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_95d306c9-a16f-4d89-98fe-f4dff0764258_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_cbd53678-ca5f-4f70-8da4-eade1852bd7c_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining life (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7837b70b-362f-4364-8086-77a607461bab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_d70f4a66-b90a-4948-b344-955dd0e79068_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_99fe4cc6-6072-44e4-a076-7f7d8ebc415f_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue" xlink:href="ardx-20230331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_77fbf374-5054-4fcf-8ae4-24dba0614b57_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_81995715-3a3f-496d-a94a-8aa5e6ad1a88_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6eae8ad-7252-4ab7-bd9a-03106ce75f8f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_91175e4a-2891-4fbb-81f0-f24ba1e1f0d0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_544ffcf6-df5d-4874-b7ae-1c1f09e86d56_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_7ba1bcc4-6cb8-4270-8fa4-a24d29019429_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_2bff9dac-ba4c-4319-a2e2-677c91ec6fa9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise&#160;Price&#160;per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_499e5af9-7241-4aae-b459-4d18bb3c18ed_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SOFR</link:label>
    <link:label id="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_label_en-US" xlink:label="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:to="lab_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_98870f58-95cb-4c61-9496-610f2d4169e7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8df51783-70fe-44aa-a51f-e3e7ae25a64a_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CardinalHealthMember_c8830562-009c-496d-ac61-7bb897702de7_terseLabel_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_label_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health [Member]</link:label>
    <link:label id="lab_ardx_CardinalHealthMember_documentation_en-US" xlink:label="lab_ardx_CardinalHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardinal Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember" xlink:href="ardx-20230331.xsd#ardx_CardinalHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CardinalHealthMember" xlink:to="lab_ardx_CardinalHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_0fe19bc4-07e7-4b8e-98d6-bf9cfb7d0415_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_5566ae1e-e800-4a67-b374-8d0f4b98ed3c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_59629d92-e106-4971-bd10-3fd48bf8abe2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_eac09bee-c8e7-4bd4-ad31-743419ffff7f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_bdd80592-400e-44b1-ab0f-d1aac32f5d8c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_10af5b08-b393-405b-afaf-87ced75ecf22_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_287b9315-bae9-4bde-bbcd-2f06d15f8b64_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_fdcee49a-bd6f-4e06-9f5b-d4cc4fb76a1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e7f02044-6a5d-4919-a8a6-cda7391642db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableCurrent_263ff2bb-e17d-4acc-a501-6061885660b7_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_566a6287-ac62-4adb-b00e-ce696b21086e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LoansPayableCurrent_label_en-US" xlink:label="lab_us-gaap_LoansPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableCurrent" xlink:to="lab_us-gaap_LoansPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_e964da13-6b00-4156-8a8e-b330ced65d05_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Transaction Costs</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityTransactionCosts_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Transaction Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:to="lab_ardx_ContractWithCustomerLiabilityTransactionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_53f5688a-e405-4cea-82c5-c75c29d2c887_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_0477b61b-d13f-4d09-81d4-0410cd16d643_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Axis]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductIBSRELAMember_5acca38e-5275-4296-ac6b-2798c82a6496_terseLabel_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IBSRELA</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_label_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA [Member]</link:label>
    <link:label id="lab_ardx_ProductIBSRELAMember_documentation_en-US" xlink:label="lab_ardx_ProductIBSRELAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, IBSRELA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember" xlink:href="ardx-20230331.xsd#ardx_ProductIBSRELAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductIBSRELAMember" xlink:to="lab_ardx_ProductIBSRELAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_3dd8ebcd-5e34-4e57-9780-dfa71df7d80e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Revenue Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_c53f2234-610e-4d17-9021-c930b09d9fa6_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_95619bd3-c2f9-4e33-a9fc-5c94ca62ca13_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_7332fe4c-deda-4ccf-b03f-b060f6aa2346_terseLabel_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price (in dollars per share)</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_label_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share</link:label>
    <link:label id="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_documentation_en-US" xlink:label="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the purchase price per share of shares issued to employees under the plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:href="ardx-20230331.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:to="lab_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_2fc89d11-a30c-40b2-a427-0454fd2e0740_terseLabel_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_label_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation [Member]</link:label>
    <link:label id="lab_ardx_AmerisourceBergenDrugCorporationMember_documentation_en-US" xlink:label="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AmerisourceBergen Drug Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:href="ardx-20230331.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AmerisourceBergenDrugCorporationMember" xlink:to="lab_ardx_AmerisourceBergenDrugCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_7d1ef6c0-c57e-415e-862a-1e19a9744f4c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_71a2d08d-d4a6-4cbd-9d7c-5eed6addb110_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development and commercialization milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development And Commercialization Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of future development and commercialization milestone under collaborative arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ddca32c6-c09d-4443-a931-3ce668006ccd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b5cffcc3-7d57-4b4b-9648-ad6e58f4e829_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_79f93a2d-789f-4872-8dc6-f6505466433f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LeaseArrangementsAxis_7ec88ea5-cdf4-47a8-88ea-da5e0f38182c_terseLabel_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsAxis_label_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsAxis_documentation_en-US" xlink:label="lab_ardx_LeaseArrangementsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LeaseArrangementsAxis" xlink:to="lab_ardx_LeaseArrangementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_e58dfdd9-b85f-481a-8bac-1492a00fd665_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_031accdd-99b0-4090-b41e-a94a8c51e55b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_426b7ece-16c6-4055-bd75-23ae583f0e66_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_1203c270-dd9d-489b-9863-0aee66913a2a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_e654e7de-7570-4499-bc44-948cf7511e6f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_0e66e42b-2420-4f91-bece-9d8c56ec1448_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7ca1878e-a383-4661-9dce-0920b9898d6f_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_ae9b1d79-7c1d-4f8d-8ff2-56c45ae69782_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_500cd7ad-79a8-4b4f-af60-d005df305523_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_a3452efe-4cb5-4518-ac22-f029b5b71e97_terseLabel_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_label_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:label id="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_documentation_en-US" xlink:label="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross To Net Sales Accrual And Reserve Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:to="lab_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1643ace9-4f30-4560-854d-d5da5dc25aaf_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_edfea126-bd70-4324-b4f4-4b9eb1cd4b8e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_ca7c9b58-4521-4b66-be0c-4a0b7c486710_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41a923b8-5b96-49ba-a5ed-2ab8d3817f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_d549d3bc-b78f-452d-b89b-855f46593c6c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Remaining Vesting Period (Years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_05504b5d-dad1-4658-8a70-c877fe1f7f46_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from ESPP</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans" xlink:to="lab_us-gaap_ProceedsFromStockPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022Member_6b7b402e-dab6-48af-aaff-ecd017c48525_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_label_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022Member" xlink:to="lab_ardx_TermLoan2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ab98badc-2a3e-4c66-90bf-bd2de8889380_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_d71e5709-2a50-4aed-b16e-d90c46b7a12c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c6659616-e846-4333-9053-ec8cfd6ed843_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_58d045e2-3188-438f-b4d4-1eb53b7df32d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock in at the market offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_aa95857a-c126-41ce-9b31-d22b471f20d5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_4265b2ab-8042-4bba-9471-8705e7d72c69_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7bb82b3e-f774-481c-9bd7-ab9117edc436_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_60dca679-ed48-426a-8d2f-0886ad2329ed_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_06a1160f-1112-47a7-a734-e87cade20cb3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_d5191ae7-adc8-48ce-a92f-5880210a3b86_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_587e995a-ac40-4969-a2cc-aa15f075a211_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b88b638a-889a-4a59-a181-73564d97ac7f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_199a2241-7e21-4551-a850-2f9dd33439e1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1b34c7f9-eb9c-46b9-9d40-dacde2c0491e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_6510dcb9-3737-499a-862d-a29c7430727a_terseLabel_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_label_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing, Current</link:label>
    <link:label id="lab_ardx_PrepaidCommercialManufacturingCurrent_documentation_en-US" xlink:label="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Commercial Manufacturing, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent" xlink:href="ardx-20230331.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PrepaidCommercialManufacturingCurrent" xlink:to="lab_ardx_PrepaidCommercialManufacturingCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9e87329d-adaa-4735-91c3-1d3100205413_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_0aefc8c3-912d-4454-a270-f7f4f4ac92f6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from 2022 Loan, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_71d6b2a6-bf66-4a4c-97c4-2122667381b7_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_18bc7c0c-5747-4c51-9d70-c695b67ca237_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_89e05a8f-d2f7-4dd8-be9d-015e41de8796_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0f820e57-7105-4577-b268-6c3276342515_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_76f7d2ab-2dee-43b8-a454-9fe72fad6a11_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_972c850d-84d6-4777-b3bb-7bf5d3433b30_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_b7bc7aa6-0181-43a2-bc1f-82b6102529d2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_50a9d904-2b13-49a1-a6eb-1ac298ec8a44_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_be7769b6-f45e-438c-9ec0-155894e3f302_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_bfbb0e24-2190-4006-802f-a8df501fd477_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_240f0346-d3db-4abb-ae7b-0340d93ebaf7_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3c8ecf39-5f08-4174-8cb4-375e8cd90c3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_7fbd47d2-0a25-4a65-9c98-4e3fc29a07fe_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_7db17aa0-dae1-4a36-81ab-76b3b861757f_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment premium (as a percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Prepayment Fee, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentPrepaymentFeePercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The percentage of fee payable on prepayment of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:to="lab_ardx_DebtInstrumentPrepaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c5a132a9-7c2a-44c6-bef0-86682a6a4ae0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_cd01981a-461f-478a-b391-a349c4f00b9d_terseLabel_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term securities, contractual maturities maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_label_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:label id="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_documentation_en-US" xlink:label="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:href="ardx-20230331.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:to="lab_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a2349ff7-c4c6-4552-a079-42ed704109ed_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_68157d31-7ce8-4084-b07c-9006986d320f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon occurrence of certain conditions</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_85c78650-1bf2-463c-8550-007a0b95ba8c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreed amount for exit fee upon change of control or regulatory approval</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_c828d614-8766-41c1-97f9-427dc9c11ee2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0b08430d-ae87-4a35-bf54-0e1fa5163573_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_dfd9301a-a678-40da-b949-8e604759135e_terseLabel_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold percentage of net sales for tiered royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_label_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold Percentage of Sales For Tiered Royalties</link:label>
    <link:label id="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties_documentation_en-US" xlink:label="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the threshold percentage of net sales for tiered royalties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:href="ardx-20230331.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:to="lab_ardx_ThresholdPercentageOfSalesForTieredRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_0c760072-10f4-4b1f-9806-91bfa071aa6b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_37363f1d-6576-4205-ad61-7585937c031e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_09c11ed7-8ee0-4055-85ba-b8b7f22db2dd_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_50e0ff3d-2ae6-4ee3-a28d-be25d6aadb96_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d11f524a-38de-4106-b408-1d2203e7bbbd_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_2beb9df3-feb6-4e0d-9ee7-000423d3dea5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unaccreted value of final fee</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFeeAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFeeAmount" xlink:to="lab_us-gaap_DebtInstrumentFeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_54973ac9-e3ed-452b-a711-4cf6201ef2f0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3e4cc475-a811-43f8-92dc-3d82c5a515a6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common stock - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_2a0b89bf-4a2b-41aa-ab30-9da6d3103a68_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_6ccc01c5-214e-4e45-862b-123d7e2ca0b0_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2023, At The Market Offering</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2023, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2023, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:href="ardx-20230331.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_f4de6d86-515d-4113-a7af-d3e375392ad1_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, term (in years)</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeTerm_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeTerm" xlink:to="lab_ardx_LoanAgreementExitFeeTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3606044c-0f7d-4bf6-b9e8-059cb6494715_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_595c216e-1409-4dce-b373-360b45c70dce_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_96ddd0eb-4c41-4a42-8e30-45e917bf8552_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_7633c1e1-72bf-4279-a4cb-2c5dcf9e7880_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_42932f43-1e70-424e-bfe8-7ea80ce96654_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_87254c58-a53d-4220-b314-90f87b9ea7c1_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cf954a15-b5a9-414c-8ea7-8fa6756634a6_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_9060d4cd-c739-480d-bad8-560c7451c6a3_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board of directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_cdc302b6-b9c4-4176-85cf-a717aab5fcfc_terseLabel_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Pharma</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_label_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shanghai Fosun Pharmaceutical Industrial Development [Member]</link:label>
    <link:label id="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_documentation_en-US" xlink:label="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents Shanghai Fosun Pharmaceutical Industrial Development.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:href="ardx-20230331.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:to="lab_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_1702fb3f-8654-48de-b677-ed12728a88fe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_2f9ce4c4-eb9b-4d0b-b52d-dac1890fbc64_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_b298d82c-e520-4bb5-aa12-ddd10ba2099a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit loss on available for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_dec5d210-7dcd-4f81-9173-62c62a0953c7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_d810fb00-3cb9-48a6-9ee4-9fe6ba414578_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Canada [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ec791de8-86ba-4c44-8c88-ec751f1eb6bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_c4b0b180-c147-4a55-81d8-b49820e13fe7_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8538175d-57b0-4a0b-b85c-53767259d7cb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Changes in Fair Value of Derivative Liability</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_bea942c7-6ecf-4679-9a0e-5205892249d0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_b860c119-31fd-41cb-a0df-d5696284f682_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_443ca77b-652c-4926-afbc-4e1e360fb4cf_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d88c2e47-32a5-450c-9740-8be7f1bc69e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5b47e8cf-1d25-4d4f-a934-a858154fcd97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock-Based Compensation Expense Recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_ac29186d-09a5-46aa-a3c1-5575dc3ec9be_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e44833e0-4151-4f19-92bc-82449b079470_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_1e68b7a8-2d4e-4d99-9b08-76ec83adfdf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1ae17d32-b704-452a-b458-5191fb921a26_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_52fe1a10-23d3-48b3-954c-41d0a9897e74_terseLabel_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP shares issuable</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_ardx_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_ardx_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EmployeeStockPurchasePlanMember" xlink:to="lab_ardx_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0c3ff519-975f-4f45-9bf5-0a25a97c64ed_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_25039d69-614b-46a0-b997-7d122f3a2bb6_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper, Not Included with Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_948d51f2-ec69-4d06-a188-655b1984ccd5_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_536033cf-c08d-4981-906a-0a23a41032aa_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_a45afd98-8e78-4700-8168-52897500b80e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5ca22755-70e4-4857-ba1a-decd702007d9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_ad9a81bc-32ee-4abc-a52b-23ee836e8faa_terseLabel_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average sales price per share (in dollars per share)</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_ardx_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:href="ardx-20230331.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_ardx_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_37836f0b-b765-46ad-9d4c-43ba41ae5f96_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_1067368e-a234-4fb7-abfc-24f2fe2732b6_terseLabel_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate cost of revenue recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_label_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Of Revenue, Aggregate Amount Recognized</link:label>
    <link:label id="lab_ardx_CostOfRevenueAggregateAmountRecognized_documentation_en-US" xlink:label="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue, aggregate amount recognized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:href="ardx-20230331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CostOfRevenueAggregateAmountRecognized" xlink:to="lab_ardx_CostOfRevenueAggregateAmountRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_8d78c39d-9353-4af0-900e-a947516ec148_terseLabel_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AZ Termination Agreement</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_label_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement [Member]</link:label>
    <link:label id="lab_ardx_AstraZenecaTerminationAgreementMember_documentation_en-US" xlink:label="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca Termination Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:href="ardx-20230331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstraZenecaTerminationAgreementMember" xlink:to="lab_ardx_AstraZenecaTerminationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_985d5956-bb97-4353-9652-375b3f519287_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_84256317-f7e9-4724-a983-bf2ab9bb2956_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_69030958-ff3a-4d50-8790-65d757d7573d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_f53815cf-03c2-47c8-a794-be4d446c4cbf_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_92a6cc37-a460-4e14-8d63-b44899d5d308_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_25e1320f-6eec-45c4-9ef2-3381972da5b2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c8599b61-7b53-41b3-a06a-c3c1272329d2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_b6eb5076-5ad3-4f53-be41-74bae045f0c4_terseLabel_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California</link:label>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_label_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California [Member]</link:label>
    <link:label id="lab_ardx_FacilityFremontCaliforniaMember_documentation_en-US" xlink:label="lab_ardx_FacilityFremontCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility, Fremont California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember" xlink:href="ardx-20230331.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FacilityFremontCaliforniaMember" xlink:to="lab_ardx_FacilityFremontCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_7b710376-c9d1-4327-a961-754a3d937fd2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_bb083f23-4cb9-41f1-9b3f-6e391f801c12_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_9b13891a-4994-4571-b448-367a81357b27_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_7531bb8f-50ee-4756-8583-8d8274531da4_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liabilities for exit fees</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_c7b4b779-d028-4738-98fa-99aa68b86c3c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments, Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:to="lab_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_60efc09b-f53e-4925-a990-6d9edeee0f52_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a7e0c81b-4c1b-4d91-aee0-b503aca20fae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_93a27f7a-0488-489c-919e-6d2451d98980_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_4d5365f4-95e6-4aa0-ad24-508d2a31fb90_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_164ee40a-650d-430b-bcfb-2d942e57687d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_0558286c-1508-49de-8011-fd01ca77bd48_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_16eeed12-2400-4d96-81f6-ee854d5f765d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_5bf2b842-b837-4ad6-88c6-f30e74efbe7c_terseLabel_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of non-royalty revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_label_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Non-Royalty Revenue</link:label>
    <link:label id="lab_ardx_PercentageOfNonRoyaltyRevenue_documentation_en-US" xlink:label="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents percentage of non-royalty revenue.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:href="ardx-20230331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PercentageOfNonRoyaltyRevenue" xlink:to="lab_ardx_PercentageOfNonRoyaltyRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d32d813d-117c-45fd-88f6-df74551cd21c_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_5795497a-6197-4db4-8cdd-b61ce8e2c4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a2a37045-cd09-47ed-84f2-08db67068409_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_d3be59a7-431e-466f-a253-b5034bbc5b2e_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34c6aab0-88e6-4844-a49b-38f4db54f831_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_90b108b8-6a4e-46c2-9e25-d3d713cac27f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8cd80a5d-60d9-450f-b5ac-f53b16094f72_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2d4ee60c-5906-412f-b562-02eafeac61f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_286306d5-40f5-4fd9-89b6-dc1a4279abd7_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_36e916ec-22f6-44ca-9013-5d54690dc855_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_9c42e924-65d8-4d41-be1a-f752049dc4cc_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_409e5d9a-a30b-47c2-a3c4-3a43e34d16f8_terseLabel_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product supply revenue</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_label_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue [Member]</link:label>
    <link:label id="lab_ardx_ProductSupplyRevenueMember_documentation_en-US" xlink:label="lab_ardx_ProductSupplyRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Supply Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember" xlink:href="ardx-20230331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ProductSupplyRevenueMember" xlink:to="lab_ardx_ProductSupplyRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFeePercentage_06129d4c-9208-49e6-ac12-1886e0c846d9_terseLabel_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee (percent)</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_label_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:label id="lab_ardx_ExitFeePercentage_documentation_en-US" xlink:label="lab_ardx_ExitFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage" xlink:href="ardx-20230331.xsd#ardx_ExitFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFeePercentage" xlink:to="lab_ardx_ExitFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_386fee48-7884-4ae8-a6cc-04bad7eaa6ca_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_6ab0dfeb-c519-4307-a541-8474c3293db3_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="lab_us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1aa6a7c3-c19e-42ca-a235-103c6eebc59a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_92f7f6c7-a195-4498-b941-32275e521b3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_679bce84-589a-4cb9-978c-18b090caf6b9_terseLabel_en-US" xlink:label="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of gross proceeds</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_label_en-US" xlink:label="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Proceeds From Shares Issued Since Inception</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_documentation_en-US" xlink:label="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Proceeds From Shares Issued Since Inception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:href="ardx-20230331.xsd#ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:to="lab_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_48afef85-6f80-46b3-9253-91185f3b9411_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_840a2628-aec4-4e8b-ae5f-882d8e3b9673_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c5baf626-2d44-4d19-84cd-dcca50e9c445_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_22f42187-deec-499e-be2e-63c04755667d_terseLabel_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission on sale of stock per agreement (percent)</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_label_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:label id="lab_ardx_StockIssuanceCostCommissionPercent_documentation_en-US" xlink:label="lab_ardx_StockIssuanceCostCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issuance Cost, Commission, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent" xlink:href="ardx-20230331.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StockIssuanceCostCommissionPercent" xlink:to="lab_ardx_StockIssuanceCostCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_032b70ba-f28b-4ee0-8ed0-80bb93d321fb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_412595d5-d64b-4ce6-84f7-2fb18202466e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_786ebe42-ca1c-4097-942f-448bd5eae439_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_14dfec1c-1f7b-4553-9ace-562a3e6624a4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9a844163-336a-4056-8908-844488116c59_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_9d541836-6261-444c-aa5e-6a52a4216a6f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0e1c043d-de7d-429b-9d29-4a5170b302fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_39479ef7-7225-4f7e-bcb9-eb1616706c00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7654641f-d5b3-49bc-8a66-67e5c18f4604_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_666a3e48-0271-4d39-bb39-0eb218008ff2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_bba2e58d-b0f9-40e3-9008-b01d7896d80c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_be528635-e198-4c89-b196-16a9778858d0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c11e9a59-cf7a-4870-b761-4d74b5b218f2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_344b5d3c-8b4b-44c6-bab1-240a02fa6fe6_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_label_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:label id="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:to="lab_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8722294b-f928-45a0-a252-0e5e975eb5d3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_AstrazenecaMember_e180c79e-2cd8-44b6-b515-4ca5634a1cdd_terseLabel_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AstraZeneca</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_label_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Astrazeneca [Member]</link:label>
    <link:label id="lab_ardx_AstrazenecaMember_documentation_en-US" xlink:label="lab_ardx_AstrazenecaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to AstraZeneca.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember" xlink:href="ardx-20230331.xsd#ardx_AstrazenecaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_AstrazenecaMember" xlink:to="lab_ardx_AstrazenecaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_3dcb041b-ac93-401c-9588-650b1e85a3ba_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_c1700658-0052-4c01-a2cb-b659d0dd6bb3_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, percentage change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:href="ardx-20230331.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:to="lab_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception_3ade29df-6985-41ef-a3be-c4d5833f45fa_terseLabel_en-US" xlink:label="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of shares sold</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception_label_en-US" xlink:label="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Shares Issued Since Inception</link:label>
    <link:label id="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception_documentation_en-US" xlink:label="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Sales Agreement, Shares Issued Since Inception</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:href="ardx-20230331.xsd#ardx_EquitySalesAgreementSharesIssuedSinceInception"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:to="lab_ardx_EquitySalesAgreementSharesIssuedSinceInception" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_271bda33-4bd4-42d5-a6c0-71ef484b716d_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_2bd6c3b0-9de1-4d9f-a9b4-90e04d9edf6f_terseLabel_en-US" xlink:label="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone payments</link:label>
    <link:label id="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="ardx-20230331.xsd#ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_312ad1a6-adb9-42fd-a8f1-01c1547d14bd_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of payment tranches for fee receivable for reduction in royalty rate</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:to="lab_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_25ff5740-7b6d-4b3c-b768-1960901daaab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_056118df-b1b7-4cf1-9364-4ebfa3aeb706_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 300,000,000 shares authorized; 214,462,050 and 198,575,016 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_cad16ce2-facd-4c35-bdb1-be1ee8043e80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1d5782a8-1363-4540-a7e7-bcc30bd15a53_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2018Member_d85daa9e-8e5e-4133-8046-b2f712615b4e_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Term Loan</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_label_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018 [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2018Member_documentation_en-US" xlink:label="lab_ardx_TermLoan2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member" xlink:href="ardx-20230331.xsd#ardx_TermLoan2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2018Member" xlink:to="lab_ardx_TermLoan2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a71abe9c-4305-47fe-931e-6edaea2c6391_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_659b8add-bf40-4230-99a8-176225ca941e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_041848c1-150e-4a3b-8fa3-52f371977d26_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_59ac033e-4878-4ef2-93fb-98c055b40b37_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_0749fd4b-0dce-4e9f-a419-f3682dcfd384_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fosun Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In China [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DerivativeIssued_3f7e93bd-8e19-49e0-8d69-796ccef2e0b0_terseLabel_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of derivative in connection with issuance of loan payable</link:label>
    <link:label id="lab_ardx_DerivativeIssued_label_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:label id="lab_ardx_DerivativeIssued_documentation_en-US" xlink:label="lab_ardx_DerivativeIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued" xlink:href="ardx-20230331.xsd#ardx_DerivativeIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DerivativeIssued" xlink:to="lab_ardx_DerivativeIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b33c71fb-4536-4e65-b03e-843b9ac0f6ed_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_bdcf0e0b-a4e1-45ba-8f68-a1b4c79b8efb_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_bdcce914-f2af-471b-8bf0-7d16d72c8dba_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - non-current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Noncurrent, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:href="ardx-20230331.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_d6c07846-3102-444c-bbb8-e0dae7117aee_terseLabel_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Chargebacks, Discounts and Reserve Balances</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_label_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals [Table Text Block]</link:label>
    <link:label id="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_documentation_en-US" xlink:label="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Gross To Net Sales Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:href="ardx-20230331.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:to="lab_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_adb524f1-f9ad-427d-9085-e030731fa4df_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_33521049-2107-4043-b536-317cf6226373_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_ac3c5567-66eb-4835-9df6-c2387066d93a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022AMember_67a39aec-0960-4670-b18e-16138cf27366_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_label_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022AMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022AMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022AMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022AMember" xlink:to="lab_ardx_TermLoan2022AMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_2ebb18d3-056c-4002-b4ac-b4ffc583a240_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit fee, net product revenue threshold</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:to="lab_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_6b5de5d7-c8cd-427c-85be-5507b0872f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from royalties received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRoyaltiesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Royalties Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="lab_us-gaap_ProceedsFromRoyaltiesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fd322380-80fb-4a98-979e-8b1c130471e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_cf46e9c0-b685-43d5-b534-98fd0072b937_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee addition at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_ae90bf51-3f43-4ecc-ba93-bdbd80d7f874_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase due to unbilled prepayments recorded during the period</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_9cd02e83-f208-42d3-b954-c3faa2d8640e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6ab1212e-168c-41ae-9838-895cbf45c1ea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a5eafb67-ea6e-4e04-9aae-414ec6e9f323_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_f8b530fe-ad8d-4d03-a119-9c2a1ecb252d_terseLabel_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017 KKC Agreement</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_label_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Development Commercialization Distribution In Japan [Member]</link:label>
    <link:label id="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_documentation_en-US" xlink:label="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:to="lab_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_8272da93-b464-47ef-a12e-245bd4508f08_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_e1ad81ed-02c6-4dbe-b507-16b03cdb20cd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_04277748-dbf7-4617-a4b5-b14cb66d149d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in continuous unrealized loss position for more than one year</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7c0f4410-320a-4888-8d71-c5537af0ea8a_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fabf23dd-1727-42e9-bb9a-9a5301e7d565_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_af73dd0b-42e2-4075-a9f9-cc9b56211865_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in derivative liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6cb9c3b9-7609-45b1-a032-d6190a101145_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_0cadeb9f-4c8e-4ef6-9fef-9084cdff67a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_29411173-038d-4fcc-b7c8-0435378aa34f_terseLabel_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate amount paid</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_label_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Of Uncharged License Fees, Aggregate Amount Paid</link:label>
    <link:label id="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_documentation_en-US" xlink:label="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of uncharged license fees, aggregate amount paid.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:href="ardx-20230331.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:to="lab_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_54ed4ea8-449c-4ac3-b00f-7246251b9c93_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_us-gaap_LossContingencyNewClaimsFiledNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, New Claims Filed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:to="lab_us-gaap_LossContingencyNewClaimsFiledNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_7660de6b-c721-476f-98bd-ce89d870e687_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_87958be0-611e-45a7-8530-b9b77937aa45_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_b1b71464-93a6-4f58-b752-97baa6edf902_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_4e2d4fee-eeb7-4c7c-9a55-633fb5ff1bf8_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentVariableRatePlusOption_0b8e8358-6761-48a4-8c4f-d50ce0c1ec4c_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition plus to floating per annum rate (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRatePlusOption_label_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Plus Option</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRatePlusOption_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Plus Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentVariableRatePlusOption" xlink:to="lab_ardx_DebtInstrumentVariableRatePlusOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7a30d176-8f17-4280-9d7f-f732aa58b519_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_765e44fd-5171-447c-96e5-71d1f86e5d1a_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_51f789b1-9949-415b-ade5-4e2282a53afe_terseLabel_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Open Market Sales Agreement</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_label_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering [Member]</link:label>
    <link:label id="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Sales Agreement 2021, At The Market Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:href="ardx-20230331.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:to="lab_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_465df57b-d970-4eb0-891d-da8bfec94bcd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_1488e47b-0708-4d4e-b1a7-5525827ed6ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_560f1347-3476-4cc6-909d-07d7add4288b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_2f05cc27-f484-4daf-9cb6-0ce98740061b_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4ba8bb3f-664a-4f0d-bcf8-226f8a174598_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_94591515-4bbd-4f76-a096-5134dd85075a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_462a2e42-aab8-4523-8fe3-4768c9ab60b3_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced, for which cash has not yet been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Increase For Amounts Invoiced</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:to="lab_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_31daa903-6255-44ff-aed9-764567814e3d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, impairment loss</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseImpairmentLoss" xlink:to="lab_us-gaap_OperatingLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_79bcc76a-fa89-44a2-b0ff-3f5b76fbf66c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_929861c1-2315-4c87-8668-2187fd1c06a4_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_216048e2-0f4f-4a6e-b7eb-cdbbcce24789_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_fef44c16-8889-4dfd-9fb7-406ebcdf6b06_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential development milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:to="lab_ardx_CollaborativeArrangementPotentialDevelopmentMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a0cc3070-469b-4fd1-9aa5-5a7f2a2fc465_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, beginning (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a5ce0d06-a877-4d92-b564-1d4470dddb3e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, ending (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4b6929b7-499e-41b1-8290-cbb74f7d6793_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_d8cb21c8-e078-4f56-b0ca-8229235872c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_17395cb3-f018-4640-8329-74f3f188356e_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases to amounts invoiced, for which cash has not yet been received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Invoiced But Cash Not Received</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Revenue Invoiced But Cash Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:to="lab_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f515e39e-532a-4eac-aa1c-daa655e71c41_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_bb1ac05e-bf2d-4820-be62-defd40971bbf_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions_ff22524a-6f29-4d6f-a6b6-295cfb9821e5_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Provisions</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales, Provisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesProvisions" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesProvisions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesProvisions" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesProvisions" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LeaseArrangementsDomain_c6809f1d-dd17-4c22-856b-276ebb00ea3c_terseLabel_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsDomain_label_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_ardx_LeaseArrangementsDomain_documentation_en-US" xlink:label="lab_ardx_LeaseArrangementsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LeaseArrangementsDomain" xlink:to="lab_ardx_LeaseArrangementsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8a2404d3-d399-4c29-8ed6-03445b93e2d3_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8e36e014-0122-4a69-8393-dadc0b0cfff6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_262c12d2-a0f6-4955-9081-87db0e8c5ec4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_0a6457e5-87a1-4218-8516-30c71addcad9_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_2b3d483e-aba4-480c-87d8-6dcea44fd378_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets and lease liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_44d79407-0ea6-422d-b2a3-e701c1fb87d0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_bd5fc036-3575-4cbc-8e4c-1f8b5c777d37_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase common stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_47359741-fcd0-4dce-b05e-546650bf18c2_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_8a06a02c-9f46-4533-91f0-8ee156d7f1c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_60714b74-6a88-4d42-ad38-3136e7e86f56_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e525913e-e853-4b9d-9b1d-75e42153ee69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_bd82b66e-df06-4af8-b1a2-27c7b2b3d08b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_d98aefd0-ed41-492d-a7a8-ca3e6ecd9444_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_29a13699-6285-47bd-a96c-e4680f777d98_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_188c393d-ecde-4c7e-afc1-18ed525b55c9_terseLabel_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare royalty partners IV, L.P</link:label>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_label_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthCare Royalty Partners IV, L.P [Member]</link:label>
    <link:label id="lab_ardx_HealthCareRoyaltyPartnersIVLPMember_documentation_en-US" xlink:label="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HealthCare Royalty Partners IV, L.P</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:href="ardx-20230331.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:to="lab_ardx_HealthCareRoyaltyPartnersIVLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_614ff83d-2b5a-4519-8104-3cfe9712214e_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_59fb9899-c8c5-463b-9599-89fbcdb5bcd1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_99634abe-895f-4fdc-8b12-aa6fb4f72bbc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d51053e4-ba93-4618-867b-98e01af7be13_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_9dd76d61-3ea0-448b-b65d-cd5948260e73_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_ebf36fb8-963e-480a-a152-ee4a341dda93_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_fe354ca8-8c7f-4c0e-9329-126f1824bbe8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock_8752c836-ab29-4e74-b452-c727c6fb2908_terseLabel_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation Related To The Sale Of Future Royalties</link:label>
    <link:label id="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Retirement Obligation Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:to="lab_us-gaap_AssetRetirementObligationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_14cd611b-307c-463d-9850-a085d9bf9074_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_46ebc2a6-7773-4fd3-b673-501fcd9e5510_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_67a9a16f-806a-4630-aa18-a283c60d54f6_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_049c5a14-25a9-4265-8154-bfedafbc5fca_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0862273f-4a82-4615-a77f-65a24464b321_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de28e0e3-48b0-478b-a340-22bdc65707ea_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_19721df5-85fb-44cd-93a2-f27bcdb7e7a3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_58d98072-4a66-45d9-a54d-09c8a4fefe7e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_8b2e7abb-e673-4ea7-ac7d-6d4a2840a83c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_f69556d0-e035-4e91-8163-2b9fa1799b4a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number&#160;of&#160;Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_3631668f-7e9d-4f73-8971-37b3e8a79b69_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfDebtDiscountPremium_label_en-US" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_05b5086b-7b44-4fcc-9a08-b77386849e60_terseLabel_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_label_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Knight Therapeutics Inc [Member]</link:label>
    <link:label id="lab_ardx_KnightTherapeuticsIncMember_documentation_en-US" xlink:label="lab_ardx_KnightTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to Knight Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember" xlink:href="ardx-20230331.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_KnightTherapeuticsIncMember" xlink:to="lab_ardx_KnightTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_d6857946-c26a-419d-9302-9c3572e9d612_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6ee671f2-78d9-44b0-b875-442fddfa5e3e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_StrezsakVersusArdelyxIncMember_13f7dcee-5aa3-489c-baec-ae1440cffcc4_terseLabel_en-US" xlink:label="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strezsak v. Ardelyx, Inc.</link:label>
    <link:label id="lab_ardx_StrezsakVersusArdelyxIncMember_label_en-US" xlink:label="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strezsak Versus Ardelyx, Inc. [Member]</link:label>
    <link:label id="lab_ardx_StrezsakVersusArdelyxIncMember_documentation_en-US" xlink:label="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strezsak Versus Ardelyx, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StrezsakVersusArdelyxIncMember" xlink:href="ardx-20230331.xsd#ardx_StrezsakVersusArdelyxIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_StrezsakVersusArdelyxIncMember" xlink:to="lab_ardx_StrezsakVersusArdelyxIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_9a4f5cf1-6e53-41aa-87f7-9b222c0ce386_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional details</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_f7321fcd-ce65-48e6-8e11-c1d0875e22f9_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_8d8640b7-49f2-4ee8-ad9d-9b63058a2d8b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d754a275-f67c-4ddc-a66b-2237aecf7b2c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_c3937a0a-0b8c-49f5-abfe-39800b2c99ba_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_93656114-893b-42fa-96f2-77c78f69ed0f_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsAbstract_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">n/a</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9e7720a5-f760-461c-8848-3bc6d8d15875_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_33dc6d22-1353-4d8f-bf46-e3df2a02c435_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c09a7f32-5fb3-475b-a64b-79e2e284342a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e30fcdda-4f79-45cf-9eed-6b7cb24713c9_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_9f279c07-d327-4b29-bca0-f5e7a773dd3d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_353a82d6-2838-4d19-92b4-f4d8239d3253_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_8f17924f-0e2f-4431-909b-a56e466cd86f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fca7bea7-19cb-4588-93fa-a1193d350916_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_6dd6bf67-9fab-4f24-9ee5-fb21f94712e2_terseLabel_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue - current</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_label_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]</link:label>
    <link:label id="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_documentation_en-US" xlink:label="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Contract With Customer Liability, Current, Rollforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:href="ardx-20230331.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:to="lab_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_e1326d2f-8963-4f21-bd26-4f3219ee1dc5_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember" xlink:to="lab_us-gaap_SalesRevenueProductLineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_38712d4f-4211-4727-a472-e1f0bb16c554_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and short-term investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_75c1ec27-318d-4955-9383-5db5b77db301_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Fair Value</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_5b74dc3a-f3f5-40f9-b2a6-052b8d1a790b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_96c93e7d-a6fd-412f-8ba4-c214c18df4ca_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in at the market offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_890d770a-d842-4a7b-b03f-600bf74eb4d4_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per share - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c1b2cf1-48f9-4410-b69e-fe8f50ab3dad_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_6cb8b2b7-a53d-4fca-b833-b13def44d352_terseLabel_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred royalty obligation related to the sale of future royalties</link:label>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_label_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:label id="lab_ardx_DeferredRoyaltyObligationNoncurrent_documentation_en-US" xlink:label="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Royalty Obligation, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent" xlink:href="ardx-20230331.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DeferredRoyaltyObligationNoncurrent" xlink:to="lab_ardx_DeferredRoyaltyObligationNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_057c0f5a-2d9f-47e6-b9be-b5e00577cd3a_terseLabel_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_label_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:label id="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_documentation_en-US" xlink:label="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:href="ardx-20230331.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:to="lab_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_a9640ae5-62b0-4d83-9540-91480d7fd205_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_c196c3b1-f525-4029-b031-36cb949fbb3c_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_f7f690f4-f071-4185-8ae3-37ce31af4e43_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and Chargebacks</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Discounts And Chargebacks</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:to="lab_ardx_ContractWithCustomerDiscountsAndChargebacksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_073fd547-03f9-4bf7-8f61-b43941c787e2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_6bfe2a03-dc9e-4aac-bb61-b4c63f638677_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_66e2f25c-6d57-4888-a521-b3f2f8285b7e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 14)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_05dedb27-d669-40d6-be7a-b7de904f412b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_64f5d6af-3157-4da9-8a7d-9d9971c6eba7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, beginning (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b8a40114-bad8-4828-a2b7-84457f0022e1_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding balance, ending (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_0b668ccb-842e-47e5-98c4-0c6264c8eb33_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing revenue</link:label>
    <link:label id="lab_us-gaap_LicenseMember_b79c7389-91db-47ea-9180-de4def8b2de9_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_295d862a-f07b-4956-9ee2-a72a8ab59c80_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt refinancing costs</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnRestructuringOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (Losses) on Restructuring of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:to="lab_us-gaap_GainsLossesOnRestructuringOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_2b11b2ef-1786-4021-86bd-d9c6f2e43a07_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_c001ecb7-54d3-4cc6-903f-dc1d3458dce9_negatedTerseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:to="lab_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_865bd26a-2300-4ce8-b908-7da7c642d208_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermBLoanMember_5544efa7-6d29-4d4d-9f58-546f615139c6_terseLabel_en-US" xlink:label="lab_ardx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:label id="lab_ardx_TermBLoanMember_label_en-US" xlink:label="lab_ardx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan [Member]</link:label>
    <link:label id="lab_ardx_TermBLoanMember_documentation_en-US" xlink:label="lab_ardx_TermBLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term B Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermBLoanMember" xlink:href="ardx-20230331.xsd#ardx_TermBLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermBLoanMember" xlink:to="lab_ardx_TermBLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_8e39ae8f-23f2-4bf1-b3f7-7a55deda4720_terseLabel_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential payment per agreement</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_label_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:label id="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_documentation_en-US" xlink:label="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:to="lab_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_e020b4ee-f096-46ab-aac4-037f09f23954_terseLabel_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront license fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_label_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:label id="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_documentation_en-US" xlink:label="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And Licensing Agreements, Upfront License Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:to="lab_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_5a078617-f9aa-451f-854f-7203d03ec9d7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f303f6f8-f930-4d44-b0fa-5f79f2331064_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_668de2db-ef59-4c35-b0b7-0bf103b6fde6_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates, Wholesaler and GPO Fees</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_label_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates [Member]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerRebatesMember_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Rebates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerRebatesMember" xlink:to="lab_ardx_ContractWithCustomerRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b13762f7-ad0b-44fa-ad96-262b51069340_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_06db6f32-b3c5-41ae-a06a-a3ab14d289e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_1ffa0d6b-6245-456d-a40d-61d8c13b43dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d85c77c3-a7ba-4bd3-881c-0e451822988b_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plans</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_f460af61-d7ee-4afb-b770-a1833816f5a4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Revenue, Net</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_3bfdb975-a885-4c48-a41d-482d7a304afa_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future obligation upon loan funding or other events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_label_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:label id="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_documentation_en-US" xlink:label="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Future Obligation Upon Funding Or Other Events</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:to="lab_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_fca525e0-845e-4427-bd7e-9aadb8beab5b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After first anniversary through second anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ec479943-b6e4-437f-9a7f-0c4f5c2e5616_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6dbbc69c-8979-44f8-807f-0cee7401a638_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_3b8da4bc-ff3d-4388-af1f-5682bf5be467_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payments and commercial milestone payments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Royalties Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInRoyaltiesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_b8487d56-bbd8-458a-bf59-bcd77e4f27b5_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fb4aea02-c502-4a1c-9d9c-3dce0e03735d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_54ecb6bc-5987-4700-a9d1-03aaf4d1a47b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_3717e8d3-4dbd-49ed-a546-1783a9b93ed7_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits/payments</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Credits Or Deductions Issued</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Credits Or Deductions Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:to="lab_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_27c8167e-b2d5-4aec-879f-b0b48b3eb423_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8ef90211-827b-46ef-a8bf-7f4b9b80148d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_d8ba8932-ecf9-438a-b9b9-feccb5e99fc6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to first anniversary of closing date</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a3d9fe5b-e576-4210-b2a6-79dc6ad1dda0_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ff970659-beca-44b4-9cdc-297c8a1b119d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest expenses</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_2ac7f4c1-20b8-488f-b1f5-c1759b74c158_terseLabel_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_label_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Cash Equivalents And Investments Gross Unrealized Gains</link:label>
    <link:label id="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_documentation_en-US" xlink:label="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and investments gross unrealized gains.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:to="lab_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_7ac8d06a-8777-470a-88e1-d42a61cd7f8e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common stock - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_55635a0a-327d-466e-a0ca-f50639727e2c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share of common stock - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_8c2bf15d-4862-4367-86b2-4e6f6722ac88_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvanceRoyaltiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Royalties [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract" xlink:to="lab_us-gaap_AdvanceRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_9ddfa4b1-4749-441c-b020-dfb8fd925db7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_ed6e425a-e8a9-498a-a948-98a6a0560662_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization, effective interest rate, percent</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_label_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</link:label>
    <link:label id="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:to="lab_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b385c07f-a67a-4412-8d9c-35a73ecb03ba_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_c05d7110-4493-4617-90e5-ede504a71a00_terseLabel_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_label_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:label id="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_documentation_en-US" xlink:label="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:to="lab_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_ee717e3c-450f-42c4-967b-cad1ef799ee7_negatedTerseLabel_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid commercial manufacturing</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_label_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Commercial Manufacturing Expense</link:label>
    <link:label id="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_documentation_en-US" xlink:label="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Commercial Manufacturing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:href="ardx-20230331.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:to="lab_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_839df6e5-df38-4fcb-9291-886f8809eb68_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_36a01364-b4f7-49e3-87a9-1ed8178bb494_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_e52ce68a-fe21-4fa8-bfc5-e393450fbc4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_e6bd1b21-2998-4a4a-b09f-0d84ffc8972d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments:</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5c7c142c-ea44-4c11-82bf-264495565753_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_TermLoan2022BMember_1fa67814-90b7-43c6-9a93-f2744143c811_terseLabel_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_label_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B [Member]</link:label>
    <link:label id="lab_ardx_TermLoan2022BMember_documentation_en-US" xlink:label="lab_ardx_TermLoan2022BMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan 2022 B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022BMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_TermLoan2022BMember" xlink:to="lab_ardx_TermLoan2022BMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_4795ab07-a14b-46f8-8299-f8cb8d5871c9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock for services (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_5c326375-24e8-417f-a839-453e69939024_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment to be received</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_38b8b705-db1f-414e-836f-389e927cbc76_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_cc482260-f65e-4bb3-95ad-34738651919c_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_db30ed06-2a8c-4008-a53a-4cf78f2562fc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_8d4ea8db-b6f7-46ce-8c71-e9de02ac4f0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_8e5c10dd-5e06-43c1-b7f9-83a6ee10006a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of revenue</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_e6bf7db5-d65d-4e91-a674-f0a97cec21ac_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_2f287ec6-a932-4c04-89f5-493912f10ce0_totalLabel_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and investments, Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_label_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:label id="lab_ardx_InvestmentsAndCashAmortizedCost_documentation_en-US" xlink:label="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments And Cash, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:href="ardx-20230331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_InvestmentsAndCashAmortizedCost" xlink:to="lab_ardx_InvestmentsAndCashAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_f106dc26-2e08-4e61-bb7b-1c4cbbc10f22_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_9a88d697-ed18-4787-b9a0-8c44fa5b59e1_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_5391605e-7803-4e8c-b0f1-2a7eb473c7ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_McKessonCorporationMember_84f8b036-1e4e-4f43-9943-d683d4043895_terseLabel_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_label_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation [Member]</link:label>
    <link:label id="lab_ardx_McKessonCorporationMember_documentation_en-US" xlink:label="lab_ardx_McKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember" xlink:href="ardx-20230331.xsd#ardx_McKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_McKessonCorporationMember" xlink:to="lab_ardx_McKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_GoVersusRaabMember_971df4de-fb4d-4cab-8fce-81b9ba1b24e8_terseLabel_en-US" xlink:label="lab_ardx_GoVersusRaabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go v. Raab</link:label>
    <link:label id="lab_ardx_GoVersusRaabMember_label_en-US" xlink:label="lab_ardx_GoVersusRaabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go Versus Raab [Member]</link:label>
    <link:label id="lab_ardx_GoVersusRaabMember_documentation_en-US" xlink:label="lab_ardx_GoVersusRaabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Go Versus Raab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GoVersusRaabMember" xlink:href="ardx-20230331.xsd#ardx_GoVersusRaabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_GoVersusRaabMember" xlink:to="lab_ardx_GoVersusRaabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_577bdd41-57d8-443e-b3c8-7f1f5d3b0bc9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_53b62b8d-8e88-4d58-805c-26511559722b_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_4252563f-777d-46cc-9364-750492f0feaa_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_97379feb-23d4-49ed-a542-6c4cde37d9c2_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and redemptions of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_25ea8e46-5199-4f83-a4f0-d7584bf2a3be_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_393c3561-e2a5-4622-b617-7df325be2a06_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, non-current</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_357b6579-14e4-4379-9081-700643aac7a8_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_d41f2510-2f32-4fef-bb3f-cb63d66bd111_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored agency bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_ca3abe74-6416-4d81-bf56-a939bb990009_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_f4b8f90f-290b-4ed9-a65a-a1a831ebce92_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2766d9f4-bb5e-416d-9ea3-d328f1f5b44b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8a3c83ff-76e4-4bca-849d-f0a0f418afeb_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_933ea677-9bcc-4827-af90-a8fac66048e5_terseLabel_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross-to-net sales accruals and reserves</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_label_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual [Roll Forward]</link:label>
    <link:label id="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_documentation_en-US" xlink:label="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Gross To Net Sales Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:to="lab_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_aed2e88e-6b05-4c2d-867b-de72df0b375a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLicenseFeesReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from License Fees Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLicenseFeesReceived" xlink:to="lab_us-gaap_ProceedsFromLicenseFeesReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_795d794a-2c38-4220-a9e4-f2a0b93cae85_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_dd2ccfdc-7bdb-4929-bd50-9f2a3f5770f8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_236357d2-38c4-4b21-81fd-da9247fd182f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_985b4118-7281-45f7-9a25-5b015ea3a348_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_1eeb5cee-3d57-4dfb-b43a-5f7ba3324025_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_eadddbb7-8d92-4379-8fb5-103bf3af0b08_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for 2018 Loan, net of costs</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSecuredDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Secured Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSecuredDebt" xlink:to="lab_us-gaap_RepaymentsOfSecuredDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_873db0fb-48f1-4be5-9085-9120aac3eb81_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_d3b254cf-775a-4849-96ee-97d97dac6687_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709a1ef3-1dac-4fdc-870d-c37befccc7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_8fee263e-6423-4835-8e27-bf5189220fd6_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2018Member_2c6500b0-3be9-4430-80fd-d50851efdae1_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_label_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2018Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2018Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2018</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2018Member" xlink:to="lab_ardx_ExitFee2018Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2e591aa0-1258-4561-96ab-b505283182ec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_203f50d4-b26a-4e2e-a0e6-7129467ecff2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_e70bb086-8375-46ec-acc8-2b78be94eaae_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9f374c6f-511b-4e0a-9158-d1652c99225f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_ac74831e-c9af-4074-a552-b2be19e4d8ca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_f6df86d5-51f3-4d71-9432-e124d80e37ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6b4b3e97-7f05-4dfb-8809-82cef00bdce5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_91f505b5-3458-4775-99d7-83690a26231a_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_ExitFee2022Member_fa1b718c-c94f-4b61-8368-e1ea46a16e2f_terseLabel_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Exit Fee</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_label_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022 [Member]</link:label>
    <link:label id="lab_ardx_ExitFee2022Member_documentation_en-US" xlink:label="lab_ardx_ExitFee2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit Fee 2022</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_ExitFee2022Member" xlink:to="lab_ardx_ExitFee2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_2cd04b54-b672-4f11-adce-aeb693699d95_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8d512720-cbb4-4510-a997-490282bdd147_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of non-cash activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7407131d-3187-40fb-8dac-7f1c8083d68c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_fec7ef07-c9f2-4bd2-a63d-2650940ab01f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Noncurrent Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_90dcb778-6a46-475e-b409-24e8edf6d05c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermLoansPayable_2aa88d7a-71f1-4ae7-93a6-8ff66101c2ac_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermLoansPayable_label_en-US" xlink:label="lab_us-gaap_LongTermLoansPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermLoansPayable" xlink:to="lab_us-gaap_LongTermLoansPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_3a3345ab-5d1f-454e-8752-7d1025069a4a_terseLabel_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Addition to floating per annum rate (percent)</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_label_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:label id="lab_ardx_DebtInstrumentVariableRateBaseOption_documentation_en-US" xlink:label="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Variable Rate, Base Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_DebtInstrumentVariableRateBaseOption" xlink:to="lab_ardx_DebtInstrumentVariableRateBaseOption" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3c484587-2575-44bc-b207-e45d72c0e413_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_d9d1a5b5-4ef9-49cb-b148-85fb485f6067_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_c69f5ef4-f347-42f1-97c3-3d6dc5e566f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_5d53d7df-498e-4627-9934-d117f7c1f86c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_9416f735-8a3d-4f52-b574-9ee3217faaa8_terseLabel_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum aggregate offering price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_ardx_MaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_ardx_MaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of maximum aggregate offering price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice" xlink:href="ardx-20230331.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ardx_MaximumAggregateOfferingPrice" xlink:to="lab_ardx_MaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7b9a9f5d-c7f7-4010-98a2-89b53ae66268_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>ardx-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:5e53bfed-5618-4e24-885d-bb49c3b2394c,g:e63de3a8-8715-46e5-89c4-d16db17c8afb-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ardelyx.com/role/Cover" xlink:type="simple" xlink:href="ardx-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_6af20d6d-93e1-4bff-b237-8b3d94c4b8d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_DocumentType_6af20d6d-93e1-4bff-b237-8b3d94c4b8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c262dbff-51ca-43e7-a707-84c6967ce45a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_DocumentQuarterlyReport_c262dbff-51ca-43e7-a707-84c6967ce45a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3c46070d-2794-49e3-abb1-48d6a6da0687" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_DocumentPeriodEndDate_3c46070d-2794-49e3-abb1-48d6a6da0687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_fe2d7289-f10c-46ac-a1c2-30685aa23f8d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_DocumentTransitionReport_fe2d7289-f10c-46ac-a1c2-30685aa23f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1568316f-fcc4-4a39-ab20-029d6199868d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityFileNumber_1568316f-fcc4-4a39-ab20-029d6199868d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_5e9deb03-a5e9-489f-989b-687d04861db8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityRegistrantName_5e9deb03-a5e9-489f-989b-687d04861db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_aa08056d-7b39-4f4d-8860-05a9fc3a664c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_aa08056d-7b39-4f4d-8860-05a9fc3a664c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_13795c13-0715-4133-9e70-e226ce3b83e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityTaxIdentificationNumber_13795c13-0715-4133-9e70-e226ce3b83e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9aa65357-83e8-489a-b292-af26cf46aa65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityAddressAddressLine1_9aa65357-83e8-489a-b292-af26cf46aa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d35d9543-589e-429a-a6a2-776785220691" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityAddressAddressLine2_d35d9543-589e-429a-a6a2-776785220691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_367a5f6d-008a-4727-9c5b-4fdaba37dafa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityAddressCityOrTown_367a5f6d-008a-4727-9c5b-4fdaba37dafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_a573f5ca-60c0-48e1-b30c-6197b0b46e7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityAddressStateOrProvince_a573f5ca-60c0-48e1-b30c-6197b0b46e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_9f03fe86-5499-442f-89ca-592038432327" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityAddressPostalZipCode_9f03fe86-5499-442f-89ca-592038432327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_211416e8-227a-4de4-99f5-6b99cedaee83" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_CityAreaCode_211416e8-227a-4de4-99f5-6b99cedaee83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_b4c88e13-2967-4590-b00a-0961435a2f08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_LocalPhoneNumber_b4c88e13-2967-4590-b00a-0961435a2f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_46396173-4a25-4db8-a3c5-710bb1cc79c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_Security12bTitle_46396173-4a25-4db8-a3c5-710bb1cc79c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a232f1c7-4152-453b-a65b-6d3bc60ff684" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_TradingSymbol_a232f1c7-4152-453b-a65b-6d3bc60ff684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_2bd24357-1f90-40bb-bdd4-eec42238f30c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_SecurityExchangeName_2bd24357-1f90-40bb-bdd4-eec42238f30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_82c5edc0-9983-42db-b4ce-12451b0a6595" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityCurrentReportingStatus_82c5edc0-9983-42db-b4ce-12451b0a6595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_dcaafb92-1295-4dd8-94b2-b4b3b422c793" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityInteractiveDataCurrent_dcaafb92-1295-4dd8-94b2-b4b3b422c793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_0b800445-c3ba-4a66-a691-489219ee1295" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityFilerCategory_0b800445-c3ba-4a66-a691-489219ee1295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_54d74b40-942f-4eb2-acbc-92b7fa7dda10" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntitySmallBusiness_54d74b40-942f-4eb2-acbc-92b7fa7dda10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_eac28113-4426-4dd1-bb4f-0fed1cb5341e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityEmergingGrowthCompany_eac28113-4426-4dd1-bb4f-0fed1cb5341e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4cfd2e2a-e79f-40db-b472-25addbb513d2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityShellCompany_4cfd2e2a-e79f-40db-b472-25addbb513d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6ab0ef11-c0b5-4943-8372-2b3052156c40" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6ab0ef11-c0b5-4943-8372-2b3052156c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ffa3e654-813b-4cac-8ff7-205907749531" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_EntityCentralIndexKey_ffa3e654-813b-4cac-8ff7-205907749531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ff968d5e-f489-4dde-9f71-2c82be61ba22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_CurrentFiscalYearEndDate_ff968d5e-f489-4dde-9f71-2c82be61ba22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_56381acf-76ff-4574-9fca-806c3e408150" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_DocumentFiscalYearFocus_56381acf-76ff-4574-9fca-806c3e408150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cc7c23b6-fd31-4191-918e-3a6abb439ca7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cc7c23b6-fd31-4191-918e-3a6abb439ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_fcc12fb0-7ada-4d4f-88ac-bb5eeb39aef5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_c87b6110-14ab-466b-a5a2-72f6335297d5" xlink:to="loc_dei_AmendmentFlag_fcc12fb0-7ada-4d4f-88ac-bb5eeb39aef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cc30cbcc-271e-4985-92e2-a78e514f29b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc30cbcc-271e-4985-92e2-a78e514f29b1" xlink:to="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:to="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bfd193a4-e3e3-4ef1-aa20-705a47861473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bfd193a4-e3e3-4ef1-aa20-705a47861473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2e712c3-77eb-4493-af71-0aa27a79c281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2e712c3-77eb-4493-af71-0aa27a79c281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4dd909ce-5622-42eb-8a92-bb5ada36e270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4dd909ce-5622-42eb-8a92-bb5ada36e270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_f7808a3e-4b8e-43c9-aaff-2ccc57936e14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_us-gaap_InventoryGross_f7808a3e-4b8e-43c9-aaff-2ccc57936e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_306326b8-cab2-402b-b978-e7c868235caa" xlink:href="ardx-20230331.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_306326b8-cab2-402b-b978-e7c868235caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2047e578-1792-47d3-8652-1f1be0040bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2047e578-1792-47d3-8652-1f1be0040bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bfaa73f6-ba13-4170-8a28-db10aa81b97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_b8d10a02-a3f0-4b22-b669-eb166f49cc6d" xlink:to="loc_us-gaap_AssetsCurrent_bfaa73f6-ba13-4170-8a28-db10aa81b97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_cb21c5ce-15f4-42e3-bc75-6326e6282ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:to="loc_us-gaap_InventoryNoncurrent_cb21c5ce-15f4-42e3-bc75-6326e6282ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_57d3614d-0a44-446c-a32a-bcc1484ee598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_57d3614d-0a44-446c-a32a-bcc1484ee598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5c502f2c-0a4a-4c83-a4b6-cffcb03d1871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5c502f2c-0a4a-4c83-a4b6-cffcb03d1871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b5cb48d4-a3c2-4785-ac24-8b1fe83baed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b5cb48d4-a3c2-4785-ac24-8b1fe83baed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_76a9fa02-1906-4425-9ae9-9321f0658116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_4e559509-e4f5-4db8-88c7-06c3bdec9779" xlink:to="loc_us-gaap_Assets_76a9fa02-1906-4425-9ae9-9321f0658116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc30cbcc-271e-4985-92e2-a78e514f29b1" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_04c00d72-ca44-4656-b0ea-874e58515340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_AccountsPayableCurrent_04c00d72-ca44-4656-b0ea-874e58515340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b93eb1af-76a8-4c35-8eda-98866ccfd429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b93eb1af-76a8-4c35-8eda-98866ccfd429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_df26b3b5-f58a-456b-a14f-ed9a63978465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_LoansPayableCurrent_df26b3b5-f58a-456b-a14f-ed9a63978465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_61b5779a-47b9-493f-8cf0-1c3289c94458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_61b5779a-47b9-493f-8cf0-1c3289c94458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9af5a25d-b4b2-4024-920a-fdbfc9e54925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_9af5a25d-b4b2-4024-920a-fdbfc9e54925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e5d713e6-002d-4f11-9039-2aa3192ef37a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_AccruedLiabilitiesAndOtherLiabilities_e5d713e6-002d-4f11-9039-2aa3192ef37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_400f2468-b506-44a3-ba85-2f3f2ea3890a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_942da473-0c91-4d99-a5a4-8ca4a30e047c" xlink:to="loc_us-gaap_LiabilitiesCurrent_400f2468-b506-44a3-ba85-2f3f2ea3890a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_67857826-563b-49cf-ac3f-b5a63f09ae36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_67857826-563b-49cf-ac3f-b5a63f09ae36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_88261302-32f1-4c56-bc44-d43e033561a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_88261302-32f1-4c56-bc44-d43e033561a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DeferredRoyaltyObligationNoncurrent_cfcd5cd2-3539-4c7b-8265-09b13db34d89" xlink:href="ardx-20230331.xsd#ardx_DeferredRoyaltyObligationNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_ardx_DeferredRoyaltyObligationNoncurrent_cfcd5cd2-3539-4c7b-8265-09b13db34d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ded05aa7-a22e-4c81-afbf-7d2ca8d40c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_Liabilities_ded05aa7-a22e-4c81-afbf-7d2ca8d40c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_aab9129d-f4c7-463a-9f12-e0ebdc89acf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_CommitmentsAndContingencies_aab9129d-f4c7-463a-9f12-e0ebdc89acf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_029dd5cb-ee32-4851-a213-4693587ab2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:to="loc_us-gaap_PreferredStockValue_029dd5cb-ee32-4851-a213-4693587ab2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_242d833d-98de-483d-a144-6d04c8c298c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:to="loc_us-gaap_CommonStockValue_242d833d-98de-483d-a144-6d04c8c298c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a43082cb-7305-4895-afe7-4facd04b2c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_a43082cb-7305-4895-afe7-4facd04b2c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f1d99f00-2385-456c-96d3-302369d55bb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f1d99f00-2385-456c-96d3-302369d55bb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3882a04e-556b-4df6-8cae-c89498c00884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3882a04e-556b-4df6-8cae-c89498c00884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_25fda865-0ec0-433a-a1b2-a669a8e51e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ee4d94ae-ea56-4323-9bef-f4fddb53851d" xlink:to="loc_us-gaap_StockholdersEquity_25fda865-0ec0-433a-a1b2-a669a8e51e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_96689d7a-8b90-4a7c-8a51-f09bb185bdee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_caae6a4c-5432-4fc0-97ab-b82b6b8d9303" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_96689d7a-8b90-4a7c-8a51-f09bb185bdee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_04e9077a-31b5-4257-86e0-4c3b7a7f39f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_04e9077a-31b5-4257-86e0-4c3b7a7f39f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2aa472e9-31b7-4dcb-8469-62f59b31d514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2aa472e9-31b7-4dcb-8469-62f59b31d514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_eae5014f-e543-4c90-afb4-797178d161da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_eae5014f-e543-4c90-afb4-797178d161da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_3bfc45b2-c35e-49a2-ac35-93ca8b1f07cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_3bfc45b2-c35e-49a2-ac35-93ca8b1f07cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_681c85a8-3982-44f4-bfcb-faf43a31a217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_681c85a8-3982-44f4-bfcb-faf43a31a217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_3435e706-4827-4ea4-82ea-1df9ab2456f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_3435e706-4827-4ea4-82ea-1df9ab2456f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_03115899-5b64-448e-b2d5-9bd3a3c125c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_CommonStockSharesIssued_03115899-5b64-448e-b2d5-9bd3a3c125c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_64e4850f-e89f-4543-8cbc-90eb2326cef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8c2f296a-5999-4ba6-9926-2acb9acc5fb3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_64e4850f-e89f-4543-8cbc-90eb2326cef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_b13ec147-eec2-4216-862b-59825232683b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_b13ec147-eec2-4216-862b-59825232683b" xlink:to="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:to="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_550f5e76-2acc-4a35-ba0d-074d904882a2" xlink:to="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_52842966-675d-4733-975c-87357918d0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:to="loc_us-gaap_ProductMember_52842966-675d-4733-975c-87357918d0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductSupplyRevenueMember_18132404-982c-4a7c-955d-f69b7b917555" xlink:href="ardx-20230331.xsd#ardx_ProductSupplyRevenueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:to="loc_ardx_ProductSupplyRevenueMember_18132404-982c-4a7c-955d-f69b7b917555" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_9fda976a-6435-40c6-930f-ff287b783141" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_3e886ee0-ad84-479e-91cf-4071a132ba99" xlink:to="loc_us-gaap_LicenseMember_9fda976a-6435-40c6-930f-ff287b783141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a7a3cabf-9db8-4d78-ac9e-3b537a2b67af" xlink:to="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_22d771b3-674f-483a-b6a7-2c4524af26aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_RevenuesAbstract_22d771b3-674f-483a-b6a7-2c4524af26aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae440eb5-69df-47f6-aad3-963661a85167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_22d771b3-674f-483a-b6a7-2c4524af26aa" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ae440eb5-69df-47f6-aad3-963661a85167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_cdce5318-5185-4c84-8e58-75cc88abec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_CostOfRevenue_cdce5318-5185-4c84-8e58-75cc88abec4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_59a079ca-5823-457b-b534-94a31ebedd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_59a079ca-5823-457b-b534-94a31ebedd5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4395700-030b-4579-baf0-5bbeb81efcec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_e4395700-030b-4579-baf0-5bbeb81efcec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4db068bf-4690-49dd-8cdf-ace00bbbd473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7606b405-cdfd-48ab-93a6-45b100f1872d" xlink:to="loc_us-gaap_CostsAndExpenses_4db068bf-4690-49dd-8cdf-ace00bbbd473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_b80f73f6-08ec-450c-9767-037e536404db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_OperatingIncomeLoss_b80f73f6-08ec-450c-9767-037e536404db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_4a2d9697-66e5-4745-9350-c38f4e5daad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_InterestExpense_4a2d9697-66e5-4745-9350-c38f4e5daad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_447ff905-90f2-41a4-8b5c-d39e2c4ccf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_447ff905-90f2-41a4-8b5c-d39e2c4ccf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_fdcc04ec-5cb9-4a6c-8416-b672a3ebb760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_fdcc04ec-5cb9-4a6c-8416-b672a3ebb760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40d5d6ea-9ba3-4188-b067-33d2e1ca5563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40d5d6ea-9ba3-4188-b067-33d2e1ca5563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d4e6a21c-360e-486f-8b51-23a308b7a926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d4e6a21c-360e-486f-8b51-23a308b7a926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a842e7f8-4cc0-448c-aad9-a94237d27b34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_NetIncomeLoss_a842e7f8-4cc0-448c-aad9-a94237d27b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_907bb19b-389c-4881-bc1c-75cdc2e13c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_EarningsPerShareBasic_907bb19b-389c-4881-bc1c-75cdc2e13c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_88c407a9-2e20-473d-8df7-af27a95d41c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_88c407a9-2e20-473d-8df7-af27a95d41c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d27aa54-2340-49d5-b274-361bb8f5b6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5d27aa54-2340-49d5-b274-361bb8f5b6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3b31164-b1c6-40bb-90f3-515bd38157f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3b31164-b1c6-40bb-90f3-515bd38157f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6ba56f32-823d-4024-b74a-5c69501bd1f6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_87cc00a2-705d-4885-88dd-75203ff5ba40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:to="loc_us-gaap_NetIncomeLoss_87cc00a2-705d-4885-88dd-75203ff5ba40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fb2c045a-4dec-409b-aa71-e8a7bb9995cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_fb2c045a-4dec-409b-aa71-e8a7bb9995cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_50a1cacd-e3d7-4216-9241-91957b9ae83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a8f89dec-2d5a-4e69-befd-3ad0c947cb98" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_50a1cacd-e3d7-4216-9241-91957b9ae83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c569f41f-e26e-4a79-b9ca-3e3b04f22e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c569f41f-e26e-4a79-b9ca-3e3b04f22e3e" xlink:to="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1043937f-24a6-4bfe-b36f-ba5b5a37352e" xlink:to="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_2b20f745-ffe7-4191-a6b2-b5b107533ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_CommonStockMember_2b20f745-ffe7-4191-a6b2-b5b107533ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c5ea629a-a18e-4cf6-a10d-9618ce7c30ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c5ea629a-a18e-4cf6-a10d-9618ce7c30ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_737deab7-6094-49c8-a193-7bc90bcf3894" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_RetainedEarningsMember_737deab7-6094-49c8-a193-7bc90bcf3894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8be567d-c267-4ced-9c3a-5a33b9920dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_7ba7fc2f-c438-4363-82ee-a52e465843de" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_b8be567d-c267-4ced-9c3a-5a33b9920dd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7f277b9b-33d7-4eec-a7e1-77e99053da4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_72fff5f3-5541-47a6-a125-e8217f49aadd" xlink:to="loc_us-gaap_StatementLineItems_7f277b9b-33d7-4eec-a7e1-77e99053da4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7f277b9b-33d7-4eec-a7e1-77e99053da4e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_1277eb97-db98-47c2-9a38-f50f57c5e67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_SharesOutstanding_1277eb97-db98-47c2-9a38-f50f57c5e67f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2e4b502e-e40a-491c-a4e0-f56c59f7940e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockholdersEquity_2e4b502e-e40a-491c-a4e0-f56c59f7940e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1da0cd3c-d5f8-4bfb-be25-96f3a1a808b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_1da0cd3c-d5f8-4bfb-be25-96f3a1a808b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c458ceff-0cb3-43f1-b998-123fcd816ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_c458ceff-0cb3-43f1-b998-123fcd816ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42a4143c-fa75-40b8-bae8-19fd6e807a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_42a4143c-fa75-40b8-bae8-19fd6e807a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0b9853c7-e217-43ee-ba67-506768c467f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_0b9853c7-e217-43ee-ba67-506768c467f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e0248f2f-460b-42b2-b9df-7361f28a088b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_e0248f2f-460b-42b2-b9df-7361f28a088b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_accc102e-ca87-44ac-b885-4626e020b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_accc102e-ca87-44ac-b885-4626e020b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd19ac05-468f-4a15-b91a-a4bd7ee3a295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_dd19ac05-468f-4a15-b91a-a4bd7ee3a295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71ce7e78-2d1c-4b39-aaa9-3dfc820d3e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_71ce7e78-2d1c-4b39-aaa9-3dfc820d3e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_46e2baaa-ee96-495c-917e-106d60d01c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_46e2baaa-ee96-495c-917e-106d60d01c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_226c61a0-d85d-48d0-b0f9-01081d845f80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_NetIncomeLoss_226c61a0-d85d-48d0-b0f9-01081d845f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_383b4e06-6828-4fc4-b81e-280c2ae94023" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_SharesOutstanding_383b4e06-6828-4fc4-b81e-280c2ae94023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9baa3d6e-b6b5-46f6-b6fa-2be3e58a05c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e30247de-a69c-43d8-bcf0-bc6743b05763" xlink:to="loc_us-gaap_StockholdersEquity_9baa3d6e-b6b5-46f6-b6fa-2be3e58a05c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ardx-20230331.xsd#CONDENSEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ca5cf03-e438-4d4d-a7a1-7fbcfb764102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ca5cf03-e438-4d4d-a7a1-7fbcfb764102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f8aa5c6b-1ac2-4405-a642-4594db6ab4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ca5cf03-e438-4d4d-a7a1-7fbcfb764102" xlink:to="loc_us-gaap_NetIncomeLoss_f8aa5c6b-1ac2-4405-a642-4594db6ab4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ca5cf03-e438-4d4d-a7a1-7fbcfb764102" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5ce7f3a8-b8b7-4d18-9c73-29b84617ef52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5ce7f3a8-b8b7-4d18-9c73-29b84617ef52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3471be73-81f8-4758-a99e-679b47b6483b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_3471be73-81f8-4758-a99e-679b47b6483b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c2bec70c-ce0c-45db-81f1-a50e88bec966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_ShareBasedCompensation_c2bec70c-ce0c-45db-81f1-a50e88bec966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_d6522efa-d28a-4bfb-9556-a65fa7a5e569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_d6522efa-d28a-4bfb-9556-a65fa7a5e569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnRestructuringOfDebt_7bc22d7f-ec05-405c-ba65-3b8f3ec973d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnRestructuringOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_GainsLossesOnRestructuringOfDebt_7bc22d7f-ec05-405c-ba65-3b8f3ec973d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_0c65cdc7-a002-4a4e-b34c-8e77d5c7646c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_0c65cdc7-a002-4a4e-b34c-8e77d5c7646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_8270a1e5-ba58-4f1b-be4c-8eca5d7f4cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_8270a1e5-ba58-4f1b-be4c-8eca5d7f4cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_9fad3ed0-2313-427c-b3e0-ee760d5443ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfDebtDiscountPremium"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_9fad3ed0-2313-427c-b3e0-ee760d5443ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_d4dfe618-1046-4d94-9200-b996217a9c67" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e0fa006e-4b8d-4a4d-8bd5-03234f65ba95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e0fa006e-4b8d-4a4d-8bd5-03234f65ba95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_d3221413-0eb9-4fe4-918b-f6e87eaf3c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_d3221413-0eb9-4fe4-918b-f6e87eaf3c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_21d78502-5c89-4c4b-b887-bb06cddd0324" xlink:href="ardx-20230331.xsd#ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense_21d78502-5c89-4c4b-b887-bb06cddd0324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b9b19c89-29a8-4185-b9e9-1d13a1368b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b9b19c89-29a8-4185-b9e9-1d13a1368b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_521922c9-6e48-4657-9406-21047268def6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_521922c9-6e48-4657-9406-21047268def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ff6834ba-31b8-4f6a-911c-b1bd8a69ccce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_ff6834ba-31b8-4f6a-911c-b1bd8a69ccce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d3a7abec-b73a-46e6-8c3b-8efcfa689b0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d3a7abec-b73a-46e6-8c3b-8efcfa689b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f8122aed-103d-4b25-ad1c-492ae384f7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f8122aed-103d-4b25-ad1c-492ae384f7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8712eeaf-f622-400e-9420-5402986fd7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_713209a7-87d8-4d38-adc7-28a757260ae2" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_8712eeaf-f622-400e-9420-5402986fd7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53a1d4d7-67ad-422f-85e4-22e87e2043d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8ca5cf03-e438-4d4d-a7a1-7fbcfb764102" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_53a1d4d7-67ad-422f-85e4-22e87e2043d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_925e441b-ab40-48d4-a36a-0cbf5920e26b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_925e441b-ab40-48d4-a36a-0cbf5920e26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c71bc2ca-8621-4540-b368-38cb273250f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_c71bc2ca-8621-4540-b368-38cb273250f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2a7bc162-e66f-454e-a0b6-e2316f25ff45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2a7bc162-e66f-454e-a0b6-e2316f25ff45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8772bdb5-8adf-40a5-9b89-29649916024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8772bdb5-8adf-40a5-9b89-29649916024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d828e2c-a4c6-4aca-8c3f-2a63c2bd626b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_84a92338-4340-47cf-a9bd-7d76adfe9202" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1d828e2c-a4c6-4aca-8c3f-2a63c2bd626b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_1f012dd6-727c-4a7e-9758-1f3982600ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSecuredDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSecuredDebt_1f012dd6-727c-4a7e-9758-1f3982600ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSecuredDebt_b1484dcb-0c26-46ba-9099-137ebf6f557a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSecuredDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:to="loc_us-gaap_RepaymentsOfSecuredDebt_b1484dcb-0c26-46ba-9099-137ebf6f557a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49dd1ae4-9e2c-4f74-93a2-2a0dbdb53a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_49dd1ae4-9e2c-4f74-93a2-2a0dbdb53a31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_05668a45-d444-46fd-b92f-2c9709c288aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_05668a45-d444-46fd-b92f-2c9709c288aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7e35807-7236-4913-a4d5-02b40e6dadef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_ee938324-4669-4c4f-b0a2-9d300327b965" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d7e35807-7236-4913-a4d5-02b40e6dadef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2b5139c-383a-493b-876a-3f85380a3fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e2b5139c-383a-493b-876a-3f85380a3fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f26f30f-6581-4e4c-aabb-49276bbbbc85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9f26f30f-6581-4e4c-aabb-49276bbbbc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5164938-b75a-44f5-8295-16d6c8bc37bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e5164938-b75a-44f5-8295-16d6c8bc37bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_88c14764-0e40-4cb1-972c-0cacf184c1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_88c14764-0e40-4cb1-972c-0cacf184c1c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_7abe4e0e-b43e-4575-9cfb-1de11e8998ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_88c14764-0e40-4cb1-972c-0cacf184c1c4" xlink:to="loc_us-gaap_InterestPaidNet_7abe4e0e-b43e-4575-9cfb-1de11e8998ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_a04170b2-d188-4186-8984-868e4f51aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_88c14764-0e40-4cb1-972c-0cacf184c1c4" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_a04170b2-d188-4186-8984-868e4f51aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0aca310f-3407-4694-a6f2-88cba337c797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_bd89d933-c09c-4793-afb3-7a4fa963d3c0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0aca310f-3407-4694-a6f2-88cba337c797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DerivativeIssued_be84f617-b364-47f0-9d13-b46021ab9326" xlink:href="ardx-20230331.xsd#ardx_DerivativeIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0aca310f-3407-4694-a6f2-88cba337c797" xlink:to="loc_ardx_DerivativeIssued_be84f617-b364-47f0-9d13-b46021ab9326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="ardx-20230331.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_674113ef-b2f8-4415-9aeb-61081b330669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_09b2a5a6-1ac2-45ab-af15-2a6eb7b2263d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_674113ef-b2f8-4415-9aeb-61081b330669" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_09b2a5a6-1ac2-45ab-af15-2a6eb7b2263d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_7899f2fb-8dd0-422e-956f-0bf9182d4f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_c7a0f8af-5b42-47a0-9d0e-9b9757b3905b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_7899f2fb-8dd0-422e-956f-0bf9182d4f68" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_c7a0f8af-5b42-47a0-9d0e-9b9757b3905b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="ardx-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bca8a637-290d-43f9-930d-cc5c03a6ca9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4ccb519a-d2d7-4074-8c0b-44136333035b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bca8a637-290d-43f9-930d-cc5c03a6ca9e" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4ccb519a-d2d7-4074-8c0b-44136333035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Inventory" xlink:type="simple" xlink:href="ardx-20230331.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6d18d1d8-9eae-4005-bf7a-a4dfda26d5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_0c3b3be8-4d0d-47b6-acd7-af5966a8ba5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6d18d1d8-9eae-4005-bf7a-a4dfda26d5da" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_0c3b3be8-4d0d-47b6-acd7-af5966a8ba5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="simple" xlink:href="ardx-20230331.xsd#ProductRevenueNet"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e53e00a4-b502-4b64-bc47-6b9bad202b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0785d6b8-3c43-4be4-a962-140cfae6df76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_e53e00a4-b502-4b64-bc47-6b9bad202b1b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_0785d6b8-3c43-4be4-a962-140cfae6df76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="simple" xlink:href="ardx-20230331.xsd#CollaborationandLicensingAgreements"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_26fee985-1b96-4263-8758-c054913defeb" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5d9e2daf-e498-4663-85a9-47b1fd1cc9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_26fee985-1b96-4263-8758-c054913defeb" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_5d9e2daf-e498-4663-85a9-47b1fd1cc9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" xlink:type="simple" xlink:href="ardx-20230331.xsd#DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_449facfb-0c4c-4d0c-b6f6-cec63a80e282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock_3a5ee692-b977-4fc6-8968-0bb669c66309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetRetirementObligationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_449facfb-0c4c-4d0c-b6f6-cec63a80e282" xlink:to="loc_us-gaap_AssetRetirementObligationDisclosureTextBlock_3a5ee692-b977-4fc6-8968-0bb669c66309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Borrowing" xlink:type="simple" xlink:href="ardx-20230331.xsd#Borrowing"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Borrowing" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4c565793-a826-48f9-b94f-1af87ee7d447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_22e6faa3-dc69-47d3-bfba-b329ca7e3a63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4c565793-a826-48f9-b94f-1af87ee7d447" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_22e6faa3-dc69-47d3-bfba-b329ca7e3a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilities" xlink:type="simple" xlink:href="ardx-20230331.xsd#DerivativeLiabilities"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d55be268-2984-4c0d-b559-7a2659757bdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f7450ac6-b7e8-4605-88c3-0560adee48ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_d55be268-2984-4c0d-b559-7a2659757bdf" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f7450ac6-b7e8-4605-88c3-0560adee48ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Leases" xlink:type="simple" xlink:href="ardx-20230331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9592dc8d-f92d-43b9-8517-e67e565dd270" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7b38c40f-a975-4b81-ac2a-fe9a3a8ed4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9592dc8d-f92d-43b9-8517-e67e565dd270" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7b38c40f-a975-4b81-ac2a-fe9a3a8ed4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="simple" xlink:href="ardx-20230331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_b26827fa-bdc9-4cc7-baaa-2e278a3968b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ff8e6d3-d11f-40b2-ba57-83ec65038c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_b26827fa-bdc9-4cc7-baaa-2e278a3968b0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6ff8e6d3-d11f-40b2-ba57-83ec65038c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlans"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74589ebe-313e-4411-ae3a-c8af85a4f83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a7713c29-c319-43b2-8c76-23cce624a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_74589ebe-313e-4411-ae3a-c8af85a4f83a" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a7713c29-c319-43b2-8c76-23cce624a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="simple" xlink:href="ardx-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8faa9793-162b-43c6-bf96-40425e9f53c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_ad83848f-de2a-448d-9f08-d4c3f152576e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8faa9793-162b-43c6-bf96-40425e9f53c9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_ad83848f-de2a-448d-9f08-d4c3f152576e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/Contingencies" xlink:type="simple" xlink:href="ardx-20230331.xsd#Contingencies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/Contingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b93c1271-669d-4d60-a8a5-106e98f1e196" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d498ea18-1827-44ae-a3e8-28478c545cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b93c1271-669d-4d60-a8a5-106e98f1e196" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_d498ea18-1827-44ae-a3e8-28478c545cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="simple" xlink:href="ardx-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_71c5b1c4-c084-4980-a99a-b2443d0920bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_5b05ec1e-6a0e-4657-9405-f84c140f2602" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_71c5b1c4-c084-4980-a99a-b2443d0920bf" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_5b05ec1e-6a0e-4657-9405-f84c140f2602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="simple" xlink:href="ardx-20230331.xsd#OrganizationandBasisofPresentationPolicies"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f93539-d392-4e8c-b205-5f952127ba35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e03a752b-d98c-4fe3-b31e-fb3e80893036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f93539-d392-4e8c-b205-5f952127ba35" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e03a752b-d98c-4fe3-b31e-fb3e80893036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_ae2a5643-62f4-4d40-b647-a750ce69a4c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f93539-d392-4e8c-b205-5f952127ba35" xlink:to="loc_us-gaap_UseOfEstimates_ae2a5643-62f4-4d40-b647-a750ce69a4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93685dd3-d03d-400e-a98f-7617bae224d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f93539-d392-4e8c-b205-5f952127ba35" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_93685dd3-d03d-400e-a98f-7617bae224d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b5f62787-9fe3-4071-82e9-95cdcc3b1744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_20f93539-d392-4e8c-b205-5f952127ba35" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b5f62787-9fe3-4071-82e9-95cdcc3b1744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_4d1f43ae-989d-40d4-9fc7-addd897c3a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_24a957e2-dad8-4506-b3e6-44966495bd23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_4d1f43ae-989d-40d4-9fc7-addd897c3a3c" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_24a957e2-dad8-4506-b3e6-44966495bd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_18e4c7cf-ea29-43c5-bb3f-e2b112084d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_92ea68df-42ce-4545-8998-caa3d6853f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_18e4c7cf-ea29-43c5-bb3f-e2b112084d0b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_92ea68df-42ce-4545-8998-caa3d6853f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1ae67a47-bd72-42c4-a0eb-43bdd11ff645" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_36067665-d13b-43fc-b5e2-518040cbbac5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1ae67a47-bd72-42c4-a0eb-43bdd11ff645" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_36067665-d13b-43fc-b5e2-518040cbbac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_3d7a1746-12b1-4f8a-accf-65391ddda676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1ae67a47-bd72-42c4-a0eb-43bdd11ff645" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_3d7a1746-12b1-4f8a-accf-65391ddda676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#ProductRevenueNetTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f16d839f-e8e0-4efc-8158-07f39b9692c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_ad2aad55-53a9-49a3-8a0e-0f3c8cbc2345" xlink:href="ardx-20230331.xsd#ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f16d839f-e8e0-4efc-8158-07f39b9692c1" xlink:to="loc_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock_ad2aad55-53a9-49a3-8a0e-0f3c8cbc2345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#CollaborationandLicensingAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_cb99cc3c-1ba6-44b7-acfa-ed2f28118397" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8b16fce6-6202-46e5-afbd-ab21640fdeb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_cb99cc3c-1ba6-44b7-acfa-ed2f28118397" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_8b16fce6-6202-46e5-afbd-ab21640fdeb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a8a911ee-365d-44d2-a2d9-619e99779070" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a95de451-ca93-4db9-9b28-dfae1e6b9ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a8a911ee-365d-44d2-a2d9-619e99779070" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_a95de451-ca93-4db9-9b28-dfae1e6b9ff4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#DerivativeLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6326d555-6ed7-441b-b685-467218fba639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a9b76e84-68bc-4072-836b-df64c03643cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6326d555-6ed7-441b-b685-467218fba639" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a9b76e84-68bc-4072-836b-df64c03643cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_df80b11f-4e8a-46d4-aeea-a99f2d20c313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_1c094d37-f796-4483-b61c-674c8051670f" xlink:href="ardx-20230331.xsd#ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df80b11f-4e8a-46d4-aeea-a99f2d20c313" xlink:to="loc_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock_1c094d37-f796-4483-b61c-674c8051670f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_bae147b1-6bd2-4ef1-aa8f-f4d47df8139a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df80b11f-4e8a-46d4-aeea-a99f2d20c313" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_bae147b1-6bd2-4ef1-aa8f-f4d47df8139a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_906874c3-90c2-480e-99c9-9f9a9abfb18c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_df80b11f-4e8a-46d4-aeea-a99f2d20c313" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_906874c3-90c2-480e-99c9-9f9a9abfb18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16f0864d-ece3-4d64-af7f-4ad27448ab2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a2771e22-5100-49f5-88a0-c51537f00080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16f0864d-ece3-4d64-af7f-4ad27448ab2d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_a2771e22-5100-49f5-88a0-c51537f00080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_bdc3148f-53dd-4ee4-b696-be42bfac2897" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16f0864d-ece3-4d64-af7f-4ad27448ab2d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock_bdc3148f-53dd-4ee4-b696-be42bfac2897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d462d13a-7543-4ea1-b6a5-0c8c5bd83565" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16f0864d-ece3-4d64-af7f-4ad27448ab2d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d462d13a-7543-4ea1-b6a5-0c8c5bd83565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_88d9c306-9da4-47ce-a616-3d114a25837a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_16f0864d-ece3-4d64-af7f-4ad27448ab2d" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_88d9c306-9da4-47ce-a616-3d114a25837a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="ardx-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aaf49888-ef00-4a1b-95ef-d667d7c78e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a538a24f-4d57-4e35-93e8-400302248d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aaf49888-ef00-4a1b-95ef-d667d7c78e8f" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a538a24f-4d57-4e35-93e8-400302248d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8ce29fc6-ccd1-4930-98e6-8c3761ca8236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aaf49888-ef00-4a1b-95ef-d667d7c78e8f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_8ce29fc6-ccd1-4930-98e6-8c3761ca8236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b49e3ec4-1b47-43d0-9c14-1d98977da036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_3b2191a0-6c98-4d07-a56f-df4b502d42f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b49e3ec4-1b47-43d0-9c14-1d98977da036" xlink:to="loc_us-gaap_NumberOfOperatingSegments_3b2191a0-6c98-4d07-a56f-df4b502d42f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_b463dca7-c153-4ea8-be5b-fa798523991c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b49e3ec4-1b47-43d0-9c14-1d98977da036" xlink:to="loc_us-gaap_InvestmentsAndCash_b463dca7-c153-4ea8-be5b-fa798523991c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7e36d2bb-5801-4ed0-8c27-175a5686dd6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b49e3ec4-1b47-43d0-9c14-1d98977da036" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7e36d2bb-5801-4ed0-8c27-175a5686dd6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_c735fc5c-6771-4378-a36e-8cfabe17dfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_c735fc5c-6771-4378-a36e-8cfabe17dfdd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_ec6aa231-d869-49de-9ec3-5fd2f384d959" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_110f2d29-ac3e-4ec6-9fad-c7b369d76ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:to="loc_us-gaap_CashMember_110f2d29-ac3e-4ec6-9fad-c7b369d76ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_5f1059f3-ce15-4be8-98a9-4d5c79d88681" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_340669fb-1b18-4c16-b435-e8e488c8ed4f" xlink:to="loc_us-gaap_MoneyMarketFundsMember_5f1059f3-ce15-4be8-98a9-4d5c79d88681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d29f1c60-06c0-45c0-b0cc-6943a6ede254" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5a674a40-8bac-4864-bc2e-5134a1375ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember_5a674a40-8bac-4864-bc2e-5134a1375ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_cdbe9486-1362-4665-8c3b-9620df71dc76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_cdbe9486-1362-4665-8c3b-9620df71dc76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_15d9c399-1645-47ed-8e19-ed92ccdd3d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_15d9c399-1645-47ed-8e19-ed92ccdd3d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_ad580ad4-b86e-4581-916e-419a5a2d6c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9cc37f73-ae34-45ee-bea7-1e9ab413f9e7" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_ad580ad4-b86e-4581-916e-419a5a2d6c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_8e980939-0559-464b-a69d-78ad84d2dfc7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_4cdd3de4-f5ef-4f53-af8a-db2a49301f68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_4cdd3de4-f5ef-4f53-af8a-db2a49301f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e8624b4-20ef-4b01-94fc-84c703653aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract_4cdd3de4-f5ef-4f53-af8a-db2a49301f68" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e8624b4-20ef-4b01-94fc-84c703653aff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab9249f9-1323-4b35-9d7d-7d8ebf8fd3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_ab9249f9-1323-4b35-9d7d-7d8ebf8fd3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_413291ec-f9db-4a67-b913-83eedfb882a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_413291ec-f9db-4a67-b913-83eedfb882a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37768e2c-da11-4fb0-8d5c-476997354329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_37768e2c-da11-4fb0-8d5c-476997354329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8e3b23b-24cc-4b42-b830-630eb570b52f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_c9584db6-d881-4310-819c-af695e56294c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a8e3b23b-24cc-4b42-b830-630eb570b52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_ab59df09-e5e0-4aa9-ba84-7f4836cec1bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermInvestmentsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_ab59df09-e5e0-4aa9-ba84-7f4836cec1bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_InvestmentsAndCashAmortizedCost_fc2cd4cb-7e49-44a5-82c8-5b635b85a0c2" xlink:href="ardx-20230331.xsd#ardx_InvestmentsAndCashAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_ardx_InvestmentsAndCashAmortizedCost_fc2cd4cb-7e49-44a5-82c8-5b635b85a0c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_644ca3d5-7047-426d-8048-eebe28c5c4f1" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains_644ca3d5-7047-426d-8048-eebe28c5c4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_ad9abd73-c280-4001-a59f-1bf9d21dd463" xlink:href="ardx-20230331.xsd#ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses_ad9abd73-c280-4001-a59f-1bf9d21dd463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_549b75f0-55fc-45fd-9c25-dd813c779974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5941295-a356-452b-b3b6-fabf7493edbd" xlink:to="loc_us-gaap_InvestmentsAndCash_549b75f0-55fc-45fd-9c25-dd813c779974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CashCashEquivalentsandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_05d608f8-7e77-401d-90f4-1e4204fc77f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_ea627280-86e4-492a-9ad2-6b01958845d8" xlink:href="ardx-20230331.xsd#ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_05d608f8-7e77-401d-90f4-1e4204fc77f4" xlink:to="loc_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum_ea627280-86e4-492a-9ad2-6b01958845d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_216d4400-fd2a-4a0d-8280-ef6c1383beaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_05d608f8-7e77-401d-90f4-1e4204fc77f4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_216d4400-fd2a-4a0d-8280-ef6c1383beaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ffd8ac54-3e35-4ac4-9ea8-31d2b43e176d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ffd8ac54-3e35-4ac4-9ea8-31d2b43e176d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5aa645a-3a22-4cb0-8ec0-46b5b59676b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a88ec4a3-fdbd-4cdf-95ea-9e94fc7a5e3a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5aa645a-3a22-4cb0-8ec0-46b5b59676b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_c6f3c92c-4094-4e14-95e1-35938e871f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c5aa645a-3a22-4cb0-8ec0-46b5b59676b6" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_c6f3c92c-4094-4e14-95e1-35938e871f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_0d7006bc-0a6f-4a41-9795-4d5988ebd145" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_e68cb5bd-2199-4e53-aa04-d77f2cac26bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_e68cb5bd-2199-4e53-aa04-d77f2cac26bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_64f09076-8c1c-4081-868e-6110fbb3d8f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_64f09076-8c1c-4081-868e-6110fbb3d8f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_8587612d-953b-428d-921c-4720076257c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f417a72d-51b0-447e-85e4-3a6f38b1f389" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_8587612d-953b-428d-921c-4720076257c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_641cb082-e630-4687-8cdd-47be560ad5a4" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_cdfa4553-2d85-4c43-a6f1-e63b403a1603" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_MoneyMarketFundsMember_cdfa4553-2d85-4c43-a6f1-e63b403a1603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_b09f1de6-3df9-4e42-bd13-1541c1327ca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_CommercialPaperMember_b09f1de6-3df9-4e42-bd13-1541c1327ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_caed91f1-82e4-48e2-be16-ed19a719425a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_caed91f1-82e4-48e2-be16-ed19a719425a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a7ad9ff1-7bc7-44dc-8d96-480f7fa7ab70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_a7ad9ff1-7bc7-44dc-8d96-480f7fa7ab70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e7817229-7dc1-404b-9ea1-6dc8dbb8c140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_3c321b48-9812-49b8-91ae-0a08d8af7cac" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e7817229-7dc1-404b-9ea1-6dc8dbb8c140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b714b9c5-4e70-407d-8295-f94cf89fbd46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_e917eb1c-5b34-42a1-86be-08a7d50f2e38" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b714b9c5-4e70-407d-8295-f94cf89fbd46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_a2493809-adec-4c4b-8b4b-02e76da36b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_b714b9c5-4e70-407d-8295-f94cf89fbd46" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_a2493809-adec-4c4b-8b4b-02e76da36b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_2ce4781d-46e3-4d1c-8efa-dbba76e8c9f5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_344d8be3-9f11-4ea1-bd2f-7821a0f7da1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_344d8be3-9f11-4ea1-bd2f-7821a0f7da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_c87d6067-d1e5-49c4-afa5-ccb16186a6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_344d8be3-9f11-4ea1-bd2f-7821a0f7da1a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_c87d6067-d1e5-49c4-afa5-ccb16186a6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6a1d57f-2053-42db-8d06-442e84d56279" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_826aa643-9c15-4314-8c84-9a206555e3cf" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6a1d57f-2053-42db-8d06-442e84d56279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_964aa137-753e-495d-aa45-46c49351986f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_a6a1d57f-2053-42db-8d06-442e84d56279" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_964aa137-753e-495d-aa45-46c49351986f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8d67c754-7361-4d1e-a238-27d367a32b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_626f2b82-a94f-4538-b78b-9a9606394a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d67c754-7361-4d1e-a238-27d367a32b1e" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_626f2b82-a94f-4538-b78b-9a9606394a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#InventoryScheduleDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_4cb0c382-9416-4553-9a1c-41813a64989e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:to="loc_us-gaap_InventoryRawMaterials_4cb0c382-9416-4553-9a1c-41813a64989e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_0eefc0ab-05ba-4ceb-a241-2a3d5856d7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:to="loc_us-gaap_InventoryWorkInProcess_0eefc0ab-05ba-4ceb-a241-2a3d5856d7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_06a41282-b758-43dc-bb8e-173265396044" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:to="loc_us-gaap_InventoryFinishedGoods_06a41282-b758-43dc-bb8e-173265396044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_d99392ee-ac93-479f-b14b-98dba869f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:to="loc_us-gaap_InventoryGross_d99392ee-ac93-479f-b14b-98dba869f7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_323089ed-dd5d-44f2-a3df-bffb0122cb0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:to="loc_us-gaap_InventoryNoncurrent_323089ed-dd5d-44f2-a3df-bffb0122cb0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5ad82016-9515-43c9-a0bc-d777bebda509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c5f78fee-8017-4617-bcbc-1dd29b7a95df" xlink:to="loc_us-gaap_InventoryNet_5ad82016-9515-43c9-a0bc-d777bebda509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryScheduleDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#InventoryScheduleDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryScheduleDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fc9fa690-2c8b-4a7e-83ec-8ced09d12698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PrepaidCommercialManufacturingCurrent_34f00592-b13f-47f2-a445-787192f3f2e1" xlink:href="ardx-20230331.xsd#ardx_PrepaidCommercialManufacturingCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fc9fa690-2c8b-4a7e-83ec-8ced09d12698" xlink:to="loc_ardx_PrepaidCommercialManufacturingCurrent_34f00592-b13f-47f2-a445-787192f3f2e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#ProductRevenueNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a68e0d87-efa7-4be4-9935-a355825d5f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a68e0d87-efa7-4be4-9935-a355825d5f36" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_e9780fd6-f2c1-492f-9e6d-106638d449a0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_07056edd-b87c-43c1-b3cc-9d622c55e840" xlink:to="loc_srt_ProductsAndServicesDomain_e9780fd6-f2c1-492f-9e6d-106638d449a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ProductIBSRELAMember_dba4cde0-c05f-4c6d-9745-2acb4b91418b" xlink:href="ardx-20230331.xsd#ardx_ProductIBSRELAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_e9780fd6-f2c1-492f-9e6d-106638d449a0" xlink:to="loc_ardx_ProductIBSRELAMember_dba4cde0-c05f-4c6d-9745-2acb4b91418b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de80b258-20c7-4fba-8294-3bcef86df977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_1867dcb9-2ec3-49e7-83d6-169a259c2b3f" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de80b258-20c7-4fba-8294-3bcef86df977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_261ead89-c4be-4b99-b20e-b24e0801657d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueProductLineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_de80b258-20c7-4fba-8294-3bcef86df977" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_261ead89-c4be-4b99-b20e-b24e0801657d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_21f84c7c-ba64-488c-b799-dc085b7d9f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_16514527-aaf7-4371-917f-ccea3cb3308c" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_21f84c7c-ba64-488c-b799-dc085b7d9f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_50a360bd-fb24-46c6-80c0-981bb54ae79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_21f84c7c-ba64-488c-b799-dc085b7d9f8f" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_50a360bd-fb24-46c6-80c0-981bb54ae79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4a1c585e-3994-4b35-80fa-85fc54a4a1b6" xlink:to="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CardinalHealthMember_ac76d34f-14ff-45c8-9951-6cc97c012c3e" xlink:href="ardx-20230331.xsd#ardx_CardinalHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:to="loc_ardx_CardinalHealthMember_ac76d34f-14ff-45c8-9951-6cc97c012c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AmerisourceBergenDrugCorporationMember_5cacac72-1c30-48b1-b98d-177e9ce5c210" xlink:href="ardx-20230331.xsd#ardx_AmerisourceBergenDrugCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:to="loc_ardx_AmerisourceBergenDrugCorporationMember_5cacac72-1c30-48b1-b98d-177e9ce5c210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_McKessonCorporationMember_ffebb7b3-48a7-49e1-a49a-4810ca631611" xlink:href="ardx-20230331.xsd#ardx_McKessonCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7521973b-adea-49b5-a09c-e757b6654d85" xlink:to="loc_ardx_McKessonCorporationMember_ffebb7b3-48a7-49e1-a49a-4810ca631611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_b01c5f4a-92cd-4cce-aa5b-03ae52b2557e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32fb1da4-efed-4149-be7d-21f14cebb321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32fb1da4-efed-4149-be7d-21f14cebb321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_727b9cb4-821f-4730-98bb-c9c24e870c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ee3437e6-886b-4fbb-8022-5348d8e0519a" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_727b9cb4-821f-4730-98bb-c9c24e870c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#ProductRevenueNetGrosstoNetSalesAccrualsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_00f388ad-c5ab-4a6e-b2f0-fbdce63650a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_00f388ad-c5ab-4a6e-b2f0-fbdce63650a6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:href="ardx-20230331.xsd#ardx_GrossToNetSalesAccrualAndReserveClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis_bf0ecdc0-a1ba-4c0a-95c0-bd0b79ad1345" xlink:to="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_2f1940d4-1207-4852-869b-cc41e4b0d56a" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerDiscountsAndChargebacksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:to="loc_ardx_ContractWithCustomerDiscountsAndChargebacksMember_2f1940d4-1207-4852-869b-cc41e4b0d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerRebatesMember_46b6d152-90a3-41af-9549-0fe7fd81e824" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerRebatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:to="loc_ardx_ContractWithCustomerRebatesMember_46b6d152-90a3-41af-9549-0fe7fd81e824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5667d8d1-dc26-498d-84a1-96ea33c8e3f5" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_GrossToNetSalesAccrualAndReserveClassificationDomain_710756f2-0653-4f74-9ed9-95bf5843efc2" xlink:to="loc_ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember_5667d8d1-dc26-498d-84a1-96ea33c8e3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_0d0c6d7e-7b16-462d-a3e6-482ebabd9de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_1019b7c5-bb60-437e-8e6e-f9b645d1e37f" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_0d0c6d7e-7b16-462d-a3e6-482ebabd9de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_0d0c6d7e-7b16-462d-a3e6-482ebabd9de9" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_70c79fb7-d9ab-4f17-aaa5-bc0614b5ff59" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_70c79fb7-d9ab-4f17-aaa5-bc0614b5ff59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesProvisions_defef042-e326-4657-98ac-ecd9663d1c84" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesProvisions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesProvisions_defef042-e326-4657-98ac-ecd9663d1c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_43688a3e-eb80-477b-9c34-cb74b6d6246d" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued_43688a3e-eb80-477b-9c34-cb74b6d6246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_37936293-a730-4396-824f-35258682c222" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerGrossToNetSalesAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward_2fb1f49c-9aaf-46d7-baf8-cf2802e3dc42" xlink:to="loc_ardx_ContractWithCustomerGrossToNetSalesAccruals_37936293-a730-4396-824f-35258682c222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CollaborationandLicensingAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_207d2e93-d578-4dbd-9d2a-35127d89247b" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_207d2e93-d578-4dbd-9d2a-35127d89247b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_783be50f-b796-4d06-9747-92a90df420ef" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KyowaKirinCo.LtdMember_a5705410-cf58-4c08-86ce-7b8e6d70048b" xlink:href="ardx-20230331.xsd#ardx_KyowaKirinCo.LtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_KyowaKirinCo.LtdMember_a5705410-cf58-4c08-86ce-7b8e6d70048b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_4b90534f-b511-489a-9ab6-e5b0ea7e9a66" xlink:href="ardx-20230331.xsd#ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember_4b90534f-b511-489a-9ab6-e5b0ea7e9a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_KnightTherapeuticsIncMember_8af87b5e-8223-445b-8dd5-e398cbcf5e01" xlink:href="ardx-20230331.xsd#ardx_KnightTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_KnightTherapeuticsIncMember_8af87b5e-8223-445b-8dd5-e398cbcf5e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstrazenecaMember_14ec9a69-5c9f-4ff8-ad3d-748c4e96ca30" xlink:href="ardx-20230331.xsd#ardx_AstrazenecaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d9ab9839-5dd6-431e-a23a-4b99e4d65e8a" xlink:to="loc_ardx_AstrazenecaMember_14ec9a69-5c9f-4ff8-ad3d-748c4e96ca30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c04c68db-2a59-4eec-a95f-f5fc99efaf5c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_f175fd1d-56b5-4685-a699-67679079810e" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_f175fd1d-56b5-4685-a699-67679079810e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_2cabef5e-9e43-4d41-b964-105f38824250" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember_2cabef5e-9e43-4d41-b964-105f38824250" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_0ece98e1-4274-4456-b9d5-4a43ff29652b" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember_0ece98e1-4274-4456-b9d5-4a43ff29652b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_AstraZenecaTerminationAgreementMember_f3d3c235-c84d-47ee-8065-5775e3d2f11c" xlink:href="ardx-20230331.xsd#ardx_AstraZenecaTerminationAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_042206ce-1182-4e75-8e71-12a95a6a1a8e" xlink:to="loc_ardx_AstraZenecaTerminationAgreementMember_f3d3c235-c84d-47ee-8065-5775e3d2f11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ece178e5-0f6a-4ec1-8a1f-e548d10e2df3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3c34b5cb-a1a6-4018-b00e-fe9f9eb6650d" xlink:to="loc_srt_ProductsAndServicesDomain_ece178e5-0f6a-4ec1-8a1f-e548d10e2df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_33076a8e-ce4f-4020-a3d0-6f49b56d51b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ece178e5-0f6a-4ec1-8a1f-e548d10e2df3" xlink:to="loc_us-gaap_LicenseMember_33076a8e-ce4f-4020-a3d0-6f49b56d51b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a232ee95-fee1-4a47-9733-3a55cb7982b8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_76f5d15d-237f-456c-87b7-34d32a0e9975" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees_76f5d15d-237f-456c-87b7-34d32a0e9975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_6f61d53d-0e4c-4a74-976b-23e317db0d20" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentMilestones"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentMilestones_6f61d53d-0e4c-4a74-976b-23e317db0d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0ceaa95c-0e15-4b77-ac13-ce9963e3799e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0ceaa95c-0e15-4b77-ac13-ce9963e3799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_bd18d27e-9945-4578-a215-af7921c556b7" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialCommercializationMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialCommercializationMilestones_bd18d27e-9945-4578-a215-af7921c556b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_d06f5681-4172-4dfd-95a7-15038531241b" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate_d06f5681-4172-4dfd-95a7-15038531241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_6b12508b-cbb5-459c-ae17-81bece90854d" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches_6b12508b-cbb5-459c-ae17-81bece90854d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f01171cf-30a9-4e22-940c-d462e35a42cc" xlink:href="ardx-20230331.xsd#ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount_f01171cf-30a9-4e22-940c-d462e35a42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLicenseFeesReceived_6c59feb7-282c-4c95-9fe8-a5096e35780c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLicenseFeesReceived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_ProceedsFromLicenseFeesReceived_6c59feb7-282c-4c95-9fe8-a5096e35780c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_361dc440-62dd-44f7-ae81-701514d5e441" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones_361dc440-62dd-44f7-ae81-701514d5e441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_564e75cb-dac6-477e-ba23-180d61c1c202" xlink:href="ardx-20230331.xsd#ardx_ThresholdPercentageOfSalesForTieredRoyalties"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_ThresholdPercentageOfSalesForTieredRoyalties_564e75cb-dac6-477e-ba23-180d61c1c202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfRoyaltyRevenue_f79c3f15-b382-4a5c-9548-010113b84ac8" xlink:href="ardx-20230331.xsd#ardx_PercentageOfRoyaltyRevenue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_PercentageOfRoyaltyRevenue_f79c3f15-b382-4a5c-9548-010113b84ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PercentageOfNonRoyaltyRevenue_4b99dc9a-6a87-4669-9c3a-65cf6baecc5b" xlink:href="ardx-20230331.xsd#ardx_PercentageOfNonRoyaltyRevenue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_PercentageOfNonRoyaltyRevenue_4b99dc9a-6a87-4669-9c3a-65cf6baecc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_dd5454dd-6888-49a9-8a1b-65cf5010aa38" xlink:href="ardx-20230331.xsd#ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum_dd5454dd-6888-49a9-8a1b-65cf5010aa38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CostOfRevenueAggregateAmountRecognized_ed1cf561-e3e9-4bd4-8bac-6e79178a142f" xlink:href="ardx-20230331.xsd#ardx_CostOfRevenueAggregateAmountRecognized"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_CostOfRevenueAggregateAmountRecognized_ed1cf561-e3e9-4bd4-8bac-6e79178a142f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_b9bce2ba-9f0b-46f9-ae8c-4dde6e60580d" xlink:href="ardx-20230331.xsd#ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid_b9bce2ba-9f0b-46f9-ae8c-4dde6e60580d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_9988f04b-775c-4ddd-87e0-4d8f3a8ce81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4218f940-d83d-4caf-83ed-e0c443c69b7a" xlink:to="loc_us-gaap_CostOfRevenue_9988f04b-775c-4ddd-87e0-4d8f3a8ce81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#CollaborationandLicensingAgreementsDeferredRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ardx_CollaborationAndLicensingAgreementsAbstract_908a975e-e637-4883-aa5b-5e9d8eda1d80" xlink:href="ardx-20230331.xsd#ardx_CollaborationAndLicensingAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_CollaborationAndLicensingAgreementsAbstract_908a975e-e637-4883-aa5b-5e9d8eda1d80" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:to="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dbcec75-1dde-4135-9aa7-5bf1c0da07cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_68bd013c-d648-498a-8ed9-e86ee468d508" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dbcec75-1dde-4135-9aa7-5bf1c0da07cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_de41f128-cb03-462f-80f4-71780e9b4a73" xlink:href="ardx-20230331.xsd#ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7dbcec75-1dde-4135-9aa7-5bf1c0da07cd" xlink:to="loc_ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember_de41f128-cb03-462f-80f4-71780e9b4a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_32b80134-02bb-427b-ae85-08768d18a3d8" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:href="ardx-20230331.xsd#ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a402bb1-fa18-4136-b6fa-4cc46def9aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2a402bb1-fa18-4136-b6fa-4cc46def9aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_4bf607d6-3ab0-4afd-9087-7f2436ec604b" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths_4bf607d6-3ab0-4afd-9087-7f2436ec604b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_04cc5d1d-bea5-41a3-8d16-5b69606e44c6" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived_04cc5d1d-bea5-41a3-8d16-5b69606e44c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ffbfc69-2ebe-46b3-89ba-412ad3224cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward_caea2484-0774-43a7-a6fd-b3f5e7a2c825" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_2ffbfc69-2ebe-46b3-89ba-412ad3224cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:href="ardx-20230331.xsd#ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3da7c358-8ead-4432-9957-0c6adbee210d" xlink:to="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2105ea5f-7e72-493e-a29f-6a3f085131d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2105ea5f-7e72-493e-a29f-6a3f085131d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f64a2467-d48b-4038-b446-afd212933595" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced_f64a2467-d48b-4038-b446-afd212933595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_6aba0b94-fe53-4ed0-8418-3f343b7a2122" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded_6aba0b94-fe53-4ed0-8418-3f343b7a2122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_5cc1d6a4-9cca-417e-81ce-b75cd8e45f7f" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths_5cc1d6a4-9cca-417e-81ce-b75cd8e45f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_59924923-7c67-4a2e-965f-78d70a5131ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward_efaddd75-91e7-40c9-ba11-20afe96f43ff" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_59924923-7c67-4a2e-965f-78d70a5131ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvanceRoyaltiesAbstract_214ddd1c-dfe3-4e57-8c96-82adc9ab4835" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvanceRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdvanceRoyaltiesAbstract_214ddd1c-dfe3-4e57-8c96-82adc9ab4835" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:to="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f82b3ff-585f-4c2a-8aa1-2f2ae70d87eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d4663e1a-66a7-45e5-96b2-e86c4322ad8c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f82b3ff-585f-4c2a-8aa1-2f2ae70d87eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_527e6531-96cd-40ef-82d9-7b2f16e94b67" xlink:href="ardx-20230331.xsd#ardx_HealthCareRoyaltyPartnersIVLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2f82b3ff-585f-4c2a-8aa1-2f2ae70d87eb" xlink:to="loc_ardx_HealthCareRoyaltyPartnersIVLPMember_527e6531-96cd-40ef-82d9-7b2f16e94b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:to="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dcd836d8-6cd0-4e89-9574-f20909dde167" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4419ff8b-7f3d-407f-96fe-8c584d616427" xlink:to="loc_srt_ProductsAndServicesDomain_dcd836d8-6cd0-4e89-9574-f20909dde167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_54272bc2-620f-40a6-9fa5-d75d18f3aa3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dcd836d8-6cd0-4e89-9574-f20909dde167" xlink:to="loc_us-gaap_LicenseMember_54272bc2-620f-40a6-9fa5-d75d18f3aa3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7567a3e8-64d1-43c0-aeed-ad4a03887887" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_500a4226-62cf-404c-99ae-b2a77898b2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInRoyaltiesPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_IncreaseDecreaseInRoyaltiesPayable_500a4226-62cf-404c-99ae-b2a77898b2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_21147312-4efb-41ab-91b8-28a7cb7d51d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_ContractWithCustomerLiability_21147312-4efb-41ab-91b8-28a7cb7d51d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_80436242-867a-4909-9028-c05bbf161eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_80436242-867a-4909-9028-c05bbf161eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_9c05956b-8083-47fc-bbf8-864407622345" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityTransactionCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_ardx_ContractWithCustomerLiabilityTransactionCosts_9c05956b-8083-47fc-bbf8-864407622345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_e8509085-0138-49e8-b884-0aa33bc32a38" xlink:href="ardx-20230331.xsd#ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent_e8509085-0138-49e8-b884-0aa33bc32a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfAdvanceRoyalty_18c9870f-4a1e-44f5-9ea1-f1ccd200c8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_AmortizationOfAdvanceRoyalty_18c9870f-4a1e-44f5-9ea1-f1ccd200c8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRoyaltiesReceived_8a323fb1-2c5b-46f1-84ba-a7fc74452ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRoyaltiesReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4fcd45bb-09b7-4b52-ad4b-309586cd9f02" xlink:to="loc_us-gaap_ProceedsFromRoyaltiesReceived_8a323fb1-2c5b-46f1-84ba-a7fc74452ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3bfaa9fa-3ee8-4db3-ae38-369a40b0ff4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3bfaa9fa-3ee8-4db3-ae38-369a40b0ff4d" xlink:to="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_55e91019-409a-4c95-bc99-8f1236d550c9" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_0d1632e5-1aaa-481c-be06-afe28e2ed335" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:to="loc_ardx_ExitFee2018Member_0d1632e5-1aaa-481c-be06-afe28e2ed335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_781441e1-4509-4f00-a941-6a30633ce391" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c9450cd2-909f-4936-87cf-98a838614fb2" xlink:to="loc_ardx_ExitFee2022Member_781441e1-4509-4f00-a941-6a30633ce391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_992ea41b-b13c-4917-9e9f-bbc1e6b13876" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2018Member_bb08d54f-c6d9-42d8-8eca-ad92255ed8b9" xlink:href="ardx-20230331.xsd#ardx_TermLoan2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:to="loc_ardx_TermLoan2018Member_bb08d54f-c6d9-42d8-8eca-ad92255ed8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:to="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022AMember_377abeb0-5ebf-4a44-9770-eb3c30439b02" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022AMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:to="loc_ardx_TermLoan2022AMember_377abeb0-5ebf-4a44-9770-eb3c30439b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermLoan2022BMember_04b728c5-a58b-4011-be36-0d6e67fa565c" xlink:href="ardx-20230331.xsd#ardx_TermLoan2022BMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_TermLoan2022Member_e0a73f83-0ac8-4c59-a60a-c5d3d227c78d" xlink:to="loc_ardx_TermLoan2022BMember_04b728c5-a58b-4011-be36-0d6e67fa565c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_TermBLoanMember_c6dff7e8-b2d9-49f8-99b3-c55a7e6b3d64" xlink:href="ardx-20230331.xsd#ardx_TermBLoanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_25cffe89-2846-4b35-a7e0-0d99802a8aea" xlink:to="loc_ardx_TermBLoanMember_c6dff7e8-b2d9-49f8-99b3-c55a7e6b3d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d05efc7c-a414-4eb7-a94a-73c397c3818a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_d799dcfb-59ec-40da-ab4d-acdc1d60b1b7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d05efc7c-a414-4eb7-a94a-73c397c3818a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_97a2be19-f082-4dc6-8b60-f3767c36f5e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d05efc7c-a414-4eb7-a94a-73c397c3818a" xlink:to="loc_us-gaap_LoansPayableMember_97a2be19-f082-4dc6-8b60-f3767c36f5e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_842bd989-22eb-44af-9422-ba3c98508004" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_195eee11-4463-471d-b105-09beb0d72ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_195eee11-4463-471d-b105-09beb0d72ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7be7a398-f361-45c8-97a0-4b4a398397fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_7be7a398-f361-45c8-97a0-4b4a398397fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_37941d46-b26d-4cf3-b786-e95ca74d2294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_c0ed2e16-4440-42c0-8896-8a4885f01da2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodThreeMember_37941d46-b26d-4cf3-b786-e95ca74d2294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_997bc564-e206-4e36-87f1-53932029bfbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_29fff8b3-6922-42fb-bc02-a7e6aea7e877" xlink:to="loc_us-gaap_VariableRateDomain_997bc564-e206-4e36-87f1-53932029bfbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e79621f5-8d6c-427f-ad3d-5486be8f46e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_997bc564-e206-4e36-87f1-53932029bfbf" xlink:to="loc_us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember_e79621f5-8d6c-427f-ad3d-5486be8f46e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_13b8bd61-459d-4ea5-92c0-96134b8eeca7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bb70ece8-789e-4750-97f2-5d7c8a333b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bb70ece8-789e-4750-97f2-5d7c8a333b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_decd61cd-b826-43a9-8340-7fc8c50426c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_decd61cd-b826-43a9-8340-7fc8c50426c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_da5876b8-2490-4600-b912-7d379769a9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_da5876b8-2490-4600-b912-7d379769a9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c5f12842-7fde-4927-928d-ed4537b52d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c5f12842-7fde-4927-928d-ed4537b52d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_34716a57-a669-478b-b348-c34f20028fe1" xlink:href="ardx-20230331.xsd#ardx_RemainingFundingBasedOnConditionalMilestoneAchievement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement_34716a57-a669-478b-b348-c34f20028fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0794629a-89fe-48f1-b5a9-d4f7cac154b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0794629a-89fe-48f1-b5a9-d4f7cac154b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRateBaseOption_e5f1081b-64b3-4662-8ae2-e46e4314c882" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentVariableRateBaseOption"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentVariableRateBaseOption_e5f1081b-64b3-4662-8ae2-e46e4314c882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentVariableRatePlusOption_eb1271d9-b77b-4e25-8ebe-98b7606e8879" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentVariableRatePlusOption"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentVariableRatePlusOption_eb1271d9-b77b-4e25-8ebe-98b7606e8879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_c7523fef-db17-42d6-8294-f66ffdacda6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_us-gaap_DebtInstrumentTerm_c7523fef-db17-42d6-8294-f66ffdacda6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentClosingFeeAmount_882257c9-a100-4dd8-8847-176bd86e971a" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentClosingFeeAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentClosingFeeAmount_882257c9-a100-4dd8-8847-176bd86e971a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d14c7dfb-8f78-42aa-8ec4-fa250fb10add" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents_d14c7dfb-8f78-42aa-8ec4-fa250fb10add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_964f2246-fdb3-46bb-b62e-26b148795715" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage_964f2246-fdb3-46bb-b62e-26b148795715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ffdf560b-2833-48b6-87c2-d449abf35ee7" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentPrepaymentFeePercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentPrepaymentFeePercentage_ffdf560b-2833-48b6-87c2-d449abf35ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_c2fb05f8-f7db-4ed4-a887-56df18d8c9a1" xlink:href="ardx-20230331.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_ExitFeePercentage_c2fb05f8-f7db-4ed4-a887-56df18d8c9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1d58bbd3-7cfc-404d-b019-56b1f39757bd" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_1d58bbd3-7cfc-404d-b019-56b1f39757bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeTerm_d12e1551-80fc-4212-a193-ba32a2b6c92d" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeTerm"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementExitFeeTerm_d12e1551-80fc-4212-a193-ba32a2b6c92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_e2b878c2-6b27-44f5-bbd1-af32baa4d00c" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum_e2b878c2-6b27-44f5-bbd1-af32baa4d00c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_0624ede8-beb2-4757-8046-534da48060d3" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod_0624ede8-beb2-4757-8046-534da48060d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_ee88ddee-17c9-4a50-a97f-e1f8fa3d33c4" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum_ee88ddee-17c9-4a50-a97f-e1f8fa3d33c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_7f1fde0d-04a1-4986-8067-8e1b585b9714" xlink:href="ardx-20230331.xsd#ardx_DebtInstrumentInterestRateOnDefaultPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0d20956c-16bd-461b-ba90-2557a1033eb2" xlink:to="loc_ardx_DebtInstrumentInterestRateOnDefaultPercentage_7f1fde0d-04a1-4986-8067-8e1b585b9714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingFuturePaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_a4543eea-f05c-4c9f-bef8-6f8d965484f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_a4543eea-f05c-4c9f-bef8-6f8d965484f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4bcd2539-63c0-4123-8cc8-ffbb7fd03e47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_4bcd2539-63c0-4123-8cc8-ffbb7fd03e47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFeeAmount_da2dbd71-2090-4bb7-bb46-5c963668c8a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:to="loc_us-gaap_DebtInstrumentFeeAmount_da2dbd71-2090-4bb7-bb46-5c963668c8a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_98aab54a-b161-46d7-b053-fbf22f9b50ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:to="loc_us-gaap_LongTermDebt_98aab54a-b161-46d7-b053-fbf22f9b50ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableCurrent_44188511-2b84-4913-9c45-74c2caa43b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:to="loc_us-gaap_LoansPayableCurrent_44188511-2b84-4913-9c45-74c2caa43b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermLoansPayable_d2db5eac-e4f2-4bb5-b94a-608d5bf065d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermLoansPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_43d80d16-3450-4e9f-9cce-01a5171c13cf" xlink:to="loc_us-gaap_LongTermLoansPayable_d2db5eac-e4f2-4bb5-b94a-608d5bf065d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#BorrowingFuturePaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#DerivativeLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e23e70d3-a1e5-499d-a20d-6ef7a963dd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e23e70d3-a1e5-499d-a20d-6ef7a963dd12" xlink:to="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_259e488c-3bfc-4f7a-bca9-2e96627900e0" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_c2e8f115-6162-4ca0-85b5-aa785fa57b23" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:to="loc_ardx_ExitFee2018Member_c2e8f115-6162-4ca0-85b5-aa785fa57b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_de5774e1-e794-413b-b32d-8c3e9b327048" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8ebc1914-88b5-4cbd-80a1-e4dc428b09ee" xlink:to="loc_ardx_ExitFee2022Member_de5774e1-e794-413b-b32d-8c3e9b327048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc85dfe5-44bb-4c62-b9da-4ce884a3fd40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5eb31b13-0584-4b1d-a71f-eca36a94297f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc85dfe5-44bb-4c62-b9da-4ce884a3fd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c35523ae-5d76-435f-8c52-5562cef45839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc85dfe5-44bb-4c62-b9da-4ce884a3fd40" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c35523ae-5d76-435f-8c52-5562cef45839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_c4d89690-4662-43f1-bea5-d158e6b293cc" xlink:to="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_eb21cda2-a800-47ce-8658-6f5ba12396ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_eb21cda2-a800-47ce-8658-6f5ba12396ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c6f2d73b-8d89-4871-b3eb-bab0d48df79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_c6f2d73b-8d89-4871-b3eb-bab0d48df79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_da4f83e1-6c7b-45a3-937d-e776f6d2a79d" xlink:href="ardx-20230331.xsd#ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage_da4f83e1-6c7b-45a3-937d-e776f6d2a79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_e82c31f4-22ac-4e2a-b8c8-3a21a1af1431" xlink:href="ardx-20230331.xsd#ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation_e82c31f4-22ac-4e2a-b8c8-3a21a1af1431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFeePercentage_80b4c519-f288-4317-9117-ccc17989c316" xlink:href="ardx-20230331.xsd#ardx_ExitFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_ExitFeePercentage_80b4c519-f288-4317-9117-ccc17989c316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7068559a-71f1-4b9e-8536-34418841b451" xlink:href="ardx-20230331.xsd#ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_ff44a71f-814b-4652-98ec-3001bf3e26eb" xlink:to="loc_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum_7068559a-71f1-4b9e-8536-34418841b451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#DerivativeLiabilitiesChangesinFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e075a11-9cda-4aa2-8844-62ffe00bdffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8e075a11-9cda-4aa2-8844-62ffe00bdffe" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_87c2c8d6-a33d-40be-8a1c-073b6fa7294f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_347ac0d4-b322-4337-857d-dc21fda7aa09" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_87c2c8d6-a33d-40be-8a1c-073b6fa7294f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_20e80a9f-62a1-4bbf-a8db-ac19a67b5e9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_87c2c8d6-a33d-40be-8a1c-073b6fa7294f" xlink:to="loc_us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember_20e80a9f-62a1-4bbf-a8db-ac19a67b5e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_9c8d5690-1171-4b45-a1b4-ae2d659110ce" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2018Member_fefc27d9-956f-4d36-bffa-dd4c79f0fcaa" xlink:href="ardx-20230331.xsd#ardx_ExitFee2018Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:to="loc_ardx_ExitFee2018Member_fefc27d9-956f-4d36-bffa-dd4c79f0fcaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ExitFee2022Member_fd89034e-cbbc-4aa6-917d-b3825f231334" xlink:href="ardx-20230331.xsd#ardx_ExitFee2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_35d1f0df-0687-4675-b4ef-a6735bd8b11d" xlink:to="loc_ardx_ExitFee2022Member_fd89034e-cbbc-4aa6-917d-b3825f231334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f5e9a876-4baa-4a44-9836-b605c8656dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_004b8a99-ad81-40c2-8cb2-76fb2820646c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f5e9a876-4baa-4a44-9836-b605c8656dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_f5e9a876-4baa-4a44-9836-b605c8656dc3" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1c294d57-bc72-4382-b511-81e079e416d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_1c294d57-bc72-4382-b511-81e079e416d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f83c3d87-28d0-4831-abf8-63384f35ad48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_f83c3d87-28d0-4831-abf8-63384f35ad48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd2fcc3-10bf-4297-94f6-d5a4d31e8ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_8dd2fcc3-10bf-4297-94f6-d5a4d31e8ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b8e663fb-63d2-48ea-a5a9-c8106379266b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_a3095de4-2f70-4dff-8b19-8568d60549c3" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_b8e663fb-63d2-48ea-a5a9-c8106379266b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesAdditionalDetailsofLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ab15d58c-dbcd-4a7c-b325-2c74da783bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_e454f288-f273-41ed-9755-c7750e004505" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab15d58c-dbcd-4a7c-b325-2c74da783bcf" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_e454f288-f273-41ed-9755-c7750e004505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_feab01bc-121b-4342-a62a-e6d54a161540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_e454f288-f273-41ed-9755-c7750e004505" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_feab01bc-121b-4342-a62a-e6d54a161540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3dec2616-d301-456f-a662-7bf215829e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_e454f288-f273-41ed-9755-c7750e004505" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3dec2616-d301-456f-a662-7bf215829e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_80865932-ad21-443f-bbfe-75d3ba711685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_e454f288-f273-41ed-9755-c7750e004505" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_80865932-ad21-443f-bbfe-75d3ba711685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_9826d5a8-dc35-40bf-9bd1-5b09a099e908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_e454f288-f273-41ed-9755-c7750e004505" xlink:to="loc_us-gaap_OperatingLeaseLiability_9826d5a8-dc35-40bf-9bd1-5b09a099e908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_61841d01-c68e-45f1-ac24-a6dd9f9050b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ab15d58c-dbcd-4a7c-b325-2c74da783bcf" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_61841d01-c68e-45f1-ac24-a6dd9f9050b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20948b0b-7533-42ba-94d0-366e712e98f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_61841d01-c68e-45f1-ac24-a6dd9f9050b0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_20948b0b-7533-42ba-94d0-366e712e98f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_79f96271-9864-4fd2-85ca-c52d58822bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_61841d01-c68e-45f1-ac24-a6dd9f9050b0" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_79f96271-9864-4fd2-85ca-c52d58822bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesLeaseCostsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesLeaseCostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_9d54d667-e8b3-4147-bb06-12079233c220" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_5c254156-472a-42cb-88c0-ced8f5121cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_9d54d667-e8b3-4147-bb06-12079233c220" xlink:to="loc_us-gaap_LeaseCostAbstract_5c254156-472a-42cb-88c0-ced8f5121cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_1eb796fb-028c-48bb-bfef-cb1747172c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5c254156-472a-42cb-88c0-ced8f5121cff" xlink:to="loc_us-gaap_OperatingLeaseCost_1eb796fb-028c-48bb-bfef-cb1747172c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_b4c218fa-5252-4e50-835a-9cb10cdded59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_5c254156-472a-42cb-88c0-ced8f5121cff" xlink:to="loc_us-gaap_OperatingLeasePayments_b4c218fa-5252-4e50-835a-9cb10cdded59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesUndiscountedCashPaymentObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8374b44c-eff6-4796-9505-a82a73aee432" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8374b44c-eff6-4796-9505-a82a73aee432" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43b76bc6-34ee-46cf-bc58-a0f4d7e98f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_43b76bc6-34ee-46cf-bc58-a0f4d7e98f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_420db158-21c7-457f-8a4e-31af0e2678ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_420db158-21c7-457f-8a4e-31af0e2678ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe2568f3-34f4-466f-bffa-7f5593fc8370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fe2568f3-34f4-466f-bffa-7f5593fc8370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb5790df-053f-4b63-ba91-3893f08daa7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_eb5790df-053f-4b63-ba91-3893f08daa7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_26587ed1-5578-4935-8e07-2df791cada1b" xlink:href="ardx-20230331.xsd#ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree_26587ed1-5578-4935-8e07-2df791cada1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0d5deb7-62d5-4863-93ec-3823177a512e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f0d5deb7-62d5-4863-93ec-3823177a512e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f57d3c75-e529-43c1-a551-133b586d3785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f57d3c75-e529-43c1-a551-133b586d3785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bb1eb927-9cea-4476-8bc0-d8b47fd31d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_OperatingLeaseLiability_bb1eb927-9cea-4476-8bc0-d8b47fd31d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ee15f49f-84c9-4b6b-80b1-24836a85f611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ee15f49f-84c9-4b6b-80b1-24836a85f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_884be0a1-b8bd-44fd-80c6-41dcf3516769" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_909523b2-ff97-4a8f-bf1a-9f0313d57839" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_884be0a1-b8bd-44fd-80c6-41dcf3516769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesUndiscountedCashPaymentObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d8eab809-b7c8-4afc-bf47-760ffd1fe551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d8eab809-b7c8-4afc-bf47-760ffd1fe551" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:to="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_LeaseArrangementsDomain_9230a57d-6958-4a86-9b28-4df08218766b" xlink:href="ardx-20230331.xsd#ardx_LeaseArrangementsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsAxis_fa61465c-70e3-4696-b28b-a42f2417bd7d" xlink:to="loc_ardx_LeaseArrangementsDomain_9230a57d-6958-4a86-9b28-4df08218766b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_FacilityFremontCaliforniaMember_cf087199-4c74-4056-86a9-b14ce9c991a3" xlink:href="ardx-20230331.xsd#ardx_FacilityFremontCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ardx_LeaseArrangementsDomain_9230a57d-6958-4a86-9b28-4df08218766b" xlink:to="loc_ardx_FacilityFremontCaliforniaMember_cf087199-4c74-4056-86a9-b14ce9c991a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:to="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_761cce50-3a28-4c11-890e-90d5545f00c6" xlink:to="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_0209e336-825a-4b48-960d-a976e68fc84b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:to="loc_srt_MinimumMember_0209e336-825a-4b48-960d-a976e68fc84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_af27d656-361e-46ae-be88-74b897636693" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_627f4969-0a73-4783-97fb-dc4ac6b6fe46" xlink:to="loc_srt_MaximumMember_af27d656-361e-46ae-be88-74b897636693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_02d973a6-846e-46bb-8c3d-27cdb3ab6dc8" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_337b3544-2622-4275-a22f-22c1d05df43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AreaOfRealEstateProperty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_337b3544-2622-4275-a22f-22c1d05df43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseImpairmentLoss_0fb58e0d-7df4-439d-b492-13e6f7b16c23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_65a8d84b-eb79-45ec-ba8f-231cc5a4d319" xlink:to="loc_us-gaap_OperatingLeaseImpairmentLoss_0fb58e0d-7df4-439d-b492-13e6f7b16c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e68c40de-b725-4af9-bec9-ebd70f260c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e68c40de-b725-4af9-bec9-ebd70f260c48" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_571405c0-b002-4d56-ab01-e3df5bb68188" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_d8cd6c62-9f63-469e-a767-cc743d390767" xlink:href="ardx-20230331.xsd#ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:to="loc_ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember_d8cd6c62-9f63-469e-a767-cc743d390767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_f4ef2018-e6a7-4230-9e1e-952575e3f590" xlink:href="ardx-20230331.xsd#ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_cdbc1177-fa19-4110-8f9f-19b4eb8c0975" xlink:to="loc_ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember_f4ef2018-e6a7-4230-9e1e-952575e3f590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_75578fc2-5ade-4ae9-9a0d-eecec55e2758" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_e67a38e7-f87f-4931-96e9-58a831ebb6b9" xlink:to="loc_us-gaap_ClassOfStockDomain_75578fc2-5ade-4ae9-9a0d-eecec55e2758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_6b53bd84-5aec-4710-9106-4778ee01eb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_75578fc2-5ade-4ae9-9a0d-eecec55e2758" xlink:to="loc_us-gaap_CommonClassAMember_6b53bd84-5aec-4710-9106-4778ee01eb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_6571ce9a-3117-478f-a46a-1b068741ba2d" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_MaximumAggregateOfferingPrice_86b19ee1-4c1d-40e1-aeb8-296a956d05b3" xlink:href="ardx-20230331.xsd#ardx_MaximumAggregateOfferingPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_MaximumAggregateOfferingPrice_86b19ee1-4c1d-40e1-aeb8-296a956d05b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StockIssuanceCostCommissionPercent_7e785735-2a81-4686-b136-f1cae2bed0a3" xlink:href="ardx-20230331.xsd#ardx_StockIssuanceCostCommissionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_StockIssuanceCostCommissionPercent_7e785735-2a81-4686-b136-f1cae2bed0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7a300b0a-9cc1-4a11-8eaf-64ba862bae0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7a300b0a-9cc1-4a11-8eaf-64ba862bae0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3ba7013f-5058-4550-85e4-af22db23a5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3ba7013f-5058-4550-85e4-af22db23a5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_SaleOfStockWeightedAveragePricePerShare_f55e8cd6-4532-43e7-974f-3f774ef30ba0" xlink:href="ardx-20230331.xsd#ardx_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_SaleOfStockWeightedAveragePricePerShare_f55e8cd6-4532-43e7-974f-3f774ef30ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_4bb5e107-9b65-4bb7-96c8-4b2fdc6a6be5" xlink:href="ardx-20230331.xsd#ardx_EquitySalesAgreementSharesIssuedSinceInception"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_EquitySalesAgreementSharesIssuedSinceInception_4bb5e107-9b65-4bb7-96c8-4b2fdc6a6be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_de5b5584-c2fb-4cb0-bc3a-ac2dcd3d764b" xlink:href="ardx-20230331.xsd#ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_22799940-c4c9-48c0-be42-305a3ac71aa8" xlink:to="loc_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception_de5b5584-c2fb-4cb0-bc3a-ac2dcd3d764b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d04a3e5b-adc7-49f3-873b-2478200e1443" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d04a3e5b-adc7-49f3-873b-2478200e1443" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9de18ed4-e49d-4f97-b988-d981ae3aa2bc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1af785bc-09ad-465c-9f18-74cecdae7f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1af785bc-09ad-465c-9f18-74cecdae7f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78d1b967-057a-436e-8d60-a662a475fb52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c335e9fc-b69e-4764-a5bb-832978fb4d2a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_78d1b967-057a-436e-8d60-a662a475fb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6a444e93-f6f5-40aa-901a-8c2c03b75958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c8c76764-1b12-4441-b6c3-f500eaf06f5f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6a444e93-f6f5-40aa-901a-8c2c03b75958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_fb6268f0-7705-4c53-8b55-1fe5640b8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6a444e93-f6f5-40aa-901a-8c2c03b75958" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_fb6268f0-7705-4c53-8b55-1fe5640b8dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02da75ed-c1a4-4761-9dd3-30405c2e8a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02da75ed-c1a4-4761-9dd3-30405c2e8a0b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:to="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_821de445-2a43-4f5d-a9c0-003d704c5bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_110b96a3-da56-4984-9e52-6ba10e23d4f5" xlink:to="loc_us-gaap_PlanNameDomain_821de445-2a43-4f5d-a9c0-003d704c5bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_6be4b3bd-fa01-41bc-8462-1688ecc1f232" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_821de445-2a43-4f5d-a9c0-003d704c5bc8" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_6be4b3bd-fa01-41bc-8462-1688ecc1f232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:to="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8edba548-61fa-4e55-ab28-df874e7c335e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_94f8ac31-9832-4b82-96f5-e1f13bb83ed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_94f8ac31-9832-4b82-96f5-e1f13bb83ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_cd864cf4-5bd1-40a0-a454-9282c37cb2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1db1da5-fb27-4ab6-88b4-e3bfb39c24b0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_cd864cf4-5bd1-40a0-a454-9282c37cb2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_a0700b16-fbfb-4c8b-9031-32c1a54478b1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8165534-9005-4e80-8b1c-1be492f51d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8165534-9005-4e80-8b1c-1be492f51d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3d733f0-f99e-4e52-a603-f518ec6377bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_99593f2d-557c-4169-852d-c36a12100ffe" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c3d733f0-f99e-4e52-a603-f518ec6377bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcd73b2f-1962-4926-b050-ef46b9754979" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcd73b2f-1962-4926-b050-ef46b9754979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3c899e08-2210-45fa-9e22-5af30ce5a71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3c899e08-2210-45fa-9e22-5af30ce5a71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_337e034f-7014-4815-921b-1f9d4c4b63ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_337e034f-7014-4815-921b-1f9d4c4b63ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0967da36-3ace-481d-8d49-db59a3f857b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_0967da36-3ace-481d-8d49-db59a3f857b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_351de342-cfd8-48e5-af0c-80c86a39583e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_351de342-cfd8-48e5-af0c-80c86a39583e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d36d688b-0d24-4df3-92a5-3c561d39f75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_739e0b4a-7198-4bbe-8577-a31b575c252b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d36d688b-0d24-4df3-92a5-3c561d39f75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b0f5598e-7558-4879-8ecf-566e17c555ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcd73b2f-1962-4926-b050-ef46b9754979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_b0f5598e-7558-4879-8ecf-566e17c555ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcd73b2f-1962-4926-b050-ef46b9754979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c2b1f18-0634-4827-9bff-1e40f5782f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c2b1f18-0634-4827-9bff-1e40f5782f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a907de34-754a-42b3-8bd5-9244931c0cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_a907de34-754a-42b3-8bd5-9244931c0cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_392d73ed-c88a-44ac-b7b0-156ba86839eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_392d73ed-c88a-44ac-b7b0-156ba86839eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d87868a7-21c0-4732-9b1c-138e6ccaea0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d87868a7-21c0-4732-9b1c-138e6ccaea0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_affcbd40-d98d-4912-8913-5f46f0406c59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_806e8dd6-c683-432e-83b2-b179b8ee6a47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_affcbd40-d98d-4912-8913-5f46f0406c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a0d53756-96cf-4cb2-af05-0daeb7e39821" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_dcd73b2f-1962-4926-b050-ef46b9754979" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_a0d53756-96cf-4cb2-af05-0daeb7e39821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansRestrictedStockUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22ffb014-a76c-4008-95bb-008ad6882eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_22ffb014-a76c-4008-95bb-008ad6882eb3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:to="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c8216e-dbf1-4e55-8918-840d6b2f2e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_15406126-bde8-4384-bee7-dd0405051c89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c8216e-dbf1-4e55-8918-840d6b2f2e8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e91ada-92e6-43fd-8d13-a6e73a3ab627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a5c8216e-dbf1-4e55-8918-840d6b2f2e8b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_e0e91ada-92e6-43fd-8d13-a6e73a3ab627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34d079e5-e04a-4dc3-adcd-9b676d592038" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b1e5c5a-32dd-42f4-b2be-45334c852e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b1e5c5a-32dd-42f4-b2be-45334c852e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2840bd73-2a0c-4dce-a2c3-2ffb8929d67e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2840bd73-2a0c-4dce-a2c3-2ffb8929d67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3d67592-adc1-4c74-810c-6bf53fce45ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c3d67592-adc1-4c74-810c-6bf53fce45ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0a6fc258-91a6-48cd-a3c1-20c71732c029" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0a6fc258-91a6-48cd-a3c1-20c71732c029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15d8d868-0e20-4e23-afbb-a869dd0cb684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_fba63352-6ce4-4f53-bd18-6f171b02cd16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15d8d868-0e20-4e23-afbb-a869dd0cb684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f8dc99e8-4680-4321-9f8c-5ba7d9aebf7d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7ab49693-b5c1-4f5a-b868-9eaba17e1266" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_7ab49693-b5c1-4f5a-b868-9eaba17e1266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f254a66d-732d-49f3-8cb2-c7dbfb28b813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f254a66d-732d-49f3-8cb2-c7dbfb28b813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_da3ea7a1-0922-4e46-aac4-9e96161f8221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_da3ea7a1-0922-4e46-aac4-9e96161f8221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_209e58c2-574a-4f1f-80b5-edcc1653a02d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_209e58c2-574a-4f1f-80b5-edcc1653a02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_add9d55a-92bf-4d52-bf72-d45f0c5a451b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1b9a1a7f-5e16-4ad6-953e-acda34dbf596" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_add9d55a-92bf-4d52-bf72-d45f0c5a451b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#EquityIncentivePlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d9adfa7-9ea8-4c15-86ab-19d096994f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7d9adfa7-9ea8-4c15-86ab-19d096994f20" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:to="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb7cda5a-7a94-4617-be0b-4ce995492625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6fdf40d7-4e6a-4559-99c4-9c089e4ce271" xlink:to="loc_us-gaap_PlanNameDomain_fb7cda5a-7a94-4617-be0b-4ce995492625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_bee5f826-87bb-42b2-bec8-7935511031e2" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb7cda5a-7a94-4617-be0b-4ce995492625" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_bee5f826-87bb-42b2-bec8-7935511031e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:to="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51244fbe-afa7-473e-b37e-c786cf846cf3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_cdde637f-a65f-4203-bea5-99153ac19339" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51244fbe-afa7-473e-b37e-c786cf846cf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_e4e7767a-c965-4c5e-87f0-2a1eb6f054e0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_51244fbe-afa7-473e-b37e-c786cf846cf3" xlink:to="loc_srt_DirectorMember_e4e7767a-c965-4c5e-87f0-2a1eb6f054e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6e60156-af27-4b90-a98c-0930694fc4c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c8842b2e-b54a-4755-a0c8-adfab08d149b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_c8842b2e-b54a-4755-a0c8-adfab08d149b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_12b0dec8-ca86-4aa9-8b05-926b5e448872" xlink:href="ardx-20230331.xsd#ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare_12b0dec8-ca86-4aa9-8b05-926b5e448872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockPlans_1c1fe809-055c-41e0-ba8b-4b03c435e9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_ProceedsFromStockPlans_1c1fe809-055c-41e0-ba8b-4b03c435e9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d4c41afd-b578-4312-98da-1af877162593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0fd0e83e-4422-4b6c-9a5f-acc881218d0e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_d4c41afd-b578-4312-98da-1af877162593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#NetLossPerShareComputationofNetLossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_346510e2-8ad4-449c-8fb2-36e142c6de50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_919a3bb2-2720-4384-b92f-89ad4a687aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346510e2-8ad4-449c-8fb2-36e142c6de50" xlink:to="loc_us-gaap_NetIncomeLossAbstract_919a3bb2-2720-4384-b92f-89ad4a687aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ba1f81b-f365-4192-a695-ee5508d0c1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_919a3bb2-2720-4384-b92f-89ad4a687aeb" xlink:to="loc_us-gaap_NetIncomeLoss_0ba1f81b-f365-4192-a695-ee5508d0c1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9f911266-0d14-4d8b-af20-d676bd70eb4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346510e2-8ad4-449c-8fb2-36e142c6de50" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9f911266-0d14-4d8b-af20-d676bd70eb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a54f16c8-cf4b-4f51-8c20-77dd03a1efe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9f911266-0d14-4d8b-af20-d676bd70eb4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_a54f16c8-cf4b-4f51-8c20-77dd03a1efe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12dce4de-e62c-45e4-8aba-54a788c1bf35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_9f911266-0d14-4d8b-af20-d676bd70eb4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_12dce4de-e62c-45e4-8aba-54a788c1bf35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ad390c97-2123-4da1-9dfc-851ece25f02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346510e2-8ad4-449c-8fb2-36e142c6de50" xlink:to="loc_us-gaap_EarningsPerShareBasic_ad390c97-2123-4da1-9dfc-851ece25f02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_f86fca4a-129c-4344-8947-d2b7d066e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_346510e2-8ad4-449c-8fb2-36e142c6de50" xlink:to="loc_us-gaap_EarningsPerShareDiluted_f86fca4a-129c-4344-8947-d2b7d066e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_6dd358be-f7d2-44a3-aa46-59a01520d57a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_6dd358be-f7d2-44a3-aa46-59a01520d57a" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:to="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cd7af919-7f87-4074-9504-02f7fb51bff1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0985dc5d-2b85-4b49-8a88-72cfc22c07d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0985dc5d-2b85-4b49-8a88-72cfc22c07d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_2b53e8b4-b475-4911-8758-1a5218730803" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_2b53e8b4-b475-4911-8758-1a5218730803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_EmployeeStockPurchasePlanMember_8c661c54-a1b9-4ac3-b050-464ba40acf9f" xlink:href="ardx-20230331.xsd#ardx_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dbda9ccc-1802-4d8c-a2be-bbea13928858" xlink:to="loc_ardx_EmployeeStockPurchasePlanMember_8c661c54-a1b9-4ac3-b050-464ba40acf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32f92e27-de1a-4d76-9268-f3e18d51eaae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_e0b3a9f5-4631-4247-99b3-a5d96b8d8672" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32f92e27-de1a-4d76-9268-f3e18d51eaae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84b4532c-0dad-4f47-a3eb-90fb4f2c9ebb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_32f92e27-de1a-4d76-9268-f3e18d51eaae" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_84b4532c-0dad-4f47-a3eb-90fb4f2c9ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="simple" xlink:href="ardx-20230331.xsd#ContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.ardelyx.com/role/ContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2315f7f0-9524-48c7-9a12-3b0e2ebc8004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2315f7f0-9524-48c7-9a12-3b0e2ebc8004" xlink:to="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:to="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_6e693654-353c-4bfc-be86-2d9dac4a1ed3" xlink:to="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_StrezsakVersusArdelyxIncMember_59be7131-94eb-4fbe-9b6a-767560129240" xlink:href="ardx-20230331.xsd#ardx_StrezsakVersusArdelyxIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:to="loc_ardx_StrezsakVersusArdelyxIncMember_59be7131-94eb-4fbe-9b6a-767560129240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ardx_GoVersusRaabMember_d38c9d3b-e8dc-4980-9807-172de037a06a" xlink:href="ardx-20230331.xsd#ardx_GoVersusRaabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_29244737-5712-45f5-bb87-3454c636b060" xlink:to="loc_ardx_GoVersusRaabMember_d38c9d3b-e8dc-4980-9807-172de037a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_ed0bc8da-b536-42db-88f8-ebb691684698" xlink:to="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNewClaimsFiledNumber_25ffcd3f-4259-4e28-be9c-0933dec079eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNewClaimsFiledNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingencyNewClaimsFiledNumber_25ffcd3f-4259-4e28-be9c-0933dec079eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNumberOfDefendants_edcaae1b-40a6-4e03-8b09-607f200ebb81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNumberOfDefendants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingencyNumberOfDefendants_edcaae1b-40a6-4e03-8b09-607f200ebb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f83654a8-766d-4d6b-8151-a2ce323f1bbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_4258f0e4-acb9-43db-aaf0-0dc1df7014c5" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_f83654a8-766d-4d6b-8151-a2ce323f1bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>ardx-20230331_g1.jpg
<TEXT>
begin 644 ardx-20230331_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 Z17AI9@  34T *@    @  U$0  $
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3B1N/?\ 2L6\_P""N&DHY^S^"M0E7'!DU!(SG\$;\Z\JIXE\,T_BQ<?DI/\
M*+/5I^&G$U3X<)+YN*_.2/L"BOBNZ_X*[S/%^Y\ QQOGJ^M%QCZ" ?SJG<?\
M%<-6:%A#X)T^.3LSZB[*/PV#^=<<O%CA=;8AO_MRI^L4=D?"?BA[X=+_ +?I
M_I(^X**^%?\ A[7XB_Z%'1?_  )EH_X>U^(O^A1T7_P)EK'_ (BYPS_S^?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MC6HU*4W2JIQDG9IJS371H****T,PHHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI]Q;R6EQ)%+&\<L;%'1UVLC#@@CL1Z4ROYEVT9_35[ZH**** "BBB@ HHHH
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MX/\ >-?:DOL^D7OWEZ:E%%%?N1^&A1110 4444 %%%% !1110 4444 %%%%
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MDTULT]FC^/<1AZE"K*C6BXRBVFGNFMTPHHHK8Q"BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L#XH?$G2_A%X$U+Q%K,WDV&FQ&1L?>E;HJ*.[,Q"@>I[#FM^O
MSE_X* _M2?\ "[O'W]@:/<%O#'AZ5E1E/RWUR,JTWNHY5/;<?XN/C>.>+:60
M9:\0[.K+2$>\N[\H[OY+=H^RX&X3JY_F4</JJ<=9R[1[+SELOF]DSR?XX?&/
M5?CO\2+_ ,1ZLW[VZ;9!"#E+2$$[(E]@#^))/4FN1HHK^+<5BJN)K2Q%>3E.
M3;;>[;W9_:6%PM+#48X>A%1A%))+9);(****YSH"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ]F_84^!J_&WX\V*7</F:-H(&I7V5RL@0CRXSV^9\9'=0_I7Z=5
MX)_P3K^"_P#PJSX!6VI7,>S5/%A749B1\RPXQ G_ 'P2_P!92.U>]U_8WA?P
MXLJR2$ZBM4K>_+O9_"ODNG1MG\<^*'$;S7.YPIN].C[D>UU\3^<NO5)!1117
MZ,?G(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 0W]C#JEC-:W,4<]O<1M%+&Z[ED1A@J1W!!QBORI_:F^!TW
M[/WQFU30=LITYF^U:;*__+6V<G9SW*D%"?5#7ZN5\[_\%(/@3_PM'X,'7K*'
M?K'A'==#:/FEM3CSE_X" ']@C8ZU^8>*W"_]JY0\127[VA>2[N/VH_<KKS27
M4_3_  IXH_LK-UAZK_=5[1?92^S+[W9^3;Z'YST445_(1_7H4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %.@GDMIDDC=HY(V#*RG#*1R"#ZBFT4 ?I9^PQ^U*G[0?P\^
MPZG,O_"5:"BQWH)P;R/HMP![]&QT;G@,HKW2OR'^#GQ9U3X)?$33O$FD28NK
M&3+Q,?DN8SP\3_[+#CVX(Y K]5OA5\3=+^,/@#3?$6CR^99:E$'"G[\+CAHV
M]&5@0?IZ5_7'A=QM_;."^IXJ7^T4EKWE'92]5M+SL^I_(_BCP3_8V-^N86/^
MSU7IVC+=Q]'O'RNNAT5%%%?JA^5A1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !117,_&+XK:;\%/ASJ?B35F_T73XMRQ X>XD/"1K_ +3,0/;DG@&L<1B*
M>'I2KUGRQBFVWLDM6S;#X>KB*L:%&/-*3226[;T2/#?^"C'[3W_"K/ __"(Z
M/<;/$'B*$_:'C;YK*T.0Q]FDY4>@#'@XK\]ZW/B5\0]3^*_CK4O$.L3>=J&J
M3&60C[J#HJ*.RJH"@>@%8=?Q1QMQ55S[,Y8IW5-:0CVC_F]W]VR1_:W!/"M+
M(<LCA59U'K-]Y?Y+9??NV%%%%?('V 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7;?LZ_"F3XU_&CP_P"'%5VM[ZY#7;*<;+=/GE.>QV*P'N0.]<37VA_P2?\
MA3QXB\:7$7II5BQ'TDF(_P#(0R/]H5]5P3D?]KYU0P4E>+=Y?X8ZO[[6]6?*
M\;9Y_9&2U\;%VDE:/^*6B^Z]_1,^S;:WCL[>.&&-8XHE"(BC"HHX  ]!3Z**
M_N+;1'\.WOJPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H[JUCOK:2&:-)89E*.CC<KJ1@@CN"*DHH
M>NC!-K5'Y/\ [4/P;D^!'QMUK0 K"Q27[1I[$YWVTGS1\]RO*D^J&O/Z^^?^
M"H_P8_X2KX9V'C"TAW7OAN3R+HJ.7M96 R?79)MQZ"1S7P-7\2\?<._V-G57
M"P5J<O>A_AET^3O'Y']M< \1?VSDM+%3=ZD?=G_BCU^:M+YA1117QI]D%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 J(TKJJJ69C@ #))K]9?V:?A8OP9^
M!WAWP^4"75K:B2[P.MQ)\\GUPS$#V K\]_V&OA5_PMG]I'0;>6/S+'2'.JW?
M'&R$@J#[-(8U/LQK]0J_HSP-R/EIU\VFM_<CZ*SE][Y5\F?SGXY9YS5*&4P>
MWOR]7=1^Y<S^:"BBBOZ /Y_"BBB@ HHHH **** "BBB@ HHHH **** "BBJN
MIZW9Z+%OO+RUM$QG=-*L8_,FIE)15Y.R*C%R=HJ[+5%4]+\1:?K@_P!!OK.\
MX)_<3+)T^A-7*(SC)7B[H)1E%VDK,****HD**** "BBB@ HHHH **** "BBB
M@ HHHH SO%WA>S\;^%=2T;4(_-L=4MI+2=?5'4J<>^#P>QK\BOB/X&O/AGX]
MUCP_?+BZTB[DM7.,!]IP&'LPPP]B*_8:OA#_ (*I?"#^P?'^D^,K6+;;Z[%]
MCO& X%Q$/D8GU:/  _Z9&OQ?QIR#ZSED,SIKWJ+L_P#!+3\)6]$V?M'@MG_U
M;,YY;4?NUE=?XXZ_C&_JTCY.HHHK^6S^I HHHH **** "BBB@ HHHH ****
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MZLK ^%G@&W^%OPXT3P[:;6AT>SCMMX&/-91\SX]6;+'W-;]?W5PKDJRG*:&
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M_+T'Q,4LKO<?EAER1#+[88[2>RNQ[5^E=?V?X=\5+/,IC5J/][3]V?JMI?\
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M["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV@N;_MYZ1_5K_"?D_C%GGU+)/JD'[U=\O_;JUE^B?^(]"HHHK^M#^2PHHHH
M**** "BBB@ HHHH **** "BBB@#YR_X*:_%/_A!_@$NB03>7>^*KD6V <-]G
MCQ)*1^/EJ1W$AK\[*^@O^"DWQ3_X3_\ :)GTN%]UEX6MUL%P?E:8_/*WU!8(
M?^N=?/M?QIXGYU_:/$%9Q=X4OW<?^W=__)N;Y6/[+\,,E_LWA^BI*TZO[R7_
M &]M_P"2J/SN%%%%?GQ^@A1110 4444 %%%% !7V%_P2A^*_V+7?$'@NXEQ'
M>H-4LE)X\Q<)*![E?+/TC-?'M==\!OB;)\'?C!X?\21E]FFW:M.J]7A;Y95_
M%&85]-P;G;RG.:&-;M%2M+_#+27W)W]4CYGC+)/[6R:O@DO><;Q_Q+6/WM6]
M&S]<J*CM;J.]MHYH762&90Z.IR&4C((^M25_<R=]4?PR[K1A1110 4444 %%
M%% !1110 4444 %%%% '._%GX>VWQ7^&FN>'+O:(=8M'MPY&?*<CY'^JL%8>
MZU^1>N:+<^&];O-.O(S#>6$[VT\9ZQR(Q5A^!!%?LM7YT_\ !2[X1_\ " ?'
MO^V[>/;8>+(?M8P,*MPF$F'X_(Y]Y#7X7XW9#[;!4LUIK6F^67^&6S^4M/\
MMX_=/!'/O8XVKE51Z5%S1_Q1W2]8Z_\ ;I\ZT445_,Y_3 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** /3OV._BQ_P *<_:%\/ZI))Y5A<S?
M8+XDX7R)OD+-[(Q5_P#@%?JE7XOU^K7[)OQ3/QB_9^\-ZU+()+W[,+6\.<MY
M\1\MR?=MH?Z.*_HCP-SS2OE,W_T\C^$9?^VO[S^=_'+([.AFT%_T[E^,H_\
MMR^X]&HHHK^A#^>PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /*_P!M/XFGX5?LW>)+Z*0QWEY!_9UJ0<,))ODR#ZJI=O\
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MBBB@ HHHH *^SO\ @DW\3\2^)O!LTGW@NKVBG\(IO_:/'L:^,:](_9'^)/\
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ML"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "OT-_X)A_"K_A#/@7-X@GBV
M7GBJY,JDC#?9XB4C'KRWF-[AA7P-X'\)77C[QEI6AV*[KO5KN*TBXR SL%!/
ML,Y/L*_7OPAX8M?!/A33='L4\NSTJUCM(%]$10H_' K]O\$<C]OF%7,YK2DN
M6/\ BE_E&Z?^)'XAXW9Y[#+Z660>M5\TO\,=OODTU_A9HT445_3I_,04444
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MUZ+XE_X#=^J1^E>%.??V=GU.G-VA6]Q^K^%_^!67HV?GG1117\>G]A!1110
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M9:4[S?\ VZM/_)G$^9:***_C<_L@**** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %=5\#OAM-\7_BWX?\-Q;L:I>)',R]4A'S2M^"!C^%<K7UY_P2
MB^%/]I>*M?\ &5Q'F+38AIMF3T,LF&D(]U0*/I*:^FX/R5YMG%# M>[*5Y?X
M5K+\$UZM'S7&&=+*<GKXY/WHQM'_ !/2/XM/T3/M^RLH=-LH;>WC6&"W18XT
M485% P /8 5+117]RI)*R/X9;;=V%%%%,04444 %%%% !1110 4444 %%%%
M!7Y4_M>?%,?&#]H7Q)JT4GF6,=Q]CLR#E?)A_=J1[,07_P"!U^B'[67Q3/P=
M_9^\2:U%)Y=[]F-K9G/S>?*?+0CW7<7^B&OREK^>O'+.M,/E,'_T\E^,8_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *_5+]CSX4_\ "G?V>?#NES1^7?7$'V^]!7#":;YRK>Z
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M/DFBBBOXG/[8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO_ KZ=$T?V-X6Y]_:60TU-WG2]Q_+X7_ . VUZM,****_.3]&"BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ^W?^"1VK^=X=\<6'_/O<VEP/^!K*O_M.OL.OA;_@DIJ?
ME?$+Q=9\?Z1IT,V,?W)".O\ VTK[IK^Q_"FO[3AC#I_9YU_Y/+]&C^./%:A[
M/B?$/^;D?_DD?U3"BBBOT4_.@HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *^=?\ @I_?_8_V8_+X_P!*U:VBZXZ"1_Q^[7T57R[_ ,%8+S9\"-!M]O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M])GDV6/BJ V+ GY1.OSPGZDAD'_72OT<K^R?"_//[2R"ESN\Z7[N7_;OP_\
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M?>^&,K<3X1^<O_2)'PO1117\8G]GA1110 4444 %%%% !1110 4444 %%%%
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M117 =X4J(TKJJJ69C@ #))I*]@_86^%7_"U_VD="AFC\RPT=SJMWE<KMA(*
M^S2&-3GL3UZ5Z&59?4Q^,I8*C\522BOF[7^6[//S7,*> P=7&UOAIQ<G\E>W
MJ]D?H1^S=\+E^#7P/\.>'BFRXL[17N^G-Q)^\EY[X=F ]@*[BBBO[SP>%IX7
M#PPU%6C!**]$K(_@S&8NIBL1/$UG>4VY/U;NPHHHKI.8**** "BBB@ HHHH
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M6O\ P&BH_P"'2GAW_H;M:_\  :*C_B$?$W_/E?\ @<?\P_XBYPS_ ,_G_P"
M2_R/A6BONR'_ ()+>&EE7S/%FN-'GD+!$I/X\_RJW_PZ;\&?]#)XG_.#_P"-
MU4?"'B5[THK_ +?C_F3+Q>X:6U63_P"W)?Y'P117WO\ \.F_!G_0R>)_S@_^
M-UY5^V'^PMX=_9S^$T?B#2]8UJ^N7OXK0QW1B\O:ZN2?E4'/RCO7'F7A?GV
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M_GZT7_P7K_C1_P /,_BE_P _6B_^"]?\:^?:*/\ 7CB#_H,J?^!,/]1^'_\
MH#I_^ H^@O\ AYG\4O\ GZT7_P %Z_XT?\/,_BE_S]:+_P""]?\ &OGVBC_7
MCB#_ *#*G_@3#_4?A_\ Z Z?_@*/H+_AYG\4O^?K1?\ P7K_ (UX%?7LVI7L
MUQ<2--/<.TDDC'+.Q.23[DFHJ*\O,\^S',5%8ZM*IRWMS-NU][7[V1ZF69#E
MV7.3P-&-/FM?E25[;7MVNPHHHKR3U@HHHH _1[_@GK^SQ9_"CX/6?B"ZMT;Q
M#XH@6ZEF9<M!;-\T42GL"NUV]6.#G:,?059_A&VCLO"FEPQ+MCAM(D1?0!
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MK_Z$:^@J^??^"F?_ ":W=?\ 81M?_0C7RO''_)/XS_KW+\CZK@?_ )*#!_\
M7R'YH_.&BBBOX=/[B"BBB@ HHHH **** "BBB@ HHHH ^R_^"3_Q7\J[\1>"
M[B3B4#5K)2>XVQS ?4>4<?[+'UK[5K\E/V=?BBWP9^-?AWQ%N9;>QNU%T!D[
MK=_DE&.YV,V/<"OUIAF6XB62-EDCD 964Y# ]"#7]7^#>>?7,F>"F_>H.W_;
MLM8_CS+T2/Y1\9<C^IYRL;!>[75_^WHV4OPY7ZMCJ***_73\A"BBB@ HHHH
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M .@M7M<-_P#(VPO_ %\A_P"E(\;B+_D4XK_KW/\ ])9^J5%%%?WD?P8%%%%
M!1110 4444 %%%% !1110 5\*_\ !6O_ )*)X1_[!TO_ *-K[JKX5_X*U_\
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M!@[?\_(_F?G+1117\.G]Q!1110 4444 %%%% !1110 4444 %?IU^P5\5?\
MA:G[-FBM-)YE]H0.D7.>N8@/+/J<Q&,D]SFOS%KZB_X)9_%;_A&/B]J/A>XD
MVVOB:U\R!3_S\0 L/IF,R9]=JU^F^$V>?V?GT*4W[E9<C]7K'_R96^;/S/Q9
MR/\ M#(9U8+WZ+YUZ+27_DK;^2/OZBBBOZ_/X_"BBB@ HHHH **** "BBB@
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M$N;]3^'N.L5[?B#&5/\ IY)?^ OE_0****^K/E HHHH **** "BBB@ HHHH
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M,8_[C_'0^P\/X\W$6#7]]'Y]T445_$9_;@4444 %%%% !1110 4444 %%%%
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MGM4BF_)[-?)W7R"BBBO'/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBKWA?0Y/%'B;3M-BXDU&ZBM4^KN%'\ZJ
M$)3DH1W>A,YJ$7.6RU/U?_9T\._\(I\!/!NG[=KV^C6OF#_;,2L__CQ-=G3+
M:W2SMXX8U"1Q*$11_"!P!3Z_T!P>'6'P\*$=HQ2^Y6/\_<9B'B,1.O+>3;^]
MW"BBBNDYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B_\ X*W^
M%CM\%ZVB\?Z38S-_W[>,?^C*^+Z_1W_@IGX1/B3]F"YO%7<V@ZA;WN1U"DF
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MKQ.=82CWJ0OZ<R;_  N?/\68I8;)<77[4YV]>5I?C8_2&BBBO[L/X3"BBB@
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MX@<;UW/$Q]ROF#)[(HK[:K@?VG?A0OQJ^!GB'0%C$EY/;&:R]1<1_/'@]LL
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MYX^DM;?*5U\C^U/#G/?[5R&C6D[S@N27K'2_SC9_,****^&/N HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** -+P;X9G\:^+]
M*T>U_P"/C5KR*SBX_BD<(/U-?L-I6F0Z+I=M9VZ^7;VD2PQ+_=50 !^0K\V?
M^"=G@/\ X3?]J'1YGC\RWT&&74Y>. 579&?PD=#^%?I=7]->!N6>SR_$8^2U
MJ245Z05_SD_N/YE\<LS]IF&'P$7I3BY/UF[?E%/YA1117[D?AH4444 %%%%
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MD,WS-8?#2O2HW2:V<G\37=:)+TNM&%%%%?J1^6A1110 4444 %%%% !1110
M4444 !.!7X[_ !"\1?\ "7^/]<U;.[^U-0N+O///F2,_?GOWK]7?CKXJ_P"$
M'^"_BO5MRJ]AI-S+'DXS((VV#\6P/QK\BJ_G;QVQEYX3"+HIR?SY4OR9_17@
M3@[0Q>+?5PBOES-_F@HHHK^?#^@@HHHH **** "BBB@ HHHH **** "BBB@
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M>_\ A1\RT445_,)_3P4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M #/Z]\(\X^N\/PHR?O46X/TWC^#M\@HHHK\P/T\**** "BBB@ HHHH ****
M"BBB@ HHHH ]6_8C\;_\(%^U#X2NF?9#>7?]GRYZ$3J8AGZ,RG\*_4JOQET[
M4)M)U""ZMW:.XMI%EC<=493D'\"*_7[X8^.+?XE_#O1/$%MM\G6+**Z"J<^6
M64%E^JMD'W%?TAX%YHI8;$Y=)ZQDIKT:Y7]UE]Y_-_CIE;CB,-F,5I).#]4^
M9??=_<;E%%%?OA^!A1110 4444 %%%% !1110 4444 %<W\5OA/H?QI\%W.@
M^(+-;NQN/F!!VR0./NR1M_"PSU]"0<@D'I**QQ&'I5Z<J-:*E&2LTU=-/HT;
M8?$5:%6-:C)QE%W36C375,_,/]I[]B_Q+^SIJ$MWY<FL>&6?]SJ4,?\ J@3P
MLRC[C=L_=/8YX'C=?LY=VD5_:R03Q1S0S*4DCD4,KJ>""#P0?0U\O_M _P#!
M,C0/'4T^I>"[F/PUJ,F6-DZEK"5O]G'S19_V=R^BBOYTXP\&ZU.4L5D7O1W]
MFWJO\+>Z\GKYL_HO@_QDHU(QPN>^[+;VB6C_ ,26S\UIY(^ Z*[;XM?L[^,O
M@A>-'XCT.\LX-VU+M5\RUE]-LJY7GT)!YY KB:_#,5@Z^%JNCB8.$ENI)IKY
M,_<\+C*&*I*OAIJ<7LXM-/YH****YSH"BBB@ HHHH **** "BBB@ HHHH **
MGTW3+G6;^*UL[>>ZNIVV10PQF221O0*.2?85]$_ W_@FIXR^(KPWGB5AX2TI
ML-LF7S+V4=>(L_)Z?.01_=->QD_#^8YK5]CE])S?6RT7JWHOFSQ\XX@R[*J7
MMLPJJ"Z7>K]$M7\DSY_\+>$]3\<:];Z7H]C=:EJ%VVR*WMXR[N?H.PZDG@#D
M\5]Z?L=?L 6OPAEMO$GB];?4/$RXDMK4$26^EMU!ST>4?WONJ>F2 U>R?!3]
MG;PG^S_HQM?#>FI#-*H6XO9CYEU=8_OR8Z=]HPH/0"NXK^DN"/"?#97..-S-
MJI66J7V(OOK\37=V2Z*Z3/YMXW\6,3FD)8++$Z=%Z-_;DNVGPI]E=OJ[-H**
M**_8C\="BBB@ HHHH **** "BBB@ HHHH **** / ?\ @I5XU7PK^S!?68;;
M-X@O;>P3'WL!O.;\-L1!_P![WK\W:^MO^"K_ ,2%U7Q[X=\+0R;ETBU>]N0#
MQYDQ 4'W")GZ25\DU_'_ (M9HL9Q%4A%W5)1A]VK^Z4FOD?V!X2Y6\'P[3G)
M6=5RG]^B^^,4_F%%%%?F9^F!1110 4444 %%%% !1110 4444 %%%% !1110
M 5]+_P#!+_XK?\(=\;;KP[<2;;/Q5;%$!. +B++I^:&0>Y(KYHK2\&>*[OP)
MXNTS6K!MEYI-U'=PGMN1@P!]CC!'<&O<X;SB65YI0Q\?L23?G':2^<6T>'Q)
MD\<URNO@)?;BTO*6\7\I),_8ZBLOP5XMM/'G@_2];L6WV>K6L=W">^UU# 'W
M&<$=B*U*_NVG4C4@JD'=-73[I['\)5*<J<W3FK-.S79H****L@**** "BBB@
M HHHH **** "BBB@ KQ?]OGX2_\ "UOV<-7,,7F:AX?_ .)M:X'S?NP?,4=^
M8B_'<A?:O:*;-$MQ$T<BK)'("K*PR&!Z@BO.S?+:>88*K@:WPU(N/I=;^J>J
M\ST<HS*IE^-I8ZC\5.2EZV>WHUH_(_&&BNX_:0^%;_!?XV^(O#NUEM[.Z+VA
M/\5N_P \1SW^1@#CN#7#U_!N,PM3"XB>&K*TH-Q:\T[,_O+!XNGBL/#$T7>,
MTI)^35T%%%%<QTA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7:?L[?#<_%SXW^&?#YC\R'4+Y/M*_],$_>2_^0U:N+KZX_P""47PP_M3Q
MKX@\73QYCTJW73[4D?\ +64[G(]U10/I+7TW!N3_ -J9UA\$U>,I)R_PQ]Z7
MX)KU/F>,LX_LO)<1C4[2C%J/^*7NQ_%I^A]T ;1@4445_<Q_#(4444 %%%%
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MW(6BBBOZ,/YS"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>]0E?_MV5D_QY7Z)GV%1117]6'\IA1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!F98"K@<74P=;XJ<G%^J=O\ A@HHHKN.$**** "BBB@ HHHH **** "BBB@
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M445XY[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI+[D[KS2/R/HJ2ZM9+&ZDAF1HYH6*.C#!5@<$'Z&HZ_AMW6C/[D3NKH****
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MPN)I8BC'$4'S0DDTUU3U3"BBBL#<**** "BBB@ HHHH **** "BBB@ HHHH
M**** "O0O@7^T_XP_9ZU'S- U$FQD??/IUR#):3GW7(*M_M(5;@<XXKSVBNK
M X[$8.LL1A9N$X[-.S_K\SEQV!P^,HO#XJ"G"6Z:NOZ_(_2+X"?\%#O!7Q>2
M&SU:9?"FN287R+V0?9IF_P"F<W"\^C[3DX&>M>^JP=0RD,K#(([U^,%>H_!3
M]L3QY\"?)M]*U9KS2HN!IM^#/; >BC(9/^ ,M?NG#/C94@E1SNGS+^>"2?\
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M@?C5I^FS1L=%T\B]U1\<>2I'[OZNV%]0"3VK]2H($M8$CC18XXU"HBC"J!P
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M_A?G;JS^CO!GB[GIO(L3+6-Y4[]5O*/R^)>5^B1XO1117X"?OP4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5J>$O&VL> M56^T/5-0TF\
M7CSK2=H7(]"5(R/8\&LNBM*=2=.2G3;36S6C7S(J4X5(N%1)I[IZI_(^C/AO
M_P %.?B%X/$<.L+IOB>V7 )N8?(N,>@>/ _%E8U[Q\/_ /@J;X%\1>7'KVGZ
MQX<F;[S[!>6Z_P# DPY_[]U^?=%?>93XH<18"T57]I%=)KF_'XO_ "8^"S;P
MOX=Q]Y.A[.3ZTWR_A\/_ )*?K7X*_:-\!_$0*-'\6:'>22?=A-TL<Q_[9OA_
MTKM:_%^NC\(_&#Q7X!VC1/$FN:4J\;+6^DC0CT*@X(]B*_0\O\=IK3'85/SA
M*W_DK3_]*/SS,/ F+UP.*?I.-_\ R9-?^DGZ^T5^9GAC_@H;\5_#>Q6\11:E
M"G2.]LH9,_5E4.?^^J[WP_\ \%8O&%H%&I^'/#E\JX!-OYUNS=.N7<9Z]!CG
MI7V&#\9N'JO\7GI^L;_^DN1\?B_!CB&E_"Y*GI*W_I2B?>U%?'.C?\%<K*50
M-0\#W4+ <M;ZFLN3]&C7'TR?QKI],_X*N> ;@A;K1?%ELQ.,K!!(H'J3YH/Y
M U[]#Q*X9J_#BXKU4H_G%'@5_#7B:E\6$D_1QE^4F?3]%?/5G_P4Y^%]RBEY
MM>MR3C$EADCW^5C6BG_!1WX2NZJ=>O%!."QTRXP/R2O2AQMP_+58RE\YQ7YL
M\V?!/$$='@ZORA)_DCW2BO%_^'A7P?\ ^AN_\I5[_P#&:/\ AX5\'_\ H;O_
M "E7O_QFMO\ 6[(O^@VC_P"#(?\ R1C_ *HY[_T!5O\ P7/_ .1/:**\7_X>
M%?!__H;O_*5>_P#QFH;O_@HG\(K95*>)YKC)Y$>EW8Q_WU&*'QAD25_KM+_P
M9#_,%P?GS=OJ57_P7/\ R/;J*\%N_P#@I1\*;95*:KJ5QD\B/3I1C_OH"LC4
M?^"I?PULMWEVOBF\P<#R;*(9]_GE6N:IQUP]#?&4_E)/\KG33X%XAG\.#J?.
M+7YV/I&BODW5O^"M'A>$-]A\*Z]<GG'GS10Y]/NEZY77/^"N.H3!AIO@FSM^
MRM<ZDTWKR0L:>W&?7FO*Q'BEPQ1WQ*;\HS?Y1M^)ZN'\+>)ZNV&:7G*"_.5_
MP/MRBOSK\1_\%0OB9K.X6B^'M(4_=-M9&1@/K*[@G\/PKSSQ5^V!\3O&087O
MC77%5LAEM)A9J0>H(A"#'M7S>,\;<DIZ4*=2;]$E][=_P/I,'X)9W4UKU*<%
MZMO[DK?B?J/XB\5Z7X0LOM.K:EI^EV_/[V[N$A3CKRQ KR?QW_P4 ^%O@7>G
M_"0?VQ<)_P LM+A:XW?1^(__ !^OS/U+5+K6;MKB\N+BZG?[TDTAD=OJ3S5>
MOB\R\<\?4NL#AXP\Y-R?X<J_,^TRWP,P%.SQV(E/RBE%?CS/\C[*^(G_  5H
MN)1)%X3\*Q0\_+<ZK,7)'_7*/&#_ -M#7S[\3_VM_B%\7?,CU?Q-?+9R9!L[
M1OLMOM/\)6/&X?[^XUYO17YOG''.>YFG'%XF7*_LKW8_-1LG\[GZ1D_ V198
MU+"8>/,OM/WI?)RNU\K!1117R9]8%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MZ#\!OVF_%G[.VL&?0;[=8S.&N=.N 9+6Y^J_PM_M*0W'7'%>?45U8''8C!UH
MXC"S<)QV:=G_ %^9RX[ X?&498?%04X2W35T_P"NG8_0_P"$O_!3?P+XUMXH
M?$2W?A74& #>:AN+5F_V9$&1_P "50/6O;?#GQC\)>+XE?2_$_A_4 W007\4
MC#V(#9!X/!YXK\@Z*_7\K\;LVH04,;2C5MUU@WZVNONBC\AS3P1RFO-SP56=
M*_3227I>S^^3/V3_ .$DT[_G_LO^_P"O^-'_  DFG?\ /_9?]_U_QK\;**]G
M_B/%3_H"7_@S_P"T/%_X@/3_ .@U_P#@O_[<_9";Q7I=M$TDFI:?'&HR6:X0
M ?CFJO\ PLCP[_T'M%_\#HO_ (JOQYHJ9>/%;I@U_P"!O_Y J/@/1^UC'_X
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M/!G_ $-WAC_P:0?_ !5?D-12_P"([8O_ *!(_P#@3_R'_P 0)PG_ $%R_P#
M5_F?K1XP^(G@+QOX3U/1K[Q9X9>SU:UDM)P-4@SL=2IQ\W7!K\I/$FBMX;\1
M:AIS36]RVGW,EL9H'#Q2E&*[E8<%3C((Z@U2HKX'C;CB7$;I2JT%3E3OJFW=
M.VCNELUIZL^]X)X'CPXJL:5=U(U+.S25FKZJS>]]?1!1117P9]X%%%% !111
M0 4444 %%%% !7T7_P $Z?V<O^%M_%'_ (2/4H-V@^%I%EPP^6ZN^L<?N%^^
MWT4'AJ\(\$>#-0^(GB[3]#TF!KG4=4G6"",=V/<GLH&23V )K]7O@7\(-/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%?6'["O["S>.WM/&7C*T*Z&I$NG:=*N#J)ZB60?\\?1?X^OW?O>YP[P[C,
MZQD<%@HW;W?2*ZMOLOO;T6IX?$7$6#R7!RQN-E9+9=9/HDNK?W):O0N?L&?L
M-_\ "3FQ\=>,+?\ XEJE9]*TZ0?\?9'*S2#_ )Y]U7^+J?EP&^Y*1$6)%55"
MJHP !@ 4M?V7PKPO@\BP2PF%5WO*763[OR[+HO.[?\:<5<48S/<:\7BGIM&*
MVBNR\^[ZOY)%%%%?2GS04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?[8?[&&F_M%:-)JFFK#
MI_C"UBQ!<_=CO57I%-_(/U7CJ.*]THKS<WR?"9GA98/&P4H2_!]&GT:Z,]+*
M,XQ>68J.,P4W&<?Q75-=4^J/QO\ %/A74O!'B"ZTG5K*XT_4;&0QSV\R[7C;
M_ ]01P001D&L^OT^_:S_ &0='_:6\/>>OEZ=XHL8BME?@?*XZB*;'+1DYP>J
MDDC/*G\W/B'\.]8^%7BZ\T/7K&6PU*R;:\;]&'9E/1E/4,.#7\?\;<"XOA_$
M>][]&3]V?Z2[2_![KJE_8'!/'6$X@P_N^Y6BO>A^L>\?Q6SZ-XE%%%?"GW04
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>NWEJ_GGCOPC=Y8_(8^<J7ZP_P#D?_ >D3^AN!/%Q/EP&?2\HU?TG_\ )?\
M@75GP+15[Q+X9U#P;KMSIFJV=QI^H6;^7-;SH4DC/N#^>>A'-4:_GV<)0DX3
M5FM&GNF?T%"I&<5.#NGJFMF@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVV[MA11174<H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!YK^T1^RQX7_:/T3RM6M_LNJPH5M-4MU N+?T!_OID_<;CDXP>:_/
M']H3]EOQ5^SCK7DZQ:_:-,F<K:ZG;@M;W'L3_ _^RV#P<9'-?JQ5+Q%X<T_Q
M=HMQINJ6=MJ%A=ILFM[B,21R#T(/%?G/&GAOE^>Q=>'[NOTFEH_*:Z^NZ\TK
M'Z-P7XD9AD4E0G^\H=8-ZKS@^GIL_)ZGXV45]>?M1?\ !-&ZT'S]:^':S7]G
MR\NC2/NN(1U_<L>9%_V6^?C@L3@?(]Y9S:==R6]Q%)!/"Q22.12KQL.""#R"
M/0U_+'$'#.8Y+B/J^/I\O9K6,O.+Z^FZZI']3\/\39=G6'^L8"IS=T])1\I+
MIZ[/HV1T445X![X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M=_&O]E?P3\?+=CKVDHNH;=J:C:$0WB>GS@?,!V#A@/2OCWXW?\$R/%W@5IKS
MPK/'XJTU3D0@"&^C'NA^5\>JG)_NBOT&HKXGB3P_R;.KSQ%/EJ/[<=)?/I+Y
MIGVW#?B!G.2VAAZG-37V):Q^76/R:/QGU;2+O0-1FL[ZUN+*[MVV2P3Q&.2-
MO1E8 @^QJO7ZY_%/X%^$_C3IWV?Q+H=EJ6U=L<S+LN(?]R5<.OT!P>X-?*GQ
MF_X)3W%N9;SP+K2W"9+#3M3.UQ[),HP?0!E'3EC7X/Q#X.YO@;U, U7AY:37
M_;KW_P"W6V^Q^\</>,648ZU/'IT)^>L'_P!O+;_MY)+N?&]%=)\1_@_XH^$6
MI?9/$FAZAI$I)5&FC_=R_P"Y(,H_U4FN;K\GQ&'JT*CI5HN,ENFFFO5/4_6,
M/B*5>FJM"2E%[---/T:T"BBBL38**** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBK6BZ'?>)-2BLM.L[J_O)SMC@MHFEDD/H%
M4$G\*J,7)\L5=LF4E%<TG9(JT5])?!W_ ()E^-_'ABN?$4EOX3T]N2LW[^\8
M>T2G"^GSL"/0U]9?!;]B/X?_  3,5Q::4-6U6/G[?J6)Y5/JBX")]54''<U^
ME</^%.>9E:I5A[&F^L]'\H[_ 'V7F?FO$'BMD>6WA2G[:IVAJOG+;[KOR/AG
MX)_L0^/OC=Y-Q;:6='TF3G^T-2S#&P]47&]_8JNWW%?8GP._X)U>!?A1Y%YJ
ML3>+-8C^8S7R 6R-_L0<K_WV7/TKWZBOWCAOPMR7*K5)Q]M47VIV:3\H[+RO
M=KN?@_$GBEG6:WI0E[&F_LPNFUYRW?G:R?8;%&L,:HBJJ* JJHP !V%.HHK]
M(/S<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"KK.B6?B+39+/4+.UOK.8;9(+B)98Y!Z%6!!_&OG_XM_\
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M5I'_ ,!5E\VK^84445](?-A1110 4444 %%%% !1110 4444 %%%% !1110
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MKK:\O_ I7E^)^<YMQ?G.976-Q,I)]+VC_P" QM'\ HHHKZ0^;"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?]\J/0?E6S117O4J-.G'EIQ279*QX-2M4J2YJC;?=NX4445H9A1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881567680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Apr. 28, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36485<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARDELYX,&#160;INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-1303944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Fifth Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">745-1700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARDX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,462,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001437402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881932512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 92,487<span></span>
</td>
<td class="nump">$ 96,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">37,886<span></span>
</td>
<td class="nump">27,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">12,120<span></span>
</td>
<td class="nump">7,733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">4,823<span></span>
</td>
<td class="nump">3,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingCurrent', window );">Prepaid commercial manufacturing</a></td>
<td class="nump">13,835<span></span>
</td>
<td class="nump">13,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,896<span></span>
</td>
<td class="nump">5,112<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">167,047<span></span>
</td>
<td class="nump">153,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">40,124<span></span>
</td>
<td class="nump">25,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">7,972<span></span>
</td>
<td class="nump">9,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">1,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">774<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">217,019<span></span>
</td>
<td class="nump">190,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">10,513<span></span>
</td>
<td class="nump">10,859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">5,074<span></span>
</td>
<td class="nump">7,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">26,880<span></span>
</td>
<td class="nump">26,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="nump">4,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">11,053<span></span>
</td>
<td class="nump">12,380<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">63,063<span></span>
</td>
<td class="nump">65,603<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">4,814<span></span>
</td>
<td class="nump">5,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, non-current</a></td>
<td class="nump">11,498<span></span>
</td>
<td class="nump">9,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DeferredRoyaltyObligationNoncurrent', window );">Deferred royalty obligation related to the sale of future royalties</a></td>
<td class="nump">12,223<span></span>
</td>
<td class="nump">11,254<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">91,598<span></span>
</td>
<td class="nump">91,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized; 214,462,050 and 198,575,016 shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022, respectively.</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">932,330<span></span>
</td>
<td class="nump">878,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(806,910)<span></span>
</td>
<td class="num">(780,137)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">125,421<span></span>
</td>
<td class="nump">98,329<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 217,019<span></span>
</td>
<td class="nump">$ 190,066<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DeferredRoyaltyObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Royalty Obligation, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DeferredRoyaltyObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881523296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">214,462,050<span></span>
</td>
<td class="nump">198,575,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">214,462,050<span></span>
</td>
<td class="nump">198,575,016<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331882639168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 11,369<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">1,537<span></span>
</td>
<td class="nump">85<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">9,093<span></span>
</td>
<td class="nump">8,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">26,803<span></span>
</td>
<td class="nump">19,339<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">37,433<span></span>
</td>
<td class="nump">28,275<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(26,064)<span></span>
</td>
<td class="num">(27,807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,028)<span></span>
</td>
<td class="num">(746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfAdvanceRoyalty', window );">Non-cash interest expense related to the sale of future royalties</a></td>
<td class="num">(969)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="nump">484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income taxes</a></td>
<td class="num">(26,759)<span></span>
</td>
<td class="num">(28,069)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,773)<span></span>
</td>
<td class="num">$ (28,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common stock - basic (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common stock - diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per share - basic (in shares)</a></td>
<td class="nump">207,023,127<span></span>
</td>
<td class="nump">130,934,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net loss per share - diluted (in shares)</a></td>
<td class="nump">207,023,127<span></span>
</td>
<td class="nump">130,934,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,773)<span></span>
</td>
<td class="num">$ (28,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(26,739)<span></span>
</td>
<td class="num">(28,153)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">11,355<span></span>
</td>
<td class="nump">450<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember', window );">Product supply revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfAdvanceRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfAdvanceRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductSupplyRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881703872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,182,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 82,617<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 795,540<span></span>
</td>
<td class="num">$ (712,930)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,907,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">5,921<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">5,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">3,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="num">(82)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(28,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,071)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136,330,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">64,190<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">805,265<span></span>
</td>
<td class="num">(741,001)<span></span>
</td>
<td class="num">(88)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198,575,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">98,329<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">878,500<span></span>
</td>
<td class="num">(780,137)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of options (in shares)</a></td>
<td class="nump">36,000<span></span>
</td>
<td class="nump">36,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock upon vesting of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,773<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,477,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock in at the market offering</a></td>
<td class="nump">50,719<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">50,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gains (losses) on available-for-sale securities</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(26,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26,773)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,462,050<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 125,421<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 932,330<span></span>
</td>
<td class="num">$ (806,910)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884041616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,773)<span></span>
</td>
<td class="num">$ (28,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Non-cash lease expense</a></td>
<td class="nump">902<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,912<span></span>
</td>
<td class="nump">3,722<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Change in derivative liabilities</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnRestructuringOfDebt', window );">Debt refinancing costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Gain on sale of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(710)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of long-lived assets</a></td>
<td class="nump">429<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense</a></td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,387)<span></span>
</td>
<td class="num">(3,892)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(16,601)<span></span>
</td>
<td class="num">(3,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense', window );">Prepaid commercial manufacturing</a></td>
<td class="num">(268)<span></span>
</td>
<td class="num">(9,393)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(774)<span></span>
</td>
<td class="nump">9,086<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(346)<span></span>
</td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="num">(2,474)<span></span>
</td>
<td class="nump">882<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(937)<span></span>
</td>
<td class="num">(836)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued and other liabilities</a></td>
<td class="num">(1,396)<span></span>
</td>
<td class="num">(1,041)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">3,807<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(44,795)<span></span>
</td>
<td class="num">(27,620)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and redemptions of investments</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">27,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(20,763)<span></span>
</td>
<td class="num">(25,763)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(9,777)<span></span>
</td>
<td class="nump">2,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt', window );">Proceeds from 2022 Loan, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSecuredDebt', window );">Payments for 2018 Loan, net of costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(33,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="nump">50,719<span></span>
</td>
<td class="nump">5,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">50,919<span></span>
</td>
<td class="num">(63)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(3,653)<span></span>
</td>
<td class="num">(25,351)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">96,140<span></span>
</td>
<td class="nump">72,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">92,487<span></span>
</td>
<td class="nump">47,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Cash paid for income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplementary disclosure of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DerivativeIssued', window );">Issuance of derivative in connection with issuance of loan payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 375<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DerivativeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DerivativeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Prepaid Commercial Manufacturing Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2443-110228<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnRestructuringOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6402221&amp;loc=d3e15743-112638<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnRestructuringOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331887593808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">ORGANIZATION AND BASIS OF PRESENTATION<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ardelyx, Inc. (&#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#8220;IBS-C&#8221;). In April 2023, we resubmitted a New Drug Application (&#8220;NDA&#8221;) to the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the approval of XPHOZAH (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease (&#8220;CKD&#8221;) on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy, under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery phase asset, RDX020 for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, which is the development and commercialization of biopharmaceutical products.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2022. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2023, or for any other interim period or future year.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of approximately $130.4&#160;million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of March&#160;31, 2023 is $806.9&#160;million. Our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these condensed financial statements on May&#160;3, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these condensed financial statements. We plan to address our operating cash flow requirements with our current cash, cash equivalents and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, our potential receipt of anticipated milestones payments from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash, cash equivalents and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note 2 to our audited financial statements for the fiscal year ended December&#160;31, 2022, included in our Annual Report on Form 10-K. There have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements subsequent to filing our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331886422080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text">CASH, CASH EQUIVALENTS AND INVESTMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and short-term investments as of March&#160;31, 2023 and December&#160;31, 2022 are summarized below (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,393&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist of money market funds with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive loss within stockholders&#8217; equity on our condensed balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income, net, in the statement of operations and comprehensive loss.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the short-term available-for sale securities held as of March&#160;31, 2023 and December&#160;31, 2022 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired or subject to credit losses, we write it down through the statement of operations and comprehensive loss to its fair value and establish that value as a new cost basis for the investment. Our unrealized losses as of March&#160;31, 2023 and December&#160;31, 2022 were not material. We determined that none of our available-for-sale securities were other-than-temporarily impaired as of March&#160;31, 2023 and December&#160;31, 2022, and no investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884456032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and the 2022 Exit Fee, as defined and discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2023 and December&#160;31, 2022, due to their short-term nature. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have not recorded an allowance for credit losses for these securities as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of March&#160;31, 2023 and December&#160;31, 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 2 inputs used to estimate the fair value of the liability.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of March&#160;31, 2023 and December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be paid to us by Kyowa Kirin Co., Ltd. ("Kyowa Kirin") over the life of the agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of the liability.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884530800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text">INVENTORY<div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:64.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Prepaid commercial manufacturing of $13.8&#160;million and $13.6&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, consisted of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884595920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Product Revenue, Net</a></td>
<td class="text">PRODUCT REVENUE, NET<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $11.4&#160;million and $0.5 million during the three months ended March&#160;31, 2023 and 2022, respectively. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up 22.2%, 21.6%, and 20.8%, respectively, of our product sales, net during the three months ended March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Wholesaler and GPO Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884520608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and Licensing Agreements</a></td>
<td class="text">COLLABORATION AND LICENSING AGREEMENTS <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kyowa Kirin Co., Ltd. (&#8220;Kyowa Kirin&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, we entered into an exclusive license agreement with Kyowa Kirin (&#8220;2017 Kyowa Kirin Agreement&#8221;), under which we granted Kyowa Kirin an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 Kyowa Kirin Agreement, Kyowa Kirin is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for Kyowa Kirin&#8217;s use in development and commercialization throughout the term of the 2017 Kyowa Kirin Agreement, provided that Kyowa Kirin may exercise an option to manufacture the tenapanor drug substance under certain conditions. In October 2022, we entered into a Commercial Supply Agreement with Kyowa Kirin to further define the obligations of the parties with respect to the commercial supply of tenapanor drug substance (&#8220;2022 Kyowa Kirin Supply Agreement&#8221;). As detailed below under the heading &#8220;Deferred revenue&#8217; we have received advanced payments from Kyowa Kirin for the manufacturing of tenapanor drug substance that will be used to satisfy Kyowa Kirin needs. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed these arrangements in accordance with Accounting Standards Update (&#8220;ASU&#8221;) No. 2014-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers (Topic 606) and related amendments (&#8220;ASC 606&#8221;) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and concluded that the contract counterparty, Kyowa Kirin, is a customer. Under the terms of the 2017 Kyowa Kirin Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30.0&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 Kyowa Kirin Agreement, and as such, each of the performance obligations is distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the 2017 Kyowa Kirin Agreement, Kyowa Kirin paid us an up-front license fee of $30.0&#160;million. We may be entitled to receive up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0&#160;million in total development and regulatory milestones, of which $20.0&#160;million has been received and recognized as revenue as of March&#160;31, 2023. We may also be eligible to receive approximately &#165;8.5&#160;billion for commercialization milestones, or approximately $64.1&#160;million at the currency exchange rate on March&#160;31, 2023, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future royalties and commercial milestone payments we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments was fully constrained at March&#160;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, we entered into a second amendment to the 2017 Kyowa Kirin Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and Kyowa Kirin have agreed to a reduction in the royalty rate payable to us by Kyowa Kirin upon net sales of tenapanor for hyperphosphatemia in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the future commercial milestones and royalties we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, Kyowa Kirin agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment due following Kyowa Kirin's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following Kyowa Kirin&#8217;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, we announced that Kyowa Kirin submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from Kyowa Kirin for an aggregate of $35.0 million for milestone payments and payments under the 2022 Amendment. We received these payments during the fourth quarter of 2022 and recorded them as licensing revenue on our statement of operations and comprehensive loss. The remaining variable consideration related to the reduction in the royalty rate was fully constrained at March&#160;31, 2023. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the 2017 Kyowa Kirin Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#8220;Fosun Pharma&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into an exclusive license agreement with Fosun Pharma ("Fosun Agreement") for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$12.0 million in up-front license fees which was recognized as revenue when the agreement was executed. Based on our assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be entitled to receive development and commercialization milestones of up to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.0 million, of which $3.0 million has been received and recognized as revenue as of March&#160;31, 2023, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%. The variable consideration related to the remaining development milestone payments was fully constrained at March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the Fosun Agreement. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Knight Therapeutics, Inc. (&#8220;Knight&#8220;) &#160;</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, we entered into an exclusive license agreement with Knight Therapeutics, Inc., ("Knight Agreement") for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on our assessment, we determined that the license and the manufacturing supply services were the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Knight Agreement, we received a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.3 million non-refundable, one-time upfront payment in March 2018 and may be eligible to receive additional development and commercialization milestone payments worth up to CAD 22.2&#160;million, or approximately $16.3 million at the currency exchange rate on March&#160;31, 2023, of which $0.7 million has been received and recognized as revenue as of March&#160;31, 2023. We are also eligible to receive royalties ranging from the mid-single digits to the low twenties throughout the term of the agreement, and a transfer price for manufacturing services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The variable consideration related to the remaining development milestone payments was fully constrained at March&#160;31, 2023.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the Knight Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AstraZeneca AB (&#8220;AstraZeneca&#8221;)</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2015, we entered into a termination agreement with AstraZeneca (the &#8220;AstraZeneca Termination Agreement&#8221;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or other NHE3 products, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of March&#160;31, 2023, to date in aggregate, we have recognized $16.4 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $11.9 million. During the three months ended March&#160;31, 2023, we recognized and recorded $1.2 million as cost of revenue related to the AstraZeneca Termination Agreement. During the three months ended March&#160;31, 2022 we recognized $0.1 million as cost of revenue related to the AstraZeneca Termination Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period, which are all attributable to the 2017 Kyowa Kirin Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884541888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Royalty Obligation Related To The Sale Of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvanceRoyaltiesAbstract', window );"><strong>Advance Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetRetirementObligationDisclosureTextBlock', window );">Deferred Royalty Obligation Related To The Sale Of Future Royalties</a></td>
<td class="text">DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, we and HealthCare Royalty Partners IV, L.P. (&#8220;HCR&#8221;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#8220;HCR Agreement&#8221;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#8220;Royalty Interest Payments&#8221;) that we may receive under our 2017 License Agreement with Kyowa Kirin based upon Kyowa Kirin's net sales of tenapanor in Japan for hyperphosphatemia. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $10.0 million upfront payment, and we are eligible to receive a $5.0 million payment following Kyowa Kirin's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $5.0 million payment in the event net sales by Kyowa Kirin in Japan exceed a certain annual target level by the end of 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 Kyowa Kirin Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 Kyowa Kirin Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 Kyowa Kirin Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 Kyowa Kirin Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 Kyowa Kirin Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received the $10.0 million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation related to the sale of future royalties ("deferred royalty obligation") on our balance sheet. Due to our ongoing manufacturing obligations under the 2017 Kyowa Kirin Agreement, we account for the proceeds as imputed debt and therefore will recognize royalties received under the arrangement as non-cash royalty revenue. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from Kyowa Kirin. As part of the sale, we incurred approximately $0.4 million in transaction costs, which, along with the deferred royalty obligation, are being amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by Kyowa Kirin, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be received from Kyowa Kirin under the 2017 Kyowa Kirin agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to HCR are made in U.S. dollars while the underlying sales of the products by Kyowa Kirin are made in Japanese yen, and other events or circumstances that could result in reduced royalty payments from Kyowa Kirin, which are not within our control, and all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the deferred royalty obligation. We periodically assess the estimated royalty payments from Kyowa Kirin and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation. As of March&#160;31, 2023, our effective interest rate used to amortize the liability is 34.4%. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we recognized approximately $1.0 million of non-cash interest expense for the amortization of the deferred royalty obligation. As of March&#160;31, 2023, we have received no royalty payments from Kyowa Kirin and, therefore, the deferred royalty obligation has not begun to be reduced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetRetirementObligationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7569-110849<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2175671<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6392692&amp;loc=d3e7535-110849<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetRetirementObligationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884584000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowing</a></td>
<td class="text">BORROWING <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solar Capital and Western Alliance Bank Loan Agreement</span><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#8220;2018 Lenders&#8221;). The 2018 Loan Agreement provided for a loan facility for up to $50.0 million with a maturity date of November&#160;1, 2022 (the &#8220;2018 Loan&#8221;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">SLR Investment Corp. Loan Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 23, 2022 (&#8220;Closing Date&#8221;), we entered into a loan and security agreement (&#8220;2022 Loan Agreement&#8221;) with SLR Investment Corp. as collateral agent (&#8220;Agent&#8221;), and the lenders listed in the 2022 Loan Agreement (collectively the &#8220;2022 Lenders&#8221;). The 2022 Loan Agreement was subsequently amended on August 1, 2022 and February 9, 2023. We concluded that the Loan amendments were modifications to the 2022 Loan Agreement and are accounted for accordingly. The 2022 Loan Agreement as amended provides for a senior secured loan facility, with $27.5 million (&#8220;Term A Loan&#8221;) funded on the Closing Date and an additional $22.5 million which we may borrow on or prior to December 20, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by November 30, 2023, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (&#8220;Term B Loan&#8221;, and collectively, the Term A Loan and the Term B Loan, the &#8220;2022 Loan&#8221;). The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027. </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the 2022 Loan as amended bear interest at a floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#8217;s Website. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024, which date will be extended to March 31, 2025 if we receive approval by the FDA for our NDA for XPHOZAH on or prior to November 30, 2023 or achieve a defined net product revenue threshold for 2023. Accordingly, beginning on April 1, 2024 or April 1, 2025, we will be required to make monthly payments of interest plus repayment of the 2022 Loan in consecutive equal monthly installments of principal over 36 months or 24 months, respectively. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of March&#160;31, 2023 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1. Organization and Basis of Presentation: Liquidity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these condensed financial statements.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331886821216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Liabilities</a></td>
<td class="text">DERIVATIVE LIABILITIES<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash ("2018 Exit Fee") upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of XPHOZAH and (ii) FDA approval of IBSRELA, which was obtained on September 12, 2019 (&#8220;2018 Exit Fee Agreement&#8221;). Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expense and other current liabilities on the accompanying condensed balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the estimated fair value of the 2018 Exit Fee was $1.3 million and $1.2 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals, and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative instrument and it is estimated that a 10% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Exit Fee</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#8220;2022 Exit Fee&#8221;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the estimated fair value of the 2022 Exit Fee was $0.5 million and $0.4 million, respectively.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis by November 30, 2023, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our condensed statements of operations and comprehensive loss and were as follows for the three months ended March&#160;31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:63.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331886378256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,894</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease costs, which are included in operating expenses in our condensed statements of operations and comprehensive loss, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a sub-lease Agreement (the &#8220;Sub-lease&#8221;) with Chronus Health, Inc. ("Chronus). The Sub-lease permits use by Chronus of a portion of the space in our facility in Fremont, California. We lease the facility from a different counterparty under a separate head lease that commenced in September 2008 and has been amended multiple times to add space and to extend the lease term through March 2025. We have sub-leased to Chronus approximately 21,644 square feet of the 72,500 square foot building's interior space, plus corresponding exterior support space and parking. The term of the Sub-lease shall expire on February 1, 2025. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with the Sub-lease we recognized an impairment of long-lived assets totaling $0.4 million during the three months ended March&#160;31, 2023, which consisted primarily of impairment to the Fremont facility right-of-use asset. The Sub-lease commenced in April 2023 and we have recognized no income from the sub-lease as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884576704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At the Market Offerings Agreement</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we filed an additional prospectus supplement under a Registration Statement which was filed in July 2020 for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, received a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2023 we sold 15.5 million shares and received gross proceeds of $51.9 million at a weighted average sales price of approximately $3.35 per share under the 2021 Open Market Sales Agreement. As of March&#160;31, 2023, we have sold a total of 95.2 million shares and received the maximum gross proceeds of $150.0 million under the 2021 Open Market Sales Agreement.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#8220;at-the-market offerings&#8221; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. As of March&#160;31, 2023, there have been no sales of our common stock under the 2023 Open Market Sales Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884514432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity Incentive Plans</a></td>
<td class="text">EQUITY INCENTIVE PLANS<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:70.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.761%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,309&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:59.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,185&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2023, we sold approximately 0.2 million shares of our common stock under the ESPP. The shares were purchased by employees at an average purchase price of $0.83 per share resulting in proceeds to us of approximately $0.1 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuance of Common Stock for Services</span></div>Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the three months ended March&#160;31, 2023, we issued no shares of our common stock to members of the board of directors in accordance with the program.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884511200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three months ended March&#160;31, 2023 and 2022, all potential common shares were determined to be anti-dilutive. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,071)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:69.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,266</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,931</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,991</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,832</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884541888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies</a></td>
<td class="text">CONTINGENCIES<div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Strezsak v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 4:21-cv-05868-HSG, and Siegel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> v. Ardelyx, Inc., et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Case No. 5:21-cv-06228-HSG (together, the &#8220;Securities Class Actions&#8221;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#8217; fees. On July 19, 2022, the court consolidated the two putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#8217;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their complaint and defendants filed an opposition to the motion for leave to further amend the complaint. On April 6, 2023, the court granted plaintiff&#8217;s motion for leave to further amend the complaint. With the second amended complaint, the plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between March 6, 2020 and July 19, 2021.  The parties have stipulated to a schedule for the filing of Defendants second motion to dismiss on June 2, 2023, and a hearing on the motion to dismiss to held on September 14, 2023. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#8217;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets, for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#8217;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#8217; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#8217;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of March&#160;31, 2023, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of March&#160;31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884485568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS[<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881659088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and pursuant to the requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#8217; equity, and cash flows for the interim periods presented.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2022. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2023, or for any other interim period or future year.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Accounting Pronouncements - Recently Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted no new accounting pronouncements subsequent to filing our most recent Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3 &#8211;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9. Derivative Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, are classified as Level 3.</span><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts reflected in the condensed balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2023 and December&#160;31, 2022, due to their short-term nature. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have not recorded an allowance for credit losses for these securities as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Debt</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of March&#160;31, 2023 and December&#160;31, 2022. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8. Borrowing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 2 inputs used to estimate the fair value of the liability.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of March&#160;31, 2023 and December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be paid to us by Kyowa Kirin Co., Ltd. ("Kyowa Kirin") over the life of the agreement. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the Level 3 inputs used to estimate the fair value of the liability.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884544320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Securities Classified as Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities classified as cash, cash equivalents and short-term investments as of March&#160;31, 2023 and December&#160;31, 2022 are summarized below (in thousands):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:43.914%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.416%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,333&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,618&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,620&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,906&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,886&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,393&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,373&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.075%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.373%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,140&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,823&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,963&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,909&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884566112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):</span></div><div style="text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,387&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,501&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,886&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liabilities for exit fees</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored agency bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,313&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,769&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative liability for exit fee</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884503072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Current Inventory</a></td>
<td class="text">Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:64.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Noncurrent Inventory</a></td>
<td class="text">Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"><tr><td style="width:1.0%"/><td style="width:64.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.546%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.397%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,702&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory, non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,947&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,346&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331882417168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock', window );">Schedule of Chargebacks, Discounts and Reserve Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Discounts and Chargebacks</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Rebates, Wholesaler and GPO Fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Copay and Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provisions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits/payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(726)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,685)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,909)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of March 31, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,284&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331886378256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsAbstract', window );"><strong>Collaboration and Licensing Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Deferred Revenue Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present changes in our current and non-current deferred revenue balances during the reporting period, which are all attributable to the 2017 Kyowa Kirin Agreement (in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.519%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,211&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.760%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.030%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred revenue - non-current</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,727&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases to amounts invoiced, for which cash has not yet been received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,282&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,829&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increase due to unbilled prepayments recorded during the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(809)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,498&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331885674176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Debt Payment Obligations</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total repayment obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized discount and debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,282)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unaccreted value of final fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(699)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,880&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884595920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Schedule of Changes in Fair Value of Derivative Liability</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our condensed statements of operations and comprehensive loss and were as follows for the three months ended March&#160;31, 2023 and 2022 (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:63.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.324%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.325%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1,</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee addition at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018 Exit Fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Exit Fee</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31,</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,726&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331885482528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock', window );">Summary of Additional Details of Leases</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.765%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.174%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.177%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,972</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,998</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,894</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,855</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining life (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease costs, which are included in operating expenses in our condensed statements of operations and comprehensive loss, were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,064&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for operating lease</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2023 (in thousands):</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.520%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Remainder of 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,505&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liability, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,814&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure of additional details of the leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881732736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Stock-Based Compensation Expense Recognized</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:70.435%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.761%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,722&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock', window );">Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2023, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.323%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrecognized Compensation Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Remaining Vesting Period (Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock option grants</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,127&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSU grants</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,309&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our stock option activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:59.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise&#160;Price&#160;per<br/>Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,472&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.65&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options forfeited or canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.84&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,343&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2023</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,185&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.97&#160;</span></td><td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Restricted Stock Units Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our RSUs activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.929%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted-Average<br/>Grant&#160;Date&#160;Fair<br/>Value Per&#160;Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,406&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-vested restricted stock units at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,982&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884106640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Net Loss Per Common Share</a></td>
<td class="text"><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26,773)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,071)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding - basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of common stock - basic and diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.13)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):</span></div><div style="margin-top:12pt;text-align:justify;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:69.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase common stock</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,855</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,266</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,931</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,412</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP shares issuable</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,991</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,832</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884092816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash and short-term investments</a></td>
<td class="nump">$ 130,373<span></span>
</td>
<td class="nump">$ 123,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 806,910<span></span>
</td>
<td class="nump">$ 780,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878623120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Fair Value</a></td>
<td class="nump">$ 92,487<span></span>
</td>
<td class="nump">$ 96,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">37,906<span></span>
</td>
<td class="nump">27,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">37,886<span></span>
</td>
<td class="nump">27,769<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_InvestmentsAndCashAmortizedCost', window );">Total cash equivalents and investments, Cost</a></td>
<td class="nump">130,393<span></span>
</td>
<td class="nump">123,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains', window );">Total cash equivalents and investments, Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses', window );">Total cash equivalents and investments, Gross Unrealized Losses</a></td>
<td class="num">(31)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Total cash equivalents and investments, Fair Value</a></td>
<td class="nump">130,373<span></span>
</td>
<td class="nump">123,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">23,353<span></span>
</td>
<td class="nump">25,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">23,333<span></span>
</td>
<td class="nump">25,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">12,618<span></span>
</td>
<td class="nump">1,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">12,620<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Short-term investments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Fair Value</a></td>
<td class="nump">7,986<span></span>
</td>
<td class="nump">11,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract', window );"><strong>Cash and cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Fair Value</a></td>
<td class="nump">$ 84,501<span></span>
</td>
<td class="nump">$ 84,313<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized gains.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, cash equivalents and investments gross unrealized losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_InvestmentsAndCashAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments And Cash, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_InvestmentsAndCashAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331885702736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Investments - Narrative (Details) - investment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum', window );">Short-term securities, contractual maturities maximum</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Investment in continuous unrealized loss position for more than one year</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878283264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details) - Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 122,387<span></span>
</td>
<td class="nump">$ 112,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,501<span></span>
</td>
<td class="nump">84,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">23,333<span></span>
</td>
<td class="nump">25,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">12,620<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,501<span></span>
</td>
<td class="nump">84,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">84,501<span></span>
</td>
<td class="nump">84,313<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">37,886<span></span>
</td>
<td class="nump">27,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">23,333<span></span>
</td>
<td class="nump">25,291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">12,620<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">1,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Derivative liabilities for exit fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government-sponsored agency bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878426176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit loss on available for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884097424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Schedule (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 21,702<span></span>
</td>
<td class="nump">$ 22,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">22,566<span></span>
</td>
<td class="nump">5,324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">679<span></span>
</td>
<td class="nump">723<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Inventory</a></td>
<td class="nump">4,823<span></span>
</td>
<td class="nump">3,282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, non-current</a></td>
<td class="nump">40,124<span></span>
</td>
<td class="nump">25,064<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">$ 44,947<span></span>
</td>
<td class="nump">$ 28,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878402448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PrepaidCommercialManufacturingCurrent', window );">Prepaid commercial manufacturing</a></td>
<td class="nump">$ 13,835<span></span>
</td>
<td class="nump">$ 13,567<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PrepaidCommercialManufacturingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid Commercial Manufacturing, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PrepaidCommercialManufacturingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881550096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 11,369<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | Cardinal Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | AmerisourceBergen Drug Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Gross product revenue | Customer | McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember', window );">IBSRELA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 11,400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_CardinalHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_CardinalHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_AmerisourceBergenDrugCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ardx_McKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ardx_McKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ardx_ProductIBSRELAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331881547136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">$ 2,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesProvisions', window );">Provisions</a></td>
<td class="nump">5,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/payments</a></td>
<td class="num">(4,320)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">4,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember', window );">Discounts and Chargebacks</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesProvisions', window );">Provisions</a></td>
<td class="nump">824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/payments</a></td>
<td class="num">(726)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember', window );">Rebates, Wholesaler and GPO Fees</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesProvisions', window );">Provisions</a></td>
<td class="nump">2,361<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/payments</a></td>
<td class="num">(1,685)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">2,120<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember', window );">Copay and Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward', window );"><strong>Gross-to-net sales accruals and reserves</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Beginning balance</a></td>
<td class="nump">1,258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesProvisions', window );">Provisions</a></td>
<td class="nump">2,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued', window );">Credits/payments</a></td>
<td class="num">(1,909)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerGrossToNetSalesAccruals', window );">Ending balance</a></td>
<td class="nump">$ 1,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Credits Or Deductions Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales Accruals</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerGrossToNetSalesProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Gross To Net Sales, Provisions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerGrossToNetSalesProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerDiscountsAndChargebacksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_GrossToNetSalesAccrualAndReserveClassificationAxis=ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331877410400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Narrative (Details)<br> $ in Thousands, $ in Millions, &#165; in Billions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">65 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>JPY (&#165;)</div>
</th>
<th class="th">
<div>Oct. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($) </div>
<div>payment_tranche</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember', window );">KKC | 2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees', window );">Upfront license fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones', window );">Potential commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,100<span></span>
</td>
<td class="nump">&#165; 8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate', window );">Fee receivable for reduction in royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches', window );">Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember', window );">KKC | 2017 KKC Agreement | Licensing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Proceeds from milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember', window );">Fosun Pharma | Fosun Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties', window );">Threshold percentage of net sales for tiered royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember', window );">Knight | Knight Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones', window );">Potential development milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLicenseFeesReceived', window );">Upfront payment received</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones', window );">Potential development and commercialization milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,300<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember', window );">AstraZeneca | AZ Termination Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PercentageOfRoyaltyRevenue', window );">Percentage of royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PercentageOfNonRoyaltyRevenue', window );">Percentage of non-royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum', window );">Maximum potential payment per agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_CostOfRevenueAggregateAmountRecognized', window );">Aggregate cost of revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid', window );">Aggregate amount paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration And Licensing Agreements, Upfront License Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Commercialization Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of future development and commercialization milestone under collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialDevelopmentMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Development Milestones</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialDevelopmentMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_CostOfRevenueAggregateAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of revenue, aggregate amount recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_CostOfRevenueAggregateAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments of uncharged license fees, aggregate amount paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfNonRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of non-royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfNonRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_PercentageOfRoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of royalty revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_PercentageOfRoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ThresholdPercentageOfSalesForTieredRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold percentage of net sales for tiered royalties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ThresholdPercentageOfSalesForTieredRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLicenseFeesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from licensees for license fees during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLicenseFeesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KyowaKirinCo.LtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_KnightTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_AstrazenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_AstrazenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_AstraZenecaTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878611744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Licensing Agreements - Deferred Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 4,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">11,498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember', window );">2017 KKC Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward', window );"><strong>Deferred revenue - current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Beginning balance</a></td>
<td class="nump">4,211<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths', window );">Increases due to amounts reclassified from non-current, to be recognized in the next twelve months</a></td>
<td class="nump">809<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="nump">525<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Ending balance</a></td>
<td class="nump">5,545<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward', window );"><strong>Deferred revenue - non-current</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Beginning balance</a></td>
<td class="nump">9,025<span></span>
</td>
<td class="nump">4,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced', window );">Increases to amounts invoiced, for which cash has not yet been received</a></td>
<td class="nump">3,282<span></span>
</td>
<td class="nump">3,829<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded', window );">Increase due to unbilled prepayments recorded during the period</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths', window );">Decreases due to amounts reclassified as current, to be recognized in the next twelve months</a></td>
<td class="num">(809)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Ending balance</a></td>
<td class="nump">$ 11,498<span></span>
</td>
<td class="nump">$ 8,563<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Current, Rollforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change In Contract With Customer Liability, Noncurrent, Rollforward</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase For Amounts Invoiced</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Revenue Invoiced But Cash Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331882692880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfAdvanceRoyalty', window );">Amortization of the deferred royalty obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 969<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from royalties received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember', window );">Healthcare royalty partners IV, L.P | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable', window );">Royalty payments and commercial milestone payments</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Upfront payment</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Payment to be received</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent', window );">Amortization, effective interest rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ContractWithCustomerLiabilityTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Transaction Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ContractWithCustomerLiabilityTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfAdvanceRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfAdvanceRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRoyaltiesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRoyaltiesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ardx_HealthCareRoyaltyPartnersIVLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878685984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowing - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,861,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member', window );">2018 Term Loan | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Term loan face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage', window );">Final fee due upon maturity, acceleration, prepayment, or termination (percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod', window );">Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum', window );">Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage', window );">Additional default interest rate</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Loan Agreement | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Floating per annum rate (percent)</a></td>
<td class="nump">7.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Loan Agreement | Prior to first anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Loan Agreement | After first anniversary through second anniversary of closing date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member', window );">2022 Term Loan | Loan Agreement | After second anniversary to maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentPrepaymentFeePercentage', window );">Prepayment premium (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember', window );">Term Loan A | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from the sale of future royalties, net of issuance costs</a></td>
<td class="nump">$ 27,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Payment term</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentClosingFeeAmount', window );">Closing fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember', window );">Term Loan B | Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement', window );">Remaining funding based on milestone achievement</a></td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Payment term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents', window );">Future obligation upon loan funding or other events</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ardx_TermBLoanMember', window );">Term B Loan | Loan Agreement | SOFR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRateBaseOption', window );">Addition to floating per annum rate (percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_DebtInstrumentVariableRatePlusOption', window );">Addition plus to floating per annum rate (percent)</a></td>
<td class="nump">0.022%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon occurrence of certain conditions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeTerm', window );">Exit fee, term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentClosingFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Closing Fee Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentClosingFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentInterestRateOnDefaultPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional default interest rate on the event of default.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentInterestRateOnDefaultPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentPrepaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of fee payable on prepayment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentPrepaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRateBaseOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Base Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRateBaseOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_DebtInstrumentVariableRatePlusOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Variable Rate, Plus Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_DebtInstrumentVariableRatePlusOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Future Obligation Upon Funding Or Other Events</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_RemainingFundingBasedOnConditionalMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Funding Based On Conditional Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_RemainingFundingBasedOnConditionalMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022AMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermLoan2022BMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ardx_TermBLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ardx_TermBLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331882569296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowing - Future Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total repayment obligations</a></td>
<td class="nump">$ 28,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized discount and debt issuance costs</a></td>
<td class="num">(1,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Less: Unaccreted value of final fee</a></td>
<td class="num">(699)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">26,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansPayableCurrent', window );">Less: Current portion of long-term debt</a></td>
<td class="num">(26,880)<span></span>
</td>
<td class="num">$ (26,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermLoansPayable', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331879376368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 23, 2022</div></th>
<th class="th"><div>Feb. 28, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">Agreed amount for exit fee upon change of control or regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation', window );">Fair value analysis, effect on fair value based on 10% change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ExitFeePercentage', window );">Exit fee (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum', window );">Exit fee, net product revenue threshold</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage', window );">Fair value analysis, percentage change in probability of occurrence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ExitFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exit Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ExitFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878648512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Liabilities - Changes in Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member', window );">2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member', window );">2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit Fee derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">1,656<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">2022 Exit Fee addition at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit Fee derivative liability | 2018 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember', window );">Exit Fee derivative liability | 2022 Exit Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in estimated fair value</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=ardx_ExitFee2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331879008272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Additional Details of Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Right-of-use assets and lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 7,972<span></span>
</td>
<td class="nump">$ 9,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease liabilities</a></td>
<td class="nump">3,998<span></span>
</td>
<td class="nump">3,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">4,814<span></span>
</td>
<td class="nump">5,855<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 8,812<span></span>
</td>
<td class="nump">$ 9,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract', window );"><strong>Additional details</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining life (years)</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescriptionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescriptionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884480608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,064<span></span>
</td>
<td class="nump">$ 1,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating lease</a></td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="nump">$ 1,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878302448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Undiscounted Cash Payment Obligations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Undiscounted cash payment obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2023</a></td>
<td class="nump">$ 3,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">4,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">1,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted operating lease payments</a></td>
<td class="nump">9,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest expenses</a></td>
<td class="num">(693)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">$ 9,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion of operating lease liability</a></td>
<td class="num">(3,998)<span></span>
</td>
<td class="num">(3,894)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 4,814<span></span>
</td>
<td class="nump">$ 5,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331885318304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - Facility, Fremont California<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseImpairmentLoss', window );">Operating lease, impairment loss | $</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft)</a></td>
<td class="nump">21,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Office space area (sq ft)</a></td>
<td class="nump">72,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from impairment of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 25<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123399704&amp;loc=SL77918431-209957<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_LeaseArrangementsAxis=ardx_FacilityFremontCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878918368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,719,000<span></span>
</td>
<td class="nump">$ 5,921,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Commission on sale of stock per agreement (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock in at the market offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock in at the market offering, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average sales price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EquitySalesAgreementSharesIssuedSinceInception', window );">Total of shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception', window );">Total of gross proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember', window );">2021 Open Market Sales Agreement | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember', window );">Open Market Sales Agreement 2023, At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_StockIssuanceCostCommissionPercent', window );">Commission on sale of stock per agreement (percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember', window );">Open Market Sales Agreement 2023, At The Market Offering | Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_MaximumAggregateOfferingPrice', window );">Maximum aggregate offering price</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Sales Agreement, Proceeds From Shares Issued Since Inception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_EquitySalesAgreementSharesIssuedSinceInception">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Sales Agreement, Shares Issued Since Inception</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_EquitySalesAgreementSharesIssuedSinceInception</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_MaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_MaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_StockIssuanceCostCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Cost, Commission, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_StockIssuanceCostCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331885282240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock-Based Compensation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 2,912<span></span>
</td>
<td class="nump">$ 3,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based Compensation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 824<span></span>
</td>
<td class="nump">$ 1,214<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878864288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 21,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 7,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized Compensation Expense</a></td>
<td class="nump">$ 292<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average Remaining Vesting Period (Years)</a></td>
<td class="text">3 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878377616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number&#160;of&#160;Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding balance, beginning (in shares) | shares</a></td>
<td class="nump">13,963,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">6,472,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(36,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited or canceled (in shares) | shares</a></td>
<td class="num">(56,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding balance, ending (in shares) | shares</a></td>
<td class="nump">20,343,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">9,185,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise&#160;Price&#160;per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 4.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited or canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">5.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">4.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.97<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331884037872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Restricted Stock Units (Details) - Restricted stock units<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number&#160;of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, beginning (in shares) | shares</a></td>
<td class="nump">1,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,784<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding balance, ending (in shares) | shares</a></td>
<td class="nump">2,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant&#160;Date&#160;Fair Value Per&#160;Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, beginning (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">2.78<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">2.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding balance, ending (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878859584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Incentive Plans - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board of directors</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for services (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare', window );">Purchase price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from ESPP | $</a></td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the purchase price per share of shares issued to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ardx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331878939728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Computation of Net Loss Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (26,773)<span></span>
</td>
<td class="num">$ (28,071)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">207,023,127<span></span>
</td>
<td class="nump">130,934,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">207,023,127<span></span>
</td>
<td class="nump">130,934,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock - basic (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share of common stock - diluted (in dollars per share)</a></td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.21)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331879400448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">22,991<span></span>
</td>
<td class="nump">17,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">19,855<span></span>
</td>
<td class="nump">13,266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ardx_EmployeeStockPurchasePlanMember', window );">ESPP shares issuable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">154<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ardx_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ardx_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140331879290336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 19, 2022 </div>
<div>claim</div>
</th>
<th class="th">
<div>Aug. 12, 2021 </div>
<div>defendant </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 29, 2022 </div>
<div>defendant </div>
<div>claim</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ardx_StrezsakVersusArdelyxIncMember', window );">Strezsak v. Ardelyx, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of lawsuits | claim</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ardx_GoVersusRaabMember', window );">Go v. Raab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNewClaimsFiledNumber', window );">Number of lawsuits | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Number of defendants | defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14615-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNewClaimsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total number of new claims filed pertaining to a loss contingency during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNewClaimsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ardx_StrezsakVersusArdelyxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ardx_StrezsakVersusArdelyxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ardx_GoVersusRaabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ardx_GoVersusRaabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>ardx-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ardx="http://www.ardelyx.com/20230331"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ardx-20230331.xsd" xlink:type="simple"/>
    <context id="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i932880f720fe40d8811f3a60e39b01d9_I20230428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2023-04-28</instant>
        </period>
    </context>
    <context id="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie1d859c85d4441f7bfee95af8eb909d2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6fb93e39ef444d8695c887cc09b73b80_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2066d1e80c264bcd99c9924963c7c7a2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3856b2b0524045fc9db6e2c44a8cf2c2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iad51cff0cb0e45ad810a4a4575f2c6c1_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductSupplyRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea4a8d7b8d644fb08f9938d356a671ec_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8a79ad494fe042bdbf346769d0ee7b48_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id5bfad961f86457581b6f4e9d7d22270_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i49fc5e3d4b4f406d86613fc88394fa6d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5db9eb9e722e416eb7e2bf74dcb73ce3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia2a18458262545e9818256bcffdfdbe9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i65db80588fcc4d449903945de63379d9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2922df2535ca423a89973f8f65fca675_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i95d3925bde5c401ca56d5a208ae6d39b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3b66658c70174c7b964c4278cadb803b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6b50ab59575f44aab60c0aaa8d0ca9f7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i96ca73985d3c4d82b3a1980bbe2e8e76_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i52f0e7c126f849cc86ce9adbfbd89603_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4732bae904484aa5a7c90237b85d7ac9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if4bd3bd1b1284974bcdb1a2b8b9df930_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic18098bd479c463a8c870397cfa95c5e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id4809599b3f643b0b0ebea13fe0a5062_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i87f50508ad334e6eb7ed23017eb62096_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="if280f015aeed4a60931d60002bd4d221_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i57175b056d77462ea9709d3fefc23984_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i61e2e4a4f64d40aab8d29960cdd46227_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id804dfa2f8bf4491961e64ab1900b30b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i6a28be02017a44cf8e2c9f9690207ec4_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5c831a5fa23047d39e1d3768ebd72dfa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie5547c702f0548338c9eda648f780448_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i702563bc994044d4830a60b075943f6b_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia0d688e400e645008fb72d473b88ac99_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic936e46468054162a36dcf4e97de128d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie12a2be0e30248e18c0e219442faa6a9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie631368284b2408aad835684afa02e95_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0524220fccc7435abcb990a758edda9f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id884382c6adf4ee689a124f5a304b668_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id0d87663204949f4982bae6de6a652c0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if52a556a61d24bc0b97c984c978c2ced_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifc0743eef5b24b739e5fe93758972073_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i702ac6a7149a4273b8841d440aaca4c1_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if787129ae8904e9fa759cc369c4db88f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iadea2dc595e045b693f4c3806a5d3b16_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3daca4f51d947b5945b812330581364_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i85a8b0761bd5415db96033f744c6140a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1c74497a62594f85876db914b650f7c4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i588c4fa500554006860c6007e40ee0a5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3ad9611ed2ff4e919a234ed94bba8aed_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i883fa34c97c54813bb2d78e911d603f8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ide24937bdbc64ce28cc5e6cbfbd5e742_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifaf58162db324fe59ce07df2c57faf57_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib8afaa29db094d8f940e22612a879ea8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib68a978d30bb4163a635630e070edcb7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4dda51aa0a8049d1968ca0f7b120ceef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i89592ca2da2742faaa3ad4dd4f55e876_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3a9ba30f7b5548f8acfc7d00df9d940a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4dece602bb7b484e80d6317ab479a4e9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iab7f44ca18fe47858c896bf995bca00b_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i766e68b72c6f4313991c6e312bae923e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1ad81d2394b2450fba8397056389cb20_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i803ae491ae4247699729cd6edb089399_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i19b484f382e14cee9bae114778c4b2ee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5e493e744f814e32a4f525d3b099f39a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i199726c1e7c64eed97aea0f720596607_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i45e32429d8b040ce8d79b9dde9e922f7_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecb4976c60f342fa953b24367cd3820e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i669a009daaeb4d2db79701235b95e376_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic39295831f6047c59873ab434e7a7cf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iede9e2d88ec041849965bcef8bfb9c17_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i57102aa94d874a13b6507d22ca28cdc0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8dd2aff3e0974780a6b2aa931ebb28f9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae1010cf9f614aa9b7166c1b910413d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic892b663020e42b1bd246832a5009260_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2db82a67dfd141e8a7a89f9559c2902d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1fb1446d2f5f4438a3d7554393bc9a1f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i242fd96eb50447d3991a0de8c6a76b37_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i44fae79f843e424798285c554872b550_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i63206a33055f4c71bee2ac6cc2b4f155_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8517689b41a2471a8481ff5ea1df4049_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9711e441836a4f0d870c15d342503a53_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i87660283b17b44d686672983be8c5c21_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i69de1d9e70cd4b0088ef12543981f292_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i440c55b90eec415db702e87c2679f87b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0576a7417fb0498fb1ea19dcab1a3146_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id5d8d964b58e482b9ff481926c12e415_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if376b021c40b4857af8ed796b6f678c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iebfb6b4b245549c1925014c3d197a60d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4861c96b38f245e58dee1fb635b16e2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i644fdcb9f2ec487eb5257a431392d340_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if10e10eb21804ecea009554e9a64bbfe_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9daeb86042c74be28a77bbfb542222af_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ardx:ProductIBSRELAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i077fb918ffd34a16a2ba56d845e7c0eb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:CardinalHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45042f4036a348d9ac0c4307237e2fe3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:AmerisourceBergenDrugCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i35fb475dbd8e4857a5165d3acdca2256_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ardx:McKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5d628cc8068943659267d334778f7341_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff654685dbff4d14b4f04d9a1f3d82ad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie2484e9556a94cb28d490b54b7654b83_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i26d95d2f372e4305b5ab02ab183e81cc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6abe21dd0e894e529281c08515f218a9_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ie70fd6a1343d4c07ab6c0418986dd561_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i06d909b1486e465d9d1e0fae1f8ce528_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerDiscountsAndChargebacksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i94828b9e8bfc49a9821ddf83aaed8bd3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia4d507187469461589702c69e8af394f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:GrossToNetSalesAccrualAndReserveClassificationAxis">ardx:ContractWithCustomerOtherFeesCopayAndReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i083920320a754056a514534f83b44efb_D20171101-20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="i1bd3e10bb611407aa9b181ac0b231f2b_I20171130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-30</instant>
        </period>
    </context>
    <context id="ife5f1ab287944b9d9bde070bbcbc67e0_D20171101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i288cfb8144d94e34b13ad2293ba44e8a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i39875fb6603e44a9a08e3395ebc9b749_I20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="ie00d1c1778d04b16b85402b79f1486b1_I20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KyowaKirinCo.LtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="i2907f661c6604d53a0fd946c446d11e8_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ib45bb64e3dd84ca6aef388e7e5e6f6e7_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if8a535f9627a421383052d6cea68607f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInChinaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i863345a922844c66bd8d54af304f6cdf_D20180301-20180331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-01</startDate>
            <endDate>2018-03-31</endDate>
        </period>
    </context>
    <context id="i63261ab5ac574aa09e991359cd4c71ad_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3052a28a1e664c948b14b97c701206d4_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:KnightTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54e4c9709e43489db08f10738e1a7672_D20150601-20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-06-01</startDate>
            <endDate>2015-06-30</endDate>
        </period>
    </context>
    <context id="i3b884d0ed6cd421f8a251db830a1fdce_I20150630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-30</instant>
        </period>
    </context>
    <context id="i57d1ca4ad84940028b209e173e66500a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i731cea5b5a1d4df7b9a2e29a37cd3494_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i86a688e614d249fb9330ee9f05c52190_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:AstrazenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:AstraZenecaTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i659312f8037b43898d098e16388710fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iace679a5607d492699456f44241140e4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i52f7c183ef764b48ab94110300434074_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia95bc99b5de94628b6f1a6c5d5185452_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ardx:LicenseAgreementDevelopmentCommercializationDistributionInJapanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i7e9a3bf71e144239ab9f7e4ab68a77fb_D20220601-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id6b3392a8c3747ae86ad7d9a483555ca_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ieebd3c9bdbf5498bb3059d158b5c146a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3d8e929085924d668d54e66064fca686_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ardx:HealthCareRoyaltyPartnersIVLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id26a7d8749644b05b1f668cab705f3da_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i65852187d2a644d0b3d856dac714bdd5_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i1bde4623e9a04dc39eee1626eaee265d_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i94ae49ee7695430e996b24c23504b630_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i638a555d6cc245828c93ab8f2f4152fd_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermBLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i3f29b0505e0a4f2687c88c38e53ea1dc_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022BMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i0b5ab525e6ab435aaf3c6a02a1de068a_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022AMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i0c94dd239cb747d4badb5a4357da4ad9_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="ia083898fba8644ae8992ef5a76d16d15_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i3eef16572d6e4271b1f76a0150bcab0d_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i0f1ad1d3f45248538bc7fb75b496d6b7_I20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-23</instant>
        </period>
    </context>
    <context id="i33c8ecd2354241aaae56ac9dd1838668_I20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-02-28</instant>
        </period>
    </context>
    <context id="i144ee9ba68854c9cb614235c5e0c2141_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i409069f3154040ff8c6970a5bfafb1ee_D20220223-20220223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ardx:TermLoan2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-23</startDate>
            <endDate>2022-02-23</endDate>
        </period>
    </context>
    <context id="i33de1b72f71545d986edc3214d5d9beb_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="idfb8182a2d794133b5db7776b72a7c32_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id77334cdee644ae3adb652a17ffda146_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibb1c667d3f6845b9821defdd369f3334_D20220201-20220228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="iad99515dc2cb43bbac4c617f035dbea6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic39c3311ee344cb6bd0f358d159ff052_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie825c96e303040cbac67e9975c1d3916_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i378e186ad3f24c9db722bd214a0cd23c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i70a72bd3fdec4799bf7cbc921bbe7771_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9097418276724d54ae8d794f40b08e52_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i76f025b503164e55a2c09bb438e74e2c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i417a6c105f4849fc8598601744a8fe4a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3182ceda3b1f402a8c202c06dedcee6f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2018Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie1c3cd44c6894dfbaeaedc130ea028db_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifc6e80a67a6b4e47b639149a2c278dfd_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">ardx:ExitFee2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3794a3d76c384e9fa5e39ef7474a6713_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8a1c090223594681b449fb7259dff90c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i40d30043fca4421a8cdd707a81f722ba_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia852c2d1c80946b885ed9b389837f281_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i90fedc697a1647b9a3c9a1fdd6f348f5_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ardx:LeaseArrangementsAxis">ardx:FacilityFremontCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i38ec05cddf3c49969f8932f33a355bdd_I20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i08f1310f62044e3a8e64483b5dd18dda_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2021AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i847e1d01ce2b4b5196fbe950423d7527_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i210c86e09a944a939b0007a9a24d4ece_I20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="i71e4928ba21947689d3e92f7f3fc1047_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ardx:OpenMarketSalesAgreement2023AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <context id="i1377563bc1bf4114b883c22f97c51e4a_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="id437a6bae6684761a2b82865b44768bb_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia72321f082eb4141ae92b05ddd125028_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2cdbd17f499a48b8a163d1b51e42ad39_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i97aaff4ee70847809b2728fcf21c8527_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8e0beb2c643043e5ac96aa6e57782a75_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i569028c12e1a4c889833813e64570cc9_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iffc784fcdb3041df855d022e9e60e484_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i38458ac6496e4b97bcf456606e115021_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iab6e5d2a709c4d4a89b9436290d7efe6_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3414587956434b98b32c8ddc23e1990e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="idee67a217ee640f3ae98f97ef8b95003_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9b51b129be104da4b12d3221e1e2ce43_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ardx:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib1cf5f5ae42646abb1e513d35f625822_D20210730-20210812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-08-12</endDate>
        </period>
    </context>
    <context id="i85da43d6cf444786a450dbf73698f7f9_D20220719-20220719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:StrezsakVersusArdelyxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-19</startDate>
            <endDate>2022-07-19</endDate>
        </period>
    </context>
    <context id="icfbdf47e462e49459e70036c484a3c1f_D20211207-20220329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001437402</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ardx:GoVersusRaabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-07</startDate>
            <endDate>2022-03-29</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>ardx:segment</measure>
    </unit>
    <unit id="investment">
        <measure>ardx:investment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="jpy">
        <measure>iso4217:JPY</measure>
    </unit>
    <unit id="payment_tranche">
        <measure>ardx:payment_tranche</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="claim">
        <measure>ardx:claim</measure>
    </unit>
    <unit id="defendant">
        <measure>ardx:defendant</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8wLTEtMS0xLTU4MDc3_5ee2ac52-e7e2-45c9-842f-fadb601a9be6">0001437402</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8xLTEtMS0xLTU4MDc3_c02e61e6-2bac-4d3b-abad-0cac6d6a5ac1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8yLTEtMS0xLTU4MDc3_73444ad5-05bf-4ceb-85ca-57e2494c1d74">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF8zLTEtMS0xLTU4MDc3_84dd57bc-49e7-436e-b569-3f9f58691885">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80L2ZyYWc6OGYzMDc5ODRiZmU3NGVkZTk2NzA0M2IyYTk5ODg4YmUvdGFibGU6MWRhMWU1ZjE1Y2Q4NDFiOWJlMmE4MGEzY2E5NzViMTQvdGFibGVyYW5nZToxZGExZTVmMTVjZDg0MWI5YmUyYTgwYTNjYTk3NWIxNF80LTEtMS0xLTU4MDc3_41fa3fe9-42b1-4811-a4aa-3cea4ce2efe0">false</dei:AmendmentFlag>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV84Mi9mcmFnOjRhYTNjNDk3ZTE3MzQyYmNiOTY3YzRhYWVkYTZhMTY4L3RleHRyZWdpb246NGFhM2M0OTdlMTczNDJiY2I5NjdjNGFhZWRhNmExNjhfNTMx_b57924bc-f07d-458c-91ac-ab563c636991">SUBSEQUENT EVENTS[</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTIw_ab70b336-9cd2-450e-95da-6f702803689c">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6M2Y2YjdhODM3YWMyNDU3YWJkNTBhYjc2ODQzOTgyYzgvdGFibGVyYW5nZTozZjZiN2E4MzdhYzI0NTdhYmQ1MGFiNzY4NDM5ODJjOF8wLTAtMS0xLTU4MDc3_89823e31-acf5-4956-9915-7dc1229a5c8e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8xMzg_0383135b-e634-40f5-a585-76efe0aad028">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6NGNkMTBhYjdjMGQwNGJhMDgwODNjMDQzNjVkMzNmMDIvdGFibGVyYW5nZTo0Y2QxMGFiN2MwZDA0YmEwODA4M2MwNDM2NWQzM2YwMl8wLTAtMS0xLTU4MDc3_11e697c5-f2f9-41eb-a3be-936ea9bda28b">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI2_c5fe2caf-4315-47f3-b141-7583d6817b36">001-36485</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI3_37382cc1-417c-496b-a369-f680b718c791">ARDELYX,&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6ZDQ4ZGY4ZmRmNWFlNGI2OWE0ZGMwOThmOTFlYjZmNjUvdGFibGVyYW5nZTpkNDhkZjhmZGY1YWU0YjY5YTRkYzA5OGY5MWViNmY2NV8wLTAtMS0xLTU4MDc3_a1f166f8-6629-4a08-80ad-28ed27551b61">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6ZDQ4ZGY4ZmRmNWFlNGI2OWE0ZGMwOThmOTFlYjZmNjUvdGFibGVyYW5nZTpkNDhkZjhmZGY1YWU0YjY5YTRkYzA5OGY5MWViNmY2NV8wLTEtMS0xLTU4MDc3_001206af-a21f-4b4f-9aab-5150f82579b9">26-1303944</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI4_498146a6-7bf1-4002-9c2a-fe01817913a9">400 Fifth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE0_273cafd0-95d7-464a-ac77-af576ae17e08">Suite 210</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE2_8b65c84e-8cbd-4933-98b5-ffa60eb0df78">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE3_970ae751-05ba-4f43-ba1e-c49cdb01d802">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTA3_48e7b4d6-6a7b-46a9-a348-08630159154e">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTIz_0a8f7a39-382c-4117-8e39-e7e7487b9a3f">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTEw_9be98edb-37bf-4484-bcfd-4ccd56af0911">745-1700</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MWVhOWRiMmJmZDIxNGNhNzhjNmRjY2M1MzU1YjAzMzMvdGFibGVyYW5nZToxZWE5ZGIyYmZkMjE0Y2E3OGM2ZGNjYzUzNTViMDMzM18xLTAtMS0xLTU4MDc3_58a20bbd-5e58-44d1-a607-8699ef2cec5a">Common Stock, par value $0.0001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MWVhOWRiMmJmZDIxNGNhNzhjNmRjY2M1MzU1YjAzMzMvdGFibGVyYW5nZToxZWE5ZGIyYmZkMjE0Y2E3OGM2ZGNjYzUzNTViMDMzM18xLTItMS0xLTU4MDc3_36bb7ecd-7529-4460-9a6a-e98eb3173074">ARDX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MWVhOWRiMmJmZDIxNGNhNzhjNmRjY2M1MzU1YjAzMzMvdGFibGVyYW5nZToxZWE5ZGIyYmZkMjE0Y2E3OGM2ZGNjYzUzNTViMDMzM18xLTQtMS0xLTU4MDc3_878c893c-66a3-4a10-b422-20797491e6b7">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTE4_d7e41cce-8fe9-453b-9c41-50d371e21946">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTA5_a58076f3-8f5d-43d4-a282-68aee53ca1db">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MjAxZTdhNzhhNzBmNDQzMDk0NThkZjNmNGJiNzEwNmEvdGFibGVyYW5nZToyMDFlN2E3OGE3MGY0NDMwOTQ1OGRmM2Y0YmI3MTA2YV8yLTEtMS0xLTU4OTUx_e56e64fe-286b-4138-bf27-f8443ad7f01a">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MjAxZTdhNzhhNzBmNDQzMDk0NThkZjNmNGJiNzEwNmEvdGFibGVyYW5nZToyMDFlN2E3OGE3MGY0NDMwOTQ1OGRmM2Y0YmI3MTA2YV8yLTUtMS0xLTU4MDc3_b798df14-f8b3-40f0-8b75-7b73c58e7349">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGFibGU6MjAxZTdhNzhhNzBmNDQzMDk0NThkZjNmNGJiNzEwNmEvdGFibGVyYW5nZToyMDFlN2E3OGE3MGY0NDMwOTQ1OGRmM2Y0YmI3MTA2YV80LTUtMS0xLTU4MDc3_b1d6fa47-8794-46d8-aba2-67adb0e14e0e">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTI1_8f3a54ac-9c97-43db-a434-69818844ad3b">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i932880f720fe40d8811f3a60e39b01d9_I20230428"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xL2ZyYWc6ODZkNDc3YzUxZjdiNDI2M2JkOTZjMDA4YzdkM2I5MDQvdGV4dHJlZ2lvbjo4NmQ0NzdjNTFmN2I0MjYzYmQ5NmMwMDhjN2QzYjkwNF8yMTAx_68c76548-9ebb-46ec-8d92-9f1fede44818"
      unitRef="shares">214462429</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNC0xLTEtMS01ODA3Nw_8555c5a2-4714-44b4-94d4-32b7dc82b616"
      unitRef="usd">92487000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNC0zLTEtMS01ODA3Nw_889ef05c-1c43-48ff-9c77-9a7c0264e8bb"
      unitRef="usd">96140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNS0xLTEtMS01ODA3Nw_73f166ba-4661-4b79-a2d8-568127fccf48"
      unitRef="usd">37886000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNS0zLTEtMS01ODA3Nw_4c0ea3b7-c7d1-40e1-bbce-a00be26900a3"
      unitRef="usd">27769000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNi0xLTEtMS01ODA3Nw_194acb50-1071-4c9d-b0c9-643fa24be268"
      unitRef="usd">12120000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNi0zLTEtMS01ODA3Nw_58c84d7c-186e-4c61-a7e9-76983163a31b"
      unitRef="usd">7733000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryGross
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNy0xLTEtMS01ODA3Nw_f4ca1e12-1209-40b9-8e8a-89776f652783"
      unitRef="usd">4823000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfNy0zLTEtMS01ODA3Nw_b6b26f84-1690-499d-a35f-83d34f2678c2"
      unitRef="usd">3282000</us-gaap:InventoryGross>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOC0xLTEtMS01ODA3Nw_38c597d9-5fac-4c64-a2ec-4671c495e0e6"
      unitRef="usd">13835000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOC0zLTEtMS01ODA3Nw_201e62d5-1622-45a8-a194-9c0dec951520"
      unitRef="usd">13567000</ardx:PrepaidCommercialManufacturingCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOS0xLTEtMS01ODA3Nw_54e73a2a-f774-4954-ac63-b9d713d08bad"
      unitRef="usd">5896000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfOS0zLTEtMS01ODA3Nw_cc865f42-31d4-4bb7-8d1e-de05d0f96133"
      unitRef="usd">5112000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTAtMS0xLTEtNTgwNzc_0b3997d3-1fb1-4a3b-9d01-b847d9d4a54e"
      unitRef="usd">167047000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTAtMy0xLTEtNTgwNzc_00a4a617-8071-46e8-be44-30f190c8532a"
      unitRef="usd">153603000</us-gaap:AssetsCurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMS0xLTEtNTgzOTE_abe71248-4550-4d85-8e23-2e7324234739"
      unitRef="usd">40124000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMy0xLTEtNTgzOTE_733cc68d-7bc9-4f35-8045-a87a159b7fcf"
      unitRef="usd">25064000</us-gaap:InventoryNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMS0xLTEtNTgwNzc_c71c5fb8-6ed7-4bb4-9b3a-21bb79b1ba23"
      unitRef="usd">7972000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTEtMy0xLTEtNTgwNzc_b8c32a53-7d49-4c16-8b12-7623686f4049"
      unitRef="usd">9295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTItMS0xLTEtNTgwNzc_84f50b65-1aaa-4970-8335-a7f3024f53fe"
      unitRef="usd">1102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTItMy0xLTEtNTgwNzc_13eed775-9977-415f-821e-fa7d11a02822"
      unitRef="usd">1223000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTQtMS0xLTEtNTgwNzc_79cb9aa0-5b67-402c-89ac-8a1965fd2547"
      unitRef="usd">774000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTQtMy0xLTEtNTgwNzc_62c98c83-b548-493c-815a-2fbef82d5186"
      unitRef="usd">881000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTUtMS0xLTEtNTgwNzc_ca0def20-53bd-4bd3-b1f3-0bdabaf93993"
      unitRef="usd">217019000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTUtMy0xLTEtNTgwNzc_9b89f8a1-7329-49fa-ad20-585e80d5a843"
      unitRef="usd">190066000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTgtMS0xLTEtNTgwNzc_31a13f1c-7056-481a-af4a-fe63873bcb1c"
      unitRef="usd">10513000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTgtMy0xLTEtNTgwNzc_435dffc6-8377-4064-a9cc-381108a676a8"
      unitRef="usd">10859000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTktMS0xLTEtNTgwNzc_8661ae48-b153-40a7-aff1-d6b6ea1139ef"
      unitRef="usd">5074000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMTktMy0xLTEtNTgwNzc_b984b407-dc68-4293-b26f-d8b3ff8c65f1"
      unitRef="usd">7548000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjAtMS0xLTEtNTgwNzc_8f86646f-cbb0-48a1-88aa-f48b2d3ff30b"
      unitRef="usd">26880000</us-gaap:LoansPayableCurrent>
    <us-gaap:LoansPayableCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjAtMy0xLTEtNTgwNzc_944f32e6-24ab-4118-afc8-9e6ff2d7f1ca"
      unitRef="usd">26711000</us-gaap:LoansPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjEtMS0xLTEtNTgwNzc_65f4e5e0-f308-4152-b093-3c3a2f3dce9d"
      unitRef="usd">3998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjEtMy0xLTEtNTgwNzc_e2191630-5005-4636-b01d-f9d917992a1f"
      unitRef="usd">3894000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjItMS0xLTEtNTgwNzc_39f601b6-6833-4735-9690-db29618ce322"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjItMy0xLTEtNTgwNzc_b4b24c00-a1e7-4a88-b1ba-1d822f28cdcd"
      unitRef="usd">4211000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjMtMS0xLTEtNTgwNzc_0ffbaff3-5e70-4594-922c-ea14d12c7df2"
      unitRef="usd">11053000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjMtMy0xLTEtNTgwNzc_c98520ff-7fdb-4f89-92fd-24668bb7effd"
      unitRef="usd">12380000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LiabilitiesCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjQtMS0xLTEtNTgwNzc_cc53fbca-01e1-4c10-8193-6697415e8002"
      unitRef="usd">63063000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjQtMy0xLTEtNTgwNzc_54ca7a0c-2393-490b-afac-946f8645fdb6"
      unitRef="usd">65603000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjUtMS0xLTEtNTgwNzc_40155aa3-aa66-4fd3-a37d-84e8603fea1e"
      unitRef="usd">4814000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjUtMy0xLTEtNTgwNzc_d821884d-520a-4132-a414-490900ed314a"
      unitRef="usd">5855000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjctMS0xLTEtNTgwNzc_e13288b2-3cf6-40e9-9645-8aa084cb0a68"
      unitRef="usd">11498000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjctMy0xLTEtNTgwNzc_7b6d3f8c-4fed-422c-ae9f-d930f5897c26"
      unitRef="usd">9025000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:DeferredRoyaltyObligationNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjgtMS0xLTEtNTgwNzc_7da3ddbc-fffe-4211-88b8-ee36ba0321d8"
      unitRef="usd">12223000</ardx:DeferredRoyaltyObligationNoncurrent>
    <ardx:DeferredRoyaltyObligationNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjgtMy0xLTEtNTgwNzc_8eb5979d-0c77-45eb-8f2a-935dc59336f9"
      unitRef="usd">11254000</ardx:DeferredRoyaltyObligationNoncurrent>
    <us-gaap:Liabilities
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjktMS0xLTEtNTgwNzc_a7604d67-7e88-4584-9b31-4a8680753027"
      unitRef="usd">91598000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMjktMy0xLTEtNTgwNzc_472764ac-6b28-4114-84e2-981d671cfa40"
      unitRef="usd">91737000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzAtMS0xLTEtNTgwNzc_063e9f61-1376-4b1c-8bf0-0c26acb1c9de"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzAtMy0xLTEtNTgwNzc_e63264d9-71fa-478a-962a-66e3190f08cf"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8yMQ_b47a075e-6f92-475a-b045-53f6d9a9e113"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8yMQ_dcc0866f-bf97-49d7-9172-7a3141f00633"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8zNQ_42663b23-4ae4-4da0-8b5c-a9e0e9765a64"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV8zNQ_5f57dc06-fdd8-437c-8324-63b548b44ce4"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_0a4e1da7-a045-413f-859e-151f5c575888"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_5565429f-169d-48a5-9d42-6901dc2ad5a4"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_82e719a2-e5fc-4946-a871-559e5ae2083d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjo5NjQwY2Q2YmQ1Nzg0ZTUzOGUwNTBmYTY2OTUyNDIyZV81Nw_8e53936d-6336-447b-9e08-a2feb455e9d6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMS0xLTEtNTgwNzc_2c34cee4-611d-4e1f-926a-47b46a8f3cbd"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzItMy0xLTEtNTgwNzc_8f43e5a9-42a3-47c7-8c32-d957463fdd20"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8xOA_015b392e-7742-4c68-8e19-7cc945a0b02b"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8xOA_7e6415b5-d0cf-4c56-b2ec-841f181f8fa6"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8zMg_42a21d41-9850-41a8-be1f-40b51bfc6a59"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF8zMg_d49902d9-4af8-4695-9948-8be2c0a8d442"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF81NA_7dfd8ab6-b576-4b85-865f-35d9614f7197"
      unitRef="shares">214462050</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF81NA_94443183-748f-4409-96ba-a047d5d1d07f"
      unitRef="shares">214462050</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF82MQ_0239454d-86a7-4463-adbb-41ce4173945f"
      unitRef="shares">198575016</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMC0xLTEtNTgwNzcvdGV4dHJlZ2lvbjoyZDc2MjViNjljZWM0NDNjYjAwMzQ2ZjdmMGI3OGQ4OF82MQ_fac2b182-b031-428e-829d-38dc1f6903b9"
      unitRef="shares">198575016</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMS0xLTEtNTgwNzc_512111dd-4ae9-411c-a941-57e68f1e4714"
      unitRef="usd">21000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzMtMy0xLTEtNTgwNzc_7282df36-407b-4f2c-90d7-fc83ec6995cc"
      unitRef="usd">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzQtMS0xLTEtNTgwNzc_f1e119c5-99e9-4e91-af1e-81d9e4f1d520"
      unitRef="usd">932330000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzQtMy0xLTEtNTgwNzc_daddcbce-2f7d-4f8a-89dd-e21fc9964c51"
      unitRef="usd">878500000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzUtMS0xLTEtNTgwNzc_e24863ca-f9db-48c6-856e-34214cf29d0f"
      unitRef="usd">-806910000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzUtMy0xLTEtNTgwNzc_9afdec92-2693-446c-a605-cec6c8034388"
      unitRef="usd">-780137000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzYtMS0xLTEtNTgwNzc_7a650600-1665-441c-8a5e-d51499a561ad"
      unitRef="usd">-20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzYtMy0xLTEtNTgwNzc_ccdcd9c2-33fb-4733-9a09-9bfe20bcbbb1"
      unitRef="usd">-54000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzctMS0xLTEtNTgwNzc_235dbf6c-245f-496d-928a-2ac23132dc45"
      unitRef="usd">125421000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzctMy0xLTEtNTgwNzc_79e2115a-b6e0-49c4-b411-67a91660e2ee"
      unitRef="usd">98329000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzgtMS0xLTEtNTgwNzc_d8277279-7095-4657-93f3-df10d237a364"
      unitRef="usd">217019000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8xOS9mcmFnOjMzYWEyYWUyNjVjMTQwZDhhNTAxYWI1MGIwMDA1NjQyL3RhYmxlOmMyNGYyMDgxZmU0MTQ1NmY5OTQzYmFhNTJmMzRkNzVjL3RhYmxlcmFuZ2U6YzI0ZjIwODFmZTQxNDU2Zjk5NDNiYWE1MmYzNGQ3NWNfMzgtMy0xLTEtNTgwNzc_fc09f755-46a5-4727-8d16-80cc97ed6c2e"
      unitRef="usd">190066000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6fb93e39ef444d8695c887cc09b73b80_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMy0xLTEtMS01ODA3Nw_728dab60-d64c-4326-ace6-51eae7fd246b"
      unitRef="usd">11355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2066d1e80c264bcd99c9924963c7c7a2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMy0zLTEtMS01ODA3Nw_8b42a534-f6e1-47c9-b4b3-dc036630f0f9"
      unitRef="usd">450000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3856b2b0524045fc9db6e2c44a8cf2c2_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNC0xLTEtMS01ODA3Nw_94e07c5a-904e-406d-82d3-e6bf17dedf06"
      unitRef="usd">2000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad51cff0cb0e45ad810a4a4575f2c6c1_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNC0zLTEtMS01ODA3Nw_a3295653-f419-4b48-94a6-0d49028cb89d"
      unitRef="usd">14000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iea4a8d7b8d644fb08f9938d356a671ec_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNS0xLTEtMS01ODA3Nw_264a3e9c-15c2-405b-9548-c2076f6c73ac"
      unitRef="usd">12000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a79ad494fe042bdbf346769d0ee7b48_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNS0zLTEtMS01ODA3Nw_59f407be-a4a3-4e0a-a492-46c5e9f18f9f"
      unitRef="usd">4000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNy0xLTEtMS01ODA3Nw_7295421c-1870-4678-af2b-e4e1be03e938"
      unitRef="usd">11369000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfNy0zLTEtMS01ODA3Nw_344fa0e6-8662-4b22-8ad9-9381597a83ee"
      unitRef="usd">468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfOS0xLTEtMS01ODA3Nw_ed655b57-57b9-4b86-a770-320a1cae9350"
      unitRef="usd">1537000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfOS0zLTEtMS01ODA3Nw_c7e38098-5d63-44b6-b5df-82982dd44fc7"
      unitRef="usd">85000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTAtMS0xLTEtNTgwNzc_d0b4414d-4320-4f12-8486-484d9dd81874"
      unitRef="usd">9093000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTAtMy0xLTEtNTgwNzc_60b7d2b2-1ddb-492c-af80-d355fe660d80"
      unitRef="usd">8851000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTEtMS0xLTEtNTgwNzc_eb59048e-07b7-4916-a646-778b77223d4c"
      unitRef="usd">26803000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTEtMy0xLTEtNTgwNzc_4d183b41-e560-4714-aecc-b71968ece81e"
      unitRef="usd">19339000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTItMS0xLTEtNTgwNzc_e19a9c05-cbcc-4ee8-800b-381df76fe988"
      unitRef="usd">37433000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTItMy0xLTEtNTgwNzc_1bbc15af-5e50-4cc8-82b9-7b22beb28495"
      unitRef="usd">28275000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTMtMS0xLTEtNTgwNzc_b8fe71c0-1f73-4c2e-bd30-3d771303c3e0"
      unitRef="usd">-26064000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTMtMy0xLTEtNTgwNzc_6bc80542-9ad9-4136-9611-d98709c9543b"
      unitRef="usd">-27807000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTQtMS0xLTEtNTgwNzc_5ce7b6ed-8f13-44d9-b752-75a8773ea534"
      unitRef="usd">1028000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTQtMy0xLTEtNTgwNzc_1d584563-aa9b-4485-abe6-93835f4c1683"
      unitRef="usd">746000</us-gaap:InterestExpense>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTUtMS0xLTEtNTgwNzc_b340ae10-b2f7-463b-84b4-b785e221a3d4"
      unitRef="usd">969000</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTUtMy0xLTEtNTgwNzc_956750e7-67c7-4e61-ab98-6dc7b6fd3e34"
      unitRef="usd">0</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTYtMS0xLTEtNTgwNzc_f8b8e482-e7cc-4e36-8d78-0277b01765ba"
      unitRef="usd">1302000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTYtMy0xLTEtNTgwNzc_5dab9210-ea2c-42cd-bd10-76f7fcf1ba3e"
      unitRef="usd">484000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTctMS0xLTEtNTgwNzc_ded7d8e5-1887-46f7-9c61-b163497b4392"
      unitRef="usd">-26759000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTctMy0xLTEtNTgwNzc_65131862-785a-4017-a981-4fc1027293bb"
      unitRef="usd">-28069000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTgtMS0xLTEtNTgwNzc_1bd99c3a-2c12-41e6-88d8-6e2bdd97f123"
      unitRef="usd">14000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTgtMy0xLTEtNTgwNzc_c291eb8d-544e-420d-91f6-85d2fd3724ae"
      unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTktMS0xLTEtNTgwNzc_e4d5b482-947f-4e05-a6dc-9769a1fd3ccf"
      unitRef="usd">-26773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMTktMy0xLTEtNTgwNzc_26fc15c3-c0d1-4c82-b442-9cf0dbb30cfa"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMS0xLTEtNTgwNzc_575bbec2-5877-4464-bd98-8f8a146a7c70"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMS0xLTEtNTgwNzc_bdc2aa34-2b87-4883-aff9-4d4797747afd"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMy0xLTEtNTgwNzc_8d255744-bcfa-454f-8b32-4796fbf6236b"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjAtMy0xLTEtNTgwNzc_9a4941f5-c124-496c-a43d-c85cb01cc45e"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMS0xLTEtNTgwNzc_5fe20d64-f214-4bc5-82aa-d1a0eb5ae0e2"
      unitRef="shares">207023127</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMS0xLTEtNTgwNzc_6a733c5a-b97e-441c-9141-7b355dd86683"
      unitRef="shares">207023127</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMy0xLTEtNTgwNzc_567004c8-8db7-47fd-8168-584c90d1e984"
      unitRef="shares">130934795</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjEtMy0xLTEtNTgwNzc_94bc9076-4bc7-46cd-8f98-228558b0c9cb"
      unitRef="shares">130934795</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjMtMS0xLTEtNTgwNzc_4e43641e-eb26-433c-8932-da1540d68b77"
      unitRef="usd">-26773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjMtMy0xLTEtNTgwNzc_5e935bf5-3fc9-45d7-b1d2-98e7d59f6875"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjQtMS0xLTEtNTgwNzc_684a1ae7-016c-458c-8c99-b1552198dc6b"
      unitRef="usd">34000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjQtMy0xLTEtNTgwNzc_491cf5d6-febf-4b56-bf41-a4be9d188b54"
      unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjUtMS0xLTEtNTgwNzc_ea075c9b-fbc8-4e23-b635-562d67ac9bf7"
      unitRef="usd">-26739000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yMi9mcmFnOmJiYWMwZmNhMGQ3MTQ1Yzc5MjIyZmU2OWVjMDU3NDVlL3RhYmxlOmFlNWM3MTgyZWFiNTQ0YTJhMTQyZWI1MDUxMDdiY2Q4L3RhYmxlcmFuZ2U6YWU1YzcxODJlYWI1NDRhMmExNDJlYjUwNTEwN2JjZDhfMjUtMy0xLTEtNTgwNzc_ae6a399a-ba27-4554-a21a-3c79137d421c"
      unitRef="usd">-28153000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="id5bfad961f86457581b6f4e9d7d22270_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy0xLTEtMS01ODA3Nw_084513f0-1dab-4695-8cce-fa841264d14f"
      unitRef="shares">198575016</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id5bfad961f86457581b6f4e9d7d22270_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy0zLTEtMS01ODA3Nw_8a5273b6-6c32-47e4-a587-4cb22609f9a1"
      unitRef="usd">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i49fc5e3d4b4f406d86613fc88394fa6d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy01LTEtMS01ODA3Nw_df7a9715-7f4e-456e-8613-73909d521e66"
      unitRef="usd">878500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5db9eb9e722e416eb7e2bf74dcb73ce3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy03LTEtMS01ODA3Nw_e0ca0ab7-26ba-4195-8b18-7ae94d8edcfd"
      unitRef="usd">-780137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2a18458262545e9818256bcffdfdbe9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy05LTEtMS01ODA3Nw_b88dd74a-445a-4208-a7fb-e6a6e7af166a"
      unitRef="usd">-54000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMy0xMS0xLTEtNTgwNzc_7130bb3b-325d-4b30-bb77-32e13dd50dd0"
      unitRef="usd">98329000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNC0xLTEtMS01ODA3Nw_1f366df6-40fa-4fcd-8425-c3bab352efe1"
      unitRef="shares">165969</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNC01LTEtMS01ODA3Nw_3a520d09-3740-4a12-90f3-e7509423f374"
      unitRef="usd">138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNC0xMS0xLTEtNTgwNzc_5d5f4784-b04a-4f00-b67b-dcc2aa0792e9"
      unitRef="usd">138000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNi0xLTEtMS01ODA3Nw_cafad80e-5c91-4119-b7ed-53d87a2e7191"
      unitRef="shares">36001</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNi01LTEtMS01ODA3Nw_e02d6b6b-b8d9-4d3d-9941-7440230ae5a1"
      unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNi0xMS0xLTEtNTgwNzc_71aecd0c-8a7d-4fef-9b00-e8ae31324548"
      unitRef="usd">62000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfNy0xLTEtMS01ODA3Nw_35e8fc16-2afc-4a25-9122-93d2615157f2"
      unitRef="shares">207773</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS0xLTEtMS01ODA3Nw_2c453ec8-d548-4c01-a8f6-2d1d609bdbad"
      unitRef="shares">15477291</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="icc4c8cc36cfa48c397f9cd3b27be59ed_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS0zLTEtMS01ODA3Nw_dd9e4236-9f1f-4b44-9a68-c6fbcc67ae06"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS01LTEtMS01ODA3Nw_cfae60fd-55b3-4a5d-a093-dec24628da0d"
      unitRef="usd">50718000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfOS0xMS0xLTEtNTgwNzc_76c5d9a0-709a-4f1a-b195-c131354451a7"
      unitRef="usd">50719000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i65db80588fcc4d449903945de63379d9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTAtNS0xLTEtNTgwNzc_1fa03708-ff50-4364-bece-ab30aa48ef8a"
      unitRef="usd">2912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTAtMTEtMS0xLTU4MDc3_ff5b0558-4c20-47fe-b3b4-2e14a8f6a531"
      unitRef="usd">2912000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i2922df2535ca423a89973f8f65fca675_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTEtOS0xLTEtNTgwNzc_9f54ecfb-e405-48f0-be8e-541cb84f702d"
      unitRef="usd">34000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTEtMTEtMS0xLTU4MDc3_64d57c57-0ee5-4839-a7f3-412f091539be"
      unitRef="usd">34000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i95d3925bde5c401ca56d5a208ae6d39b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTItNy0xLTEtNTgwNzc_c5ef3707-2938-4c2d-8dec-5e388543d5ad"
      unitRef="usd">-26773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTItMTEtMS0xLTU4MDc3_fd7c5f82-67c5-4925-8877-f96fecc0744d"
      unitRef="usd">-26773000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i3b66658c70174c7b964c4278cadb803b_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtMS0xLTEtNTgwNzc_71e71d62-b7d3-4bbb-a04c-9c4e575c00fe"
      unitRef="shares">214462050</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3b66658c70174c7b964c4278cadb803b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtMy0xLTEtNTgwNzc_ba44b822-68b6-46d9-af6c-274f1c5a017f"
      unitRef="usd">21000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b50ab59575f44aab60c0aaa8d0ca9f7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtNS0xLTEtNTgwNzc_e30465ea-d89d-4af9-860f-760b76a6d855"
      unitRef="usd">932330000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i96ca73985d3c4d82b3a1980bbe2e8e76_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtNy0xLTEtNTgwNzc_c82b57bd-ede3-420b-9086-6c0172af8c30"
      unitRef="usd">-806910000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i52f0e7c126f849cc86ce9adbfbd89603_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtOS0xLTEtNTgwNzc_b623f48d-bb00-4e9b-9f2f-e926a9178151"
      unitRef="usd">-20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOmE2MWVjMDViMTlhNDQ5OGM5NmRmNmYzYWEwODc5ZjA0L3RhYmxlcmFuZ2U6YTYxZWMwNWIxOWE0NDk4Yzk2ZGY2ZjNhYTA4NzlmMDRfMTMtMTEtMS0xLTU4MDc3_68b3c191-0b11-43c4-b5d5-0d55c3e7b046"
      unitRef="usd">125421000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i4732bae904484aa5a7c90237b85d7ac9_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy0xLTEtMS01ODA3Nw_f2e6a3d0-0df7-4649-820e-103aab5701de"
      unitRef="shares">130182535</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4732bae904484aa5a7c90237b85d7ac9_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy0zLTEtMS01ODA3Nw_9c6b48d5-e58a-469a-8bbc-e854c2cd0223"
      unitRef="usd">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4bd3bd1b1284974bcdb1a2b8b9df930_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy01LTEtMS01ODA3Nw_65e58832-7819-4c29-aaee-1c237f6111ab"
      unitRef="usd">795540000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic18098bd479c463a8c870397cfa95c5e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy03LTEtMS01ODA3Nw_560892e5-78e7-432c-a819-ec3b3ad85752"
      unitRef="usd">-712930000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id4809599b3f643b0b0ebea13fe0a5062_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy05LTEtMS01ODA3Nw_9f9c3664-d928-421f-9303-09fe72113a6b"
      unitRef="usd">-6000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i87f50508ad334e6eb7ed23017eb62096_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMy0xMS0xLTEtNTgwNzc_3a5ef842-ce87-4e17-8558-d1ac79dc7a0c"
      unitRef="usd">82617000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNC0xLTEtMS01ODA3Nw_cd759762-124b-459a-aab3-a97bf7ac35e5"
      unitRef="shares">127100</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="if280f015aeed4a60931d60002bd4d221_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNC01LTEtMS01ODA3Nw_4b7b39d3-3339-43bb-b102-30046170ee62"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNC0xMS0xLTEtNTgwNzc_92edd8d1-ad03-4961-b41a-89369493ac21"
      unitRef="usd">83000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfNy0xLTEtMS01ODA3Nw_2f9b58e7-4da9-48f9-b744-f2331203612e"
      unitRef="shares">113469</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS0xLTEtMS01ODA3Nw_cfdc3dca-5f07-4119-b3c4-90bb7569ece1"
      unitRef="shares">5907256</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ie9ffef6ee8da44bcb94556ef451f40c8_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS0zLTEtMS01ODA3Nw_06d4d601-2b33-42a5-ae51-389c875c45b3"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="if280f015aeed4a60931d60002bd4d221_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS01LTEtMS01ODA3Nw_c6c7b271-bd21-495f-99ad-acafa97e5163"
      unitRef="usd">5920000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfOS0xMS0xLTEtNTgwNzc_a9abde45-efc4-4a9c-aa3c-49acd32edc23"
      unitRef="usd">5921000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if280f015aeed4a60931d60002bd4d221_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTAtNS0xLTEtNTgwNzc_74eb2242-684e-4522-aa59-928d138db604"
      unitRef="usd">3722000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTAtMTEtMS0xLTU4MDc3_a9aa88c4-17c6-4e11-9ced-e4e88f47345e"
      unitRef="usd">3722000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i57175b056d77462ea9709d3fefc23984_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTEtOS0xLTEtNTgwNzc_1c151cfe-0b5f-4f2f-a04f-314dfa58da2d"
      unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTEtMTEtMS0xLTU4MDc3_9480c1a1-2f03-48b5-ab2e-80fe7094afa3"
      unitRef="usd">-82000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="i61e2e4a4f64d40aab8d29960cdd46227_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTItNy0xLTEtNTgwNzc_aa657dca-fef2-40f1-ab2a-b4b5b4af4905"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTItMTEtMS0xLTU4MDc3_a53ef67b-4110-40d3-9fe6-c241023007a7"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="id804dfa2f8bf4491961e64ab1900b30b_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtMS0xLTEtNTgwNzc_af0c79f5-f1a3-45a3-904e-e87c54bbb923"
      unitRef="shares">136330360</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="id804dfa2f8bf4491961e64ab1900b30b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtMy0xLTEtNTgwNzc_c602d32b-72b2-45b7-9a27-a3e91ed9d14e"
      unitRef="usd">14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6a28be02017a44cf8e2c9f9690207ec4_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtNS0xLTEtNTgwNzc_6e77b08d-dbb4-49b3-b7f6-74715bbfe545"
      unitRef="usd">805265000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5c831a5fa23047d39e1d3768ebd72dfa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtNy0xLTEtNTgwNzc_ad9af0a7-4185-4cad-bcab-cf587cf4e692"
      unitRef="usd">-741001000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie5547c702f0548338c9eda648f780448_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtOS0xLTEtNTgwNzc_1971bb7d-e9a5-4498-92ef-2ec814af4f3c"
      unitRef="usd">-88000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i702563bc994044d4830a60b075943f6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yNS9mcmFnOmFjNzRkMzJlODkwZTQyZmI5NDhlNzlhZjQyMmExYTY0L3RhYmxlOjgyOGMyMmI4MmVmZTRhMGJhOTllMGU2ZjU3YWFmZTU2L3RhYmxlcmFuZ2U6ODI4YzIyYjgyZWZlNGEwYmE5OWUwZTZmNTdhYWZlNTZfMTMtMTEtMS0xLTU4MDc3_505d691a-4303-4be6-88d9-1e0acf472af6"
      unitRef="usd">64190000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMy0xLTEtMS01ODA3Nw_2f46fb96-0926-4f0a-8633-983dfdb6bff6"
      unitRef="usd">-26773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMy0zLTEtMS01ODA3Nw_3d9637cf-a049-4365-897d-f78013ffa928"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNS0xLTEtMS01ODc5Nw_a2dd6376-6407-49c2-99f0-581ceec21dbf"
      unitRef="usd">-3000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNS0zLTEtMS01ODc5Nw_c33a795e-8a78-4284-bf4d-8722ba909bdf"
      unitRef="usd">463000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNi0xLTEtMS01ODA3Nw_c5ffb626-6456-4622-b1be-e4135636491c"
      unitRef="usd">902000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNi0zLTEtMS01ODA3Nw_0bb06b2a-b262-4f23-87fd-7f07f6cf870e"
      unitRef="usd">842000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNy0xLTEtMS01ODA3Nw_06c54d1f-970c-488e-94c1-15d8b37fa656"
      unitRef="usd">2912000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNy0zLTEtMS01ODA3Nw_4c7ffc98-7255-4964-a486-5f5f7415f3fc"
      unitRef="usd">3722000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOC0xLTEtMS01ODA3Nw_176c197e-63bc-4492-973e-52089fb3a642"
      unitRef="usd">70000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:IncreaseDecreaseInDerivativeLiabilities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOC0zLTEtMS01ODA3Nw_9f04b969-511d-42fd-966e-b7ba7f8e59a2"
      unitRef="usd">15000</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOS0xLTEtMS01ODA3Nw_ffb63b63-d8a6-4586-8189-91267c633622"
      unitRef="usd">0</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainsLossesOnRestructuringOfDebt
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfOS0zLTEtMS01ODA3Nw_c42fa6ab-4ded-4243-85ef-4976259a6e9a"
      unitRef="usd">-102000</us-gaap:GainsLossesOnRestructuringOfDebt>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTAtMS0xLTEtNTgwNzc_71981d99-0fda-4b70-9c76-ae771dac50ce"
      unitRef="usd">0</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTAtMy0xLTEtNTgwNzc_8f4ddb3e-f8fb-4972-a1ec-b75d0493f55a"
      unitRef="usd">710000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMS0xLTEtNjAyODI_76440837-1e43-4162-9bd3-7c237569b62c"
      unitRef="usd">429000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMy0xLTEtNjAyODI_c57dd955-3a7c-4aa8-87e0-4eaea9eb8c5e"
      unitRef="usd">0</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMS0xLTEtNTgwNzc_71b9605b-bb78-4d85-a3e6-df417844c3b8"
      unitRef="usd">1044000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTEtMy0xLTEtNTgwNzc_8129db3d-1f64-43a2-b020-33c8a321da82"
      unitRef="usd">109000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTQtMS0xLTEtNTgwNzc_148adc5b-da25-4c14-b820-30dd98ba9631"
      unitRef="usd">4387000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTQtMy0xLTEtNTgwNzc_5ac856d8-dcaf-4af8-a4f0-b6ad10a8cb59"
      unitRef="usd">3892000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTUtMS0xLTEtNTgwNzc_332547b1-056e-40b4-ba99-9b71a6729225"
      unitRef="usd">16601000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTUtMy0xLTEtNTgwNzc_9a284503-f428-4f01-be3f-ced541999a6a"
      unitRef="usd">3487000</us-gaap:IncreaseDecreaseInInventories>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTYtMS0xLTEtNTgwNzc_7e702fc1-1611-4640-849a-b81ffe6e85a2"
      unitRef="usd">268000</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTYtMy0xLTEtNTgwNzc_0bb351aa-fdb9-4b4e-8276-d76c4401a643"
      unitRef="usd">9393000</ardx:IncreaseDecreaseInPrepaidCommercialManufacturingExpense>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTctMS0xLTEtNTgwNzc_859467db-5956-4371-b9ec-c033f1ef298b"
      unitRef="usd">774000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTctMy0xLTEtNTgwNzc_21f0147b-3dab-4dff-ba51-a9cf006b40e1"
      unitRef="usd">-9086000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTgtMS0xLTEtNTgwNzc_d9af6da4-7a8b-4677-8f5b-cd4515cbcef1"
      unitRef="usd">-346000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTgtMy0xLTEtNTgwNzc_c2e47f68-3bc6-4f60-8be3-fa7f3de7e14b"
      unitRef="usd">753000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTktMS0xLTEtNTgwNzc_07b799df-ef93-43a3-b9f4-aec3a4cc7057"
      unitRef="usd">-2474000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMTktMy0xLTEtNTgwNzc_5ab20f63-21a4-4d96-a49e-95356c49662c"
      unitRef="usd">882000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjAtMS0xLTEtNTgwNzc_f407a33e-3a61-482c-ba4e-a2e805f2cbcb"
      unitRef="usd">-937000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjAtMy0xLTEtNTgwNzc_659798cd-adc0-47aa-a5be-1e972115579b"
      unitRef="usd">-836000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjEtMS0xLTEtNTgwNzc_25423668-3f7f-449f-bfe7-369adb889bf2"
      unitRef="usd">-1396000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjEtMy0xLTEtNTgwNzc_2f31dbd0-7f32-4a00-ac4a-e3a054750c63"
      unitRef="usd">-1041000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjItMS0xLTEtNTgwNzc_b73ae2ea-5ce5-49fb-b60b-32d4d6989bcd"
      unitRef="usd">3807000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjItMy0xLTEtNTgwNzc_e01d9550-a950-40b1-91a5-705cde0b5e44"
      unitRef="usd">3836000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjMtMS0xLTEtNTgwNzc_30cc39f4-b2b4-4658-9e42-69a2faeae3ef"
      unitRef="usd">-44795000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjMtMy0xLTEtNTgwNzc_d4210a47-42e0-41f9-95f7-c72e26c7f4d8"
      unitRef="usd">-27620000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjUtMS0xLTEtNTgwNzc_e38803b7-ac80-4563-a0f6-08eb835bfe1b"
      unitRef="usd">11000000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjUtMy0xLTEtNTgwNzc_9d86404b-8a96-4a9c-a761-5e0a2a4ffe7a"
      unitRef="usd">27300000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjYtMS0xLTEtNTgwNzc_2016697c-95ee-4391-9eda-fa4477f744f9"
      unitRef="usd">20763000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjYtMy0xLTEtNTgwNzc_b3a98e6e-bfe6-4cd4-b271-553a97fb1bb8"
      unitRef="usd">25763000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjctMS0xLTEtNTgwNzc_cbfd944f-5ad3-40e0-a0d4-366384c329a0"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjctMy0xLTEtNTgwNzc_cc8821e3-8f32-41db-b3fb-a3a6d5b3349d"
      unitRef="usd">795000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjgtMS0xLTEtNTgwNzc_c1453d7a-832f-491a-9434-4ee59c8f8f25"
      unitRef="usd">14000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjgtMy0xLTEtNTgwNzc_f4d3752e-ae40-453f-bee4-b0ad11d241d6"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjktMS0xLTEtNTgwNzc_fbbdf827-9de6-4f27-a557-f02e6d369222"
      unitRef="usd">-9777000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMjktMy0xLTEtNTgwNzc_f9cbf7d7-56c5-4aca-9304-a32beff30cc3"
      unitRef="usd">2332000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzEtMS0xLTEtNTgwNzc_d6a65a97-c45a-4d55-96f5-90ccead7624b"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfSecuredDebt
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzEtMy0xLTEtNTgwNzc_0cc472c6-8d94-46f0-b741-81b7376c57b2"
      unitRef="usd">26971000</us-gaap:ProceedsFromIssuanceOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzItMS0xLTEtNTgwNzc_04d3e45f-4336-46ed-8479-dc7d3d63ed3c"
      unitRef="usd">0</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:RepaymentsOfSecuredDebt
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzItMy0xLTEtNTgwNzc_65d719a3-3731-43be-a45b-c36d942c9c4f"
      unitRef="usd">33038000</us-gaap:RepaymentsOfSecuredDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzctMS0xLTEtNTgwNzc_4b4eeee2-e4cb-46d4-b7a8-e893c47fc4d6"
      unitRef="usd">50719000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzctMy0xLTEtNTgwNzc_35f8bfe9-14c2-41ad-bbfa-a46b38d92aac"
      unitRef="usd">5921000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzgtMS0xLTEtNTgwNzc_7f8ed64b-1047-4b94-9a17-a0ffc281d3c9"
      unitRef="usd">200000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfMzgtMy0xLTEtNTgwNzc_cc33b33e-9fe6-4322-9e6e-72a87b5a8876"
      unitRef="usd">83000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDEtMS0xLTEtNTgwNzc_1c0986dd-758c-46d8-ba9d-7dc6c176d7ec"
      unitRef="usd">50919000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDEtMy0xLTEtNTgwNzc_27de5b3c-19a1-4da9-a27e-13bc8e137bac"
      unitRef="usd">-63000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDItMS0xLTEtNTgwNzc_b7860fd8-1a1b-4c76-8618-a7679ba7dbb5"
      unitRef="usd">-3653000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDItMy0xLTEtNTgwNzc_545bd496-e25f-43ac-abfc-a8e40c42812c"
      unitRef="usd">-25351000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDMtMS0xLTEtNTgwNzc_526a6dde-077a-4b12-aa7c-c739abe9e125"
      unitRef="usd">96140000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i87f50508ad334e6eb7ed23017eb62096_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDMtMy0xLTEtNTgwNzc_1959cc41-1a9e-4dc1-aa2e-6ea7d94d70fb"
      unitRef="usd">72428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDQtMS0xLTEtNTgwNzc_187a050c-7def-4dd5-9e15-c292e62d2b9a"
      unitRef="usd">92487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i702563bc994044d4830a60b075943f6b_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDQtMy0xLTEtNTgwNzc_daa91035-ac84-45d1-bcdb-1c27a5275f5b"
      unitRef="usd">47077000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDYtMS0xLTEtNTgwNzc_cd6435d6-e048-43cc-aa83-d969c7fa83d3"
      unitRef="usd">860000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDYtMy0xLTEtNTgwNzc_6531fc4b-7dd2-46d1-ba2f-bf6baae20b6e"
      unitRef="usd">741000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDctMS0xLTEtNTgwNzc_8cfe2e8f-190c-4c52-b8d7-c191ee829c77"
      unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNDctMy0xLTEtNTgwNzc_c96dd1a5-3819-4b4b-8b1e-cada3708da0b"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaidNet>
    <ardx:DerivativeIssued
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNTEtMS0xLTEtNTgwNzc_0ed73fc5-6c3c-4113-963f-3276d7de290c"
      unitRef="usd">0</ardx:DerivativeIssued>
    <ardx:DerivativeIssued
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8yOC9mcmFnOjQwYzE0M2NiMDk1MzQwYzA4MGY2NGVmZjNlMTBmYjc3L3RhYmxlOmRiOWRiMWFlZjBlNzQ2OTJiOTA2OTBjZmM5NjcxM2JkL3RhYmxlcmFuZ2U6ZGI5ZGIxYWVmMGU3NDY5MmI5MDY5MGNmYzk2NzEzYmRfNTEtMy0xLTEtNTgwNzc_27252d43-ecd5-41b6-bf59-4af444aea910"
      unitRef="usd">375000</ardx:DerivativeIssued>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTc_f10db0d7-8e1f-4dcd-959d-a643dd9a4378">ORGANIZATION AND BASIS OF PRESENTATION&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ardelyx, Inc. (&#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; or &#x201c;our&#x201d;) is a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. We developed a unique and innovative platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The first molecule we discovered and developed was tenapanor, a targeted, first-in-class, oral, small molecule therapy. Tenapanor, branded as IBSRELA, is approved in the U.S. for the treatment of adults with irritable bowel syndrome with constipation (&#x201c;IBS-C&#x201d;). In April 2023, we resubmitted a New Drug Application (&#x201c;NDA&#x201d;) to the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) for the approval of XPHOZAH (tenapanor) for the control of serum phosphate in adult patients with chronic kidney disease (&#x201c;CKD&#x201d;) on dialysis who have had an inadequate response or intolerance to a phosphate binder therapy, under the brand name XPHOZAH. We also have a development stage asset, RDX013 for adult patients with CKD and/or heart failure with hyperkalemia, or elevated serum potassium, and a discovery phase asset, RDX020 for adult patients with metabolic acidosis, a serious electrolyte disorder, in patients with CKD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment, which is the development and commercialization of biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2022. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2023, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, we had cash, cash equivalents and short-term investments of approximately $130.4&#160;million. We have incurred operating losses since inception in 2007 and our accumulated deficit as of March&#160;31, 2023 is $806.9&#160;million. Our current level of cash, cash equivalents and short-term investments alone is not sufficient to meet our plans for the next twelve months following the issuance of these condensed financial statements on May&#160;3, 2023. These factors raise substantial doubt regarding our ability to continue as a going concern for a period of one year from the issuance of these condensed financial statements. We plan to address our operating cash flow requirements with our current cash, cash equivalents and short-term investments, cash generated from product sales of IBSRELA, and if approved, cash generated from sales of XPHOZAH, our potential receipt of anticipated milestones payments from our collaboration partners, our potential receipt of anticipated payments from our Japanese collaboration partner under the second amendment to our License Agreement, with additional financing sources and through the implementation of cash preservation activities to reduce or defer discretionary spending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are no assurances that our efforts to meet our operating cash flow requirements will be successful. If our current cash, cash equivalents and short-term investments as well as our plans to meet our operating cash flow requirements are not sufficient to fund necessary expenditures and meet our obligations for at least the next twelve months following the issuance of these financial statements, our liquidity, financial condition and business prospects will be materially affected. These financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event that we can no longer continue as a going concern. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our significant accounting policies are described in Note 2 to our audited financial statements for the fiscal year ended December&#160;31, 2022, included in our Annual Report on Form 10-K. There have been no material changes in our significant accounting policies as previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements subsequent to filing our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMjg5_372dbe63-ae23-47bc-a40b-52efaec57140"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTg_f56ea377-31e7-45c5-a5a5-b655199b8d96">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and pursuant to the requirements of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) for interim reporting. As permitted under those rules&#160;and regulations, certain footnotes or other financial information that are normally required by U.S. GAAP have been condensed or omitted. These condensed financial statements have been prepared on the same basis as our most recent annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary to present fairly our financial position, results of operations, changes in stockholders&#x2019; equity, and cash flows for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed financial statements and related financial information should be read in conjunction with the audited financial statements and the related notes thereto included in our Annual Report on Form 10-K for the&#160;year ended December&#160;31, 2022. The results for the three months ended March&#160;31, 2023 are not necessarily indicative of results to be expected for the entire&#160;year ending December&#160;31, 2023, or for any other interim period or future year.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTI_88b8127e-9b5d-4f55-94ed-9b45fcf5f554">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and judgments that affect the amounts reported in the financial statements and accompanying notes thereto. On an ongoing basis, management evaluates its estimates, including those related to recognition of revenue, clinical trial accruals, contract manufacturing accruals, utilization of inventory, fair value of assets and liabilities, income taxes and stock-based compensation. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:InvestmentsAndCash
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMjQ0OA_f0485ceb-8e9f-499f-ad78-5100c448dafd"
      unitRef="usd">130400000</us-gaap:InvestmentsAndCash>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMjU0Mg_8bc1570c-5cf9-476a-a847-acac008f4871"
      unitRef="usd">-806900000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNC9mcmFnOmRkN2IzYWFmMjMxYjRmM2M4YjFhYmJiMGQzNGU3OWNjL3RleHRyZWdpb246ZGQ3YjNhYWYyMzFiNGYzYzhiMWFiYmIwZDM0ZTc5Y2NfMTYyNTU_cc44aff9-1486-45dc-9202-b66f4a4f59f5">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New Accounting Pronouncements - Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted no new accounting pronouncements subsequent to filing our most recent Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were various accounting standards and interpretations issued recently, none of which are expected to have a material impact on our financial position, operations or cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfMjMxMg_ef014fbb-f129-4a12-ab14-a6a1becccedd">CASH, CASH EQUIVALENTS AND INVESTMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and short-term investments as of March&#160;31, 2023 and December&#160;31, 2022 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist of money market funds with original maturities of three months or less at the time of purchase, and the carrying amount is a reasonable approximation of fair value. We invest our cash in high quality securities of financial and commercial institutions. These securities are carried at fair value, which is based on readily available market information, with unrealized gains and losses included in accumulated other comprehensive loss within stockholders&#x2019; equity on our condensed balance sheets. We use the specific identification method to determine the amount of realized gains or losses on sales of marketable securities. Realized gains or losses have been insignificant and are included in other income, net, in the statement of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the short-term available-for sale securities held as of March&#160;31, 2023 and December&#160;31, 2022 had contractual maturities of less than one year. Our available-for-sale securities are subject to a periodic impairment review. We consider a debt security to be impaired when its fair value is less than its carrying cost, in which case we would further review the investment to determine whether it is other-than-temporarily impaired. When we evaluate an investment for other-than-temporary impairment, we review factors such as the length of time and extent to which fair value has been below cost basis, the financial condition of the issuer and any changes thereto, intent to sell, and whether it is more likely than not we will be required to sell the investment before the recovery of its cost basis. If an investment is other-than-temporarily impaired or subject to credit losses, we write it down through the statement of operations and comprehensive loss to its fair value and establish that value as a new cost basis for the investment. Our unrealized losses as of March&#160;31, 2023 and December&#160;31, 2022 were not material. We determined that none of our available-for-sale securities were other-than-temporarily impaired as of March&#160;31, 2023 and December&#160;31, 2022, and no investment was in a continuous unrealized loss position for more than one year. As such, we believe that it is more likely than not that the investments will be held until maturity or a forecasted recovery of fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfMjMxMw_3ce4c2f1-37f8-4065-b9b2-5e7668181d95">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Securities classified as cash, cash equivalents and short-term investments as of March&#160;31, 2023 and December&#160;31, 2022 are summarized below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.416%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.075%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia0d688e400e645008fb72d473b88ac99_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNC0xLTEtMS01ODA3Nw_3755db2f-9ff3-438a-b7d9-94326e7226cd"
      unitRef="usd">7986000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia0d688e400e645008fb72d473b88ac99_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNC03LTEtMS01ODA3Nw_09f1bac5-8777-47b3-a0f1-9a73ab621d30"
      unitRef="usd">7986000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic936e46468054162a36dcf4e97de128d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNS0xLTEtMS01ODA3Nw_3492fe7f-847d-44b0-81a6-8a804f6c8ea4"
      unitRef="usd">84501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic936e46468054162a36dcf4e97de128d_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfNS03LTEtMS01ODA3Nw_70d1b3e6-063e-4d71-b18e-4d750b845ec7"
      unitRef="usd">84501000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfOC0xLTEtMS01ODA3Nw_630c3578-afdb-4045-8b70-a25bd9da745d"
      unitRef="usd">92487000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfOC03LTEtMS01ODA3Nw_6c799c0f-cc04-48fd-a24a-5320f3fc6478"
      unitRef="usd">92487000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtMS0xLTEtNTgwNzc_f8c558b1-8c7f-460b-ba07-0653de14e3af"
      unitRef="usd">23353000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtMy0xLTEtNTgwNzc_4639b065-fd3f-4f35-afc3-b9633d40b2f1"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtNS0xLTEtNTgwNzc_e434b322-a2bd-4e0e-8e88-fac8515d854e"
      unitRef="usd">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie12a2be0e30248e18c0e219442faa6a9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTAtNy0xLTEtNTgwNzc_36becf21-8640-4956-b499-2f95b243b18e"
      unitRef="usd">23333000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie631368284b2408aad835684afa02e95_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtMS0xLTEtNTgwNzc_42af485b-8e00-473e-8474-8dd4e980a3c9"
      unitRef="usd">12618000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie631368284b2408aad835684afa02e95_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtMy0xLTEtNTgwNzc_ce9fa4c2-5091-44eb-9908-ef92a7911035"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie631368284b2408aad835684afa02e95_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtNS0xLTEtNTgwNzc_bf19b186-f02f-46b6-8d7a-341eafa78206"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie631368284b2408aad835684afa02e95_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTEtNy0xLTEtNTgwNzc_799f3515-3394-46e6-9ca9-acb27183fdf3"
      unitRef="usd">12620000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0524220fccc7435abcb990a758edda9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtMS0xLTEtNTgwNzc_a87462ab-208a-493a-a576-748cb1929811"
      unitRef="usd">1935000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0524220fccc7435abcb990a758edda9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtMy0xLTEtNTgwNzc_ced05eb3-208d-4747-b75d-ca72bea117c0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0524220fccc7435abcb990a758edda9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtNS0xLTEtNTgwNzc_1107a2b7-6cb2-439a-bf62-f84f29d3b0ae"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0524220fccc7435abcb990a758edda9f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTMtNy0xLTEtNTgwNzc_2f0c0556-58c7-4fcf-adec-0851ef80a016"
      unitRef="usd">1933000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtMS0xLTEtNTgwNzc_c7a3cd85-ef4a-44a1-9e0e-4df9deb7cb1d"
      unitRef="usd">37906000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtMy0xLTEtNTgwNzc_5d45bd7f-7c08-4668-bef6-6c75dc10b14d"
      unitRef="usd">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtNS0xLTEtNTgwNzc_f1526a52-d0bf-480f-bffc-4bcbebade49a"
      unitRef="usd">31000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTQtNy0xLTEtNTgwNzc_51f25b37-516e-4b88-8acc-5b20329eeee3"
      unitRef="usd">37886000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtMS0xLTEtNTgwNzc_594a98e6-3f4c-4bb4-8129-1be505bdcc04"
      unitRef="usd">130393000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtMy0xLTEtNTgwNzc_adff7718-2865-4943-8aef-5d9301a06898"
      unitRef="usd">11000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtNS0xLTEtNTgwNzc_5ceda6d2-e77a-4ffc-a824-3e4dfbee7d50"
      unitRef="usd">31000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOjRhYTJiOWZiYTZlYTRhZGE4M2ZiNDY0ZGY5MTY0Y2NjL3RhYmxlcmFuZ2U6NGFhMmI5ZmJhNmVhNGFkYTgzZmI0NjRkZjkxNjRjY2NfMTUtNy0xLTEtNTgwNzc_43115a44-b8d3-4d2c-9828-777112fd71b4"
      unitRef="usd">130373000</us-gaap:InvestmentsAndCash>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id884382c6adf4ee689a124f5a304b668_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNC0xLTEtMS01ODA3Nw_da30f8a7-6461-4903-87c0-9a5766184ae8"
      unitRef="usd">11827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id884382c6adf4ee689a124f5a304b668_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNC03LTEtMS01ODA3Nw_60de364b-503d-40a5-96e8-b13b4a47fd03"
      unitRef="usd">11827000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0d87663204949f4982bae6de6a652c0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNS0xLTEtMS01ODA3Nw_f1e417c7-c2b4-4056-9890-daf3446206c4"
      unitRef="usd">84313000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0d87663204949f4982bae6de6a652c0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfNS03LTEtMS01ODA3Nw_e6149b42-ab1c-4105-a0b5-b1d9bfe86251"
      unitRef="usd">84313000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfOC0xLTEtMS01ODA3Nw_902eb8fb-93aa-4651-9bc0-5540f9720e43"
      unitRef="usd">96140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfOC03LTEtMS01ODA3Nw_5017b2dd-285c-4594-9a10-ee2a568e84ef"
      unitRef="usd">96140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtMS0xLTEtNTgwNzc_63bd9c3b-aa46-4210-bc4f-53bc49834e0d"
      unitRef="usd">25336000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtMy0xLTEtNTgwNzc_61cfea11-c751-4fc0-a9c7-1f1415815ca9"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtNS0xLTEtNTgwNzc_565c5768-46c2-4d48-bf0e-54ec089a81e3"
      unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if52a556a61d24bc0b97c984c978c2ced_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTAtNy0xLTEtNTgwNzc_b48a53c6-b50e-4eff-a2df-255d20c3e80d"
      unitRef="usd">25291000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtMS0xLTEtNTgwNzc_a4cdb1bd-d710-4717-94e6-6ec3db6dc70d"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtMy0xLTEtNTgwNzc_e1b4b639-7e0f-485d-b5b7-e1f92f35dda2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtNS0xLTEtNTgwNzc_c43560d3-5e41-4669-8744-94ab16de4824"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifc0743eef5b24b739e5fe93758972073_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTEtNy0xLTEtNTgwNzc_520497f3-9d65-4f41-9148-096beda42be7"
      unitRef="usd">999000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItMS0xLTEtNTgwNzc_588af114-6d8c-4652-b6c4-98aef41e4237"
      unitRef="usd">1487000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItMy0xLTEtNTgwNzc_943264b7-c78a-4faf-96d3-fe9800d62091"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItNS0xLTEtNTgwNzc_54e1ec8f-b02c-4325-b3aa-3811d060d41a"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccb2d8b60a884c85ac3e24336cb63e2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTItNy0xLTEtNTgwNzc_375fd65b-4d11-4c76-83f3-df27de3e5c5a"
      unitRef="usd">1479000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtMS0xLTEtNTgwNzc_1d0b3e37-1f80-44d5-8414-0a551716f03f"
      unitRef="usd">27823000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtMy0xLTEtNTgwNzc_84dece6b-258b-4035-b0bd-b8fc6e0a7d22"
      unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtNS0xLTEtNTgwNzc_6d54c3dd-d821-4665-915e-98ba1a6e040d"
      unitRef="usd">60000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTQtNy0xLTEtNTgwNzc_ae15b541-d1a0-419b-ab72-8caacf7a28ac"
      unitRef="usd">27769000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <ardx:InvestmentsAndCashAmortizedCost
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctMS0xLTEtNTgwNzc_6ffbbbb7-cf96-429d-98d6-ec001c3d3890"
      unitRef="usd">123963000</ardx:InvestmentsAndCashAmortizedCost>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctMy0xLTEtNTgwNzc_1313d5cd-f6e1-4089-bbd9-963f18b43f10"
      unitRef="usd">6000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedGains>
    <ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctNS0xLTEtNTgwNzc_2b7ef108-826e-4a23-bb09-98c8b74b521d"
      unitRef="usd">60000</ardx:CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses>
    <us-gaap:InvestmentsAndCash
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RhYmxlOmU4ZTYwNTdiNDZlNzRmZmRiMTI2MTU2MGJjYWY5MWNkL3RhYmxlcmFuZ2U6ZThlNjA1N2I0NmU3NGZmZGIxMjYxNTYwYmNhZjkxY2RfMTctNy0xLTEtNTgwNzc_b122c032-8923-4a24-840b-f4a2692022e0"
      unitRef="usd">123909000</us-gaap:InvestmentsAndCash>
    <ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODE5MjU0_67959fd0-591b-456f-904d-cb82e4dbe212">P1Y</ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum>
    <ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum
      contextRef="i702ac6a7149a4273b8841d440aaca4c1_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODE5MjU0_d170a811-9e0c-4903-b033-dec257e5aeb7">P1Y</ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODIwMzM2_0d4d035f-a3f7-48fd-9d01-a4d45bf89e72"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV8zNy9mcmFnOjE5YjVhMTM4YjY2MjQwMWJiMzA2MTUzZDlkMjQzNDllL3RleHRyZWdpb246MTliNWExMzhiNjYyNDAxYmIzMDYxNTNkOWQyNDM0OWVfNTQ5NzU1ODIwMzM2_f2fc5fae-fdc8-429f-b629-0e5b8b3e003b"
      unitRef="investment">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfMjU5MQ_f2f68bc4-841d-4ac8-8278-f409db34b82e">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Where quoted prices are available in an active market, securities are classified as Level 1. We classify money market funds as Level 1. When quoted market prices are not available for the specific security, we estimate fair value by using benchmark yields, reported trades, broker/dealer quotes and issuer spreads. We classify U.S. government-sponsored agency bonds, U.S. treasury notes, corporate bonds, commercial paper, and asset-backed securities as Level 2. In certain cases, where there is limited activity or less transparency around inputs to valuation, securities or derivative liabilities, such as the 2018 Exit Fee and the 2022 Exit Fee, as defined and discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the condensed balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2023 and December&#160;31, 2022, due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have not recorded an allowance for credit losses for these securities as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of March&#160;31, 2023 and December&#160;31, 2022. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8. Borrowing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 2 inputs used to estimate the fair value of the liability.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of March&#160;31, 2023 and December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be paid to us by Kyowa Kirin Co., Ltd. ("Kyowa Kirin") over the life of the agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 3 inputs used to estimate the fair value of the liability.&lt;/span&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfMjU4OA_250fbc5f-dbe7-47f0-8ef9-40ccba390246">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The three-level hierarchy for the inputs to valuation techniques is briefly summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations are based on quoted prices in active markets for identical assets or liabilities and readily accessible by us at the reporting date.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3 &#x2013;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuations based on unobservable inputs for which there is little or no market data, which require us to develop our own assumptions.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, are classified as Level 3.&lt;/span&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts reflected in the condensed balance sheets for cash equivalents, short-term investments, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values at both March&#160;31, 2023 and December&#160;31, 2022, due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on our procedures under the expected credit loss model, including an assessment of unrealized losses in our portfolio, we concluded that any unrealized losses on our marketable securities were not attributable to credit and, therefore, we have not recorded an allowance for credit losses for these securities as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal amount outstanding under our term loan facilities is subject to a variable interest rate. Therefore, we believe the carrying amount of the term loan facility approximates fair value as of March&#160;31, 2023 and December&#160;31, 2022. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8. Borrowing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 2 inputs used to estimate the fair value of the liability.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of the deferred royalty obligation related to the sale of future royalties approximates its fair value as of March&#160;31, 2023 and December&#160;31, 2022 and is based on our current estimates of future royalties and commercialization milestones expected to be paid to us by Kyowa Kirin Co., Ltd. ("Kyowa Kirin") over the life of the agreement. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the Level 3 inputs used to estimate the fair value of the liability.&lt;/span&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfMjU4OQ_741897bb-5c66-47bd-a884-748acb65ddf5">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the fair value of our financial assets and liabilities that are measured or disclosed on a recurring basis by level within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liabilities for exit fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored agency bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 12.25pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative liability for exit fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if787129ae8904e9fa759cc369c4db88f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy0xLTEtMS01ODA3Nw_f2d49633-6880-48f7-9c4b-98de16ff2b11"
      unitRef="usd">84501000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iadea2dc595e045b693f4c3806a5d3b16_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy0zLTEtMS01ODA3Nw_24ad43bc-e02a-4d64-bfd6-15088079f538"
      unitRef="usd">84501000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic3daca4f51d947b5945b812330581364_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy01LTEtMS01ODA3Nw_07cbb4ef-355b-4026-9ba0-e893e3f4e361"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i85a8b0761bd5415db96033f744c6140a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMy03LTEtMS01ODA3Nw_58949255-4346-4e59-9470-2ca4525da89b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1c74497a62594f85876db914b650f7c4_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC0xLTEtMS01ODA3Nw_a7cbd015-ee33-4add-8ab0-0c8edbb606bf"
      unitRef="usd">23333000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i588c4fa500554006860c6007e40ee0a5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC0zLTEtMS01ODA3Nw_86d71c86-8ebe-488f-afc7-dee979eb57e5"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3ad9611ed2ff4e919a234ed94bba8aed_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC01LTEtMS01ODA3Nw_9d2f51db-62f2-4c1d-a564-afc33a6df21b"
      unitRef="usd">23333000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i883fa34c97c54813bb2d78e911d603f8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNC03LTEtMS01ODA3Nw_bb8a18ef-a5d7-42ed-ad26-36f4979936b1"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ide24937bdbc64ce28cc5e6cbfbd5e742_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS0xLTEtMS01ODA3Nw_bade551e-6393-4d8a-be4a-7e9556ce3087"
      unitRef="usd">12620000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifaf58162db324fe59ce07df2c57faf57_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS0zLTEtMS01ODA3Nw_8b350d8c-43f4-4c20-934a-f67c865c07c4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib8afaa29db094d8f940e22612a879ea8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS01LTEtMS01ODA3Nw_427b0020-846e-4583-b4dd-2c99533efa0e"
      unitRef="usd">12620000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ib68a978d30bb4163a635630e070edcb7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNS03LTEtMS01ODA3Nw_67ca3d4d-4f53-48b9-9a45-80739dd39b98"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4dda51aa0a8049d1968ca0f7b120ceef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy0xLTEtMS01ODA3Nw_a8449a5f-95a4-4e8c-a43f-b2dcb4f699d1"
      unitRef="usd">1933000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i89592ca2da2742faaa3ad4dd4f55e876_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy0zLTEtMS01ODA3Nw_ecf35676-ec16-4f4e-a91b-caa6473f568b"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3a9ba30f7b5548f8acfc7d00df9d940a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy01LTEtMS01ODA3Nw_60d59a40-6e7c-4f15-930e-90909173419b"
      unitRef="usd">1933000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4dece602bb7b484e80d6317ab479a4e9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfNy03LTEtMS01ODA3Nw_f86bc9cf-0f7f-4db6-be60-45bb157db404"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iab7f44ca18fe47858c896bf995bca00b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS0xLTEtMS01ODA3Nw_7408b24c-9aa7-4571-814d-3d2aec8e3c62"
      unitRef="usd">122387000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i766e68b72c6f4313991c6e312bae923e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS0zLTEtMS01ODA3Nw_29b6d2d2-cf7e-4e55-b8bb-a68502244d38"
      unitRef="usd">84501000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1ad81d2394b2450fba8397056389cb20_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS01LTEtMS01ODA3Nw_a1b7c324-da13-4ef2-b247-1c15356ad98d"
      unitRef="usd">37886000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i803ae491ae4247699729cd6edb089399_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfOS03LTEtMS01ODA3Nw_077a231e-c641-4c46-b8c2-072e43c96659"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i19b484f382e14cee9bae114778c4b2ee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItMS0xLTEtNTgwNzc_f4a31e52-cb90-4f49-b072-38c5212292bb"
      unitRef="usd">1726000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i5e493e744f814e32a4f525d3b099f39a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItMy0xLTEtNTgwNzc_729b1001-5367-4290-aadd-a5519161c49a"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i199726c1e7c64eed97aea0f720596607_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItNS0xLTEtNTgwNzc_dd28da0d-6bf6-4d3a-bee6-b27b0457b33f"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i45e32429d8b040ce8d79b9dde9e922f7_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTItNy0xLTEtNTgwNzc_f2b9805c-d414-45f6-9c5c-bee68a8434fe"
      unitRef="usd">1726000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iab7f44ca18fe47858c896bf995bca00b_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtMS0xLTEtNTgwNzc_7df5211e-a80d-4bf3-9ec6-26d6ffb8545a"
      unitRef="usd">1726000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i766e68b72c6f4313991c6e312bae923e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtMy0xLTEtNTgwNzc_00cb6429-d141-4f00-98b2-b5564d8067c0"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1ad81d2394b2450fba8397056389cb20_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtNS0xLTEtNTgwNzc_de2bcc62-6e4b-4694-9d17-6884128b7478"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i803ae491ae4247699729cd6edb089399_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjI5MjcxODJmMDBiMzRhZTU5YWY5YTIxNjZkODA2NjVhL3RhYmxlcmFuZ2U6MjkyNzE4MmYwMGIzNGFlNTlhZjlhMjE2NmQ4MDY2NWFfMTMtNy0xLTEtNTgwNzc_4b1a757a-9784-48e7-be16-f0b2550dd487"
      unitRef="usd">1726000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iecb4976c60f342fa953b24367cd3820e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy0xLTEtMS01ODA3Nw_4c093ae0-5017-4409-a79d-3dc0905aef11"
      unitRef="usd">84313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i669a009daaeb4d2db79701235b95e376_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy0zLTEtMS01ODA3Nw_9873eddc-8849-4bb0-9103-e2d2b08596d4"
      unitRef="usd">84313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic39295831f6047c59873ab434e7a7cf7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy01LTEtMS01ODA3Nw_6477d5d7-cef7-4aa4-9ad1-48435e407db9"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iede9e2d88ec041849965bcef8bfb9c17_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMy03LTEtMS01ODA3Nw_1e879518-f9c3-4255-b105-3681008bd46d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i57102aa94d874a13b6507d22ca28cdc0_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC0xLTEtMS01ODA3Nw_bb22f6f5-747e-48ec-ad41-e3f8aa71ed90"
      unitRef="usd">25291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8dd2aff3e0974780a6b2aa931ebb28f9_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC0zLTEtMS01ODA3Nw_a9ef636f-cec1-465b-bf8f-23bd87b7934e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iae1010cf9f614aa9b7166c1b910413d5_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC01LTEtMS01ODA3Nw_fd3db347-2773-45d9-ae31-0e2657f4a946"
      unitRef="usd">25291000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic892b663020e42b1bd246832a5009260_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNC03LTEtMS01ODA3Nw_76b9f927-f519-42d6-8023-5996e207d969"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2db82a67dfd141e8a7a89f9559c2902d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS0xLTEtMS01ODA3Nw_97a3675f-491a-46c6-8efd-cd8970dd217e"
      unitRef="usd">999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1fb1446d2f5f4438a3d7554393bc9a1f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS0zLTEtMS01ODA3Nw_f4a21fdd-f8e6-4bcb-b0c3-d42486dccd6f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i242fd96eb50447d3991a0de8c6a76b37_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS01LTEtMS01ODA3Nw_c92c1777-7420-4201-af6f-c6cb0477c595"
      unitRef="usd">999000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i44fae79f843e424798285c554872b550_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNS03LTEtMS01ODA3Nw_bbec08d9-3ffb-4ad8-a55f-b211b3fded52"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i63206a33055f4c71bee2ac6cc2b4f155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi0xLTEtMS01ODA3Nw_c5f547c3-e5a9-4013-a44a-30750d9f3be0"
      unitRef="usd">1479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8517689b41a2471a8481ff5ea1df4049_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi0zLTEtMS01ODA3Nw_ec9860f2-2e78-4551-8ab5-3c87c87163fc"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9711e441836a4f0d870c15d342503a53_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi01LTEtMS01ODA3Nw_116cacda-8f5f-4fc0-b5e8-ee3df6c65ebf"
      unitRef="usd">1479000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i87660283b17b44d686672983be8c5c21_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfNi03LTEtMS01ODA3Nw_ee37994b-d7c6-4052-b49c-1f88816b1511"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69de1d9e70cd4b0088ef12543981f292_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS0xLTEtMS01ODA3Nw_d0a90809-f4d9-4e5d-93fe-1826a258f9ce"
      unitRef="usd">112082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i440c55b90eec415db702e87c2679f87b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS0zLTEtMS01ODA3Nw_16e7a96d-0915-482c-8edb-d4d0dff12337"
      unitRef="usd">84313000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0576a7417fb0498fb1ea19dcab1a3146_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS01LTEtMS01ODA3Nw_985c024e-9c14-47bd-9ca7-17466993b78e"
      unitRef="usd">27769000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id5d8d964b58e482b9ff481926c12e415_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfOS03LTEtMS01ODA3Nw_12c299b9-1699-40aa-96d4-8746f3f854e4"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if376b021c40b4857af8ed796b6f678c4_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItMS0xLTEtNTgwNzc_7c1dc8e2-6c83-4a3c-a79d-fb853632a4c6"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="iebfb6b4b245549c1925014c3d197a60d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItMy0xLTEtNTgwNzc_f668dd90-4f3d-4c32-ae12-f636b96968f7"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4861c96b38f245e58dee1fb635b16e2b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItNS0xLTEtNTgwNzc_49ef4e27-ad27-4f7c-9e32-a85cc3be8531"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i644fdcb9f2ec487eb5257a431392d340_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTItNy0xLTEtNTgwNzc_47905b47-d7f4-47b6-92be-4f07943ffad6"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i69de1d9e70cd4b0088ef12543981f292_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtMS0xLTEtNTgwNzc_5ea25859-905c-429a-8a31-173d10fe6043"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i440c55b90eec415db702e87c2679f87b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtMy0xLTEtNTgwNzc_4917eda7-fdac-4495-84e8-eccd88b8f43d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i0576a7417fb0498fb1ea19dcab1a3146_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtNS0xLTEtNTgwNzc_69fbb1c1-af8b-43d9-ab67-71635a1a0ef9"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id5d8d964b58e482b9ff481926c12e415_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RhYmxlOjMzYmNjMmI0MmM1NTQwYjFiZTM3MTEyOGZkNjM0Zjc3L3RhYmxlcmFuZ2U6MzNiY2MyYjQyYzU1NDBiMWJlMzcxMTI4ZmQ2MzRmNzdfMTMtNy0xLTEtNTgwNzc_211de9fd-f6f1-4a58-aed5-c367627a7879"
      unitRef="usd">1656000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfNTQ5NzU1ODE4OTE1_9153827a-44f4-42d7-aefe-e987ab7ccde7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80MC9mcmFnOmQ4ZDQ1ZjQ0MWI1MTRjYmViNjZhZWE1NjNmNWIzNzE5L3RleHRyZWdpb246ZDhkNDVmNDQxYjUxNGNiZWI2NmFlYTU2M2Y1YjM3MTlfNTQ5NzU1ODE4OTE1_d7172663-a9ec-4568-aa67-9355aff48fc5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNzI1_8c8e6e11-df48-47fc-ad4e-fa6722ba5f15">INVENTORY&lt;div style="margin-bottom:3pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We began capitalizing inventory during the fourth quarter of 2021, at which time our intent to commercialize IBSRELA was established and we commenced preparation for the commercial launch of IBSRELA. Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Prepaid commercial manufacturing of $13.8&#160;million and $13.6&#160;million as of March&#160;31, 2023 and December&#160;31, 2022, respectively, consisted of prepayments to third party contract manufacturing organizations for the manufacture of IBSRELA for production orders which we expect work to commence within the next 12 months.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNzI2_5db9b7a0-ca69-4850-84dc-9c9f0e129da8">Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNzI2_d9f26f40-8d15-410b-8d2f-41cde20694ac">Inventory as of March&#160;31, 2023 and December&#160;31, 2022 consisted of the following (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.953%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.397%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.065%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMS0yLTEtMS01OTcyNQ_79f3c415-f732-4306-9624-7775c6cd254d"
      unitRef="usd">21702000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMS0yLTEtMS01ODA3Nw_123656cb-c626-46d7-a59a-c400cc5ca3a1"
      unitRef="usd">22299000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMi0yLTEtMS01OTcyNQ_f1b4120d-1e95-4b4d-b99c-7854b345aaae"
      unitRef="usd">22566000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMi0yLTEtMS01ODA3Nw_2a82a730-2445-4eda-b7bc-6e562292403c"
      unitRef="usd">5324000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMy0yLTEtMS01OTcyNQ_89068557-e082-4b2b-88c1-42f9b617a67d"
      unitRef="usd">679000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfMy0yLTEtMS01ODA3Nw_cbc49ad4-ddc0-4a32-9337-e80358f82c7b"
      unitRef="usd">723000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNC0yLTEtMS01OTcyNQ_dcc3f97e-6e1b-4c6a-99c6-704eb4da46c9"
      unitRef="usd">44947000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNC0yLTEtMS01ODA3Nw_5245b5ee-92fb-47de-9fb3-914bc4d0ade6"
      unitRef="usd">28346000</us-gaap:InventoryNet>
    <us-gaap:InventoryGross
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNi0yLTEtMS01OTczNQ_63f77af8-7067-4260-8792-e91f9bfdd0f0"
      unitRef="usd">4823000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNi0yLTEtMS01ODA3Nw_44f243b0-efaf-4bd9-8753-f24ba10f193a"
      unitRef="usd">3282000</us-gaap:InventoryGross>
    <us-gaap:InventoryNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNy0yLTEtMS01OTczNQ_5bbda677-5f5c-4bfe-9556-8197ccaf21e1"
      unitRef="usd">40124000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfNy0yLTEtMS01ODA3Nw_eacaa38d-1db5-4077-96b9-fd69c17619dc"
      unitRef="usd">25064000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNet
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfOC0yLTEtMS01OTczNQ_11c5b431-4d85-45bf-b50e-b7a978cc9eef"
      unitRef="usd">44947000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RhYmxlOjkxMDY5OTY0MmFjMTRjYTViMzVhZjE3ZGMyZGY2MGZmL3RhYmxlcmFuZ2U6OTEwNjk5NjQyYWMxNGNhNWIzNWFmMTdkYzJkZjYwZmZfOC0yLTEtMS01ODA3Nw_8a5cde44-5661-433c-b949-76df537b5834"
      unitRef="usd">28346000</us-gaap:InventoryNet>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNTQ5NzU1ODE1MTkx_8ed05eb5-a0ab-42b2-84ac-83b3b3e41907"
      unitRef="usd">13800000</ardx:PrepaidCommercialManufacturingCurrent>
    <ardx:PrepaidCommercialManufacturingCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80My9mcmFnOjcwYjQ3MTE2NjRiYTQxYzg4NDFlMDlmNmQ2YzVhYjhiL3RleHRyZWdpb246NzBiNDcxMTY2NGJhNDFjODg0MWUwOWY2ZDZjNWFiOGJfNTQ5NzU1ODE1MTk5_c7fc6b84-f9f0-4123-8231-ae9f1382cb2e"
      unitRef="usd">13600000</ardx:PrepaidCommercialManufacturingCurrent>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNzUz_6e4790b2-8eaa-406e-9ae5-9d8b9a6edd37">PRODUCT REVENUE, NET&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received approval from the FDA in September 2019 to market IBSRELA in the U.S. We began selling IBSRELA in the U.S. in March 2022. We recorded net revenue for IBSRELA of $11.4&#160;million and $0.5 million during the three months ended March&#160;31, 2023 and 2022, respectively. We distribute IBSRELA principally through major wholesalers, specialty pharmacies and group purchasing organizations ("GPOs") (collectively, our "Customers"). Our Customers subsequently sell IBSRELA to pharmacies and patients. Separately, we enter into arrangements with third parties that provide for government-mandated rebates, chargebacks and discounts. Revenue from product sales is recognized when our performance obligations are satisfied, which is when Customers obtain control of our product and occurs upon delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales to Cardinal Health, AmerisourceBergen Drug Corporation, and McKesson Corporation made up 22.2%, 21.6%, and 20.8%, respectively, of our product sales, net during the three months ended March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Wholesaler and GPO Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if10e10eb21804ecea009554e9a64bbfe_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfMjgw_beca11ee-63fd-4182-bfa6-bbc35bf91c11"
      unitRef="usd">11400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9daeb86042c74be28a77bbfb542222af_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfMTY0OTI2NzQ0NjI5MA_031d1316-111d-434a-aff2-72582d046b51"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i077fb918ffd34a16a2ba56d845e7c0eb_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNTQ5NzU1ODE0OTcx_d7016b3f-c3a2-4144-954a-fa43ed28aa76"
      unitRef="number">0.222</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i45042f4036a348d9ac0c4307237e2fe3_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNDQ4_9baf88e9-41bb-4a03-b4f0-0b8ce62652cf"
      unitRef="number">0.216</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35fb475dbd8e4857a5165d3acdca2256_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNDYw_75ff93be-b8f3-4c58-a4d3-7ed201df77a7"
      unitRef="number">0.208</us-gaap:ConcentrationRiskPercentage1>
    <ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RleHRyZWdpb246ODM0Njg3YTg3OTc4NDAxNWJkNzYxNWY0ZjNmNWZlMjhfNzU0_14a56f5c-4d07-426e-b03f-c4d2f17ff9a7">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Discounts and Chargebacks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Rebates, Wholesaler and GPO Fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Copay and Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credits/payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(726)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,685)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,909)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,320)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i5d628cc8068943659267d334778f7341_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS0xLTEtMS01ODA3Nw_f0283c62-29a4-4451-bd6c-4a1025d21beb"
      unitRef="usd">142000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="iff654685dbff4d14b4f04d9a1f3d82ad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS0zLTEtMS01ODA3Nw_01db96b1-f6db-4e5b-8825-189a412aafaf"
      unitRef="usd">1444000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ie2484e9556a94cb28d490b54b7654b83_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS01LTEtMS01ODA3Nw_855dd474-2bdd-4024-9982-e97771e93279"
      unitRef="usd">1258000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMS03LTEtMS01ODA3Nw_2b0e0a18-d499-4f82-8279-d5aa41d87b5e"
      unitRef="usd">2844000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesProvisions
      contextRef="i26d95d2f372e4305b5ab02ab183e81cc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi0xLTEtMS01ODA3Nw_cc2e73d9-3872-423f-bc2b-692c4990a1b9"
      unitRef="usd">824000</ardx:ContractWithCustomerGrossToNetSalesProvisions>
    <ardx:ContractWithCustomerGrossToNetSalesProvisions
      contextRef="i6abe21dd0e894e529281c08515f218a9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi0zLTEtMS01ODA3Nw_a23439a1-3bda-4be7-b6ce-c62f6e9452ef"
      unitRef="usd">2361000</ardx:ContractWithCustomerGrossToNetSalesProvisions>
    <ardx:ContractWithCustomerGrossToNetSalesProvisions
      contextRef="ie70fd6a1343d4c07ab6c0418986dd561_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi01LTEtMS01ODA3Nw_bec9ba34-94a5-4ed8-8617-7daa4b324f06"
      unitRef="usd">2575000</ardx:ContractWithCustomerGrossToNetSalesProvisions>
    <ardx:ContractWithCustomerGrossToNetSalesProvisions
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMi03LTEtMS01ODA3Nw_bbb6c416-444c-4c7c-96bc-2608325c9fbe"
      unitRef="usd">5760000</ardx:ContractWithCustomerGrossToNetSalesProvisions>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="i26d95d2f372e4305b5ab02ab183e81cc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0xLTEtMS01OTc2Nw_c998f3ab-d2b8-427f-9313-fb4edc41c5cc"
      unitRef="usd">-726000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="i6abe21dd0e894e529281c08515f218a9_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0zLTEtMS01OTc2Nw_e82c317a-7638-4217-9349-30c55f7f3ac3"
      unitRef="usd">-1685000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="ie70fd6a1343d4c07ab6c0418986dd561_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy01LTEtMS01OTc2Nw_4db8ba2a-a588-43e7-b7c2-5b37ec9812ce"
      unitRef="usd">-1909000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy03LTEtMS01OTc2Nw_93dfb9b6-1eb4-46d1-88d4-a5af932544d4"
      unitRef="usd">-4320000</ardx:ContractWithCustomerGrossToCreditsOrDeductionsIssued>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i06d909b1486e465d9d1e0fae1f8ce528_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0xLTEtMS01ODA3Nw_af5b04c9-be3f-4755-bbb9-a58959c8755f"
      unitRef="usd">240000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="i94828b9e8bfc49a9821ddf83aaed8bd3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy0zLTEtMS01ODA3Nw_62edba38-6659-41e6-84c9-71cff9359f07"
      unitRef="usd">2120000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ia4d507187469461589702c69e8af394f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy01LTEtMS01ODA3Nw_2d6a164c-25af-4820-880a-a38587ff18de"
      unitRef="usd">1924000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <ardx:ContractWithCustomerGrossToNetSalesAccruals
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80Ni9mcmFnOjgzNDY4N2E4Nzk3ODQwMTViZDc2MTVmNGYzZjVmZTI4L3RhYmxlOmZhYTAxN2U1Mzg4OTQzMzA5MGEzMWY3YjU3OWU3ZGY4L3RhYmxlcmFuZ2U6ZmFhMDE3ZTUzODg5NDMzMDkwYTMxZjdiNTc5ZTdkZjhfMy03LTEtMS01ODA3Nw_8f286c2e-9d6a-4628-a4ff-b043ebecb3df"
      unitRef="usd">4284000</ardx:ContractWithCustomerGrossToNetSalesAccruals>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMTAzOTk_97f97662-134c-48f6-8a91-3a80f1830fe8">COLLABORATION AND LICENSING AGREEMENTS &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kyowa Kirin Co., Ltd. (&#x201c;Kyowa Kirin&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, we entered into an exclusive license agreement with Kyowa Kirin (&#x201c;2017 Kyowa Kirin Agreement&#x201d;), under which we granted Kyowa Kirin an exclusive license to develop and commercialize certain NHE3 inhibitors including tenapanor in Japan for the treatment of cardiorenal diseases and conditions, excluding cancer. We retained the rights to tenapanor outside of Japan, and also retained the rights to tenapanor in Japan for indications other than those stated above. Pursuant to the 2017 Kyowa Kirin Agreement, Kyowa Kirin is responsible for all costs and expenses incurred in the development and commercialization of tenapanor for all licensed indications in Japan. We are responsible for supplying the tenapanor drug substance for Kyowa Kirin&#x2019;s use in development and commercialization throughout the term of the 2017 Kyowa Kirin Agreement, provided that Kyowa Kirin may exercise an option to manufacture the tenapanor drug substance under certain conditions. In October 2022, we entered into a Commercial Supply Agreement with Kyowa Kirin to further define the obligations of the parties with respect to the commercial supply of tenapanor drug substance (&#x201c;2022 Kyowa Kirin Supply Agreement&#x201d;). As detailed below under the heading &#x201c;Deferred revenue&#x2019; we have received advanced payments from Kyowa Kirin for the manufacturing of tenapanor drug substance that will be used to satisfy Kyowa Kirin needs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assessed these arrangements in accordance with Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2014-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers (Topic 606) and related amendments (&#x201c;ASC 606&#x201d;) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and concluded that the contract counterparty, Kyowa Kirin, is a customer. Under the terms of the 2017 Kyowa Kirin Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30.0&#160;million in upfront license fees, which was recognized as revenue when the agreement was executed. Based on our assessment, management determined that the license and the manufacturing supply services were its material performance obligations at the inception of the 2017 Kyowa Kirin Agreement, and as such, each of the performance obligations is distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the 2017 Kyowa Kirin Agreement, Kyowa Kirin paid us an up-front license fee of $30.0&#160;million. We may be entitled to receive up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$55.0&#160;million in total development and regulatory milestones, of which $20.0&#160;million has been received and recognized as revenue as of March&#160;31, 2023. We may also be eligible to receive approximately &#xa5;8.5&#160;billion for commercialization milestones, or approximately $64.1&#160;million at the currency exchange rate on March&#160;31, 2023, as well as reimbursement of costs plus a reasonable overhead for the supply of product and royalties on net sales throughout the term of the agreement. As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the future royalties and commercial milestone payments we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. The variable consideration related to the remaining milestone payments was fully constrained at March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, we entered into a second amendment to the 2017 Kyowa Kirin Agreement ("2022 Amendment"). Under the terms of the 2022 Amendment, we and Kyowa Kirin have agreed to a reduction in the royalty rate payable to us by Kyowa Kirin upon net sales of tenapanor for hyperphosphatemia in Japan. The royalty rate will be reduced from the high teens to low double digits for a two-year period of time following the first commercial sale in Japan, and then to mid-single digits for the remainder of the royalty term. As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7. Deferred Royalty Obligation Related to the Sale of Future Royalties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the future commercial milestones and royalties we may receive under the 2017 Kyowa Kirin Agreement will be remitted to HealthCare Royalty Partners IV, L.P. pursuant to a Royalty and Sales Milestone Interest Acquisition Agreement. As consideration for the reduction in the royalty rate, Kyowa Kirin agreed to pay us up to an additional $40.0&#160;million payable in two tranches, with the first payment due following Kyowa Kirin's filing with the Japanese Ministry of Health, Labour and Welfare of its application for marketing approval for tenapanor and the second payment due following Kyowa Kirin&#x2019;s receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, we announced that Kyowa Kirin submitted an NDA to the Japanese Ministry of Health, Labour and Welfare for tenapanor for the improvement of hyperphosphatemia in adult patients with CKD on dialysis, which resulted in payment to us from Kyowa Kirin for an aggregate of $35.0 million for milestone payments and payments under the 2022 Amendment. We received these payments during the fourth quarter of 2022 and recorded them as licensing revenue on our statement of operations and comprehensive loss. The remaining variable consideration related to the reduction in the royalty rate was fully constrained at March&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the 2017 Kyowa Kirin Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. (&#x201c;Fosun Pharma&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, we entered into an exclusive license agreement with Fosun Pharma ("Fosun Agreement") for the development, commercialization and distribution of tenapanor in China for both hyperphosphatemia and IBS-C. We assessed these arrangements in accordance with ASC 606 and concluded that the contract counterparty, Fosun Pharma, is a customer. Under the terms of the Fosun Agreement, we received&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$12.0 million in up-front license fees which was recognized as revenue when the agreement was executed. Based on our assessment, we determined that the license and the manufacturing supply services represented the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be entitled to receive development and commercialization milestones of up to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$110.0 million, of which $3.0 million has been received and recognized as revenue as of March&#160;31, 2023, as well as reimbursement of cost plus a reasonable overhead for the supply of product and tiered royalties on net sales ranging from the mid-teens to&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%. The variable consideration related to the remaining development milestone payments was fully constrained at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the Fosun Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Knight Therapeutics, Inc. (&#x201c;Knight&#x201c;) &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2018, we entered into an exclusive license agreement with Knight Therapeutics, Inc., ("Knight Agreement") for the development, commercialization and distribution of tenapanor in Canada for hyperphosphatemia and IBS-C. We assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, Knight, is a customer. Based on our assessment, we determined that the license and the manufacturing supply services were the material performance obligations at the inception of the agreement and, as such, each of the performance obligations are distinct.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Knight Agreement, we received a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.3 million non-refundable, one-time upfront payment in March 2018 and may be eligible to receive additional development and commercialization milestone payments worth up to CAD 22.2&#160;million, or approximately $16.3 million at the currency exchange rate on March&#160;31, 2023, of which $0.7 million has been received and recognized as revenue as of March&#160;31, 2023. We are also eligible to receive royalties ranging from the mid-single digits to the low twenties throughout the term of the agreement, and a transfer price for manufacturing services.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The variable consideration related to the remaining development milestone payments was fully constrained at March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023 and 2022, we did not recognize a material amount of revenue pursuant to the Knight Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AstraZeneca AB (&#x201c;AstraZeneca&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2015, we entered into a termination agreement with AstraZeneca (the &#x201c;AstraZeneca Termination Agreement&#x201d;) pursuant to which we have agreed to pay AstraZeneca (i) future royalties at a royalty rate of 10% of net sales of tenapanor or other NHE3 products by us or our licensees, and (ii) 20% of non-royalty revenue received from a new collaboration partner should we elect to license, or otherwise provide rights to develop and commercialize tenapanor or other NHE3 products, up to a maximum of $75.0 million in aggregate for (i) and (ii). As of March&#160;31, 2023, to date in aggregate, we have recognized $16.4 million of the $75.0 million, which has been recorded as cost of revenue, and have paid AstraZeneca $11.9 million. During the three months ended March&#160;31, 2023, we recognized and recorded $1.2 million as cost of revenue related to the AstraZeneca Termination Agreement. During the three months ended March&#160;31, 2022 we recognized $0.1 million as cost of revenue related to the AstraZeneca Termination Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period, which are all attributable to the 2017 Kyowa Kirin Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to amounts reclassified from non-current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to unbilled prepayments recorded during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to amounts reclassified as current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i083920320a754056a514534f83b44efb_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzIxMA_dd4c8e7f-f1cc-43e2-8eff-ff35331981b4"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees
      contextRef="i083920320a754056a514534f83b44efb_D20171101-20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzYzNg_dd4c8e7f-f1cc-43e2-8eff-ff35331981b4"
      unitRef="usd">30000000</ardx:CollaborationAndLicensingAgreementsUpfrontLicenseFees>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i1bd3e10bb611407aa9b181ac0b231f2b_I20171130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzY3Ng_9e3abeb1-9d50-4e8b-990e-96cd30f6a3c5"
      unitRef="usd">55000000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife5f1ab287944b9d9bde070bbcbc67e0_D20171101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzczNg_f921ac16-bd43-401f-871c-4a7b8847632d"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="i288cfb8144d94e34b13ad2293ba44e8a_I20230331"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzg0Mg_99ae6fdd-5064-43f3-9acd-8d4e6f67b856"
      unitRef="jpy">8500000000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialCommercializationMilestones
      contextRef="i288cfb8144d94e34b13ad2293ba44e8a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMzg5Ng_cf3e3579-9eeb-4e70-a55c-2e78322928ba"
      unitRef="usd">64100000</ardx:CollaborativeArrangementPotentialCommercializationMilestones>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate
      contextRef="i39875fb6603e44a9a08e3395ebc9b749_I20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTYxMw_2c92ca97-9173-4f26-a2ac-e9137db8513b"
      unitRef="usd">40000000</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate>
    <ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches
      contextRef="i39875fb6603e44a9a08e3395ebc9b749_I20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTYyNw_fc6d4197-54e2-4394-a14f-6cb3cf02a75d"
      unitRef="payment_tranche">2</ardx:CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches>
    <ardx:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="ie00d1c1778d04b16b85402b79f1486b1_I20221031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTQ5NzU1ODMwNjg2_796af493-6cef-4eb5-ab92-f798a2538364"
      unitRef="usd">35000000</ardx:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i2907f661c6604d53a0fd946c446d11e8_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzI4Mw_bb40d7b6-3979-4a8a-a959-639b6a6ac459"
      unitRef="usd">12000000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="ib45bb64e3dd84ca6aef388e7e5e6f6e7_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzM5MQ_6e01ac71-4818-4664-a2b3-7fff62ecf022"
      unitRef="usd">110000000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="if8a535f9627a421383052d6cea68607f_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzQwNA_e278728d-6e32-40c6-87d8-d0559b89194c"
      unitRef="usd">3000000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <ardx:ThresholdPercentageOfSalesForTieredRoyalties
      contextRef="ib45bb64e3dd84ca6aef388e7e5e6f6e7_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNzYxMQ_49bbd0a2-6e2a-4833-a999-9c557bd97190"
      unitRef="number">0.20</ardx:ThresholdPercentageOfSalesForTieredRoyalties>
    <us-gaap:ProceedsFromLicenseFeesReceived
      contextRef="i863345a922844c66bd8d54af304f6cdf_D20180301-20180331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODI5Nw_56f944c1-92a5-407a-81c0-495f6748da0f"
      unitRef="usd">2300000</us-gaap:ProceedsFromLicenseFeesReceived>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i63261ab5ac574aa09e991359cd4c71ad_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODM2Ng_49adcb18-efb5-4728-aa56-e6e456b652f4"
      unitRef="cad">22200000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones
      contextRef="i63261ab5ac574aa09e991359cd4c71ad_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODQzNg_16b2d071-31f2-41ed-881b-8e369caaf9b0"
      unitRef="usd">16300000</ardx:CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones>
    <ardx:CollaborativeArrangementPotentialDevelopmentMilestones
      contextRef="i3052a28a1e664c948b14b97c701206d4_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfODQ4NQ_cf02ebf4-20b6-4a99-9b3f-cce30d35760a"
      unitRef="usd">700000</ardx:CollaborativeArrangementPotentialDevelopmentMilestones>
    <ardx:PercentageOfRoyaltyRevenue
      contextRef="i54e4c9709e43489db08f10738e1a7672_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTMxOQ_fd99eeaf-2ff7-44c4-a105-1dc2aa79bc53"
      unitRef="number">0.10</ardx:PercentageOfRoyaltyRevenue>
    <ardx:PercentageOfNonRoyaltyRevenue
      contextRef="i54e4c9709e43489db08f10738e1a7672_D20150601-20150630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTQwNA_260f1769-41c9-487d-b236-00352b36fdaa"
      unitRef="number">0.20</ardx:PercentageOfNonRoyaltyRevenue>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i3b884d0ed6cd421f8a251db830a1fdce_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTUxNA_8e72f77e-a7f7-4839-9303-f4b20ac35864"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:CostOfRevenueAggregateAmountRecognized
      contextRef="i57d1ca4ad84940028b209e173e66500a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTU5OQ_0643ffa8-ccd1-4e6b-be65-d93a1fc0dda0"
      unitRef="usd">16400000</ardx:CostOfRevenueAggregateAmountRecognized>
    <ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum
      contextRef="i3b884d0ed6cd421f8a251db830a1fdce_I20150630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTYwOQ_8e72f77e-a7f7-4839-9303-f4b20ac35864"
      unitRef="usd">75000000</ardx:CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum>
    <ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid
      contextRef="i57d1ca4ad84940028b209e173e66500a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTY4Mw_7e30eeb9-52b6-44e5-a87e-ac5f7516d6d3"
      unitRef="usd">11900000</ardx:PaymentsOfUnchargedLicenseFeesAggregateAmountPaid>
    <us-gaap:CostOfRevenue
      contextRef="i731cea5b5a1d4df7b9a2e29a37cd3494_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfNTQ5NzU1ODQ4MTE1_a2868808-558b-4ed6-bcb3-03d45bfbcbf1"
      unitRef="usd">1200000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i86a688e614d249fb9330ee9f05c52190_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfOTg4Mg_a311d98d-c242-4db1-9e90-5c0f5f8d4e2a"
      unitRef="usd">100000</us-gaap:CostOfRevenue>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RleHRyZWdpb246NDA3MTdmZWVhNjJlNDAzZGI4YmVlYTM3ZWJlYTQ5NjJfMTA0MDA_a72bb004-0b62-4660-ae5c-6ffbf62e31af">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present changes in our current and non-current deferred revenue balances during the reporting period, which are all attributable to the 2017 Kyowa Kirin Agreement (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,211&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases due to amounts reclassified from non-current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.030%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred revenue - non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases to amounts invoiced, for which cash has not yet been received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increase due to unbilled prepayments recorded during the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases due to amounts reclassified as current, to be recognized in the next twelve months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(809)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i659312f8037b43898d098e16388710fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMS0xLTEtMS01ODA3Nw_f1381207-1a13-4045-b5ba-9a7805c1e5eb"
      unitRef="usd">4211000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="iace679a5607d492699456f44241140e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMS0zLTEtMS01ODA3Nw_327ecfa2-329a-489c-90cc-8086226428e6"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths
      contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMy0xLTEtMS01ODA3Nw_a5a8fef2-0bbc-41d8-a110-89afea563331"
      unitRef="usd">809000</ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths>
    <ardx:ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths
      contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfMy0zLTEtMS01ODA3Nw_cc818316-26bf-4607-b237-5350be3fd276"
      unitRef="usd"
      xsi:nil="true"/>
    <ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived
      contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfNC0xLTEtMS01ODA3Nw_74f3ed3a-dbce-42eb-bfaf-2b91d9978cc5"
      unitRef="usd">525000</ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived>
    <ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived
      contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfNC0zLTEtMS01ODA3Nw_1a764730-afef-4579-8b19-ef949bc4fad4"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i52f7c183ef764b48ab94110300434074_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfOC0xLTEtMS01ODA3Nw_decf79ba-bd4a-43a5-814f-c9f2b7427294"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia95bc99b5de94628b6f1a6c5d5185452_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjFjMjkxYjU5YjI3OTQxOWE5ZmM3Yjk1OTRiOTlhYWQ4L3RhYmxlcmFuZ2U6MWMyOTFiNTliMjc5NDE5YTlmYzdiOTU5NGI5OWFhZDhfOC0zLTEtMS01ODA3Nw_1782337c-f61c-4291-803c-e3ca0e7c08e9"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i659312f8037b43898d098e16388710fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMS0xLTEtMS01ODA3Nw_8b526927-0341-4146-8b04-bb30a4a59a81"
      unitRef="usd">9025000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="iace679a5607d492699456f44241140e4_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMS0zLTEtMS01ODA3Nw_38bfffe5-1309-4490-8b06-88fe42e94144"
      unitRef="usd">4727000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMy0xLTEtMS01ODA3Nw_ddc24af6-1325-413b-a697-533f0e927605"
      unitRef="usd">3282000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced
      contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfMy0zLTEtMS01ODA3Nw_c663133d-7f8e-45d9-a039-9c05367d7102"
      unitRef="usd">3829000</ardx:ContractWithCustomerLiabilityIncreaseForAmountsInvoiced>
    <ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded
      contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNC0xLTEtMS01ODA3Nw_6d7d7ab6-1943-4a99-b651-a07b40c0e198"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded>
    <ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded
      contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNC0zLTEtMS01ODA3Nw_e2caf3d5-c8a2-4a57-81c3-f8aefa26d613"
      unitRef="usd">7000</ardx:ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded>
    <ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths
      contextRef="i8f0464629a7d41e9a51288c53068a05e_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNS0xLTEtMS01ODA3Nw_954d918c-0717-49f2-a73a-2da1668a7059"
      unitRef="usd">809000</ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths>
    <ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths
      contextRef="ib1d947e78348482b9985a2649fa2ca53_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNS0zLTEtMS01ODA3Nw_3777427d-495e-4ba8-a182-446df4534084"
      unitRef="usd">0</ardx:ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i52f7c183ef764b48ab94110300434074_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNy0xLTEtMS01ODA3Nw_23431cde-8fbf-41b4-9fe6-2adb94dfd5c6"
      unitRef="usd">11498000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="ia95bc99b5de94628b6f1a6c5d5185452_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV80OS9mcmFnOjQwNzE3ZmVlYTYyZTQwM2RiOGJlZWEzN2ViZWE0OTYyL3RhYmxlOjQ3ZDQ2OGYzMjJiYzQ5ZjI4MTBjOGViZjgyMzUzMjBjL3RhYmxlcmFuZ2U6NDdkNDY4ZjMyMmJjNDlmMjgxMGM4ZWJmODIzNTMyMGNfNy0zLTEtMS01ODA3Nw_4e54914f-1ceb-45ee-af04-8e6f09fd7657"
      unitRef="usd">8563000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:AssetRetirementObligationDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNDU4MQ_b50d91f0-8066-4165-9cfe-fc155efc60a9">DEFERRED ROYALTY OBLIGATION RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, we and HealthCare Royalty Partners IV, L.P. (&#x201c;HCR&#x201d;) entered into a Royalty and Sales Milestone Interest Acquisition Agreement (&#x201c;HCR Agreement&#x201d;). Under the terms of the HCR Agreement, HCR has agreed to pay us up to $20.0 million in exchange for the royalty payments and commercial milestone payments (collectively the &#x201c;Royalty Interest Payments&#x201d;) that we may receive under our 2017 License Agreement with Kyowa Kirin based upon Kyowa Kirin's net sales of tenapanor in Japan for hyperphosphatemia. As consideration for the sale of the Royalty Interest Payments, HCR paid to us a $10.0 million upfront payment, and we are eligible to receive a $5.0 million payment following Kyowa Kirin's receipt of regulatory approval to market tenapanor for hyperphosphatemia in Japan, and another $5.0 million payment in the event net sales by Kyowa Kirin in Japan exceed a certain annual target level by the end of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The HCR Agreement is effective until terminated by the mutual agreement of the parties and contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to prosecution, maintenance, defense and enforcement of certain patent rights in Japan, restrictions regarding our ability to forgive, release or reduce any Royalty Interest Payments due to us under the 2017 Kyowa Kirin Agreement, to create or incur any liens with respect to the Royalty Interest Payments, the 2017 Kyowa Kirin Agreement or certain patents, or to sell, license or transfer certain patents in the field and territory described in the 2017 Kyowa Kirin Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the HCR Agreement contains customary events of default with respect to which we may incur indemnification obligations to HCR for any losses incurred by HCR and related parties as a result of the event of default, subject to a specified limitation of liability cap. Under the HCR Agreement, an event of default will occur if, among other things, any of the representations and warranties included in the HCR Agreement proves not to have been true and correct in all material respects, at the time it was made, we breach any of our covenants under the HCR Agreement, subject to specified cure periods with respect to certain breaches, we are in breach or default under the 2017 Kyowa Kirin Agreement in any manner which is likely to cause a material adverse effect on the Royalty Interest Payments, the occurrence of a termination of the 2017 Kyowa Kirin Agreement under certain circumstances or we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, or we are unable to pay our debts as they become due.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We received the $10.0 million upfront payment from HCR during June 2022 and recorded it as a deferred royalty obligation related to the sale of future royalties ("deferred royalty obligation") on our balance sheet. Due to our ongoing manufacturing obligations under the 2017 Kyowa Kirin Agreement, we account for the proceeds as imputed debt and therefore will recognize royalties received under the arrangement as non-cash royalty revenue. Non-cash interest expense will be recognized over the life of the HCR Agreement using the effective interest method based on the imputed interest rate derived from estimated amounts and timing of future royalty payments to be received from Kyowa Kirin. As part of the sale, we incurred approximately $0.4 million in transaction costs, which, along with the deferred royalty obligation, are being amortized to non-cash interest expense over the estimated life of the HCR Agreement using the effective interest method. As future royalties are remitted to us by Kyowa Kirin, and subsequently from us to HCR, the balance of the deferred royalty obligation will be effectively repaid over the life of the HCR Agreement. There are a number of factors that could materially affect the fair value of the deferred royalty obligation. Such factors include, but are not limited to, the amount and timing of potential future royalty payments to be received from Kyowa Kirin under the 2017 Kyowa Kirin agreement, changing standards of care, the introduction of competing products, manufacturing or other delays, intellectual property matters, adverse events that result in governmental health authority imposed restrictions on the use of the drug products, significant changes in foreign exchange rates as the royalties remitted to HCR are made in U.S. dollars while the underlying sales of the products by Kyowa Kirin are made in Japanese yen, and other events or circumstances that could result in reduced royalty payments from Kyowa Kirin, which are not within our control, and all of which would result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the deferred royalty obligation. We periodically assess the estimated royalty payments from Kyowa Kirin and, to the extent that the amount or timing of such payments is materially different than our original estimates, we prospectively adjust the imputed interest rate and the related amortization of the deferred royalty obligation. As of March&#160;31, 2023, our effective interest rate used to amortize the liability is 34.4%. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we recognized approximately $1.0 million of non-cash interest expense for the amortization of the deferred royalty obligation. As of March&#160;31, 2023, we have received no royalty payments from Kyowa Kirin and, therefore, the deferred royalty obligation has not begun to be reduced.&lt;/span&gt;&lt;/div&gt;</us-gaap:AssetRetirementObligationDisclosureTextBlock>
    <us-gaap:IncreaseDecreaseInRoyaltiesPayable
      contextRef="i7e9a3bf71e144239ab9f7e4ab68a77fb_D20220601-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODIzOTkz_26a832a1-ae74-4e63-bca6-035458f905ce"
      unitRef="usd">20000000</us-gaap:IncreaseDecreaseInRoyaltiesPayable>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI0MzMw_43ebacc9-64dc-4c34-b92e-325ecc81f2a0"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI0Mzg0_1c779472-9a23-4f59-ae5f-49bd8a09905e"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI0NTA3_4515864c-534c-484a-b9a0-7edbc3cebb78"
      unitRef="usd">5000000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="id6b3392a8c3747ae86ad7d9a483555ca_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI2MzU5_43ebacc9-64dc-4c34-b92e-325ecc81f2a0"
      unitRef="usd">10000000</us-gaap:ContractWithCustomerLiability>
    <ardx:ContractWithCustomerLiabilityTransactionCosts
      contextRef="ieebd3c9bdbf5498bb3059d158b5c146a_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI3MDU4_01c56bf6-a175-4755-9916-9df65e07dde2"
      unitRef="usd">400000</ardx:ContractWithCustomerLiabilityTransactionCosts>
    <ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent
      contextRef="i3d8e929085924d668d54e66064fca686_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNTQ5NzU1ODI4Nzk3_4e2b144b-66bf-449f-9737-22e1cf34a075"
      unitRef="number">0.344</ardx:ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent>
    <us-gaap:AmortizationOfAdvanceRoyalty
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNDM2MA_79561f72-75c6-4d09-af75-bd727f3ad91e"
      unitRef="usd">1000000</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:ProceedsFromRoyaltiesReceived
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81Mi9mcmFnOjg0YWNlM2Q4ZjczZTQyNTBiMGRlYjk1ZWMxOWU3OWJhL3RleHRyZWdpb246ODRhY2UzZDhmNzNlNDI1MGIwZGViOTVlYzE5ZTc5YmFfNDQ3Ng_c61ba55f-ac90-46c4-b994-e8396db57cd1"
      unitRef="usd">0</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNzU0Nw_a87f06d1-e8b2-40a0-9853-7ea9865b00fb">BORROWING &lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solar Capital and Western Alliance Bank Loan Agreement&lt;/span&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, we entered into a loan and security agreement (as amended on October 9, 2020, March 1, 2021, May 5, 2021, and July 29, 2021) (the "2018 Loan Agreement") with Solar Capital Ltd. and Western Alliance Bank (collectively the &#x201c;2018 Lenders&#x201d;). The 2018 Loan Agreement provided for a loan facility for up to $50.0 million with a maturity date of November&#160;1, 2022 (the &#x201c;2018 Loan&#x201d;). As of the Closing Date for the 2022 Loan, as discussed below, we owed $25.0&#160;million in principal payments from the 2018 Loan, which we repaid in full at that time.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 9. Derivative Liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash upon the occurrence of certain conditions (the "2018 Exit Fee"). Our obligations for the 2018 Exit Fee remain outstanding following the full repayment of the 2018 Loan in February 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;SLR Investment Corp. Loan Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 23, 2022 (&#x201c;Closing Date&#x201d;), we entered into a loan and security agreement (&#x201c;2022 Loan Agreement&#x201d;) with SLR Investment Corp. as collateral agent (&#x201c;Agent&#x201d;), and the lenders listed in the 2022 Loan Agreement (collectively the &#x201c;2022 Lenders&#x201d;). The 2022 Loan Agreement was subsequently amended on August 1, 2022 and February 9, 2023. We concluded that the Loan amendments were modifications to the 2022 Loan Agreement and are accounted for accordingly. The 2022 Loan Agreement as amended provides for a senior secured loan facility, with $27.5 million (&#x201c;Term A Loan&#x201d;) funded on the Closing Date and an additional $22.5 million which we may borrow on or prior to December 20, 2023; provided that (i) we have received approval by the FDA for our NDA for XPHOZAH by November 30, 2023, and (ii) we have achieved certain product revenue milestone targets described in the 2022 Loan Agreement (&#x201c;Term B Loan&#x201d;, and collectively, the Term A Loan and the Term B Loan, the &#x201c;2022 Loan&#x201d;). The 2022 Term A Loan funds were used to repay the 2018 Loan with the 2018 Lenders. The 2022 Loan has a maturity date of March 1, 2027. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings under the 2022 Loan as amended bear interest at a floating per annum interest rate with 7.95% plus the greater of (a) one percent (1.00%) per annum and (b)(i) 0.022% plus (ii) 1-month CME Term SOFR reference rate as published by the CME Term SOFR Administrator on the CME Term SOFR Administrator&#x2019;s Website. We are permitted to make interest-only payments on the 2022 Loan through March 31, 2024, which date will be extended to March 31, 2025 if we receive approval by the FDA for our NDA for XPHOZAH on or prior to November 30, 2023 or achieve a defined net product revenue threshold for 2023. Accordingly, beginning on April 1, 2024 or April 1, 2025, we will be required to make monthly payments of interest plus repayment of the 2022 Loan in consecutive equal monthly installments of principal over 36 months or 24 months, respectively. We were obligated to pay $0.2 million, upon the closing of the Term A Loan, and we are obligated to pay $0.1 million on the earliest of (i) the funding date of the Term B Loan, (ii) July 25, 2023, and (iii) the prepayment, refinancing, substitution, or replacement of the Term A Loan on or prior to July 25, 2023. We are obligated to pay a final fee equal to 4.95% of the aggregate original principal amount of the 2022 Loan funded upon the earliest to occur of the maturity date, the acceleration of the 2022 Loan, and the prepayment, refinancing, substitution, or replacement of the 2022 Loan. We may voluntarily prepay the outstanding 2022 Loan balance, subject to a prepayment premium of (i) 3% of the outstanding principal amount of the 2022 Loan if prepaid prior to or on the first anniversary of the Closing Date, (ii) 2% of the outstanding principal amount of the 2022 Loan if prepaid after the first anniversary of the Closing Date through and including the second anniversary of the Closing Date, or (iii) 1% of the outstanding principal amount of the 2022 Loan if prepaid after the second anniversary of the Closing Date and prior to the maturity date. The 2022 Loan is secured by substantially all of our assets, except for our intellectual property and certain other customary exclusions. Additionally, in connection with the 2022 Loan, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis, tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire 10 years from the Closing Date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2022 Loan Agreement contains customary representations and warranties and customary affirmative and negative covenants, including, among others, requirements as to financial reporting and insurance and restrictions on our ability to dispose of our business or property, to change our line of business, to liquidate or dissolve, to enter into any change in control transaction, to merge or consolidate with any other entity or to acquire all or substantially all the capital stock or property of another entity, to incur additional indebtedness, to incur liens on our property, to pay any dividends or other distributions on capital stock other than dividends payable solely in capital stock or to redeem capital stock. We have agreed to not allow our cash and cash equivalents to be less than the eighty percent (80%) of the outstanding 2022 Term Loan balance for any period in which our net revenue from the sale of any products, calculated on a trailing six (6) month basis and tested monthly, is less than sixty percent (60%) of the outstanding 2022 Loan balance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the 2022 Loan Agreement contains customary events of default that entitle the Agent to cause our indebtedness under the 2022 Loan Agreement to become immediately due and payable, and to exercise remedies against us and the collateral securing the 2022 Term Loan, including our cash. Under the 2022 Loan Agreement, an event of default will occur if, among other things, we fail to make payments under the 2022 Loan Agreement, we breach any of our covenants under the 2022 Loan Agreement, subject to specified cure periods with respect to certain breaches, certain Lenders determine that a material adverse change has occurred, we or our assets become subject to certain legal proceedings, such as bankruptcy proceedings, we are unable to pay our debts as they become due or we default on contracts with third parties which would permit the holder of indebtedness to accelerate the maturity of such indebtedness or that could have a material adverse change on us. Upon the occurrence and for the duration of an event of default, an additional default interest rate equal to 4% per annum will apply to all obligations owed under the 2022 Loan Agreement. We have classified the 2022 Loan balance as a current liability as of March&#160;31, 2023 due to the determination of the existence of substantial doubt about our ability to continue operating as a going concern discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1. Organization and Basis of Presentation: Liquidity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and our assessment that the material adverse change clause under the 2022 Loan Agreement is not within our control. The lenders have not invoked the material adverse change clause as of the date of issuance of these condensed financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="id26a7d8749644b05b1f668cab705f3da_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNDAx_e1571a37-6cbf-439f-8976-1be311042174"
      unitRef="usd">50000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="id26a7d8749644b05b1f668cab705f3da_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTM1_21e4c608-31ae-46bd-8188-b06a342a3cdb"
      unitRef="usd">25000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNzg3_03750d93-1b45-4021-aebf-70835b059489"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i65852187d2a644d0b3d856dac714bdd5_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODI4Mjgz_58e9e7d9-4b81-40e2-8171-97cebc987acc"
      unitRef="usd">27500000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <ardx:RemainingFundingBasedOnConditionalMilestoneAchievement
      contextRef="i1bde4623e9a04dc39eee1626eaee265d_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODI4MzQ4_90dba6c7-5547-4831-93d8-10d2be449508"
      unitRef="usd">22500000</ardx:RemainingFundingBasedOnConditionalMilestoneAchievement>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i94ae49ee7695430e996b24c23504b630_D20220223-20220223"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM3MTQ0_685f5bfe-a3d5-4dfd-8555-71489f5ebb3f"
      unitRef="number">0.0795</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <ardx:DebtInstrumentVariableRateBaseOption
      contextRef="i638a555d6cc245828c93ab8f2f4152fd_D20220223-20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM3MTg1_8eb4484f-9b4e-42f8-8bc6-56ea86c84521"
      unitRef="number">0.0100</ardx:DebtInstrumentVariableRateBaseOption>
    <ardx:DebtInstrumentVariableRatePlusOption
      contextRef="i638a555d6cc245828c93ab8f2f4152fd_D20220223-20220223"
      decimals="5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM3MjEx_4cebded1-e320-48c3-bca0-99c9e32df451"
      unitRef="number">0.00022</ardx:DebtInstrumentVariableRatePlusOption>
    <us-gaap:DebtInstrumentTerm
      contextRef="i65852187d2a644d0b3d856dac714bdd5_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMDQ5_1caac3e1-2a28-4834-81ca-1f0fe62db2ae">P36M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm
      contextRef="i3f29b0505e0a4f2687c88c38e53ea1dc_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMDU2_4029fc5f-5fe5-4ce8-bb06-708f988845fc">P24M</us-gaap:DebtInstrumentTerm>
    <ardx:DebtInstrumentClosingFeeAmount
      contextRef="i0b5ab525e6ab435aaf3c6a02a1de068a_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMTAw_98182d9f-5115-4a83-bd19-740670c4586c"
      unitRef="usd">200000</ardx:DebtInstrumentClosingFeeAmount>
    <ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents
      contextRef="i1bde4623e9a04dc39eee1626eaee265d_I20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwMTcw_dd56165e-b40e-494a-bb17-495743334dcc"
      unitRef="usd">100000</ardx:LoanAgreementFutureObligationUponFundingOrOtherEvents>
    <ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage
      contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwNDE2_24d9854a-b169-4da9-8c3d-20695ce58e72"
      unitRef="number">0.0495</ardx:DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="ia083898fba8644ae8992ef5a76d16d15_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwNzUx_7e788547-fe81-4ce5-bfd3-d6d5c7164ce2"
      unitRef="number">0.03</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i3eef16572d6e4271b1f76a0150bcab0d_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMwODgy_6a69b9f7-5623-43e3-aa07-f3e19d389783"
      unitRef="number">0.02</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:DebtInstrumentPrepaymentFeePercentage
      contextRef="i0f1ad1d3f45248538bc7fb75b496d6b7_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMxMDcz_25670614-5187-4b9c-a7c0-c512a7b30ad5"
      unitRef="number">0.01</ardx:DebtInstrumentPrepaymentFeePercentage>
    <ardx:ExitFeePercentage
      contextRef="i33c8ecd2354241aaae56ac9dd1838668_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMxNDky_98097814-baad-43f1-93c6-e628bd00ffe7"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="i144ee9ba68854c9cb614235c5e0c2141_D20220223-20220223"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMxNjc1_7ff5ec04-b4ae-4c1e-a04e-ece3f4ffc848"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <ardx:LoanAgreementExitFeeTerm
      contextRef="i144ee9ba68854c9cb614235c5e0c2141_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfMjc0ODc3OTA5MTc4NQ_65e024bf-13b2-444b-9fb2-5081d30b3baa">P10Y</ardx:LoanAgreementExitFeeTerm>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMyNzA0_b5e211a4-44e9-404e-b681-821f7c2b9c72"
      unitRef="number">0.80</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod
      contextRef="i409069f3154040ff8c6970a5bfafb1ee_D20220223-20220223"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMyODUy_f37ac6fe-2484-433a-992b-e9b84b7677d0">P6M</ardx:LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod>
    <ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum
      contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODMyOTE3_e174ac34-0d1c-4781-a75e-8cbc53441c03"
      unitRef="number">0.60</ardx:LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum>
    <ardx:DebtInstrumentInterestRateOnDefaultPercentage
      contextRef="i0c94dd239cb747d4badb5a4357da4ad9_I20220223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNTQ5NzU1ODM0MDQ2_cc9de9d2-de7b-42ca-ba77-90e153b8b1c9"
      unitRef="number">0.04</ardx:DebtInstrumentInterestRateOnDefaultPercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RleHRyZWdpb246NzRiMzc4NzZlMzBlNGIwNzk1OTkyNzI2NjcyODdkYTJfNzU0OQ_7ff92822-afe6-4b30-9b7b-0cf291582541">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, our future payment obligations related to the 2022 Loan, excluding interest payments and the 2022 final fee, were as follows (in thousands) and may be condensed to the 24 months ending March 1, 2027 if certain conditions noted above to extend the interest-only period are achieved:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total repayment obligations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized discount and debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,282)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unaccreted value of final fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(699)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,880)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMC0xLTEtMS01ODA3Nw_777d84aa-4410-49e1-8662-104483b21138"
      unitRef="usd">28861000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMS0xLTEtMS01ODA3Nw_7c012467-3387-4be9-9994-ec13a9a94135"
      unitRef="usd">1282000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMi0xLTEtMS01ODA3Nw_185df367-c65c-4708-aacf-31606885e42a"
      unitRef="usd">699000</us-gaap:DebtInstrumentFeeAmount>
    <us-gaap:LongTermDebt
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfMy0xLTEtMS01ODA3Nw_c5d2ccf1-2f1b-4e72-8f6e-373414ddecfe"
      unitRef="usd">26880000</us-gaap:LongTermDebt>
    <us-gaap:LoansPayableCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfNC0xLTEtMS01ODA3Nw_d4d71771-5042-4abb-b27d-ddcba4e8fca4"
      unitRef="usd">26880000</us-gaap:LoansPayableCurrent>
    <us-gaap:LongTermLoansPayable
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81NS9mcmFnOjc0YjM3ODc2ZTMwZTRiMDc5NTk5MjcyNjY3Mjg3ZGEyL3RhYmxlOjAwYjExN2U1ZDk0ZjQxYWJiMGM2Nzk0YjA3ZWE0ZDYzL3RhYmxlcmFuZ2U6MDBiMTE3ZTVkOTRmNDFhYmIwYzY3OTRiMDdlYTRkNjNfNS0xLTEtMS01ODA3Nw_fd56942e-6963-4d18-a6c7-95b5deeaedde"
      unitRef="usd">0</us-gaap:LongTermLoansPayable>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNDUxNQ_6ffc4aad-c0c5-4580-8c9a-18c632afc628">DERIVATIVE LIABILITIES&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, in connection with entering into the 2018 Loan Agreement, we entered into an agreement pursuant to which we agreed to pay $1.5 million in cash ("2018 Exit Fee") upon any change of control transaction in respect of the Company or if we obtain both (i) FDA approval of XPHOZAH and (ii) FDA approval of IBSRELA, which was obtained on September 12, 2019 (&#x201c;2018 Exit Fee Agreement&#x201d;). Notwithstanding the February 2022 prepayment of the 2018 Loan, our obligation to pay the 2018 Exit Fee will expire on May 16, 2028. We concluded that the 2018 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2018 Exit Fee is recorded as a derivative liability and included in accrued expense and other current liabilities on the accompanying condensed balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the estimated fair value of the 2018 Exit Fee was $1.3 million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the derivative instrument include: (i) our estimates of both the probability and timing of a potential $1.5 million payment to Solar Capital Ltd. and Western Alliance Bank as a result of the FDA approvals, and (ii) a discount rate which was derived from our estimated cost of debt, adjusted with current LIBOR. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative instrument and it is estimated that a 10% increase (decrease), not to exceed 100%, in the probability of occurrence would result in a fair value fluctuation of no more than $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, in connection with entering into the 2022 Loan Agreement, we entered into an agreement, whereby we agreed to pay an exit fee in the amount of 2% of the 2022 Loan funded (&#x201c;2022 Exit Fee&#x201d;) upon (i) any change of control transaction or (ii) our achievement of net revenue from the sale of any products equal to or greater than $100.0 million, measured on a six (6) months basis ("Revenue Milestone"), tested monthly at the end of each month. Notwithstanding the prepayment or termination of the 2022 Loan, the 2022 Exit Fee will expire on February 23, 2032. We concluded that the 2022 Exit Fee is a freestanding derivative which should be accounted for at fair value on a recurring basis. The estimated fair value of the 2022 Exit Fee is recorded as a derivative liability and included in accrued expenses and other current liabilities on the accompanying condensed balance sheets. As of March&#160;31, 2023 and December&#160;31, 2022, the estimated fair value of the 2022 Exit Fee was $0.5 million and $0.4 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the derivative liability was determined using a discounted cash flow analysis and is classified as a Level 3 measurement within the fair value hierarchy since our valuation utilized significant unobservable inputs. Specifically, the key assumptions included in the calculation of the estimated fair value of the 2022 derivative liability include: (i) our estimates of both the probability and timing of achieving the Revenue Milestone and (ii) the probability and timing of funding the Term B Loan, which is dependent upon (a) approval by the FDA for our NDA for the control of serum phosphorus in adult patients with CKD on dialysis by November 30, 2023, and (b) achievement of certain product revenue milestone targets. Generally, increases or decreases in the probability of occurrence would result in a directionally similar impact in the fair value measurement of the derivative liability and it is estimated that a 10% increase (decrease) in the probability of occurrence would not result in a material fair value fluctuation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our condensed statements of operations and comprehensive loss and were as follows for the three months ended March&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIwNjky_03750d93-1b45-4021-aebf-70835b059489"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i33de1b72f71545d986edc3214d5d9beb_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIxNDU0_f3f46261-4382-42c3-9e22-cb355de554bd"
      unitRef="usd">1300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="idfb8182a2d794133b5db7776b72a7c32_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIxNDYy_21625c6c-6eea-4899-bb51-2e7c5f6e1eaa"
      unitRef="usd">1200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:DerivativeLiabilityNotionalAmount
      contextRef="i4fcd0ea1cd1e428982ca7b50b09585db_I20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIxOTEw_03750d93-1b45-4021-aebf-70835b059489"
      unitRef="usd">1500000</us-gaap:DerivativeLiabilityNotionalAmount>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="id77334cdee644ae3adb652a17ffda146_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIyMzA5_647d5f95-d2ce-40b6-82b6-99ce451792d0"
      unitRef="number">0.10</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation
      contextRef="id77334cdee644ae3adb652a17ffda146_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODIyNDQ0_fe7645e4-4459-40cb-afd3-5f75207b222f"
      unitRef="usd">100000</ardx:FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation>
    <ardx:ExitFeePercentage
      contextRef="i33c8ecd2354241aaae56ac9dd1838668_I20220228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI0NjIx_98097814-baad-43f1-93c6-e628bd00ffe7"
      unitRef="number">0.02</ardx:ExitFeePercentage>
    <ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum
      contextRef="ibb1c667d3f6845b9821defdd369f3334_D20220201-20220228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI0ODA0_f34b6bdb-3a92-4dc5-b694-db2420a9f6a6"
      unitRef="usd">100000000</ardx:LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="iad99515dc2cb43bbac4c617f035dbea6_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI1NDAw_a8f40429-7c40-458a-a637-266a45ac237f"
      unitRef="usd">500000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic39c3311ee344cb6bd0f358d159ff052_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI2ODQz_4df79c98-bde8-4df6-8b15-7ac105c3d1ca"
      unitRef="usd">400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage
      contextRef="ie825c96e303040cbac67e9975c1d3916_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNTQ5NzU1ODI2MzQ0_5ed17218-d80a-4880-b6fd-5c9f5611a8cb"
      unitRef="number">0.10</ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RleHRyZWdpb246M2M2YTkxZmIyN2I0NGQ2ZThkZjk3MGYxMGE0ODNlZTJfNDUxNg_ede32e6b-ca39-4dac-8e25-3772f296793c">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of recurring measurements included in Level 3 of the fair value hierarchy are presented as other income, net in our condensed statements of operations and comprehensive loss and were as follows for the three months ended March&#160;31, 2023 and 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.324%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.325%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee addition at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 Exit Fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31,&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i378e186ad3f24c9db722bd214a0cd23c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMS0xLTEtMS01ODA3Nw_be2fdbff-0dd0-4e57-9d27-4aec1856e2ca"
      unitRef="usd">1656000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i70a72bd3fdec4799bf7cbc921bbe7771_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMS0zLTEtMS01ODA3Nw_f72d8c45-e12e-4325-863c-5a341542a910"
      unitRef="usd">698000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i9097418276724d54ae8d794f40b08e52_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMi0xLTEtMS01ODA3Nw_03933c8b-f1a1-4899-902e-8a387f1cea0e"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases
      contextRef="i76f025b503164e55a2c09bb438e74e2c_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfMi0zLTEtMS01ODA3Nw_1744adf2-0e91-4789-8056-36ced858d61c"
      unitRef="usd">375000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i417a6c105f4849fc8598601744a8fe4a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNC0xLTEtMS01ODA3Nw_79313a5a-0c15-4d34-93a9-5a311b61bf00"
      unitRef="usd">48000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i3182ceda3b1f402a8c202c06dedcee6f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNC0zLTEtMS01ODA3Nw_d70d2027-1fb4-4730-b323-c27e540d120a"
      unitRef="usd">15000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ie1c3cd44c6894dfbaeaedc130ea028db_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNS0xLTEtMS01ODA3Nw_4189678c-7a2a-4f59-adde-b29d555e8cd3"
      unitRef="usd">22000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="ifc6e80a67a6b4e47b639149a2c278dfd_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNS0zLTEtMS01ODA3Nw_5f617b7d-205d-4b67-9e3c-9e0e6510318f"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i3794a3d76c384e9fa5e39ef7474a6713_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNi0xLTEtMS01ODA3Nw_2868bfc2-7c3c-42a0-8c82-dcb5badbca70"
      unitRef="usd">1726000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i8a1c090223594681b449fb7259dff90c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV81OC9mcmFnOjNjNmE5MWZiMjdiNDRkNmU4ZGY5NzBmMTBhNDgzZWUyL3RhYmxlOmEzNmMwZDlkNTkwNTQ0ODZiMTBhNWZjZWRiNTBiNTY3L3RhYmxlcmFuZ2U6YTM2YzBkOWQ1OTA1NDQ4NmIxMGE1ZmNlZGI1MGI1NjdfNi0zLTEtMS01ODA3Nw_89c5d1b9-2091-4b5c-9ec5-8a094464e776"
      unitRef="usd">1088000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY2_3670b816-544c-45de-ba6c-1c176ff15912">LEASES&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our leases are operating leases and each contain customary rent escalation clauses. Certain of the leases have both lease and non-lease components. We have elected to account for each separate lease component and the non-lease components associated with that lease component as a single lease component for all classes of underlying assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,295&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,998&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,894&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,855&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease costs, which are included in operating expenses in our condensed statements of operations and comprehensive loss, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023, we entered into a sub-lease Agreement (the &#x201c;Sub-lease&#x201d;) with Chronus Health, Inc. ("Chronus). The Sub-lease permits use by Chronus of a portion of the space in our facility in Fremont, California. We lease the facility from a different counterparty under a separate head lease that commenced in September 2008 and has been amended multiple times to add space and to extend the lease term through March 2025. We have sub-leased to Chronus approximately 21,644 square feet of the 72,500 square foot building's interior space, plus corresponding exterior support space and parking. The term of the Sub-lease shall expire on February 1, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In accordance with the Sub-lease we recognized an impairment of long-lived assets totaling $0.4 million during the three months ended March&#160;31, 2023, which consisted primarily of impairment to the Fremont facility right-of-use asset. The Sub-lease commenced in April 2023 and we have recognized no income from the sub-lease as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY3_2fa79b5c-bce8-4296-9170-c12c7f1a307a">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides additional details of our facility leases presented in our condensed balance sheets (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.174%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.177%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Facilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,972&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,295&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,998&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,894&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,814&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,855&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMS0xLTEtMS01ODA3Nw_7cf7ebe8-3ff0-4f96-93e2-72bfbcf0f786"
      unitRef="usd">7972000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMS0zLTEtMS01ODA3Nw_bb9990b3-48d1-41e1-adb9-efd00e42c903"
      unitRef="usd">9295000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMy0xLTEtMS01ODA3Nw_b010bae3-4dc4-4b1a-836b-28518d958528"
      unitRef="usd">3998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfMy0zLTEtMS01ODA3Nw_9f39dfae-8247-43fc-bf5d-f67fb165b205"
      unitRef="usd">3894000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNC0xLTEtMS01ODA3Nw_8f4af06d-12ab-4d2a-a031-42aadd5f541f"
      unitRef="usd">4814000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNC0zLTEtMS01ODA3Nw_c1897ff4-f0f0-449c-a69f-f8a0a219f58f"
      unitRef="usd">5855000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNS0xLTEtMS01ODA3Nw_e9484d45-d306-453e-856e-4acf6e133cd1"
      unitRef="usd">8812000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNS0zLTEtMS01ODA3Nw_0ea70d7e-80fd-4d6d-b905-321f88cca015"
      unitRef="usd">9749000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNy0xLTEtMS01ODA3Nw_c6843cc3-844e-4ae3-97d5-5f6f63adb998">P2Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfNy0zLTEtMS01ODA3Nw_9e0eaa33-910e-4673-9368-5ff25d708fb0">P2Y4M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfOC0xLTEtMS01ODA3Nw_87572797-ba20-46d1-bc31-8d215dc440ae"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVjYzNhZWEzMDg3ZTQ2NGE5YWQ0NjUxZTBlODdjOTQ3L3RhYmxlcmFuZ2U6ZWNjM2FlYTMwODdlNDY0YTlhZDQ2NTFlMGU4N2M5NDdfOC0zLTEtMS01ODA3Nw_f0d3ef0a-f910-4468-9ba9-ac6681c0dee0"
      unitRef="number">0.068</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY4_21ede784-fcda-49a6-8ebb-eb876640bf6d">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease costs, which are included in operating expenses in our condensed statements of operations and comprehensive loss, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.683%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for operating lease&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMi0xLTEtMS01ODA3Nw_f7a8753e-8f34-4aa4-b011-ba07e56b7cf4"
      unitRef="usd">1064000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMi0zLTEtMS01ODA3Nw_91ccc65b-1364-4c0e-bc2e-01ea7d482663"
      unitRef="usd">1064000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMy0xLTEtMS01ODA3Nw_40746798-02d0-4de3-9721-5e2b41181dd1"
      unitRef="usd">1098000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOmVmYzE4NGFhNDQwNTRiMzk4ZWU0YzNjNjE1NTkzYjgwL3RhYmxlcmFuZ2U6ZWZjMTg0YWE0NDA1NGIzOThlZTRjM2M2MTU1OTNiODBfMy0zLTEtMS01ODA3Nw_d35435f7-6550-4e14-a584-cd18dcabade8"
      unitRef="usd">1058000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNzY5_f7706a1d-0214-413f-b52f-ed5da5af8e07">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our undiscounted cash payment obligations for our operating lease liabilities as of March&#160;31, 2023 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.520%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Remainder of 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,589&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liability, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMC0xLTEtMS01ODA3Nw_d3cc60dc-cb5b-4dd8-b167-5a10ff570767"
      unitRef="usd">3343000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMS0xLTEtMS01ODA3Nw_a9103b09-b9ca-44f7-8f7b-6480feb22b28"
      unitRef="usd">4589000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMi0xLTEtMS01ODA3Nw_bf2aa311-2f67-4678-846e-7851a5f39a04"
      unitRef="usd">1321000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMy0xLTEtMS01ODA3Nw_7108122d-f194-4d2e-84c1-c6c355671820"
      unitRef="usd">252000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <ardx:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfNS0xLTEtMS01ODA3Nw_4ccf3f0b-1f9c-42bc-adbf-cecf334c823f"
      unitRef="usd">0</ardx:LesseeOperatingLeaseLiabilityToBePaidAfterYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfNi0xLTEtMS01ODA3Nw_febc9b2d-43c8-4250-ace4-677d5eaad993"
      unitRef="usd">9505000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfNy0xLTEtMS01ODA3Nw_61f06b34-b686-47a7-9b52-2f1da11ad10d"
      unitRef="usd">693000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfOC0xLTEtMS01ODA3Nw_e36c4fac-e289-4ee0-9543-e55c14d6c4ca"
      unitRef="usd">8812000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfOS0xLTEtMS01ODA3Nw_24d8ef6e-85c3-46f3-97b1-543a563d83fa"
      unitRef="usd">3998000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RhYmxlOjVjNTg1Yzc4OTI2ZDQ5OWI5OWE1ODQyMWE0ZTMxOGYxL3RhYmxlcmFuZ2U6NWM1ODVjNzg5MjZkNDk5Yjk5YTU4NDIxYTRlMzE4ZjFfMTAtMS0xLTEtNTgwNzc_41c9cfe6-7080-43b3-ba68-ac59f72b1bc8"
      unitRef="usd">4814000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i40d30043fca4421a8cdd707a81f722ba_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNjA0NzMxMzk1NzEwMg_84dad655-500e-4268-820a-8580c1559879"
      unitRef="sqft">21644</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="ia852c2d1c80946b885ed9b389837f281_I20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNjA0NzMxMzk1NzExMA_ec9b0119-5644-4e6c-85b3-e130b185bbac"
      unitRef="sqft">72500</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="i90fedc697a1647b9a3c9a1fdd6f348f5_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82MS9mcmFnOmJiNWE5OTNmODdlNzQ5Zjk5Y2Q0NTBhOTYwYTI1OWY1L3RleHRyZWdpb246YmI1YTk5M2Y4N2U3NDlmOTljZDQ1MGE5NjBhMjU5ZjVfNTQ5NzU1ODE4MDk5_4b5b2fd0-4420-4b3f-a500-5c0b422489ef"
      unitRef="usd">400000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMjE5NA_ad50e710-a4d4-47fa-898c-06f4ab1a982e">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At the Market Offerings Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, we filed an additional prospectus supplement under a Registration Statement which was filed in July 2020 for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement we entered into with Jefferies (the "2021 Open Market Sales Agreement"), pursuant to which we may, from time to time, sell up to $150.0 million in shares of our common stock through Jefferies. Pursuant to the 2021 Open Market Sales Agreement, Jefferies, as our sales agent, received a commission of up to 3% of the gross sales price for shares of common stock sold under the 2021 Open Market Sales Agreement. During the three months ended March&#160;31, 2023 we sold 15.5 million shares and received gross proceeds of $51.9 million at a weighted average sales price of approximately $3.35 per share under the 2021 Open Market Sales Agreement. As of March&#160;31, 2023, we have sold a total of 95.2 million shares and received the maximum gross proceeds of $150.0 million under the 2021 Open Market Sales Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we filed a Form S-3 registration statement, which became effective in January 2023 ("2023 Registration Statement"), containing (i) a base prospectus for the offering, issuance and sale by us of up to a maximum aggregate offering price of $250.0 million of our common stock, preferred stock, debt securities, warrants and/or units, from time to time in one or more offerings; and (ii) a prospectus supplement for the offering, issuance and sale by us of up to a maximum aggregate offering price of $150.0 million of our common stock that may be issued and sold, from time to time, under a sales agreement with Jefferies LLC ("Jefferies"), deemed to be &#x201c;at-the-market offerings&#x201d; ("2023 Open Market Sales Agreement").&#160;Pursuant to the 2023 Open Market Sales Agreement, Jefferies, as sales agent, may receive a commission of up to 3.0% of the gross sales price for shares of common stock sold under the 2023 Open Market Sales Agreement. As of March&#160;31, 2023, there have been no sales of our common stock under the 2023 Open Market Sales Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i38ec05cddf3c49969f8932f33a355bdd_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTA5OA_694295ed-b6e4-4dc1-abcf-9f91d0578492"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i38ec05cddf3c49969f8932f33a355bdd_I20210831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTMzNA_694295ed-b6e4-4dc1-abcf-9f91d0578492"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTU3Nw_599dbc31-2978-4a0c-b7ab-549b6bb08562"
      unitRef="number">0.03</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTcyMg_6fbd54aa-702b-49ea-afe9-54061d67374f"
      unitRef="shares">15500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTc2Mw_c1e85444-4cc1-484f-98d1-9c39025ca23f"
      unitRef="usd">51900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <ardx:SaleOfStockWeightedAveragePricePerShare
      contextRef="i39984333e24f4d5088fda6b5a260ea33_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMTgxNw_e88659ac-457a-44d6-ada3-7a0af1c6905b"
      unitRef="usdPerShare">3.35</ardx:SaleOfStockWeightedAveragePricePerShare>
    <ardx:EquitySalesAgreementSharesIssuedSinceInception
      contextRef="i08f1310f62044e3a8e64483b5dd18dda_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMjA5OA_3cd96b4e-00a2-496d-97a2-6f08cfd6444b"
      unitRef="shares">95200000</ardx:EquitySalesAgreementSharesIssuedSinceInception>
    <ardx:EquitySalesAgreementProceedsFromSharesIssuedSinceInception
      contextRef="i08f1310f62044e3a8e64483b5dd18dda_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfMjE0OQ_e8970505-21a9-41b0-be9d-4ac1774cfa03"
      unitRef="usd">150000000</ardx:EquitySalesAgreementProceedsFromSharesIssuedSinceInception>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i847e1d01ce2b4b5196fbe950423d7527_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfNTQ5NzU1ODE3MTg0_d14ef385-e063-4c49-8ee2-eb218b148fb8"
      unitRef="usd">250000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:MaximumAggregateOfferingPrice
      contextRef="i210c86e09a944a939b0007a9a24d4ece_I20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfNTQ5NzU1ODE3NDMy_f84bd699-bbf5-42de-b9b4-454eecbd648a"
      unitRef="usd">150000000</ardx:MaximumAggregateOfferingPrice>
    <ardx:StockIssuanceCostCommissionPercent
      contextRef="i71e4928ba21947689d3e92f7f3fc1047_D20230101-20230131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82NC9mcmFnOmM3NTZkZWViZGY2ZTQ1YjM4ZjQ2Y2UwZGYxYmM2YTc1L3RleHRyZWdpb246Yzc1NmRlZWJkZjZlNDViMzhmNDZjZTBkZjFiYzZhNzVfNTQ5NzU1ODE3NzUw_b85e8a4f-90f1-4402-b847-1613cb43b930"
      unitRef="number">0.030</ardx:StockIssuanceCostCommissionPercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2NA_d4b64791-a38a-4b44-922e-868f905987dc">EQUITY INCENTIVE PLANS&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option grants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2023, we sold approximately 0.2 million shares of our common stock under the ESPP. The shares were purchased by employees at an average purchase price of $0.83 per share resulting in proceeds to us of approximately $0.1 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Issuance of Common Stock for Services&lt;/span&gt;&lt;/div&gt;Under Our Amended and Restated Non-Employee Director Compensation Program, members of our board of directors may elect to receive shares of our stock in lieu of their cash fees. During the three months ended March&#160;31, 2023, we issued no shares of our common stock to members of the board of directors in accordance with the program.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2NQ_45ba54fb-7a03-4664-9f15-4b1b71f8dd81">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for stock options, restricted stock units ("RSUs"), and our employee stock purchase program (the "ESPP") are recorded as operating expenses in our condensed statements of operations and comprehensive loss, as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.435%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.761%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1377563bc1bf4114b883c22f97c51e4a_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMi0xLTEtMS01ODA3Nw_04eaaa44-a978-42a0-be68-c71ffe173f87"
      unitRef="usd">2088000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id437a6bae6684761a2b82865b44768bb_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMi0zLTEtMS01ODA3Nw_6a0bafd8-727e-41de-aa19-29c9c5bf786e"
      unitRef="usd">2508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia72321f082eb4141ae92b05ddd125028_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMy0xLTEtMS01ODA3Nw_3d7ff2d9-101d-4598-b9b2-6ba462dae4fe"
      unitRef="usd">824000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2cdbd17f499a48b8a163d1b51e42ad39_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfMy0zLTEtMS01ODA3Nw_6311ad1a-3736-4c43-b16f-810290f6f210"
      unitRef="usd">1214000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfNS0xLTEtMS01ODA3Nw_e8f2fd6a-2e37-4a66-a4bd-1ddbc2091217"
      unitRef="usd">2912000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjA4MzVlZGExOWJmOTRiZDc4YzhmZjU0NDBkZWY2YTU1L3RhYmxlcmFuZ2U6MDgzNWVkYTE5YmY5NGJkNzhjOGZmNTQ0MGRlZjZhNTVfNS0zLTEtMS01ODA3Nw_d587269d-c5b2-412c-bacf-3f80ec14dfd5"
      unitRef="usd">3722000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2Ng_5a1244c4-eb5c-45cf-8ec9-f1dc7eb24bd3">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2023, our total unrecognized stock-based compensation expense, net of estimated forfeitures, and average remaining vesting period, included the following (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.323%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrecognized Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Remaining Vesting Period (Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock option grants&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSU grants&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i97aaff4ee70847809b2728fcf21c8527_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMS0xLTEtMS01ODA3Nw_380f1f06-1159-4e37-b5e9-319fe2bf11cf"
      unitRef="usd">21127000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8e0beb2c643043e5ac96aa6e57782a75_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMS0zLTEtMS01ODA3Nw_de545355-0c66-4fe3-8fef-0395deaafcb0">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMi0xLTEtMS01ODA3Nw_178589d0-c51e-49ce-9a7b-62aaf55176d2"
      unitRef="usd">7309000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMi0zLTEtMS01ODA3Nw_eb99b23d-7a02-4689-9d37-cd20d36ad3f9">P3Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i569028c12e1a4c889833813e64570cc9_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMy0xLTEtMS01ODA3Nw_b3aabedb-1aa9-4ad9-b8dc-b66b2a64e647"
      unitRef="usd">292000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjdlMGE5ZjkwNjQxMTQ3NDBiMGY1NjE0YjczNTZlN2RiL3RhYmxlcmFuZ2U6N2UwYTlmOTA2NDExNDc0MGIwZjU2MTRiNzM1NmU3ZGJfMy0zLTEtMS01ODA3Nw_314d3429-2f36-4685-9ab8-3f1926465314">P0Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2Nw_4907251a-d6cb-4df9-b944-9886dffe0bc5">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our stock option activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.354%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.021%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.557%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&#160;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise&#160;Price&#160;per&lt;br/&gt;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options forfeited or canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMS0xLTEtMS01ODA3Nw_49c88788-04ca-45f5-bc7b-42a73c0ee733"
      unitRef="shares">13963000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ie1d859c85d4441f7bfee95af8eb909d2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMS0zLTEtMS01ODA3Nw_d19c3ecd-7756-41b9-a11b-eff6400053b6"
      unitRef="usdPerShare">4.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMi0xLTEtMS01ODA3Nw_adb4ed13-3af9-4ccb-a3f1-886fe0bea6a4"
      unitRef="shares">6472000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMi0zLTEtMS01ODA3Nw_88bf651d-2463-43b0-ab3a-98928a40e951"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMy0xLTEtMS01ODA3Nw_fa45d1bd-8c9b-45b2-946d-d7fca3418a1e"
      unitRef="shares">36000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfMy0zLTEtMS01ODA3Nw_143cfa17-2cae-425b-a48b-3b37a08111ec"
      unitRef="usdPerShare">1.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNC0xLTEtMS01ODA3Nw_e0bdc9bb-aa2c-4748-8c3f-9a7f6186924c"
      unitRef="shares">56000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNC0zLTEtMS01ODA3Nw_67be8eba-bf7d-40e4-be10-1aad6fbab827"
      unitRef="usdPerShare">5.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNS0xLTEtMS01ODA3Nw_257f8bcd-30c1-4c88-b0a4-facb48a8ed74"
      unitRef="shares">20343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNS0zLTEtMS01ODA3Nw_00daba24-dc6e-4ad6-b43e-6baa3463f8ac"
      unitRef="usdPerShare">4.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNi0xLTEtMS01ODA3Nw_cdaff733-1cd5-45fb-9642-76bce9f04d1a"
      unitRef="shares">9185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjFhYjQ5ZDc2OWRmMzRjNTZiNzk4YmNjNzA1ODQzYzlmL3RhYmxlcmFuZ2U6MWFiNDlkNzY5ZGYzNGM1NmI3OThiY2M3MDU4NDNjOWZfNi0zLTEtMS01ODA3Nw_431e36b5-0629-40ba-83db-31e19a945dd1"
      unitRef="usdPerShare">5.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTc2OA_a81df142-86b8-49ae-8850-550bbf8d0bc2">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our RSUs activity and related information for the three months ended March&#160;31, 2023 is as follows (in thousands, except dollar amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.157%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.929%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number&#160;of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Grant&#160;Date&#160;Fair&lt;br/&gt;Value Per&#160;Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(208)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-vested restricted stock units at March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iffc784fcdb3041df855d022e9e60e484_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMS0xLTEtMS01ODA3Nw_d3f4b0f9-1087-4149-b7c2-5a79a1e3ce0b"
      unitRef="shares">1406000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iffc784fcdb3041df855d022e9e60e484_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMS0zLTEtMS01ODA3Nw_7583ee25-ba59-4b8c-9c18-931bda7cf146"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMi0xLTEtMS01ODA3Nw_752fd6c0-b714-450f-b128-e95c741bd9e9"
      unitRef="shares">1784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMi0zLTEtMS01ODA3Nw_a709b5d2-387a-402c-84c5-b58040c81f53"
      unitRef="usdPerShare">2.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMy0xLTEtMS01ODA3Nw_5f385c16-8ffe-4d6d-8b42-6d0270770761"
      unitRef="shares">208000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfMy0zLTEtMS01ODA3Nw_bc491041-a52d-418e-a83c-36177dba075e"
      unitRef="usdPerShare">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNC0xLTEtMS01ODA3Nw_8542f338-5867-40b1-b88b-2b5eaff1427b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNC0zLTEtMS01ODA3Nw_71920061-89bf-4f9b-8c52-581de82869e2"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNS0xLTEtMS01ODA3Nw_a3555aeb-2f5d-41aa-a276-168962422b81"
      unitRef="shares">2982000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i8bad1512067f4cfc8126e45f3d15fd8f_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RhYmxlOjZhY2Q5MzgxNzg2ZjQ5MDNhM2RlNTUzODNlMmEyNWJkL3RhYmxlcmFuZ2U6NmFjZDkzODE3ODZmNDkwM2EzZGU1NTM4M2UyYTI1YmRfNS0zLTEtMS01ODA3Nw_633be465-7840-42af-92dc-425265483884"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTIzMA_414e06e1-05a2-4529-9e85-13e9e5716cd3"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare
      contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTM0Nw_93f8d916-5325-4d8f-8edb-428622e24f09"
      unitRef="usdPerShare">0.83</ardx:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare>
    <us-gaap:ProceedsFromStockPlans
      contextRef="ic136c74cd48c4bbb87c705f1715c6dfa_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTQwNQ_b894a51e-067d-420a-afce-0c77c06a418d"
      unitRef="usd">100000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i38458ac6496e4b97bcf456606e115021_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV82Ny9mcmFnOjkzMzBkMWNjZmY3NjQwM2ZiZjUyMWRhODE1MjQ4ZjZjL3RleHRyZWdpb246OTMzMGQxY2NmZjc2NDAzZmJmNTIxZGE4MTUyNDhmNmNfMTY2Ng_aecab418-6964-4f2d-9f28-a211de6a1059"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RleHRyZWdpb246NjUzNmU1Y2JiOTgwNDgyMmIxYWMwMzNkMDg3MjgwNWVfOTQw_a628d829-ca60-4f15-818c-4a6666d27401">NET LOSS PER SHARE&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding during the period, less shares subject to repurchase, and excludes any dilutive effects of stock-based awards and warrants. Diluted net loss per common share is computed giving effect to all potential dilutive common shares, including common stock issuable upon exercise of stock options, and unvested restricted common stock and stock units. As we had net losses for the three months ended March&#160;31, 2023 and 2022, all potential common shares were determined to be anti-dilutive. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of common stock - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods presented, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,266&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,931&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,832&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RleHRyZWdpb246NjUzNmU1Y2JiOTgwNDgyMmIxYWMwMzNkMDg3MjgwNWVfOTQx_fe4af8bd-b806-4791-969f-175824cf4c5a">&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the computation of net loss per common share (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26,773)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share of common stock - basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfMi0xLTEtMS01ODA3Nw_797a9159-cf6e-4521-8501-0f23a366fed5"
      unitRef="usd">-26773000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfMi0zLTEtMS01ODA3Nw_e3f39439-a797-474b-bd99-2539a2fbba49"
      unitRef="usd">-28071000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0xLTEtMS01ODA3Nw_1ad1197c-662f-4b11-8e73-9c8e357186af"
      unitRef="shares">207023000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0xLTEtMS01ODA3Nw_4a62271b-e979-4a80-b6a6-0f047b8b6500"
      unitRef="shares">207023000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0zLTEtMS01ODA3Nw_6be147f6-0b7b-4c4c-aac6-9c7c74ff3bb2"
      unitRef="shares">130935000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNC0zLTEtMS01ODA3Nw_ea82c96f-963d-4205-b796-3b502843c81b"
      unitRef="shares">130935000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0xLTEtMS01ODA3Nw_6d33f965-059d-44df-be1a-8b2854173443"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0xLTEtMS01ODA3Nw_c0c8c457-ba99-481c-b6fc-db5ea3523b89"
      unitRef="usdPerShare">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0zLTEtMS01ODA3Nw_c589ed2b-4fa4-4069-942f-13059322e8e5"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk4OTY0YWJjMWQzNDQ1MTNhY2QwMGNhODhiZTJjMzFlL3RhYmxlcmFuZ2U6OTg5NjRhYmMxZDM0NDUxM2FjZDAwY2E4OGJlMmMzMWVfNS0zLTEtMS01ODA3Nw_c77a3f8a-e073-4cda-b9c0-4852c1855820"
      unitRef="usdPerShare">-0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RleHRyZWdpb246NjUzNmU1Y2JiOTgwNDgyMmIxYWMwMzNkMDg3MjgwNWVfOTQy_d65e5dbd-38cf-4f55-8834-2c9241d7897f">&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods presented, the total numbers of securities that could potentially dilute net income per share in the future that were not considered in the diluted net loss per share calculations because the effect would have been anti-dilutive were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:69.809%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.406%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.992%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,855&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,266&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,931&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,412&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP shares issuable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,991&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,832&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8e0beb2c643043e5ac96aa6e57782a75_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfMi0xLTEtMS01ODA3Nw_7437164d-2ad2-4396-b215-2e0eb07bacb2"
      unitRef="shares">19855000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iab6e5d2a709c4d4a89b9436290d7efe6_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfMi0zLTEtMS01ODA3Nw_f1c4d620-e98b-4f00-b67b-977f97f58217"
      unitRef="shares">13266000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if085e4b6c55540ee9d2aec7aebfae379_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNC0xLTEtMS01ODA3Nw_570add34-8cee-41ec-8ccc-31cd9e9140e1"
      unitRef="shares">2931000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i3414587956434b98b32c8ddc23e1990e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNC0zLTEtMS01ODA3Nw_fb51c3a9-b3c8-4bf9-8c2a-8d83d4b2fea6"
      unitRef="shares">4412000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idee67a217ee640f3ae98f97ef8b95003_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNi0xLTEtMS01ODA3Nw_e3b9e762-7426-4f2c-89ba-99a853fd943d"
      unitRef="shares">205000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9b51b129be104da4b12d3221e1e2ce43_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNi0zLTEtMS01ODA3Nw_1213074a-bb5a-4ebc-83d5-644d10a59223"
      unitRef="shares">154000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNy0xLTEtMS01ODA3Nw_efba8f49-26ec-4241-ad89-1b51f38a46b3"
      unitRef="shares">22991000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6382ad2666154075a0c20fa2d19a62aa_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83My9mcmFnOjY1MzZlNWNiYjk4MDQ4MjJiMWFjMDMzZDA4NzI4MDVlL3RhYmxlOjk0ZmZjY2JkZjgxNzRlYjNiNDA4NzA3NzJjMzE2YWU3L3RhYmxlcmFuZ2U6OTRmZmNjYmRmODE3NGViM2I0MDg3MDc3MmMzMTZhZTdfNy0zLTEtMS01ODA3Nw_af49ad7b-e4c6-4a93-ba00-51c147be66ef"
      unitRef="shares">17832000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfMjg2MQ_4d2b0714-5389-43df-a5e7-b913e45c37b5">CONTINGENCIES&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30 and August 12, 2021, two putative securities class action lawsuits were commenced in the U.S. District Court for the Northern District of California naming as defendants Ardelyx and two current officers captioned &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Strezsak v. Ardelyx, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 4:21-cv-05868-HSG, and Siegel&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; v. Ardelyx, Inc., et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Case No. 5:21-cv-06228-HSG (together, the &#x201c;Securities Class Actions&#x201d;). The complaints allege that the defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 thereunder, by making false and misleading statements and omissions of material fact related to tenapanor. The plaintiffs seek damages and interest, and an award of costs, including attorneys&#x2019; fees. On July 19, 2022, the court consolidated the two putative class actions and appointed a lead plaintiff and lead counsel. The lead plaintiff filed an amended complaint on September 29, 2022. Defendants filed a motion to dismiss the amended complaint on December 2, 2022. In January and February 2023, in lieu of filing a response to defendant&#x2019;s motion to dismiss, plaintiffs filed a motion seeking leave to further amend their complaint and defendants filed an opposition to the motion for leave to further amend the complaint. On April 6, 2023, the court granted plaintiff&#x2019;s motion for leave to further amend the complaint. With the second amended complaint, the plaintiffs seek to represent all persons who purchased or otherwise acquired Ardelyx securities between March 6, 2020 and July 19, 2021.  The parties have stipulated to a schedule for the filing of Defendants second motion to dismiss on June 2, 2023, and a hearing on the motion to dismiss to held on September 14, 2023. We believe the plaintiff&#x2019;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S. District Court for the Northern District of California purportedly on behalf of Ardelyx against certain of Ardelyx&#x2019;s executive officers and members of our board of directors, captioned Go v. Raab, et al., Case No. 4:21-cv-09455-HSG, and Morris v. Raab, et al., Case No. 4:22-cv-01988-JSC. The complaints allege that the defendants violations of Section 14(a) of the Securities Exchange Act of 1934, as amended, breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets, for personally making and/or causing Ardelyx to make materially false and misleading statements regarding the Company&#x2019;s business, operations and prospects. The complaint seeks contribution under Sections 10(b) and 21D of the Securities Exchange Act of 1934 from two executive officers. On January 19, and April 27, 2022, the court granted the parties&#x2019; stipulation to stay the Go and Morris actions, respectively, until resolution of the anticipated motion(s) to dismiss in the Securities Class Actions. On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action. We believe the plaintiff&#x2019;s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, we may be involved in legal proceedings arising in the ordinary course of business. As of March&#160;31, 2023, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of March&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="ib1cf5f5ae42646abb1e513d35f625822_D20210730-20210812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODE5MzE5_bf43f123-a543-469d-b840-21ac52ea4601"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="ib1cf5f5ae42646abb1e513d35f625822_D20210730-20210812"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODE5NDgw_045852fb-fc43-44c3-a0e3-e645935ff83a"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="i85da43d6cf444786a450dbf73698f7f9_D20220719-20220719"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODIwMjEy_fa70f8d1-4bf7-45f5-8b65-7014e5816ed0"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNewClaimsFiledNumber
      contextRef="icfbdf47e462e49459e70036c484a3c1f_D20211207-20220329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODIwOTg4_f104ad26-bcbc-4033-b572-1086b2e895fa"
      unitRef="claim">2</us-gaap:LossContingencyNewClaimsFiledNumber>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="icfbdf47e462e49459e70036c484a3c1f_D20211207-20220329"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfNTQ5NzU1ODIxODQ5_a148b08f-63a5-462a-9a58-af4b6aeb1a87"
      unitRef="defendant">2</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmVhNmEwYjFlYTY1NTQwNjA5M2ViOWU5NTFjMDMzMTNlL3NlYzplYTZhMGIxZWE2NTU0MDYwOTNlYjllOTUxYzAzMzEzZV83OS9mcmFnOjM2YWNkZjlmYzZjYzQ1OGZhZmEyYmUxMDU1ZjBiNjQyL3RleHRyZWdpb246MzZhY2RmOWZjNmNjNDU4ZmFmYTJiZTEwNTVmMGI2NDJfMjgxNA_8e3cdf79-78e3-423c-a9b3-fdc003dc610f"
      unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M22=HP99Y6ZDO_.$#VP34 2QX);O_Z&%C&TQ0T4K%Z\U@0%"73?^;_]PD8F<
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M%?2OIEU" V]%V=S9P"9F#FE*HQ%:FU44)W:XZ19N^B*X["<PI62RFSY<K9B
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M-2-=_($P 7I^SKEZZICRHBPG_3]02P,$%     @ VH"C5BT(-,8"!@  H1L
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MRT 4YT'%A>+K_$CEB2O%X_SGBM& B<P GB\X5[N+[ 7EJ=SH/U!+ P04
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MK+E<TFA.2V[ GB^*HGZZX=]![#[%&?\+4$L#!!0    ( -J HU:!9JBVX@<
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MWC]TG9>=V6!.5K3\J\C%[F:RF("<;'%;BC_H\V]DWZ&Y\I?1DG=_P?/>-IB
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MC@]>CH0-WT'#@S<5?WM$X?:FX)\9A@QE:0/>+PU0;!Y(0?<Q^OS_4$L#!!0
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MJQFJ905U[U3*)5(=^4UX#BC!W\>E=OD=15OR&TA1JRBNV(:-V#?3&R=FE>%
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M+-I,FTA57;(25^DZSG*4"V4\0M/,.DNC^H8V&?2EG'FLR[C4R)Y#:OT"WUJ
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M48TB0=Q7^<K)AHH9-Q7#4C$PJ@>Z=?[#^W03H/Q<Z%Z$6'8L4<J93^72LI-
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M\ND;4KJ)KI;O-@N'MYI2+C$EH??Q!JPOG8O=#1_0?\@[^P]02P,$%     @
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M^ .*HS@YPY<,-2:!+WEKC>AAMC%6NX[X?:K<CFURFLU/R=34M( ,NS$PH/>
M\_?OQI?1YS-:)X/6R3GVM]W'?RC6\]7BQWIQ^Q,M[MVZ>CBEBQSUC "]"Y-A
M4*$::;OV&;S#\,VZGGM)[R;7W=>.28,X;!TT&GV\P$AWT] 95M6A S?*NGX.
MV\H](*!]@HMOE;('PQ\P/$GY7U!+ P04    " #:@*-6K:L;3KL)  #$&0
M&0   'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6RE6=MN&SD2_15" PP20)9L
M.8DS\05P;KN+)!/#3F:P6.P#U4VIF;#)#LFVK/GZ/55DMUJ)K&2R+W9?6,6Z
MG#I5;)VMG/\<*J6BN*N-#>>C*L;FV70:BDK5,DQ<HRS>+)RO9<2M7TY#XY4L
M6:@VT]GAX9-I+;4=79SQLRM_<>;::+155UZ$MJZE7S]7QJW.1T>C[L&U7E:1
M'DPOSAJY5#<J?FRN/.ZFO992U\H&[:SP:G$^NCQZ]OR$UO."/[1:A<&U($_F
MSGVFFW^5YZ-#,D@95432(/'O5KU0QI BF/$EZQSU6Y+@\+K3_II]AR]S&=0+
M9_[49:S.1T]'HE0+V9IX[5;_5-F?QZ2O<";P7['*:P]'HFA#='46A@6UMNF_
MO,MQ^!&!61:8L=UI([;RI8SRXLR[E?"T&MKH@EUE:1BG+27E)GJ\U9"+%^_]
M4EK]ETPALJ5X+H,.PBW$E5=!V9C>/+AR1A=:A8=GTXAM27A:Y"V>IRUF]VQQ
M+-XY&ZL@7ME2E=OR4YC;VSSK;'X^VZOPG?03<7PT%K/#V?$>?<=]#(Y9W_$/
MQ& L7C@;X&RY"<E6)!"9U]I*6VAIQ T>*D T!O&?RWF('B#[[ZX()0,>[3:
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M'TQ&#JCFDFX,(\OZ8HREH6NV;F;TKD%E)]#X6DIS,.P"W4MI]1]02P,$%
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*U6;6_;-A#^*P=U*!+
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M=)#7L+!JX25MJBP)I)^6]$="[0SH?*:4W2P<0?./R_X"4$L#!!0    ( -J
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MEO1Y@=I=H/.U(F%T"^=@_\$R_Q=02P,$%     @ VH"C5KX9^&K, @  7@<
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M:@:=:J989O:(9<:%>J- Y/H_M &IK+0V015@N"\H\()A<*2J)<P/KKRK)NR
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MZO<U8_+'1?%Z2_TZT_Q_4$L#!!0    ( -J HU9&/H4XI (  /L&   9
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MLFNCL73L4A=0]. 7P_AQ,D 04Q^Z9B2[9LR30<9K;H]8.CY@R2A)^PH:AE]
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M%'PJHE?!#MZQFR'X9K:B-D3"!C'!Y-,5);KOR]ZQJO%/.U,6&\6;)8XRT"X
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MP$^W 3_]BQ\1I>.[YI/$#!(S2<PZW5^CU9ZLSY+S.?OS#9^LSI+3>23FDU@
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M0&GM@ULT32A=VKWX4QMVY637^**:@6HFJEFUMOL9]F3O RPZI8-J;JV-9#?
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M7?;4GO(I+8ITN3ZY$.%,9-45RK_?IN5'R_I,-<%#FOVVOCF3_P%02P,$%
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M>W+.\75\1ULN'F0,H,A3EC(YMF*E5N>V+<,8,BK/^ H8/EEPD5&%4[&TY4H
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M)9@1><IS9/K+G(N,*-T5"U?F DEL@[+4#3RO[6:$,F?8MV,3,>SS0J64X42
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MW,.D73-I-S(9+5'H<PQNT1R&E"W@$TIEWA,4E,=P] 6)D,?["#4CA[ VD1!
M5FX1/X"8K&5#^CHUZ4XC]*VF*&BD=/*L>:%@5.W=O8TX3USD;LVR^Y\MW'T&
M=;U:7>_?6[CWBX4[H=?;[V#?VUX&WK-Y^#?0&Q.'M8F[OS.QOW.)^8W@5]/)
M!*19?0E4RH+,TKU9:X9YXCK[P99F\)]]7!'XQP*W5Z/??#<^R<H5YJ/CN!<<
ML/+VUO,;KYV_LW(S])]8V-TIR3(4"UMX2ETH%$R5U5D]6A>WH[*DVTXO*V-=
MR"RH+CA2G.M0[[2CKR]1%IME1_'<%G@SKG2Y:)N)+M!1F GZ^YQSM>F8']0E
M__ G4$L#!!0    ( -J HU8U/>+^:P,  (P,   9    >&PO=V]R:W-H965T
M<R]S:&5E=#4V+GAM;+67;8_:.!" _XJ55E4K=9,X;X0]B+3;;M5^:(NZNNMG
MDPQ@;6*GMH&M=#_^[#@$VA .T-T7_!+/S..Q/3-,MEP\R16 0L]5R>3462E5
MWWJ>S%=0$>GR&IC^LN"B(DH/Q=*3M0!2-$)5Z06^GW@5H<S))LW<3&03OE8E
M93 32*ZKBHB?]U#R[=3!SF[B&UVNE)GPLDE-EO (ZL]Z)O3(Z[04M (F*6=(
MP&+JW.';>YP8@6;%7Q2V\J"/S%;FG#^9P:=BZOB&"$K(E5%!=+.!=U"61I/F
M^-$J=3J;1O"PO]/^H=F\WLR<2'C'R^^T4*NIDSJH@ 59E^H;WWZ$=D.QT9?S
M4C:_:&O7CF('Y6NI>-4*:X**,MN2Y]81!P)A," 0M )!PVT--93OB2+91/ M
M$F:UUF8ZS58;:0U'F3F51R7T5ZKE5/;P8TW53_2)Y<",?]"L)$RB&_2H>/Z$
MOM;&=Q*]?@^*T%*^F7A*6S6R7MY:N+<6@@$+(?K,F5I)], **'Z5]S1MAQSL
MD.^#DPH_$^&B$+]%@1^$Z"7RD%P1 ;)M3E@(.Z>$C85PP,*7=34'\>H%3OP_
M^,*VCT>46UJK*SJNR[RJ6UF3'*:.?C82Q :<S*H\01IUI-$I[=GN?/1[DXJP
M@K*EOJ3Z"'-XB^:PI(R9J=>4M=YY@_X^ZB>[%6LL;HR9][S)<#A.0M_W)][F
M"&;<8<9G82X%80J*LWGB'D\2C8)!G*3#2<["@6<0.947 "4]H)LP&>09=3RC
MLWATD%T -0[B N7F$,L+V$9]MGB8+>W8TNMO&-CQN81ICS#PPVCX>HT[QO$E
MYTGF)9S--.XQC7$:#R)A?Q]8_9-!Y'N3$*"XN=N T D./;2WS3[^F:!YVZU!
MH":\' VN_O\07O!!>L#_58 I>%D2(9'93N-OX_A]>#ZZ.6L\/?!^Y*;A@.N#
M/71P<;BYALY:P;]<6'>4#N#MLPL^F1(&PL\U@&$?$+M)/ "X3RKXO*PR'(^N
M@8WZL+&;1@.P^]2"S\LM_Q:@KD&.^\B1BX<NP#[]X(OR3Q>OKD%,>B\H=L>C
MWPB]@P*Q K%LRF")<KYFRM:*W6Q7:M_9 G._W-;INOK2CUZB$A9:U'=-82ML
MZ6L'BM=-N3GG2A>O37>E_RZ , OT]P7G:C<P!KH_(-D_4$L#!!0    ( -J
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M8%F9K""%4-+-]Z=L&?Z6+53^Z->>,J<-\&DG\*Q!,)2R@2'70C!CH23@P',
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M,$L!I\(?<%"^<RG1G BT2+ @Z ;->)87"IM]YDNT8P-S&0R7II=W1&&:RBL
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M8U%F7Q.LFT&: ?A](X3>-\P?U)7XXB=02P,$%     @ VX"C5B65Z7IS P
ME!,  !D   !X;"]W;W)K<VAE971S+W-H965T-C$N>&ULK9C;;MLX$(9?A5"+
M10L4ULEV#K4-))':S:(I@@3M7BQZ04MCFPA%>DG*3A;[\"4I6;$"68D!WM@D
MQ?_C\!]I!'&RY>)!K@ 4>BPHDU-OI=3ZW/=EMH("RP%? ]-7%EP46.FN6/IR
M+0#G5E10/PJ"L5]@PKS9Q([=BMF$EXH2!K<"R;(HL'BZ!,JW4R_T=@-W9+E2
M9L"?3=9X"?>@?JQOA>[Y#24G!3!).$,"%E/O(CQ/P\@([(R?!+9RKXW,5N:<
M/YC.=3[U A,14,B406#]MX$KH-20=!S_UE"O6=,(]]L[^A>[>;V9.99PQ>G?
M)%>KJ7?JH1P6N*3JCF__A'I#(\/+.)7V%VVKN7'LH:R4BA>U6$=0$%;]X\?:
MB#U!%!P01+4@>B&(#PGB6A"_53"L!<.7(44'!*-:8+?N5WNWQB58X=E$\"T2
M9K:FF89UWZJU7X29&^5>"7V5:)V:77&F"%L"RPA(]"$!A0F5'R>^TG SQ<]J
M4%*!H@.@(;K1J)5$*<LA;^M]'5036;2+[#+J!?Y5T@$*SSZA*(@BE%%,BHZH
MKOHA%^520R(+"<T-!"S'3!W$)?VX&RP&*-K%]#HN?0,N#BTN1C_N$_3A_<<>
MZ^(FJ;'EQF]*ZC_?]&5TK:"0OSIBO*Q8PVZ6*53G<HTSF'JZ$DD0&_!F?[P+
MQ\'GKG2XA"4N8:DC6"LAPR8APS[Z<T(4H@3/"27*9.9_]+XK(;VL8Q/B$I:X
MA*45;&QAYGVVF043?]/A\JAQ>=3KLF[#?Q(_H,T 78@<Z-/C)W3-LD&7R;VH
M8TUV"4M<PE)'L%8^QDT^Q@[+T-AE0ES"$I>PU!&LE9"3)B$GO0_(][*8@T!\
M@2C>RI(H4X(.O;LN*]9H[_F,FN>S<OG5&4EO/,=:YPC6LNZTL>[TC=8U;WUC
M7M/I,K"7>.P=??JJURZ72QW!6EZ?-5Z?]7K]E9L*?H?QO,O57NVQKKJ$)2YA
MJ2-8*P%A\/Q5$#@LW37,44Z<TA*GM-05K9V6O8^UT&$![X<=G1:7M*2F]=2S
MU-6";:^C9Z\CYQ6_'WFTXRYI24WK==S1@I7C_MZI1 %B:8^#),IXR51U0-&,
M-D=.%_:@Q7^>7IU7Z0_E)6$245AH:3 XT;L0U1%0U5%\;<\XYEPI7MCF"G .
MPDS0UQ><JUW'+- <Q,U^ U!+ P04    " #;@*-6'EN/>&@#  "P%@  #0
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MTZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0
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ML_HU%X+*6N0@&_20=>#R&9DJ8\B":9)N78'GDT$JZ"&[8.0&**X[,IG5'_L
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M4$L! A0#%     @ VH"C5M64<=8  P  6@H  !@              ("!(!4
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( -J HU8M"#3&
M @8  *$;   8              " @588  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " #:@*-6-;CAFDP'  "6,P  &
M@(&.'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ VH"C
M5H%FJ+;B!P  Q",  !@              ("!$"8  'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( -J HU;SG<40^@L  (X>   8
M      " @2@N  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" #:@*-6JSW"A4X'  #.$@  &               @(%8.@  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ VH"C5BSHB'2="   F!8  !@
M             ("!W$$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( -J HU;>- V/'0,  +<&   9              " @:]*  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ VH"C5HA03'+]!
MAPH  !D              ("! TX  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " #:@*-6TLX)%"X-   U+0  &0              @($W
M4P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( -J HU8!
M_;>X"0H  !4;   9              " @9Q@  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ VH"C5D_I1R5R#0  YR0  !D
M     ("!W&H  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -J HU8L*NS_=@0  "4*   9              "
M@6V1  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ VH"C
M5D2T0FRL!P  U!,  !D              ("!&I8  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " #:@*-6(O>>)0("  ">!   &0
M        @(']G0  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( -J HU:MJQM.NPD  ,09   9              " @3:@  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ VH"C5G5"JNS: P  [@D
M !D              ("!**H  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " #:@*-6@!YD7IH#   U"0  &0              @($YK@
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( -J HU9M806%
MU0(  /T'   9              " @0JR  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ VH"C5N6>B6,M P  L 8  !D
M ("!%K4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #:
M@*-6J[FXMG #  !2"   &0              @(%ZN   >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( -J HU8/Q6^#,P,  .P&   9
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M970S,BYX;6Q02P$"% ,4    " #:@*-6OAGX:LP"  !>!P  &0
M    @(&.T   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M -J HU;+O;ICY04  -HD   9              " @9'3  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ VH"C5D8^A3BD @  ^P8  !D
M             ("!K=D  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " #:@*-66=7$-(L(   340  &0              @(&(W   >&PO
M=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( -J HU:^0=^[.0(
M "@%   9              " @4KE  !X;"]W;W)K<VAE971S+W-H965T,S<N
M>&UL4$L! A0#%     @ VH"C5F,=H!C# @   0@  !D              ("!
MNN<  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    " #:@*-6
MH*XD/C("   0!0  &0              @(&TZ@  >&PO=V]R:W-H965T<R]S
M:&5E=#,Y+GAM;%!+ 0(4 Q0    ( -J HU:)<UJ!G0,   <1   9
M      " @1WM  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%
M  @ VH"C5C&]#JO2 P  "Q   !D              ("!\?   'AL+W=O<FMS
M:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " #:@*-6Z9'%7!(+  !2DP
M&0              @('Z]   >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+
M 0(4 Q0    ( -J HU:%A.WH2@0   X3   9              " @4,  0!X
M;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ VH"C5M@KP9H!
M!   !A$  !D              ("!Q 0! 'AL+W=O<FMS:&5E=',O<VAE970T
M-"YX;6Q02P$"% ,4    " #:@*-6U!FIH]0(  !O3@  &0
M@('\" $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( -J
MHU;;*>_N^ (  %()   9              " @0<2 0!X;"]W;W)K<VAE971S
M+W-H965T-#8N>&UL4$L! A0#%     @ VH"C5NRH^)X:!0  B2<  !D
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M=#4Q+GAM;%!+ 0(4 Q0    ( -J HU9@Z'3SS0(  (H(   9
M  " @5PH 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @
MVH"C5OB:/"E_!0  \2<  !D              ("!8"L! 'AL+W=O<FMS:&5E
M=',O<VAE970U,RYX;6Q02P$"% ,4    " #:@*-6,>K^@04#   K"P  &0
M            @($6,0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4
M Q0    ( -J HU;6,M=%4 ,  /X+   9              " @5(T 0!X;"]W
M;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ VH"C5C4]XOYK P
MC P  !D              ("!V3<! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX
M;6Q02P$"% ,4    " #:@*-6:*D1+$8#   )"P  &0              @(%[
M.P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( -N HU;>
MG9+0)@,  !<)   9              " @?@^ 0!X;"]W;W)K<VAE971S+W-H
M965T-3@N>&UL4$L! A0#%     @ VX"C5LLWA&(: P  _0D  !D
M     ("!54(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4
M" #;@*-68N=_>G<#  "5#P  &0              @(&F10$ >&PO=V]R:W-H
M965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( -N HU8EE>EZ<P,  )03   9
M              " @51) 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L!
M A0#%     @ VX"C5AY;CWAH P  L!8   T              ( !_DP! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #;@*-6EXJ[',     3 @  "P
M        @ &14 $ 7W)E;',O+G)E;'-02P$"% ,4    " #;@*-6T6;."_X$
M  !/*   #P              @ %Z40$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ VX"C5O5)DLP! @  7B0  !H              ( !I58! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ VX"C5M9,P)+@ 0
MXR,  !,              ( !WE@! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     $4 10#:$@  [UH!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>197</ContextCount>
  <ElementCount>287</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>68</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS</Role>
      <ShortName>CONDENSED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Cash, Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</Role>
      <ShortName>Cash, Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Product Revenue, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNet</Role>
      <ShortName>Product Revenue, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Collaboration and Licensing Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</Role>
      <ShortName>Collaboration and Licensing Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties</Role>
      <ShortName>Deferred Royalty Obligation Related To The Sale Of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Borrowing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Borrowing</Role>
      <ShortName>Borrowing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilities</Role>
      <ShortName>Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Equity Incentive Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlans</Role>
      <ShortName>Equity Incentive Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/Contingencies</Role>
      <ShortName>Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Organization and Basis of Presentation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</Role>
      <ShortName>Organization and Basis of Presentation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Cash, Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CashCashEquivalentsandInvestments</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/FairValueMeasurements</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Product Revenue, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetTables</Role>
      <ShortName>Product Revenue, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/ProductRevenueNet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Collaboration and Licensing Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables</Role>
      <ShortName>Collaboration and Licensing Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/CollaborationandLicensingAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Borrowing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingTables</Role>
      <ShortName>Borrowing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Borrowing</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilitiesTables</Role>
      <ShortName>Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DerivativeLiabilities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Equity Incentive Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansTables</Role>
      <ShortName>Equity Incentive Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/EquityIncentivePlans</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/NetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash, Cash Equivalents and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Inventory - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryScheduleDetails</Role>
      <ShortName>Inventory - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Product Revenue, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails</Role>
      <ShortName>Product Revenue, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails</Role>
      <ShortName>Product Revenue, Net - Gross-to-Net Sales Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails</Role>
      <ShortName>Collaboration and Licensing Agreements - Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails</Role>
      <ShortName>Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Borrowing - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingNarrativeDetails</Role>
      <ShortName>Borrowing - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Borrowing - Future Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails</Role>
      <ShortName>Borrowing - Future Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Derivative Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails</Role>
      <ShortName>Derivative Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Derivative Liabilities - Changes in Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails</Role>
      <ShortName>Derivative Liabilities - Changes in Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Leases - Additional Details of Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails</Role>
      <ShortName>Leases - Additional Details of Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Leases - Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesLeaseCostsDetails</Role>
      <ShortName>Leases - Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails</Role>
      <ShortName>Leases - Undiscounted Cash Payment Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/StockholdersEquity</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails</Role>
      <ShortName>Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Equity Incentive Plans - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails</Role>
      <ShortName>Equity Incentive Plans - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails</Role>
      <ShortName>Equity Incentive Plans - Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Equity Incentive Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails</Role>
      <ShortName>Equity Incentive Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Computation of Net Loss Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Net Loss Per Share - Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ardx-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ardelyx.com/role/ContingenciesDetails</Role>
      <ShortName>Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ardelyx.com/role/Contingencies</ParentRole>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:SubsequentEventsTextBlock -  ardx-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:DepreciationDepletionAndAmortization has a value of -3000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:DepreciationDepletionAndAmortization fact are: Context: idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331, Unit: usd, Rule Element Id: 721. ardx-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="ardx-20230331.htm">ardx-20230331.htm</File>
    <File>ardx-20230331.xsd</File>
    <File>ardx-20230331_cal.xml</File>
    <File>ardx-20230331_def.xml</File>
    <File>ardx-20230331_lab.xml</File>
    <File>ardx-20230331_pre.xml</File>
    <File>ardx-20230331xex311.htm</File>
    <File>ardx-20230331xex312.htm</File>
    <File>ardx-20230331xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ardx-20230331_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="541">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>79
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ardx-20230331.htm": {
   "axisCustom": 2,
   "axisStandard": 26,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 541,
    "http://xbrl.sec.gov/dei/2022": 30
   },
   "contextCount": 197,
   "dts": {
    "calculationLink": {
     "local": [
      "ardx-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ardx-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ardx-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ardx-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ardx-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ardx-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 489,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 1,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 6
   },
   "keyCustom": 56,
   "keyStandard": 231,
   "memberCustom": 30,
   "memberStandard": 33,
   "nsprefix": "ardx",
   "nsuri": "http://www.ardelyx.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ardelyx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Inventory",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.ardelyx.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Product Revenue, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.ardelyx.com/role/ProductRevenueNet",
     "shortName": "Product Revenue, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Collaboration and Licensing Agreements",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreements",
     "shortName": "Collaboration and Licensing Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties",
     "shortName": "Deferred Royalty Obligation Related To The Sale Of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetRetirementObligationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Borrowing",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.ardelyx.com/role/Borrowing",
     "shortName": "Borrowing",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Derivative Liabilities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilities",
     "shortName": "Derivative Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.ardelyx.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.ardelyx.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Equity Incentive Plans",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlans",
     "shortName": "Equity Incentive Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.ardelyx.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
     "shortName": "CONDENSED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.ardelyx.com/role/Contingencies",
     "shortName": "Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.ardelyx.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Organization and Basis of Presentation (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies",
     "shortName": "Organization and Basis of Presentation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Cash, Cash Equivalents and Investments (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables",
     "shortName": "Cash, Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Inventory (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.ardelyx.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Product Revenue, Net (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetTables",
     "shortName": "Product Revenue, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Collaboration and Licensing Agreements (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables",
     "shortName": "Collaboration and Licensing Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Borrowing (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.ardelyx.com/role/BorrowingTables",
     "shortName": "Borrowing (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Derivative Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilitiesTables",
     "shortName": "Derivative Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.ardelyx.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Equity Incentive Plans (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansTables",
     "shortName": "Equity Incentive Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.ardelyx.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Organization and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Securities Classified as Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Cash, Cash Equivalents and Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails",
     "shortName": "Cash, Cash Equivalents and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ardx:AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "iab7f44ca18fe47858c896bf995bca00b_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities Measured on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "iab7f44ca18fe47858c896bf995bca00b_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Inventory - Schedule (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.ardelyx.com/role/InventoryScheduleDetails",
     "shortName": "Inventory - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:PrepaidCommercialManufacturingCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Inventory - Narrative (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.ardelyx.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
     "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Product Revenue, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails",
     "shortName": "Product Revenue, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i077fb918ffd34a16a2ba56d845e7c0eb_D20220101-20220331",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ie1d859c85d4441f7bfee95af8eb909d2_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
     "shortName": "Product Revenue, Net - Gross-to-Net Sales Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ie1d859c85d4441f7bfee95af8eb909d2_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "ardx:ContractWithCustomerGrossToNetSalesAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Collaboration and Licensing Agreements - Narrative (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
     "shortName": "Collaboration and Licensing Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ife5f1ab287944b9d9bde070bbcbc67e0_D20171101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ie1d859c85d4441f7bfee95af8eb909d2_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
     "shortName": "Collaboration and Licensing Agreements - Deferred Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i659312f8037b43898d098e16388710fb_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfAdvanceRoyalty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
     "shortName": "Deferred Royalty Obligation Related To The Sale Of Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromRoyaltiesReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Borrowing - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
     "shortName": "Borrowing - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "id26a7d8749644b05b1f668cab705f3da_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Borrowing - Future Payment Obligations (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
     "shortName": "Borrowing - Future Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i4fcd0ea1cd1e428982ca7b50b09585db_I20180531",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilityNotionalAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Derivative Liabilities - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
     "shortName": "Derivative Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "id77334cdee644ae3adb652a17ffda146_I20230331",
      "decimals": "2",
      "lang": "en-US",
      "name": "ardx:FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idfb8182a2d794133b5db7776b72a7c32_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Derivative Liabilities - Changes in Fair Value (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
     "shortName": "Derivative Liabilities - Changes in Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i378e186ad3f24c9db722bd214a0cd23c_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Leases - Additional Details of Leases (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails",
     "shortName": "Leases - Additional Details of Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ardx:ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i4732bae904484aa5a7c90237b85d7ac9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i4732bae904484aa5a7c90237b85d7ac9_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Leases - Lease Costs (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.ardelyx.com/role/LeasesLeaseCostsDetails",
     "shortName": "Leases - Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Leases - Undiscounted Cash Payment Obligations (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails",
     "shortName": "Leases - Undiscounted Cash Payment Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i90fedc697a1647b9a3c9a1fdd6f348f5_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.ardelyx.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i90fedc697a1647b9a3c9a1fdd6f348f5_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stockholders' Equity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.ardelyx.com/role/StockholdersEquityDetails",
     "shortName": "Stockholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i847e1d01ce2b4b5196fbe950423d7527_I20230131",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ardx:MaximumAggregateOfferingPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Equity Incentive Plans - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i97aaff4ee70847809b2728fcf21c8527_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
     "shortName": "Equity Incentive Plans - Unrecognized Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i97aaff4ee70847809b2728fcf21c8527_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ie1d859c85d4441f7bfee95af8eb909d2_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Equity Incentive Plans - Stock Options (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails",
     "shortName": "Equity Incentive Plans - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ie1d859c85d4441f7bfee95af8eb909d2_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "iffc784fcdb3041df855d022e9e60e484_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Equity Incentive Plans - Restricted Stock Units (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
     "shortName": "Equity Incentive Plans - Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "iffc784fcdb3041df855d022e9e60e484_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i38458ac6496e4b97bcf456606e115021_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Equity Incentive Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
     "shortName": "Equity Incentive Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "i38458ac6496e4b97bcf456606e115021_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesIssuedForServices",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Computation of Net Loss Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Net Loss Per Share - Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Anti Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Contingencies (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.ardelyx.com/role/ContingenciesDetails",
     "shortName": "Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "ic5e2cd326ad44e20a5811dc34fe37f1a_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.ardelyx.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Cash, Cash Equivalents and Investments",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments",
     "shortName": "Cash, Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.ardelyx.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ardx-20230331.htm",
      "contextRef": "idb7e9c0ebd4c41bcbc2ef64dea301e94_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 68,
   "tag": {
    "ardx_AmerisourceBergenDrugCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AmerisourceBergen Drug Corporation",
        "label": "AmerisourceBergen Drug Corporation [Member]",
        "terseLabel": "AmerisourceBergen Drug Corporation"
       }
      }
     },
     "localname": "AmerisourceBergenDrugCorporationMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstraZenecaTerminationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AstraZeneca Termination Agreement",
        "label": "AstraZeneca Termination Agreement [Member]",
        "terseLabel": "AZ Termination Agreement"
       }
      }
     },
     "localname": "AstraZenecaTerminationAgreementMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AstrazenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to AstraZeneca.",
        "label": "Astrazeneca [Member]",
        "terseLabel": "AstraZeneca"
       }
      }
     },
     "localname": "AstrazenecaMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "label": "Available-For-Sale Securities, Debt Securities, Current, Contractual Maturities, Maximum",
        "terseLabel": "Short-term securities, contractual maturities maximum"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrentContractualMaturitiesMaximum",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_CardinalHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardinal Health",
        "label": "Cardinal Health [Member]",
        "terseLabel": "Cardinal Health"
       }
      }
     },
     "localname": "CardinalHealthMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedGains": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized gains.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Gains",
        "terseLabel": "Total cash equivalents and investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedGains",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, cash equivalents and investments gross unrealized losses.",
        "label": "Cash Cash Equivalents And Investments Gross Unrealized Losses",
        "negatedTerseLabel": "Total cash equivalents and investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsGrossUnrealizedLosses",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Current, Rollforward",
        "label": "Change In Contract With Customer Liability, Current, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityCurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Contract With Customer Liability, Noncurrent, Rollforward",
        "label": "Change In Contract With Customer Liability, Noncurrent, Rollforward [Roll Forward]",
        "terseLabel": "Deferred revenue - non-current"
       }
      }
     },
     "localname": "ChangeInContractWithCustomerLiabilityNoncurrentRollforwardRollForward",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Collaboration and Licensing Agreements",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsAbstract",
     "nsuri": "http://www.ardelyx.com/20230331",
     "xbrltype": "stringItemType"
    },
    "ardx_CollaborationAndLicensingAgreementsUpfrontLicenseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration And Licensing Agreements, Upfront License Fees",
        "label": "Collaboration And Licensing Agreements, Upfront License Fees",
        "terseLabel": "Upfront license fees"
       }
      }
     },
     "localname": "CollaborationAndLicensingAgreementsUpfrontLicenseFees",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate",
        "terseLabel": "Fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRate",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "label": "Collaborative Arrangement, Fee Receivable For Reduction In Royalty Rate, Number Of Payment Tranches",
        "terseLabel": "Number of payment tranches for fee receivable for reduction in royalty rate"
       }
      }
     },
     "localname": "CollaborativeArrangementFeeReceivableForReductionInRoyaltyRateNumberOfPaymentTranches",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ardx_CollaborativeArrangementPotentialCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Commercialization Milestones",
        "label": "Collaborative Arrangement, Potential Commercialization Milestones",
        "terseLabel": "Potential commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of future development and commercialization milestone under collaborative arrangements.",
        "label": "Collaborative Arrangement, Potential Development And Commercialization Milestones",
        "terseLabel": "Potential development and commercialization milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentAndCommercializationMilestones",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialDevelopmentMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Development Milestones",
        "label": "Collaborative Arrangement, Potential Development Milestones",
        "terseLabel": "Potential development milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialDevelopmentMilestones",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "label": "Collaborative Arrangement, Potential Payment Per Termination Agreement, Maximum",
        "terseLabel": "Maximum potential payment per agreement"
       }
      }
     },
     "localname": "CollaborativeArrangementPotentialPaymentPerTerminationAgreementMaximum",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerDiscountsAndChargebacksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Discounts And Chargebacks",
        "label": "Contract With Customer, Discounts And Chargebacks [Member]",
        "terseLabel": "Discounts and Chargebacks"
       }
      }
     },
     "localname": "ContractWithCustomerDiscountsAndChargebacksMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerGrossToCreditsOrDeductionsIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Credits Or Deductions Issued",
        "label": "Contract With Customer, Gross To Credits Or Deductions Issued",
        "terseLabel": "Credits/payments"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToCreditsOrDeductionsIssued",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccrualRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accrual",
        "label": "Contract With Customer, Gross To Net Sales Accrual [Roll Forward]",
        "terseLabel": "Gross-to-net sales accruals and reserves"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccrualRollForward",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales Accruals",
        "label": "Contract With Customer, Gross To Net Sales Accruals",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesAccruals",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerGrossToNetSalesProvisions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Gross To Net Sales, Provisions",
        "label": "Contract With Customer, Gross To Net Sales, Provisions",
        "terseLabel": "Provisions"
       }
      }
     },
     "localname": "ContractWithCustomerGrossToNetSalesProvisions",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent",
        "label": "Contract With Customer, Liability, Amortization, Effective Interest Rate, Percent",
        "terseLabel": "Amortization, effective interest rate, percent"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAmortizationEffectiveInterestRatePercent",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months",
        "label": "Contract With Customer, Liability, Decrease In Revenue, To Be Recognized In Next Twelve Months",
        "negatedTerseLabel": "Decreases due to amounts reclassified as current, to be recognized in the next twelve months"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDecreaseInRevenueToBeRecognizedInNextTwelveMonths",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded",
        "label": "Contract With Customer, Liability, Increase Due To Unbilled Prepayments Recorded",
        "terseLabel": "Increase due to unbilled prepayments recorded during the period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseDueToUnbilledPrepaymentsRecorded",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityIncreaseForAmountsInvoiced": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "label": "Contract With Customer, Liability, Increase For Amounts Invoiced",
        "terseLabel": "Increases to amounts invoiced, for which cash has not yet been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncreaseForAmountsInvoiced",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Revenue Invoiced But Cash Not Received",
        "label": "Contract With Customer, Liability, Revenue Invoiced But Cash Not Received",
        "terseLabel": "Increases to amounts invoiced, for which cash has not yet been received"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueInvoicedButCashNotReceived",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months",
        "label": "Contract With Customer, Liability, Revenue To Be Recognized In Next Twelve Months",
        "terseLabel": "Increases due to amounts reclassified from non-current, to be recognized in the next twelve months"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueToBeRecognizedInNextTwelveMonths",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerLiabilityTransactionCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Transaction Costs",
        "label": "Contract With Customer, Liability, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityTransactionCosts",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ContractWithCustomerOtherFeesCopayAndReturnsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Other Fees, Copay And Returns",
        "label": "Contract With Customer, Other Fees, Copay And Returns [Member]",
        "terseLabel": "Copay and Returns"
       }
      }
     },
     "localname": "ContractWithCustomerOtherFeesCopayAndReturnsMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ContractWithCustomerRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Rebates",
        "label": "Contract With Customer, Rebates [Member]",
        "terseLabel": "Rebates, Wholesaler and GPO Fees"
       }
      }
     },
     "localname": "ContractWithCustomerRebatesMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_CostOfRevenueAggregateAmountRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of revenue, aggregate amount recognized.",
        "label": "Cost Of Revenue, Aggregate Amount Recognized",
        "terseLabel": "Aggregate cost of revenue recognized"
       }
      }
     },
     "localname": "CostOfRevenueAggregateAmountRecognized",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentClosingFeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Closing Fee Amount",
        "label": "Debt Instrument, Closing Fee Amount",
        "terseLabel": "Closing fee"
       }
      }
     },
     "localname": "DebtInstrumentClosingFeeAmount",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "label": "Debt Instrument, Fee Due Upon Maturity, Acceleration, Prepayment, Termination, Percentage",
        "terseLabel": "Final fee due upon maturity, acceleration, prepayment, or termination (percent)"
       }
      }
     },
     "localname": "DebtInstrumentFeeDueUponMaturityAccelerationPrepaymentTerminationPercentage",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentInterestRateOnDefaultPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional default interest rate on the event of default.",
        "label": "Debt Instrument, Interest Rate On Default, Percentage",
        "terseLabel": "Additional default interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateOnDefaultPercentage",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentPrepaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of fee payable on prepayment of debt.",
        "label": "Debt Instrument, Prepayment Fee, Percentage",
        "terseLabel": "Prepayment premium (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentPrepaymentFeePercentage",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentVariableRateBaseOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Base Option",
        "label": "Debt Instrument, Variable Rate, Base Option",
        "terseLabel": "Addition to floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableRateBaseOption",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DebtInstrumentVariableRatePlusOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Variable Rate, Plus Option",
        "label": "Debt Instrument, Variable Rate, Plus Option",
        "terseLabel": "Addition plus to floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentVariableRatePlusOption",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_DeferredRoyaltyObligationNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Royalty Obligation, Noncurrent",
        "label": "Deferred Royalty Obligation, Noncurrent",
        "terseLabel": "Deferred royalty obligation related to the sale of future royalties"
       }
      }
     },
     "localname": "DeferredRoyaltyObligationNoncurrent",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_DerivativeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Issued",
        "label": "Derivative Issued",
        "terseLabel": "Issuance of derivative in connection with issuance of loan payable"
       }
      }
     },
     "localname": "DerivativeIssued",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan [Member]",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "ESPP shares issuable"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_EquitySalesAgreementProceedsFromSharesIssuedSinceInception": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Sales Agreement, Proceeds From Shares Issued Since Inception",
        "label": "Equity Sales Agreement, Proceeds From Shares Issued Since Inception",
        "terseLabel": "Total of gross proceeds"
       }
      }
     },
     "localname": "EquitySalesAgreementProceedsFromSharesIssuedSinceInception",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_EquitySalesAgreementSharesIssuedSinceInception": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Sales Agreement, Shares Issued Since Inception",
        "label": "Equity Sales Agreement, Shares Issued Since Inception",
        "terseLabel": "Total of shares sold"
       }
      }
     },
     "localname": "EquitySalesAgreementSharesIssuedSinceInception",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ardx_ExitFee2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2018",
        "label": "Exit Fee 2018 [Member]",
        "terseLabel": "2018 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2018Member",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFee2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee 2022",
        "label": "Exit Fee 2022 [Member]",
        "terseLabel": "2022 Exit Fee"
       }
      }
     },
     "localname": "ExitFee2022Member",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ExitFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exit Fee, Percentage",
        "label": "Exit Fee, Percentage",
        "terseLabel": "Exit fee (percent)"
       }
      }
     },
     "localname": "ExitFeePercentage",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FacilityFremontCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility, Fremont California",
        "label": "Facility, Fremont California [Member]",
        "terseLabel": "Facility, Fremont California"
       }
      }
     },
     "localname": "FacilityFremontCaliforniaMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "label": "Fair Value Sensitivity Analysis, Change In Probability Of Occurrence, Percentage",
        "terseLabel": "Fair value analysis, percentage change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisChangeInProbabilityOfOccurrencePercentage",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "label": "Fair Value Sensitivity Analysis, Ten Percent Change In Probability Of Occurrence, Effect On Valuation",
        "terseLabel": "Fair value analysis, effect on fair value based on 10% change in probability of occurrence"
       }
      }
     },
     "localname": "FairValueSensitivityAnalysisTenPercentChangeInProbabilityOfOccurrenceEffectOnValuation",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_GoVersusRaabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Go Versus Raab",
        "label": "Go Versus Raab [Member]",
        "terseLabel": "Go v. Raab"
       }
      }
     },
     "localname": "GoVersusRaabMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Axis]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Axis]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationAxis",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_GrossToNetSalesAccrualAndReserveClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "label": "Gross To Net Sales Accrual And Reserve Classification [Domain]",
        "terseLabel": "Gross To Net Sales Accrual And Reserve Classification [Domain]"
       }
      }
     },
     "localname": "GrossToNetSalesAccrualAndReserveClassificationDomain",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_HealthCareRoyaltyPartnersIVLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HealthCare Royalty Partners IV, L.P",
        "label": "HealthCare Royalty Partners IV, L.P [Member]",
        "terseLabel": "Healthcare royalty partners IV, L.P"
       }
      }
     },
     "localname": "HealthCareRoyaltyPartnersIVLPMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_IncreaseDecreaseInPrepaidCommercialManufacturingExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Prepaid Commercial Manufacturing Expense",
        "label": "Increase (Decrease) In Prepaid Commercial Manufacturing Expense",
        "negatedTerseLabel": "Prepaid commercial manufacturing"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidCommercialManufacturingExpense",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_InvestmentsAndCashAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments And Cash, Amortized Cost",
        "label": "Investments And Cash, Amortized Cost",
        "totalLabel": "Total cash equivalents and investments, Cost"
       }
      }
     },
     "localname": "InvestmentsAndCashAmortizedCost",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_KnightTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Knight Therapeutics Inc.",
        "label": "Knight Therapeutics Inc [Member]",
        "terseLabel": "Knight"
       }
      }
     },
     "localname": "KnightTherapeuticsIncMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_KyowaKirinCo.LtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Kyowa Kirin Co., Ltd.",
        "label": "Kyowa Kirin Co. Ltd [Member]",
        "terseLabel": "KKC"
       }
      }
     },
     "localname": "KyowaKirinCo.LtdMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ardx_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease Arrangements [Domain]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LesseeOperatingLeaseLiabilityToBePaidAfterYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Three",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Three",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearThree",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution fo tenapanor in Canada. The Knight Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Canada [Member]",
        "terseLabel": "Knight Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInCanadaMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInChinaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in China. The Fosun Agreement.",
        "label": "License Agreement Development Commercialization Distribution In China [Member]",
        "terseLabel": "Fosun Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInChinaMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LicenseAgreementDevelopmentCommercializationDistributionInJapanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement for the development, commercialization and distribution of tenapanor in Japan. The 2017 KKC Agreement.",
        "label": "License Agreement Development Commercialization Distribution In Japan [Member]",
        "terseLabel": "2017 KKC Agreement"
       }
      }
     },
     "localname": "LicenseAgreementDevelopmentCommercializationDistributionInJapanMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Calculation Period",
        "terseLabel": "Loan agreement, covenant, cash and cash equivalents as percentage of outstanding loan balance, calculation period"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceCalculationPeriod",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Cash And Cash Equivalents As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, cash and cash equivalents as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantCashAndCashEquivalentsAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "label": "Loan Agreement, Covenant, Net Product Revenue As Percentage Of Outstanding Loan Balance, Minimum",
        "terseLabel": "Loan agreement covenant, net product revenue as percentage of outstanding loan balance, minimum"
       }
      }
     },
     "localname": "LoanAgreementCovenantNetProductRevenueAsPercentageOfOutstandingLoanBalanceMinimum",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "label": "Loan Agreement, Exit Fee, Net Product Revenue Threshold Metric, Trailing Six Month Basis, Minimum",
        "terseLabel": "Exit fee, net product revenue threshold"
       }
      }
     },
     "localname": "LoanAgreementExitFeeNetProductRevenueThresholdMetricTrailingSixMonthBasisMinimum",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_LoanAgreementExitFeeTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Exit Fee, Term",
        "label": "Loan Agreement, Exit Fee, Term",
        "terseLabel": "Exit fee, term (in years)"
       }
      }
     },
     "localname": "LoanAgreementExitFeeTerm",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ardx_LoanAgreementFutureObligationUponFundingOrOtherEvents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "label": "Loan Agreement, Future Obligation Upon Funding Or Other Events",
        "terseLabel": "Future obligation upon loan funding or other events"
       }
      }
     },
     "localname": "LoanAgreementFutureObligationUponFundingOrOtherEvents",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_MaximumAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum aggregate offering price.",
        "label": "Maximum Aggregate Offering Price",
        "terseLabel": "Maximum aggregate offering price"
       }
      }
     },
     "localname": "MaximumAggregateOfferingPrice",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_McKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson Corporation",
        "label": "McKesson Corporation [Member]",
        "terseLabel": "McKesson Corporation"
       }
      }
     },
     "localname": "McKessonCorporationMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2021AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2021, At The Market Offering",
        "label": "Open Market Sales Agreement 2021, At The Market Offering [Member]",
        "terseLabel": "2021 Open Market Sales Agreement"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2021AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_OpenMarketSalesAgreement2023AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Sales Agreement 2023, At The Market Offering",
        "label": "Open Market Sales Agreement 2023, At The Market Offering [Member]",
        "terseLabel": "Open Market Sales Agreement 2023, At The Market Offering"
       }
      }
     },
     "localname": "OpenMarketSalesAgreement2023AtTheMarketOfferingMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_PaymentsOfUnchargedLicenseFeesAggregateAmountPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of uncharged license fees, aggregate amount paid.",
        "label": "Payments Of Uncharged License Fees, Aggregate Amount Paid",
        "terseLabel": "Aggregate amount paid"
       }
      }
     },
     "localname": "PaymentsOfUnchargedLicenseFeesAggregateAmountPaid",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_PercentageOfNonRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of non-royalty revenue.",
        "label": "Percentage Of Non-Royalty Revenue",
        "terseLabel": "Percentage of non-royalty revenue"
       }
      }
     },
     "localname": "PercentageOfNonRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PercentageOfRoyaltyRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents percentage of royalty revenue.",
        "label": "Percentage of Royalty Revenue",
        "terseLabel": "Percentage of royalty revenue"
       }
      }
     },
     "localname": "PercentageOfRoyaltyRevenue",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_PrepaidCommercialManufacturingCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Commercial Manufacturing, Current",
        "label": "Prepaid Commercial Manufacturing, Current",
        "terseLabel": "Prepaid commercial manufacturing"
       }
      }
     },
     "localname": "PrepaidCommercialManufacturingCurrent",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_ProductIBSRELAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, IBSRELA",
        "label": "Product, IBSRELA [Member]",
        "terseLabel": "IBSRELA"
       }
      }
     },
     "localname": "ProductIBSRELAMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ProductSupplyRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Supply Revenue",
        "label": "Product Supply Revenue [Member]",
        "terseLabel": "Product supply revenue"
       }
      }
     },
     "localname": "ProductSupplyRevenueMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_RemainingFundingBasedOnConditionalMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Funding Based On Conditional Milestone Achievement",
        "label": "Remaining Funding Based On Conditional Milestone Achievement",
        "terseLabel": "Remaining funding based on milestone achievement"
       }
      }
     },
     "localname": "RemainingFundingBasedOnConditionalMilestoneAchievement",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Proceeds from milestone payments"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ardx_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Weighted-Average Price Per Share",
        "label": "Sale Of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average sales price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_ScheduleOfAdditionalDetailsOfLeasesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure of additional details of the leases.",
        "label": "Schedule Of Additional Details Of Leases [Table Text Block]",
        "terseLabel": "Summary of Additional Details of Leases"
       }
      }
     },
     "localname": "ScheduleOfAdditionalDetailsOfLeasesTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ScheduleOfGrossToNetSalesAccrualsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Gross To Net Sales Accruals",
        "label": "Schedule Of Gross To Net Sales Accruals [Table Text Block]",
        "terseLabel": "Schedule of Chargebacks, Discounts and Reserve Balances"
       }
      }
     },
     "localname": "ScheduleOfGrossToNetSalesAccrualsTableTextBlock",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ardx_ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Shanghai Fosun Pharmaceutical Industrial Development.",
        "label": "Shanghai Fosun Pharmaceutical Industrial Development [Member]",
        "terseLabel": "Fosun Pharma"
       }
      }
     },
     "localname": "ShanghaiFosunPharmaceuticalIndustrialDevelopmentMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the purchase price per share of shares issued to employees under the plan.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award, Purchased Price of Share",
        "terseLabel": "Purchase price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasedPriceOfShare",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ardx_StockIssuanceCostCommissionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issuance Cost, Commission, Percent",
        "label": "Stock Issuance Cost, Commission, Percent",
        "terseLabel": "Commission on sale of stock per agreement (percent)"
       }
      }
     },
     "localname": "StockIssuanceCostCommissionPercent",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ardx_StrezsakVersusArdelyxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strezsak Versus Ardelyx, Inc.",
        "label": "Strezsak Versus Ardelyx, Inc. [Member]",
        "terseLabel": "Strezsak v. Ardelyx, Inc."
       }
      }
     },
     "localname": "StrezsakVersusArdelyxIncMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermBLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term B Loan",
        "label": "Term B Loan [Member]",
        "terseLabel": "Term B Loan"
       }
      }
     },
     "localname": "TermBLoanMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2018",
        "label": "Term Loan 2018 [Member]",
        "terseLabel": "2018 Term Loan"
       }
      }
     },
     "localname": "TermLoan2018Member",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022AMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 A",
        "label": "Term Loan 2022 A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoan2022AMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022BMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022 B",
        "label": "Term Loan 2022 B [Member]",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoan2022BMember",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_TermLoan2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan 2022",
        "label": "Term Loan 2022 [Member]",
        "terseLabel": "2022 Term Loan"
       }
      }
     },
     "localname": "TermLoan2022Member",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ardx_ThresholdPercentageOfSalesForTieredRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold percentage of net sales for tiered royalties.",
        "label": "Threshold Percentage of Sales For Tiered Royalties",
        "terseLabel": "Threshold percentage of net sales for tiered royalties"
       }
      }
     },
     "localname": "ThresholdPercentageOfSalesForTieredRoyalties",
     "nsuri": "http://www.ardelyx.com/20230331",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r184",
      "r185",
      "r285",
      "r314",
      "r495",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board of directors"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r236",
      "r511",
      "r572",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r352",
      "r469",
      "r480",
      "r490",
      "r491",
      "r508",
      "r519",
      "r524",
      "r570",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r352",
      "r469",
      "r480",
      "r490",
      "r491",
      "r508",
      "r519",
      "r524",
      "r570",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r236",
      "r511",
      "r572",
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r234",
      "r470",
      "r509",
      "r523",
      "r565",
      "r566",
      "r572",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r234",
      "r470",
      "r509",
      "r523",
      "r565",
      "r566",
      "r572",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Products and Services [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r345",
      "r352",
      "r379",
      "r380",
      "r381",
      "r445",
      "r469",
      "r480",
      "r490",
      "r491",
      "r508",
      "r519",
      "r524",
      "r562",
      "r570",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r345",
      "r352",
      "r379",
      "r380",
      "r381",
      "r445",
      "r469",
      "r480",
      "r490",
      "r491",
      "r508",
      "r519",
      "r524",
      "r562",
      "r570",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r184",
      "r185",
      "r285",
      "r314",
      "r496",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r554",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r15",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r160",
      "r476",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r23",
      "r26",
      "r100",
      "r436",
      "r481",
      "r482",
      "r539",
      "r540",
      "r541",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r7"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r547",
      "r548",
      "r549",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r94",
      "r95",
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyaltiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advance Royalties [Abstract]"
       }
      }
     },
     "localname": "AdvanceRoyaltiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfAdvanceRoyalty": {
     "auth_ref": [
      "r32",
      "r47"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.",
        "label": "Amortization of Advance Royalty",
        "negatedLabel": "Non-cash interest expense related to the sale of future royalties",
        "terseLabel": "Amortization of the deferred royalty obligation"
       }
      }
     },
     "localname": "AmortizationOfAdvanceRoyalty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r35",
      "r47",
      "r124",
      "r304"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Non-cash interest expense"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Office space area (sq ft)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r516",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "terseLabel": "Asset backed securities",
        "verboseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetRetirementObligationDisclosureTextBlock": {
     "auth_ref": [
      "r262",
      "r263",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an asset retirement obligation and the associated long-lived asset. An asset retirement obligation is a legal obligation associated with the disposal or retirement from service of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.",
        "label": "Asset Retirement Obligation Disclosure [Text Block]",
        "terseLabel": "Deferred Royalty Obligation Related To The Sale Of Future Royalties"
       }
      }
     },
     "localname": "AssetRetirementObligationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r129",
      "r140",
      "r156",
      "r182",
      "r225",
      "r228",
      "r232",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r400",
      "r402",
      "r417",
      "r522",
      "r568",
      "r569",
      "r614"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets and Liabilities, Lessee [Abstract]",
        "verboseLabel": "Right-of-use assets and lease liabilities"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r152",
      "r162",
      "r182",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r400",
      "r402",
      "r417",
      "r522",
      "r568",
      "r569",
      "r614"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r240",
      "r253"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1": {
       "order": 2.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r65",
      "r239",
      "r253",
      "r471"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r64",
      "r253"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value to Amortized Cost, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Short-term investments:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r49",
      "r154",
      "r493"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails_1": {
       "order": 1.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]",
        "terseLabel": "Cash and cash equivalents:"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Text Block]",
        "verboseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r42",
      "r49",
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r42",
      "r123"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplementary disclosure of non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r182",
      "r202",
      "r203",
      "r205",
      "r207",
      "r214",
      "r215",
      "r246",
      "r273",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r312",
      "r313",
      "r316",
      "r320",
      "r327",
      "r417",
      "r492",
      "r531",
      "r544",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r397",
      "r398",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and Licensing Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r574",
      "r607"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents.",
        "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r21",
      "r133",
      "r145"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r71",
      "r266",
      "r267",
      "r489",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r547",
      "r548",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r79"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized; 214,462,050 and 198,575,016 shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022, respectively."
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r27",
      "r164",
      "r166",
      "r171",
      "r472",
      "r477"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r121",
      "r122",
      "r236",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r121",
      "r122",
      "r236",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r56",
      "r57",
      "r121",
      "r122",
      "r236",
      "r488",
      "r627"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r56",
      "r57",
      "r121",
      "r122",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r121",
      "r122",
      "r236",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Deferred Revenue Balances"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r329",
      "r330",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r329",
      "r330",
      "r342"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r329",
      "r330",
      "r342"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Deferred revenue, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r516",
      "r518",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r31",
      "r182",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r417",
      "r568"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of revenue"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r55",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r78",
      "r180",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r298",
      "r305",
      "r306",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowing"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Borrowing"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r130",
      "r131",
      "r139",
      "r186",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r425",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Floating per annum rate (percent)"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r131",
      "r139",
      "r309"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Principal outstanding",
        "verboseLabel": "Total repayment obligations"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r125",
      "r127",
      "r282",
      "r425",
      "r504",
      "r505"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Term loan face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument.",
        "label": "Debt Instrument, Fee Amount",
        "negatedTerseLabel": "Less: Unaccreted value of final fee"
       }
      }
     },
     "localname": "DebtInstrumentFeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r20",
      "r186",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r425",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to first anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Three [Member]",
        "terseLabel": "After second anniversary to maturity date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r137"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "After first anniversary through second anniversary of closing date"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r20",
      "r80",
      "r81",
      "r82",
      "r83",
      "r124",
      "r125",
      "r127",
      "r138",
      "r186",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r307",
      "r425",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Payment term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r126",
      "r294",
      "r310",
      "r504",
      "r505"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedLabel": "Less: Unamortized discount and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r241",
      "r253",
      "r257",
      "r258"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit loss on available for-sale debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r244",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Investment in continuous unrealized loss position for more than one year"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r47",
      "r223"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFinancialInstrumentsLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents derivative instrument obligations meeting the definition of a liability which are reported as of the balance sheet date. Derivative instrument obligations are generally measured at fair value, and adjustments to the carrying amount of hedged items reflect changes in their fair value (that is, losses) that are attributable to the risk being hedged and that arise while the hedge is in effect.",
        "label": "Derivative Financial Instruments, Liabilities [Member]",
        "terseLabel": "Exit Fee derivative liability",
        "verboseLabel": "Derivative liabilities for exit fees"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r107",
      "r108",
      "r110",
      "r111",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r115",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r602",
      "r603",
      "r604"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "Agreed amount for exit fee upon change of control or regulatory approval",
        "verboseLabel": "Agreed amount for exit fee upon occurrence of certain conditions"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r106",
      "r109",
      "r110",
      "r112",
      "r113",
      "r114",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r341",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetGrosstoNetSalesAccrualsDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r356",
      "r384",
      "r385",
      "r387",
      "r391",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "verboseLabel": "Equity Incentive Plans"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r172",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r200",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r407",
      "r408",
      "r473",
      "r478",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common stock - basic (in dollars per share)",
        "verboseLabel": "Net loss per share of common stock - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r172",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r202",
      "r205",
      "r206",
      "r207",
      "r211",
      "r407",
      "r408",
      "r473",
      "r478",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common stock - diluted (in dollars per share)",
        "verboseLabel": "Net loss per share of common stock - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Stock-based Compensation [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r386"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized Compensation Expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Average Remaining Vesting Period (Years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r79",
      "r150",
      "r167",
      "r168",
      "r169",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r213",
      "r247",
      "r328",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r406",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r436",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r409",
      "r410",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r116",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r296",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r410",
      "r442",
      "r443",
      "r444",
      "r504",
      "r505",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r409",
      "r410",
      "r411",
      "r412",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r296",
      "r346",
      "r351",
      "r410",
      "r442",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r296",
      "r346",
      "r351",
      "r410",
      "r443",
      "r504",
      "r505",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r296",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r410",
      "r444",
      "r504",
      "r505",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r117",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Derivative Liability"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r413"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "auth_ref": [
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "terseLabel": "2022 Exit Fee addition at fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r117"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesChangesinFairValueDetails",
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r296",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r442",
      "r443",
      "r444",
      "r504",
      "r505",
      "r516",
      "r517",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DerivativeLiabilitiesNarrativeDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r414",
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r242",
      "r243",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r259",
      "r307",
      "r325",
      "r404",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r502",
      "r556",
      "r557",
      "r558",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "auth_ref": [
      "r543",
      "r560",
      "r561"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "negatedTerseLabel": "Gain on sale of equipment"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnRestructuringOfDebt": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a debtor, the aggregate gain (loss) recognized on the restructuring of payables arises from the difference between the book value of the debt before the restructuring and the fair value of the payments on the debt after restructuring is complete.",
        "label": "Gains (Losses) on Restructuring of Debt",
        "negatedTerseLabel": "Debt refinancing costs"
       }
      }
     },
     "localname": "GainsLossesOnRestructuringOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r28",
      "r128",
      "r134",
      "r148",
      "r225",
      "r227",
      "r231",
      "r233",
      "r474",
      "r501"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r261",
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r183",
      "r198",
      "r199",
      "r224",
      "r392",
      "r395",
      "r396",
      "r479"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r498"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDerivativeLiabilities": {
     "auth_ref": [
      "r542"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).",
        "label": "Increase (Decrease) in Derivative Liabilities",
        "terseLabel": "Change in derivative liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInDerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r542",
      "r610"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInRoyaltiesPayable": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the obligations due for compensation payments related to the use of copyrights, patents, trade names, licenses, technology. Royalty payments are also paid by the lease holders for oil, gas, and mineral extraction.",
        "label": "Increase (Decrease) in Royalties Payable",
        "terseLabel": "Royalty payments and commercial milestone payments"
       }
      }
     },
     "localname": "IncreaseDecreaseInRoyaltiesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r126",
      "r136",
      "r170",
      "r222",
      "r424"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r176",
      "r178",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r534"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/InventoryScheduleDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "terseLabel": "Inventory",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r161",
      "r494",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/InventoryScheduleDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/InventoryScheduleDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Inventory, non-current",
        "verboseLabel": "Inventory, non-current"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r536"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r535"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/InventoryScheduleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "ardx_InvestmentsAndCashAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Cash and short-term investments",
        "verboseLabel": "Total cash equivalents and investments, Fair Value"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease costs"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "verboseLabel": "Summary of Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Additional details"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Summary of Undiscounted Cash Payment Obligations for Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r612"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest expenses"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r182",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r401",
      "r402",
      "r403",
      "r417",
      "r500",
      "r568",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r132",
      "r143",
      "r522",
      "r546",
      "r559",
      "r608"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r153",
      "r182",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r401",
      "r402",
      "r403",
      "r417",
      "r522",
      "r568",
      "r614",
      "r615"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "terseLabel": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "Licensing revenue",
        "verboseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableCurrent": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.",
        "label": "Loans Payable, Current",
        "negatedTerseLabel": "Less: Current portion of long-term debt",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LoansPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails",
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Loan Agreement"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r131",
      "r141",
      "r295",
      "r311",
      "r504",
      "r505"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Investments [Abstract]",
        "terseLabel": "Long-term investments:"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermLoansPayable": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Loans Payable, Noncurrent",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermLoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingFuturePaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r20",
      "r76"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r72",
      "r73",
      "r268",
      "r269",
      "r270",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r268",
      "r532"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "terseLabel": "Contingent liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNewClaimsFiledNumber": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total number of new claims filed pertaining to a loss contingency during the period.",
        "label": "Loss Contingency, New Claims Filed, Number",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNewClaimsFiledNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "auth_ref": [
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of defendants named in a legal action.",
        "label": "Loss Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ContingenciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r42",
      "r45",
      "r48"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r29",
      "r48",
      "r135",
      "r147",
      "r151",
      "r163",
      "r165",
      "r169",
      "r182",
      "r190",
      "r192",
      "r193",
      "r194",
      "r195",
      "r198",
      "r199",
      "r204",
      "r225",
      "r227",
      "r231",
      "r233",
      "r246",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r408",
      "r417",
      "r501",
      "r568"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r225",
      "r227",
      "r231",
      "r233",
      "r501"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r430",
      "r521"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseImpairmentLoss": {
     "auth_ref": [
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from impairment of right-of-use asset from operating lease.",
        "label": "Operating Lease, Impairment Loss",
        "terseLabel": "Operating lease, impairment loss"
       }
      }
     },
     "localname": "OperatingLeaseImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "verboseLabel": "Undiscounted cash payment obligations"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: Current portion of operating lease liability",
        "terseLabel": "Current portion of lease liabilities",
        "verboseLabel": "Current portion of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r427"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails",
      "http://www.ardelyx.com/role/LeasesUndiscountedCashPaymentObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r428",
      "r431"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Cash paid for operating lease"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesLeaseCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r426"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r543"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r433",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r432",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining life (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/LeasesAdditionalDetailsofLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r52",
      "r53",
      "r61",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.",
        "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]",
        "terseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r97",
      "r98",
      "r99"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized gains (losses) on available-for-sale securities",
        "verboseLabel": "Unrealized gains (losses) on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding as of March\u00a031, 2023 and December\u00a031, 2022, respectively."
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from the sale of future royalties, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock in at the market offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSecuredDebt": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.",
        "label": "Proceeds from Issuance of Secured Debt",
        "terseLabel": "Proceeds from 2022 Loan, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r39",
      "r92"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "verboseLabel": "Proceeds from issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLicenseFeesReceived": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from licensees for license fees during the current period.",
        "label": "Proceeds from License Fees Received",
        "terseLabel": "Upfront payment received"
       }
      }
     },
     "localname": "ProceedsFromLicenseFeesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRoyaltiesReceived": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for royalties during the current period.",
        "label": "Proceeds from Royalties Received",
        "terseLabel": "Proceeds from royalties received"
       }
      }
     },
     "localname": "ProceedsFromRoyaltiesReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r63",
      "r173",
      "r174"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds from maturities and redemptions of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r39"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r69",
      "r144",
      "r475",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSecuredDebt": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to repay long-term debt that is wholly or partially secured by collateral. Excludes repayments of tax exempt secured debt.",
        "label": "Repayments of Secured Debt",
        "negatedTerseLabel": "Payments for 2018 Loan, net of costs"
       }
      }
     },
     "localname": "RepaymentsOfSecuredDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r96",
      "r149",
      "r622"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r84",
      "r142",
      "r484",
      "r486",
      "r522"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedTerseLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r150",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r247",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r406",
      "r481",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r220",
      "r221",
      "r226",
      "r229",
      "r230",
      "r234",
      "r235",
      "r236",
      "r340",
      "r341",
      "r470"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r338",
      "r339",
      "r343",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Product Revenue, Net"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Payment to be received"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Gross product revenue"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/ProductRevenueNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-Dilutive Securities Not Considered in Diluted Net Loss Per Common Share Calculation"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Securities Classified as Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails",
      "http://www.ardelyx.com/role/DeferredRoyaltyObligationRelatedToTheSaleOfFutureRoyaltiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Schedule of Computation of Net Loss Per Common Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r90",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense Recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities Measured on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r1",
      "r12",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Current Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Noncurrent Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Debt Payment Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r353",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r86",
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost not yet recognized and weighted-average period over which cost is expected to be recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost [Table Text Block]",
        "terseLabel": "Summary of Total Unrecognized Stock-Based Compensation Expense, Net of Estimated Forfeitures"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedCompensationCostNonvestedAwardsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.",
        "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]",
        "terseLabel": "SOFR"
       }
      }
     },
     "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding balance, ending (in shares)",
        "periodStartLabel": "Outstanding balance, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number\u00a0of RSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant\u00a0Date\u00a0Fair Value Per\u00a0Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited or canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding balance, ending (in shares)",
        "periodStartLabel": "Options outstanding balance, beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number\u00a0of\u00a0Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding balance, ending (in dollars per share)",
        "periodStartLabel": "Options outstanding balance, beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise\u00a0Price\u00a0per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansRestrictedStockUnitsDetails",
      "http://www.ardelyx.com/role/EquityIncentivePlansUnrecognizedStockBasedCompensationDetails",
      "http://www.ardelyx.com/role/NetLossPerShareAntiDilutiveSecuritiesExcludedfromComputationofDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited or canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r182",
      "r202",
      "r203",
      "r205",
      "r207",
      "r214",
      "r215",
      "r246",
      "r273",
      "r275",
      "r276",
      "r277",
      "r280",
      "r281",
      "r312",
      "r313",
      "r316",
      "r320",
      "r327",
      "r417",
      "r492",
      "r531",
      "r544",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r22",
      "r79",
      "r150",
      "r167",
      "r168",
      "r169",
      "r187",
      "r188",
      "r189",
      "r191",
      "r197",
      "r199",
      "r213",
      "r247",
      "r328",
      "r388",
      "r389",
      "r390",
      "r393",
      "r394",
      "r406",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r436",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r187",
      "r188",
      "r189",
      "r213",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r5",
      "r6",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for services (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/EquityIncentivePlansNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r5",
      "r6",
      "r79",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Issuance of common stock upon vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r79",
      "r84",
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Issuance of common stock upon exercise of options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.ardelyx.com/role/EquityIncentivePlansStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r5",
      "r6",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r5",
      "r6",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock in at the market offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r79",
      "r84"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r62",
      "r522",
      "r546",
      "r559",
      "r608"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS",
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r181",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r326",
      "r328",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r437",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/StockholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r70"
     ],
     "calculation": {
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r242",
      "r243",
      "r307",
      "r325",
      "r404",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r556",
      "r557",
      "r558",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsDeferredRevenueDetails",
      "http://www.ardelyx.com/role/CollaborationandLicensingAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "U.S. government-sponsored agency bonds",
        "verboseLabel": "U.S. government-sponsored agency bonds"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CashCashEquivalentsandInvestmentsSecuritiesClassifiedasCashCashEquivalentsandInvestmentsDetails",
      "http://www.ardelyx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesMeasuredonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r216",
      "r217",
      "r218",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/OrganizationandBasisofPresentationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/BorrowingNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r201",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted average common shares outstanding - diluted (in shares)",
        "verboseLabel": "Shares used in computing net loss per share - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r200",
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "verboseLabel": "Shares used in computing net loss per share - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS",
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.ardelyx.com/role/NetLossPerShareComputationofNetLossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 12
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6392692&loc=d3e7569-110849",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "https://asc.fasb.org/subtopic&trid=2175671",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r525": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r529": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2443-110228",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123399704&loc=SL77918431-209957",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r628": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r629": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r631": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r632": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r633": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r634": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=6402221&loc=d3e15743-112638",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>80
<FILENAME>0001628280-23-015212-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015212-xbrl.zip
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M9Z/,T+^&66Z5DSR7"N67@M?DL^,Q$&=BQBCF&9.19A8SG$FNJ!<*2TM%*KS
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MZH;G%5*/BSB,T JJ@//#Y<AT12LY\>P=7<%43WQ4@E; *IV3ATTSJZ>3P'R
M8/!USKFCE#7U^TS\$,#/:[BT7=4/!+NO")^YGXK"E"IKY[1K^YW?!C\2]7]2
M$S&N0"DA$4[<0=JUM@'"\_@@AU\N).R/Y(KNI<QF:6X>?25#K<1.,;$E5\ZE
M\5PO=/WT\6#KTW;>[/[=W5O?/&F]:1VTSL!8[FX?[I(F;IY]P+N'Z5[-ZPL5
MTK/QO3>;I[O=O2_-PPVT2S;HUILFV7O3 M/[PUFK_3$OWPO#,UY/W'-E"++6
M9SQP!<:WQYD1"'Q"H76(Q 7'354L#7 N>S4N-XY,T?AJ.J/0^-^E4KX[AC(1
M.;!@A.\Q0BV(*SF\X()[<,'F52Z@P@(%G,\D3^4K3*!,&V&RY)A:BB5%DI45
MD_]90'TV9/Y&K66K&M_K^8JD@^<X5?'8W/#^6O,#J9S2U&5"&)HQ@U%F&2%
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M5V[Q62WHD<K4_I]_8#G=H'3C-Y"<!F[<+WX_7TR>M$?1[R3RP+"C;N/HH#^
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M"%9R'56RTKFN!3P+/BZ$CW-9Q481YU1 8&S"1VXT,A0BHN UR3'NR'QBF+I
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M..0#%T0D44),2,3X/ X5[T=CE;=9@9:BLDNJ[ QY2.C*590:,>=SNUB)D7;
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MB%N"7E_E"+0-F@3*# <ZD(M 6LV,PD(R;;RCN(&X98*X^=BB)4YY1CD*EC"
MN$013*-"Q!/!A+3!Z+"RSM2JUK*!N ;BGB7$:<QLY(; #] -:8RBQ@<9@\/:
M *=K(J]+@F[SD5>LE*6,1.0E)XA[+H' >8JPHI&S7.Y(F-O>K':W\'9^-4$B
M?E).\')++H!5A*Y1<1M9IAD\+O3'N7K-F8XO42+LIHGWUL3G$.V>J55VO<S\
ME]TXWCQC>9[QG':^;L)MWTI=S3/%U'+=T?B]/:I27-P&>^/E^J4;A<LSY?.Z
M^&3X,#%Y T)BFD;"H:/&V4@(5TI[[FB\=%1S!C4;O_\NTS#NO,VLN"SAM';V
MCEH__)?$+1!C09%W!N>]@08YH,6(:2^ #5-#7=E4I.B-_?[EVU34(-,3128!
M;CJ+BO.D"8^,YI35-.?-Q\8D9BZ]T?$JR-2XZ]<'I>.SH*2H<3#G! DF<QX9
M0":;LS):(8@ADGAN[#+NE&I@J8&EGQ,F W;4DZB\Y#$&HVS,QZ H%D9*?.G3
MK@TLW0LLM>:X4@A4!XL#DBY)Q /+R6.B1"X?9N=".<92 TL-+"U%WZZRHUP
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MT+1[Q2*4FWX_:\9R8&%N&U7I7OWU).9@U)H1+(<=)F<W)R^>1"36ZKU/9S>
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M+Y$&/X< VNMVKU[PW>OWPYU$T"X%8)=-4_NH >S6.<AT\M[DN6LPZBH8=;Q
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M8X-UW,M/ YQWUG/]QN<SG'M6$\?FI\_5\8-$VT!6Y$FJUNL=^]TZQOR7GYC
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MK<"H.,L1V6Y,VX>/056Q0T"CC<8KC1C>+29%%IA>\"(0LB[P',4P<'"ISY:
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M\ 9%@:E)EAC'6<)3$A*9$YPBDALI>9XQZN)DTJO(Z02T'>-!LQLY-B(MS=,
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M HJVYU0J25&'%JE)E9#"F>L#7K7_8YU*\.&ZO4*]RPRY8W:4LAR;&3 0M%R
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M,.EJ3CM&D+G8Z\> (5L8]5AT6HS8FBQI+3S111NUHHO/7\NU!AP489I*EO4
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M17$L49[2Q!HFP)P#<P6S_<G&;(O=&F&1 )<A&Q<,CA30U.68OL' ;#1YGF=
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M*4QD-DD@FA0UHBH%%)2:R3P0ZW5ZZXVB?J>J-_7(A<Z.9X\$>192*HQ(&<G
M&!":VE09PYGT.0=;H,PC)E4>\3TBP8KCE^'X:6V'Y)QK%VB2>D5P3KU*9"JR
MA&76.RFDRXA=>\GRV92]^^/VW]R)^%YY=BS^,R_)Z:]KN':7MG@?Q#UN4VLE
M[(&?\OP^8BNI-%W53W*=84YHX)*K8*50,DLCA,G@N;YO_?2M;G7>=?O]G3(
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M/=\QN9/8 3<H5\ZVS-9 >FI9Y+8&TEK)(BQ=:07.*@)G/@W!,PW?M*Q83\R
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M$)D>EM#P"<WXG!=:*,10 WE%$*>#27^<CH!2Q[1WN+!QK&:"-\ 70 X"/U6
MRS"< ?P)C'!V7N^10U,ZYQ>BWAFZOUPR/AKEV0^0<&/1O]*6BN7B/\EX1BXS
M([8-@]E)Q!FS3.Y'<>P9'O=-8&<K7"*7C5FQO),+?I@<P;[O$>3SAQS]H;O&
M$HS-E,;W+QS\MF/TK@]^'%Q_-WO7>Y<'9U]]%O/8=1S=,;#IC@4RU0<M"6:U
M;T2FXP2^%[SZW3([+IN7K%KQGPFB<R="&G5(3ZL0 ?<=*[)B,_*-@+FA[SLB
M#D+;#WS0S99OMD3P^$3PXV#GJX@"!"T,= =V66?"C6#_0<4*TS9"$SZ"EGSU
MNV=U@$B6$T&6C;5PDO91_?V?0IX$I5DN)4]'&_5!8$09&$O%*!O&$K^]O&0R
M0L';$%(@#+_#)5)TDW12]%6+\>*<]_MXSI3"VX'2WHDPAY%<:;)B$X373Z"V
MKY'*Y!&L6LQ!!4AM-[T*E]A',<K.AO#0&)9.2P<CGN:R^#71^MGP3.^G%_A;
M48@QZH,QS!16_Y<5S.C 2$0<N8''39=Y8<#M*.!F$L?@>#,_<6X#97)NMJ?W
MJS'_G15W+ AQ7QK?GGQT>M>?P(S>8P=@/G]EH1-:">(K,6R)%-J)SH%!=2<R
M0F99S ]$\NIWH[M ;@.A]G''XTE.-=7(8X25/J"*'$W46.G35=!E3P8@CB(M
M\,!WE*=8B0WJ'ZBM07M@)>!CE9U46T-D_NI9HJ/U120Y:YY-&3P[\/R^+,!&
ML7"IS)$&R0\S[ Z1#80TM,AJJYZUM)R[.X\;,H\30O1U*^:"RU[=MS'$$P.)
MDT3I'9[L::;9U1X9Q^%XG$7?S[,^F+?%WG\FY"R/J;U1/RLF^=J@-_3>EGQ\
M8/=.3K^??OXG/7W_Q3H]^6A^^78 +NE'ZXOUZ1*^^_%E )QZ$LWS\75D]@9'
M_=//?WT__7;:[^W^DQY<GP]ZN_#7R1_PW;OTR_7I>>_ZG^3@&_#USE<>.X;P
M3$/G+ :=ZR5@<P5^I!MNPGAH\L"WA!3"0),BWD%I*( I?,/WF06[$H$XMJ/8
M!D,-;G!-7SBS> _')X=O__WGX=^[>T?'E/SGO='V/G[:/_FRM(7B<F"06U^^
M-N1/3_PM1347W8$A=L8D-$!(? <S]A"]-!"*1>V";H<9L3,Y@S&A\#/)]4[2
MOC08,&"!V\S[(,RS8B2B,5AJ:)+UI0=>NJA'X@QDOD2GT8[+#CM*(UQB\QQZ
M)$CMOR:@#^!-!F%NX.IF:ED[6EH4$S)F4)X7H,K1!Y?N]V1$WJHVX.!33L!I
M/H,M.$.GN+P=U4U$X#:K6"^V+R+# 0\SL2,6!&Z0^(%M);;-;<<)XYC\#-/P
MIXV6_=Z[J7SG SFJG7)0):5\P"%MALWRY++N9,<YW/GJ!LP*P+?30U=@'49D
MZCR,$CU( C,V',]G@?7J=],QN@O<B])6P;-.ZO$T (,"^ <TAPR0#/B5%@JB
M*R+H&,-Q<4>9 \!%9(O OYTZV *[40!YE3&FV4@4V=E_"=I@N)!"4*^01C2P
M6X>EJ#BFIU1BXM6OX.1,<J1N,G\47P@<X,+1% +\%TGS+35O!#4?7/<>B)I!
M2(+_FHMB"5W+2%Q%@EWM0X.RD!QOH\9.?7.'S&!X1TGV]#.8T$+ZA?1N8!_%
M99(B5^N,:0>!SVS;%A9+&%@VOI_$W T=;KD&V(SV+?[A+'&2[;BO% 7"NK^M
M1KAV/3&?G@H_X0&X$P0Q=<"U L_7&3<B/?1XJ#LL"-TP-'S'!2J<SS[\[S*0
M<@:ZOE D(;4JZNJ:**<($B6JDIYW(;ZNMKNJ9XF"DMZR/(!(0WM8PIL/3%2D
M)V(YAP\8HHJ/Z>5@C=%/&Q*B>'K2C*X.SKZZ21@[C'/=,ZQ09X'@.D]$H*/[
M;,:N9WLL00'9G<_@K^2CHD/4YI6@DA0+-FHD1%RL; 0^-*5\4 -Y!YJ]E%6'
MR5MB&Z*BEDB6$(EU</DU,H7O, PW1Z! F<] @?JQJ0>1'1B6$W$J67/,[CPN
M244D8/QQ[5+U3]:X;* \)=+P3&_JC.I&B@%6)SY_6,JQIE4;C.XP(?J8Z?Q,
MEE<]A#4YGGAZ\CC[@?FJON\Z 8]TYGB(6Q.[.H^YK7O<X(D9N8'AA*#>NO8"
M&3(22H^MI+%VEH4*.U74D?03EQ%TO'@U567XB6F;1N):!F/"YKYP&?/MT(D1
M>SI>EHKB3)&/C*31X*NQ2]TD==9Q"E)H'_XWPA&U$FAQ!(Z\4CN* S=D0C<,
M;H&:<F,]\."3FQA^E,2P.0Q(+'"Z\QG1-ZHI)+<R@O%S*NO1**:INEKJ63E^
M:QQ^! $5>(9C.+IE\D!G9FCHH0ABL,0CT_-8E'##OM4+7$$^;4<0\B\^I"/:
M2JZJ**3V#BA-.]9M8*-&D+%JXUV>.X4B LK6T+.-$**=@HV-9VJO7]$_BT.5
M&*%!!N/I$)V3U^FO\.:04H+JP.=:1"Q]Y@DS-LP(&Z:$CAF 32T"QV"6'7N.
MY2G.-]L8SP-S=^.4U<8V$U]CDXG$]AU=&*X-QBH+=%\(2Q>A9?JAR?PD]!%#
M9M7890<(0\!VY-2MGKZ(13C6"A$APCF%;2YYGG/L80^$]Z\L)X(I%H02*4%M
M"$26@YN=U[17O"&2?9T2H2\.[J\%N5NF$?FN, (>,,8#.PA!$GD\X!:+&>C5
MEMR?@-Q[NP=77Q.?A;$;!'H8)H[.K%CH81""E^8P(2+XB?G\>4/UTZ'YO_]^
M"S*_^ALE?(Q74IIB6"6.\K$.1*X/I&ZM^$.ED99:X\;@?E=Z!0OBL#?>.!N'
MG8K!XGHHN_%!PK">*5A@^2&WS(!YKA_$M@BLQ$OL)#(-YLUZJK<P5!N&O2/G
M7'^Z_!KZCO YAC&,Q 2/U;#T$-2X;KJF'87,#@/;0(]UGF\>*B1[(QW>Z.".
M$3-+^KB42CS,U"@6<?(*[[Q+DLU+;L83+&_&LT+^D5?E'[4=?%Y6!Y\U2;BY
M0[Z9]>CY9G5F&07A$7V&=N$(!8B(47T5%.OX ZL82CBGM<E"NU+JZ]MW^.Z/
M[P>?>]].!U_LWK>/EP?6:7KZ[=/5P>>C<U WYL&WCZ#.3K_-JJ_#$WC_^X\_
MOEB]P>FWR.KM[ER?#OX:]$Y@#._WV,')IZO>+JBS08^B\+V=KS$+7>8%ILYM
MG^LL9$P/+(3)=/TD,##[/XYFL] "W[<\89E6P"S&;# (X]APS0334%TGC&>S
MT&3&F;;?>[L'(_EG3_OP]T[O>%D&VH-UC5LQ"^P.&7"W3WQZH:P$ZQM,VPYC
MGR7@W20^V,^Q:_+0 W/:W]B,.;(+=>(CK<EJ<VOXF.FET;F()WB6LC<8];,K
M(8Y%?@$V4\WCS:'M](')Z1-6BI3)P_)LET3#BQ8$'[\R)^0.2T(\8,%Z>A<$
M06*"!QB:H6<"X<:^N1WMQ"3QAD2\48-"2L2R9FXYF=]D]&84$2\P;:88 SV/
MR["-#,J !WET_(G<3_1JT686BBS59:,)V-TJU'B6\X%**ML[_O#AU:\:'E;A
M>_.8"C4:J!XECEI9A A\%.,7<1T<+1HX(-CG#$> ,\O%.5R)OB7H1>E]RCYJ
MQ7V:F<UNJ[2<%^WJTS8\"_RN$03WZ7?F&5UF.P_?[PPMZ>!>C[WY-X<]SF#=
M.P]H<YK0+D?:6-:VN[HTF+MT 4Z$HO[G0468T\H*^!KSK&1/'6VOSK/2P,]?
M"@:T+HO>0$)9 3=JS7=D47>_^\[XQ:V<]>@TVR+LWP]^Y5CT^W12=":&8'3T
MR>#@\2 =JC/7"[$JPM+/H2JNW0JMW/#R[O/?&F0>T_8\Q[7#R P39IHL]'T[
MLJPD\"+'%(S?EH\Y!]&C7#P1+_8 ]Z0AO1DX/??T A5.SPX[N/ZG#Y[>C\//
M?PT.3X[2T]V(?;D^!V_PD]';_>/[Z><OUI>33^8L3L_![MEU[_,_W[^<[#E?
M!E^<WON_OO>NS[\=OC\%[_&C<?#^J _O.N^=_+.HPY/!!.><,9U34KK%,2G&
M]?4(7,A$F)Z=^!X(]X[ASZ.RW:\+P:.C3-Y3CL^JZU8 M@)P1@#&S/:X&W+A
MNCX#)XQ;H6_YKA,R/+H-0Q* 5BD K58 KJ$ O)Y%!>=&R)/8USW+$SHS8Z%S
M;@:Z%41!Y(2)Y[L"!:!C;+@ W ++>P-[R1R)0I!+CQ9W+"Y$/QM-5:BWO?MF
M(:8\R[;,Q/ M$3*3F5P$5F@X<1R;EF-8_J-9F:T<O;L<G>^N8,=>DEAQH,/&
MQ#IS A_3T"P=U"5SK9@+E@#C^]9#H3T^I:4X\\JE@9T7S[M6%(>QZ24L"#CS
M0Y^;KAV;(7J'%H_MH#60UI^QYPPDFWJC<-WV;!?3J6T]--U$]TW#"HS$32Q,
M@#$[UH,!N;8VT!H/>%.N?,A>$YY,M%MG.Y,ZZ-S3$VDQV1]I:;9&K]\K^Z?5
MZ^NCUQ=TH!5^8B6QRW5+V)[.N.OJG(6Q;L8Q;*\1F)9)D=_@Y_L+/2!/;490
MN)6HK42]6:*ZM@\>D>6ZKNDPPW.X 3R7<"LV ^Y:G+>>TOI+U%E/*79\SW(#
M('PGM'1F6I$.W)#H=N(; GNV);&#'8X\:WLEZIHZ C>WYGBJO.=/PSI3M<F<
MF,[<RX87 O&9=RYY'A=44/*B,YS/OCK<M!@LNRY"!V%E@)5\$05Z8L:1)^"A
M86QO1X;S#85^F$$\5@WI&WG.Q2TYT57;+J I0E*BU.A$I.-)3G6MPQI^*1<#
MA:^ %$@EX91EWT&8[OXD5@@I,A.98!AB3 G.*<-YQ9QD9^$^/'D*,NCKKB%U
M]JHYR*[=#1S_X=-Z6=?U'R4'V5[^TGL/UNO:EGVGQSY<FNEFY4,V9?U4R8VF
M3+$[)$MN[>(H_#3MJ)(\_RC)(^M[M-=?!,B7Z;:/+R)1LU&ZHIT1E$B;F-GF
M)=W6Z\7C/$F8$)[A,\\W@M#R+#^)$LN,_!I[Z%8?\DYU>;.&*MHF\\;L^(L8
MUU5[+\'MC/O8_^7TVW<8T\<?!R<?;7 UTX/W,,YO>\:7;]%U[^2TW[..TKE6
MB]:GRR\GV$=F!\SBO1^]W0A<S?U+>)]U .YK[_K [ T^V:?O_TH.Y@-YMF\D
M9F*XNFDZV"C<]O30$8%NFT$BK# QS2BAAF"FY6UV"M/*X;I5GK&1M1@WBHZ%
M#JTOC!!\I\AEML%LX? H<#EWA>-YOL6]Q7VAGDA,2.7_+LO55WB=.24[8$6B
MW^))?@7F02LM[B(MYH)4PF&.[3BZ$;FNCDUU=3\1B6[8@1,+T"-12* WUM*&
M,RM8]9M@8!P=?[K9TMH>FVD[K1\_Y+'IF);A>@F+DL@W+5<P)['AVR3VD];Z
MV1YY-E_ 8GJ^XP>QH6,-DLZ"2.@!]T(=#U$2QS$]-[9>_>YU;&,>EOQ&X^?Q
MS)@M<.M7MSL2PW<$"]W(01@E(8+8XB+RN @3#B9KT-H=V\6GLW:'" -P2^T8
MX4HLG;E^H <QN"I1;!FQ[?+83@*"A_\9NV,K8D (,+*J0[8]-LK=IK@UQHOC
M!H;E1Z8E3,XB'QMIV[YI"Y<YGA%%P1H8+ZU]<G>Y-U\7$=J<AR(.=9,CZCR/
M SWTXT@/73>TN,M@IS'-*GBHE( -C;YLCZ$3F;8;>2R*F1^Q, Q]+_(,)S$]
MTXG<.%E<)=\:.AO+\+.&CFVRV&96H%L)UDNXO@,.2>CK=F(&ELM<!R[ )M]W
M,'1NSEK98"1"[5""LST/_.!B?J*!J7'M8*N*='S59N%<?F6!X5F.R?78C4*=
MQ0DHL !11WT?Q%DBC#"::V.]H5DX6C$9#+ QB0+1;@():ES1A&H=1!"U6CJ4
MLA,O*/LRW+%[8EHLA??K:.('=O319)Z-Q@>@,<?W1/V[89&?&/;/[;+ O$_*
MC1-T;8<]?!:+VS6L^Z;5W)ARXW@//E@+'NO>+>WHI:;<]*C!@F2S+)'_REY9
M+SG7INQ9J*NDF_\;YO_Z?>^'R*.T$*I#!G8ND!]'(J<+:-U>7.CE#]Z7?73&
MVJZ(!)*3I@3V<G"[FZJ^;SM;WJIZ\(4]%(49^TX0^4[,&#,3+TR$"!R>^"(,
MC""V*,!AF=;2OB:5_;88)1K[+9T1J.X?5W-@\>0:*9ON<#(NQJ!=8;5[JA/+
M]A_+O#O_\NVC<[H;68>?CP8'UT??P.L!#^8[^S+H?>M=[X#7\O'ZRW5_,%<+
M\?E=VMOM?^]=?W%.WW^Y[KU'KV??/CPY3[]8!_;![B?6V^U]._Q\NB@IA<&6
M^Y[OZP:+N,Z<Q-'#R L18<RSP9 7GHW-]NQ.X,YWO'[@I)3GB(G</I@'PQM[
M"<'?K2\/6]+(^'[2TWI$V3G3 KDT)%3'ME94WBXJYS)RS""R113KB*Z)?4D#
MG9MFJ /=NT!(AF.'[JO?6=??#$&Y6FJ0Q%=8<W&EN$"F"8GX#I;@UIMU/XD(
M\ CVW7O*X=H?RACW>VS,UEIX#R:VYA-O>!PR$9NV;O,DT%D4A3JW$U/W?1>#
M@M@VB[WZW>TP;\6CK:=/O&D3_=90["PWBGY2]JQN'14KB9[60OI943-K(?E^
MF+B.&>L6PX[.=FCH/+2Y'OB!Y7-F8#>^5[];76]%B-8G,'=6PYE:<W%3VD%"
MD?1=+*'[IRRMGZQZ_>PV4MG>5\2[$VJ431)'!KF;!YBET-F6])TG$CWSZ3L)
M9TYLAK'N1T&H,P3V")@;Z[&71-QFIL]-\>IWVYT3/+]N<.).FVVXY6&EM;.@
M2GG5&E$/)LEFC2B3V5'"34^W(BYT9CG@KS$_U.W0]KCAFZ8IHE>_FUW76:-,
MQ"T.)BDX%A%K6:Y%>.S8W];0TO/;33\96WI70^>4 JHUK%801[VW\_"31AB#
M205"B%N1SCSF@XEE)UB\E;BF[P86 W'DW-VP:L-&;=AHLXR>!5*E-7M^5L[,
MP==[H?!%R/4P\6*=&8+IH3 -+,>(W23DH6]Y(&>Z_HKH]6L4.UIK6=-(J:IZ
MVVHWMEEM\ZEN,HXB1UA1;%LNCQD3EL$=,-WCR$8D!R\Q^>*"L3:?:J/$V'P^
ME>5XB1]&L6X;D:ECI: >&IP!148A\[DO8H]A$]Z.S38C3>"YNS2^A"#62\V:
MNI^,;+.FUED@SMIUAA'SD%M,CR-78%VMJX?,%MAOC-O,M1.?1Y@U93YZV\:G
M"'1M12]$1?54='0O<_"N:.>S/[5&X5,9A8TM;HW"!Y:!\RE84<R3Q+-MW8QB
M!Y/L0SUPF:5[;AB)(#%8;/)7OP<=TU\UIO\0G/:D0;C'DPUK)T:7FH$/L@0;
M*A;7WAAL2,;6&/Q903AK##+;%+8;.KKA6H'.C)#KOAV'.GQM!CQ@3AR;&.0+
M5@7 ?4XY> <("/P;B3T=3H@<IVK"%>,P2W8O'&4%X7W\1K7KZ86H6R'\]W3%
MOIJN4=_"0S!W)^/EM\R5P#Y3";]E3)?(-_][GM>ZY$SH82[X=YTG,-C?>/^2
M7Q6O_C5=4Y\.]9DU7#;]G\'?2))'6P\Y#A!J64[D\1OX#R+'JV X?&W&HIWG
M**G_*\6<<2,TX1_$"'2-P!9A@,F=$8IG6WS%3K.$R8$(#6]1RA-L*_]]T:[/
M\(84K%;B.U9DVG88^Z !C"#Q8Y?%KLE#SV'"E\H#[@'QC$:KB%W'X :W+"MF
M9AR&CNN'KNF9OF=RSMV'HX,GQF$Y$L489 CF'TA(ED^@2I\)D*6",JH'16.B
M(;58+ J+Y7#G*_?-.#'!PO?=T-=9P(7N^XZA.XX1AD#)!FS#EF*Q'!U_*C8=
M@V6CVAP97?,18$Q,OQM8&]/FR.WZ_MUP9UK,%<1<(>@0Y-06<&4&<(5*A.0R
M[8+4DI_>\52BK?S#^Q.!O8\:H#4O#GP%K !=F@$@VBOC1&)PH9]?M+ L#Q<Q
M3I+( P,XBD/; +L6K&(GAM44@7 -P7RV&%A@'G?VWF&1O?],0)'O#V&C)Y0L
M=0AZ.S\YYT,5,*F,PI<32#X]_V)]= ZNSW[TKL^LTV_P>;=W?F =]>&]UX>[
MO?[!8.^J]_FO[W.8E8-WWTYWO\,U>_;A[NF@M_L=W@=C>O\)YGC #JQ/5U].
M]LTO@Z-%:"VQG;#02 +=-'Q/9R8+]-"++-WA7L!-84?""%_];G; *=N(T[06
MK*5-.WCZ2//]9.K#19KO+E)G(M!DG*!9@@8)V2*M&+V+&)T-0WN.;PMA.7K(
ML1-;Z$=Z$)F^'MAF&',O M?=Q3IE\]'[L+7%-XNY^GV+X/)3#5F>QQ2<QE=H
M+<$'$V'S*06>8R6Q&QE@_YE,9XZ1Z*%I^;H(G,AC(,8"$: EZ#U'OGQ;GK/-
MUM//R:,G-*-NA'MI;:G[":)96XI[1A ZL:7;OL=U9EB1[K,(3"O'-Y@1^6;B
MV"WFR^-S\C_D,+1 +UMB2LGMW+(BYB<24O/H,$YB^TYDNKJ?)$)GL1OK?L@L
MW06_WS,\^'\7@:F,>1G5PL.L$[^W\# ;:HI-B[/6%'L0*3=KBH41"TR#F3IW
MK%AGIB]T[MN1;KNFY\4A-SQ'H"GF/E2I31N\6LC)[TK$F#9\M5$V5[5OBR-8
M2?I#Q/JUR+/6'%M!4"W E/$=9B6V[>N.[WJ8!F[JH>^'NA4Z@B>8..>%KT F
M^99IO6G#5VWXZD7:3 W8F3L83,LD52N?;I=/<^>#9F 9AFOJ?A F.DN"4/<C
MQP)Q9<;"MWPW$-8SRJ<VR4PEF3TX4,WM!40O+?_,#WEL.J9EN%["HB3R3<L5
MS$EL^#:)_>2N?<_;_+/-$XSS^6?<!JT)JE*W$@<]3,YU;GFN;KI^X%K,LD(?
MXVB=P'^H-ND/P9AK'H9[--FS=D+]OAEJ/[<T&RJ.EYNP]Y/);?[:QHKA.:Q$
MVPX%<QW=\YF!K1H3/;#B",&B+==AONW["#+6=8PMD,)W**_>S,K.O<&HGUT)
MH>HZ/TS F 56TS[T^?"!&X@_1V6@;'RQ0I5?1[L42#RQQD>C//L!<FLL^E?:
MBA [INU&'HMBYD<L#$/?BSS#24S/="(W3OAM\49GI5X>Y1[21>4.X@;>L:>9
MNYD"\"?J8_>O#W:^,I,)PQ6F;CC<TIEC!7H@?$<W;1$(QS/=*+9?_6YTYZU(
M#2BUCU0@-[^L.HVRP0"_5/XAB",BO+WC#Q^ZV@E\4I=?BEQH([5/L19>:4+M
M(#F4P"5<JJKJ(FV$<!_XGE_N VKR<]18Z6S0NC_NK[!+PHP)NN0P42-5-&B\
M.!H\,$")!G;BQX'IZHYM.3H#NTGW18R=CWW7LH3%$B- &ES0SE,; 7T116%P
M8M(?HZ!+AT J&>C+N-#&F38AVIR69#=2T&/+L0]J<._R;"#%52NFEI,(C/_C
MU] /&'=,H8.E#>ZN98"[FT3P9^1YD>%R9OHQDHBY5$QU?ZX*?3T,%51^A U-
M8!XD:*7)@E7\QR*_ *$R@TAQ(^#-YM@PB[%);L<:^40:Z! 4T\Y VCL(A("H
M&82$@,'-ROK;37,1C6$EFT)= VX]R_F@HPVHC+92=&$&\AS_B-5MA3;@H,7Z
M\ >*'?A2I!=B1CU*O0@2JI^*"7X)RC'%;B;%N9: [NMJ][/64C*+5K30;)\Y
M/H]<%H#7&@9>&"7,<5VT!TS'L,P';K<FOW^7Y26EWGJJ^_*D'5QU]I6+B(<@
MTG0W<)G.$BO6@\3R=6Z99BQ<;AH.*,1A-B_L;K#%@"0;%(SDM8""@3!Y%($7
M25+F,AV?TY4CR0/=>6FBS8M5R9FW 1-Y]JLUD\4W2M[>X<F>9MI=[9$A?O9X
M/@2V*4HK=DW@>^R#BA.^F ?7I_W>YU[ZY=MW=K#[D1U\^RL]^"R??[J[PWK7
M^_#]/_U93NA]^W3=&WPROUA_I8<G9Y>]W;.K@\'^CR^?#RX/KGO?#W;/[(-O
M\/WG?Y)#&/]7[EI^[(-+$G'7 #XP'=TW_4AGW(7_BRV/&>8L_)0'M[B6G026
M'3'L=AJZ1N@ZD>>$X->$[BS83V_O1/O[\/A8^[!WI!W_N7.T-X\9M\1PN+NV
M_)TP*^:@HN85VJVCO^< GEI=@^,#S#$48ZV?%47#2D\+T'7]:"*!B,#K@^FD
M&)FJ+X8O4>9<EJ @I1\XI%,EE%>E7%/"K@8-U^):>8Y(\W2TOH!GJDN+2?BM
M4L^E7]DADT#\B/J3&)W/(0ZJ/T' /TTD"5Q/$I.DJ!Z2M\K1EROH/OA$Q2V@
MN/$F^'%JULVATN3!M*"KSF#>,%+Y AP0[_>U48;X;"GOUR.8FFL'!#0.$^^<
M$NZH_@DG:3*"[\INL]6PM4R&@^54)\/Y\]RII^%%C0/>KK:#_KIVSNO)B6)5
MY"A\*%9S=V9F.KV9%!:(Q5CD R"J&!<F%'#O.-7+)>DNT#D/Q9%/ MXV*^.)
M67:&L2*@=8)M>PZY_^-K(AA/_##60]]P=>8%IAZX0:*;GN-;#(S4R.$W@;:M
MKUS$ )@$3R,Q):'-Q)B82=E:4D)(G0#\NUR:+ 9?JT5MA;_V6/QRXX,V";G-
M,[J!YSX\&)K5!<]J4Y#;<+#^71^[X#2^W$<0H6(]KOQ9A+E@0^'43D@A'TB%
MO%<K9,S/N@/,W),L^GHE22Q%Z@/+$_SBW^ZP:DN/7A><OJXY_=R8PK?BC.^
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MP )T!Y/'IAEXD>ZZ5J*ST 3/1WBV'D2^L!W/]%V>K"O!S%$*G9*VY/*(Y,+
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M,H+ -967H@(@47:!N2VQN!#];$3"DW(;<S1\8!R@SX:9.G)(TKS .>LR'V
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M)@@07!\'*<D.+PC3(9_.L:$+]?K=4TM;">EY)V3SB9#\SZ;J:"BT68_M&$W
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M&%\U2^M(LC1J@.8RXLZG]G9(PJ%ICU8%]TV)H7T^3V756A,W@D8PGL2PVV*
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MLOAF+C&TTP#Y(\>G#!2'5RIV5 XM;42>#00$*X$D)-Z7$JBS"U4-<<3!A9G
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M (@ BNF_D8%9.$]R$B^<"%_<O@%3<4A??;WX";!21KN[7T4"L/]L]&3W^Y,
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MX.8N.B![.:^BM7PIJES7EH-&^[EH\IC5".]PUW5>4TYJ#10A.:U.U!7\MX?
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M"(YDQY9V\P#OI"CH.*E@Z23:/S:T*UR?, JC%P@G%8B:#;8-#:)^2 )^;TC
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MY\=XA>D4&:/*0W53AMKN,)7_9$CE#ZG\.ZR3WP<5KD[%45[-JPP[0V4&:J%
M.%H%LWI6.)R/Q?_$(:E8[&(7L0UKT!TK945!/JX@:'H9]- A"A*)YA.["*N*
M_K#+)4$?/A04<T4MCNA8<8.PP&C4+F&4WDW2"%P?Y$7IO"B("+G.&%(\:NMW
M'&4ME7N;_AR*0B#%E7;U1CTAV=JUA>S$IY-) K8:IU"\?+K?HAGS!9VL^:(=
MYW /([FX]VE(G>VAWNSJ$F#,F,]H;0F77^,W3/'*G?T:#2_X%@ K[)HJUW?=
M'02^D$M!;;MC00J>FS7G["Q;,&K9\J[P&06/HS_10%<6^TZ7.5X]'H[SZE-0
M=FB0B;)74SN:6^TDY\^J\@)FDI,UQ%.D#8"8\+<BE6%A]4*S*%!"/U)J&5?O
M@17,;0VU2$@!!-RGN*P^,ZD. A4$2.2U7*=(6ZVP7B5NYB0\]SLCL@&I)UJS
M,*@CQ/3C]8EM/DFUG]_NW +Z"8^,]GM;8;$T)ZB4U-<:Y%3/A>B5D!(H8B_Q
MS&:I;)CZ+ULOZ8*YDW=R,^4%O&R1=VYPE2G;^O3ES:5S.M/U9'2(<\'"Q 4'
M*VR=GI#8<B&!R D1E;?,+X=UN_YUZ\LS#VMR\VNBO5)Z&];XNI'+FPFVRF>G
M!A<<0L[OW6&YX0*8H_R06[1CORFW#O\X2,EU2HF/$,SFE/VA)=]@]00G/O<*
MC3U"23WJ+1$_]=*C!,BPLM>XLI5AA"H%)1OQCPB]J.RM%A++:^6Y.UJ&%&M%
MD? E@!XYXW)-Y_G:I]P+\Y?!=R%G%/6L)(80(JM7K,W7.0FVU^.7A@,+#@[J
M:6Q?47<[D76MH3@T9;4D?B-OSOV 1;UU3/B(/61T=9Y<U&TFW3*T WIREF!L
M@6K1Q69D,E8?4:7/T,-I+27599WDUG).W8LMHF T3C$18TI49?5GOS&!6XX.
M05-8+J %M&L;BWFX-NUG(PF(3D=PDGH:UK2M>,?AD"RH0' A/4]1"D0)U-4&
MPT;@_>;$E\*\W=Y:=@EA;(U.C5ZR,"3HEUS8W!RBD\V927-I3XP^S#_;BKC'
M,O1ZVT+;S_@=#U&220VEMA4;LPQHZZ1U 4VB-4YRP[63E+5?79M)GF2=9E T
M3"VI)]HV(SCJSIN\OS#<"XX('Q!ZD50%EVD49YS4%E')M,=[R;79A3D#*<<@
M#K9OHA[B=H32%%CI#N%Q\-@*MZLA%B :OD>WAA&!&L2ZL<!5;@B%@*!VSL@B
M#?<AHY^"K2>8L.T4;^$'LO2!YB1&*=$AZ^9Q2\W"3'Q;*I5UJ33J0N6&RX,%
MB;F0@EV&VOK(P+4VG!>^.H&EK]+<*^*'$64<Z:1*<W( F# I[I<C&[<> B?7
M:>RE1C.IW 3%YR9"X1F<JNM<#5'MDJ%V77B&5;C.5< T25HE%]PSHD/P8 D@
MBF:(.%QSQ*%NA V0#E@NX&"P.1Z19\-6N?8U2;!K!%AI8G4XZT#*BFO7UY$U
MFI@,PRI=YRKY%N6\+$R#Q(B(*$VE5J*KV*AIB=0&#$MUO<$W"W\(*(2H#E2I
M\ZFI'_&-VY.*48%Y,L;:VZX_!W=B)(^B;G[?DV%IKW-IM0>CM#X8 MO7O0!-
MMY5GA]T$HT4[O%>V8X(?0*,A:/1P (T.H-$['*#^0"EOOPO8V*7"-)?C]8]=
M#>AY#?&:#@4WNB_"*U(NC#8QK3!QP[TF,;[H8H6:5%L??>7PY:*25AF5UFUT
M(M9>4## WKL0<\@$8S]TP]?%0NT)XV"\DX2R5[,F*TR R+385DWTSS8]TR:[
MM6D:Z=0NY-3,;$./SKB:DR;+, OGQ0Q)@>B+A9%SO!2\@DZ_-D3)N,'Z%Y]@
ME,*FEI3%W:/KP1 P]_M%F6<,/,!0,<';M'K1<C=RQB%E-G-8[MJ66MLHO]?Q
M8LV:4O#-XI/H147I#4OIR9BBRK7]X^FJV:3G4B.=9N2#,6=@_"G6-_%GF^EU
MOF#;&]L+B"22ILCC!-8:;F\E5N8\^&)ETHH[#61X1\7^+M(6@O)!7"C(7S2*
MWI>581Z"H+HC]M_C/=X*[^JJTHZ,,-A9%FY#LA!YH]&Y]/9DZT+X.;59N3=)
M4*^A5-(0!@<3]_WI?R'O.B>B,5-D90#AQ,L_FZ5#;_8EE[GM^KW(99XXPE1N
M1:/X=69&QK(WQQ_E&-YB98!;2<#1R9#D-H-LN1$L'+;#G$QL6)S(X0HIQ_A@
MR>J4N.WRM;.]3"@%BBOIP3,^44LPIT"1,YB8HT2%;GZ\Y0<.GBH'0S9?&*GC
M[K36W8QF $7R3T:?2?-Z0PK9YW'USO$@/Y=A I;?TH?D'45O.!&,I1.$3\H3
MHJ>]?!+[/E/9CA1F;@$"U&0$6\EI*S]I\8=SC#$SC\/9'EIPE:.51XZ!\RQM
MB?JL$%W,K7I<+3<:VFE#&=#Z<Y8+69Z'?_?SB9TT)LU]'*'JZVL#(WVF^DEA
M;'NQ@(1REN&4PD0S)L;J%P9J!_HC*@/K";F-:D'<LQ_74-[2K__CEGD%YFOQ
M;!YGY=H*EJG/-.U4EJMJX;:W.*=G!OGR%G J8VV*D"3U@'U\0)PH4T\UT-9D
MY="L:$E/4A&ZSJ@J[%&^#FRN4!T1BOMQ'AT)3I16!'F\L2R4<0&N!<\J51F1
MCKGT?,PU/1/A\-/^A0CNL0Q_'$_KD/H)VLKKJ:!D4B$&JL,1W=N$+ [+QQQ]
M]%5ZBJT[ZJY<?7-;SDP\1L[R<JQ,<1ZF(D=&#C $B?\%*5(0[V*P(Y<]'&7#
M2>WS:K-'N^\)N1%'4SA7*D$M*!><2H'?X)RVJ&,<8\"Q _XHC6B,]!0Q\6+!
M4=CRT4 ^FM)H65E#.!-M</E01WZ1(0_@W&OG(U:LO$9:E1=^7=D*R:7'@D(8
M%_"Y$M  ;_54XZ>'PBW\@W-V6I7W$:<SSSZC:!.Q&E%QNK9FB@201AU,JB?6
MMRR(P%^6I@GHYZC[!Y&^<CW.ILT7VPUO*4>8$#58)9PD\GK$H'$MN3]A[0Y*
M"A/+TFQ23:?[DL;J<KWMI;^7>[I^XSK(+/P3UK1.)6 >2QMX62_\C%).M*(&
MTQ9EA&5A)IV%:VGH;M?]I;2?S!IM9B:G''FM4R[8+ L691\S;^LTI:GH2\^I
MMGXD=2&EUBMFE0%/^GY^FJGO,_4[1GD,?"OKQ=]D10IFG(XS@O;6G@QI77[H
MK#&43"%>??J=N_UTE;SLX%BP6%C?Y>UC[N^I0XS#>@7GL@=@<D=3H)U9W787
MQ!2M#4,+^Y9O)9[AFE=252EAS[RBA3")L[(9$Y4KB>D04VK _(I1A60N4:(0
M%1(KR://?;BN]ZL1@2]"E'[0Y4 8,&T#,;O+'O*I=51W9BR8&C+8/#1G]U1"
M-E9M.0J+BXP4(=OZZDEXL7HHT1D6$E_4X'^"O4DX4# W^2#:U)I16N<JVQ/^
MBWE\X/<:*_E8@M)3_"URQ4R(T4E_=<3<VWLO7CR-"9\[)\\E7ADO)E':_(Q;
MBB)\DS&5C_0XI9HAH7#]Y>W'(\?>R[JK[N]_K3K9:2).IW!C'$:MD>T7V\-8
M=/,\H]ZX/%(!A;K*D\"9<E4,S$H[XTGR=(#U;20\O'J%TO'Y._F18V.R1>5!
M*S.ZQT;_Y-G=[F(@+8]=.,X3M%ZK-SA#>0UHND?1*PH12!]Z4M7)1$E2LVK2
MSFLZD?Q^;V$0TX>(PJ,2*: FQ^@\*Q&6(^]ZR,KCV$DLHM)9.1.]85HN&A,P
M5:_U6[K;"Z0;M8Q5_.)F,_EJ@^$DB>T6NMK4SZY7L[@^B'9EZ1!=H-NJO,0:
M[::0LN\N!4W5/%TC)%!DB%$0J\.(D)LOONDAK=_0X&P==%^;?,&*PN=6:H20
M"PS.N)(>='#UQ"^.(;@2CO4$\U0,X/XHLXLZ[-%/Q\<?CWYZ#+)*1[0M],;-
M\&M2M(B/V8L1P[_+]A)>+W9E[>D*NV;2H1N_P'NYHL=K*8)BW5W[FJKC.7CV
M'BPOSAEM*UC*E/I_6>+.'M/$&RG14Z<RI1,8;.[M4?P=[U!Q53$7!%) !1=*
MB$$?1"&>B64>I:.*E:?6N<_(J=$SB>-48 QFLY(B67(R8$%%4M?EA+,09-QY
M#_/0>S;XMK*0NGXG/-.RC!]/<!F9<AR%Z_(%E0:W0>LG.L=X67#ZF#&+#Z)-
M1W6P6H7+BXAI8,*&=+XU+C(I4B-6)UX?Y%T*?F-+?T'+(8%'-:%2QW5!6USK
M5MC?I"VT0/=&+E&YH0(2C 4B/PB9K=P-XVW#:DE%G+O/>M/?_?:$>=AES_^;
MXX>TCUW]POEJ=X#U?<'\_>"?I'9O>&9S0*#CZQ$RMFTXUN50K;6F3;RU,:0E
M6?$J*T!=2F20-";I[ 56AU#^;$!\^(B/IP/B8T!\W"@!T$;Y_)\,!24#C7@L
M8;5)V\31[TW"P8MC' >88JPQ::>/L24MJ G4_DQ-19:.&' 4<6.$A<87B?L'
MHR53<FVH^VQ3$4"]Q'Q\URY319>#%5-+:V\_J(>'.)S5$]OCO;;&F^?AAQ95
M,<TSY:OR#@<.,=)-<\PV>:I2NT?"/=8Q9"")S_^]WI$EPS*V1Z;\"XYCE^Y+
MD9B\04O-4^U][B[',1P6@ARA]2TB.HV/IU[0:E/(OB\:?Q7NJWOGFP1I3NJ[
M(A+]";8$->D1K]EV6WGSZ3AHLS/'=>/@W!&<855AEC6SNB=A"RGM?^/'Y-<7
M6+*C(HB+,&=7%M2RM"\L7QO;&32PJ5V\F]WFQ0)\;ZF8;0L0,^I< 9H2 ]#G
MIN-.< \I+\( <\"]J/5WE,;%G"B(.7Y1W9@%A3(_&[-P+H 41/0'%6FPW"N&
M*>B;MK&C2X0RSGT(9T]9MIG/CU*P%':UECWNC%.9T<-'R6--)*]=93"I6?O
M)TI;P5H:X\(ZVX(.VL%V=N=@O6F"CFPH"Z\A5>G-"X6IQ:E@$ &;H!IKPA#^
M7%L6LTSX4P2&+W8.EY9#*.>:?49O4M(N".MRJ;E$BH0TV.UXMINRS&N?N<1^
M#_O'V,$F.F]SE&3;H>LAZPK!EY"IO#8#U\W;K5'V5:LH%]\[X(031?>#E$MG
M/\)EW!6JTR'J]P)?H+KG%;[XHWOQB7V1:W;VZN.)568K;B.\YCU\X_[NWG/V
M2,0;E#KS%1?,2QR0<^^G_[I8#3S'Y,#?OJW9B)JFL2)DQ&4KRM$_&?&C^AB2
MM5>=Y["J8^[[J$P66H[QT5X0V4]82/]$?U57TJG.[YI2SRYM2N<-9!JU"Q09
M^+R#IT]>[N]&<^QP7I)B>_(GU1%)46"419+&4CAA84C>,_6<6 J9.K9]P-24
MT+N"P^B%D\..9G;>Y(MQ@B6=5Z^D<GUQMS?2OS'42\'R*G/!D7,C $53.*8&
M"<XX"D)O+AF$,^OFC]T2J9GX$D7TUS9?4I!*V^H1XG,*OT>[RT*'7O_N.G[^
M^OIW*_4**9J5%RL$J&A&P7:5)DZ:W@SG0H+<^((_@ZCJG) 5.Z;Z)=!EJ<3G
MX0\:PA'>?]HW3+I8\QZAY)VX]6X-[/ZC1@9*TN&5,6D(6]!2MK^[SSXVR8D\
M@VS=]Q1[AWG;C\-<.DR4(^#G$$C0".\LFPOR*.6 !X/#).6MGVL"Q?82IU<[
MC6;,2?[Z]QUZIZ@IGI4W53(WQ)2)034K-A:MAG:W62+%"('&!(L&"T=L%=PV
M"6;](\P,Y2^BO^'_X-Q\F#0E8L:>40!L'W_UNIA)T_739 J#I60*+@CH47R3
M=%\\A<>BRGH+K\^%; /M!"$0&CD%QFAC3ZGCC(%1E3$XVNO,*E*"DF@O8*$5
M819X,]A5!3/ \$*?BYF% 4.-4EMI(7FT(H.$%%07C*T/0B87^;Y_P,_@GUBC
MQBOY=E+]^LB:$.$YXTP+,).R2EO,\P 8B\9@OM@S7^FK9LE*_\YQZ2MO?3#_
M0,'5$K:(4C7#O>$71'8*8+>R..>8#JQ47.&U^NT^(-)@UJ%!%PEUM&ACO$@)
ML>&3_O,_]IX>O-Q[-CI<U<ZBDINV*C#L"0JVUEZWUNAGQBLFW*=-JP>\TY-X
M00=AT0^9=_&^WC2&+4(0AP]5VH5K&#PDLC&1[15Y*"/O&DS=)0"0>".YHTL/
M45_=L!^R4O+Z)@,VOE"3T://FI<I :ECEY%"M<QN1:Z-12B&C)UT:Z)%@UDJ
M4-*HG00(MB]<)$A%R>D%?9$&3X0<F[I[\>AM(&/E,[3%M1+).E-L:ZB+ %&\
MYM)PEF!>F !<A#'NT&(6&#-/R&3!OMTK3)EVN#T-FMTB2Q-1/X!264N$&-^X
MZUYO>HIXXRM<1N*6SZ;HHJ)98TC3=0I]0O@1/<G%>)J2*-4$VK**:[D$=RD*
MH =Z>94M?A_HS!W162 -*"+>3O1;_[+;;,5)J@4B"D-Z\$37=$"(.659?/G6
MV)M2=VJ 4A#X#J5WJB*DZ</8%A1X&2L.&V9UU2Y\.Q3E%_8S$INYO)4_5F4!
M$824%1)RS#BJV0J^(IFHGV9K*?PG"3@>X7.MT-1:1K&PP^S50<%K,<'WH1YF
MLR3&6XJBXF"#@LL@"E2 ?)Q1N1CU:K85@H2I3*IEMR%]& V2L+8XQR %W6*9
MS3M DY-5 C9I.VDD/JVHT5#D):A.T4,<V(0(X;2RQ8WKXGOLX1"0RE8DXYX:
M;A1JZ]HXOC9EB%,H_;Z?F9'%;_ATQR">J7 /<#B/"43L-NMNH'YP G>A<A5,
MFF;X=OT%YFRII8T41Q4CP*\'Y#B@^VZ-]3$SK80/Z7!<-SN$^N)>)]J0@[K#
M+6NNYS(X6U592&<1WZ&F-B\2)_5;W-;J>[ECEJ7(ZWJ@"DQ2\$X7*NH.1)B;
ME4H53M!0T*KNNIPVV$(PYMBGV#\P6IA2B61K7,(>]U,Q4K;8%,(8)[HU!-V)
M[5A2$28J?-G O7/+$<:V89Z@%&?5YGDVC"7<E')2>02BB5<W1?;1#MI'RPBF
M-M66U\3_X""T=%#HD;)>* 8\@(\'>#;@ 08\P!TV8SYLI^[ZU TXU^YXM_UI
MU&(6+&.?:;3I;',G8.C5E5X?$SP"8K)K-&.5:Q%B,OEL?2P][2JQKEV;]Q;C
M/>=9Q4"S.>Y&>-BC'TS?L];5Z5\9,SH;Q='-40K]]%<\TLHYSLWC&,-N+6::
MP%L!0:!.O3BU<)C6\QC)AO'G'%-D\Q8!W,Z[(#.!3" M;@016,+9M,,+1FX+
M_P*6JQ)V"0RR<7]QBGL:,/46,S!!*&8B]SEA(:AE'A&^PQ@ZX&OPNN8$K,>K
M9P(0*2.L^D)[8-;.,:Z,GQ"#:"1MBE3-1<85F2G2]Z<VKRP%X/IF-"]P-(WT
M/.>8Y YG^'%4_B]VI(\3QG)8Z!'V6WA(0CEZ2RZG&FNY+!J:&-KF<@S/O-(2
MLMJ&9MSAK;MVS:WWPO?"G+WRJ'NI>>6^]EWJ2&&\Z'UWZIV;&;&WL.QU93&R
MLNA[">.E4R SN)[V@49Y'3A<]!H]1W<)QK%FVHN<JRYLRC)A+"Z;;+'4>JO%
M[HF:2"/&N^>$IO=W@K=YV/.O. $WH^BGFGGVI9W.@FS0&NKRW&AF:5Z.L<U-
M:LX]/ F+VCH#L8/ZUF4*010N*.+'&'+#R8+&8U]8^QH;_>MUW&S%"IG7W00Q
MKHLK&8$1@I?2>O5FFK0M).EBFJC3DM*MEJ6$L 0(%[.2#B<,.3-"#?G5<AM0
M\2HVO9!A23JB+5QO-QHFN(^(\F'PAOD"[P 'MPO4" D<E$>!$C0X[.Q?F$/6
M9O-29].G@)I2ZSUK.+0;.$1C%^DB #%(%F>U<IX'<+(P:25$.=).]-_$*=]D
MVCL 7R#@ID2Z$/M9#\<H@!AJ).2T! G>\+G,4W@LO$PR.8M<D*@N9[CX'O7#
MBORY-(HM!L:R7L+\X1*LLE4(H7PVM353& KN_1@78W8UD8:+.)$3A2%"$WH,
M<]WKH-+6,V>X(X 7OFD9=$& 'A)%-T>V3,KWN;FZZ3QL0H2//R^S-.+/=2D^
M*HNFUD8@V>-I6T^D9R JI$EDT&&&J71%M35'MBGVD,DWPH:A?(L'22MA5M M
M'[=8UV9M+[ALSB88+#S5LHO;CK? "3RO7:0 ']21?*]0R]4W2.0KZ,[H)Y5[
MH5Q*?40D+(&NZN+S^^+$I "D2Q@G[RBGP$*L'^_3-SGB$9M:]:_LIA;:@N%I
M)K1H,9\ SO62*@7K>M5:L?811:B[T6(7B?):MHH+?B_L!(G16JH?UM0Z.Q+^
MJ3@AQUEP3"#C"92%0*_ 0@@$TNY@4CII*0N<([&/#?E)PV#50^PA^?6$+$AJ
M'Q,(DR$-Q!47FC?(!TY\#^.V03W$5 N%@)DOC(1H)]A9@[Z>#H- ;+2TWB^*
MIKX:7>8Z6U3M&50=*>J8$3P:'2MK5FZQ 1-#GZL/"4OI;-=B[J4!ZI&9RAR*
MC/AA$L93:'W>*KQV Q<*$YI*QC<@6IL*ZI/,NNY\<[ZC#L*41!3A>[\]L5QK
MH 1I35+_G"N1(&UP$(/M070"'@RK6YX;Q*_#/*)3AUY+*_:&4R;3"QK _/_L
MO6F3&T>6+?A78#WVQE1F09;66EHS8Y;B4N+KHLA'4J4W\RT .#*C"$2@(@*9
MRO[UX_?<Q:_'@LR45$DRA0]=+2: 6'RY?I=SS^&ZSYH9^M118\>K=2UJ XC;
M3('HB(C6KZH5/02BGYQXSO--QO?G(%FE)1.C0SJL!YP=S#B%A.VAU8"3+!9C
M6V0$L1T\K<^224HJ<$KF! I2O939X'YMFJ+1K:<*/W) DH?3)-3W916N,,4'
MWP=W,U>#=(JNW-;:[4#OTJS>/XA#B3)NKM?#.;6^!GAD07!J),UT:NL?&G!$
MGF;M)]<&CJBQX2<0FGQ')V+RY^F 81?0UG@(O1HGY1Q(<)*!F%3&G1(O<=E0
M2N\: E7L1:7AJ(76-",_N7%D"EN@%E"NC+,%\9ZL\=&[\B6,U6ZL#SC<2[=9
MX/$X6+-&V;]CH7\T9D]+7'1>,7@)N[OL^H1&0E%[P'2:3E, "Z7M_:+:1X/T
MSR;.^@(*6RW#Z?Z(PXJT=9$:)-&S<X4Z2PE<'>]XH(.S#SR!<2EMA!57RJ#N
MK@]#HE,G0)/S\P-KW%>3-,KQZ"_CXS-UK&/+RK&-V7!C7C-$U/R<2C)D,+74
M!$$;G/&4'@\Y.=G:$^"+!M/48>:6JYL.2@CNJU'^SO)P;H29X>>*Q1<SES=E
M$@MS\66A'QEF/.1_73=7Y>*_JE8XQVX8<W2\7\>3=Q]=SOT%V=[H'1,:GK[P
M+5_S+:5G+LIJ\;SI#O7B=<X#^8)I,LDB/74,HT^:QXN_]]$U_.P__,_^XP^_
M_+%HF%]\]_;1$WK )Q?1CFK5G@%+\4A"!9YTCND;95VN2QF6&MU2[Z+/7.[Q
MY'%MO*A7]'C\V>T?C!\!/:[#1_R6ERG=\>6S=]7;R1M*]P"^8.T#ND=NEIQ%
M7IH.CDVSK1KZY[N_O?DF1CE-70ETDG*SO.VBSPS.('D&BD9+#B>1M_1QHB?_
M))*5$-X;0ZETG4TOO@3@5D( <CU$NYBB1W\)^1$7,I1+._L&DY-6+';TB-O7
M%,PJ#6H,#.7T!(@/Y&8HS:A6YXT&@IUC,@."T8F6X+P-P:HY*AHZHXKJ%"_Q
M*/,V;OH"/F<K77),UN=R)G!)%!\:/Z5O(E"G2!8LLLB6M8&9W1<$@(F3&20_
MX*NG1RP'LI%*%I[9O>#M9.Y+);*;E&XR=O/Z>OI^_*L3S,/#//YR@GF<8!X?
ME2]^=+V2A:MZS_(_4E5WAY@U/H! 3]BNBYFCC=/<S"?MM)*[9%C81&VYB":$
M6RZ5W0GO.><9I,$1/Y0QXPL 4%=J2^Q/%*9)7T&Y>/+F[ZEKZ?G3,WK^DIO6
MR9K^$/]"SV>B1<^SCJA7/SQ-O=W:CP4FZE(\/K3,;[7)*=ZM8-A)=UC&8>U%
M.V)P&WJY7;5^=!;/R"V(E]3L4Y?[$LH6,:)EXD%Y8^X_HK)7TO8>W=R@_TO%
M%\HWZ0$&H^NYRB>'0JM7QG=APLB4)5@JJ;]=1WV>>*%"ULVVO,Z_S!.NO\BT
MC=/7.=*V9:9NB$(NDZ-R=V[/7],C\0F%TU1Q:^KS!M3\FI265?+J'R^>/OKB
MKPMJ0(M.[JI0?T$Z>PX]SB5PK.TK?(5R^JC3R\X-DZ3$<J/B%TU(,971G4L
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M\BZI:@4=@@PASNO#@-7]9&MYK*E".RW$+7WQKT/Y/C@:BE$$8W;?\2 PCZ/
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MFN*+E2;*> )$[T8Z#>.VK,BIX!&24':(?;A!(\55 S>\+^2M)S),5PZ<7<^
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M$+]>1^6V6=0)96;8:?;,#%17^>SXC.A25M_R*\FCEXM,9"6CAQ?TH(?IW8X
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M75K-K]F;%JI/R#C^AQ]K],J^94&GUY(8CK;ZG9(H+EX1[CYI(/[X]O6[5R:
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MIA:O.<4O1IM9QF;9V.)<4BTY\4=EQ,6S%?>![YOG.9AE.8;VAG^FQ/Y18MU
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MB6,]*[R/0Q/0J::RM'.4$QPU85&U4^*FB,X<;T]O^H#2+)-B>L8BU^:H5W9
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M9U#>RP Z3(6AG.;NX]F#BC^_,^;\M"4_]);T&:!50QVYQI,RP#X#%Y'#IN/
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MVG(#)+EN^(/\4]NL%N=-LZ9.:YS\:W8.X@3$S9-]GS#G#3$/4 )H2]I-:PF
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MR3;?XDU(&J)&C-Z\U:H8B966MZ' CU\R%;XI+9GQ2T:MAJRIRZ'/+_0[_NR
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M_WKYXFWZ@(<!QM-N$::IOJ ;_](MO_EBEL)B.>??Q/7@QD_4K^#L8U"_!5R
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MB]\X]\G7.!_/\M4H;J5 ]S^G#V'Z'M^$!>Z7@FDQLD&:(%(!;DP$%;*$&&4
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M81$,&$MX8BC!(!SQWCLB4HZ6TR2@>OQEUW-ZW+0]*49TD7W6=3"TU, #SH@
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MD5BTLA9/KH9]\DS940,5HV[N0_I\#*D_:<['+Z!8 07JZZ:90NI)H:W%/99
ML&B]&Q.(BT*2&(P,.J$YH=.^E-DX^I-E3AU]5'PIW7I3%,8)S9T@OB272.$T
ML1S=?Z&XLMKRR'EMTV7O3+@[KZT99<5HQFT]Z#*A4K<8-)#L@I8J,1"F]B/?
M@TA+V<4DJR[P8Z>ES)BZGI5GP_0!2OHSS+*;^[D?9[.=W96&3''GCY1X],6(
MC-03I_"O(15OS2<F5IOQ;%@EVX]]DF]#6^E\=#C9US;;MH.[S(AO 7C]PU(5
MTASC5>D@NMV=1WLHYB0891@U2F=.J"Y-D+.1Q$%RB#YD9:6 '-L=TJ?#I UO
M50^#2-OHXQ">9&EJ/9H.9QDKSR_\^#.>Z/&/9=4,GIF3-$G".#5XWBM.K':!
MQ"@9R$"3TGYG$^_.H0_L%W2OR_O<@GJ*.,0UU0=$-[DLKB(U^B4,,3GJ41#,
MET:=TA&:P>1D&:!?L#--;@SUY&BQNZ /L7N<3RY@_ J@>3[ZZG_,Y#*9CH=+
MN$IKDVQB),5R%5*>!*WTC#@-7HAH0:QVE]^"%W>/_>2(4E$5!WG/>SX:(,,6
MCXZ^%*B,Y8 ??CY#SV'>8*A&1:1=AMG_76_OR:V\[=$L)/6!)4VC%-1X89*1
M022#].$T]'89<-]HZ<L1O\$9?O3P\WR<>2W1N.''G_"KQL_ONZYN&"1G-N,!
M1Y(5)6 0]S4K(!' Z4H1\:0S]2N=U\._Y[YZ375G:U7W^U?<;H:3^4^@+/(>
M*AZ=994(1W^92*4CL288(F02W%-PSK3=6G<8_AAAQD>BV\K&V[6NZAMOZP7S
M?H0;S*3O!R]*A[71U_*]MWT\NB:C(4+66;.D4#@49"32EZ/)Z( S ,%,0H.3
MMPN4VFW\G_SJ3%L=I$GL4K6,1O >_6R$S!21P1CB(Q,DXFK0"-NXZJD3#Z*\
MW-%Y>"BEUG_ZO&?I7#6 Z?_W/-+M:@&%Q&SB!HAS$H$K8XGG. 6?2T!55$H'
M4V>[NP/%$R3;8357_[%T/7 \]#] A/ZL'.ZK$?KPBQ?>U\,/HQ]^,/GQ 7WZ
M7J)H%VC+T(\WG,B42V-3;PA35%@E&)>L7=F;_7#\I%WGVJN8F%0!^KMI4<]Y
M?N]_+,4:+XH5$1A7U 820RA+R47B@1EB6< /==0JV38.I -X/VEZ+%W?9J_:
MB[T+R^(#%"V@!?$>QGDT_H+(X#P,^O-7XW_Z<;_,#&V/IH^#SCVN+^6&O)<I
M8X;%3 3UI6D;YP0E&TF2FH-07O(86Q%U7R1/E9,'U>!M^NE]'9;WXU$$2$TQ
M;J\YZO/U!*FGHW(9T$/GEI=B\4X1_#M:%HHZC?B,I;7+A-P#Z0DRK0MEW>:2
M.=CM2GG7N\.0%>C"HS HT;STXI49?2= \\)0IIA,"J1LEZU4#],3)-TQM7J;
MG'8O<GY"FC07HT&Z*@M^GF?/4V@N?.K#&-+<4N@C4*4E&!4#23[J$G0*)'@N
M"+,T:1991**UHM\VHSY5@G6FF=L4<ON5:[V&;VE5SL_^'OK7463TM(.PZ/]X
M%<M3M"64X=DN@I4^VE:$V3S&4Z5'):FON>G=[RWA.BZ4Q@JT4N@M1>>)]M80
MJ;4K8>OXU]+P)7B(4;6LXGO7,#\YL:_LU]!BW\"0>X[+A?.)4_@$XR_]X=P3
M6+Z8O?7?^U^F7WHI*8E>9R+:6DND0\? >A9F<U#(;^]7>W?N:@"UPO-4B78$
M;:YAY+YO <WD,NS\;!&*#G/?LW0F^SSL_S=Z#I#0!56:$1" 7FA(DMC@(]%@
M'#,(5_+<DG%MQGNZC*JNC36,V>\J?T'JYCS_/HRSZ,MTS==< ?W>]U,ON!"!
M!X_.)@VXY697+'MT0%,"#9HJ-,_:'7?;#OU4>=2MCM90:N\>PS>8WW/.VESZ
M91LTYPN&1*P!BE_9++R-Z!?6#W*Z!N )\F9_1:RAQ<ZWWY?ED^,%I.D +;D*
M IIG5:%#R %*[TP AGZ!-,09(8CP"EU'XRP/M1N?UY_%H1(>3X:61R;"L5,J
M2U&CYV6SAO%7/Y[\* 6.9BDYQHH BN92+53CLJ2Z=#?!F7#O:,J24VB5B'M/
MC;UU8Q\K9_+85!A55$GE6HP?X.MTC =^ Y=>QBK$94!]"Y 5ZW*V!G;X.IW[
MZW!T* 4<C2VEEHNSPA&5$H(5# @N&3_K6  R:06VE3UVVBRYH[+GD4BRC=QK
M)S']YX_1G_X_^^/^\/GH+V\F:5FZ4AFJ)*,$/5!;<D ML3J6@@<6=#*4RI8=
MR-9__F'K!':DB5%=,=8.=/]X@2?AA>^_&C73X7MT#[_X"--)/Y;&\&G:3,8K
MX=.+C+K@J"I%2X-B>$A:A\ZB#YJ "A2\ >>U;J7YW<9_=,PX@!JJ[PG#_N>+
MR:<+&/NO,ZC-ZV%<X+(^6Q,4$,NY(%*J0&Q*BH!P-@:D.=!VK_)W#/+H.%!+
MH+5#Q,^0??Z_80C1+] P"1&IA5.,+A.9LR4^H1MGI(T2G(Y>M*P'O/K1CTZI
M^PFO@XX^I<_$>;[F <W,ETAEU#8%PKTJD640B7<JDZQRQ!EFGU7MT*VU0)ZX
M'UE/21TTIKPM#+]^_@NBMX';47^H+:$>IV=4!26/#J^A#A+AMH5-)>>T&,B,
ME6@.,(I8,(PP]+64UYYY6SL)[B0(=4^GJ>/S:1O%U#9'%V]:EP?Y-6/Y5J3A
MBWXQJ,-T'O?___BO_K)^.S,J)Y:(TB7 7UM%\*AV1!MM',5-F]%V_2NJP#G\
MTU.G&A\=55VU/>?=9_#\HC]<6H,\XL>B^4[0C$3#/LG2 T)+PJC*PEHNN6IG
M2E>!\Y-P%=5U.CO<<S_T:3D%6C*5;#%)N9'%E=0X!70ET4(5.7.G%6]W:5<'
MST_*U518)[[__S=S7]>&K2VV89%$Y$*1:&4BT@ 02[4BRA@%(O',6+O,LE;#
M/6+&U!=WQ1N$<F.R:(9R/OX(XV]([YF)*:*0H83:X\0TD919$B@%='Q==E Z
MZ:S&=.WT(K1N["=^7U!%)=U0I,Q_@:A97**U 57QG7DCD,._*^^OH]L*KR3@
MRN_(F\'A*<:,!45HUAXWQ<A*:',FH*1-:*?SE,7#T_H=[\0'4OHV<NW@\F9A
MY"R.)B&HT7BZD0@RX_0X)5XD2G0N[=5T4BT;^FYQ-7,#P&'?#RHI951+HAM=
MW -7H'P!&<8E&V\>.=IM'<H-@QVD&F6;B:[4I)1:2UKL>26H3$DYL,:@3VF$
MYL*$U*8FY89A3Z@RI4C>1*$LVKV^)/ *7IJ:&D*C]BD <-;.)'R0E2G+6SZ@
M$[>F_M>;O@_]07_RX_D4%3B<E'8Y>=XNYWKGG.C!<VDEH::X?,(;XG5.)(BL
MP'@>+6]9IG)O+ \\_'T;(MY,OSFL%BO>3E[)\7[D/>[Q2 F!D>S1%)%,:!)T
M+@7]H]2H;8=SJ+Y0[\=UZ/Y6!U;VK3R+RIHZ1!'S2X#+/C6C9W"5E_9Z^ X/
MOD]_PN ;O,5_?='T9,B:FJ31HPT4'=Q2^HM:0TSF4FB(FLJVA=OV1_,T"'8<
MY1VB/=_J!%X/OXW04$K/II/GOKEX-YI<5KJAN$)4>20*X%6I_B\(VN":J*"=
MIAJDC.UB%??#\9-Q72BL@PBI=KMQSB%'[0B' $3J@!A=:83#N$^"<YP"/?JY
MV87A6BRP.UD#V:>4C"*.@4&'-3H2/&,X'Y_!H=LJ<LOT\!IP?IJOA])E!W=+
M+<'W4 H*MXI,#)2BHDZ4Z$R7B?8B4ZN88,D<<C%>03O%3;^NUK<Q97=4V4&M
MV=?#. ;?E-J@\Y3X9GE2];*6>!YJ0Y*T >4B+ E2:H+&$&?<":'<[GUY6@!X
M,F0ZF)8.:JDN,;\HYO;O0_SF -+[,7Q=%&@H]C>"2#WM@Z?!29*A-#B"1(F5
MZ/.)+*0(:'BQ/3H$;PWG)^NZU> A>E%?SN %S&?P>MC6\5,QLJ2])"[&8MZ6
MQK,L @E&Q61!JKS:W7D7,FZ-ZR<K#Z33BD78M[41E'-<.BZ(B;B=XZX.Q.EB
M,MADJ"\V0JP=Y[V36;>]!#H('Q$\6,H$.NL\A!(J%DK1'D6H-1J]9^M%^EG*
MY&1\M!,APK%+F=R=NJ!M2#B32)*6I1B>]2CBY A8#2!Q,HK6IO1C3TK;BARM
MDM*V4=()Y ZU@?LS*6TO)>^91+2+ADZ 6":%"!%M.Y82E.<YM/*\-T2%S")-
MGII8.^+A) BU4U+:(?FTC6).)V7C>I93 LDRXY;$0-&;U#P32[,DAAE+P07I
MC6CE@CV1I+2M-%X_*6T;=1TD8N\R7&Q>_?JJU\P'&/@)I$^C3Q=0ZNB?YU?3
MR70,EU7T]XC<VW_0_2/X*D]\)9(OT\A!^6PICQ)H",H'=.2M-AG_$F-O_^%/
M**)/YIBD0J.1NH#.>%"<^"0#$=0IJV-R>;73Q:.(Z%MBN;SZN[IL62KKO?\Q
MLZT5I5YRKHGFL43JRHA^H <2N#?&.AMX<I4E=#^J!_[^N0WK5@V%RBH[=(1>
MCS,FC6 E@2R'$@81B&/!$FZ]B<$DQ5+M6/H[ 3UA*M535'=]I.]N*]>S5 K-
M)2=X/GDTN:DCCA8CA:),,M,,?*C,IE; GC"KZBONH.^9UP12"H4W/8>0G-(!
MS5V+AJ_)D2#"4LQ02FHTYT)6>!]?'?8)$JACW1ST1?+LRV@\6?A4+W.&6*3V
MNM1@@V92>K$N6OCTP"I:.JP2RD2Y,P!+@BW!B=X+$:+@[1O=5(#SDW6'TF4'
M#Y#7<9[GL_2M;+D++ZW';'364#0'/8/2>U 1!YZ1S&),G-*(/Z]]D7<'GB=(
MM.IJJMB*>5U[U4NWXC*"V7K!10Z,\*AF'508L3)XXG'?-5(J'J%V=/"=@)XP
MB>HIJH..RAV\\!F%9J+ #57+Q(@4D1*/\R\"\U18:_!_/^, 3HVE1R;"L>,
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M_VVC)="5YXWL*7CNA:%42ZO >\=IUMJ@J1(1>&_SQ^[9E&H:FG[J^_&/CWX
MYWDVSM7E%>?&.2<IB3*6)@R1(@\D)X(J+WPTS/O:5WIW(]K+!UIP_.SSYS%\
M]A/\\ PE#NC]N!^A9W5@#H"5PZK$D.%7'H(EW*']KG2B*K3S@.X<YO!7U155
M?,,3JB?-VB_;LQF^;IJI'T9X/FHFST=?OO2;8KTL2KGW#!BKC%"$^Q+0I='_
M"PP/J\RB!UYJFK1T=^\?Z_%HO+)<N^BQMT0(Z<5T1L99:]>/%WX,S3OX<_8C
M-$Z]H#103UR,B-(7XQ1\)EH&;S4/'FCM%+9VR!X%5SI41@<AD._'HPB0FE<H
MFB6WSW-A]F@XFT%/!&\H$YDH6NZ*E"I%5D$2-))X"EQX!;6?ON\%]:B(4E<%
MM?NE7)ONOZ#T>X1T]@W&_C/,3CHD]8S1O:P4V)@TPA,EC0(,6MXR$Y%+@=<L
M:/"TW9'2;L!'08'.)%R[^<K<Z"Y(F\O6'O.=;+[#?>PC:5_C_\^N('LR! 6,
M(L"@54D2P*]T1.H&GE/47@=0[4+IMAKW\7"B0WE7[)"R$>KU+>T.V E44*4"
M9RS-C64,*)XH//&1IYA$,GKU8FD+FK3#\+@ITX$>;M-'[VVV7DKD?#R?Q5N8
M7(S2Z^$W:"8 U^3T[,?M7U[^VOSA0RO#(CA/1&E,)8W-Q$OM"0LEVE6RX'EM
M<Z4F_D/%[71I^!Y+G<>.\[E3MO.ZPX9)JHHP*<4C/"E-?*",@$A9A: MLP>Y
M4#KFJ^7QZ+&1I_NHJ0LW_@K.._\%O_PT]L/&QZ*=9<7R%@@[2DZ[']UQ4M0J
MJ7.5)-WHXCBLB2E$7">&9,]P5V<,_<CL,F$N2 BXR3NC'@E;[LE8.QI9ME%!
M[2"H\Z\P?.O'?\#DII6(2F-GDT\7,/_A\B9[V:*E^)REW+G+>A8'!L0;77I^
M&BF2<!3_TLI(WVGX(]CGE94X.J@&:C\FW(%8;$:<)>22YT= >SR6D0G$ 0/B
M%%=&@<C*M;L,VFGX)\.92AKHY"7"3V8H9V4JKN^OH(T7%E .UF0BG6#$:7!$
M66\% ]QA0^VDL8U@?IK 5=34P;/$=3R+!=0&44<F[VTT1S)QZZAKU(FL.]A%
MUB S2B'#(R?*)R#2(RCG:2( $:)2P(VJ[4$?2OOWF:R'4OXV(NY"Z;.'KWE]
MKF545U B)"L1$43<XO#L=(QJ_,I8 (I3M+7]EMLH#F]5[*N;557O)]B#-!]:
M'G EFJ+_#=X/T(R:GX.^@80S0&.HF54FVB, ;OM!]@^,VW-B*P%S2AHJ/;<@
M9)8^2F=5XEE(9:5DF9G>]L/MMVA?HMQ'/]!R@?&W?H396\.MH<X&LP_"KTK&
M=QQ]'O;_&](\+*+$TS17]\_:2RG!"9)U5D12[XFCS!,;>:0B&.6J;_.5I[!W
M*8+Y2)#6 WGYO7P)O1PTUS938@PMO5B5(#8H15@&I24--OG:=;[;(3O\=GE,
M#MXJ:U!?>QT4.?@8+R!-BZ]11W:+9K V&FVT1 ^$<8(R9"3HB&)4E(+/%*59
MNVYI)Q,YU%/<*?'V^(PXE4<\/#M'7^#2Z'ZSF.>\I%D"9B%) M(E(K,S)#AK
M27*6>1#>\U [@/(..$>[Q3@^5T;=Z*P#KV8#M&4^;@MP'=UMW GL.-<<U=38
MCAY[Z.#@1(E"*' YXIIPZ/^5=>)5R>T5W*%C&&3B_N$3Y)Z;D./P8QO1=W&C
M#@/\T>>_PQ#&?G V3&?I"PJ[F<PKOBTLRF659N:SL2I$0IU',90R#BZSDL$6
M(28/)K-6R;;;V&#; #R\=U!1N:LV4V>:Z<#D_P -X =>(,P7I0WUZ&N1Q@+C
M,G'<)A:<-H0JXXD4&DAIUT6\UMQ+HW)0O#)Y6L!Z3)2IK86#)*&NNU/Z?3B^
M-.4.<D_7?L!N[NQVG/#*_1V3&AAU$4U=)YW3(7+%N*,\,%<RE]?>W[4?>L^3
M9KWY?E5%YMF/JU]Y[W^4;YV5?G]7+JASRHG,$U'*1"*9+CW_\*]1:,\XHS3G
MVH7X]T>][];:R@MZ-YH_WJ;9V,VGT<0/KO^\>$+O1I/_#9,K'ZF7+--*"8E^
M?+DF DM+'\6(+A):.3PKEG3M#;FSR1PA...P?%[=ZT^#%AV8$IU-;'XG\&HT
M7GRK_![#\S89(3(EV97S%A3'HY"6BP$T^*,6QH3:@?V'G>'/E7$Z!.K"@;N\
M+KM7[,TFN<^OR#PUE :F20ZS=!T;< <0C @>F5=2&MP%.KM@WQ/\P?);CDOM
MXRC[5.[.B[E:XB!G-S*,471CO"#)*TVDLWA>E;6G@V<4N$@RUP[>N#[^\6_'
M#\J U=SR7371P0:XQ++PG]N@Z>C.^R:2XUQR[ZZ9#2K>0ZS=*]MRED#*4AA%
M"H(02B6T2 FE>"A3&56H7AS]$$J^YZ*Z*QUO(\WJG8^61ENY@7@_'<<+W+4*
MOLN0,I!!A$2RIPQ/S1!+"5).F+9H9466N5CQ53?E=-\]T.&MY7V4,.I(@AVX
M=?.3!W]YQEH+*> A8XEFV1>C61%?*@6G;(T$,[L$K1U?=!W TSZ^=]=%!S'Y
MNPOB:AK#M+J*6LRIJT36#N9S'%MB#YJL^BVGHN,N'/ NYI98"@Q/=%S=W!#I
M@R;6!DE X&H7KO3JHD^6M_>81R=.VVU4VP%=;Y@)Y[-"+0L#P<EL?2Q9'K84
M@@J6$U="_8!E)D*P E+MQ_V-8$[PTK)S76^ZQMQ+4=V\]4_&_3A9/!?^CIII
M/GS\?=FJ(5DM8Y9$A52:.GM*O%3HE'#+HS Q\& JL^A.0#^95%%A1PL(6#>%
MRB$ =PW1S:-_ZTFM//-'H9VD+'#'N=1*.9HD=2HB*7(*+JQ]YK]KL*,_[&>;
MHG-@2VU;2J3@N+=E&Y&2WB3G(>35?F6/X&%_9P1+]2Y[8C?GDPL8?[KPP_DQ
MT5P^;GT8#0:O1N/RCWHY>(W&#B<Z@BP7"X+@@D>[*#/# N4QU8_=.^@,3W"G
MK\O\K<W3XQ&HBZRB[F?[;CIOLA$8J*@\$3PE(CF>C7@(0BF0*F2TBJ/;\/!6
MRGQR#VB1'("EAU]0.U#L&'<6.T_T[_@1D^;U<!XKT>-6TI",(-S32&2*0#Q:
ME83G'*SC+FES,A%[6\[MYTHZRDK:@V#'N+S>>9[_G.GC<IY1X$R4X\2G4L^_
MM$&T#&>L ^HEHX)4]83L0\WMYT(ZRD+:@V 5FP%T/T_40H;^]:E2KW/DRA+'
MO"Y5B!/Q B?-:33,"!XIKUXK['#3^[F<CK*<]J-9Q<8*AS=FF4HV66T)!8X^
M+'!!? Z!>*M=2C0&;>6#64]W^DLGJ865[AXS ^F%G\ KWQ__TP^F<'WQL. \
M\R83!0Q)Z9,F3@DTFF+R0B;<[-T#O 7:1@0/:']\,-=$G5'P0?F^[<71,SZ4
M?J)X<JEB;67E22@[J ,?/#/ N'Z,R_ !K;U3(/\)+N2MF/N@5N_-BX7[!9&Y
MDE[K1-"42T2Z+(B-@9-H4(N!VV!9JP[()[&$MYS\SW5\FNNX2PX_X-NS^P6!
M2@-O/"/4<8XNC-3$^UA"Z9UFFF7+>?7<MU.9_,_%?)J+N4L./\0;O.D8FONE
MP*D#94LI8R,]VB<L$TN#(I!B9%H)3^LW:CN)F?]<QJ>YC#MC[\.\,[Q?!CXE
MEQ3Z%8Z'7%HE<1*RX21)E6E47BKV<)ZZ=O6-CUD( -<*-<A# K20,$51'H52
MZ0)K=%*.4U&]G> 3+ 2PUYW>491]*H4 ;F9X,"6I9ER3D(HPA94D !B2$I54
M4<6BK?V<]\AR";?BP)VYA-OHXJ'D8K69T\]<PJUR";>BR2&2LG;1\4/AKU?1
M<J9Q3PF9S3/@K&.66$F3#CQSL >WITZ&MUOE$IX<;;=1;0=TO3NQ""@XYE.Q
MXP'=,9$3L8GAT:+!""]\T/QG)EC'.M\J$VP;A1VM;=,[/YX70*Z<_G7K<[O)
M^;H;_DJB5Z+>:AL"M2Q+&;DOUQE"@TH^.L'TVD2O6R,</;N+YD3!"B!2EHO)
MH"-Q7F7B8[26<6;QQZ?BT+^IEMU5%MCKIIE">C$M'53GU[BS49N-M5J:'HI$
M\L"!!%5L<5/RU6FT:)!GCT1(3+KJI_5N4$]P/ZW+Q=MM3;M7:>U&RSN+;#F%
M]!X/C*6/V6,\T 2(/>+.1*3WCMA %9X8.BB0TEK3K@Q375Q/AHK'UFD7)=W&
MHPB0FE<HX_GBF2T:%ED&2QVA2I4RF4!)\#:@G*B(LM3(A^KU'=<B>3+<JJB0
M+F(%[MI\Y]]_-1HO:OXVO22C9!XMV*!,<=48)\ZB:8O?L\8PS96K'IVS%<(G
M1ZL.%=C%:W:UR]6D05.F-/&Y5.X(CA+O;&G4(JAV,D><Z,_7E.-2\RC*/I77
ME!OE1'5.6=*$V$&CK:J4(\Z5())(K0,9@9O:@5"/JZSR5@RXJZSR-IKHOM)N
M&S1/I:SR5IJYN^3N+F+M7MDYF)B\\L1X)XG4S)  M%09!>>41,> =U5;_53*
M*E?4\3;2/'19Y0"@LN6:6!,0$0\<L:$K:)Q0BC$J&#R.LLI;*6&;LLK;2+#B
MY4XSGO0^]2?EQ'H]3/UO_33U@QES8TJ@A4'+1Z/Y(SD5",BC.^^8$CXR)T2K
M< @<X=K"Q;]=+=J-@S_-X[N.+BKZS&L!_:L_N?@ @YD\FHO^UT^CE\-)?_)C
MV7>P!=1M#OAMZ7,WO,.>^I44>A<].M!&Q;-C%\B*<2DSKE>?/:X<@ZY8$ 9(
M-%;';"7^T>K&Y2$09X,E<7S>;*.$RGQYT1]#Q!\O'Y,E&*.-)]%IA<>L CPA
M,R7<,P@Z4R6A507K>^AP<]3#F1F=*V=41;('>:9_!Y,WHZ9Y#^/9R7J&<W[1
M'TS+&_1'B-,Q?CXT+[_'P31!*B(L1_-T,A/3*,]^%=+*A^SQNM\EG/V# @XF
MK)58@FP<DTEP)F62,: 9G*0" 99*K35-O2Z![1GNBU#21BBO;D(YSR_]>-@?
M?KX$\?^W=RVK;<5 =-]_$>BMT:804EH*I846N@VC5PE-8K 32OKU'<5N@NTX
M\<V593OMPEYX<7VD,[;F<6;TD"-4LGA)D1N=_*+J7)VM12Y@164!R8B,V/S6
MD4;81TNFQ^$XN9S<7%V?@0[:*$GN<*JWC!?M&*I<;QXI01<9?0ZMQ0E-@/</
M/_=BLVO:[.ZD[V+NZWUL-W(Y\P"/@GZ%OM#!:94@3XQ6XWU0#$WR-M0Y1JL*
MAH;EF!8KZ%63.0@+WB/YAU*>698@Q^2P>.&9*T ^)'>:><,UX[*X$HP(I;2N
MSQQ8LTM_0WBRXV4((<?2,;#-FOYWO SJ>!ED)CU:!U["\;'8;PH)?8R1">"2
M3AR(#.MT[1 R"N4E@&G>P'HT=CNHX^7@S'8(M5UOS^(>3(HF,1F CI6@/0,$
M8$[&$J6,W*76@K-7?WO6$*ZWOCUK"%'=;\^2P:A<[W4*VA$X+P0#9X )-%*
M4QQX:ROZ%WJFQEA2.\)Z%_<A6BNBT0Q%\$QC5"QPP\GGU0$UQUA\.<[B_L$8
M27,>-E:!6R;L3RE2I9@H7T6*G$9DVA]]SO@4^?/P5G+;B'5F 29T*+7)V4M=
MDK;9.8YHBSM[](GC_L=KFGOIL0\)#RT-%)Z)[UCY5BDPQ,(93U&DXKC0L;5\
M:C.:L>?5\I-O/^=?IQ=X?CE[?WYQ/P!<FE)B4K6P:7P=  XL9'\GFE IQSI;
MHG5:> M8_?^6&MG$Z@G4FH(=>#6K$.] ?2GO<J'?:9U)>9931,PBU!LF+0'D
MJG89>6:Y*Y+S' *T3EP]"^K56LBX[=]!W+0"\"3&:95&7)_B='I+'R[&D8*R
M1B/YXG4FJ4XV,!!&U!M]LI*JB!!:S^[;"MAKM9,&-.R@TVMM[8N4;>(AU@X@
M\KC)@B6M&Z  (].U7EC0UK=.ZCR.I%<!IHL-O&A[]UT:J:*83[3G/^[<_E/R
MMN>:[6Q]M5RFC(H4V9=(9R!8)I-/&#6*O%T*YAG)T?HW[ZLHTH+*2;,M;:PG
M6T930[:_/1-;8&JH5-V$H[\D=2P_&ZD>N;F]B)<4UVFG'#-.4(!NBJ'8'!Q3
MVNAHE0W<MI 4]B7\"2EI#[Z'[&GK_-6WZVG^/<.?W_-T=C,[F:<!/E[%1=K$
M^)"=4()YG<EOK<))'RR25^*,Y:(B7Z%[TZR))[^GKV:T#1&3W>QBZ^$C'R9S
M4%\1PP).4A!]4H%E2&3 'CBCEV/"R41!B4-N<2M2UY]][$2.W*V-O\X-F</%
MQ_4MT K>OOD#4$L#!!0    ( -N HU;X._K8*-H  (LG 0 4    87)D>"TR
M,#(S,#,S,5]G,2YJ<&?LO =8D]W6-O@@*HH%09 F1 6D"2A% 8&(O("(@( 0
M>E1$>E4Z) H"4B-%4$"B(-*)=&F)= $1J9'0";TFE!!(F_C--_//-7/.S/>=
M]SW_N?YKSB8K/->5PEY[K76O>ZV]'QB_&%/ J=LZ>CH "PL+<)_Y S"F 57M
M .?' &!@ $@! ' $8#4^!; PKUA^/QES @=_7P. K(@QU_^X9OX&&*. %G"
MA>7WXS\'ZR'6W^/PP8.LA]@.L[']EB-'CQT]<H3]"!L;^PEV]F/'F8/MZ$F.
M$\=/_K[^_26_/_[[4\S'\2-L1X[_MP?C*\!YY.#G@Y]962X !SA96#E9&*T
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M,C1LM!FO1^1VK@N5#62Q7^Z[)OR0!HA\.7N:IM<$NWA?H?+ST)H^)[5D28Z
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M8.K4V^3@@A!)XG#>])H=2/QN__SE;VSCWD.V1KX.YY]O7_B\L@$E2Z)6%QC
M442X"'$X[;"OS"&U$NV[3]0_!<"?")YE '7?C<9Y"&9P+F+>\<%O%7I3$Y_)
M[REM:UO68*5?=-P4^F)>UIQ7N\S%QI'2?FMJUDKG;Q2_&/JGNR]KT#+HFIDW
M125@MQ.=9*DF7:SZZ<.1[M!W=<=>@":@,ZP;<F=??:%='J@2#(4:A:T/.ZW+
M>.18?DB].I:4<[Q(\NPIS8,"5 ?4Y]]%UF05DF0V!N90T_:EQWIU4,[,F#.
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MY9EN-499IED=#S\+SY[<:<7B0 0F:D6H!<2VIW$&.9M?TNW7>\D OFF)T#Y
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M2]SW^LTL(8MYU-/79IJ("U]U^CQ$M^0:Q+W< RGM$W<:_J!QO G'78&^\]U
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M: GQ[]!%YA^.C&(V@4+.-&-P)_#4X,-YM3A?2E:DR].')$?L;GW=T?$,R>I
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MU'1'$MTI?:JM;_76C-AE>]M7NCZ6XYA-C"!P-\D?W-/=%ZI%QSJI1!,?O3#
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MH7R][OLJV0&"B/76QRK^)RC54;MXL/5+K]GG\*TL\#:M1)W>]^+X-V%]DPF
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M_6  BCQ:2>:YFAC'/7:44:.(W!LO3#DP]3L%P-$.'"F>5*)*N V#+</.4FO
MEFXKSK?9V(MB[G%<+7H#$'P!B1K ,>_<!/4*1XBCGN^AFKH)+J'91I^DO)@>
MN7TMF8S7%%0_(+N%?B%)*FYX$DZ1U,C7EOCU80Z945K>"H$*4>[6)^]0(.?3
M+0TV7DXGY#W'_KS\1];C)++B'\$GA6J^R42J,YXFJ<-<7\A(RW5)Y0JZ./\Y
MFCZ\WLGRD8IT@HN#*\:Z)D./38_6=P< ?(ON0)'$'%XP )-*M"_/?5/!<CC-
M$&L#&^5#D$<.A.A?="ZR-;3'YO!,:B>HP7:Z-%N$:^$0XJ?A*C@1]JR=]OE!
MZ'>M!0-IPWY77-S=O:U.Z#=@R-^51.S+C*V&! 9@K\OK#KY#P'9#6K30=V6
M1TK!/%Y&(^\%7'&>$R*MRL)FQOOY#+I>N0*KS?10^=P#$:G<IPVY]/"OXA)R
MO*'1)*R6%ZX$45],2)_*"E,X"4Q@?T<IK21?90"JF;+M?.7 :>CWP7:IVY<O
M^#S&<O*%;QET$L&80I\<GV0U604,3Z;(?-_ !!-'/ 1^>_@TAB+HNIT,1X>,
M7^KV]K#-;O1%&JI(H2C7-]'YDA,(D@A+&+88(T,*U;$?KOP<)V:$K":T5@!W
MV@L0K!0\MDA-O"G -N2+=.%L^*[N",&1KDRT.DR@ZEEOHBXE_)1@ ,+VRASG
M0^?^C-NRM.*8WO5R#8\-5?&.N/0)Y#E9+F/CLMA?=)*I2E[H(NNTQ3)A)Z%%
MP[-OG/#6O&N&V/*HQ2;RF9<^]V!%Z?MY#'M/0Q/ I0[+0U_H';A3HH71]J@;
M-?8)>M62ZQUGX%."J0\?'09>CY!!SZ)X*@PR+QEWRA"KQ>Q4G\=T*<V(V"V6
M]J63K6I3+V5!6-?5;M20K.MH#[><?!O'R.J7'1+V"D-T*87_=;#ZW_/I ,MP
M $RXDC1%]- BC%6X"VQ.C-W$KM>-P9V@A#ONJ1F!XUA+!<J1Y[E'7%RFS%U6
MTLW3(K6YN+0!@M_9()U8@N':D)EA((8M%CH@145S.G>]Z"H?+RS[8?>:+'^"
MIT8F/2>9=A(Z8,-)2%Z/^(J7E2VU['=1[X74H1QRW?H[31 72/F-;SLV%$/K
M;VU^&1,M>X8X;=W_!J27?W8O:SIZ]T\K74X'0J,8@!/5>Y.C$,BM#BM5;*GB
ML?#JC<Y$(3#<?P?=AXO"2.SU'9C AFVYM*(?9(RV"1K(GXLLXV@L!/-2P]!S
M;@)?$U)/'ZD4;Z'N&E,3:5P3!L=_->)QD"/H!'E$TM[I!8IC_MQ?)3?GD;B(
M<M @''<U&'^S;:5[[>2<":7[&MS"!%'#)T-UWJK[N2ZE_5/RM;#NQY2#T3]"
M)1:U-5E^A5%MT3U_]%5T(UG@BKT2V+I]$^A\MIF&L1M<5]ET!%.M+LQ]NPZM
M\0&F^JMIP3ZG=SNG:N3J@LR82V^EAP#EEP,[A7[Z<->R=EVO:XE[/F6 5NV_
MM^R[=39^5QFT[]T4ZH@E["K!/O<33GI)W;)?3]=G6C+['M(]&>D.?3LN2RC%
M!59;9#N6M\R,.T&,+6^#1[0EW%>:!?LH E 4F& "9D)K*-6QF"A5;?6$>M<E
M\>;>M!N=;1[#2^38B@&\QN5'-CCIK*2[-EMB3H@0Z(RD%?4VK:I6;6?07E&N
M%3F6@V9R0^J4/P,0#)3[D]$<_^6&YU-$K2A<D!9;1[](O)V]83.J\WGDJ\ 9
MQ0WAYJ]RYSIS>"G[JP>V-4E,6<U:M>U.*$@0AEOW#(6W12/?Z\G*%6HL58.H
MAVLDL!450''ZSQ^%@V;YTB8X4N8:^%L5##FYJMR!+?$8-1!7;4[,I)^EY*[=
M8@#V8L B,N[OQ?^]XL^7!=3+]!92\"0#P'6=9[TT7+NHXK[RJ;IG&2@SG>9N
ME5TYK#X#X+86XH"'++?E[QKM)B0=M;8\KN)KL0%>/ZU+PF/E)'>/-;:C%N]I
MJG39K#SZ7..5\'.1B;SDG3JUJ:5J,*L<?.O,!$T).;&RON>K,F##WVYY6&T+
M$;'4<]!2CE<%B=O7?;UI*&F_DRKO0^ 1K0A6VBUTD[7JG0^ZO><JR[VB\,-:
M\4H"1G'3P.]A-#C)=BH<\09Q?-/PA)7+NF?XQ8*7V9WQ%IIVY-Q'0'=HM^"A
MV3#S)P;68GG,6^2=07@FC".42 OO*O R0Q%F,08<?1IV.V.TIAFF=V* @7\:
ME#P07)C3\PA>&+?'1]++#M=E5XW[FB/"QS66H\L)A9W0:YH_A 5CPII/AF;:
M)'_I#XM[E-<#T=>(Y'M Y'(TC7PLYQYGW6.I,&#2V0X>]M\&$4'+"U_TO&=:
M\GSL4#LJ<;(,0,Y!0O%%2N0(^/GVE0F?,?A/ZV$MA+/PZ4;^7^V9PE%:; 59
M+X^HG0A@AV$I>T,$Y10X!/0U,B>JWE,5O[3$7S;(S!-QVW;?T$)M>X.8JO[Y
M%,?AI;MQ7RVX:P1H'_S0A/+*=;_=8C(HB/HHW5BV;@ZS7+;]ADEO&N([.YRF
MD2_F"T;P \MK4Z"7W)' UYNJ;<I*+GJE4+E^J'Y1 01U37/NK>0;=+VLN0K)
MLB!*]/@IJVS1I%WY'35IN1")&'1(4K+-3RF%/V8USZG\^68"2K]'VO,#*?_)
MREQE94J9%IMLHG!TS?XHW6VN3</O.))H5@3F0K52JLB#22GQPA%1J-RVT<#K
MXG4_V/1)6H]-DV'];I0S9'!F,QEG)<6=ZP?ZH :;>BVWG)-0UB[Q13K!#WNC
M%"'<B:)*3:H;-O-N81+2!\<>6P:// D;'Y=;G9M7/9Z1"I@F0OW@S=#"0^@Z
M'I=J7?Q6>:_:[8J8X=Z3(ICX,<U.G3B$_VKV0LP!2!&,DY92+48!SS<-U/L]
MOJZ0<P:_;3MK;6U+6;?-"DAGY;@J68%>D#Y"0+&_^ZD\VI'S+CX[X#6&3-7W
M]M)+J[Q-=YE"G)&]DB'RLNUTEM8\;B1F):L.9>=%KKJ\MY$[B&S^W<X+QS[F
M&GWGTP>3I,A +4)&E%Z#7)9/ _WW5<]2+S=H,@#^XU@EYR4W$C.&- 3WP?PG
M<<>NB\YT2]EL3Q]H3I3=I[ES))&L"Q4>(#( X19I3>Y<-[7&C(U"QW(IF:(8
MG6V65]^L:@DK5UHL^IZA<&F4*4[Z'K68=5@(_$LAHL?T/1!=$E$G0"Q;JB\_
MY5),-/UZX^#$L==%"[N?WOK'2,Z&=1,<PE:I1_$K\I:%+@E)^KW>3U-'HH,
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M2'@-.EEX(]OV7'AJXK/]$90D&O07%9A!>F2KW[TY!HY I%L)JR&^7\V7V";
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MB038'9*:FFJ K(MMW:TR!D!V]W/IE75S1-7+T%],FNJ'"4>WH(;:INSFEAD
MHO-M(E?9[KG@Z@^#3'!M[B@^.2LV\**^ZYT^/-_'N^$R_-*O)UOZ*GC57/9K
MG!7EB1QM%V1:HTF\]$I"5EB\\[M+(@Z4Q3/AJU/;=CN.U+[QN750V*C$>EX?
M?AX].E"=8 <J!6)-IY?+I/]BF^9?;5+"M;6LXA(WP'U*^/+V?+>>4$HN;V",
M[C* !]V*'$Z?>H("PA47A^<=Z)UF%.GD2 ;@TLK;M\E>4C'37M+.2X8D\805
M7@PK0<6'3P_EFHL_0FW;OMY^QE?(K?^:+'VQ3*==<L*/[D1,#XL7.LF?<)PV
M[)8$?U863A\S6.O8T=DL#^*7()!\'<R#UTQV'L"C,6CZ^..V%J\])C\IMOJ[
M7GW_1]^^^')C\S$=!>FNCF,L.G=?YAW7!%Z'YN/VT44;B>&3+*%473[Q@%M=
MED]K3GGNVD'KM!Z0(-,N 35,+O")A-X>.] @R%81*V?^0U%51(QN@3EU1SWH
M(-B"'5X[\=-WZS;>G ?K5>W" +AIK\#YV_K2F7J$IPB</TULUO3O%4%0O,P,
MB3/P-Z@'>W32'"'^6SH)MT?47L6<9@#J"F@9BA;GD6V%Q!.\I1@6P(^;<0C<
MKSF!(%::/#H),9&%.XJ=5""==\-+^NS8^)A-WYP^KE^2(1Q$<!/_CPD9.G^;
MD+'V_YF0,??'A S<M_^8D'%*KZMX8Z]%]E0/Y>\8VIE17)Q@5!TV?F3<*<N=
MW_UCF^KI%X MT23]JG,N(EX!*7^\,KTR\ F?X4503:1$XVNR6CMX_<1!1(GD
M\N(4!@"[%#I17CO&4N\>O*&P9,HM72.<@O&UFK?^(#C(-3BPPWUH&C'$H\AV
MVF8=DD#*S*5\*$_;ZRCF@!W>[8 ]AB]Y(4FV:93NJHV]B1CDV)D_31#[J\/^
M!,3$%RP+>%*:9&B+;S/WMO%YZ))P2$?*69Q5=]6KI9!RV ,*&%A."%-3<I@"
MLB_R&GPZD=1\MSRF'R]/O;EH&CKMO*Z$+Z]OZWR%.[F%8L<YK/!J]5RU.KL!
MR5$6C,@T]Y=!SX)X2?Z+)+)OJ<AJW[TB!H#?# 5#;,8C#$CB#6#S[R:MC[%^
ML;-(DO 6)7,OS1'%!%3B@>W?Y\%^!4\D,@"EIQ8@UR?[OST]<RS!Z;E%QI.#
M;]>WF?I!*!ZZ77[<^R(ZZC\&P11(3<?P3+@+/Q/B<ASD?WED7G-.<9,?U& >
M$2L; N;HT07-AH^!;5*2##]M4(WJ*V!KTJD'3@Z88[[&#*$'*ET\P0X7T2=H
M;\"/JQ##8M\1MKVB4> SCE]S<%IUM&P5J3J.Z]_O:RSY';Y'"4"XV/&4\<G7
M7>=[E: @6E!=E364E6[=B;^'$V^8>?]MPMU])ED A;*O^EQJ6,A< @N"_U:@
M@H@1RZ<.)Q! DV7I>'V+T%C[]R$G!OV_(4??! S2KY[R.5QI;7BWO.OY4GC;
MM_3RTM+(S"0+OL<WPN3:#>\#.N .\&%4J0*NQ+L!*-TXC:PCJRKX/=>1G$N-
M?#I%Z8C:1\D-K)5"!4^MRF6^M5MU=^I/Z>5&68 OTJ7;LG?N':@M]:#67M/-
MD2G^L+[ -0>JM=Y4Z\0;-@CHX=%1I> 3BQN^PR'95Y*N:2P>#PN?S_EX4> %
M5Z@6%]76LF2Q]YUEP7JL2WF5FQDNFY:B'7&Q)U)B;_Z92)'>C82/S)>5^/'O
M>@?I\!8<%W92'P8GK)8*IUHCAP]E$L6.3>NM7]%H>\L F'#-*4#LH9&Y00T]
MC5VD3R(BBRD_;]<?TN,)R7Z5A^9IW&NJ!_]E9&-%X8&9,P#!]115'X1QO*$<
M_2=H>:DGN3SE.+?[CMT@T]E4MB3HZVWNFU\K;OFT@MEO9H.TT0S <<1A>W/6
M"GYK9N@.2TZ&YC Y< @SIE9%G?@SA\YC ,[XV/<T8;A[2_Q)U#8IXV$]W8$^
M@5O)_A/]P5R*XDWN3Y,J_12G355B7L5-+/=G;SM2O8@[0:YT =*(V2^W!&X_
MK='XF.3[LMJ2%?[\C_Q/6G!MB5&YY"?!5"'@F><X+JOFLI&&LG'3V@-TF_/[
MGL&_OB?2IR!MGE2Q1AZ%HN1^S'ZKOPT+H>*[:$-UN[T>3W)"-%1_2M"-+75A
M&7MIS1.IA+]\[5@&H/:*QG%$70>)=CC;79"F5.>H>%1.V6GC-?=2!3=3_=I7
M[\?>QMX'!0$)7Q .8QIZ[ZMK( V/'GM;W).3#)PY3]8)BFI?@:;[6-?CAA-G
MKNC;I #A4% P;,9%):/S)\P(#URNCLJXOV)<_@V(:J ;86KX=,KW DD$@O\?
MV9?X7QE_3"5WR)0D7&<MU%PF0\T[_"'[G0"'* \'7>T5ZF9C0.:]G49$Z!DP
MMP;_DB!?+X3&;5;NJ&<K*KH8P^%Y/T^]$=9\ED#UR/M<P+*BZ(/IMFQ>&]J]
M' !F<3]8]&0X7G4YRTF:Z*>W.N:; ;]J9&D#(N2O!5:;?ID?CA/E6Y&>7'&X
M/M3U6GF+_Y'@U.%B9Y)7YI5K!J?-G(8*.H"C)HO:&283JTF5 3U,W_GXNV&,
M!_PGT0V1MI.@R">>M.,+^9['6$8C^QX!&Z+ ;\R?ZGQ"]W(,56V'=3$ 3AP
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MT'RV=/ZCKY4Q/-'I26<NSM<?,N<_ 0])1T^6>Z:#OYVN_'WEX"9P*&@BC@$
M8N06+%ES::&(84\>;J3HT!%IC\&R:P=H<UQS?60QYKL>)1W!':.?*'^-GAS*
M)16*U*T"%2Z_L!?9'HN9ZV7"YH@/HAZD^O/\-><=HYTL.E</?=S+)A(3VD *
M;&@3;IFSX=@IVGE %QN@CT'@V=)979>]F/KEZ<A(T]O:_4>F(@]S<;(!6#YR
MB7!"MHMT)85(F65C@_^2%FL"$TR00SO/AJ@W>ESHJVU2MO=7NGF0]'"Q<=DE
MJ(.96P1,Q'8*Q[K(*YU]I*)GZZ;@N$^GYX,@Y#65H,$7SK.D\E"G.5_KVP=W
M'A,#,LH03"X%U*V[IP41[A"?6EA.R:AJ7,6:SL:"^1T+BJ>\ZZRO3R :5B#U
M?B_L8^KN3K=%2+6+O9\&KDD?5^6/2ONF0A=L?) SN:3'8?&L5>HS2KO$D3Y9
MAW=Z>+'YI.;&-5V% 9.MO;$?WT?_,E_^%^80O8<N0TLM!<I?[=7]&KW3F74O
M2"1C;NP9:SGEIFD%_U38QK!D[H&HAOM+E[3/N)Z.ZE %+VU<<1_DUY +K\=_
MS#KJFE1)QPIMAD^(43E5:Z'<,7SJEG:$S]]$N7_4O U(LF< /GL\K29K],0&
MII:NY=3VRKUMK3\7M46JM4DGW-UN(,Y]1XGB;O4E;=P*#_R,"U(O% R3XP%/
ML)52LMA(0\9'C7XN;(#F7NHR "-=76#S$>HE*NA-]>FLRTN/WEV!KNN785>&
M'@]DH.G"\*PNJ"P5N%?Y25)MDA3 ADFY5H-@@X?O\7VX#%Z[.(Z]5@$<1Z=1
M07B:9-.P,=21_"XJUT%L++7;,TF>E"VDT4>)UV](M'<^#L.4.$RG9-0\7![H
M (;,J2DESMR=;K_8*NAB ^J^M4!-W)NU6^'SCV&T;U8C>GACDJFM B_YE;^6
MLL>&GQLT1Y6,SE$R(:_ :^^XULN;$"0)Z.OJVZ+%!-</'*'Y?!(@:7=WG_I>
M$+F"_MZCV9)4S0 TL,5>-% .:[T+?2BX62-0 MW>T!E^) B<\ZTRKN]R#Z)X
M[-@NHG,9@/*[&K](B<2@>C#+<\,5CE-+9_Q,O['<?U<LW.!U@\=!HY4=9D>Y
MAJ@U]$2>$1YV"Y3*^/7$2F(X\KM9==SS7>YWX4L;2M=8DW:#&@6E^M1<\EJ^
M./,&KV8'*.$J*A,SHVL.F\<&#C[G0D$#B3KA0ZD/4]A85L4Q/S?@10M,LC>T
M6[SSDYL0>JDM"8VDT;3&+(]UJR-6EM#"^E\>*_'6; Y [G9X>CQMG(F'@(0C
M_.)M6\1Z>Q6,H#&W]*N*MRH:1?80_?P_I0;O$>@UWI,N?LUW"Q/SUTH6NF?'
M39?X7]>^"_WUXG$*EU%<NLC%*L6O<A%VW#R26=_(,P1)/!U%')CT2L#KJT=K
M35^]=XW/O33%)T8(%S)O('=$_4A!)58688L8QJQM.Q-S=3SGK'V@)D\5C]G-
MI*D?)$9,^:R"WVBK! MMIM<)RG93 R;;K*VT,>6]ST=Z3UU7D_IV#R&C<^WX
M$;43[ A[ @?OG<Y"R<1,FZ/B>[Q8KY@JF(*FVC6/<D//-VO<&#M:50>E. <,
MX$O77"0NIF$V2;_+%CRP ::S<A!0=*[0%6".(1O<!H77XLT[R\_R[$;ZTBS+
M$Z_CDO5+FY)T5@0AG7X:%+A-OU".])P+=KT1=75ZY-8U92JPU>U^/C2UE/H
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M_,F&0ZV:IH#@<73K*42,>G<8$4'R@=0R &0^[/H[?P:@R9$!" V& ?>:4S(
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MYM#+_+-RF%1TD;1'19V4?THO%"#)8T_Z(Z@!I$3"@#E):\IJC6,I_O. 46%
MP;?1(O$9:PZB)-L)1/2//%[:#5H!V$Y?:3N!8-.WODS5_9Q^.<4/DKTT_</O
M_2!=PE>@EMI!# W: @-(21LZ_9=F>[:D-*YS$F[)_$!$'[S_4N[(N8@@:+.:
M[W=2%+!QR,9$E-:"6"FBKU/-<G.@@Z,LS6?AY^JLAQ4G:D@,P$H7?8DJB$SW
M+3'2@O'L_&65X/]DN\JC !G&$0P9@,&$990M<2[B$E'IU#SY^<*.:G[[BYW5
M,+^G8UY3\Q70$'??V<O*:A(;<97:ZE8T;LBGC6JCAL';R .7[,5WM=7MI-_
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M#;<5_8V_\3?^QK\>&,G@/P!02P,$%     @ VX"C5M\T6?&A[   QL$) !4
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M'.M5@68)1"+&D,:!@#B+6&(,CWJ=<#FQG^IH:FO C5)S+D']:T"UT."'\F]
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M?<)DAGB&H CT)A8E+(48JP!*1&48Q%QRZ72!L]?ZU%B@%@X8Z7J%,>PC9\<
MO?$8>,[;0^'N_'),95_>+GMMC^O><DRM W^6HP_UC#"0E;F(J8^X0HHWS[^6
M4GQ<;JZ K[G>7K2IB&,1LDPF,% R@TA&%&*>2"@)QS(B@?Y/.JORBB[L9K%]
MUTY3?"/ <-^U"4&L/197QB(\7X)\XT1!-T([AB78CX,=)PR#[L"$88"MKVK7
M8ILT%C_\VJ#\XXZORO5YF-WC&9P1\Q7@8-_QN!$/SH <A$"XM]"/QDZXK+Q=
M%86YP$H%)6%"$8Q#'D(4)1@RCD.8Z)^F4<;2-(MF3[)@N>T6I+M#ERFUV^V
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M"24. HAHFD%FHH2Q"!1B!$L1\]EC'0[XK:)%-1G#YEG57.;\2P6'F_X[]XZ
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ME#.1A3+) J()(PD@HE) %J9Z]T,"CO1>B(9V>;6[NYD:5:R% W=&.M?;Y:-
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M9Y*0A$+*40 120FD$>>0TC!109;0* RM<S'MMCPUHFV%<TB_M(=3-QE>I/W
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MX]S]>(],!VWI%-V2;MDPS"]TN5*:66K?WW65GS0) \$U"\19G$&D]R@0IY&
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MH%9T)T5CT^P 632&& K?F3.\RO@ZV3*&@/EDAHQ!.O/D5[[=4X:S))"!4K&
M$95Z:9<RAC3" C(9)2*E5#"[^@<VG4UMN[7O#%T89^@?W$* K""V(V9?P W,
MKX<.Y%:1/I?[CA^!8RB_\=VN7M=G_(C29_W%C[W3,_?&2G/6WU:ZL??F$J3<
ME"@38:B2"%$88R$A"O6YCJ$ PU!$41#+C#'FY)AVJJ.I$<963M (VKLDW$EH
M[<C"!V #$T4OK-S3/)P!PE=:AE/=C)M&X8RR!VD/SCW?U[5M-Q;N@Y2MBT[$
M)"-"Q5!)9K82@8!$R@P&08"B6,1"TF2=5_;6Q87J:'=6G_I^.MG;$2CBDRS+
M/^N#!N6\D,:2TY3:-O&;<^/6HZ3C8?$4VG9$<0EXKQ1'K(4<P/FI$P9O+D_'
M>QG9T:E3U4/WIN['^WHXZ.58EM47.A>?935+$,EBR@F4L100)1&#- M#B+A*
MHR"4*E).D:LOVI_:/N$M+>_!HY:MODR9M\*Z^C#L0VCKL= ;F,']$QK)@!'M
M"KS_SA>KVH3VEC[.*[J8_[<FR_5#5^!&'\2H*2$*KGDU?YIW7@;V\%TX"I,W
M3X7]UD?V2SBJVJ$7PO''^LWW][0PUNU2GSW6B93F?!9+Q#G*$DBQF>NQPI!$
M@L-8X(@G- D3ZF1;.-K+U.:^!A,L\K(T]ZN YP\/^IC<I"R"@!F!Z\QX(E\L
M:-$\5&?)<S0X' <\H@'#A"F(J&98%%(**8L#2 1-11P&,4VQ6TC!Q9"/$T:P
M!WJ-9^.A/BKZ=@Q],:(#\_1:/F/5:3+\7=66<.Z/?3LA\,3!Q_L8E8D[U7S)
MQ]T/]_ $TPOH\A=:_"ZKVFV@CNLP6SSC0W%=W=[+YI<W2DEC=FZSH*6<\R#D
M"8Q")/49#B40IYI+0GV RV3$-<%8;=3ZBS U/C=*@$;0UD]IHP<PBER!ZPJ8
M;#WM,VMM'#R7^@U5-]V,,P #<U%?[,\GN/,U" Y^9(,/QD@.9=XGA)L+V44P
M=OJ2]6MY/*>RBS3?\RZ[K*4>B]&GG"XWO;S_/C>&!E-M9J:0D*G *=2' :%W
MK&$,:485%+&,LR0F$156964[>YG:DO*^C:B\ G5:&+,C?99Z/^J2=_ DHA;+
M@@^<!F9^(^*65XRY8-ZF%32"^L#)@;E]X#42.??$S8V"S^'1R;(G7QZ/2,_)
MO\>59Q_N9S$Q]P12;JQ<GTPDR,;K8UV>Z]U*_I<F!N,,+&=Q&J0!0AP&*M-4
MR50*&9$8!@GA+$4$96'B8DUQEF!J-*J_K=3MW.X.NMV9?E HAV;:6O9=@VLM
M_EYIXBH'3+:&6Z,#J)7P9Q#HC9\G8X%[_Z,:$GK#\]+(T+\A3YYGM[J=MHI;
M0A(>A:F$(0H(1()+R.(LAIKF&$IX%NB?7.1XMNUK:L1U) FG$;9GP;TND.WH
MRQ-T Q-5;]0N]ST[Q&,HU[.=GE[7\^Q0Y;..9T=><2_C]E4^ME5Y-YNNM^9"
M6A:/M*B>/^L/I/VV22J$""2#B".3QQY%$,LX@"B1),R8PDEBE2+#J=?I4<E6
M2F#$="01-\B[Z60P( <G%F<,G<K".6-R0:DX^[Y&*Q_GK/YN23GWEWNZNIH[
M0A-OJ>=L4_1GEJ5QS$,9PBPR-ZI11B!%G,&()X(K(C.,@UF55W1AMT$Y[,*)
M3#8=#3<1;DT?S75I*^<__2..PNR?@:SE=71Q/804122.%(IA*#--U!'2>SZE
MC["9I#C@DJ1I@MSC""\#]N\F"/ (GCB+$L03#&D2"XUG%.@]=(@@"13.&)$T
MXZ%K!)\/-*<=?G<$2+M]\F70#+R*[0KWO];U]ZZKJIBS554'O.E3_!=J,MAZ
M=+\^B8@OQ^O##L9UN3ZIX(&S]>DG+\T@NE-_[GHI_ET*S2-W6[>X=_.2+W(3
M;6:RPM9)86=Z@4H0#1/($JI/UR'B>G-,,X@53;,D36-$T[[)1=W%F9[#T)'D
MB];91KP,D!WCC 7ZP-RT@_9N15"Z%*#59,?+$VQU ;\-DN?8!ZK>LV3V$.65
M$FCV!^UT;LT+VG2W,;R;%Y+K3Z3UX2!!&@C$!>19K+D2!P(R*C!,TH!G* EY
M2JV2[1TV/35KP9N<%J(N%]:*:<EX1T [;PKH#\70;-0*YK$,YFE]+SC+OVAP
MM /[<45V3^4GGNCA&/+-I).^I_,/>G(OO]S3XD&/V:J:<[KXN!0K4RB3+M[)
M)[G('PT[M%\?%SP.(F9N0#DRQ=I3B!.N3%!)1BE+%%=6:;HOD&%J<[N6'C3B
M._A']!R [ND_$JQ#GZA:!< NM&L5P%8'L*-$'\_#GD/@X, R_%",G\RNS^CX
M2F-W&9Z=[C$]FQ[/>>8RW?=<:RYLJJ>E=[!:\!_R0LEYI3>IY5_E_.Z^DN):
MGV;IG:RKQ+^CE=RDAYF%61 I%BN(TT2O8":/ DNS#$H11EF$*<9NU=RGH=;T
M%L5:=BF\A/U, V-;8^4DA)W6<EY(6*L+=B$!.Y@ ]@QVGVMQ 34P5VNKZJX-
MHP8'5!H=T,)S!78 N@)KB$"+$:A! @8EL$U6YM$D.ZEQ]V4&GH92XYJ>IZ'S
M*7/WM*3K<?1<U_$SZ=G>ZLU&_B"+C3/<5[WK6*[D;?Y&FD1M=TL3GOYQ^5E^
MKV[_D(LG^8M^^[Z<18IPB?095#+"(!(!@RR)!!24AY@$BO$461]$?4@TM15X
MG>V^!&)57T$UE:5*4$B^H&4Y5W.3[E9__6"9+R%?%^!L7$Z+C::FEH')7[TT
M!N&J5A@\U!H[G+2\#+G%T7?L@1S<0:91!QA]P%JA/0_A5BEPFX,W$FSUTFLE
M,)J!1C7PRZL,F<-1>>RA&^G@/-X0NIVD?<+=>:[VTM%XIVR?N.R=N;TVW#]_
MV+:J[LOJN]>+1?Z'<>K0_WY;2#&O/N5E.6,1P29M")1)%$#$6 (I#2,HA @#
M1J. $.I6F-%=B*FMK1LIZS1#O):S28.A3S5TK9+Y)32E'8 PJ;:V1>C=\Y Y
MCYKM+?>P8S'X[?:+*N+;JN.JK3JN?[8W5HT>X)/7\FV7P.@Q YJS"*.G1^L+
MTK'<:;W;<N-.(>>S]\NJ/CEI:J'F9ESJHQ!MBY+K!W@BHC" F> "(H5#2,(L
MAFG$TX@&)(EY9L./YSJ:&@<VLH(=88UIA8)67#N..XMN-X_YQ&Q@KNH+ES49
MV6)QA'#TRO337?[TLVZBX1K]ERW%G&UX%!JQ56]-%=;/]TFJ,.=RN>,8OW-3
M\C9_T/LZ/C=I]>J3Q;MYV7B"ZK]_7+ZE2RKH^AX1AX%B00!CSHS["TU-VE8$
MB9(IHRA$28;M4S!XD6EJ)/,?2V.'VL;5N^0?\#-(%D:'\:$?F*M:A7;2R^Q>
MM!_H!':5,H?61JT^-_*^9I9#BHG1!V\DP\-V\.JZ<O?F%+)1[:I.T;<_BL8I
M5.R.I,I!)9?TD2[K7*KML/Y4IQAZ.3%]7?#['8[N?!A^NAHQ>X97;/9S;?AM
MVE=UYDW ?)NJ=I.L7_*,A$)BB/5*:>)0$<0<8ZA_GH0JE"QE5FYH[EU/;85\
M:UPY9&GF9[Y))$'+4K9NWHNMD_V?+ZWE?'(X[*P-PX \\%IXHKKS-FE'*_H@
M11;<$1NLY//)CE^Y]O,Y0,X7@3[;0C\V^RPKW5?^((WQ83-3.&(!"W$ >8A,
M?7E3^B\4&#)$<!3(,%;2REK0V<O4..JSWN\4YE-W9*#C$-J1S<7 #,PK)G%R
M(R#XP8CXXXF0P4%XI1,<3Q1RO(]1V:)3S9?$T/WPA15^=T+=VOITXF:Y7WGN
MH%#=?IVZ;0 ;3F(<9HF 2<8"32'&\P$G'"9QEF910D3&^Q7X]2CDU!CH&[^7
M8K6HDY/O[)BV;F#F%T="$QTC[P<9;SN^>^U1')@N=ZN+[FBXKC0JS,7;00'1
MPZJC+XJ.@M]NZ]\-$NPXY(CX+C+J4\37J3$Z ,@G2XP.T5>_!>:7?"F?FYS!
M'U9+4;;V+R8I01'/8"JY@BC-""0TD#")@@23*$)$.%7].=[-U$B^EA(\-,FO
ME9'3C;U/@8G3@(<A@7&H3*9DSB -A((B24D:8:12'+E%]%\.YSBQ^@,!:K>@
M70[2P$M2@TZ;:[T6T6-<JQT*GI:!$YV,2N3=BKZDXC-/]R/3K[*B\Z44ZXH@
M[>>*4,QIEC&8)A&'B$0II(KIO\E0QFF@&.+*A4R/=S,U,KWF?/6P6ICJC7IC
MK.9\[EA&[02:=I/_<HP&GOQK <&F:H__N=\-@J>Y?Z*34>=^MZ(OY_Z9I_LF
MS#45J^I40IO;><PCB3(81S2!* DX)!D*(&8R4R'C*9'$+4WNBQZF-N,; 4$M
MH6LBW)?@V<WRBR 9>(+OHC' W#ZINK?\MB_;'SFK[0GU#G/9GGJP9Y!Q:^BY
M4>\?'A?YLY3?]"ELSN6)L*E%/53Z;S=JZWC]I<ZE]S8OJW)KADD8RB36QZE0
M1)H/!%*0DAA!BA,<)DAQ09PL]X-).C5>^;9ZT$>(9V-AJ\?Y6"3H^^^/M<?)
M5C/' .'!AMV.R28QF ,SXM'PW&W8X=5Z$$5][[Q37/:JK2H]J+5M\!'P%5 [
MF)SCQL@.#?=!V.O@'?8M)Z.[-BW6W_:6-RB/2(A3 0-BMH^IJ0@;\Q F298(
M'DM.F'2S&IWH:7IFHQW"KV4&->"N!6..PVI'QQZ@&IA,VU(O1L9!:?$,$M[*
MN!SO9>1B+9VJ'I9DZ7Z\;SIS6C7)TDV,]8VJ=SS7W^?E3"*$XU@&$(5)")$*
M"201XQ!'"!$69.3_Y^[=FAO'E731OX*(.6=.KPAC#4B")#CSY*Y+[]I37?:I
MKEX3>_I!@6M99\F21Y2]RO/K#\"+1-TH@ )H]CQTM6R3S,P/8B(!9'Z)<Z<]
M^;.2IA;_5?IMHS_PA]'1L=/*>50MPS,?6(5><#K!-( P^@($WGBCS\D9F3[Z
M@KG'+-*7;KAV0?IEM7R1Y4:*K](DT'+]J1+R^W*^*1O&U=>#Z2Z2&6$Y)3 6
MIBNT*+338(C /).<)%0HH:Q*1+QH,S7'TDWJV%G1O#^5'2VYL6L#A:O&S'7%
M&'@D0J\*.X.PM>32<(RT$KP"6>^KO2&ZO-&*[@K8SJ_:KGGHE:%8]=191&64
MBR2&+$<8XC2FD.&4P#0J(L6*.*)Q-BC^JAX_.=_8:M>\:D,#KAH[QRC+&9'0
M/LH:C.%AU9[-OF.I^N%O$T#M&78V:MJ_:D!-[797QSB%^Z;UU+T>QN9$*8V5
MC&B$8)R(!&+"$EBDF.O5E$"T($4N<WN^KPO"IO8R?_CM_K[FS2S!O"R?#=8.
M1967H.U_NWT#%OA=;S5MXHY65V"4'5*1>@D\AU)3CR".5$-Z'9ANE9^6Z/26
M=%YZQGBUFI;6[!5AVMXS-?KEOU5QW:=EO;M^F487\42IU.Q_Y:F"6.%4+VI5
M"A&-4UKD/,-23(.!V=&RJ<T;M?H39V!V_?98QJ)3T7="4^-X/,S-%T]_[VJ4
M_B>1,0\<_\GS,;O:]3^$DGG@<(['RCQ4P>%YD#7;PSW5<\67E2F*7#P+*2K>
M2EH^W"Z%^9_1^X4NC,9-)!RG*"E$5L LPLR<>"/(BB*'N8CB6"4T9LQI@V6X
M*E.;AW>6@"=CBGMVY< AL9LKQP$Z]/'9#N/*BAN@[0"M(> ?%?NNMJ%)3M(?
M.M8$2O"\#E2/F: #%1D]9?0ZP$[EEE[Y1'>NR/?-ROS_?:9K[5L6KU_ETVJ]
MF168B#12,91<NT@L4 9I1 C,TI1%!<&<B]26)O*,C*FYO59-L-43U(K:<T.>
M0[/?L7G"*+#'<H?'B0OR @"#:"#//7,T!L@+1G7)'R]=.BP^NJV8E1H.R2TE
M29ID*$FX@AP1 7%A.&!11LV.1D)QA)*8.G%DGY0RM=>[4:\AFW*D=CF-HUV\
M<C4Z@5_L6K^;EMHU"(-++P:>(H?3,D8-"GK-/)SO^R\>]KYOR:&J=,$M+<@7
MK7[#4$QQ2I4H""0R)Q#G"$$2902F,2GR%"%&D&.B[T69+M_U<5)^=W1HBRKC
M=['K;K&4&Y,;TJ@.C _6RUHW;W%Y%%).XSA/4Y@C:;KZI3ED-*)02"YRI.'(
MA5.UGM<Q&,,;O_D(V/ENK[@&]N,[2)ML[4[/EIW"_GRZ-3:>_/ME>:/Z>FOS
M#_V^_8U#^F13D[U4'<D=[+W=K^=<WLMUM:\WHZ*@)&(<)K&4$%/]B:8Q@W$B
M)4DR291=".@B=&H^J-45TF:3WS0_*<&3T7EW\G35>933F%@D-@1 .O0ICFDH
M<]>DB>\.5F![L%+I;<Y=ZG.< +"Z]+_V#^](J0^^8';L;^V&5W]#:\MGC=C!
MVLVZ_9;5CO>ZN?IRO9E]-4<U55%)DFN/K0RO8IY5M7L"%L+DFB6F+0.5J2JL
M3C+VGCHU9VU2]^9EW;2]83&K4R0=ZG/V8>MWMX/!".U/A^%@_5Z?M+LO@M,W
M=*(W_=,N<MM_UB@O[DGUVS?S]!\'M80M-Z90M^J"=_O]^UI^IQM9EXWORG=G
M$<KR)",2TCC1JSS%<DB9XC#&*E8RSI/8[HC10>;47MNMHH";VE&]KELW[2/7
MCMP)+L!;1%+^X0Q^8JCQNU-M^\T;L(.VX2MP9:-P0=2I,ZIO9$?K?;KW#;T!
M=(MPW8RX\YWUU4#$#:P+G4NM'C5F;U(7VPZZCSK=.L"%WYK]UO^42\GI-[E^
MG"_K#)BVHTB3D4!$3GA2Z( J21.]3%8(%@AIAU[@/(TRR2-LW_/*2N3D'/A_
M@HZR@UI;V4%MX;.] QC\9&6K[VD0AV3XVZ'IX*^]HSI6QZA+Z'IRT4[X]'IH
MNR>-YZ"=+-OSSVYW^N$W[5!\-@R?LX*D(BW2##)6Y'J]JWUTD:4Q3/*4)29G
M/R9.)&>714[./7=X3X4/WM,3*!,<IUD2Y5#ELH XC[&>_T@"F8HI*QB+]0C,
MEM4,+;Z-#G91@WTD_\^-N=WQE-_O:^#9\)B#]J<3K+WG-]:O)J0]CTX@<MH3
M M^4J/8\ )=(:WON')B8Q+F)Y4L=S,MYU7;@B]RT792S B6H2 E4*J$0BQ1!
MDA<(9JG(T]S\ESA57/4)FZ!#KW0U:\U&6<=4I3YD[=R*+[Q"A]<M5#L]]9I=
MZ5$"VY[J53?1NJLZ,)V2;OQUL'9!RU>*4Y^H<3.=+(P^2GBRN>=*\HRZ/L44
MM:R6)D&ZVNE7I@55RA5$"8]U ,,)I'F!(9-88)QQS)D3)7ZOM*DYE*8&;J?D
M=91F)P&V<RO>8 OL5YP1&T[#T8>$;U:.D[+>AJ2CS^RSG!V]-UW9\*YSDE9N
M.R,U6RE%3#/.DQQ2G"'31@-#(C*]_,&8%(5(18*<2,ULA$[-B6S5&]A@K@]?
M.^?A&[7 /J3; &[7Z,U_W98+++Z[L/6)?)NN:A8@G.V29G.O>Y;&Y_EF_KW:
M''M'2_E-/^#]ZE$OK69Q*J,D1@IF4G*(4XYA(54,$QVJ%'DL:,IBVZ2-<T*F
MYD5V>IJ21@G^J-5TR-XX"V>_$_$%4F"GX8R/4U;')0"N2/(X^^C1<CXN&==-
M ;EX[<B,-4WE_(<?IOJS-.NB@Y2QYB]UZMB,D[0H6!;!G)DSR8@ED)KJ+9[P
M*,[C)"Z$E><86>^I.:-&>R!WZK\M]8SCU\!RS36]P0WL1#W0QFR)83K6G^"$
M:1&HDVLG0 8S;,S>FNK%4>L_!Y'+L*'P1M,R4/R /)J/E%?E*Q]UZ+Q:;M[1
MQ5RMULLY;=O19I*E*,]@2@T1IM)3%I-83UZ848EPJA"W)\*\(&QJ4TRK[@UH
M% 8[C1TR/BY!W#\3^ 8N^,+Y/&9#TF4N@>>0*.,1Q)%29 9] =VR8RQ!Z<V+
MN?2,\3)B+*W9RX6QO6<X.<O'><GIXO](NOZH?U/.<I9'*-$^E1<B@CB)<T@+
MLR!(,4U$D>3*;@70(V-JKG3+/E+K"8RBH-+4G9WE$,Y^_^D)I,!N<P ^@^A9
MSB!P%3W+X3-'IV<Y8]0I>I9SEP[;,C#GG[1\N%^O7N9"BI]??R\-=]ZV0KAI
M-#"7Y99SA#%$$A7K4(JS0J_^500+EIAMQ*2(%$$1CYQ6_^XJ3,TU[.K>Z597
MMR7[@&&P6WV'!3>P2]'*U\QSK?IFU?R3L0#,EW\!.]AW5@3ACAD.HJ>5[0 %
M1EVD#@?H<+UYQ9.NS-OX/%_*3_IC.2M8E) BHA 7A6E\DD?522M,LIR2*$ES
M%KLU+CX2,34'UNGW870$E9)#\S-V0%IN$%X%3^B]/#=DAN=A'!GO._EB)^!M
M,BZ.##R;9G%\Y;!7^[U<SU^TUWB1'^=+NC2\EAW:X);V1+N29B&>ITG$&%$P
M18:1)$\S2%*20")(G&/]1T&Q&S&5HP8NW_MQ:*IV!FSYD<PD:U(:Y8_Y!BCI
M&NFX#@K/&69Y7D"!8L,6EA!8$$5A45":$48RGG 79QQP2$;)I3.H?Y02B..1
M<6S:YSH2=MX\(+ZA%[ [1+>J=XG[=W1659SI/9%F('*>Y@E7Z:-.(@.A.9QA
MACYF:OUCMJT!OSQ7;V:&I.*H8%"EB9ZXBCB%M##5"J*00DJ)5!K/GBHZ?#W)
MKC>!3^5=]7?Q 8=6!%S4/V_*#5T*L[YD=&%2^6\ D]_G2U./4AW4UQW&)M,8
MYO!K07.).(D8Q-S\(XH(4OUE@"Q%">4T1HK*YFOQ82G^]%^*UH:1OQ*R_OE/
M\'T(G*\1<H2GG[%AV>AGBX'^6*$P@:2-H0/WUFD;SGK_.1(WA@['>!UVSBDP
M\ ABM5RUVWN?EGSU*#_\,.K*69'0.%<YA0@3O?8C!8=%5$@=U\0XC41!"H*<
M3AK.29K:*J_V'/-*Q8J.V/$TX2RBEH<&/G *?3;0T1'42H*?&C4]5G!?A,+7
M#O]9.>-NY%\R]VB__N(-PYS"W^AZ;I+&OM)-FV"/19IDJ<*P2&4&,:4(4NT(
M8(J(B&EB>I([>8-C$5-S ZV&P*CH6*O0 Z2=$[@.GL!OOR,RSJ_]>>,]O>\G
M!(SZHI\W\/ -[[GRRI+'GU^W'__77/N0-7]X_2Q?M-VFHC?*L)0849BE2$"<
M&'99KAB,18%CF>89R9TH&.S$3LT%[*KXP%;9JB/;E]N_#2JCMD3?SD?XQS2P
MW[@&SN&5D5;H^*Z-[!?Z-M615D"<K8^TNWO@9JU<Z+]^_T4N]8,7MTMQ*Q[G
MR[E),3#[Q6W\C-*4Q"3C,-)1!\2%D)"@*()*H(C3/&?"CHW13>S4G%*C]0WX
M7NM=O4%T3W/'/3 []"TWL+QC&GKWJ87SEPZ<^TJ#1FN/NT5.*/G:ZK$3.NX^
MC1,01YLL;G</<TZ&-NC=:FG66'+)Y[+\9@(R'2%)*444PQ@C9/;W,T@BE4$I
M2:H72RK/4J<(Z;28J3D?HR784Q/\42GJ& B= =7.QUP/56"?,@ E9Q?2#X(G
MEW%&R*@NHM_00Y=PX>H!%6[W4G\KEAOZ7=ZI+ZOEU]4K76Q>&V[J6<I4S B.
M(2-)#C$5V@T0GD&5()ECJ9C,K3)D+HN:FBO8*6M(TY>K)5S7^K8$Z@Y56OT8
M]WL%O\@%]@P=T.Z4.8^"C:HMK[\WT!P*V[R!-U)9VU?YI!]7G?(]7?H2^B+J
MM\*HM\JM_PGCU;A96;)7X69WQT BT!<Z7Q@7_7&U-DV3WDNV^<W0[]1IYCO>
MT5_6VK/_OEQ+NC#<_\;/_RS5:BV_T1\SD<2"1(F 490;-ATEM!?6P9A0.4[3
MB(LXXBU%L5TXYD4OJW=GG\ XL-.NM 4[=2M23-<L4C]C9A?KC3<.8^4YL@W8
M&7 #M@9"K2PT)NK?=7B13XZ8R84RM@%MG$<F4Y]8^Z(\]:+3N-RH/F$\(E'U
M^O!A/OM^O1+/O&TUD>9%BHN<PBPR)/R"84BX$)!E$9=$QAPKIUVYO:=/+NBM
ME:M;A0Y(#MB'SLX%#@8D="S;8.$_&?NDQ9X<ROZS1W4,)\TZ?,%/7^2C'?Q7
MPP!SIWXO9=5Z?D9CFN0(IY +9/HZ2!TT815#1 3+<I01C*YH0GX@;6HO<J4>
M7"GX7$I C8:.05 _MB)A,BVH:4H228BS3$$:&^Z;%"68,9ZR6+I5,WE#=YS:
MI<#XVGE.;Y@%]J1'K=NWZ&EE0:5MJ+[M9T )TK/]4-8;]FL_8W9_K_9S-PUN
M@='&:E7&H<D37<L'N2SG+[+.YFK"A 3SC%*&])K6Y%X1C"'%!8,)43K<2G5\
ME42._3#L)$_-:7?71766YI[J32:B<[\,RV&P7+"& #>P_[F]>_<)W&XVZSE[
MWE2979L5N*=K:=.B;DC###>$_'7/L)0[=BL--SA.]-5P?,!P*JIO:ZH?:[9W
MO\JGU7HS*Q"+$&$$9A2;0(?'L)!Q"D4B\BCAE,>Y56^-/B%3<T-;LJ6=HJ#6
MU)V,Z@C0?B_C"Z;0NUSN" VBHSH'P55\5$</'9V0ZIQ9IQBISE[K_I)_UI@O
M[A]62]G4K!$N"**I@!D2>H68(J47,)2;2E<69:C *K<FFCM\^-1>ZDH_4"EX
MJ3CL,G"77^)KX C\\CH@X?32GC-YT,MZ]+#17M)S9G1?SK/7#,R/Y ]2/"_D
MG3I=5O;;9L7_WI2'-1Q-KU7>PS?Y8_.S5OSOLUA@*3/$85H@O8:(8O,J9S%$
ML:1*4IY%RJE^XWJ5IN8 6HO,07*E?5,WVO*;.1)\>!@SNP7'N",1V/><K/'=
M%4VVW.PWVT%I$JN ,094UOCDA_(&K:\4SNL5&C>]TQN 1ZF?_IY\Y=YZO<(R
MYVNSF&0)RD0*,5+Z'Z6#)E*P# H>41SG!64BGVU6&[IPW//=R7#RFEM)(8.%
ML@1FX$%3B:CQ'KC1VP'2<7MW&#RC;>JV!;)&08_5L3WF^]Z^[4AXFTW;8Q//
M;M6>N'38&ZX?M#;;ON]E_?]/RT_+%ST)K=9S6<Z23!91)CF,8Z4#*LPI+%"4
MP%2D."N0X"1-!W1%[Q4Z()]HC(;HK8:.$5(_OG8NX'JXQG$&K9[@IU;3OX#Y
M$G24]><7K##QY"'Z98WJ*ZS,/O0:=C<-9??^1]/R6'NE^_5JJ3_RNL'@_6HQ
MYZ_UO[MXO^ XED6,3:-S K' $60RHE#E:8QP(3CF3FR+K@I,;45F&D6;^']K
M ]@WPI7EVW$X[#Q02) #.R6M^GEP;T"M./BC^7^0%=90]+Q1>SN*'YG8>Q@X
MQ[3> Y\SI%JF3E_Z[?GI:=&FB#?GIQ@5,A4%A=30">"<Q_H3QS"A.)$)%E%F
MERAX0<[4O-@V9;!2=4AQS'E(^UV41Z ">Z(6HUK+MA9F2+^G'K!<*F*\@#92
M.<QI\'S5O5Q$HK_HY?SM(U:\7+1AO]SE\N4#'*/ACOXHY:Z69H:R*"X$YK"(
M*SH#F4'*HQA&A&2&.Q1GPBK_\O3CI^8&/S2,Y>"GIF;+DJGS#'@6GN\J2 ([
MO)9)7$=96_6NPL/!N5V%RT@^S0D?-X]VUOQ>1W9\UWC^ZZS&>V[K_%6^MK_N
MU_*)SL5[J>1Z+45#KW"[K-..JIS(<I:03+_EF,"<$ PQE032C'.(,*,BEU3_
M0-U*\88I,F"O+'@@6&D-9*UN63&-K*HTQB$)T@/'9^B^FC?,WW3#K1V#1OUJ
M".I,TMO^(?"P"^>"8+#M.2LEWGC?S@6HRQMZ3D\;G,J]?M;^8]?#H'U\YU>S
MC#(DE&20IU%A./5R2%,<08)SS).X2 1+'-.X+TN=6AC8*'W*"?+G=95QW.EU
MXYS*;3$,=@[0.[B!_5V+:[=+RLZY?;: =$@>MSU$_G*X+62.G;]M#\.)W&V'
MFX=YIX/6[W5&6I,W47:Z*KR?+Y[U9>_G)5^LRN=UW09LV_(RTJ$;S7D"N6$!
MQS&GD,9)"B.4\$Q*QM."NK@O/VI-S;^]E\O5XWQI7IU_=?->GH;)SKV-#WY@
M_]<:!!J+FLS5*IFO,@IT^X=\E>;EUJ]7W6@B1-M2OPA[<I^>E!K5O_H%\M !
M>W[Z, _];O7XV*2L'0F>%;'*5<9UL!@5*<2X() 5.FQ,XCA/91I'+'$B&NP3
M-C5O6NL*2J/L3=/A!ZPZ+_+@QC^]D-OY4%] !O:,#8:_U1C6FMYTO:$_GV>#
MB"=/UBMJ5/]D8_2AU[&Z9\@A0]4\QO#"E+??U[(ZX[U?K[B4HORH-:^%?2I+
M'7/^-M?F?:I,-%O&65XP+@F&*2EHW5V^R F'$6&H0)RJC#F<1@S68VH>Z)O)
MH351Q/>*A^FI,<)EKW[XF-@<<HR"=.C3D+I]5V4%V)IQ UI#@+&DC>-J6T!E
M#-A:,\Z N)RRC#(P8QW'!!P@Q].;JV'M/^89_O@1SX.NQF#_X.CZQPT]86KR
MABNNLADF5$E%4I@I@B#.6 (+PYE31!%)56*"7B>:B_W'3VUB&9PTO8<9P8C&
M64P@E1Q#+ G3GU(%"8D%D1JS+$_<>(:&HS8.L9 ?W&Q/P89B$?QTJU'LIN:'
M]'EL=<ID;\=1>P\?^9CIE&''QT<GKQK8.6"WA;OMG;+;0)CQE.FH.LY@++!^
M=T540(*Y@()SFB)9<(Q3IPX"O>*FYO\ZVMX 93H#O1B%'=L(]"-L]Y;[PRWP
M6[\'6:>9TDY9C^T%K$#QU6:@7]BX[0:L##]J.V!WUX E?;5)8((OT_#ZW:K<
MF+V#>5GJ\*M)]9G%L<)Q1'(HI.00%X6$3,829@E'.$_3++-KUF8I;VJ>9*<@
M,'N%M"[AK_8,#3\\H&U0.RCUT )_BV6Z7U0#^YF:_:#5%AAU;\!.X6U.GE\4
M'=;6?M$<:0U]-:IN"V5[C'H7Q!:/&6_A:V_3W@+7X;8KFVIVIH%?)36N7]PM
MOQIZ[O5\^?UG6L[+WY<K5LKUB^$B^+1\>M[LGT5^GB_KHZ492F*6(T:ABO6J
M#DN)()%"_X,8*Q*1Q)%B@UIP>E1R:E/!+BBZV<N$:>T$%0]98RFH3+T!76-!
M9>W1^; Q&%06#VWXZ?.;81?6OO5X!YZDWG*HAS<C#3 6OEN7^E3Q;1J=!@#Y
M;%O4$+(&)J&*_^^YW%15G=]6K0CY16YVA!C?5N]H^7"_7KW,A10_O_Y>2O%I
MN67.:'AR3!):FTV$HS@M4I%"D6$]"7&9&8[X',:*141_AW"62:><U0!*3FT2
MZMAH>'37K96F6P18F%-$_5OSF6L[P;.ANIHO6_H<[:OHUD+'#+(@WP"[R>:M
MQS7P9',PI%L#@;9PG]['_-G8"5I# 7L%/_U>#_)?P(X4:&=OD/2SD /B*Y<W
MA(KCIOX&!/DH4SBDK,$58EKR-_JCJ:GX62ZEFF]F.<DDDSB&G$8<8E3DL,"Q
M@A@3)E)))4X*UT.IDY*F=SI5@5]M1:G56K_QE6?8T!^NI0SGH+4]M[H:KN '
M6!4R6L5M*=9/C98>&=(NX."OR.JDE+&KJ/I,/5$FU7OY0)[:9U;.Q9RN7^_6
M=5;!KW+SL!+F5*W<2&ER#.Y4M1WS\^OQQ>UE38-M+)3DVH%$*M>A9VHR ?27
M":993!.993&FV(FQUJ-R4PLY=^KJ\0)-MDYM'F@5OZG2=W;LMCHN.7E;>_VP
MQMY>OP)VWNZM!C;T+OQ;C*D[16X \'V1Y?I4;5S:W "@'A'HAI!Q+;WYN]5"
M_V%EXM47V>%]-E5Q7S1V9_Y<]4 PR^;5LN[W/BLHP3C*$I@D&=4A:)I!4B "
M]6\Q(5&4\=2IMYU_%:<VA>S9U>7<KLI(NS_7):6;![H$^S<-FS#\#[[EM/&F
M0QIX\AAA-*]@4_<-N'=V=6\*OA';NF^ S[.O>Y<TM"5Q0^]035CW='VW_FUC
M.%VJ3?I[N:Z2F&>%2'%$D@QF<19!/1=P2&DJ84;3F.(XRFAFU:W*3>S47/U6
MZ[:P[HDVV7=5/9TP8[8NJ]R9JK;.L;3.<BSLO+1_A -[WAVX3<6=UME$XK76
M3<:>UKNNEO#9,]D%*&_-E*V$CMQEV06(X_;+3G=?LW%:/=<XP^U9"Y(11S@1
M4,A<0!P7#!8B+B"F:90CEJ!8.5$LG)$S-7_4; 9N];0Y$''"U677]"JTQMDU
M=0)JX*;I61B\;IH>2WF#3=.SII[>-#U_^<#5[\G^-9U822^_MY<T/9%N_T'7
MHNEN\XN^<%-^,JEL\Y6HRUN2 N>%5#G,X]@THLDE9*:B5[(HBTQO=X[<NGWY
MUW%J3JC1%'PWJNJ)>C"S0(CQM%S1ONTHA=X/[;0&Z]JWMYHU&Z"G6H@9*]OF
M8:4IFC*65H2 E:W>RZ@"#H6OQ6X #<==[8:#^&BY&U#4T&0O4?5\I8M[.A>?
MEN_HTWQ#%PW3>9ZE.,.1@B)E"<0%XY#03*]Z<YGRB"B<(:>CLUYI4W/D.V6!
MT19^6H)&7]=LJCZ([3RR-^ "^]9#S.9;S$+T?[<!Q5N.49^LD9.%+,P^SOJQ
MN6EX/_>/\])TJJW\TD?]NW*691E-#'\SBO,(8I$4D#']#Y(LC@A"1"GKGL]G
MI4S-9VS[E=>:-E$!J'1U[^E^#&J_M_ &56 O,0BE07W=SZ)P56/WXZ>.WMG]
MK&&G6KN?OWA8T/!>/^FEVHG_O*TE88S&,B4",J0*B)%,8*%?<OUC)')29((@
MIYYC)V1,[F7?JGA%8<\I+.UB@BL1"OV..X+C//OWF.]ISC\E8=29OL?$P_F]
M[U*O;+\-?^4QUR&3J6E;G$(9%01B3O1\'Q49C#):Y#DAVC<@MV1=1PU<OOSC
M)/$V/%9M90;7:[[G*F=_6\"Q/1H#$(C:KN$;1JXCQJ-(%C0M(%<YA9CD"++<
M'&>*'+/41&EV$=H(XS6&.]\R_]*&^9<WI*'';*%O,%AV<T+ (0@\7SCQ+M^
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MRF!=ZPR>&J7!I[_=@,]_O7<@,K)!O-^/A, QL#/9:0L:=<'] 827TP6'8>E
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MI01:R)Q:0-0E=]^J.I!4T 9R.V_@&<C _F$@AE[8[,^@$I"'_E#BFS/(GX'
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M&\LUGY?R?JU=[2Q)A/9J<0RCQ&0%"*(@4SB#,A$JIBCF.'%R=B/J/C5_V1@
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M60>NJU^KCWC\4G!5$4;]E<V7>E]MS*('D]%5R.WF?! $QZL&5]:%'61=$.Y
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M06&!*A^EW0+M#'Y9G3&.7-;@@W=0D,= 6KK;AAV<H=UP%K$!K1+@]TH-8/0
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MPX1BR1!..>9.UZ!=G4UMPAM9024LV)/6)N?7'6<[(Q *O8'-@3]PSH;!!I%
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M!>SI4OD_&VW 3IV]2U/OR^8^XVAG;48:G8$MTY #XVS, D :R/#UD614(QD
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M21-7DO \BR(6P93)PE1=CB")3!QJ%I%,;U\%E5;7]N>;GYI-JCQX1DJ3B.O
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M%2W!$FG/YCX0^%H[G=M1]E^A!<ISL'?;3 Z@OP[:[/V^Q'?EU7(U/2%A+2=
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MU_F5N*BLO(>ON'@[7[V>G9]XKQON/+:[&+!.@^;,1TA,>ZM93!*9$4J#4,Y
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MQYJ;SQ=Q.<W3L/CY<;%^^F]X_FV>W\U^X/(<\7,XPX]E1<,O/^]^^?)K:V?
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MX0:EB:QDAH[$I50]O(LF@0^T!D-*SG'!'7W<2R+Z_5X]+(8[1>XBA'MFW?>
M]L>&P3[HM=+FXESU4LDBK 9!6*TA,')8:QHG,I>Y\LW/6@XC]40+)@]$U#ZS
M?ANI=^Q(]6 17[*<5SUL-Y9GPD5DN<9>*;AZ@!0\N,CJB!,3-2KEG-TML&U+
MUXE6^QT'X['UVX&!_K28)\2\?$LZ62_4U0+EB1=TS /3.H'BR" &%TFN3"8E
M-7ILGJ&[EY(3+3YK8UX;**<#B#VZ2:S__G:^^(R+'[2,EI-,#A0/)=/>8&N[
M1B[ NQR _N:LY49HW[SF>B\*3[08ZAEV_..4V6GC]@]X_GZ^7!*?*R:KU"_6
M#YV7Z\_HS]_GL]4WCJ@^./A=+2H2VC#:J$KA35C,"%U7U%R=Y4IE-&<HP(6L
M",$^@2M1@#3(E4@FHVY=?_ 0+<<:1A+JNQF)'ZMHKQCTW <9B2-AZ_7;5;M:
M+PHX3PP'XVQH/N7M7D+&#6R:Z'_;>!TO\ ZVTUM,3%@,O#@>H<B:_>*UM8GQ
M&A"UID"*)8ZM._#?(F!<E#10Z&,0V4NZ!T/C!R[BO!$XMNK_UC?Z-Z')S1E&
MOT[/+NAKUW4U*\_@6H+%\WHU$!B%XJ R.9>AD"RSL29FRS"JUN.8VU ^;A@[
MB-$:0:4=6+E=N28W=TJ!O%:%FQIT%Q7K-5<.+A%SUN;,9.#$@Q@)KRL"Q[62
M8R#H0!#OK\Y^L;H1YQT>)USDA"HCH!$4OVM49!=B *V"=2[Q6&3KY,J>)(YK
M1OO%:Q.5=H#8[8UJL^RR]"SY.D%42!)8X.!SH:U*<TPH=&&B]:Y_+R'CYOP&
MV<2/%W@7[N4V&YOU,"G.E!14 "Y(*DHJ@K]7%K*(-C-C4#7??Q\@9=SDW+-@
MYQ"A-T3/H-FU5[/SZ8J_Z0_\C.EB,3V?XO+-W^GL(F.N K^5EMJ(8NLA[1)P
M3<D9($<WG+B&3N.9G*5V$:'8+.HX>0DA* /:!\:U8%G;<")IO.O:DJJ._* Z
MWMY6Q\>R3="ZP 19E,$7#<I(#DK0BO8^DGAT]B;6SGS;!\0-;PFUX*#3Q.$^
MB'OX$M"SJ[@#;_'V.+64;2#/VH,MSH)B5H'73 'Y*K9$3:YN:7T5J,NYB<^/
MA$>')^ZCE@XP=7@9WB.#TG+,P:>4@#LF:L27(-1I%S%BX-(+YW3S<;0#\-'3
M\,2]8/4<PQ/WT7$'.+]5!+>^K;^I6V;>Z9QT!A$=K?^H/ 4'SH$5J20A$K.Y
M=9W#@\1T7L0X.$ZV(ZXF2NL ?8]/?Q112W110526F/&<@[/: 0]:<&<E<ZPU
M H\?W3E>#>)SH["=\L8NH7WJ>J)+QO"D%00>/:B0)$2F&3E%*@;%0BI^*_$X
MX&7/\8H)GPM@S772@:4[TAM_?U4<)T7Q H6%C+S.*+6FENXZ*!*YRYIC"*TO
MU[2BO9>+JN-'1F. X?07P:OO\XO9^<216Z.E2,!RR* *23Y(C.!9B:J(Y#&V
M+D!K0OC(8=,HF&L+_ , T&G1[NLY28*VU5DB_H\X#[CW.2T2^4\3V"@#7^MU
MI^?K?DBS?/NU5P?G5TE2(;DN]?:LUT+544QD=0,7("-#@3$YQEJWJ-J+P&,M
M9#WWN/6*S6:3&?&6 Y!3;6BSR1&<*PX(Z,9SXY3QK1-']U,RK@T;#BO;AJJ!
M'D:^Z_^>3.O7E69>D^.\;N6#QDM#+K/4,H&*)4%$9T!DGT-2@>-N&9TG[OO?
M??.XJ&FARWDSP78%BQJS;0(UX8525EK0EM:(TN39QN@L2*55,M)$9EHT@WCH
M_>.UA3A6GP]"XT#ACIT,^7R^P/]=AO_^)SWN8OEJ[1B\FZ5-W*U]1,LIY/$*
M:^TCQ?(^F@#66&T8KYRRI[R6'=[3"QX.5>)\&(F.#8Y_S-=,_!Y"W)"?I4L^
MRPCH,BT6[VC#=<P"MR(CDS8P$W8"Q-UGCY,P& 8$1TJN@^C]SCYZ'1,JH5UA
MJ""DFHR3M)>&0)X7RXGG8AE7J77%\,/4C)MF:NAM-!9\=Q#Z^0'_>GT6IM^7
M;Z=G5^,]A2XE95E;=FE?QWLZVGS]JH&-S)B8]<WO%^Y 5F<N[($(>!18QZNC
M0X1=%L83-;-<AU'12DPA(*>=EM5ISF1H:P,,#X;90A31@G2MZX.>)*HSDS4,
MNHY317_8>I72HC8;/'\=%HN?],?-##-70X?@R'\S&50V9.FYYA!$0BEDX3&V
M'L*S$V'C'BX^#\8:J&3XA/'F@_I/;0?___[/_P=02P,$%     @ VX"C5FQ
M'@+L!P  !R8  !<   !A<F1X+3(P,C,P,S,Q>&5X,S$Q+FAT;>U::V\;MQ+]
MWE_!*FAJ WJM'G[(C@''=E$#S:.&BN!^*KC+68DP=[DEN9)U?_V=(5<O2TZ4
M)KU1C :(K%W.#(><PS-#BN<_7K^[&O[G_0T;NTRQ]W^\_NWVBM4:K=:'[E6K
M=3V\9K\.W_S&>LUVQ(:&YU8ZJ7.N6JV;MS56&SM7#%JMZ73:G':;VHQ:P[L6
MF>JUE-86FL*)VL4YO<%/X.+BA_,?&PUVK9,R@]RQQ !W(%AI93YB'P38>]9H
M5%)7NI@9.1H[UFEWNNR#-O=RPD.[DT[!Q=S.>2L\G[=\)^>Q%K.+<R$G3(I7
M-2E.!$^/3H6 ^+37CXYXOQU%R7%R<I2F27H<_QFADRT4#SK6S12\JF4R;XR!
M^A_T.LWC?N'.IE*X\2!JMW^J>=&+\U3G#OLSJ!^^!C,;QAP\N 97<I0/_)!J
M077>G&BES>!%V_\[HY9&RC.I9H.?AS(#R]["E-WIC.<_URV&H6'!R#0(6OE?
M0)_0/?\X#2X?HQTE<Y@/(>J0TS</8QE+Q[I1,UKW>+NO"4XNF&_D[-7-W?#V
ME]NKR^'MN[=/>IMQ,\)(.5UXN_^XK[VMOM[6V1N9C#DH=L=Y7&<)&"?3&7-C
M[EZ^Z)^<[3J LX(+@:NAH2!%ZR?XQ@=$Y@*#,6C0FV\TR*@Y'\3_O_='T])N
M]FD:;MF83X 9F$B8(H^XL;3L]Y(;1*V:L3LHM'%,Y^P7;3(6M1N_,YVR2R-
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M=)TDI:'@K^3/+58S;1V^IQ-'M&43-/17.,AA!T^HI(AB9+%'TI7CN&L"?W)
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M=)?O;0M,.[WF44(3<2$=JGN$*V2UCV.I3@DWY:7;7(4RWT "%U5/,9>:TL(
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MV-?>NW[#,: WAMY@=!$.!YOAK(4"I_GL0QN=0/AF"./>Y>O>^7!LCOXZ&WZ
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MKN5/!_I'C.-_ 5!+ 0(4 Q0    ( -N HU:IZ&I&W: " (D_&  1
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M &%R9'@M,C R,S S,S%?9S$N:G!G4$L! A0#%     @ VX"C5M\T6?&A[
MQL$) !4              ( !U/P# &%R9'@M,C R,S S,S%?;&%B+GAM;%!+
M 0(4 Q0    ( -N HU8=VE]B4X<  +(=!@ 5              "  :CI! !A
M<F1X+3(P,C,P,S,Q7W!R92YX;6Q02P$"% ,4    " #;@*-6;$ > NP'   '
M)@  %P              @ $N<04 87)D>"TR,#(S,#,S,7AE>#,Q,2YH=&U0
M2P$"% ,4    " #;@*-6*:WR0.4'   =)@  %P              @ %/>04
M87)D>"TR,#(S,#,S,7AE>#,Q,BYH=&U02P$"% ,4    " #;@*-6C)BTF4D%
M   ?&0  %P              @ %I@04 87)D>"TR,#(S,#,S,7AE>#,R,2YH
8=&U02P4&      H "@"; @  YX8%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
